<SEC-DOCUMENT>0001274737-23-000019.txt : 20230320
<SEC-HEADER>0001274737-23-000019.hdr.sgml : 20230320
<ACCEPTANCE-DATETIME>20230320172201
ACCESSION NUMBER:		0001274737-23-000019
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230320
DATE AS OF CHANGE:		20230320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		23747179

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exdx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:b2849c68-b5c1-4aba-9f81-ca2d321b51be,g:62e4697b-763f-43ad-abbd-d704ff1dbc1d,d:5f5950d7f59540fa871ae1a67d589208--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:exdx="http://www.exagen.com/20221231" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exdx-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="f-32">2022</ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-34">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityCentralIndexKey" id="f-35">0001274737</ix:nonNumeric><ix:nonNumeric contextRef="i91bdb390f427408ea87ff211d239efb8_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-312">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-388">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i3aa1b564f2bd4571b6af808180440a8c_I20221231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="f-449">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-453">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-456">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-457">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-460">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exdx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic71131a0a18a4dcdba1f5f3a771db49c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8d55c3bc4e324e6b94b5e0875b9eefff_I20230316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia586976f14c945e092ffa77bf6eea0a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2e346101f544b3b8c12fb87ac0784e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91db90b0b71948a3a7ed62f79644090a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15bf116298a3437e8f5fc8227e8b9962_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63a7f83cab04fd3bd0a7651465bc919_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i786ad5d8770443b192b64cc933e5cec3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied976c8e24054ecbbc5ea323afd116ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i447883be0ca142b2aba0ad1f554359cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5688532efb274edc8b634de1ed329963_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09435be4441486fb5d942d843092a49_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf731ab91df4cce9e68b8a2e71e2969_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2f4d5cd9295462fbea62e01ed3d1ff3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a1b430e1df4dbb8fe1a520a779c20d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641ab5447323466db021f35839754d97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1f3e435c2ed49ca95de1a1d4a150248_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc0c73bd74d46db9cc4fcd7cc90df81_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28979da435ba4d15844df6906e3d40bc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:OtherOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie987a93eb70f4bd9b8928b29b52988fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:OtherOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad59c59cd12b4a74a51934e1011397ea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0e44acb2196c43dcb02a146b459fd4fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05aa9d3d5e8b4de399a58f24519f3448_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia584bf6fcda64608a116c549a02cfe67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id47cdbd9f44c4293adf1dcb7a5ebea10_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c26ce8e296543d08e3fb5c648736bdd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd5830dbe3d44b5a5396e5d707e5405_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d5e4c6540b4d67906da80434e50044_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ded0e51d34d43b0ba062a85bc1cb346_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ae2b104191742ba8131e5c71bd9cbf0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7a3a01918e4ff8a94493a359671d39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e981b26af96420cad2acd4d9d106893_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c3582c593ea48d582cab27bc402f10f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i908968ff669f4aff969761449a9d8cdb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88583c8fbed94b7f9798fc8421e0b721_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6955e97d9d4394a14813f7a52619d2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i481bde6d9dff47b0a38b570d9228c1c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ab3e04c8cc4b3ba4e0900905568215_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i164771fb3f1d463cbd018cef7d6365d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17536183b1b2446e830e5aa438b46c6e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0719a3c05f2d48efb32f13d66e6f6d52_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3334b98a65be47a890ddcf70cd5ede5b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a730aad2275470c92cce95e1567059c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bdb390f427408ea87ff211d239efb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9c0d3ddc18741dc8fecde8d57850025_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94b61d4be67742429ba95efb0a3804d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fb69c732f42466ca2a71e8f7eaca6ac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa77feb77bd465da489e3faf3b36c72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:JanssenPromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7294c3cf4640d08c8b4195febb6caf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic404d905bd0c456cb113003341a477fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>exdx:installment</xbrli:measure></xbrli:unit><xbrli:context id="iec3e133c80b243bc90f00f9a090a04ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07865aaa84345d4855d746dc2002ad2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id44e1098fa6e44dea992cd186d3949fe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac4677048384433e8e79ba780e14863f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325c9bd99922498897b3b864e4d0b736_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4edbe79ab016482daa691291ec25282b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced52d7820074956a7e81f9bc4bcfa12_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55b44a6651b94f84bcc98d5253339f34_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exdx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i02725e3aa13240f183a18c6bf2fc237a_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b340fe912a484a884f93b38698848e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22a684f953449cfa60a7dc422eceef9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ee2541dd1dc4aa3be549ad1f58851d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dc49921e5ab4d61aab13248e2b13794_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374c17c705bf414b91e482b616596378_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43bdad8afb4f45c6a1b22e9de4e0c1cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f33d2414c044d385a05e4a4d691a0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a4b77c71742400abbf82a14977b7937_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fea4a51c8774db69325270c6310d222_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34154d30661d4701b9a9dcb4ea066485_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21484a6d0a4a4221bf3a14d5f4de561a_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedb996e521c541bab8a8ad9236459639_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11758bdfae5647bb9010a004bb8ab441_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib914810c44274f05a6e9bda17b3ab8ba_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e65613bdd30464bac5bfc957856d90a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i147c9ab0d4e64ff080edac66d8c4f23b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e935f3a72e40e2b02e056b012588be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie483ad8f564a42bb865b2050775ce979_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib88c7c3974194380b44ecb42d60b8720_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8200bdcb0146bdbcb050345834cae4_I20210823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef633a201de4e788ff9e9950032906f_D20210823-20210823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa1b564f2bd4571b6af808180440a8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbb89d0248f64893ad1ad1c6b9502e58_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41c305776f9f4df98a125ab8c0085264_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i935801f568bd44c0858bb0fa7df69e4a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4befc2bf4a164a518ddb3977c94dc56e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6b2af557a44f209ce9709fa784684e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26007b31f51c41faa8926d8811c70043_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05cdd06cb9f34748beee2062757859f1_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:QueenMaryUniversityOfLondonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51903aede478415aba514640200f634b_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie067d973b59240a7840114c391ab933c_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0458f36c4a244111a45add1871029a6d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b2218400d14228b5ea985e6aa0008f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd84100c8b24959976b0a199271ea74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d9ffdc3698e4888aa538e6a0986c347_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib300e2ee7d144ad286aacd3426594ffd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba04ed946a3b41b5b8dd12ccca532017_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3950a651de784404bcb5123100be8933_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i546dd718a1fe4f519ecd16edbb19413d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i113a047163aa40aebcdd5ca09836f93a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ba30848a1ca43d389206c0ad496522d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2462525bac435e95ff90467072cf52_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i629348dc384e428cb5f8def2819ad0bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80eea195a57448589f21c7f4808d74e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia259598962414ddea394a3f3fe518c30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id01b77c5ef314817b937c1edcfce3899_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6adbdf0f555c4b13ba58f5c4786bdff4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b5adcc18404940a217b0bebcaf1387_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1435ec1361f4450385ff04cd5684f711_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9573d9982b2e49e9bd110183aaa2cbc6_D20201110-20201110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-10</xbrli:startDate><xbrli:endDate>2020-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca40d7976f44613b2feab35b0c59a82_D20210325-20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5d838eb19db44f7922ca98f01e9cf77_I20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe5ad06e42c406da92d33ef14794240_D20220915-20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:CowenEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06fde84d2c1f410483f0af8e4b52b90b_D20210622-20210622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-22</xbrli:startDate><xbrli:endDate>2021-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c096e88d4fa4f49adc92daf85a0d949_I20210622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b9bbb8d0ca4fd6a3ced6fba0c92324_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab6f88ec0238452293973853113c2d9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica716265618d4d869aae1d9174b631a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96869c44a89140f9a1329238fc14fd52_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93961cbee5f14ee69a98afa1d0336147_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4585060a7ed43049f692210d99fcdb0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86f954890ee9407f84dc9c97b645549a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a3014a9e6354ea58eedd096ea6a7280_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia487f414d26048018d3c769a149ec0a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94d37f040ba4631af4999316806f239_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2578607c562a474a803e1e324447c4d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if21529de837840bdaee22e04f99761a1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i834b1c4afb9e43a6897a5a3065173ce5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f089a1558114e6cba9e97065369d2c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9eb3d3b204543ea8d7fc8ac766d9865_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff44339e8e5422491a24b075e89a412_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe07b69e3094708af8420871a48901b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da55bae29084ecfb396a149ffd03213_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f9febfdc354a78a3d5c5696fe66007_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5697bc9dcbcd4e158253d63ad580c6ca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4044ff56a8a6462daa0d36da9aa8bb53_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc29ebe03b724500a8ea2d0e5fd353d0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24fe3864155b4460a854467dbba00699_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if008ef2237244062a2ec402f2b90b70e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0abc7ffcaf3c49cba83cdb2a71ec0edf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b91b506545f4d24947576347cff021d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2377d69c61584e0298f5a9998d400497_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe36546577a1446c8e1f0db960eceda1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonSharesAvailableForGrantUnderThe2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5f5950d7f59540fa871ae1a67d589208_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One) </span></div><div><span style="font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:115%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:2.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.026%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the fiscal year ended <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from     to     .</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityFileNumber" id="f-6">001-39049</ix:nonNumeric></span></div><div style="text-align:center"><img src="exdx-20221231_g1.jpg" alt="exdx-20221231_g1.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"/></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityRegistrantName" id="f-7">EXAGEN INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:0.1%"></td><td style="width:1.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="f-9">20-0434866</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="f-10">1261 Liberty Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="f-11">Vista</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="f-13">92081</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.766%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:CityAreaCode" id="f-14">(760)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:LocalPhoneNumber" id="f-15">560-1501</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant's Telephone Number, Including Area Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:TradingSymbol" id="f-17">XGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">"emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:20.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-25">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on the attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June 30, 2022 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="ic71131a0a18a4dcdba1f5f3a771db49c_I20220630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-29">61.5</ix:nonFraction> million, based on the closing price of the registrant's common stock on the Nasdaq Global Market of $5.74 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares of common stock outstanding as of the close of business on March&#160;16, 2023 was <ix:nonFraction unitRef="shares" contextRef="i8d55c3bc4e324e6b94b5e0875b9eefff_I20230316" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">16,825,696</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2023 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_13">Business.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_16">Risk Factors.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_16">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_19">Unresolved Staff Comments.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_19">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_22">Properties.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_22">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_25">Legal Proceedings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_25">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_28">Mine Safety Disclosures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_28">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_34">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_34">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_37">[Reserved].</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_37">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_40">Management's Discussion and Analysis of Financial Condition and Results of Operations.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_40">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_55">Quantitative and Qualitative Disclosures About Market Risk.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_55">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_58">Financial Statements and Supplementary Data.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_58">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_61">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_61">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_64">Controls and Procedures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_64">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_67">Other Information.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_67">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_70">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_70">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_76">Directors, Executive Officers and Corporate Governance.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_76">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_79">Executive Compensation.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_79">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_82">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_82">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_85">Certain Relationships and Related Transactions, and Director Independence.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_85">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_88">Principal Accountant Fees and Services.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_88">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_94">Exhibits and Financial Statement Schedules.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_94">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_97">Form 10-K Summary.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_97">86</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_160">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_160">92</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_100">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_100">F-1</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Part I</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Forward-Looking Statements and Market Data</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K (the Annual Report), contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, current and future product offerings, reimbursement and coverage, the expected benefits from our partnership or promotion arrangements with third parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This Annual Report also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some cases, you can identify forward-looking statements by terms such as "believe," "may," "will," "should," "predict," "goal," "strategy," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect," "seek," and similar expressions that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described under the sections &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use our trademarks in this Annual Report as well as trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, certain trademarks and tradenames referred to in this Annual Report appear without the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </span></div><div style="margin-top:9pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. Business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Overview </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, several of which incorporate Cell-Bound Complement Activation Products (CB-CAPs) technology. CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE). Our goal is to enable healthcare providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis (RA).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD allows for the testing of a number of relevant biomarkers in one convenient blood draw, as opposed to testing serially for individual biomarkers, which adds time and cost to the diagnostic process. We believe AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD may provide clinical utility for over 24 million patients in the United States suffering from these diseases, which include SLE, RA, Sj&#246;gren&#8217;s syndrome, antiphospholipid syndrome (APS), other autoimmune-related diseases such as autoimmune thyroid, and other disorders that mimic these diseases, such as fibromyalgia. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD leverages CB-CAPs technology to enable the differential diagnosis of SLE. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD provides rheumatologists and their patients with sensitive and specific results that allow for potentially faster and more accurate differential diagnosis of SLE as compared to other currently-marketed testing methods. Beyond SLE, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD allows rheumatologists to accurately diagnose other overlapping autoimmune and autoimmune-related diseases, including RA, with the same blood sample. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor testing product also leverages CB-CAPs technology by measuring two CB-CAPs biomarkers that offer insight into a patient&#8217;s disease activity. This test is designed to enable rheumatologists to effectively assess and optimize therapeutic intervention in patients diagnosed with SLE. Depending on disease severity, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor may be utilized by patients multiple times a year throughout their lives. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our RA-focused testing products include AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX is a drug monitoring test designed to aid in the optimization of methotrexate therapy, the standard of care and first-line therapy for patients with RA. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX is based on our proprietary methotrexate polyglutamate (MTXPG) technology that measures blood levels of MTXPGs, the active metabolite of methotrexate linked to disease control in RA patients. Measuring MTXPGs allows rheumatologists to identify patients presenting with inadequate exposure to methotrexate enabling them to optimize dosing and achieve therapeutic levels commensurate with adequate disease control. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Touch, the low-volume test sample collection method, is no longer offered for any of our testing products. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP, which measures anti-carbamylated protein antibody (anti-CarP), was developed by the Leiden University Medical Center, and we introduced it as a biomarker-driven RA prognostic test through a distribution agreement with Werfen USA, LLC with the goal of identifying patients prone to more severe disease.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">testing products using our specialized sales force. Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2012 and through December&#160;31, 2022, we have delivered approximately 750,000 of these tests. For the year ended December&#160;31, 2022, 135,210 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests were delivered, representing an approximate 5% increase over 2021. In the fourth quarter of 2022, the number of ordering healthcare providers reached a record 2,419 compared to 2,126 in the same period in 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we continue to populate a growing proprietary database of de-identified patient test results from our clinical studies and our clinical laboratory. We believe the insight emerging from these results has the potential to unlock value for pharmaceutical and biotechnology companies in the development and commercialization of therapeutics. We believe we also have the ability to further leverage our database to optimize patient selection in clinical trials for companies developing therapeutics for autoimmune and autoimmune-related diseases. We plan to collaborate with our existing and future pharmaceutical and biotechnology partners to help maximize the full value of our in-house database.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Strategy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We address the unmet needs of those suffering from debilitating and chronic autoimmune disorders through aiding in the differential diagnosis, prognosis, monitoring and therapeutic selection, to ultimately improve the continuum of care for patients. The key tenets of our business strategy include: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Focus on our flagship product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> CTD.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We have demonstrated a solid track record of commercial growth of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. We believe we are uniquely positioned to continue expanding our commercial presence within the autoimmune disease market by leveraging our specialized sales force and expansive network of relationships with rheumatologists across the United States. Using our specialty laboratory focused on rheumatology, we plan to build upon industry-leading quality, service and technology to support strong AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD adoption and continue to grow our ordering physician base. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Continue developing innovative testing products, using clear criteria for R&amp;D projects and commercialization milestones. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to leverage our protein and molecular assay development capabilities, bioinformatic team and proprietary technologies to pursue the development of additional testing products designed to have superior clinical utility for CTDs. We undertake research projects that have the potential for impactful results and address the top consumer needs in the rheumatology space. The research projects we support will be those that we believe will have a competitive advantage (such as using proprietary technology), a pathway for reimbursement and an established evidence development plan with sufficient market size. Criteria for developed products that we ultimately commercialize include Medicare coverage (specific to patient population), proprietary value-based pricing, published clinical utility and a strategy for medical guideline inclusion. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Maintain meaningful margin. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We seek to maintain meaningful margin by continuing to focus on increasing operating leverage through the implementation of internal initiatives, such as leveraging validation and reimbursement-oriented clinical studies to facilitate payor coverage of our testing products. We plan to increase our focus on long-term reimbursement and average sales price (ASP) growth, by optimizing revenue cycle practices, focusing managed care efforts on medical policy expansion and continuing to educate insurance payors on the published, real-world evidence of the clinical utility of our testing products, showing healthcare cost savings and reductions in time to diagnosis.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also seek to improve our per-test costs by focusing on profitable, core test offerings, reducing fixed costs and overhead, and focusing our laboratory resources on AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD optimization. Additionally, we employ a streamlined salesforce covering territories which are designed to achieve the most efficient and effective reach and frequency for the promotion of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently aligning the organization with this new focus to best accomplish our goals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Autoimmune and Connective Tissue Diseases </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Autoimmune diseases encompass a broad range of serious, chronic and debilitating conditions in which a person&#8217;s immune system creates antibodies that mistakenly react against normal healthy tissues causing inflammation and irreversible tissue damage. These antibodies are called autoantibodies and their detection through blood tests can help diagnose, prognose and monitor the course of autoimmune diseases. However, knowing when and which autoantibody to test for is challenging due to the vagueness of symptoms, the unexplained flaring and remission of symptoms, and the many conditions which can mimic autoimmune disease. Early and accurate diagnosis of the conditions causing these overlapping symptoms is critical as an incorrect diagnosis can lead to toxicity from inappropriate medications, irreversible tissue damage and other comorbidities associated with uncontrolled disease. There is no known cause or cure for these chronic conditions and current treatment interventions are targeted at managing symptoms and limiting disease progression. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTDs are a sub-category of autoimmune diseases involving inflammation of the joints, tissues and internal organs. Persons with CTDs often present to their rheumatologist with complaints of joint pain, fatigue, unexplained fever, inflammation, rash, stiffness and muscle aches. These symptoms overlap among numerous CTDs, including SLE, one of the most severe CTDs and historically difficult to rule out, as well as other autoimmune-related diseases and other disorders that mimic these diseases, such as fibromyalgia. The National Institute of Environmental Health Sciences estimates that there are approximately 24 million patients in the United States with existing cases of autoimmune diseases. Of these patients, we estimate approximately seven million are potentially referable to rheumatologists and would be candidates for an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, representing a total addressable market of approximately $7.5 billion, based on the current Medicare allowable reimbursement rate. We estimate the total addressable market for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products to be approximately $9.0 billion, based on estimated patient populations, the current Medicare allowable reimbursement rate and testing frequencies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Systemic Lupus Erythematosus </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SLE, the most common and severe form of lupus, is a chronic, inflammatory disorder that can damage any part of the body, including the skin, joints and internal organs. The blood of a person afflicted with SLE contains autoantibodies, which are the cause of the inflammation and organ damage and are one indicator of immune system abnormalities. SLE is characterized by a rise in symptoms and/or abnormal laboratory test results. SLE varies in severity, from mild cases to those in which significant and potentially fatal damage occurs to vital organs such as the brain, heart, kidneys and lungs. Detection of these autoantibodies can assist rheumatologists in the diagnosis of SLE. Diagnosis of SLE allows rheumatologists to initiate the most appropriate therapy to minimize irreversible organ damage and reduce morbidity and mortality. Current treatment for SLE involves the use of antimalarials, corticosteroids, immunosuppressants and biologic agents to prevent or suppress active disease or flares. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Standard laboratory tests for diagnosing SLE include measuring immunological biomarkers, such as antinuclear antibodies (ANA), anti-double stranded DNA (anti-dsDNA) and other autoantibody tests. ANA are a group of autoantibodies produced by a person&#8217;s immune system when it fails to adequately distinguish between self and non-self. The ANA test detects these autoantibodies in the blood and is a useful screening tool for SLE and other autoimmune and autoimmune-related diseases. The vast majority of SLE patients test positive for ANA. However, the high sensitivity of ANA for SLE is counterbalanced by somewhat poor specificity. Sensitivity measures the proportion of patients who are correctly identified as having a particular condition, while specificity measures the proportion of patients who are correctly identified as not having a particular condition. Therefore, the majority of individuals who test positive for ANA do not have SLE. Approximately 11-13% of individuals with a positive ANA test have SLE. This lack of specificity leads to many inappropriate non-autoimmune referrals to the rheumatologist from primary care physicians. For example, it has been reported that 30% of fibromyalgia patients may test positive for ANA, potentially generating as many as four million inappropriate rheumatology referrals. In addition, a study published in 2012 reported the estimated prevalence of a positive ANA test in the normal, healthy, U.S. population to be 13.8% (32 million people), indicating a significant need for a highly-specific test for this disease. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Anti-dsDNA are autoantibodies that target a person&#8217;s double-stranded DNA. The anti-dsDNA antibody test is a very specific test for SLE as anti-dsDNA antibodies are rarely found in autoimmune diseases other than SLE. A strongly positive anti-dsDNA antibody test makes it very likely that a person has SLE, although if the test is negative it does not necessarily rule out SLE. Many people with SLE have a negative anti-dsDNA antibody test, reaffirming the need for an effective testing product which adds clarity to the rheumatologist&#8217;s clinical assessment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Activation of the complement system is an integral part of the disease process of SLE. Thus, rheumatologists measure components of the complement system, including serum levels of C3 and C4, to help diagnose SLE and monitor SLE disease activity. In 2012, the Systemic Lupus Collaborating Clinics added low C3 and low C4 as immunologic criteria for classifying SLE. In active SLE, C3 and C4 complement proteins are consumed and broken down to fragments, known as complement activation products. Therefore, low levels of C3 and C4 suggest a diagnosis of SLE and that the disease is active. However, variability in the levels of C3 and C4 can occur due to factors unrelated to SLE disease presence or disease activity, making them less reliable as biomarkers for SLE. For example, C3 and C4 are acute-phase reactants and produced during inflammation. As a result, many SLE patients have normal complement levels even when the disease is active. Although relatively specific for SLE, low complement levels can also be seen in certain chronic infections, including non-lupus-related kidney inflammation, severe liver disease and other autoimmune diseases. CB-CAPs are formed when the fragments of complement activation products from C4 bind permanently to circulating cells such as red blood cells, b-cells and platelets. This binding lasts for the life of the cell and represents a more stable and reliable indicator of complement activation than measuring C3 and C4 alone. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2011, the first new biologic targeting treatment of SLE in over 50 years, GSK&#8217;s Benlysta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, was approved by the U.S. Food and Drug Administration (the FDA), and in December 2020, the FDA approved this biologic drug for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Since Benlysta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">'s approval, there have been a number of drug development programs that have failed in SLE, which may suggest that guidelines for classifying SLE patients and the endpoints used to determine clinical effectiveness have not adequately addressed the complexity of the disease process and its heterogeneous population. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rheumatoid Arthritis </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RA is a chronic, systemic autoimmune disease in which the immune system attacks the joints and can also affect other organ systems. The annual incidence and prevalence of RA in the United States is estimated to be 135,000 and 1.5 million, respectively. Patients suffering from RA develop joint damage that is associated with painful inflammation and often progresses to irreversible damage of cartilage and bone, leading to significant disability and a reduction in quality of life and the ability to work. Early diagnosis and effective treatment of RA is critically </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">important to prevent erosive bone or joint damage and disability. Rheumatologists are compelled to reach a definitive diagnosis quickly and administer effective treatment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diagnosis of RA involves performing a complete medical history with physical and/or radiographic examination of the number and distribution of swollen, tender and painful joints that have persisted for more than six weeks. Laboratory testing for rheumatoid factor (RF), anti-cyclic citrullinated peptide (CCP) antibodies and testing for general, nonspecific inflammation with erythrocyte sedimentation rate (the ESR) and C-reactive protein tests are used to assist in the diagnosis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standard of care for the treatment for RA involves the use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) which have shown, in clinical studies, the ability to slow or stop disease progression. Methotrexate remains the most commonly used DMARD, due to its low cost, effectiveness, and the extensive clinical experience with its use. It is estimated that approximately 90% of RA patients in the United States, or 1.3 million patients, are treated with methotrexate, either as a monotherapy or in combination with another DMARD. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biologics DMARDs are proteins that have been genetically modified to target cellular components of the immune system that attack healthy tissues causing the symptoms of RA. They are a targeted form of therapy, which makes them different from traditional RA treatments, such as methotrexate. The first FDA approved biologics for RA were the anti-TNFs. The anti-TNFs dominate the therapy for RA and generally are the first biologics chosen to augment methotrexate when patients are not achieving a satisfactory response. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Solution </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and RA. Our product portfolio integrates CB-CAPs technology, which is a stable and reliable method for differentially diagnosing SLE. We are focused on leveraging our sales channel targeting the approximately 4,500 rheumatologists across the United States. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Proprietary Technologies </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have two core proprietary technologies, CB-CAPs and MTXPGs, which form the backbone of several of our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">CB-CAPs </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary CB-CAPs technology determines the blood levels of complement activation proteins permanently deposited on hematopoietic cells. The determination of complement proteins in a patient&#8217;s blood is a mainstay in clinical laboratory science, and state-of-the-art methods traditionally rely on measurement of serum or plasma levels of soluble complements. C3 and C4 are the most commonly determined complement proteins in the blood and the precursors to activation of complement proteins into biologically active breakdown products. However, there are limitations with measuring C3 and C4 blood levels as indicators of complement activation. For example, increased synthesis of C3 and C4 by the liver can offset increased C3 and C4 breakdown during activation of the complement cascade, resulting in no change in serum levels. While the limitations and drawbacks of measuring standard components of the complement system, such as C3 and C4, are well recognized by the medical community, these laboratory biomarkers are part of international guidelines for the classification of SLE. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the availability of novel complement biomarkers supporting or replacing standard C3 and C4 measures will be of great value for rheumatologists and ultimately their patients. Our CB-CAPs technology directly measures protein products of complement activation, such as C4d, the product of C4 activation. These complement activation products become stably attached to surfaces of circulating blood cells to become CB-CAPs. As such, the determination of CB-CAPs in the blood provides benefits when compared to the traditional complement measurement. These include the stable, accurate and unequivocal information of complement activation that enable consistent measurement and an improved ability to assess and monitor changes in biological activity related to activation of the complement system. In a head-to-head study published in 2014, CB-CAPs (EC4d or BC4d) showed 22% higher sensitivity (66%) than C3 and C4 (44%) in diagnosing SLE, with specificity fixed at 91%. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MTXPGs </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Methotrexate is the standard of care and first-line treatment of many autoimmune diseases including RA and psoriatic arthritis. Our proprietary technology measures blood levels of MTXPGs, which are the active metabolite of methotrexate. The technology uses a dried capillary blood-based collection method coupled with liquid chromatographic tandem mass spectrometry and quantifies nanomolar concentrations of MTXPG using at least two </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">orders of magnitude lower blood volume than venipuncture. MTXPG blood levels are actionable clinical utility checkpoints and can help clinicians identify causes for a lack of response to methotrexate, such as poor activation to active metabolites, underexposure secondary to poor absorption or poor compliance, all of which are limiting factors to the achievement of a robust clinical response with this first-line treatment. We believe we can leverage this technology to optimize anti-TNF treatment by reducing the formation of anti-drug antibodies that are known to impact the clinical efficacy of these drugs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Testing Products </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception, we have been committed to developing and commercializing innovative testing products that address the challenges rheumatologists face in differentially diagnosing, prognosing and monitoring complex autoimmune and autoimmune-related diseases. We estimate the total addressable market for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products to be approximately $9 billion, based on estimated patient populations, the current Medicare allowable reimbursement rate and testing frequencies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Diagnosis </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> CTD </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, is a comprehensive test that aids in the differential diagnosis of SLE versus other common CTDs. The SLE portion of the test employs CB-CAPs technology and specifically measures activation of the complement system by quantifying the level of two CB-CAPs biomarkers in the patient&#8217;s blood, B-cell C4d (BC4d), and erythrocyte bound C4d (EC4d), which are higher in patients with SLE compared to patients with other CTDs. In addition, the comprehensive nature of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD enables testing for a series of biomarkers in one convenient blood draw to further aid in the differential diagnosis of a wide variety of CTDs and other diseases which can be challenging to diagnose as a result of overlapping symptoms. These diseases include SLE, RA, Sj&#246;gren&#8217;s syndrome, APS, other autoimmune-related diseases such as autoimmune thyroid, and other disorders that mimic these diseases, such as fibromyalgia. Our test&#8217;s ability to allow rheumatologists to effectively rule out SLE and differentially diagnose other CTDs such as RA adds clarity to the rheumatologist&#8217;s assessment, thereby making the larger diagnostic process more efficient and accurate. The clinical performance of our proprietary biomarkers and the convenience of a single blood draw make AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD an attractive choice among rheumatologists.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> Lupus </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test employs CB-CAPs technology and is the cornerstone of the SLE assessment within our more comprehensive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing product. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus measures activation of the complement system by quantifying the level of BC4d and EC4d in the patient&#8217;s blood. Rheumatologists choose to order the comprehensive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test or the more focused AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test based on medical necessity, which is determined by each patient&#8217;s symptoms and medical history. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> APS </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">APS consists of a specialized panel of autoantibody tests. This test aids in both the diagnosis and management of APS, a hyper-coagulation state leading to thrombosis, pregnancy complications and even death. Rheumatologists would typically request the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> APS test in patients who initially tested positive for one or more APS biomarkers contained in AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, or in the management of patients experiencing a high-risk pregnancy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> Vasculitis AAV </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2020, we launched AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Vasculitis AAV which utilizes a testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). AAV is a group of autoimmune diseases characterized by vascular inflammation and damage. Early signs and symptoms vary greatly and are not always indicative of the severity of the disease. Rapid and accurate testing is essential to prevent death and long-term disability.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prognosis </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> SLE Prognostic </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic is a panel of autoantibodies that have established predictive value for assessing the potential for complications affecting the kidney, brain and cardiovascular system, including lupus nephritis, lupus psychosis, strokes and heart attacks related to lupus. Rheumatologists rely on insights from the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic test to help tailor their treatment approach. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> Anti-CarP </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP, which measures anti-CarP, was developed by the Leiden University Medical Center, and we introduced it as a biomarker-driven RA prognostic test through a distribution agreement with Werfen USA, LLC. with the goal of identifying patients prone to more severe disease. We were the first commercial laboratory to make testing for anti-CarP available in the United States with the introduction of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP in 2018. This test uniquely addresses two major challenges facing rheumatologists today &#8211; (1) patients presenting with RA symptoms but lacking the common confirmatory blood tests for anti-RF or anti-CCP, known as sero-negative patients, and (2) the lack of a serologic indicator, which indicates a poor prognosis and helps guide treatment decisions. Anti-CarP can be positive in up to 26% of RA patients who are negative for anti-CCP. Furthermore, RA patients positive for Anti-CarP have an increased risk for more severe RA disease, including permanent joint damage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> PC4d </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> PC4d, introduced in 2018, reflects over 10 years of research efforts and employs CB-CAPs technology. This CB-CAP biomarker measures platelet-bound C4d (PC4d), and has been shown in clinical studies to have significant association with thrombosis and ischemic stroke in SLE. These thrombotic events can be among the most damaging and deadly forms of lupus flares and often strike without warning. Because of its strong association with thrombosis, we believe AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> PC4d promises to be a valuable tool for SLE disease monitoring. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Monitoring </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> SLE Monitor</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor is a blood test that employs CB-CAPs technology and is intended to assess the condition of a patient that has been diagnosed with SLE. It offers a unique combination of biomarkers that measure for EC4d, which has shown greater accuracy in tracking disease activity than C3 and C4, and PC4d, which is associated with thrombosis risk in SLE. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor offers additional insight into a patient&#8217;s disease activity as well as possible adverse events. Rheumatologists have limited methods for evaluating the extent of disease activity taking place inside the body of an SLE patient. They rely on imperfect biomarkers, overt symptoms or flares and patient reported history, all of which leave the rheumatologists looking for greater insights. In surveys conducted with SLE patients, it has been reported that patients tend to under report their symptoms and many healthcare providers are unaware of this bias. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor demonstrates correlation to SLE disease activity and is therefore designed to enable rheumatologists to effectively assess and optimize therapeutic intervention in patients diagnosed with SLE. Additionally, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor measures EC4d, anti-C1q, C3, C4 and anti-dsDNA which can assist physicians with managing their lupus nephritis patients. Depending on disease severity, our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor testing product may be utilized by patients multiple times a year and throughout their lives. We believe AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor will play an increasingly important role in the management of SLE patients and further solidify the role and relationship of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products for these patients. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> MTX </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MTX is a patented and validated blood test that precisely measures blood levels of MTXPG, the active metabolite of methotrexate linked to disease control in RA patients. There is large variability in the way patients absorb and metabolize methotrexate, leaving rheumatologists unsure of what steps to take when a patient has an inadequate response. Methotrexate is the most widely prescribed drug by rheumatologists in the treatment of RA. Measuring MTXPGs allows rheumatologists to identify patients presenting with inadequate exposure to methotrexate enabling them to optimize dosing and achieve therapeutic levels commensurate with adequate disease control. When faced with a patient who is not responding to methotrexate therapy, the options include increasing the dose, switching to a parenteral delivery method and/or advancing to a more costly biologic therapy. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX provides crucial information as to whether a patient has achieved MTXPG blood levels consistent with an appropriate response to methotrexate, also known as the therapeutic level, or if the MTXPG blood levels are too low to produce adequate effects. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX can allow rheumatologists to make more informed therapeutic decisions in their efforts to optimize methotrexate therapy and give patients their best chance at achieving an optimal response. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> HCQ </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HCQ is a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine (HCQ), in whole blood as they treat patients with SLE and other CTDs, including RA. HCQ is typically prescribed to patients to control SLE disease activity and prevent flares. However, there is large variability in the response to HCQ therapy, the drug can sometimes take weeks or months to have a therapeutic effect and compliance has been documented to be an issue in CTD patients. We believe measuring HCQ makes the patient accountable, and also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">helps to determine whether HCQ blood levels are adequate and consistent with clinical efficacy. The addition of new and costly biologic therapies approved for the treatment of SLE may drive interest by all healthcare stakeholders, especially payors, to adopt an approach that optimizes a generic drug before advancing to a costlier alternative. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Test Reports</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We provide the results of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products in a comprehensive and easy-to-understand test report typically sent to rheumatologists within five business days following receipt of the blood specimen. As shown below, the result of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus portion of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD report displays a gradient illustrating the likelihood of the presence of lupus, which facilitates interpretation and discussion of the result with the patient versus only reporting a numerical value. In addition, all biomarker results for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD are reported and organized by disease state, providing clarity and convenience for the rheumatologists. A sample of the full AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD report is shown below: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CTD Report </span></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20221231_g2.jpg" alt="exdx-20221231_g2.jpg" style="height:879px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20221231_g3.jpg" alt="exdx-20221231_g3.jpg" style="height:894px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Pipeline and Growth Opportunities </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We regularly confer with national experts in the clinical management of rheumatic autoimmune diseases, including RA and lupus, to help guide the organization&#8217;s leadership team on the design and execution of research projects, as well as weigh-in on known and anticipated advances in technologies affecting clinical management of autoimmune diseases. We believe there is significant potential to capitalize on our proprietary technologies by integrating with commercially validated biomarkers to develop testing products with superior clinical utility. The complement pathway is widely implicated in the pathogenesis of a variety of conditions, including autoimmune diseases and organ transplant rejection. We believe that CB-CAPs technology, owing to its stability and reliability, will allow us to produce meaningful and differentiated proprietary solutions for rheumatologists. For example, we are developing assays that we believe may have high diagnostic, prognostic, monitoring and/or therapeutic response value in patients with Lupus, RA and additional autoimmune indications. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> RADR Platform</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RA is estimated to affect approximately 1.5 million patients in the United States and can be difficult to manage due to a well-defined treatment response ceiling for the spectrum of FDA-approved biological treatments for RA. Personalized therapeutic agent selection for RA patients remains a significant unmet need. RA patients often try multiple therapies empirically before they find one that lowers their disease activity. The placement of an RA patient on an ineffective therapy risks progression and worsening of the disease, further damage to the joints, and significant wasted spend on expensive therapeutic agents. There are currently no reliable assays for predicting positive patient response prior to the selection of commonly prescribed biological therapeutic agents. In collaboration with Queen Mary University of London (QMUL), we are aiming to develop a family of patented assays pertaining to RNA expression patterns used in the prediction of patient response to biological therapeutics for RA. The assays utilize minimally invasive synovial tissue biopsies as input, which are then processed for total RNA expression data. The resulting data is then run through proprietary artificial intelligence (AI) developed algorithms that provide actionable insights on predicted biological therapeutic response for RA patients based on an individual patient's RNA expression patterns.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> SLE Monitor (2.0)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SLE is characterized by a chronic, systemic inflammatory burden, and disease progression is defined by the accumulation of irreversible organ damage typically resulting from chronic inflammation and/or chronic corticosteroid use. Among the challenges for rheumatologists responsible for the care of lupus patients is the unpredictability of the disease course defined by periods of waxing and waning episodes of inflammation. The unpredictable nature of SLE and the lack of reliable conventional biomarkers indicative of present and near-term disease activity results in a significant unmet need for a surrogate method to monitor disease activity. Our goal is to leverage clinical and laboratory data collected across multiple longitudinal SLE cohorts to identify a set of biomarkers that can inform an AI-developed algorithm aimed at guiding ongoing treatment decisions throughout the course of a lupus patient&#8217;s journey.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Lupus Nephritis</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lupus nephritis (LN) is an autoimmune disease and a frequent complication in people who have SLE. It causes the immune system to produce proteins called autoantibodies that attack the body's own tissues and organs, including the kidneys. If left untreated, LN can lead to significant health problems, permanent kidney damage and even death. Early diagnosis and treatment are key to managing LN and to preventing it from escalating. Although early onset of LN is not typically noticeable by patients, nearly 40% of SLE patients go on to develop LN. Currently, urinary protein to creatine ratio measurement is the standard means of assessing kidney damage; however, it is not necessarily indicative of kidney prognosis or treatment response. We aim to develop a test for detecting protein analytes in urine that can aid rheumatologists in the ongoing management and risk stratification of patients suffering from lupus nephritis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sales and Marketing </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our specialized sales force is focused on targeting the approximately 4,500 rheumatologists across the United States. Our sales representatives generally have extensive experience in healthcare sales with backgrounds in rheumatology, diagnostics and/or pharmaceutical sales. In addition, our sales representatives complete a comprehensive disease-level sales training program and are required to participate in regular, ongoing training activities and certifications. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our goal is for our sales representative to be viewed as a collaborative resource to the rheumatologists and their practice. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our field-based sales force is organized into 40 territories within the following four regions: West, Central, Northeast and Southeast. Our inside sales force helps further our brand awareness with, and access to, rheumatologists located in rural and outlying areas of the United States. We intend to continue to evaluate our sales force's reach and frequency of interactions with rheumatologists, including as we launch our pipeline products. To further support our promotional efforts, we have a centralized, dedicated client services department with a high level of technical training that augments our specialized sales force and marketing activities. This group enhances sales efficiency and customer satisfaction by providing personalized customer support.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adoption and Growth through Quality Testing and Service </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our focus on quality allows for a dedicated sales approach which entails a commitment to understanding the needs of both provider and patient. Through raising awareness of the benefits AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing provides, our sales team is able to deliver quality testing and support services to providers, and ultimately, their patients. To ensure our marketing and sales efforts are reaching those that we believe could benefit most from AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we emphasize execution in three core areas: targeting, messaging and call frequency. We strategically target the highest-potential practices by utilizing various data sources (e.g., market analytics, demographic data, historical therapeutic usage and diagnostic product trends). Furthermore, we believe the increased access afforded by our testing products will allow for patient-focused messaging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the increased accuracy of our testing products over current standard of care diagnostic methodologies. Finally, we execute a high-frequency promotional strategy for our top-targeted rheumatologists and their office personnel to build knowledge, understanding and retention of the benefits of our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We plan to leverage core channels for building awareness and adoption, including our participation with multiple patient advocacy organizations and medical societies, such as the American College of Rheumatology (ACR). We have also established strong relationships with multiple rheumatology care management organizations (Super Groups), which can be key in influencing favorable reimbursement. Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX testing product has been included in the clinical guidelines for two of these groups. We believe our experience with advancing a testing product from initial development through clinical adoption differentiates us and uniquely positions us to replicate success with our other testing products. Beyond working with these Super Groups, we intend to continue to augment field selling activity with a balanced marketing mix, including print and digital advertising, direct marketing, continuing medical education programs and working with key opinion leaders to support peer-to-peer educational events.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reimbursement, Clinical Validation and Clinical Utility </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reimbursement </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary source of revenue for our products is reimbursement from third-party payors and client bill arrangements. Third-party payors include government payors, such as Medicare and Medicaid, and commercial payors, such as insurance companies. Achieving and maintaining broad coverage and reimbursement of our current products by third-party payors, including Medicare, are key components that contribute to our revenue and financial results. Expanding coverage by government and commercial payors for our commercialized and pipeline tests is and will be important for our future growth. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are actively engaged in efforts to achieve broad commercial coverage and reimbursement for our current and future products, followed by contracting with commercial payors. Achieving positive coverage reduces the need for appeals and reduces failures to collect from the patient&#8217;s insurance. Additionally, achieving in-network contracts with commercial payors can shorten the time required to receive payments. Our approach to commercial payment is centered on impacting our standing in clinical guidelines and individual payor medical policies. We seek to accomplish this through continued evidence development and publication, medical director engagement and individual claim-based appeal efforts, detailed as follows: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt">Meet the evidence standards necessary to be consistent with leading clinical guidelines. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe inclusion in leading clinical guidelines plays a critical role in payors&#8217; coverage decisions. In order to change clinical guidelines, tests must carry a high level of published evidence demonstrating analytical validity, clinical validity, clinical utility and cost-effectiveness. When studies with such evidence are published in peer-reviewed journals, the authors of clinical guidelines may assess the level of evidence and determine whether modifying existing guidelines to include new technology is warranted.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt">Execute an internal managed care policy and claims adjudication function as part of our core business operations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We employ a team of in-house claims processing and reimbursement specialists who work with patients and payors to obtain maximum reimbursement. In parallel, a managed care team collaborates with our reimbursement specialists to ensure our payor outreach strategy reacts to and anticipates the changing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">needs of our customer base. Overall, we work to address payors at the national level in addition to high claim volume regional payors we have identified based on our current territory coverage.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt">Cultivate a network of key opinion leaders. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Key opinion leaders are able to influence clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We collaborate with key opinion leaders early in the development process to ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our testing products to healthcare providers and payors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we have contracts for reimbursement with a limited number of commercial payors, we are actively pursuing additional commercial payor contracts. When we contract to serve as a participating provider, reimbursements are made pursuant to a percentage of our charges or a negotiated fee schedule amount. Where we are not reimbursed in full, or receive a claim denial, for in-network and out-of-network claims, we may elect to appeal the insurer&#8217;s underpayment or denial of payment or seek payment from the patient.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Validation </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We demonstrated the clinical validity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus in a study of 794 patients conducted from 2010 to 2014 across multiple leading academic centers. The primary endpoint of the study was the specificity and sensitivity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus compared to common autoantibodies used to diagnose SLE and other CTDs, such as ANA and anti-dsDNA. The final results of this study showed that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus demonstrated 86% specificity and 80% sensitivity in distinguishing SLE from other CTDs and fibromyalgia, was 33% more specific than ANA (53% specificity/89% sensitivity) and was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We further demonstrated the clinical validity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus for detection of probable SLE (pSLE) in a 246 subject multi-center, prospective, cross-sectional study, first published in the Arthritis &amp; Rheumatology Journal in September 2019. The objective of this study was to evaluate the frequency of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and CB-CAPs as a marker of complement activation in patients with pSLE and the usefulness of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test as a predictor of the evolution of pSLE into classified SLE by the ACR criteria. Of the 92 pSLE patients, more pSLE were positive for CB-CAPs (28%) or AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (40%) than for low complement (9%) at the enrollment visit (p=0.0001, for each) and an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus index score &gt;0.08 prospectively associated with the development from pSLE to SLE by ACR classification criteria within 18 months (hazard ratio = 3.11, p&lt;0.01).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Utility </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have collaborated with both academic and community clinicians to demonstrate the clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus standard diagnostic tests in physician diagnosis, impact on patient management decisions, patient reported outcomes and health economics. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We sponsored a longitudinal, case-control, retrospective review of medical charts in 2016 to assess the value and clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus to rheumatologists. The results of this study were published in the Open Rheumatology Journal in 2016 and suggested that a positive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test aids in the diagnosis of SLE versus standard diagnostic tests. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2018, we initiated CARE for Lupus, a prospective, randomized, multi-site study to assess the performance of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus standard diagnostic laboratory tests (SDLT). A total of 145 patients were enrolled across 32 sites between July 2017 and December 2018, with 73 patients enrolled in the SDLT group and 72 patients in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group. The CARE study was published in September 2019 in Lupus Science &amp; Medicine. Results showed among patients who tested positive for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (n=9), 44% in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group had a higher likelihood of SLE, compared with 9% in the SDLT group (p=0.127), whereas among patients who tested negative for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (n=63), 60% in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group had a lower likelihood of SLE, compared with 37% in the SDLT group (p=0.012). In the group of patients randomized to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group, positive test results associated significantly with initiation of prednisone (p=0.03) and a similar trend was observed with HCQ therapy (p=0.11). Finally, in the group of patients randomized to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group, a positive test result associated with an increase in patient-reported outcomes measuring health-related quality of life using five-level EQ-5D (EQ5D-5L index score) from enrollment to visit 2 (p=0.028), and greater improvements were detectable when compared to the group of patients positive for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and randomized to the SDLT arm (p=0.049).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, a real-world retrospective analysis of patients tested with the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test was published in the journal Lupus Science &amp; Medicine, titled "A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus clinical utility study summary." A cohort of 161 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus tested patients from 12 rheumatology centers across the United States provided clinical outcome data on diagnosis and treatment decisions following AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus testing. The study findings revealed a 7 to 15-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">fold increased risk of Lupus diagnosis in AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus Positive and anti-dsDNA negative patients relative to patients negative for both tests. In addition, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus positive and anti-dsDNA negative patients were at 3 to 4-fold increased odds relative to patients testing negative for both tests of starting a new hydroxychloroquine (cornerstone therapy for Lupus) prescription following AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus testing. Collectively, the study results affirm earlier study findings demonstrating the superior clinical utility and actionability of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus vs. standard diagnostic testing for the differential diagnosis of Lupus. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2022, we announced new, real-world evidence illustrating that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing can enable decisive clinical action in the differential diagnosis of lupus. The "Complement Activation Products vs Standard ANA Testing: Treatment Outcomes, Diagnosis, and Economic Impact in Systemic Lupus Erythematosus" (CAPSTONE) study was the largest comparative utility study in lupus diagnostics and was published in the Journal of Managed Care &amp; Specialty Pharmacy. The study leveraged multiple databases encompassing electronic health records and linked insurance claims data on nearly 50,000 patients tested with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> or standard of care labs from hundreds of rheumatologists across the United States, comparing diagnosis, treatment and cost of care outcomes for new patients tested with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and those tested with a traditional ANA (tANA) approach, including specific autoantibodies. The CAPSTONE study supports that the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test is more clinically effective, both for patients who test positive and those who test negative, as compared to the current standard of care. Important key findings of the CAPSTONE study included, among other things, a: (i) 2x decrease in diagnostic testing costs in the first six-month follow-up period for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus [-] vs. tANA[-]; (ii) 3.5x less frequent repeat testing overall when using AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus vs. tANA; (iii) 6x increased odds of establishing a new SLE diagnosis with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus [+] vs. tANA[+]; and (iv) 3x increased odds of initiating one or more SLE treatments with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus [+] vs. tANA[+]. The CAPSTONE study exemplifies the advantages of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test for patients, providers and payors. Delayed diagnosis leads to increased disease burden and diminished quality of life for the patient relative to the current standard of care. By receiving conclusive results, providers are able to initiate treatment early, reducing the need for more aggressive approaches down the road that can lead to irreversible consequences for the patient. Additionally, a conclusive negative test allows providers to lower the number of repeat tests and follow-up visits which is a critical step for achieving diagnostic clarity for the patient.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Healthcare Economics</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, a study in collaboration with leading health economic experts was published in the journal ACR Open Rheumatology, titled "Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis using a Multivariate Assay Panel (MAP)." This was the first ever evaluation of the economics of diagnosing SLE with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (MAP) compared to standard diagnostic laboratory tests in a hypothetical cohort of 1,000 suspected SLE patients. Over the four-year time horizon, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus demonstrated an estimated total direct cost savings of approximately $2.0 million ($1,991 per patient). In addition, the year one savings was $0.7 million ($655 per eligible patient), with the use of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, which aligns with early benefit to health plans looking for savings in the first year. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Laboratory Operations </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests in our approximately 13,000 square foot laboratory located in Vista, California. Our laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Our laboratory is certified for performance of high-complexity testing by the Centers for Medicare &amp; Medicaid Services (CMS) in accordance with CLIA and is licensed by California and all states requiring out-of-state licensure, including the New York State Department of Health (NYSDOH). Our clinical laboratory typically reports AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product results within five business days. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our existing laboratory facility is adequate to meet our business needs for at least the next 12 months and that additional laboratory space will be available on commercially reasonable terms, if required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Quality Assurance </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quality assurance function oversees the quality of our laboratory operations. We have established oversight for systems implementation and maintenance procedures, document control processes, supplier qualification, preventive or corrective actions and employee training processes that we believe achieves excellence in operations. We continuously monitor and improve our processes and procedures and believe this high-quality service leads to customer satisfaction and retention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal competition for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products is traditional methods used by healthcare providers to test patients with CTD-like symptoms. Such traditional methods include testing for a broad range of diagnostic, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">immunology and chemistry biomarkers, such as ANA and anti-dsDNA, and serum complement biomarkers, such as C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and the Mayo Clinic, all of which have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Rheumatology Diagnostics Laboratories, Inc. (acquired by Laboratory Corporation of America in June 2020). Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Progentec Diagnostics Inc., Scipher Medicine Corporation, Genalyte Inc., Oncimmune plc, DxTerity Diagnostics Inc., AMPEL BioSolutions, and Immunovia AB. In the future, we may also face competition from companies developing new products or technologies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence in diagnostic results; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. We rely upon independent sources for phlebotomy to obtain patient samples; interruptions to this capability could dramatically impact patient access to our tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources; in addition to greater selling and marketing capabilities. Others may develop products with prices lower than ours or have preferred network status that could be viewed by rheumatologists and payors as functionally equivalent to our solution or offer solutions at prices designed to promote market penetration. This could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Agreements with Pharmaceutical Companies </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaboration Agreement with GSK </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2018, we entered into a collaboration agreement with GSK, pursuant to which we provided GSK with our test result data to provide market insight into and help increase awareness on the benefits of an early and accurate diagnosis of SLE. The agreement was amended in November 2018 to, among other things, include data from our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Prognostic and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HCQ testing products and extend the term of the agreement through December 31, 2019. The agreement was further amended in November 2019, November 2020, December 2021 and February 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we were required to deliver weekly de-identified data files to GSK covering all data obtained from the performance of certain AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, subject to applicable requirements under the Federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) internal policy requirements and other applicable laws. During the term of the agreement and amendments through December 31, 2021, the data we provided to GSK could not be provided, directly or through a third party, to any other pharmaceutical company that was marketing or developing a product for the treatment of SLE, however, the February 2022 amendment eliminated that limitation. GSK made a single upfront payment in exchange for the right to receive the applicable data files. In addition, GSK agreed to create a joint steering committee to cooperate with us in order to raise awareness and physician support for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, including through the development and delivery of approved promotional materials and the implementation of a related training plan for each party&#8217;s sales personnel. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This agreement was terminated, effective January 1, 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property Overview </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We strive to protect and enhance the proprietary technologies that we believe are important to our business and seek to obtain and maintain patents for any patentable aspects of our testing products and services and any other inventions that are important to the development of our business. Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, to defend and enforce our patents, to maintain our licenses to use intellectual property owned by third parties, to preserve the confidentiality of our trade secrets and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on continuing technological </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the fields targeted by our testing products and services. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the owner or licensee of a portfolio of patents and patent applications and possess substantial know-how and trade secrets which protect various aspects of our business. The patent families comprising our patent portfolio are primarily focused on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products for the diagnosis, prognosis and monitoring of autoimmune and autoimmune-related diseases, and are generally directed to CB-CAPs, red blood cell MTXPG exposure assessments and anti-MCV antibodies. We intend to leverage the intellectual property surrounding our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products as an important component of our business strategy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Protection for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> Testing Products </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio of patents and patent applications related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products generally relates to three aspects: CB-CAPs, red blood cell MTXPG exposure assessments and anti-MCV antibodies. The patent families which we believe are important for the protection of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are summarized below in the section entitled &#8220;License Agreements.&#8221; As of February 22, 2023, our portfolio primarily consisted of the following:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">CB-CAPs </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the exclusive licensee of five patent families related to CB-CAPs technology from the University of Pittsburgh (UPitt). We expect that these patent families (U.S. Patent Nos. 7,361,517, 7,390,631, 7,585,640, 7,588,905, 8,080,382, and 8,126,654) will expire in 2024 or 2025. A foreign patent corresponding to U.S. Patent No. 7,361,517 has issued in Europe (EP 1,756,571). Foreign patents corresponding to U.S. Patent No. 7,585,640 have issued in Australia (AU 2005242719) and Canada (CA 2,564,492). A foreign patent corresponding to U.S. Patent Nos. 7,588,905 and 8,126,654 has issued in Japan (JP 4550051). We own three issued patents (US 10,132,813, US 11,260,099, and 11,531,033), three pending U.S. nonprovisional patent applications, and seven pending foreign applications that relate to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus products. Foreign patents corresponding to our issued U.S. patent and pending U.S. nonprovisional patent applications have issued in Europe (EP 2,673,644 and EP2972365), China (CN105229470), Japan (JP 5,990,542 and JP6453299) and Hong Kong (HK1192316).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MTX Exposure Assessment Products and Services </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own four patents that relate to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX product and methods for monitoring methotrexate therapy using red blood cell MTXPG exposure assessments. These patents include U.S. Patent Nos. 6,921,667, 7,563,590, 7,582,282 and 7,695,908, which are expected to expire between 2023 and 2027.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Proprietary Rights and Processes </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may rely, in some circumstances, on proprietary technology and processes (including trade secrets) to protect our technology. However, these can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any such breach. In addition, our proprietary technology and processes may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors, contractors or any future collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology and processes, please see &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property.&#8221; </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">License Agreements </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Amended and Restated Exclusive License Agreement with the University of Pittsburgh </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2011, we entered into an amended and restated exclusive license agreement with UPitt, to amend and restate the exclusive license agreement we obtained by our purchase of the medical diagnostics division of Cypress Bioscience, Inc. (Cypress) in 2010 (the Cypress Purchase) and to obtain an exclusive license to UPitt&#8217;s patent rights in certain inventions (the UPitt Patent Rights) related to the use of CB-CAPs technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. The agreement was amended three times, once in May 2012 to, among other things, limit the territory of the license to the United States and exclude certain foreign patents and applications from the agreement, once in September 2013 to add (1) an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">additional U.S. patent to the UPitt Patent Rights licensed under the agreement and (2) the field of monitoring of organ transplantation and organ rejection to the scope of the license, and once in June 2016 to, among other things, clarify the definition of combination products for determining royalties due under the license. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the UPitt Patent Rights in the field of SLE and the field of monitoring of organ transplantation and organ rejection and to sublicense such rights. UPitt retained the right to practice under the UPitt Patent Rights and to use such rights for non-commercial education and research purposes. In addition, this agreement is subject to the rights of the U.S. government, if any, as set forth in 35 U.S.C. &#167;200, et seq. Pursuant to this law, the U.S. government may have acquired a nonexclusive, nontransferable, paid-up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the UPitt Patent Rights throughout the world. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we made certain upfront payments to UPitt on the first and second anniversaries of the agreement that increased on the third and subsequent anniversaries of the agreement until the first sale of products or services utilizing the UPitt Patent Rights. We are required to pay UPitt a low single-digit royalty on net sales of products or services utilizing the UPitt Patent Rights sold by us or our affiliates, subject to minimum annual royalty payments and other adjustment in certain circumstances. We also made a $0.2 million milestone payment to UPitt with the achievement of certain levels of net sales which we met in 2014. Our royalty obligations continue for each licensed product or service on a country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product or service in such country. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the UPitt Patent Rights, we are obligated to pay UPitt a low single-digit percentage sublicense royalty on net sales of products or services sold by our sublicensees that utilize the sublicensed UPitt Patent Rights and a low double-digit percentage of all non-royalty sublicensing income received by us.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the UPitt Patent Rights, and we have agreed to meet certain development and commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. In addition, if we fail to meet a milestone relating to development of the UPitt Patent Rights in the monitoring of organ transplantation and organ rejection field, UPitt may remove that field from our licensed rights. We are currently in compliance with these milestone requirements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may terminate the agreement upon six months&#8217; written notice to UPitt. UPitt may terminate the agreement in the event of our nonperformance of any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exclusive License Agreement with the University of Pittsburgh </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We made an economic decision to cease the maintenance and licensing of UPitt Patent Rights outside the United States, which led to such rights returning to UPitt. We subsequently made the determination to re-license these foreign patent rights from UPitt, but at the time of re-licensing these patent rights, a number of the foreign patent rights had permanently lapsed. Accordingly, in September 2013, we entered into an exclusive license agreement with UPitt to obtain an exclusive license to UPitt&#8217;s remaining ex-U.S. patent rights in certain inventions (the ex-U.S. UPitt Patent Rights) related to the use of CB-CAPs technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the ex-U.S. UPitt Patent Rights in the field of SLE and the field of monitoring of organ transplantation and organ rejection outside of the United States, and to sublicense such rights. UPitt retained the right to practice under the ex-U.S. UPitt Patent Rights and to use such rights for non-commercial education and research purposes. In addition, this agreement is subject to the rights of the U.S. government, if any, as set forth in 35 U.S.C. &#167;200, et seq. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we paid an initial license fee to UPitt. We are also required to pay UPitt a low single-digit royalty on net sales of products or services utilizing the ex-U.S. UPitt Patent Rights sold by us or our affiliates, subject to adjustment in certain circumstances. Our royalty obligations continue for each licensed product or service on a country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product or service in such country. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the ex-U.S. UPitt Patent Rights, we are obligated to pay UPitt a low single-digit percentage sublicense royalty on net sales of products or services sold by our sublicensees that utilize the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sublicensed ex-U.S. UPitt Patent Rights and a low double-digit percentage of all non-royalty sublicensing income received by us. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the ex-U.S. UPitt Patent Rights, and we have agreed to meet certain commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. We are currently in compliance with these milestone requirements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may terminate the agreement upon six months&#8217; written notice to UPitt. UPitt may terminate the agreement in the event of our nonperformance of any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Asset Purchase Agreement with Cypress (Royalty Pharma) and Proprius Pharmaceuticals, Inc.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2010, we completed the Cypress Purchase pursuant to an asset purchase agreement with Cypress and its wholly-owned subsidiary, Proprius Pharmaceuticals, Inc., under which we obtained certain assets related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and services. In 2011, Royalty Pharma Collection Trust (Royalty Pharma), acquired Cypress and became its successor-in-interest under the agreement. In consideration for the acquisition, we made certain initial cash payments to Cypress and we are currently making payments to Royalty Pharma, as a successor-in-interest to Cypress, pursuant to the August 2012 amendment, which payments are subject to acceleration in certain circumstances. Under our agreements with Royalty Pharma, we are required to pay Royalty Pharma a low double-digit royalty on the world-wide net sales of CB-CAPs products and a low double-digit royalty on the net sales of certain new products in each case, for a period of eight years, which eight-year period expired in January 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we are required to make certain one-time contingent milestone payments for two third-party commercial programs, for the launch of a CB-CAPs monitoring assay, and for the achievement of an annual, worldwide net sales level for CB-CAPs products. Our agreement with Royalty Pharma requires that we use commercially reasonable efforts to cause each of the milestones to be achieved. In December 2015, we achieved the specified annual world-wide net sales of CB-CAPs products which required us to make a $2.0 million milestone payment to Royalty Pharma. We paid the applicable $2.0 million milestone payment in 2016. In February 2017, we amended our agreements with Royalty Pharma relating to the launch of a monitoring product using CB-CAPs technology. As a result of this amendment, a prior obligation to make a one-time payment of $1.0 million upon the launch of a monitoring product incorporating CB-CAPs technology was replaced with an agreement to pay Royalty Pharma a one-time payment of $100,000 upon the launch of such a product, plus a 2.5% royalty based on future cash collections from sales of that product which incorporate the licensed technology. Future royalties under this arrangement are limited to the lesser of $1,200,000 (including the upfront payment of $100,000) or the total royalty earned through January 1, 2024. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exclusive License Agreement and Master Research Collaboration Agreement with Allegheny Health Network Research Institute </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, we entered into an exclusive license agreement with Allegheny Health Network Research Institute (AHN), under which we obtained an exclusive, worldwide license to AHN's patent rights in certain inventions (the AHN Patent Rights) related to diagnostics for autoimmune rheumatic diseases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the AHN Patent Rights and to sublicense such rights; provided, however, that any such sublicenses may only be granted with AHN's consent. AHN retained the right to practice under the AHN Patent Rights and to use such rights for teaching, research, education, public service, clinical and other research-related purposes. In addition, the agreement is subject to the rights of the U.S. government with respect to the AHN Patent Rights, including under a funding agreement between AHN and the U.S. government and under the Bayh-Dole Act (35 U.S.C. &#167;200, et seq.). Pursuant to the Bayh-Dole Act, the U.S. government may acquire a nonexclusive, nontransferable, paid-up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the AHN Patent Rights throughout the world.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we paid an initial license fee to AHN to cover past patent expenses and agreed to pay future direct patent costs related to AHN Patent Rights. We are also required to pay AHN a low single-digit royalty on net sales of products utilizing the AHN Patent Rights through the first quarter of 2024 sold by us or our affiliates, subject to adjustment in certain circumstances. Beginning in the second quarter of 2024, we are required to pay AHN an increased low single-digit royalty or a flat annual minimum royalty amount, which royalty obligations continue for each licensed product on a country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product in such country, pending approvals and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">commercialization, or the earlier termination of the agreement (excluding payment obligations accruing prior to such termination).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the AHN Patent Rights, we are obligated to pay AHN a mid-double-digit percentage of any sublicense income, whether in the form of royalties or sub-license fees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the AHN Patent Rights. If, no earlier than May 2023, we elect not to pursue intellectual property rights or expand commercialization to certain territories within a commercially reasonable period, AHN may pursue other licenses and terminate our exclusive license with respect to such territories upon 30 days prior written notice.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may terminate the agreement upon 60 day written notice to AHN provided we pay a specified termination fee. AHN may terminate the agreement in the event of our nonperformance of any of our material obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of insolvency. Absent early termination, the agreement will continue until expiration date of the longest-lived patent right included in the AHN Patent Rights.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we entered into a master research collaboration agreement with AHN, focused on the development of novel patented biomarkers for diagnosis, prognosis and monitoring of autoimmune diseases, including SLE. The agreement has a three-year initial term, expiring May 2024, with renewals thereafter for successive one-year terms upon mutual agreement with AHN. Each party may terminate the agreement upon 60 days' notice to the other party. We are required to pay AHN a collaboration fee of $0.4 million for each year of the agreement and AHN is required to make an in-kind contribution equivalent of $0.3 million for the initial term and each subsequent one-year term, if any.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exclusive License Agreement and Collaboration Agreement with Queen Mary University of London </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, we entered into an exclusive license agreement with QMUL, under which we obtained an exclusive license to QMUL's patent-pending inventions (the QMUL Patent Rights), related to diagnosis and/or development of diagnostic or companion diagnostics for rheumatoid arthritis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the QMUL Patent Rights and to sublicense such rights; provided, however, that any such sublicenses may only be granted with QMUL's consent. QMUL retained the right to practice under the QMUL Patent Rights and to use such rights for teaching, research, education, public service, clinical and other research-related purposes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we paid an initial license fee to QMUL and payment of past patent expenses and ongoing patent expenses. We are required to make a $0.1 million milestone payment upon the first commercial sale of products utilizing the QMUL Patent Rights. In addition, after the first 18 months of commercial sales under the terms of the exclusive license agreement, we are required to pay royalties in the low to high single-digits on net sales of testing products using the assigned patents, pending approvals and commercialization.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the QMUL Patent Rights, we are obligated to pay QMUL a double-digit percentage of sublicensing income, whether in the form of royalties or sub-license fees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the QMUL Patent Rights. QMUL may terminate the agreement if we fail to develop the QMUL Patent Rights in the field of diagnosis and/or development of diagnostic or companion diagnostics for rheumatoid arthritis, QMUL may convert our license to non-exclusive.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may terminate the agreement upon six month written notice to QMUL. QMUL may terminate the agreement in the event of our nonperformance of any of our material obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of insolvency. Absent early termination, the agreement will continue for a period of 20 years after the first commercial sale of any licensed product utilizing the QMUL Patent Rights.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we entered into a collaboration agreement with QMUL for a three-year term, expiring November 2024. The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for RA patients. We or QMUL may terminate the master research collaboration agreement upon 30-day written notice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulations </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Laboratory Improvement Amendments of 1988 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a clinical laboratory, we are required to hold certain federal, state and local licenses, certifications and permits to conduct our business. Under CLIA, we are required to hold a certificate applicable to the type of laboratory tests we perform and to comply with standards applicable to our operations, including test processes, personnel, facilities administration, equipment maintenance, recordkeeping, quality systems and proficiency testing. We must maintain CLIA certification to be eligible to bill for diagnostic services provided to Medicare beneficiaries. Many commercial third-party payors also require CLIA certification as a condition of payment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Vista facility holds a current CLIA certificate. To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. We elect to participate in the accreditation program of CAP. CMS has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of inspection by CMS for CAP-accredited laboratories. Because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA. The regulatory and compliance standards applicable to the testing we perform may change over time, and any such changes could have a material effect on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Penalties for non-compliance with CLIA or CAP requirements include suspension, limitation or revocation of the laboratory&#8217;s CLIA or CAP certificate, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties, as applicable. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">State Laboratory Licensing </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Vista facility also holds a state license issued by the California Department of Public Health (DPH). California law and regulations establish standards for the day-to-day operation of a clinical laboratory, including the training and skills required of laboratory personnel and quality control. In addition, California laws and regulations also mandate proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratory for quality control purposes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we receive specimens from New York, our Vista facility is also required to be licensed by the NYDOH New York laws and regulations establish standards in a variety of operational areas, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">day-to-day operation of the laboratory, including training and skill levels required of laboratory personnel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">physical requirements of a facility;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">equipment; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">validation and quality control.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether such laboratories are located in or outside of New York. If a laboratory is out of compliance with New York's statutory or regulatory standards, the NYDOH, may suspend, limit, revoke or annul the laboratory&#8217;s New York license, censure the holder of the license or assess civil money penalties. Statutory or regulatory noncompliance may result in a laboratory&#8217;s operator being found guilty of a misdemeanor under New York law. New York's law and regulations are more stringent than CLIA in certain respects. For example, NYDOH must approve a laboratory developed test (LDT) before it is offered in New York. We have received written approval from NYDOH to offer our products in New York.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to New York and California, other states, including Maryland, Pennsylvania and Rhode Island, require licensing of out-of-state laboratories under certain circumstances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal Oversight of Laboratory Developed Tests and Certain Devices</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. We perform our tests like AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX assays in our Vista, California clinical laboratory, and they are primarily regulated under CLIA, as administered by CMS, as well as by applicable state laws, as described above. The FDA regulates any diagnostic tests that meet the definition of a medical device, except under specific, narrow circumstances. The Federal Food, Drug and Cosmetic Act (FDCA) defines a medical device as "an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory, which is, among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">other animals and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes." By this definition, in vitro reagents and diagnostic tests are considered medical devices. Specifically, the FDA defines an in vitro diagnostic test (IVD), as "reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae." Therefore, the FDA generally considers diagnostic testing products like ours to be IVDs subject to the agency's regulatory requirements. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, pre-market clearance or approval, marketing and promotion and sales and distribution of medical devices, including IVDs, in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the export of medical devices manufactured in the United States to international markets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDCA classifies medical devices into one of three categories based on the risks associated with the device and the level of control necessary to provide reasonable assurance of safety and effectiveness. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices or devices deemed not substantially equivalent to a previously 510(k) cleared device, are categorized as Class III. These devices typically require submission and approval of a premarket approval application (PMA). Devices deemed to pose lower risk are categorized as either Class I or II. For most Class II devices, a manufacturer must submit to the FDA a 510(k) premarket notification submission requesting clearance of the device for commercial distribution in the United States. Some low-risk Class II devices are exempted from this requirement. When a 510(k) premarket notification submission is required, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the device is "substantially equivalent" to: (i) a device that was legally marketed prior to May 28, 1976, for which PMA approval is not required, (ii) a legally marketed device that has been reclassified from Class III to Class II or Class I, or (iii) another legally marketed, similar device that has been cleared through the 510(k) clearance process. Class II devices may also be subject to special controls such as performance standards, post-market surveillance, FDA guidelines, or particularized labeling. Most Class I devices are exempt from 510(k) premarket notification requirements, but like Class II and III devices, are subject to general controls, such as registration and listing, quality system, labeling, and reporting requirements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After the FDA permits a device to enter commercial distribution, numerous regulatory requirements apply. These include: the Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; labeling regulations; the FDA&#8217;s general prohibition against promoting products for unapproved or "off-label" uses; and the medical device reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. The FDA has broad post-market and regulatory and enforcement powers. Failure to comply with the applicable U.S. medical device regulatory requirements could result in, among other things, warning letters, fines, injunctions, consent decrees, civil penalties, repairs, replacements, refunds, recalls or seizures of products, total or partial suspension of production, the FDA&#8217;s refusal to grant future premarket clearances or approvals, withdrawals or suspensions of current product applications, and criminal prosecution.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the FDA has statutory authority to assure that medical devices, including IVDs, are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable device regulations with respect to IVDs that are designed, manufactured and used within a single high-complexity CLIA-certified laboratory for use only in that laboratory. Such tests are referred to as LDTs. We believe that all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products are LDTs, as are our near-term pipeline candidate tests. As a result, we believe our diagnostic services are currently subject to the FDA&#8217;s enforcement discretion and are not subject to the agency's direct oversight or enforcement of device regulations. However, reagents, instruments, software or components provided by third parties and used to perform LDTs may be subject to regulation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even though we commercialize our tests as LDTs, our tests may in the future become subject to more onerous regulation by the FDA. For several years, members of Congress have been working with stakeholders on a possible bill to regulate in vitro clinical tests including LDTs. Most recently, legislation called the Verifying Accurate, Leading-edge IVCT Development (VALID Act), has been garnering bipartisan and bicameral support. The VALID Act would codify into law the term "in vitro clinical test" (IVCT) to create a new medical product category separate from medical devices that includes products currently regulated as IVDs as well as LDTs. The VALID Act would also create a new system for labs and hospitals to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it takes for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is unclear whether the VALID Act would be passed by Congress in its current form or signed into law by the President. If the FDA finalizes its position on regulation of LDTs through formal notice-and-comment rulemaking, or the VALID Act or other federal legislation is passed reforming the government&#8217;s regulation of LDTs, or alternatively, if the FDA disagrees with our assessment that our tests fall within the definition of an LDT, we could be subject to enforcement of regulatory requirements such as registration and listing requirements, medical device reporting requirements and quality control requirements. Any new legislation or formal FDA regulations affecting LDTs may result in increased regulatory burdens on our ability to continue marketing our tests and to develop and introduce new tests in the future. Additionally, if and when the FDA begins to actively enforce its premarket submission regulations with respect to LDTs generally or our tests in particular, whether as a result of new legislative authority or following formal notice-and-comment rulemaking, we may be required to obtain premarket clearance for our tests under Section 510(k) of the FDCA or approval of a PMA. The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to 12 months, but it can take significantly longer and clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA generally takes from one to three years or even longer and approval is not guaranteed. PMA approval typically requires extensive clinical data and can be significantly longer, more expensive and more uncertain than the 510(k) clearance process. If premarket review is required for some or all of our tests, the FDA could require that we stop selling our products pending clearance or approval and conduct clinical testing prior to making submissions to the FDA to obtain premarket clearance or approval. The FDA could also require that we label our tests as investigational or limit the labeling claims we are permitted to make.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Regulation of Clinical Trials</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have also conducted and may in the future conduct research studies for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests and our other tests in development that involve clinical investigators and human subjects (or stored specimens from human subjects) at sites in the United States. We may need to conduct additional clinical trials for the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests, as well as other tests we may offer in the future, to drive test adoption in the marketplace and reimbursement. Should we not be able to perform these studies, or should their results not provide clinically meaningful data and value for clinicians, adoption of our tests could be impaired and we may not be able to obtain reimbursement for them.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conduct of clinical trials is also subject to extensive federal and institutional regulations intended to assure that the data and reported results are credible and accurate and that the rights, safety, and welfare of study participants are protected. Most studies involving human participants must be reviewed and approved by, and conducted under the auspices of, a duly-constituted institutional review board (IRB), which is a multi-disciplinary committee responsible for reviewing and evaluating the risks and benefits of a clinical trial for participating subjects and monitoring the trial on an ongoing basis. Companies sponsoring the clinical trials and investigators also must comply with, as applicable, regulations, guidelines and IRB requirements for obtaining informed consent from the study subjects, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. The sponsoring company or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. In addition, studies involving human subjects often require significant time and cash resources to complete and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Advertising of Laboratory Services or LDTs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Whether regulated by FDA as Class I or Class II devices or not directly subject to FDA&#8217;s device requirements as LDTs, advertising for our laboratory services and diagnostic testing products is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (FTC), as well as comparable state consumer protection laws. Under the Federal Trade Commission Act (FTC Act), the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal and State Physician Self-Referral Prohibitions</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to similar state law restrictions, such as California&#8217;s Physician Ownership and Referral Act of 1933 (PORA), and other comparable state laws. The Stark Law generally prohibits us from billing Medicare or Medicaid for certain designated health services, including clinical laboratory services, when the physician ordering the service, or any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">member of such physician&#8217;s immediate family, has a financial relationship with us, unless the arrangement meets an exception to the prohibition. A financial relationship can be a compensation arrangement or an ownership or investment interest.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanctions for a Stark Law violation include the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">denial of payment for the services provided in violation of the prohibition;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">refunds of amounts collected in violation of the Stark Law;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">significant civil penalties for each bill or claim for a service arising out of the prohibited referral, and additional penalties for each arrangement or scheme that the parties know (or should know) has the principal purpose of circumventing the Stark Law's prohibition;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the imposition of penalties of up to three times the amounts assessed for each item or service wrongfully claimed; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">possible exclusion from federal healthcare programs, including Medicare and Medicaid.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Stark Law applies regardless of any intent by the parties to induce or reward referrals or the reasons for the financial relationship and the referral. In addition, violations of the Stark Law may also serve as the basis for liability under the federal False Claims Act, which can result in additional civil penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Similarly, PORA makes it unlawful for a physician or certain other healing arts licensees to refer a person for certain healthcare services, including clinical laboratory services, if the licensee has a financial interest with the person or entity that receives the referral, unless an exemption is met. Unlike the Stark Law, PORA applies regardless of the source of payment. PORA also prohibits the submission of claims for services provided pursuant to a prohibited referral, and violation of this prohibition constitutes a public offense and is punishable upon conviction by a fine not exceeding fifteen thousand dollars ($15,000) for each violation and appropriate disciplinary action. Other states also have self-referral restrictions with which we have to comply, some of which differ from those imposed by the Stark Law or PORA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal and State Anti-Kickback Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Federal Anti-Kickback Statute makes it a felony for a person or entity, including a clinical laboratory, to knowingly and willfully offer, pay, solicit or receive any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in order to induce or in return for the referral of an individual for the furnishing of, or the recommending or arranging for the furnishing of, purchasing, leasing, ordering or arranging for or recommending purchasing, leasing or ordering of any item or service that is reimbursable in whole or in part, under any federal healthcare program. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Courts have broadly interpreted of the scope of the Anti-Kickback Statute and generally have held that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to statutory exceptions to the Anti-Kickback Statute, regulations provide for a number of safe harbors. If an arrangement meets the provisions of a safe harbor or exception, it is deemed not to violate the Anti-Kickback Statute, and the parties are immune from prosecution. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to meet the requirements of an exception or the safe harbor does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a case-by-case basis, taking into account all facts and circumstances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A violation of the Anti-Kickback Statute may result in imprisonment for up to ten years and significant fines for each violation and additional administrative civil money penalties, plus up to three times the amount of the remuneration paid. Convictions under the Anti-Kickback Statute result in mandatory exclusion from federal healthcare programs for a minimum of five years. In addition, a violation of the Anti-Kickback Statute can serve as the basis of liability under the federal False Claims Act, which is discussed in greater detail below.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the Anti-Kickback Statute applies only to items and services reimbursable under any federal healthcare program, a number of states, including California, have passed statutes substantially similar to the Anti-Kickback Statute that apply to all third-party payors, including commercial insurers, and, in some states, to patients without insurance. The California Attorney General and courts have interpreted the California anti-kickback and fee-splitting laws in substantially the same way as the courts have interpreted the Anti-Kickback Statute. Penalties under such state laws include imprisonment and significant monetary fines. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in October 2018, the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) was enacted as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. EKRA is an all-payor anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. However, unlike the Anti-Kickback Statute, EKRA is not limited to services covered by federal healthcare programs but applies more broadly to services covered by &#8220;healthcare benefit programs,&#8221; including commercial third-party payors. Although EKRA apparently was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written. Further, certain of EKRA&#8217;s exceptions are inconsistent with the Anti-Kickback Statute and regulations. EKRA permits the U.S. Department of Justice to issue regulations clarifying EKRA&#8217;s exceptions or adding additional exceptions, but such regulations have not yet been issued.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Federal and State Healthcare Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the requirements discussed above, several other healthcare fraud and abuse laws could have an effect on our business. For example, federal law permits the Office of Inspector General for the Department of Health and Human Services to exclude an individual or entity from Medicare or Medicaid for charging federal healthcare programs, including Medicare or Medicaid, substantially in excess of its usual charges for its items or services absent a finding of good cause. The terms &#8220;usual charge&#8221; and &#8220;substantially in excess&#8221; are subject to varying interpretations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal False Claims Act prohibits, among other things, a person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having knowledge of the alleged fraud pursuant to its qui tam provisions. Because the complaint in a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> action is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. Regardless of whether the government intervenes in the action, the relator, if successful, will receive a percentage of the recovery. In addition, providers and suppliers must report and return any overpayments received from the Medicare and Medicaid programs within 60 days of identification, and failure to identify and return such overpayments exposes the provider or supplier to federal False Claims Act liability. Violation of the federal False Claims Act may result payment of up to three times the actual damages sustained by the government, plus significant per-claim civil penalties. Several states, including California, have enacted comparable false claims laws that may apply regardless of payor.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal civil monetary penalties law (the CMP Law) prohibits, among other things, (1) the offering or transfer of remuneration (including a waiver of copayments and deductible amounts) to a Medicare or Medicaid beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies; (2) employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal healthcare program; (3) billing for services requested by an unlicensed physician or an excluded provider; (4) billing for medically unnecessary services; and (5) presenting or causing to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. The penalties for violating the CMP Law may include exclusion, substantial fines, and payment of up to three times the amount billed, depending on the nature of the offense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted, a person who offers or provides to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments, co-insurance and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be held liable under the CMP Law. Moreover, in certain cases, providers who routinely waive amounts owed by federal healthcare program beneficiaries can also be held liable under the Anti-Kickback Statute and the federal False Claims Act. One of the exceptions to the prohibition under the CMP Law covers non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts, and the Anti-Kickback Statute has a safe harbor. The U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG), has emphasized in guidance documents that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud, may also be implicated for similar practices offered to patients covered by commercial payors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal criminal statutes prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including those administered by commercial payors, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, this federal criminal statute requires a showing of intent, but a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Physician Payments Sunshine Act imposes annual reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare providers (such as nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians (as defined under the statute) and their immediate family members. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We cannot assure you, however, that the government will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to applicable state restrictions on laboratory billing. These laws vary from state to state but generally are intended to prevent a provider who ordered but did not perform the service from billing for that service at a markup. For example, California has an anti-markup statute with which we must comply, which prohibits a provider from charging for any laboratory test that it did not perform unless the provider (a) notifies the patient, client or customer of the name, address and charges of the laboratory performing the test, and (b) charges no more than what the provider was charged by the clinical laboratory that performed the test except for any other service actually rendered to the patient by the provider (for example, specimen collection, processing and handling). This provision applies, with certain limited exceptions, to licensed persons such as physicians and clinical laboratories regulated under California&#8217;s Business and Professions Code. A violation of this provision can lead to imprisonment and/or a fine of up to $10,000. Other states have similar anti-markup and other client billing restrictions with which we must comply. Many states also have "direct-bill" laws, which require the party that performed the service to bill for the service, with certain exceptions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our operations are found to be in violation of any of the fraud and abuse laws described above or any other healthcare regulatory laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">International Regulations </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many countries in which we may offer any of our testing products in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national healthcare program. In situations involving physicians employed by state-funded institutions or national healthcare agencies, violation of the local anti-kickback law may also constitute a violation of the U.S. Foreign Corrupt Practices Act (FCPA), and/or other applicable anti-corruption laws. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FCPA prohibits any U.S. individual, business entity or employee of a U.S. business entity from offering or providing, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the SEC to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the FCPA, including its books and records provisions and its anti-bribery provisions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standard of intent and knowledge under the FCPA&#8217;s anti-bribery provisions is minimal intent and knowledge are usually inferred from the fact that bribery took place. The FCPA&#8217;s accounting provisions do not require intent. Violations of the FCPA&#8217;s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2.0 million and officers, directors, stockholders, employees and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other Organisation for Economic Co-Operation and Development Anti-Bribery Convention members, have similar anti-corruption regulations, such as the U.K. Bribery Act. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When marketing our testing products outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our testing products or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Privacy and Security Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">U.S. Data Privacy and Security Laws</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA established comprehensive federal standards for the privacy and security of health information. In 2009, Congress enacted Subtitle D of the Health Information Technology for Economic and Clinical Health Act (HITECH) provisions of the American Recovery and Reinvestment Act of 2009. HITECH amended HIPAA and, among other things, expanded and strengthened HIPAA, created new targets for enforcement, imposed new penalties for noncompliance and established new breach notification requirements. HIPAA applies to health plans, healthcare clearing houses and healthcare providers that conduct certain healthcare transactions electronically (collectively, Covered Entities), as well as individuals or entities that perform services for them involving the use, or disclosure of, individually identifiable health information or "protected health information" (PHI) under HIPAA (Business Associates). Under HIPAA, as amended by the HITECH Act, HHS has issued regulations to protect the privacy and security of PHI used or disclosed by Covered Entities and Business Associates. HIPAA also regulates and standardizes the codes, formats and identifiers used in certain healthcare transactions and standardization of identifiers for health plans and providers, for example insurance billing. Any non-compliance with HIPAA and HITECH and related penalties, could adversely impact our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The HIPAA security standards require the adoption of administrative, physical and technical safeguards and the adoption of written security policies and procedures to maintain the security of protected health information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The HIPAA privacy regulations address the privacy of PHI by limiting the use and release of such information. They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered entity, including the right to access or amend certain records containing PHI, request an accounting of disclosures of PHI or to request restrictions on the use or disclosure of PHI. The HIPAA breach notification regulations impose certain reporting requirements on Covered Entities and their Business Associates in the event of a breach of PHI. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Covered Entities must report breaches of PHI that has not been encrypted or otherwise secured in accordance with guidance from the Secretary of HHS (the Secretary). Breaches must be reported as soon as reasonably practicable, but no later than sixty days following discovery of the breach. Reports must be made to affected individuals, the HHS Secretary, and depending on the size of the breach, the local and national media. Covered Entities like us are also subject to the HHS HIPAA audit program and may be investigated in connection with a privacy or data security complaint.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant civil and criminal fines and other penalties may be imposed for violating HIPAA directly, and in connection with acts or omissions of any agents, including a downstream business associates, as determined according to the federal common law of agency. Civil penalties are adjusted for inflation on an annual basis and can exceed one million dollars per year for failure to comply with a HIPAA requirement. A single breach incident can violate multiple requirements. Additionally, a person who knowingly obtains or discloses PHI in violation of HIPAA may face a criminal penalties (including fines and imprisonment), which increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use PHI for commercial advantage, personal gain or malicious harm. Covered Entities are also subject to enforcement by state Attorneys General who were given authority to enforce HIPAA.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, while HIPAA does not create a private right of action allowing individuals to file suit against us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, to the extent that we submit electronic healthcare claims and payment transactions that do not comply with the transaction standards established under HIPAA and HITECH, payments to us may be delayed or denied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">considered sensitive data that merits stronger safeguards. The FTC and states' Attorneys General have also brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act and comparable state laws.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The HIPAA privacy and security regulations establish a uniform federal "floor" and do not preempt state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI. Certain state laws govern the privacy and security of health-related and other personal information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. The State of California, for example, has implemented comprehensive laws and regulations. The California Confidentiality of Medical Information Act (CMIA), imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. California has also recently adopted the California Consumer Privacy Act of 2018 (CCPA), which went into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. It also creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the law includes limited exceptions, including for PHI maintained by a Covered Entity or Business Associate under HIPAA and medical information maintained by healthcare providers under the CMIA, it may regulate or impact our processing of personal information depending on the context. Further, the California Privacy Rights Act (CPRA) went into effect January 1, 2023 amending the CCPA. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data and expands the application of the CCPA to all human resources personal information of our California-based employees. It also created a new California data protection agency authorized to issue substantive regulations and is expected to result in increased privacy and information security enforcement. In addition to the CCPA, Virginia, Colorado, Connecticut, and Utah all enacted similar omnibus privacy laws that will also take effect in 2023, increasing the complexity of compliance and the risk of failures to comply.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous other federal and state laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information. In addition, Congress and some states are considering new laws and regulations that further protect the privacy and security of medical records or medical information. With the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, all 50 states have passed laws regulating the actions that a business must take if it experiences a data breach, as defined by state law, including prompt disclosure within a specified amount of time to affected individuals. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. Congress has also been considering similar federal legislation relating to data privacy and data protection. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many states, such as Massachusetts, have also implemented genetic testing and privacy laws imposing specific patient consent requirements and requirements for protecting test results. The interplay of federal and state laws regulating genetic information may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on genetic privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Information Blocking Rules</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Office of the National Coordinator for Health Information Technology (ONC), coordinates the ongoing development of standards to enable interoperable health information technology infrastructure nationwide in the healthcare sector. In May 2020, ONC released the final Information Blocking Rule to implement the interoperability and patient access provisions of the 21st Century Cures Act. We will need to continually review our practices for conduct that could be considered as likely to interfere with access, exchange or use of electronic health information, as those practices are prohibited by the Information Blocking Rule, unless one of the exceptions outlined in the Information Blocking Rule applies. Among other things, the Information Blocking Rule requires us to provide patients with on-demand access to laboratory test results. These requirements can be inconsistent with our obligations as a laboratory under state law and/or medical or ethical standards. It is currently unclear how the ONC will approach delays in providing patient access in these situations. Healthcare providers including laboratories will be subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">civil monetary penalties for violations of the Information Blocking Rule once the penalty regulations are finalized. The amount of such penalties is unknown, but the regulations for health industry numbers (HINs), health information exchanges (HIEs), and certified developers of health information technology allow for up to $1.0 million in penalties per violation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GDPR and Foreign Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to foreign privacy laws in the foreign jurisdictions in which we sell our testing products. The interpretation, application and interplay of consumer and health-related data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. In Europe, the General Data Protection Regulation (GDPR) went into full effect in May 2018. The GDPR implements stringent operational requirements for processors and controllers of personal data, including, for example, expanded disclosures about how personal information is collected and used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded) data, mandatory data breach notification requirements, more robust rights for individuals in regard to their personal data and higher standards for controllers to demonstrate that they have obtained valid consent for certain data processing activities. It provides that European Union (EU), and European Economic Area (EEA), member states may make their own further laws and regulations, which may impose further limitations, including in relation to the processing of biometric or health data, which may result in differences between member state laws, limit our ability to use and share personal data, cause our costs to increase and/or harm our business and/or financial condition. Among other requirements, the GDPR also regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and the United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the EU. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR (U.K. GDPR) which, together with the amended U.K. Data Protection Act 2018, retains the GDPR in U.K. national law. The U.K. GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how U.K. data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. In June of 2021, the European Commission granted the United Kingdom an adequacy decision with respect to data transfers under the GDPR. This adequacy decision is expected to last until June 27, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Billing and Government Reimbursement for Clinical Laboratory Services </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Medicare</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare coverage is limited to items and services, within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. With respect to Medicare coverage, Palmetto GBA, the Medicare Administrative Contractor (MAC) responsible for administering Medicare&#8217;s molecular diagnostic services program (MolDX Program), issued a Local Coverage Determination (LCD) that provides coverage for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX test. The MAC responsible for administering Medicare claims submitted by our laboratory, Noridian Healthcare Solutions (Noridian), has adopted Palmetto&#8217;s positive coverage policy, along with a related local coverage article that identifies a unique billing identifier for this test. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Medicare, payment for our laboratory tests are generally made under the Clinical Laboratory Fee Schedule (CLFS) with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act (PAMA), which substantially changed the way in which Medicare sets the payment amounts for clinical laboratory services. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or the Physician Fee Schedule (PFS) are required to report to CMS, beginning in 2017 and every three years thereafter (or annually for "advanced diagnostic laboratory tests"), private payor payment rates and volumes for their tests. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. As required under PAMA, CMS uses the rates and volumes reported by laboratories to develop Medicare payment rates for laboratory tests equal to the volume-weighted median of the private payor payment rates for the tests. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 23, 2016, CMS published the final rule implementing the reporting and rate-setting requirements under PAMA. For tests furnished on or after January 1, 2018, Medicare payments for clinical diagnostic laboratory tests (CDLTs) are based upon these reported private payor rates. For CDLTs, for which there is no comparable existing CDLT, that are assigned a new or substantially revised Current Procedural Terminology (CPT) code, CMS will set the initial payment rates using the gap-fill methodology, as under prior law. Initial payment rates for new advanced </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">diagnostic laboratory tests (ADLTs) will be based on the actual list charge. Any reductions to payment rates resulting from the new methodology are limited to up to 10% per test per year in each of the years 2018 through 2020. As noted below, federal law has delayed implementation of further reductions until 2024, at which time the reduction cap will rise to 15% per test per year. PAMA did not impact Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2022 compared to levels experienced in 2021. Additionally, PAMA and changes to the PFS will not have a significant impact to Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2023 compared to levels experienced in 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 20, 2019, the Further Consolidated Appropriations Act, which included the Laboratory Access for Beneficiaries Act (LAB Act) took effect. The LAB Act delayed by one year the reporting of payment data under PAMA for CDLTs that are not ADLTs until the first quarter of 2021. The CARES Act, which was signed into law on March 27, 2020, delayed the reporting period by an additional year, until the first quarter of 2022. Then, on December 10, 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act, which included a provision that further delayed the next PAMA reporting period for CDLTs that are not ADLTs to January 1, 2023 through March 31, 2023. The Consolidated Appropriations Act, 2023, enacted on December 29, 2022, delayed the next PAMA reporting period to January 1, 2024 through March 31, 2024, which will cover the original data collection period of January 1, 2019 through June 30, 2019. New CLFS rates for CDLTs will be established based on that data beginning in 2025, subject to phase-in limits. As a result, Medicare payment rates determined by data reported in 2017 will continue through December 31, 2024. In addition, under PAMA, as amended, the payment reduction cap will be 15% per test per year in each of the years 2024 through 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PAMA also authorized the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests, as well as ADLTs. The American Medical Association's (AMA) CPT Editorial Panel approved a proposal to create a new section of billing codes called Proprietary Laboratory Analyses (PLA) codes, to facilitate implementation of this section of PAMA. The AMA publishes approved codes on a quarterly basis. We requested a PLA code and in the quarter ended March 31, 2022, CMS agreed, effective April 1, 2022, to recognize a new PLA code for our protein-based test, AVISE&#174; Lupus. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Billing for diagnostic testing can be complicated. Depending on the billing arrangement and applicable law, we must bill various parties, such as commercial payors, Medicare, Medicaid, physicians, hospitals, employer groups and patients, all of which have different billing requirements. Additionally, compliance with applicable laws and regulations as well as internal compliance policies and procedures adds further complexity to the billing process. Changes in laws and regulations could negatively impact our ability to bill our clients or increase our costs. CMS also establishes new procedures and continuously evaluates and implements changes to the reimbursement process for billing government healthcare programs. Missing or incorrect information on test requisitions adds complexity to and slows the billing process, creates backlogs of unbilled tests, and generally increases the aging of accounts receivable and bad debt expense. Failure to timely or correctly bill may lead to our not being reimbursed for our services or an increase in the aging of our accounts receivable, which could adversely affect our results of operations and cash flows. Failure to comply with applicable laws relating to billing federal healthcare programs could also lead to various penalties, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">overpayments and recoupments of reimbursement received;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">exclusion from participation in Medicare/Medicaid programs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">asset forfeitures;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">civil and criminal fines and penalties; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the loss of various licenses, certificates and authorizations necessary to operate our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these penalties or sanctions could have a material adverse effect on our results of operations or cash flows. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Healthcare Reform </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2010, the Affordable Care Act (ACA) was enacted in the United States. The ACA made a number of substantial changes to the way healthcare is financed both by governmental and private payors. Although the ACA included a medical device tax, the tax never went into effect and was fully repealed by Congress with enactment of the 2019 federal spending package signed into law on December 20, 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since the ACA&#8217;s enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and as a result, certain sections of the ACA have not been fully implemented or were effectively repealed. However, following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court (the Supreme Court) upheld the ACA when it dismissed a legal challenge to the ACA&#8217;s constitutionality. Further legislative and regulatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">changes under the ACA remain possible, although the new Democrat-led presidential administration has been taking steps to strengthen the ACA. Future changes or additions to the ACA, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry in the United States. The uncertainty around the future of the ACA, and in particular the impact to reimbursement levels and the number of insured individuals, may lead to delay in the purchasing decisions of our customers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which went into effect on April 1, 2013, and due to subsequent legislative amendments, and the passage of the Consolidated Appropriations Act for 2023, will remain in effect through 2032, unless additional Congressional action is taken. In addition, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to certain providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additional state and federal healthcare reform measures may also be adopted in the future, any of which could have a material adverse effect on the clinical laboratory industry.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Environmental and Other Regulatory Requirements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our laboratory is subject on an ongoing basis to federal, state and local laws and regulations governing the use, storage, handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including chemicals, biological agents and compounds and blood and other tissue specimens. Typically, we use licensed or otherwise qualified outside vendors to dispose of this waste. However, many of these laws and regulations provide for strict liability, holding a party potentially liable without regard to fault or negligence. As a result, we could be held liable for damages and fines if our, or others', business operations or other actions result in contamination of the environment or personal injury due to exposure to hazardous materials. Our costs for complying with these laws and regulations cannot be estimated or predicted and depends on a number of factors, including the amount and nature of waste we produce (which depends in part on the number of tests we perform) and the terms we negotiate with our waste disposal vendors. In 2022, we disposed of all hazardous and/or medical waste that we produced across our entire business through environmentally sound methods.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations are also subject to extensive requirements established by the U.S. Occupational Safety and Health Administration relating to workplace safety for healthcare employees, including requirements to develop and implement programs to protect workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Human Capital</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, we had a total of 204 employees: 199 full-time employees and 5 part-time employees. This includes 52 in laboratory operations, 9 in research and development, 62 in sales and marketing and 76 in general and administrative functions. All of our employees are located in the United States, none of which are represented by a labor union or covered by a collective bargaining agreement. We consider relations with our employees to be good.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize that attracting, motivating and retaining talent at all levels is vital to our continued success. Our employees are a significant asset and we aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, retaining and expanding our workforce, as needed, to support our current pipeline and future business goals. By focusing on employee retention and engagement, we also improve our ability to support our business and operations, our pipeline, and also protect the long-term interests of our securityholders. Our success also depends on our ability to attract, engage and retain a diverse group of employees. Our efforts to recruit and retain a diverse and passionate workforce include providing competitive compensation and benefits packages and efforts to ensure our employees' voices are heard.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We value innovation, passion, data-driven decision making, persistence and honesty, and are building a diverse environment where our employees can thrive and be inspired to make exceptional contributions to bring novel testing products to patients.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, motivating and integrating our existing and future employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees and directors through grants of stock-based compensation awards and payments of cash-based performance bonus awards, in order to increase stockholder value and the success of our company by motivating our employees to perform to the best of their abilities and achieve our objectives. We are committed to providing a competitive and comprehensive benefits package to our employees. Our benefits package </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">provides a balance of protection along with the flexibility to meet the individual health and wellness needs of our employees. We plan to continue to refine our efforts related to optimizing our use of human capital as we grow, including improvements in the way we hire, develop, motivate and retain employees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conduct periodic anonymous employee surveys aimed at measuring the overall satisfaction of our team and make efforts to address issues brought to our attention. The results consistently show that our employees consider their work valuable and meaningful.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information About Our Directors and Executive Officers</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following persons currently serve as the directors and executive officers of Exagen:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors and Executive Officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Executive Officers</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Corporate Secretary</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Hazeltine</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tina Nova, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, CLIA US, Veracyte, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian Birk</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managing Partner, Co-Founder, Sun Mountain Capital</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ana Hooker</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Laboratory Officer, Exact Sciences Corporation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business Officer, Reneo Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ebetual Pallares, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managing Member, Proficio Capital Management, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce Robertson, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managing Director, H.I.G Capital, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frank Stokes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Castle Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James L.L. Tullis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Founder, Tullis Health Investors</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Diversity and Inclusion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our organization recognizes the importance of diversity and inclusion in recruiting, developing and retaining the best available talent. We are committed to further understanding and building upon our diversity and inclusion strengths and are continuing the process of identifying opportunities and developing initiatives.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, 58.6% of our employees identified as female, 37.9% identified as male and 3.5% of our employees identified as other or declined to self-identify. Additionally, 52.4% of our employees identified as White, 22.8% as Hispanic or Latino, 13.3% as Asian, 3.0% as Black or African-American, 2.4% as two or more races (not Hispanic or Latino), 0.6% as Native Hawaiian or other Pacific Islander, and 0.6% as American Indian or Alaska Native. 4.9% of our employees identified as other or declined to self-identify.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Environmental, Social and Governance Matters</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, we undertook a review of our environmental, social and governance (ESG), matters. In 2021, we released our initial Sustainability Report. In 2022, we created an Environmental, Social and Governance Committee (ESG Committee) with the purpose, duties and responsibility of reviewing and recommending our programs, policies and practices relating to ESG issues. The ESG Committee meets formally at least annually and plans to make recommendations to our President and Chief Executive Officer to be presented to the Audit Committee of our Board of Directors. For more information regarding our ESG initiatives, please refer to www.exagen.com/investors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Suppliers </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sole suppliers for the critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We also purchase components used in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Information </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We manage our operations and allocate resources as a single reporting segment. Financial information regarding our operations, assets and liabilities, including our net loss for the years ended December 31, 2022 and 2021 and our total assets as of December 31, 2022 and 2021, is included in our Financial Statements in Item 8 of this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We were incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, we changed our state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which we changed our name to Exagen Diagnostics, Inc. In January 2019, we changed our name to Exagen Inc. Our principal executive offices are located at 1261 Liberty Way, Vista, California 92081. Our telephone number is (760) 560-1501. Our website address is www.exagen.com. The information contained in, or accessible through, our website is not part of, and is not incorporated by reference into, this Annual Report. Investors should not rely on any such information in deciding whether to purchase our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other information with the Securities and Exchange Commission (SEC). Our filings with the SEC are available free of charge on the SEC&#8217;s website at www.sec.gov and on the "Investors" section of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_16"></div><div style="margin-top:21pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1A. Risk Factors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information included in this Annual Report on Form 10-K, including our financial statements and related notes and "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations," before making an investment decision to purchase or sell shares of our common stock. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose part or all of your investment. The risks described below are not the only ones that we may face, and additional risks or uncertainties not known to us or that we currently deem immaterial may also impair our business and future prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary Risk Factors</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the risk factors set forth in this Item 1A:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If third-party payors do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing products, or if we or our partners are unable to successfully negotiate payor contracts, our commercial success could be compromised;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may be unable to manage our growth effectively, which could make it difficult to execute our business strategy;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our commercial success depends on attaining and maintaining significant market acceptance of our testing products among rheumatologists, patients, third-party payors and others in the medical community; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and we may not be able to fund replacements or transition to alternative suppliers;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If our sole clinical laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or other operations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have identified a material weakness in our internal control over financial reporting and determined that our disclosure controls and procedures were ineffective as of December 31, 2022, in connection with the restatement of our financial statements as of and for the three and six months ended June 30, 2022. In the future, we may identify additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in material errors in our financial statements or cause us to fail to meet our period reporting obligations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial penalties;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may be required to modify our business practices, pay fines, incur significant expenses or experience losses due to litigation or governmental investigations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The FDA may disagree with our assessment that our AVISE&#174; test products and any other tests we may develop are LDTs and determine that such test products are medical devices subject to the FDCA and FDA regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to maintain intellectual property protection, our competitive position could be harmed; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Strategy </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses since our inception. For the years ended December&#160;31, 2022 and 2021, we incurred net losses of $47.4 million and $26.9 million, respectively, and we expect to incur additional losses in 2023 and in future years. As of December&#160;31, 2022, we had an accumulated deficit of $255.5 million. Over the next several years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for, our testing products and to develop future testing products. We experienced and may continue to experience decreases in test volumes due to the impact of the COVID-19 pandemic. We may not be able to generate sufficient revenue to achieve and maintain profitability. Our failure to achieve and maintain profitability in the future could cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If third-party payors do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing products, or if we or our partners are unable to successfully negotiate payor contracts, our commercial success could be compromised. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Successful commercialization of our testing products depends, in large part, on the availability of coverage and adequate reimbursement from third-party payors, including government payors, such as Medicare and Medicaid and commercial payors. For the testing products that we develop and commercialize, each third-party payor decides whether to cover the product, the amount it will reimburse for a covered product and the specific conditions for reimbursement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reimbursement by third-party payors may depend on a number of factors, including the payor&#8217;s determination that tests using our technologies are: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not experimental or investigational; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">medically necessary; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">demonstrated to lead to improved patient outcomes; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">appropriate for the specific patient; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">cost-saving or cost-effective; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">supported by peer-reviewed medical journals; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">included in clinical guidelines. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to provide third-party payors with sufficient evidence of the clinical utility and validity of our test, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenue and our ability to succeed. In addition, clinicians may be less likely to order a test unless third-party payors pay a substantial portion of the test price. Therefore, coverage determinations and reimbursement levels and conditions are critical to commercial success, and if we are not able to secure positive coverage determinations and reimbursement levels, our business will be materially adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third-party payors and other entities also conduct technology assessments of new medical tests and devices and provide and/or sell the results of their assessments to other parties. These assessments may be used by third-party payors and healthcare providers as grounds to deny coverage for or refuse to use a test or procedure. In addition, third-party payors have increased their efforts to control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization for the diagnostics industry. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective April 25, 2012, Palmetto GBA, the Medicare MolDx Program, assigned the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX assay a unique identifier and determined that the test meets the applicable Medicare coverage criteria to support dose optimization and therapeutic decision making for patients diagnosed with RA on methotrexate. Our current Medicare Administrative Contractor, Noridian, has adopted this coverage policy. In addition and effective April 1, 2022, CMS agreed to recognize a new PLA code for our protein-based test, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus. Noridian priced this PLA code at $1,085 per test. To determine pricing beyond 2022, CMS recommended crosswalking AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (0312U) to Vectra (81490) at a rate of $840.65 per test. This pricing was finalized on the 2023 CLFS and is effective from January 1, 2023 through December 31, 2025. A pricing determination is not synonymous with a coverage determination. Having a price associated with the PLA code for any particular test does not secure coverage or reimbursement for that PLA code from Medicare or any other third-party payor. So, in an effort to improve transparency regarding Medicare support of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, we submitted a formal request to Noridian for coverage of our AVISE&#174; Lupus test under the new PLA Code. On September 27, 2022, we received notice that Noridian has deemed our application for an LCD to be valid. Ultimately receiving a favorable LCD is uncertain and may be time-consuming, resource intensive and require multiple quarterly or annual periods to complete. We have faced and may again face or continue to face challenges relating to commercial payor claim processing and revenue with our tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other third-party payors make their own decisions as to whether to establish a policy to reimburse our testing products. Because approvals must be sought on a payor by payor basis, establishing broad coverage is a time-consuming and costly process. There are many third-party payors who have not yet established a coverage policy applicable to our testing products. In addition, several commercial payors issued non-coverage policies with respect to AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, determining that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus does not meet the medical criteria for coverage and is considered investigational and/or experimental. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our testing products are reimbursed by a number of third-party payors, we do not currently have contracts with significant private payors. We have in the past, and will likely in the future, experience delays and temporary interruptions in the receipt of payments from third-party payors due to changes in their internal processes, documentation requirements and other issues, which could cause our revenue to fluctuate from period to period. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are not successful in reversing existing non-coverage policies, or if other third-party payors issue negative coverage policies, these policies could have a material adverse effect on our business and operations. Even if many third-party payors currently reimburse for our testing products, such payors may withdraw coverage at any time, review and adjust the rate of reimbursement, require co-payments from patients or stop paying for our testing products altogether, any of which would reduce our revenue. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant majority of our historical revenue has been derived from the sale of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing product, which we commercially launched in 2012. In the near term, we expect to continue to derive a majority of our revenue from sales of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD. We are in various stages of research and development with respect to other testing products that we may offer, but there can be no assurance that we will be able to commercialize these testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The demand for our testing products may decrease or may not continue to increase at historical rates for a number of reasons. In addition, at any point in time we may decide to no longer commercialize any of our testing products for any number of reasons. While we have experienced revenue growth from the sale of our testing products, we may not be able to sustain this growth or maintain existing revenue levels. Further, we cannot ensure the continued availability of our testing products in commercial quantities at acceptable costs. If we are unable to increase sales of our testing products, expand reimbursement for our testing products, or successfully develop and commercialize additional testing products, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be unable to manage our growth effectively, which could make it difficult to execute our business strategy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the need to scale our testing capacity, our future growth plans may also impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees and the need to manage additional relationships with various partners, suppliers and other third parties. In addition, if we were to experience rapid and significant growth, our administrative and operational infrastructure may be strained, requiring us to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. Our ability to manage our business and growth, as well as function as a public company, will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. The time and resources required to optimize these systems is uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our ongoing and future growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our commercial success depends upon attaining and maintaining significant market acceptance of our testing products among rheumatologists, patients, third-party payors and others in the medical community. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends on our ability to continue to develop and market testing products that are recognized and accepted as safe, effective, reliable and cost effective, and any testing product that we offer may not gain or maintain market acceptance among rheumatologists, third-party payors, patients or the medical community. Market acceptance of our testing products depends on a number of factors, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the perceived accuracy of our test results by rheumatologists and patients;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the potential and perceived advantages of our testing products over alternative products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the demonstration of the performance and clinical validity of our testing products in clinical studies, the results of which, may not replicate the positive results from earlier studies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the introduction of new tests that compete with our testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the product cost in relation to alternative products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">publicity concerning our testing products or competing products and treatments;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">relative convenience and ease of administration; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we or our future partners have to withdraw a product from the market, it could harm our business and/or impact market acceptance of our other testing products. Further, our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products consist of various biomarkers, any of which could independently encounter issues with manufacturing, supply or overall quality. If any of the biomarkers in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test were to encounter any issues, we may experience an impact in the overall </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">success of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTD as a whole, including a reduction in average selling price or overall revenue, until such time as it can be remedied. Moreover, if our testing products do not achieve an adequate level of acceptance by rheumatologists, hospitals, third-party payors or patients, we may not generate sufficient revenue from that testing product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our testing products may require significant resources and may never be successful. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may experience limits on our revenue if rheumatologists decide not to order our testing products or if we are otherwise unable to create or maintain demand for our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to create or maintain demand for our testing products in sufficient volume, we may not generate sufficient revenue to become profitable. To generate increased demand, we will need to continue to educate rheumatologists about the benefits of our testing products through publications in peer-reviewed medical journals, presentations at medical conferences and other similar means. For example, in the fourth quarter of 2022, we were featured in nine scientific presentations at the 2022 ACR Annual Conference, ACR Convergence 2022. We will also need to generate demand for our testing products through one-on-one education by our sales force. We also plan to focus on educating patients about the benefits of these testing products, which we believe will be necessary to generate further demand. In addition, our inability to obtain and maintain coverage and adequate reimbursement from third-party payors may limit adoption by rheumatologists, as well as third-party payors exerting pressure on rheumatologists and healthcare providers to order in-network testing products which could adversely affect our revenue.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rheumatologists may rely on guidelines issued by industry groups regarding the diagnosis, prognosis, treatment and monitoring of autoimmune and autoimmune-related diseases, and the monitoring of the effectiveness of therapeutic drugs used to treat such diseases before utilizing any diagnostic test or monitoring solution. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The sizes of the markets for our testing products have not been established with precision, and may be smaller than we estimate. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our estimates of the annual total addressable markets for our current and potential future testing products are based on a number of internal and third-party estimates. These include, without limitation, the number of patients with autoimmune and autoimmune-related diseases and the assumed prices at which we can sell testing products and our partners can sell therapeutics in markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current and potential future testing products may prove to be incorrect. If the actual number of patients who would benefit from our testing products, the price at which we and our partners can sell future testing products, or the annual total addressable market for our testing products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may expend our limited resources to pursue a particular testing product and fail to capitalize on other testing products that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we have limited financial and managerial resources, we focus on specific testing products. As a result, we may forego or delay pursuit of opportunities with others that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. In addition, our spending on current and future research and development programs for testing products may not yield any commercially viable testing products. If we do not accurately evaluate the commercial potential or target market for a potential testing product, we may forego other similar arrangements which would have been more advantageous for us to pursue.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully market and sell our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the extent to which our current testing and future testing products, if any, are eligible for coverage and reimbursement from third-party payors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">public health crises such as the COVID-19 pandemic; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our testing products, which may change from time to time, and our ability to successfully commercialize new testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost of supplies, equipment and materials used for our testing products and laboratory operations, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expenditures that we may incur to acquire, develop or commercialize additional testing products and technologies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the level of demand for our testing products, which may vary significantly; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the receipt, timing and mix of revenue for our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the rate and extent to which payors make an overpayment determination and require us to return all or some portion of payments which we received in a prior period; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and success or failure of competing products, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, it could have a material adverse effect on our business, financial condition and results or operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and we may not be able to find replacements or transition to alternative suppliers. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sole suppliers for critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our testing products. We also purchase components used in our specimen collection and transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for many of these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. We are not a major customer of some of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours. If our suppliers can no longer provide us with the materials we need to perform the tests that comprise our testing products if the materials do not meet our quality specifications, or if we cannot obtain acceptable substitute materials, an interruption in test processing could occur and, in certain circumstances, we may be required to amend or cancel test results we have issued. For example, in November 2019, we identified a potential quality issue with reagents for Anti-CarP, a biomarker that can be ordered with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test that was resolved in September 2020. However, if we are unable to remedy future potential quality issues with unique reagent suppliers, or otherwise find a supplier for future biomarkers with issues, we may experience difficulties obtaining market acceptance for our products. Moreover, any issues with quality may result in a change from time to time of the composition of our tests, including our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTD test, which could impact the average selling price and revenues received from sales of such test.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we should encounter delays or difficulties in securing the quality and quantity of equipment we require for our testing products, we may need to reconfigure our test processes, which could result in an interruption in sales. Any such interruption may significantly affect our future revenue and harm our customer relations and reputation. In addition, in order to mitigate these risks, we may need to maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If demand for our testing products or any of our future testing products or solutions grows, we will need to continue to scale our testing capacity and processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We may also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our testing products. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available. We will also need to purchase additional equipment, some of which can take several months or more to procure, setup and validate, and increase our software and computing capacity to meet increased demand. Failure to implement necessary procedures, transition to new processes, hire the necessary personnel, obtain any necessary additional equipment and increase software and computing capacity could result in higher costs of processing tests or inability to meet demand. There can be no assurance that we will be able to perform our testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations, expand our personnel, equipment, software and computing capacities, or implement process enhancements will be successfully implemented and will not negatively affect the quality of test results. In addition, there can be no assurance that we will have adequate space in our laboratory facility to accommodate such required expansion. We are also currently collaborating with third parties in an effort to implement multiplex technology in our laboratory. We may experience difficulties securing a partner for this technology and integrating such technology into our existing laboratory operations, which could affect our ability to meet demand for our testing products. If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Billing for our testing products is complex, and we must dedicate substantial time and resources to the billing process to be paid for our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Billing for our testing products is complex, time consuming and expensive. Depending on the billing arrangement and applicable law, we bill various third-party payors, including Medicare and Medicaid, and commercial payors, as well as patients, all of which have different billing requirements. We generally bill third-party payors for our testing products and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. We may also face increased risk in our collection efforts, including long collection cycles and potential delays in claims processing, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Several factors contribute to the complexity of the billing process, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences between the list price for our testing products and the reimbursement rates of third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">compliance with complex federal and state regulations related to billing Medicare and Medicaid; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">disputes among third-party payors as to which party is responsible for payment; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences in coverage among third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effect of patient deductibles, co-payments or co-insurance; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences in information and billing requirements among third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes to billing codes used for our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">risk of government audits related to billing; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">incorrect or missing billing information; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the resources required to manage the billing and claims appeals process. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use standard industry billing codes, known as CPT codes, to bill for our testing products. If these codes were to change, there is risk that errors could be made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payor. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment received. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we introduce new testing products, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Payors also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payor makes an overpayment determination, there is a risk that we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">may be required to return all or some portion of prior payments we have received. Additionally, providers and suppliers must report and return overpayments received from the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under the federal False Claims Act. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, from time to time, third-party payors change processes that may affect timely payment. These changes may result in uneven cash flow or impact the timing of revenue recognized with these payors. With respect to payments received from government healthcare programs, factors such as a prolonged government shutdown could cause significant regulatory delays or could result in attempts to reduce payments made to us by federal healthcare programs. In addition, third-party payors may refuse to ultimately make payment if their processes and requirements have not been met on a timely basis. These billing complexities, and the related uncertainty in obtaining payment for our testing products could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, Noridian posted the calendar year 2023 Medicare Physician Fee Schedule (MPFS), and CLFS, which establishes the reimbursement rates to be paid by Medicare for our jurisdiction for services performed on or after January 1, 2023. We do not expect that PAMA or changes to the PFS will have a significant impact to Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2023 compared to levels experienced in 2022. Revenue from Medicare comprised 39% and 19% of our revenue for the years ended December&#160;31, 2022 and 2021, respectively. Revenue from the sale of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing products comprised 84% and 81% of our revenue for the years ended December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also rely on a third-party provider to provide revenue cycle management software systems for certain processing and collection functions. In the past, we have experienced delays in claims processing as a result of our third-party provider making changes to its invoicing system, as well as not submitting claims to payors within the timeframe required. If claims for our testing products are not submitted to payors on a timely basis, or if we are required to switch to a different systems provider, it could have an adverse effect on our revenue and our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At times, we share our proprietary technology and confidential information, including trade secrets, with third parties that conduct studies and other services on our behalf. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain or expand our sales and marketing force, as needed, to adequately address our customers&#8217; and future partners&#8217; needs, our business may be adversely affected. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We sell our testing products through our own specialized sales force. Our testing products compete in a concentrated specialty market of autoimmune and autoimmune-related diseases, and utilizing a specialized sales force is integral to our strategy. As such, we believe it is necessary to maintain a sales force that includes sales representatives with specific technical backgrounds and industry expertise and expect to continue to evaluate the reach and frequency with rheumatologists, including as we launch our pipeline products. We may be required to expand our specialized sales force as our company grows. Training of additional sales representatives can be costly and time consuming, particularly given the level of experience and sophistication we seek in our sales force. If we are unable to effectively retain, train and integrate additional sales representatives, as needed, it may adversely affect our ability to effectively market and sell our testing products. In addition, competition for highly specialized sales personnel is intense, and we may not be able to attract and retain personnel or be able to maintain an efficient and effective sales and marketing force. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future sales will depend in large part on our ability to maintain an effective sales force. If we are unsuccessful in this regard, it could negatively impact our revenue growth and potential profitability. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal competition for our testing products is traditional methods used by healthcare providers to test patients with CTD-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as ANA and anti-dsDNA and serum complement biomarkers, such as C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and the Mayo Clinic, all of which have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Rheumatology Diagnostics Laboratories, Inc. (acquired by Laboratory Corporation of America in June 2020). Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Progentec Diagnostics Inc., Scipher Medicine Corporation, Genalyte Inc., Oncimmune plc, DxTerity Diagnostics Inc., AMPEL BioSolutions, and Immunovia AB. In the future, we may also face competition from companies developing new products or technologies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence in diagnostic results; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by rheumatologists and payors as functionally equivalent to our solution or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To compete successfully we must be able to demonstrate, among other things, that our testing products are accurate and cost effective. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not be able to develop testing products with the clinical utility necessary to be useful and commercially successful. There are certain products for which a commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these products. In order to develop and commercialize testing products, we need to: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expend significant funds to conduct substantial research and development; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conduct successful verification, validation and utility studies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our laboratory processes to accommodate different tests; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">achieve and maintain required regulatory certifications, including the hiring of appropriately licensed laboratory personnel; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">build the commercial infrastructure to market and sell new testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our testing product development process involves a high degree of risk and may take several years. Our testing product development efforts may fail for many reasons, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to identify additional biomarkers to incorporate into our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure or sub-optimal performance of the testing product at the research or development stage;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining patient consent inclusive of genetic analysis;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty in accessing archival patient specimens, especially specimens with known clinical results; or </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure of clinical validation, utility and outcome studies to support the effectiveness of the test. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a testing product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new testing product and our ability to invest in other products in our pipeline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, we completed the conversion of approximately 8,000 square feet of warehouse space into additional clinical laboratory space and approximately 6,000 square feet of warehouse space into additional research and development facility space. In light of our renewed focus on our flagship product, AVISE CTD, and selective approach to research and development projects, we expect to sublet the converted research and development space to a third party and to continue to use the remainder of our existing laboratory space.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as we develop testing products, we may have to make significant investments in product development, marketing and selling resources. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the testing product or product feature that was the subject of the clinical study, which could harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developing new testing products and enhancements to our existing technologies is expensive and time consuming, and there is no assurance that such activities will result in significant new marketable testing products, enhancements to our current technologies, design improvements, cost savings, revenue or other expected benefits. If we spend significant resources on research and development and are unable to generate an adequate return on our investment or divert resources away from other, more attractive growth opportunities, our business and results of operations may be materially and adversely affected. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, we have entered into clinical study collaborations, and our success in the future depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The publication of clinical data in peer-reviewed medical journals is a crucial step in commercializing and obtaining reimbursement for testing products such as ours, and our inability to control when and if results are published may delay or limit our ability to derive sufficient revenue from any solution. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may acquire businesses or assets, form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our business strategy, we may pursue acquisitions of complementary businesses or assets, as well as technology licensing arrangements and other strategic transactions or collaborations with third parties. We also may pursue strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, make investments in other companies or acquire ownership rights to therapeutics that are synergistic with our testing products. To date, other than our acquisition of the medical diagnostics division of Cypress in 2010, we have not acquired other companies or therapeutics and we have limited experience with respect to the formation of strategic alliances and joint ventures. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Integration of an acquired company, business or assets also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To finance any acquisitions or investments, we may choose to issue shares of our stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings or through the issuance of debt. Additional funds may not be available on terms that are favorable to us, or at all, and any debt financing may involve covenants limiting or restricting our ability to take certain actions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize or such strategic alliance, joint venture or acquisition may be prohibited. In addition, our loan agreement restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The diagnostic industry is subject to rapidly changing technology, which could make our current and future testing products obsolete. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry is characterized by rapid technological changes, frequent new product introductions and enhancements and evolving industry standards. These advances require us to continuously develop our technology and work to develop new solutions to keep pace with evolving standards of care. Our testing products could become obsolete unless we continually innovate and expand our testing product offerings to include new clinical applications. If we are unable to develop new testing products or to demonstrate the applicability of our testing products for other diseases, our sales could decline and our competitive position could be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to maintain relationships or build new relationships with key opinion leaders could materially adversely impact our business and prospects. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Key opinion leaders are able to influence clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We rely on key opinion leaders early in the development process to help ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our testing products to healthcare providers and payors. Our failure to maintain or build new relationships with such key opinion leaders could affect rheumatologist and patient perception of our testing products and result in a loss of existing and future customers and therefore materially adversely impact our business and prospects. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are sued for errors and omissions or professional liability, we could face substantial liabilities that exceed our resources. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The marketing, sale and use of our testing products could lead to liability claims if someone were to allege that any such testing product failed to perform as it was designed. We may also be subject to liability for errors in the results we provide to rheumatologists or for a misunderstanding of, or inappropriate reliance upon, the information we provide. We may also be subject to similar types of claims related to testing products we may develop in the future. Any errors or omissions or professional liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain professional liability insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any errors or omissions or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation or cause us to suspend sales of our testing products. Similarly, any product liability lawsuit affecting our partners could also cause injury to our reputation. We may also initiate a correction or removal for one of our testing products, issue a safety alert or undertake a field action or recall to reduce a risk to health posed by potential failure of our products to perform as designed, which could lead to increased costs and lead to increased scrutiny by regulatory authorities and our customers regarding the quality and safety of our testing products and to negative publicity, including safety alerts, press releases or administrative or judicial actions. The occurrence of any of these events could have an adverse effect on our business and results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The loss of members of our senior management team or our inability to attract and retain highly skilled scientists, technicians and salespeople could adversely affect our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends largely on the skills, experience and performance of key members of our executive management team, including John Aballi, our President and Chief Executive Officer, and others in key management positions. The efforts of each of these persons will be critical to us as we continue to develop our technologies and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">test processes and focus on our growth. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists, including licensed clinical laboratory scientists and biostatisticians. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses, particularly in Southern California. Because it is expected that there will be a shortage of clinical laboratory scientists in coming years, it may become more difficult to hire sufficient numbers of qualified personnel. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. Additionally, our success depends on our ability to attract and retain qualified and highly-specialized salespeople. We may have difficulties locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our testing products. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory and sales efforts. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our sole clinical laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently derive all of our revenue from tests conducted at a single laboratory facility located in Vista, California. Vista is situated on or near earthquake fault lines. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters which may be exacerbated due to climate change, including earthquake, fire, flood, power loss, communications failure or terrorism, or public health crises such as the COVID-19 pandemic. In particular, we store all of our flow cytometers, the instrument we use to detect CB-CAPs on cells, at our Vista facility. If all of our flow cytometers were rendered inoperable simultaneously pursuant to a natural or man-made disaster, we would be unable to perform these key tests as we do in the ordinary course of our business. The inability to perform the tests contained in our testing products or to reduce the backlog of analyses that could develop if our facility is inoperable, for even a short period of time, may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. Additionally, we store our bio-repository of specimens, which were collected in collaboration with leading academic institutions and help us to further validate our testing products, at our Vista facility. If these specimens were destroyed pursuant to a natural or man-made disaster or otherwise become unavailable, our ability to develop new testing products may be delayed. Furthermore, our facility and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility or license or transfer our proprietary technology to a third party, particularly in light of the licensure and accreditation requirements for a commercial laboratory like ours. Even in the unlikely event we are able to find a third party with such qualifications to enable us to conduct the tests contained in our testing products, we may be unable to negotiate commercially reasonable terms. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to rely on a third party to perform the tests contained in our testing products (even assuming we are able to do so in compliance with applicable regulations), we would need to engage another facility with established state licensure and CLIA certification under the scope of which tests could be performed following validation and other required procedures. We cannot assure you that we would be able to find another CLIA-certified facility willing to comply with the required procedures, that any such facility would be willing to perform the tests contained in our testing products for us on commercially reasonable terms, or that it would be able to meet our quality standards. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to establish additional clinical reference laboratory facilities, we have to spend considerable time and money securing adequate space, which may include constructing additional facilities, recruiting and training employees, and establishing the additional operational and administrative infrastructure necessary to support a second facility. We may not be able, or it may take considerable time, to replicate our testing processes or results in any new or converted facility. Additionally, any new clinical reference laboratory facility opened by us would be subject to certification under CLIA and licensing by several states, including, as applicable, California and New York, which could take a significant amount of time and result in delays in our ability to begin operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe we have the capacity to meet our projected needs for at least the next 12 months, although we may grow at a rate that is faster than we expect. We may need to further expand our laboratory space in the future. Any future expansion could disrupt laboratory operations, resulting in an inability to meet customer turnaround time expectations, and could be delayed, resulting in slower realization of laboratory efficiencies anticipated from the use of the expanded facilities. Adverse consequences resulting from a delay in the laboratory expansion could harm our relationships with our customers and our reputation, and could affect our ability to generate revenue. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, provide coverage in amounts sufficient to cover our potential losses or continue to be available to us on acceptable terms, if at all. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our testing process involves the use of sophisticated state-of-the-art equipment that requires precise calibration, and issues affecting such equipment may delay delivery or impact the quality of the test results to rheumatologists or otherwise adversely affect our operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our process of determining CB-CAPs, the key biomarker detection and measurement technology incorporated into our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD products, we utilize a number of flow cytometers that require calibration and performance validation according to the requirements of the CAP at specified time intervals. While we believe we have implemented appropriate controls and metrics in our laboratory to meet such requirements, we cannot provide any assurance that our instruments will not fall out of specification, in which case we would be required to re-calibrate them. Failure to timely re-calibrate our instruments could negatively impact the test results, which could result in liability and harm our reputation. Patient specimens degrade and become unusable generally within 48 hours of collection. Therefore, if we do not have other sufficient properly functioning flow cytometers due to failure to meet specifications or they otherwise become inoperable, our ability to process patient specimens in the required timeframe would be compromised and our business could be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information technology and telephone systems are used extensively in virtually all aspects of our business, including laboratory testing, sales, billing, customer service, logistics and management of medical data. The success of our business depends on the ability to obtain, process, analyze, maintain and manage this data. Our management relies on our information systems because: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patient specimens must be received, tracked and processed on a timely basis; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">test results must be reported on a timely basis; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">billings and collections for all customers must be managed efficiently and accurately; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">third-party ancillary billing services require proper tracking and reporting; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pricing and other information related to our services is needed by our sales force and other personnel in a timely manner to conduct business; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patient-identifiable health information must be securely held and kept confidential; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory compliance requires proper tracking and reporting; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">proper recordkeeping is required for operating our business, managing employee compensation and other personnel matters. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business, results of operations and financial condition may be adversely affected if, among other things: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our information technology, telephone or other systems fail or are interrupted for any extended length of time; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">services relating to our information technology, telephone or other systems are not kept current; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our information technology, telephone or other systems do not have the capacity to support expanded operations and increased levels of business; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data is lost or unable to be restored or processed; or </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data is corrupted due to a breach of security. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Despite the precautionary measures we have taken to prevent breakdowns in our information technology, telephone and other systems, sustained or repeated system failures that interrupt our ability to process test orders, deliver test results or perform testing in a timely manner or that cause us to inadvertently disclose or lose patient information could adversely affect our business, results of operations and financial condition. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Security breaches, loss of data and other disruptions to us, our third-party service providers or our partners could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of our business, we and our partners, and our respective third-party service providers collect and store sensitive data, such as PHI (including test results), personally identifiable information and credit card information. We also store business and financial information, intellectual property, research and development information, trade secrets, and other proprietary and business critical information, including that of our customers, payors and third-party partners. We manage and maintain our applications and data utilizing a combination of on-site and vendor-owned systems. We face a number of risks related to our protection of, and our service providers&#8217; protection of, this critical information, including loss of access, unauthorized disclosure and unauthorized access, as well as risks associated with our ability to identify and audit such events and risks associated with the need to reconstruct any lost or stolen data. In addition, we have limited control over the storage of sensitive data by our third-party partners as well as risks related to the transfer and sale of de-identified data files to such partners. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure, and that of our third-party billing and collections provider, may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Additionally, most of our employees have the ability to work remotely, which may increase the risk of security breaches, loss of data and other disruptions as a consequence of more employees accessing sensitive and critical information from remote locations. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. While we do not believe that we have experienced any such attack or breach, if such an event were to occur, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. A security breach or privacy violation that leads to unauthorized access, disclosure or modification of, or prevents access to, patient information, including PHI, could implicate state and federal breach notification laws. Any such access, disclosure or other loss of information could also result in legal claims or proceedings, and liability under laws that protect the privacy of personal information, such as HIPAA, as amended by the HITECH Act, and their implementing regulations including civil and criminal penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payors or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our products and other patient and rheumatologist education and outreach efforts through our website and manage the administrative aspects of our business and could damage our reputation, any of which could adversely affect our business. Any breach could also result in the compromise of our trade secrets and other proprietary information, which could adversely affect our competitive position.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the interpretation and application of federal and state consumer, health-related and data protection laws in the United States are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, as well as private litigation, which could adversely affect our business. Moreover, these laws and their interpretations are constantly evolving and may become more stringent or inclusive over time. For example, increasing concerns about health information privacy have recently prompted the federal government to issue guidance taking a newly expansive view of the scope of the laws and regulations that they enforce. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures in connection with security incidents, we may suffer loss of reputation, financial loss, and civil or criminal fines or other penalties. In addition, these breaches and other forms of inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our financial condition, commercialization efforts and results of operations could be adversely affected by outbreaks of contagious diseases, including the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any outbreak of a contagious disease, such as the COVID-19 pandemic, or other adverse public health developments, could have a material and adverse effect on our business operations. Such adverse effects could include disruptions or restrictions on the ability of our, our collaborators&#8217;, or our suppliers&#8217; personnel to travel, and could result in temporary closures of our facilities or the facilities of our collaborators or suppliers, including our sole laboratory. The extent to which COVID-19 affects our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, additional information that may emerge concerning the severity of COVID-19 and ongoing actions to contain COVID-19 or mitigate its impact, among others, which could have a further adverse effect on our business, financial condition, results of operations, and cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Performance issues, service interruptions or price increases by our shipping carrier could adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide testing services on a timely basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expedited, reliable shipping is essential to our operations. We have been utilizing both United Parcel Service and Federal Express Corporation for reliable and secure point-to-point transport of patient specimens to our laboratory and enhanced tracking of these patient specimens. Should Federal Express, United Parcel Service, or any other carrier we may use in the future, encounter delivery performance issues such as loss, damage or destruction of a specimen, it may be difficult to replace our patient specimens in a timely manner and such occurrences may damage our reputation and lead to decreased utilization from rheumatologists for our testing services and increased cost and expense to our business. In addition, any significant increase in shipping time or disruption to delivery service, whether due to bad weather, natural disaster (which may be exacerbated due to climate change), public health epidemics or pandemics (including, for example, the COVID-19 pandemic), terrorist attacks or threats, or for other reasons, could adversely affect our ability to receive and process patient specimens on a timely basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we, Federal Express, or United Parcel Service were to terminate our relationship, we would be required to find another party to provide expedited, reliable point-to-point transport of our patient specimens. There are only a few other providers of such nationwide transport services, and there can be no assurance that we will be able to enter into arrangements with such other providers on acceptable terms, if at all. Finding a new provider of transport services would be time-consuming and costly and result in delays in our ability to provide our testing services. Even if we were to enter into an arrangement with any such provider, there can be no assurance that they will provide the same level of quality in transport services currently provided to us by Federal Express and United Parcel Service. If any new provider does not provide, or if Federal Express or United Parcel Service does not continue to provide, the required quality and reliability of transport services at the same or similar costs, it could adversely affect our business, reputation, results of operations and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inflation could adversely affect our business and financial results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inflation increased significantly during 2021 and continued to increase through 2022. The current inflationary environment has resulted in higher prices, which have impacted our costs incurred to generate revenue from our laboratory testing services, costs to attract and retain personnel, and other operating costs. The severity and duration of the current inflationary environment remains uncertain and may continue to impact our financial condition and results of operations. Inflation may continue to adversely affect us by increasing the costs of products, materials (including reagents and laboratory supplies), and labor needed to operate our business in future periods. Actions by the government to stimulate the economy may increase the risk of significant inflation, which may have an adverse impact on our business or financial results. Moreover, we may not be able to pass those costs along in the products we sell. As such, inflationary pressures could have a material adverse effect on our performance and financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The failure of financial institutions or transactional counterparties could adversely affect our current and projected business operations and our financial condition and results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 10, 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. A statement by the Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts. Although we do not have any funds deposited with SVB and Signature Bank, we regularly maintain cash balances with other financial institutions in excess of the FDIC insurance limit. A failure of a depository institution to return deposits could impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage-point change (by value) in its equity ownership by &#8220;5-percent shareholders,&#8221; as defined in the Code, over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss (NOL), carryforwards and other pre-change tax attributes to offset its post-change federal taxable income and taxes, as applicable, may be limited. We previously completed a study to assess whether an ownership change, as defined by Section 382 of the Code, had occurred from our formation through December 31, 2019. Based upon this study, we determined that ownership changes had occurred in 2003, 2008, 2012, 2017 and 2019, and that our ability to use a significant portion of our NOL carryforwards is subject to limitation under Section 382 of the Code as a result of a prior ownership change. If we undergo an ownership change as a result of subsequent shifts in our stock ownership, our ability to utilize our NOL carryforwards and other pre-change tax attributes could be further limited by Sections 382 and 383 of the Code. Similar provisions of state tax law may also apply. In addition, federal NOL carryforwards generated in periods after December 31, 2017, may be carried forward indefinitely but, in taxable years beginning after December 31, 2020, may only be used to offset 80% of our taxable income. As a result of the foregoing, if we earn net taxable income, our ability to use NOL carryforwards and other tax attributes to offset taxable income and taxes, as applicable, may be limited. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our term loan contains restrictions that limit our flexibility in operating our business, and if we fail to comply with the covenants and other obligations under our loan agreement, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations. </span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, we entered into the loan and security agreement with Innovatus Life Sciences Lending Fund I, LP (Innovatus), which we subsequently amended in November 2019 and November 2021 (the Amended Loan Agreement). The Amended Loan Agreement is collateralized by substantially all of our personal property, including our intellectual property. The Amended Loan Agreement also subjects us to certain affirmative and negative covenants, including limitations on our ability to transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends, incur additional indebtedness and liens and conduct transactions with affiliates. We are also subject to certain covenants that require us to maintain a minimum liquidity of at least $2.0 million, achieve certain minimum amounts of annual revenue, as measured on a rolling twelve-month basis, periodically deliver financial statements to Innovatus with an unqualified opinion (including no &#8220;going concern&#8221;) from our independent certified public accounting firm, and are required under certain conditions to make mandatory prepayments of outstanding principal. As a result of these covenants, we have certain limitations on the manner in which we can conduct our business, and we may be restricted from engaging in favorable business activities or financing future operations or capital needs until our current debt obligations are paid in full or we obtain the consent of Innovatus, which we may not be able to obtain. As of December&#160;31, 2022, there was $25.0 million in principal outstanding under the term loan and an additional $2.8 million outstanding representing interest at 2.0% per annum payable in-kind by adding the amount to the outstanding principal balance of the term loans. Under the Amended Loan Agreement, we are required to repay any outstanding principal and capitalized interest in monthly installments over a two-year period commencing on December 1, 2024. At December&#160;31, 2022, we were in compliance with all covenants of the Amended Loan Agreement. We cannot be certain that we will be able to generate sufficient cash flow or revenue to meet the financial covenants or pay the principal and accrued interest on our debt. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. An event of default includes, but is not limited to, our failure to pay any amount due and payable under the Amended Loan Agreement, the occurrence of a material adverse change in our business as defined in the Amended Loan Agreement, our breach of any representation or warranty in the Amended Loan Agreement, our breach of any covenant in the Amended Loan Agreement (subject to a cure period in some cases), a change in control as defined in the Amended Loan Agreement, our default on any debt payments to a third party in an amount exceeding $0.5 million or any voluntary or involuntary insolvency proceeding. If an event of default occurs and we are unable to repay amounts due under the Amended Loan Agreement, Innovatus could foreclose on substantially all of our personal property, including our intellectual property. We cannot be certain that future working capital, borrowings or equity financings will be available to repay or refinance our debt to Innovatus or any other debt we may incur in the future. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or other operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe, based on our current plan, that our current cash and cash equivalents and anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. If our available cash balances and anticipated future revenue are insufficient to satisfy our liquidity requirements, including because of lower demand for our testing products or lower-than-expected rates of reimbursement from commercial payors and government payors, or other risks described in this &#8220;Risk Factors&#8221; section, we may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 10, 2020, we filed a shelf registration statement on Form S-3. We filed a prospectus on September 15, 2022 pursuant to this registration statement, registering sales of our common stock in an amount not to exceed $50.0 million, pursuant to a Sales Agreement by and between us and Cowen and Company, LLC (the Sales Agreement). Using a shelf registration statement to raise capital generally takes less time and is less expensive than other means, such as conducting an offering under a registration statement on Form S-1 and companies may be able to receive more favorable terms by raising capital pursuant to a shelf registration statement on Form S-3. Our ability to raise capital under our current shelf registration statement (and any future registration statement on Form S-3) is, and may again in the future be, limited by, among other things, current and future SEC rules and regulations impacting the eligibility of smaller companies to use Form S-3 without restrictions. As of the date of this Annual Report, we are subject to the "baby shelf rule" because the market value of our outstanding shares of common stock held by non-affiliates, or public float, was less than $75.0 million as of the date of this Annual Report. As a result, for sales following the date of this Annual Report and until we again have a public float with a value in excess of $75.0 million, if ever, we will be unable to use our shelf registration statement on Form S-3 or the Sales Agreement to raise additional funds to the extent the aggregate market value of securities sold by us or on our behalf pursuant to Instruction I.B.6. of Form S-3 during the 12 calendar months immediately prior to, and including, any intended sale does not exceed one-third of the aggregate market value of our public float, calculated in accordance with the instructions to Form S-3.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the case of the incurrence of further indebtedness, the Amended Loan Agreement, subject to certain customary exceptions, restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus. Under the Amended Loan Agreement, we are required to make monthly interest payments at a rate equal to 8.0% (provided that 2.0% of the 8.0% is payable in-kind by adding the amount to the outstanding principal balance of the term loans). We may also consider raising additional capital in the future to expand our business, pursue strategic investments, take advantage of financing opportunities, or for other reasons. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The timing and amounts of our future capital requirements are difficult to forecast and will depend on numerous factors, including: our ability to maintain and grow sales of our testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our testing products and support reimbursement efforts; fluctuations in working capital; the costs to expand our sales and marketing capabilities; the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies; the additional costs we may incur as a result of operating as a public company and the extent to which we in-license, acquire or invest in complementary businesses or products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our stockholders could result, and the market price of our common stock could decline. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, our Amended Loan Agreement restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus, subject to certain exceptions. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our testing products or market development programs, which could lower the economic value of those products or programs to our company. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have identified a material weakness in our internal control over financial reporting and determined that our disclosure controls and procedures were ineffective as of December&#160;31, 2022, in connection with the restatement of our financial statements as of and for the three and six months ended June 30, 2022. In the future, we may identify additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in material errors in our financial statements or cause us to fail to meet our period reporting obligations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time period specified in the SEC&#8217;s rules and forms, and that the information required to be disclosed by us in such reports is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 13, 2022, management and the audit committee of our board of directors determined that we made certain errors in revenue resulting from erroneous and duplicate billings related to changes in billing practices. The errors were due to the inadequate design and implementation and precision of internal controls and procedures to evaluate and monitor the accounting for revenue recognition. As a result, revenue and accounts receivable were overstated and other liabilities was understated for the quarter and year to date periods ended June 30, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We then determined that there were material errors in the financial statements requiring a restatement of the Form 10-Q for the three and six months ended June 30, 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, management has determined that this control deficiency constituted a material weakness and, as a result, management has concluded that, as of December&#160;31, 2022, our internal control over financial reporting was not effective based on the criteria in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control Integrated Framework (2013) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management is actively engaged in the implementation of remediation efforts to address the material weakness. The remediation plan includes: (i) evaluating the staffing level, skills and qualification of accounting department personnel, (ii) enhancement of our existing control structure and processes for revenue recognition and (iii) improving the detailed review process of our revenue recognition models. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are not able to comply with the applicable requirements of the Sarbanes-Oxley Act of 2002 or if we are unable to maintain effective internal control over financial reporting, we may not be able to produce timely and accurate financial statements or guarantee that information required to be disclosed by us in the reports that we file with the SEC, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Any failure of our internal control over financial reporting or disclosure controls and procedures could cause our investors to lose confidence in our publicly reported information, cause the market price of our stock to decline, expose us to sanctions or investigations by the SEC or other regulatory authorities, or impact our results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Regulatory and Compliance Matters </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthcare policy changes, including recently enacted and proposed new legislation reforming the U.S. healthcare system, could cause significant harm to our business, operations and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA made a number of substantial changes to the way healthcare is financed both by governmental and commercial payors. The ACA also introduced mechanisms to reduce the per capita rate of growth in Medicare spending if expenditures exceed certain targets. Any such reductions could affect reimbursement payments for our tests.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2014, Congress passed PAMA, which included substantial changes to the way in which clinical laboratory services are paid under the CLFS. Under PAMA, certain clinical laboratories are required to periodically report to CMS private payor payment rates and volumes for their tests, and laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. Medicare reimbursement for CDLTs is based on the weighted-median of the payments made by private payors for these tests, rendering private payor payment levels even more significant than in the past. As a result, future Medicare payments may fluctuate more often and become subject to the willingness of private payors to recognize the value of diagnostic tests generally and any given test individually. The impact of this payment system on rates for our tests, including any current or future tests we may develop, is uncertain.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict whether or when these or other recently enacted healthcare initiatives will be implemented at the federal or state level or how any such legislation or regulation may affect us. For instance, the payment reductions imposed by the ACA and the changes to reimbursement amounts paid by Medicare for tests such as ours based on the procedure set forth in PAMA, could limit the prices we will be able to charge or the amount of available reimbursement for our tests, which would reduce our revenue. Additionally, these healthcare policy changes could be amended or additional healthcare initiatives could be implemented in the future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, the impact on our business of the expansion of the federal and state governments&#8217; role in the U.S. healthcare industry generally, including the social, governmental and other pressures to reduce healthcare costs while expanding individual benefits, is uncertain. Any future changes or initiatives could have a materially adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of accreditation under CLIA because we are accredited to perform testing by CAP. To renew this certificate, we are subject to survey and inspection every two years. Moreover, inspectors from CMS or CAP may make random inspections of our clinical reference laboratory. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we are required to hold a certificate of accreditation or compliance under CLIA that allows us to perform high complexity testing, we are not required to hold a certificate of accreditation through CAP. We could alternatively maintain a certificate of accreditation from another accrediting organization or a certificate of compliance through inspection by surveyors acting on behalf of the CLIA program. If our accreditation under CAP were to terminate, either voluntarily or involuntarily, we would need to convert our certification under CLIA to a certificate of compliance (or to a certificate of accreditation with another accreditation organization) in order to maintain our ability to perform clinical testing and to continue commercial operations. Whether we would be able to successfully maintain operations through either of these alternatives would depend upon the facts and circumstances surrounding termination of our CAP accreditation, such as whether any deficiencies were identified by CAP as the basis for termination and, if so, whether these were addressed to the satisfaction of the surveyors for the CLIA program (or another accrediting organization). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of accreditation, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for tests provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also required to maintain a license to conduct testing in California. California laws establish standards for day-to-day operation of our clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, our clinical reference laboratory is licensed on a product-specific basis by New York as an out of state laboratory and our testing products, as LDTs, must be approved by the NYSDOH on a product-by-product basis before they are offered in New York. We are also subject to periodic inspection by the NYSDOH and required to demonstrate ongoing compliance with NYSDOH regulations and standards. To the extent NYSDOH identified any non-compliance and we are unable to implement satisfactory corrective actions to remedy such non-compliance, the State of New York could withdraw approval for our testing products. New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether or not such laboratories are located in New York. Moreover, several other states require that we hold licenses to test specimens from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patients in those states. Other states may have similar requirements or may adopt similar requirements in the future. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we were to lose our CLIA accreditation or California license, whether as a result of a revocation, suspension or limitation, we would no longer be able to sell our testing products, which would limit our revenue and harm our business. If we were to lose our license or fail to obtain or maintain NYSDOH approval for our laboratory developed tests in New York or if we were to lose our license in other states where we are required to hold licenses, we would not be able to test specimens from those states, which would limit our revenue.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry and our operations are heavily regulated by various federal, state, local and foreign laws and regulations, and the regulatory environment in which we operate could change significantly and adversely in the future. These laws and regulations currently include, among others:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">CLIA&#8217;s and CAP&#8217;s regulation of our laboratory activities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">FDA laws and regulations, including but not limited to requirements for offering LDTs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">federal and state laws and standards affecting reimbursement by government payors, including certain coding requirements to obtain reimbursement and certain payment mechanisms for clinical laboratory services resulting from PAMA;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">HIPAA and HITECH, which establish comprehensive federal standards with respect to the privacy and security of PHI, and requirements for the use of certain standardized electronic transactions with respect to transmission of such information, as well as similar laws protecting other types of personal information;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">state laws governing the maintenance of personally identifiable information of state residents, including medical information, and which impose varying breach notification requirements, some of which allow private rights of action by individuals for violations and also impose penalties for such violations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Anti-Kickback Statute, which generally prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in return for or to induce a person to refer to an individual any good, facility, item or service that is reimbursable under a federal healthcare program;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Stark Law, which generally prohibits a physician from making a referral for certain designated health services covered by Medicare or Medicaid, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal False Claims Act, which imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Civil Monetary Penalties Law, which generally prohibits, among other things, the offering or transfer of remuneration to a Medicare or Medicaid beneficiary if it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or Medicaid; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">EKRA, which imposes criminal penalties for knowing and willful payment or offer, or solicitation or receipt, of any remuneration, whether directly or indirectly, overtly or covertly, in cash or in kind, in exchange for the referral or inducement of laboratory testing (among other healthcare services) covered by healthcare benefit programs (including commercial insurers) unless a specific exception applies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ACA, which, among other things, establishes a requirement for providers and suppliers to report and return any overpayments received from the Medicare and Medicaid programs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, insurance fraud laws, anti-markup laws, prohibitions on the provision of tests at no or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">discounted cost to induce physician or patient adoption and false claims acts, some of which may extend to services reimbursable by any third-party payor, including private payors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the prohibition on reassignment of Medicare claims and other Medicare and Medicaid billing and coverage requirements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">state laws that prohibit other specified healthcare practices, such as billing physicians for tests that they order, waiving coinsurance, copayments, deductibles and other amounts owed by patients, business corporations practicing medicine or employing or engaging physicians to practice medicine and billing a state Medicaid program at a price that is higher than what is charged to one or more other payors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the FCPA, and applicable foreign anti-bribery laws;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste and workplace safety for healthcare employees;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">laws and regulations relating to health and safety, labor and employment, public reporting, taxation and other areas applicable to businesses generally, all of which are subject to change, including, for example, the significant changes to the taxation of business entities were enacted in December 2017; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">similar foreign laws and regulations that apply to us in the countries in which we operate or may operate in the future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any future growth of our business, including, in particular, continued reliance on consultants, commercial partners and other third parties, may increase the potential for violating these laws. In some cases, our risk of violating these or other laws and regulations is further increased because of the lack of their complete interpretation by applicable regulatory authorities or courts, and their provisions are thus open to a variety of interpretations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have adopted policies and procedures designed to comply with these laws and regulations and, in the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance is also subject to review by applicable government agencies. However, these laws and regulations are subject to change and additional interpretation and guidance from regulatory authorities. For instance, in April 2022, the HHS OIG issued a new advisory opinion indicating that a particular clinical laboratory&#8217;s practice of contracting with hospitals for the collection of samples for testing could, based on the facts provided and assuming the requisite intent, be a violation of the federal Anti-Kickback Statute. If this Advisory Opinion ultimately limits our ability to collect samples in a hospital setting, we may be required to contract for sample collection with other collection sites or sources, such as mobile phlebotomists, that could be more expensive and less convenient for patients, which could adversely affect both demand for our tests and the margins and profitability of our tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Given the complexity of these existing and changing rules and regulations, it is not always possible to identify and deter misconduct by employees, distributors, consultants and commercial partners and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with applicable laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#8217;s attention from the operation of our business and harm our reputation. If our operations, including the conduct of our employees, consultants and commercial partners, are found to be in violation of any of these laws and regulations, we may be subject to applicable penalties associated with the violation, including administrative, civil and criminal penalties, damages, fines, individual imprisonment, exclusion from participation in federal healthcare programs, refunding of payments received by us and curtailment or cessation of our operations. Any of these consequences could seriously harm our business and our financial results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with these laws may prove costly. If we or our operations, or any of the rheumatologists or entities with whom we do business are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and/or criminal penalties, damages, fines, disgorgement, individual imprisonment, exclusion </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">from participation in U.S. federal or state healthcare programs, such as Medicare and Medicaid, and similar programs outside the United States, a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. To the extent that any of our testing products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be required to modify our business practices, pay fines, incur significant expenses or experience losses due to litigation or governmental investigations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time and in the ordinary course of our business, we have been and may be subject to litigation or governmental investigation on a variety of matters in the United States or foreign jurisdictions, including, without limitation, regulatory, intellectual property, product liability, antitrust, consumer, false claims, whistleblower, Qui Tam, privacy, anti-kickback, anti-bribery, environmental, commercial, securities and employment litigation and claims and other legal proceedings that may arise from the conduct of our business. Our activities relating to our products and services are subject to extensive regulation in the United States and foreign jurisdictions. Like many companies in our industry, we have in the ordinary course of business received inquiries, subpoenas, civil investigative demands, and other types of information requests from government authorities. For example, in February 2022, we received a subpoena issued by the U.S. Department of Justice requesting documents related to its investigation of potential federal regulatory healthcare offenses. We are fully cooperating with the U.S. Department of Justice to promptly respond to the requests for information in this subpoena, but we cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact on our business which may ultimately be greater than we expect. In addition, responding to this subpoena, and any litigation or government investigation generally, diverts the attention of our management team and diverts resources from our core business. As such, the time and attention of our management team in responding to these matters may limit their time available to devote to our business, and we may also incur significant expenses or experience losses in relation to these matters. As a result of these matters, we may also be required to alter the conduct of our operations or pay penalties. Any of these circumstances may adversely affect our business, prospects, reputation and results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The FDA may disagree with our assessment that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> test products and any other tests we may develop are LDTs and determine that such test products are medical devices subject to the FDCA and FDA regulations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA regulates any diagnostic test that meets the definition of a medical device, except under specific, narrow circumstances. The FDCA defines a medical device as &#8220;an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is , among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes.&#8221; By this definition, in vitro reagents and diagnostic tests are considered medical devices. Specifically, the FDA defines an IVD as &#8220;reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae.&#8221; Therefore, the FDA generally considers diagnostic testing products to be IVDs subject to the agency&#8217;s regulatory requirements for IVDs. However, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to LDTs, which are IVDs that are designed, manufactured, and used within a single high-complexity CLIA-certified laboratory for use only in that laboratory. We believe that all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products are LDTs, as are our near-term pipeline candidate tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the FDA were to disagree with our conclusion that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products fall within the scope of the agency&#8217;s LDT definition and determines that the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests are thus subject to FDA&#8217;s medical device authorities and implementing regulations, we would become subject to extensive regulatory requirements and may be required to stop selling our existing tests or refrain from launching any other tests we may develop. In particular, the FDA may require us to obtain PMAs or another type of device marketing authorization in order for us to commercialize our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests. The premarket review process for diagnostic testing products can be lengthy, expensive, time-consuming, and unpredictable. As part of the process to prepare regulatory submissions for FDA review, we may be required to conduct formal clinical trials before applying for commercial marketing authorization. Performing additional, new nonclinical studies or clinical trials in order to obtain product approval from the FDA, if any were to become necessary, would take a significant amount of time and would substantially delay our ability to commercialize our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests, all of which would adversely impact our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA with respect to LDTs, we cannot assure you that the FDA will agree with our determination. Any finding by the FDA or another regulatory authority that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The FDA may undertake rulemaking to regulate LDTs or Congress may reform the current legal requirements applicable to LDTs, in which case we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may develop, which may increase the cost of conducting, or otherwise harm, our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests as LDTs and may in the future market other tests as LDTs. The FDA has adopted a policy of enforcement discretion with respect to LDTs whereby the FDA does not generally actively enforce its regulatory requirements for such tests. However, in the past the FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs. If there are changes in FDA regulations and legislative authorities such that the agency begins to exercise oversight over LDTs, we may become subject to extensive regulatory requirements and may be required to stop selling our existing tests or launching any other tests we may develop and to conduct additional clinical trials or take other actions prior to continuing to market our tests. If the FDA allows our tests to remain on the market but there is uncertainty about our tests, if they are labeled investigational by the FDA or if labeling claims the FDA allows us to make do not include the claims necessary or desirable for successful commercialization, orders from healthcare providers or reimbursement for our tests may decline.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since 2017, Congress has been working on legislation to create an LDT and IVD, regulatory framework that would be separate and distinct from the existing medical device regulatory framework.  Most recently, the VALID Act has been garnering bipartisan and bicameral support. The VALID Act would codify the term IVCT to create a new medical product category separate from medical devices that includes products currently regulated as IVDs as well as LDTs, among other provisions. The VALID Act would also create a new system for laboratories to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it would take for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If Congress were to pass the VALID Act or any other legislation applicable to the FDA&#8217;s regulation of LDTs, we will likely be subject to increased regulatory burdens such as registration and listing requirements, adverse event reporting requirements and quality control requirements. Any legislation or formal FDA regulatory framework affecting LDTs is also likely to have premarket application requirements prohibiting commercialization without FDA authorization and controls regarding modification to the tests that may require further FDA submissions. The premarket review process can be lengthy, expensive, time-consuming and unpredictable. Further, obtaining premarket clearance may involve, among other things, successfully completing clinical trials, which require significant time and cash resources and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results. If we are required to obtain premarket clearance or approval and/or conduct premarket clinical trials, our development costs could significantly increase, marketing of any new tests we may develop may be delayed, and sales of our existing tests could be interrupted or stopped. Any of these outcomes could reduce our revenue or increase our costs and materially adversely affect our business, prospects, results of operations or financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The outcome and ultimate impact on our business of any changes to the federal government&#8217;s regulation of LDTs is difficult to predict. Failure to comply with any applicable FDA requirements could trigger a range of enforcement actions, including warning letters, fines, penalties, suspension of operations, product recalls or seizures, denial of applications for clearance or approval, injunctions and other civil or criminal sanctions, which could have a material and adverse effect upon our business, operating results and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, should it be required in the future, we cannot be sure that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests, or any new tests that we may develop, will be reviewed and authorized for marketing by the FDA in a timely or cost-effective manner, if authorized at all. Even if such tests are authorized for marketing by the FDA, the agency could limit the test&#8217;s indications for use, which may significantly limit the market for that product and may adversely affect our business and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">FDA regulation of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> RADR test could be disruptive to our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described further above, the FDA has long claimed authority to regulate LDTs but has exercised its enforcement discretion to limit enforcement of IVD regulatory requirements on this category of products. However, the FDA has </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">from time to time appeared to increase its attention to the marketing of pharmacogenetic tests. For example, in late 2018, the FDA issued a safety communication regarding &#8220;genetic tests that claim results can be used to help physicians identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications.&#8221; This safety communication explained that the FDA had reached out to several firms marketing such pharmacogenetic tests where the FDA believed the relationship between genetic variations and a medication&#8217;s effects had not been established, including a warning letter to Inova Genomics Laboratory. More recently, in April 2022, a safety communication from the FDA warned patients and providers about the risks of false results with genetic non-invasive prenatal screening tests, which it noted have not been authorized, cleared, or approved by the agency via one of the medical device premarket pathways. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> RADR test, one of our pipeline programs we are currently developing in collaboration with QMUL, may be considered by FDA to be a pharmacogenetic test because it involves the analysis of total RNA expression data from an individual RA patient through an algorithm to predict the patient&#8217;s biological therapeutic response.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to various public letters from the national laboratory trade association and patient groups, on February 20, 2020, the FDA announced a new &#8220;collaboration between FDA&#8217;s Center for Devices and Radiological Health and Center for Drug Evaluation and Research intended to provide the agency&#8217;s view of the state of the current science in pharmacogenetics.&#8221; Although the announcement again asserted that some of pharmacogenetic test offerings may pose significant risks to patients, the agency also acknowledged that pharmacogenetic testing &#8220;offers promise for informing the selection or dosing of some medications for certain individuals.&#8221; In conjunction with the announcement, the FDA also released an updated &#8220;Table of Pharmacogenetic Associations,&#8221; which lists gene-drug interactions that the agency believes are supported by FDA-approved drug labeling and/or &#8220;sufficient scientific evidence based on published literature.&#8221; The table has been updated periodically since that time. While these developments may signal a positive shift in the FDA&#8217;s approach to regulating pharmacogenetic tests, we cannot predict with certainty the outcome of this matter or its timing, or whether FDA may object to the ultimate form of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> RADR product candidate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The FTC and/or state enforcement or regulatory agencies may object to the methods and materials we use to promote our tests and initiate enforcement against us, which could adversely affect our business and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FTC and/or state enforcement or regulatory agencies (including but not limited to the offices of state attorneys general) may object to the materials and methods we use to promote our current tests or other LDTs we may develop in the future, including with respect to the product claims in our promotional materials, and may initiate enforcement actions against us. Enforcement actions by the FTC may include, among others, injunctions, civil penalties and equitable monetary relief.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure or perceived failure by us to comply with federal or state laws or regulations, our internal policies and procedures or our contracts governing our use and disclosures of personal information could result in negative publicity, government investigations and enforcement actions including significant penalties, claims by third parties, and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to comply with HIPAA, the HITECH Act, their implementing regulations and similar comparable state laws and regulations affecting the transmission, security and privacy of health information could result in significant penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous federal, state and foreign laws and regulations, including HIPAA and the HITECH Act, govern the collection, dissemination, disclosure, security, use and confidentiality of individually identifiable health information health-related and other personal information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of PHI within our company and with third-parties. The privacy, security and breach notification rules promulgated under HIPAA, as amended by the HITECH Act, Standards for Privacy of Individually Identifiable Health Information (Privacy Standards) and the Security Standards for the Protection of Electronic Protected Health Information (Security Standards) under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information by Covered Entities and the Business Associates. HIPAA requires Covered Entities, such as us, to develop and maintain policies and procedures with respect to individually identifiable health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect the privacy and security of such information. HIPAA also requires us to provide individuals with certain rights with respect to their PHI. If we engage a Business </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Associate to help us carry out healthcare activities and functions, we must have a written Business Associate contract or other arrangement with the Business Associate that establishes specifically what the Business Associate has been engaged to do and requires the Business Associate to comply with the requirements of HIPAA. Further, in the event of a breach of unsecured PHI we must notify each individual whose PHI is breached as well as federal regulators and in some cases, must publicize the breach in local or national media.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA also includes standards for common healthcare electronic transactions and code sets, such as claims information, plan eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered Entities, such as certain healthcare providers, are required to conform to such transaction set standards, known as the Standards for Electronic Transactions, pursuant to HIPAA. Submission of electronic healthcare claims and payment transactions that do not comply with the HIPAA electronic data transmission standards could result in delayed or denied payments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the conduct of our business, we process, maintain, and transmit sensitive data, including PHI. There can be no assurance that a breach of privacy or security will not occur. If there is a breach, we could be subject to various lawsuits, penalties and damages and may be required to incur costs to mitigate the impact of the breach on affected individuals.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Penalties for failure to comply with HIPAA requirements are substantial and could include corrective action plans and/or the imposition of civil or criminal penalties. HIPAA also authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may apply more broadly or be more stringent than HIPAA. For example, the CCPA, which went into effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the CPRA went into effect in California amending the CCPA and may increase our compliance costs and potential liability, imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data and adds opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws (for example Virginia's Consumer Data Protection Act and other similar laws that recently went into effect in Utah, Colorado and Connecticut), any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the EU. Further, from January 1, 2021, companies have to comply with the GDPR and also the U.K. GDPR, which, together with the amended U.K. Data Protection Act 2018, retains the GDPR in U.K. national law. The U.K. GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how U.K. data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The regulatory framework governing the collection, storage, use and sharing of certain information, particularly financial and other personal information, is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. Additionally, increasing concerns about health information privacy have recently prompted the federal government to issue guidance taking a newly expansive view of the scope of the laws and regulations that they enforce. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our existing practices. Any failure or perceived failure by us, or any third parties with which we do business, to comply with our privacy policies, changing expectations, evolving laws, rules and regulations, industry standards or contractual obligations to which we or such third parties are or may become subject, may result in actions or other claims against us by governmental entities or private actors, the expenditure of substantial costs, time and other resources or the incurrence of significant fines, penalties or other liabilities. In addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation and adversely affect our business and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future growth may depend, in part, on our ability to develop and commercialize our testing products in foreign markets. We are not permitted to market or promote any of our testing products before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our testing products. To obtain separate regulatory approval in many other countries, parties must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our testing products. If we obtain regulatory approval of our testing products and ultimately commercialize our testing products in foreign markets, we would be subject to additional risks and uncertainties, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">different regulatory requirements for approval of IVDs in foreign countries; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced protection for intellectual property rights; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the existence of additional third-party patent rights of potential relevance to our business; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue and other obligations incident to doing business in another country; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign reimbursement, pricing and insurance regimes; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is common; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism such as the current conflict in Ukraine, or natural disasters which may be exacerbated due to climate change, including earthquakes, typhoons, floods and fires. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to our Intellectual Property </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain intellectual property protection, our competitive position could be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to protect our technologies, such as CB-CAPs and MTXPGs, affects our ability to compete and to achieve sustained profitability. We rely on a combination of U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, and contractual restrictions to protect our intellectual property rights. We cannot be certain that the claims in our granted patents and pending patent applications covering our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products will be considered patentable or enforceable by the United States Patent and Trademark Office (the USPTO) courts in the United States, or by patent offices and courts in foreign countries. If we fail to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We apply for patents covering our testing products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important testing products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions, or we may cease our prosecution and maintenance of patents in potentially relevant jurisdictions. Currently, we own or have an exclusive license to 11 issued U.S. patents and certain corresponding foreign counterpart patents, relevant to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We own one issued U.S. patent, three pending U.S. patent applications, a pending Patent Cooperation Treaty patent application and certain corresponding foreign counterpart patents and patent applications relevant to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. While we intend to pursue additional patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if such patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary for the further development of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products or prevent others from designing around our claims. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. No assurance can be given that our patent applications will have priority over other patent applications. In addition, recent changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. While we use commercially reasonable efforts to protect our trade secrets, our licensors, employees, consultants, contractors and other advisors may unintentionally or willfully disclose such trade secret information to third parties and competitors. We attempt to protect our proprietary technology in large part by entering into confidentiality and non-disclosure agreements with our employees, consultants and other contractors. We cannot assure you, however, that these agreements will not be breached, that we will have adequate remedies for any breach or that competitors will not know of, or independently discover, our trade secrets. We cannot assure you that others will not independently develop substantially equivalent proprietary information or be issued patents that may prevent the sale of our testing products, technologies, services or know-how or require licensing and the payment of significant fees or royalties by us in order to produce our testing products, technologies or services. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of our trade secrets and other confidential information. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. If we are unable to prevent unauthorized material disclosure of our trade secrets and other confidential information to third parties, and in particular in jurisdictions where we have not filed for patent protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Certain of our testing products utilize unpatented technology that is publicly available and can be used by our competitors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, such as AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, utilize both patented technology and publicly available technology that is not protected by patents or other intellectual property rights. We believe that using certain publicly available technology allows us to offer a better and more comprehensive testing product. However, the publicly available technology which we rely upon is also used in, and may continue to be used in, products which compete with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Our competitors may independently develop competing diagnostic products and services that do not infringe our intellectual property. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the diagnostics industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Some of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work related to our CB-CAPs technology was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual property embodied in our testing products pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act). These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filing, prosecuting and defending patents on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products in all countries throughout the world would be prohibitively expensive. Moreover, we believe that obtaining foreign patents may be more difficult than obtaining domestic patents because of differences in patent laws and, accordingly, our patent position may be stronger in the United States than abroad. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Various countries limit the subject matter that can be patented and limit the ability of a patent owner to enforce patents in the medical and other related fields. This may limit our ability to obtain or utilize those patents internationally. In order to manage our foreign patent costs and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of certain of our foreign patents and patent applications related to our CB-CAPs technology, which is used in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The patent protection and patent prosecution for some of our testing products may be dependent on third parties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it may permit other parties to compete with us. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering any of our testing products, our ability to develop and commercialize those testing products may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our testing products, which could adversely affect our business. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our testing products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a party to a number of license agreements under which we are granted intellectual property rights that are important to our business. For example, certain patent rights related to AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus are licensed from UPitt. Our existing license agreements as related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products impose various regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under a license agreement, the license agreement may be terminated, in which event we would not be able to further develop or market certain AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Additionally, we may not always have the first right to maintain, enforce or defend our licensed intellectual property rights and, although we would likely have the right to assume the maintenance, enforcement and defense of such intellectual property rights if our licensors do not, our ability to do so may be compromised by our licensors&#8217; acts or omissions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including the scope of rights granted under the license agreement and other interpretation-related issues, and whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement. If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, results of operations, financial condition and prospects may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. Our outside counsel has systems in place to monitor deadlines to pay these fees and to remind us of these fees, and our outside counsel employs an outside firm to pay these fees due to the USPTO and to foreign patent agencies based on our instructions. In the aggregate, these fees can be cost prohibitive for an early-stage company. Accordingly, we made a financially-driven decision to prioritize our payment of these fees and to allow certain of our applications to lapse, particularly with respect to our ex-U.S. rights licensed from UPitt related to our CB-CAPs technology. The permanent lapse of certain of these ex-U.S. rights may result in our patent position being stronger in the United States than abroad, such as in countries that are part of the European Patent Convention, and third parties may be able to compete more effectively against us in countries outside the United States, including in those countries that belong to the European Patent Convention. Additionally, while an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Presently we have intellectual property rights, through licenses from third parties and under patents that we own, related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Because our programs may involve additional products that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license proprietary rights that we identify as being necessary for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">products. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and our business, financial condition and prospects for growth could suffer. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Third-party claims alleging intellectual property infringement may prevent or delay our development efforts. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the diagnostics industry, as well as administrative proceedings for challenging patents, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. The Leahy-Smith America Invents Act introduced new procedures including inter partes review and post grant review. The implementation of these procedures bring the possibility of third-party challenges to our patents and the outcome of such challenges could result in a loss or narrowing of our patent rights. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. As the diagnostics industry expands and more patents are issued, the risk increases that our activities related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products may give rise to claims of infringement of the patent rights of others. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure you that any of our current or future AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products will not infringe existing or future patents. Although we are not aware of any issued patents that will prevent us from marketing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, there may be third-party patents of which we are currently unaware with claims to materials or methods of manufacture related to the use or manufacture of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. If a third party that owns such a patent asserts it successfully against one of our current or future AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, we may be unable to market our product, which could materially harm our business and because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop one or more of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Defense of these claims, regardless of their merit, would involve substantial expenses and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing a third party&#8217;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or development of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, which could harm our business significantly. Even if we were able to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine the priority of invention. Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our patents in the USPTO. We may also become involved in similar proceedings in the patent offices in other jurisdictions regarding our intellectual property rights with respect to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and technology. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be involved in proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may infringe, misappropriate or otherwise violate our existing patents, patents that may issue to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">may be required to file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering one of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, the defendant could counterclaim that the patent covering such AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Such proceedings could result in an invalidation of our patents. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Such a loss of patent protection could have a material adverse impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Litigation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. We are not aware of any third-party infringement of our intellectual property rights that would have a materially adverse impact on our business. In addition, there can be no assurance that our licensors will be willing to bring and enforce claims to prevent third parties from infringing intellectual property that is licensed to us, particularly if the affected intellectual property is less important to the licensor&#8217;s business than to ours. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other companies in our industry. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#8217; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The public trading price for our common stock is affected by a number of factors, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual or anticipated variations in our and our competitors&#8217; financial condition and results of operations; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announcements by us or our competitors of new products, strategic partnerships or capital commitments; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in reimbursement by current or potential third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">issuance of new securities analysts&#8217; reports or changed recommendations for our stock; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual or anticipated changes in regulatory oversight of our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">developments or disputes concerning our intellectual property or other proprietary rights; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">commencement of, or our involvement in, litigation; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announced or completed acquisitions of businesses or technologies by us or our competitors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any major change in our management; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announcement or expectation of additional financing efforts; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future sales of our common stock by our executive officers, directors and other stockholders; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">general economic conditions and slow or negative growth of our markets, including as a result of the current conflict in Ukraine. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may not realize any return on your investment in us and may lose some or all of your investment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future sales of shares by existing stockholders could cause our stock price to decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the trading price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our directors and executive officers have and may continue to establish programmed selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. Any sales of securities by directors and executive officers, or the perception that those sales may occur, including the entry into such programmed selling plans, could have a material adverse effect on the trading price of our common stock, particularly if the trading volume of our common stock is relatively low at the time of these sales.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as of February 15, 2023, the holders of 1,277,220 shares of common stock and holders of warrants to purchase 409,108 shares of common stock are entitled to rights with respect to registration of such shares under the Securities Act pursuant to an investors&#8217; rights agreement between such holders and us. If such holders, by exercising their registration rights, sell a large number of shares, they could adversely affect the market price for our common stock. If we file a registration statement for the purpose of selling additional shares to raise capital and are required to include shares held by these holders pursuant to the exercise of their registration rights, our ability to raise capital may be impaired.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our amended and restated certificate of incorporation provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, the stockholders will not be deemed to have waived our compliance with the Federal Securities laws and rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on their most recent publicly filed beneficial ownership reports, our greater than 5% stockholders collectively own approximately 69% of our outstanding capital stock and our greater than 5% stockholders, directors and executive officers collectively own (without duplication) approximately 70% of our outstanding capital stock as of February 15, 2023. As a result, such persons, acting together, have the ability to control or significantly influence all matters submitted to our stockholders for approval, including the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future. Your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never declared or paid any cash dividends on our common stock and do not intend to pay any cash dividends in the foreseeable future. We currently intend to retain any future earnings to fund the growth of our business. In addition, our Amended Loan Agreement restricts our ability to pay cash dividends on our common stock and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">An active, liquid trading market for our common stock may not be maintained. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to our IPO, there had been no public market for our common stock. Our common stock began trading on the Nasdaq Global Market (Nasdaq) relatively recently, but we can provide no assurance that we will be able to develop and sustain an active trading market for our common stock. Even if an active trading market is developed, it may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. During 2022, our average daily trading volume has been approximately 54,446 shares.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to meet the continued listing requirements of the Nasdaq Global Market or The Nasdaq Stock Market LLC could result in a delisting of our common stock. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. Currently, we have limited analyst coverage and we do not have any control over such analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company, and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering (IPO), or December 31, 2024. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenue exceeds $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim condensed financial statements, with correspondingly reduced &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; disclosure; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we may not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our testing products or services, and there is no assurance that any efforts to reduce costs or increase the prices of our testing products or services would be sufficient to offset these increased costs or any resulting decrease in our net income or increase in our net loss. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to federal, state and local laws, rules and regulations governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, either of which could negatively affect our operating results. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, political instability, acts of war, including the current conflict in Ukraine, and other natural or manmade disasters (which may be exacerbated due to climate change) or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce our testing products. Our ability to obtain clinical supplies of our testing products could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in Vista, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our testing products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We could be subject to securities class action litigation. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. Properties.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our corporate headquarters are located in Vista, California, where we lease approximately 27,000 square feet of office and laboratory space under a lease that expires in 2027, with an option to extend a portion of the lease for an additional five-year period. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We lease an additional approximately 19,500 square feet office space in Vista, California, under a lease that is co-terminus with our other lease expiring in 2027, with an option to extend the lease for an additional five-year period. We also lease an additional approximately 28,000 square feet office space in Carlsbad, California, under a sublease that is co-terminus with our other leases expiring in 2027. We believe that our current facilities are adequate for our current needs and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_25"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 3. Legal Proceedings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently not a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_28"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items 4. Mine Safety Disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div style="text-align:center"><span><br/></span></div><div id="i5f5950d7f59540fa871ae1a67d589208_34"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Market Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock began trading on The Nasdaq Global Market on September 19, 2019 under the symbol "XGN." Prior to September 19, 2019, there was no public market for our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Holders of Record</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;16, 2023, there were approximately 36 stockholders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in "street" name with various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividend Policy</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, our ability to pay cash dividends is currently prohibited by the terms of our Amended Loan Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Part III, Item 12 of this Annual Report under the section titled "Security Ownership of Certain Beneficial Owners and Management" for information about our equity compensation plans which is incorporated by reference herein.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Performance Graph</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Proceeds</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 18, 2019, the SEC declared effective our registration statement on Form S-1 (File No. 333-233446), as amended, filed in connection with our IPO. At the closing of the offering on September 23, 2019, we issued and sold 4,140,00 shares of our common stock at the initial public offering price to the public of $14.00 per share, which included the exercise in full of the underwriters&#8217; option to purchase additional shares. We received gross proceeds from the IPO of $58.0 million, before deducting underwriting discounts, commissions and other offering expenses, which resulted in net proceeds of approximately $50.4 million and offering-related transaction costs of approximately $7.5 million. Cowen and Company, LLC, Cantor Fitzgerald &amp; Co. and William Blair &amp; Company, L.L.C. acted as joint book-running managers for the offering. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, we have used all of the proceeds from our IPO primarily related to selling and marketing activities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Purchases of Equity Securities by the Issuer</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:9pt"><span><br/></span></div><div id="i5f5950d7f59540fa871ae1a67d589208_37"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved.]</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and financial performance, includes forward-looking statements that are based on current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should read the "Special note regarding forward-looking statements" and "Risk Factors" section of this Annual Report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, several of which incorporate CB-CAPs technology. Our goal is to enable healthcare providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and RA.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market our testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of CTDs and other related diseases with overlapping symptoms. We commercially launched AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2012 and revenue from this product comprised 84% and 81% of our revenue for the years ended December&#160;31, 2022 and 2021, respectively. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests in our approximately 13,000 square foot laboratory, which is certified by CLIA and accredited by CAP, and located in Vista, California. Our laboratory is certified for performance of high-complexity testing by CMS in accordance with CLIA and is licensed by all states requiring out-of-state licensure. Our clinical laboratory typically reports all AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">testing product results within five business days. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products using our specialized sales force covering 40 territories in the United States. Unlike many diagnostic sales forces that are trained only to understand the comparative benefits of their tests, the specialized backgrounds of our sales force coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reimbursement for our testing services comes from several sources, including commercial payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid, and patients. Reimbursement rates vary by product and payor.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception we have devoted substantially all of our efforts developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. We have never been profitable and, as of December&#160;31, 2022 we had an accumulated deficit of $255.5&#160;million. We have funded our operations primarily through equity and debt financings and revenue from sales of our products. We incurred net losses of $47.4&#160;million and $26.9 million for the years ended December&#160;31, 2022 and 2021, respectively and we expect to continue to incur operating losses in the near term. We completed our initial public offering (IPO) in September 2019, raising net proceeds from the offering of approximately $50.4 million. In March 2021, we completed a public offering of shares of our common stock for net proceeds of approximately $64.7 million. As of December&#160;31, 2022, we had $62.4&#160;million of cash and cash equivalents. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management Change</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2022, we appointed a new President and Chief Executive Officer of the Company (the Change in Management). In connection with the Change in Management, in the fourth quarter of 2022, we began to update our strategy and implement cost savings and other initiatives. We are continuing the process of evaluating our operations, test offerings, research and development pursuits and facilities footprint, among other aspects of our business strategy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Factors Affecting Our Performance</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Reimbursement for Our Testing Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payors, including both commercial and government payors, such as Medicare and Medicaid. Payment from third-party payors differs depending on whether we have entered into a contract with the payors as a "participating provider" or do not have a contract and are considered a "non-participating provider." Payors will often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of commercial payors, most of which have not contracted with us to be a participating provider. In addition to the challenges described under the heading "Financial Overview" below, historically, we have experienced situations where commercial payors proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payors have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications.&#160;If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payors, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Continued Growth of Our Testing Products. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2012 and through December&#160;31, 2022, we have delivered approximately 750,000 of these tests. For the year ended December&#160;31, 2022, 135,210 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests were delivered, representing approximately 5% growth over the same period in 2021. The number of ordering healthcare providers in the fourth quarter of 2022 was a record 2,419, representing an approximate 14% increase over the same period in 2021. Revenue growth for our testing products will depend on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Synergistic Partnerships</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In August 2021, we mutually agreed to terminate the Janssen Agreement regarding our promotion efforts with SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> effective August 31, 2021. Our SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> promotion efforts contributed no revenue and $1.2 million in revenue for the years ended December&#160;31, 2022 and 2021, respectively. We will continue to rely on our existing testing products to drive revenue growth.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Development of Additional Testing Products. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test to generate the significant majority of our revenue. We expect to continue to invest in research and development in order to develop additional testing products. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our testing products and diversifying our sources of revenue.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Maintain Meaningful Margin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We seek to maintain meaningful margin through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as leveraging validation, utility and reimbursement oriented clinical studies to facilitate payor coverage of our testing products. We plan to increase focus on long-term reimbursement and ASP growth and seek to improve our per test costs by focusing on profitable, core test offerings and reducing fixed costs and overhead.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Timing of Our Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our spending on experiments and clinical studies may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence to support our commercialized AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">How We Recognize Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We record revenue on an accrual basis, using an estimate of the amount we will ultimately realize, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. Changes to such estimates may increase or decrease revenue recognized in future periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "Risk Factors."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Impact of COVID-19</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, the Biden administration announced plans to end the national emergencies for addressing COVID-19 on May 11, 2023. The full extent to which the COVID-19 pandemic may directly or indirectly continue to impact our business, results of operations and financial condition remains dependent on future developments that are highly uncertain. We have implemented business continuity plans designed to address the COVID-19 pandemic and minimize disruptions to ongoing operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Janssen Promotion Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2018, we entered into the Janssen Agreement, under which we were responsible for the costs associated with our sales force in promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States. In August 2021, we and Janssen mutually agreed to terminate the Janssen Agreement effective August 31, 2021. Pursuant to the terms of the termination, we were restricted from promoting any other biologic or Janus kinase inhibitor used for treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent until May 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, we recognized approximately $1.2 million in revenue for our promotional efforts under the Janssen Agreement. No revenue from the Janssen Agreement was recognized for the year ended December 31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Seasonality</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors. Some of these factors include the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers (including medical conferences), climate and weather conditions in our markets (for example, excess sun exposure can cause flares in SLE), seasonal conditions that may affect medical practices and provider activity (for example influenza outbreaks that may reduce the percentage of patients that can be seen) and other factors relating to the timing of patient benefit changes, as well as patient deductibles and co-insurance limits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inflationary Environment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current inflationary environment has resulted in higher prices, which have impacted our costs incurred to generate revenue from our laboratory testing services, costs to attract and retain personnel, and other operating costs. The severity and duration of the current inflationary environment remains uncertain and may continue to impact our financial condition and results of operations.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize revenue in accordance with the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We record revenue on an accrual basis, using an estimate of the amount we will ultimately receive, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. These assessments require significant judgment by management.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. We primarily market our testing products to rheumatologists in the United States. The rheumatologists who order our testing products and to whom results are reported are generally not responsible for payment for these products. The parties that pay for these services (payors) consist of commercial payors (e.g. insurance companies, health maintenance organizations, etc.), government payors (primarily Medicare and Medicaid), client payors (e.g. hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to increase our revenue will depend on our ability to further penetrate the market for our current and future testing products, and increase our reimbursement and collection rates for tests delivered.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the quarter ended March 31, 2022, CMS agreed, effective April 1, 2022, to recognize a new PLA code for our protein-based test, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus. Noridian, our MAC, priced this PLA code at $1,085 per test. To determine pricing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">beyond 2022, CMS recommended crosswalking AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (0312U) to Vectra (81490) at a rate of $840.65 per test. This pricing was finalized on the 2023 CLFS and is effective from January 1, 2023 through December 31, 2025. The process for obtaining and maintaining consistent reimbursement for new tests can be uncertain, lengthy and time consuming. A pricing determination is not synonymous with a coverage determination. Having a price associated with the PLA code for any particular test does not secure coverage or reimbursement for that PLA code from Medicare or any other third-party payor.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In an effort to improve transparency regarding Medicare support of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, on July 29, 2022, we submitted a formal request to Noridian for coverage of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test under the new PLA Code. On September 27, 2022, we received notice that Noridian has deemed our application for an LCD to be valid. Ultimately receiving a favorable LCD is uncertain and may be time-consuming, resource intensive and require multiple quarterly or annual periods to complete. In the meantime, we will continue to submit Medicare claims for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lupus, appeal denials and respond to requests for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face challenges relating to commercial payor claim processing and revenue. Now that we are billing under our PLA code, we are experiencing an increase in denials due to unfavorable medical policy with certain plans, and we expect this situation to persist.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Costs of Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment and infrastructure expenses associated with testing specimens, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead, including rent and utilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each payor, whether commercial, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payors for each period's billings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that our costs of revenue will increase in the near-term as test volume increases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general and administrative expenses consist of personnel costs, including stock-based compensation expense, direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead including rent, information technology, depreciation and utilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that our selling, general and administrative expenses will decrease in the near-term as a result of cost saving initiatives which began in the fourth quarter of 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses include costs incurred to develop our technology, test products and product candidates, in addition to costs incurred to collect clinical specimens and conduct clinical studies to develop and support those products and product candidates. These costs consist of personnel costs, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities. We expense all research and development costs in the periods in which they are incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that our research and development expenses will decrease in the near-term as a result of cost saving initiatives which began in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our amended loan and security agreement with Innovatus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect interest expense to remain consistent in 2023 as compared to 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Income</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income consists of interest income earned on our cash and cash equivalents.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Tax (Expense) Benefit</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes include federal and state income taxes in the United States.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46,051)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,067)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,984)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,669)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26,676)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,993)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,387)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26,851)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue decreased $2.7&#160;million, or 5.7%, for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021, primarily due to the $1.2 million reduction of revenue from the Janssen Agreement and a decrease in ASP, partially offset by increases in volume. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests delivered increased to 135,210 in the year ended December&#160;31, 2022 compared to 128,246 tests delivered in the same 2021 period. The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test accounted for 84% and 81% of revenue for the years ended December&#160;31, 2022 and 2021, respectively. The number of ordering healthcare providers increased to 2,419 for the three months ended December&#160;31, 2022 compared to 2,126 in the same 2021 period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Costs of Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs of revenue increased $3.6&#160;million, or 17.6%, for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021. This increase was primarily due to increases of $1.4 million in labor costs, $0.8 million in materials and supplies expenses, $0.6 million in shipping and handling costs associated with the increase in test volume and inflationary pressures in 2022 compared to 2021, and $0.6 million in overhead costs related to our expanded clinical laboratory. Gross margin as a percentage of revenue decreased to 46.9% for the year ended December&#160;31, 2022, compared to 57.4% for the year ended December&#160;31, 2021. This was primarily attributable to decreases in revenue and increased costs, as described above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general and administrative expenses increased $7.5&#160;million, or 16.8%, for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021. This increase was primarily due to an increase of $4.5 million of personnel costs, including salaries, benefits, other reimbursable employee expenses and severance expenses, in addition to increases related to marketing expenses of $1.3 million, facilities and allocated overhead of $0.7 million, legal expenses of $0.6 million, professional service fees of $0.6 million, public company expenses of $0.2 million and third-party billing expenses of $0.2 million. These increases were partially offset by decreases in expenses related to employee bonuses of $1.0 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses increased $2.6 million, or 36.5%, for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021. The increase was primarily due to an increase of $1.8 million of personnel costs, including salaries, benefits and severance expenses, increases related to lab supplies of $0.8 million, facilities and allocated overhead of 0.6 million and a long-lived assets impairment charge of $0.4 million. These increases were partially offset by decreases in expenses related to clinical studies of $0.6 million, collaboration expenses of $0.3 million and employee bonuses of $0.2 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill Impairment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our annual goodwill impairment assessment in the fourth quarter of 2022, we determined that the sustained decrease in our market capitalization constituted an indicator of impairment and as a result, a quantitative goodwill impairment test was completed as of December 31, 2022. This analysis identified an impairment of $5.5 million related to our goodwill.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense decreased $0.2 million for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021 due to lower interest rates on the company's 2017 Term Loan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Income</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income increased $0.8 million for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021 due to higher money market interest rates in 2022 compared to 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Tax (Expense) Benefit</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax expense increased $0.5 million for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021 due to a change from a deferred tax liability position to a deferred tax asset position related to indefinite-lived intangibles resulting from our goodwill. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses since our inception. For the years ended December&#160;31, 2022 and 2021, we incurred a net loss of $47.4 million and $26.9&#160;million, respectively, and we expect to incur additional losses and increased operating expenses in future periods. As of December&#160;31, 2022, we had an accumulated deficit of $255.5&#160;million. To date, we have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since becoming public, our primary sources of capital have been cash inflows from product sales, sales of our common stock and, to a lesser extent, borrowings under our 2017 Term Loan.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 10, 2020, we filed a registration statement on Form S-3 (Shelf Registration Statement) covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units. In March 2021, we completed a public offering of shares of our common stock, which shares were sold under the Shelf Registration Statement. Net proceeds from the offering were approximately $64.7 million. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2022, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0 million. The Company is not obligated to sell any shares of Company common stock in the offering and, as of December&#160;31, 2022, the Company had not sold any shares of its common stock pursuant to the Sales Agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, we had $62.4&#160;million of cash and cash equivalents. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash, money market funds and certificates of deposit.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, we entered into the loan and security agreement with Innovatus under which we immediately drew down $20.0&#160;million. In December 2018, we borrowed an additional $5.0&#160;million under the loan agreement. In each of November 2019 and November 2021, we amended the loan and security agreement with Innovatus, which we collectively refer to as the Amended Loan Agreement. Pursuant to the Amended Loan Agreement, the loan term is for nine years with a final maturity date of November 2026. The Amended Loan Agreement accrues interest at an annual rate of 8.0%, of which 2.0% will be payable in-kind. Paid in-kind interest is added to the principal balance each period. After December 1, 2024, the entire 8.0% will be paid in cash at the end of each period. On or after November 1, 2022, we may, at our option, prepay the term loan borrowings by paying the lender a prepayment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">premium. The prepayment premium was 2% as of December&#160;31, 2022 and decreases by 1% on each of November 1, 2023 and November 1, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The Amended Loan Agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain minimum liquidity of $2.0&#160;million, covenants to achieve certain minimum amounts of revenue (the performance covenant), and covenants limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The consequences of failing to achieve the performance covenant will be cured if, within sixty days of failing to achieve the performance covenant, we issue additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. At December&#160;31, 2022, we were in compliance with all covenants of the Amended Loan Agreement. In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Funding Requirements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our primary use of cash is to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term. In the short-term, we expect costs of revenue to increase as test volume increases. We expect selling, general and administrative expenses, and research and development expenses to decrease in the short-term as a result of cost saving initiatives which began in the fourth quarter of 2022. We believe we have sufficient laboratory capacity to support increased test volume. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated milestones associated with intellectual property we have licensed, payments related to non-cancelable purchase obligations with one supplier for reagents, payments related to our principal and interest under our long term borrowing arrangements, payments for operating leases related to our office and laboratory space in Vista, California and our office space in Carlsbad, California, and payments for finance leases related to our laboratory equipment (see Note 4 and Note 5 to our audited financial statements included in this Annual Report on Form 10-K). Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this filing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for our testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to maintain and grow sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">fluctuations in working capital;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation, utility and outcome studies as well as the success of our development efforts; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products as well as the success of our existing partnerships and/or in-licenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our commercial and strategic relationships. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash Flows</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,144)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(489)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,951)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows from Operating Activities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities for the year ended December&#160;31, 2022 was $32.1 million and primarily resulted from (i) our net loss of $47.4 million adjusted for non-cash charges of $13.5 million primarily related to impairment of our goodwill, stock-based compensation, depreciation, amortization, non-cash lease expenses, non-cash interest and deferred income taxes and (ii) changes in our net operating assets of $1.7&#160;million primarily related to net increases in accounts receivable and net decreases in accounts payable, partially offset by net decreases in prepaid expenses and other current assets and net increases in accrued liabilities and other current liabilities. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities for the year ended December&#160;31, 2021 was $20.3&#160;million and primarily resulted from (i) our net loss of $26.9&#160;million adjusted for non-cash charges of $6.6 million related to stock-based compensation, depreciation, amortization, non-cash interest and deferred income taxes and (ii) changes in our net operating assets of $0.1 million primarily related to net increases in accounts receivable and net decreases in accounts payable, partially offset by net decreases in prepaid expenses and other current assets and net increases in accrued liabilities and other current liabilities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows from Investing Activities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in investing activities for the year ended December&#160;31, 2022 and 2021 was $4.3&#160;million and $2.4 million, respectively, and was primarily due to net purchases of property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows from Financing Activities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in financing activities for the year ended December&#160;31, 2022 was $0.5 million, primarily consisting of principal payments on finance lease obligations and payment of taxes on vested restricted stock units, partially offset by the proceeds from the Exagen Inc. 2019 Employee Stock Purchase Plan (the ESPP) purchases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by financing activities for the year ended December&#160;31, 2021 was $64.7&#160;million and primarily resulted from the net proceeds received from our public offering in March 2021 of $64.7 million and proceeds from the ESPP purchases, partially offset by principal payments on finance lease obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our audited financial statements, which have been prepared in accordance with accounting principles generally accepted in United States of America (GAAP). The preparation of these audited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the audited financial statements, as well as the reported revenue </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe the following accounting policies are the most critical to us, in that they require our most difficult, subjective or complex judgments in the preparation of our financial statements. For further information, see Note 2, Summary of Significant Accounting Policies, to our Financial Statements, which outlines our application of significant accounting policies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, substantially all of our revenue has been derived from sales of our testing products. We primarily market our testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order our services and to whom test results are reported are generally not responsible for payment for these services. The parties that pay for these services consist of commercial payors, government payors (primarily Medicare and Medicaid), client payors (e.g. hospitals, other laboratories, etc.) and patient self-pays.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are billed at our list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors. We follow a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. Our portfolios are grouped per payor (e.g. each individual third-party insurance, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of our net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation by management. We continually assess the state of our cash collections in order to identify areas of risk and opportunity that allow us to appropriately estimate receivables and revenue. Should we later determine the judgements underlying estimated collections change, our financial results could be impacted in future periods. Included in revenues for the years ended December&#160;31, 2022 and 2021 was a net revenue decrease of $2.4 million and a net revenue increase of $0.7 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill is not amortized but is tested for impairment at least annually or more frequently whenever a triggering event or change in circumstances occurs at the reporting unit level. For our goodwill impairment analysis, we operate in a single reporting unit, and allocate all goodwill to this reporting unit. Management first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If a quantitative assessment is deemed necessary, management uses all available information to make this fair value determination, including the present values of expected future cash flows, driven by our forecast of future revenue, using discount rates commensurate with the risks involved in the assets and observed market multiples of operating cash flows. Our stock price and associated market capitalization is also considered in the determination of reporting unit fair value. A prolonged or significant decline in our share price could provide evidence of a need to record a material impairment to goodwill. We are required to recognize an impairment charge if the carrying amount of the reporting unit exceeds its fair value. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The judgments and estimates involved in identifying and quantifying the impairment of goodwill involve inherent uncertainties, and the measurement of the fair value is dependent on the accuracy of the assumptions used in making the estimates and how those estimates compare to our future operating performance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded stock-based compensation expense of approximately $4.7 million for each of the years ended December&#160;31, 2022 and 2021, respectively. We expect to continue to grant stock options, restricted stock units and other equity-based awards in the future and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase. For stock options and purchase rights granted under the ESPP, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">estimate the grant date fair value using the Black-Scholes option-pricing valuation model. For RSUs, we use the closing price of our common stock on the date of grant to determine the fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per share attributable to common stockholders could have been significantly different. See Note 2 and Note 8 to our audited financial statements in this Annual Report on Form 10-K for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted and purchases under our ESPP rights in the years ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See "Notes to the Financial Statements-Note 2-Recent Accounting Pronouncements" of our annual financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">JOBS Act Accounting Election</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." The JOBS Act permits an "emerging growth company" such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act, which will occur in 2024. However, if certain events occur prior to the end of this five-year period, including if we become a "large accelerated filer" as defined in Rule&#160;12b-2 under the Exchange Act, our annual gross revenues exceed $1.07&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to this anniversary.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_58"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and supplemental data required by this item are set forth at the pages indicated in Part IV, Item 15(a)(1) of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div id="i5f5950d7f59540fa871ae1a67d589208_61"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_64"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that the information required to be disclosed by us in such reports is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of December&#160;31, 2022, our disclosure controls and procedures were not effective to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, due to the material weakness in our internal control over financial reporting described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal controls over financial reporting may not prevent or detect all misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 13, 2022, management and the audit committee of our board of directors determined that we made certain errors in revenue resulting from erroneous and duplicate billings related to changes in billing practices. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">errors were due to the inadequate design and implementation and precision of internal controls and procedures to evaluate and monitor the accounting for revenue recognition. As a result, revenue and accounts receivable were overstated and other liabilities was understated for the quarter and year to date periods ended June 30, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We concluded that these were material errors in the financial statements requiring a restatement of the Form 10-Q for the three and six months ended June 30, 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, management has determined that this control deficiency constituted a material weakness and, as a result, management has concluded that, as of December&#160;31, 2022, our internal control over financial reporting was not effective based on the criteria in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control Integrated Framework (2013) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Remediation Plan to Address the Material Weaknesses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management is actively engaged in the implementation of, remediation efforts to address the material weakness. The remediation plan includes: (i) evaluating the staffing level, skills and qualification of accounting department personnel, (ii) enhancement of our existing control structure and processes for revenue recognition and (iii) improving the detailed review process of our revenue recognition models. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects. The weakness will not be considered remediated, however, until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for "emerging growth companies."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other than the material weakness discussed above, there have been no changes in our internal control over financial reporting during the three months ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inherent Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="margin-top:9pt"><span><br/></span></div><div id="i5f5950d7f59540fa871ae1a67d589208_70"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div style="text-align:center"><span><br/></span></div><div id="i5f5950d7f59540fa871ae1a67d589208_76"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_79"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_82"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_85"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_88"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our independent public accounting firm is BDO USA, LLP, San Diego, California, PCAOB ID #<ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:AuditorFirmId" id="f-36">243</ix:nonNumeric>.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div style="text-align:center"><span><br/></span></div><div id="i5f5950d7f59540fa871ae1a67d589208_94"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 15. Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements and Financial Statement Schedules</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(1) Exhibits</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K and is incorporated herein by reference.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(2) All financial statements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements of Exagen Inc., together with the report thereon of BDO USA, LLP, an independent registered public accounting firm, are included in this Annual Report on Form 10-K beginning on page F-2.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(3) Financial statement schedules</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_97"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000017/ex31-amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/22/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/exhibit-exagenxamendmentto.htm">Amended and Restated Bylaws, dated January 19, 2023.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/23/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, dated July 12, 2019, by and among the Company and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex43.htm">Amended and Restated Stockholders' Agreement, dated July 12, 2019, by and among the Company and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex44.htm">Form of Common Stock Purchase Warrant issued to investors by the Company in connection with private placement financings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex48.htm">Form of Common Stock Purchase Warrant to purchase common stock issued to investors by the Company in 2016.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex49.htm">Form of Warrant to Purchase Stock issued to Innovatus Life Sciences Lending Fund I, LP in connection with the Company's 2018 loan agreement.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000094/ex45-formofprexfundedwarra.htm">Form of Exchange Warrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/9/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex101.htm">Exagen Corporation 2002 Stock Option Plan, as amended, and form of option agreement thereunder.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex102.htm">Exagen Diagnostics, Inc. 2013 Stock Option Plan, as amended, and form of option agreement thereunder.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex103.htm">Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex104.htm">Form of Option Agreement under Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex105-formofrsuagreement20.htm">Form of Restricted Stock Unit Agreement under Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex105.htm">Exagen Inc. 2019 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex105.htm">License Agreement, dated September 13, 2007, by and between Prometheus Laboratories Inc. and the Company (as successor in interest to Proprius, Inc.).</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex106.htm">First Amendment to License Agreement, dated October 23, 2013, by and between Prometheus Laboratories Inc. and the Company (as successor in interest to Cypress Bioscience, Inc.).</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex106-letteragreementippur.htm">Letter Agreement, dated September 28, 2021, by and between the Company and Prometheus Laboratories Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1010.htm">Asset Purchase Agreement, dated October 8, 2010, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1011.htm">Amendment No. One to Asset Purchase Agreement, dated March 10, 2011, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1012.htm">Amendment No. Two to Asset Purchase Agreement, dated August 21, 2012, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1013.htm">Amendment No. Three to Asset Purchase Agreement, dated February 6, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1014.htm">Amendment No. Four to Asset Purchase Agreement, dated October 8, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1015.htm">Amendment No. Five to Asset Purchase Agreement, dated January 26, 2016, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1016.htm">Amendment No. Six to Asset Purchase Agreement, dated February 16, 2017, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1017.htm">Amended and Restated Exclusive License Agreement, dated August 2, 2011, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1018.htm">First Amendment to Amended and Restated Exclusive License Agreement, dated May 17, 2012, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1019.htm">Second Amendment to Amended and Restated Exclusive License Agreement, dated September 30, 2013, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1020.htm">Third Amendment to Amended and Restated Exclusive License Agreement, dated June 24, 2016, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1021.htm">Exclusive License Agreement, dated September 30, 2013, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.22&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1022.htm">Exclusive License Agreement, dated September 5, 2011, by and between Thierry Dervieux, Ph.D. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1023.htm">Co-Promotion Agreement, dated December 10, 2018, by and between Janssen Biotech, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.24&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000077/ex101-amend1tocoxpromo.htm">Amendment #1 to Co-Promotion Agreement, dated January 1, 2019 by and between Janssen Biotech, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.25&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000077/ex102-amend2tocoxpromo.htm">Amendment #2 to Co-Promotion Agreement, dated June 18, 2020 by and between Janssen Biotech, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.26&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex1025-amend3tocoxpromotio.htm">Amendment #3 to Co-Promotion Agreement, dated December 23, 2020 by and between Janssen Biotech, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000094/ex101-amend4tocoxpromotion.htm">Amendment #4 to Co-Promotion Agreement, dated June 30, 2021 by and between Janssen Biotech, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/9/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1024.htm">Standard Industrial/Commercial Multi-Tenant Lease, dated January 13, 2012, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1025.htm">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated December 1, 2013, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/secondamend1261suitebc.htm">Second Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated April 29, 2016, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/thirdamend1261suitebc.htm">Third Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated June 16, 2017, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/fourthamendmenttolease.htm">Fourth Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated March 16, 2020, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex103-fifthaddendumtolease.htm">Fifth Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated October 19, 2021, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1030.htm">Standard Industrial/Commercial Single-Tenant Lease, dated September 4, 2014, by and between Geiger Court, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/firstamend1221lease.htm">First Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated August 2, 2017, by and between Geiger Court, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/a1221libertyway-leasea.htm">Extension of Lease to Standard Industrial/Commercial Single-Tenant Lease, dated March 12, 2020, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex1034-amend1to1221liberty.htm">First Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated January 6, 2021, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex102-amend2to1221libertyw.htm">Second Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated October 11, 2021, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex10331261suitealeasev2.htm">Standard Industrial/Commercial Multi-Tenant Lease, dated March 17, 2020 by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex104-firstaddendumtolease.htm">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated October 19, 2021, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.41&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex101-subleaseagreement819.htm">Sublease Agreement, dated August 19, 2021, by and between Plum Healthcare Group, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1031.htm">Master Lease Agreement, dated February 1, 2018, by and between Celtic Commercial Finance, a division of MB Equipment Finance, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1032.htm">Loan and Security Agreement, dated September 7, 2017, by and between Innovatus Life Sciences Lending Fund I, LP and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex1036-innovatusxexage.htm">First Amendment to Loan and Security Agreement, dated November 19, 2019, by and between Innovatus Life Sciences Lending I, LP and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000097/ex101-innovatusacknowl.htm">Acknowledgement Letter to Loan and Security Agreement, dated October 7, 2020, by and between Innovatus Life Sciences Lending Fund I, LP and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex105-secondamendmentloana.htm">Second Amendment to Loan and Security Agreement, dated November 1, 2021, by and among Innovatus Life Sciences Lending Fund I, LP, other lenders and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.47#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1034.htm">Offer Letter, dated October 12, 2010, by and between Thierry Dervieux, Ph.D. and the Company, as amended on September 9, 2011 and September 6, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1034.htm">Form of Indemnification Agreement for Directors and Officers.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.49#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1036.htm">Offer Letter, dated October 7, 2011, by and between Fortunato Ron Rocca and the Company, as amended on September 4, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.50#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1037.htm">Offer Letter, dated May 16, 2017, by and between Kamal Adawi and the Company, as amended on September 4, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.51#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex1041-zackofferletter.htm">Offer Letter dated February 21, 2020, by and between Debra Zack, MD Ph.D. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.52#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1038.htm">Non-Employee Director Compensation Program.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.53#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex1046-executivecicseveran.htm">Executive Change in Control Severance Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.54#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/johnaballiceoemploymentagr.htm">Employment Agreement, dated as of October 16, 2022, by and between the Company and John Aballi</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/16/2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.55#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/exagenseveranceagreement-r.htm">Severance Agreement, dated as of October 14, 2022, by and between the Company and Ron Rocca</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/16/2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.56</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000064/ex11-xgnxsalesagreement.htm">Sales Agreement, dated as of September 15, 2022, by and between the Company and Cowen and Company, LLC</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/15/2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.57</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000080/debzackconsultingagreement.htm">Consulting Agreement, dated as of December 5, 2022, by and between the Company and Debra Zack, M.D., Ph.D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/5/2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex231-2022bdoconsent.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_160">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn311-123122.htm">Certificate of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn312-123122.htm">Certificate of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn321-123122.htm">Certifications Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2021, has been formatted in Inline XBRL.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted for confidentiality purposes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:56.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;20, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Aballi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Power of Attorney</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Aballi and Kamal Adawi as his or her true and lawful attorneys-in-fact, and each of them, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and either of them, or his or their substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:5.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ John Aballi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">John Aballi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Kamal Adawi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer and Corporate Secretary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kamal Adawi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Tina S. Nova, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Chairperson of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tina S. Nova, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Brian Birk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian Birk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Ana Hooker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ana Hooker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Wendy S. Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wendy S. Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Ebetuel Pallares, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ebetuel Pallares, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Bruce C. Robertson, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bruce C. Robertson, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Frank Stokes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Frank Stokes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ James L.L. Tullis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;20, 2023</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">James L.L. Tullis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to Financial Statements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_103">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID No. 243)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_103">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_106">Balance Sheets as of December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_106">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_106"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_106">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_106">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_109">Statements of Operations for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_109">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_109"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_109">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_109">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_112">Statements of Stockholders' Equity for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_112">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_112"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_112">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_112">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_115">Statements of Cash Flows for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_115">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_115"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_115">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_115">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_118">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5f5950d7f59540fa871ae1a67d589208_118">7</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shareholders and Board of Directors </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vista, California </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying balance sheets of Exagen Inc. (the "Company&#8221;) as of December 31, 2022 and 2021, the related statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in Accounting Principle </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed in Note 5 to the financial statements, effective January 1, 2022, the Company adopted Accounting Standards Codification Topic 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:AuditorName" id="f-37">BDO USA, LLP</ix:nonNumeric> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2017. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="dei:AuditorLocation" id="f-38">San Diego, California</ix:nonNumeric> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;20, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">62,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-40">99,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">6,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">9,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-43">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-44">3,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">72,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">112,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-47">8,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-48">4,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-49">4,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-52">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-53">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-54">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-55">86,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">123,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">2,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-61">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">5,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">6,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">9,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">9,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">28,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">27,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-72">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-73">867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-75">43,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-76">38,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-77"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-78"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-79"><ix:nonFraction unitRef="usdPerShare" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-80">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-83"><ix:nonFraction unitRef="shares" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-85"><ix:nonFraction unitRef="shares" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-86">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December 31, 2022 and December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-89"><ix:nonFraction unitRef="usdPerShare" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-90">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-91"><ix:nonFraction unitRef="shares" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-92">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2022 and December 31, 2021; <ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-93"><ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-94">16,549,984</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-95"><ix:nonFraction unitRef="shares" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96">16,164,994</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-97">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-98">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-99">297,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-100">293,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-101">255,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-102">208,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-103">42,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-104">84,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-105">86,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-106">123,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-107">45,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-108">48,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-109">24,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-110">20,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">52,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">44,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">9,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">7,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-115">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-117">91,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-118">72,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">46,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">24,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">2,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">2,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-123">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-124">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-125">47,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-126">26,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-127">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-128">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">47,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">26,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-131"><ix:nonFraction unitRef="usdPerShare" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-132">2.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-133"><ix:nonFraction unitRef="usdPerShare" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-134">1.68</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-135"><ix:nonFraction unitRef="shares" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-136">17,082,348</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-137"><ix:nonFraction unitRef="shares" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-138">15,972,256</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.358%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac2e346101f544b3b8c12fb87ac0784e_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-139">12,652,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2e346101f544b3b8c12fb87ac0784e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-140">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91db90b0b71948a3a7ed62f79644090a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-141">223,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15bf116298a3437e8f5fc8227e8b9962_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-142">181,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63a7f83cab04fd3bd0a7651465bc919_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-143">41,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock in public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="exdx:StockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-144">4,435</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-145">4,255,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-146">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-147">64,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-148">64,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock in exchange for common stock warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-149">804,951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="f-150">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-151">12,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-152">12,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock warrant in exchange for retirement of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-153">12,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-154">12,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-155">11,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-156">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-157">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-158">32,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-159">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-160">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-161">4,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-162">4,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231" decimals="INF" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" format="ixt:num-dot-decimal" scale="0" id="f-163">17,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="f-164">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="f-165">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i786ad5d8770443b192b64cc933e5cec3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">26,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-167">26,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied976c8e24054ecbbc5ea323afd116ad_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-168">16,164,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied976c8e24054ecbbc5ea323afd116ad_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447883be0ca142b2aba0ad1f554359cd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">293,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5688532efb274edc8b634de1ed329963_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">208,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">84,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock from vested restricted stock units and payment of employees' taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie09435be4441486fb5d942d843092a49_D20220101-20221231" decimals="INF" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" format="ixt:num-dot-decimal" scale="0" id="f-173">64,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231" decimals="-3" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" scale="3" id="f-174">239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" scale="3" id="f-175">239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie09435be4441486fb5d942d843092a49_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-176">245,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09435be4441486fb5d942d843092a49_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-177">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-178">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-179">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie09435be4441486fb5d942d843092a49_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-180">75,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-181">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-182">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-183">4,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-184">4,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibaf731ab91df4cce9e68b8a2e71e2969_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">47,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">47,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2f4d5cd9295462fbea62e01ed3d1ff3_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-187">16,549,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f4d5cd9295462fbea62e01ed3d1ff3_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-188">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a1b430e1df4dbb8fe1a520a779c20d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-189">297,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i641ab5447323466db021f35839754d97_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-190">255,527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">42,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_115"></div><hr style="page-break-after:always"/><div style="min-height:24.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.950%"><tr><td style="width:1.0%"></td><td style="width:75.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-192">47,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-193">26,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-194">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="f-195">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-196">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-197">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-198">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-199">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-200">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-201">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="exdx:NonCashLeaseExpense" scale="3" id="f-202">967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="exdx:NonCashLeaseExpense" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="f-204">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-206">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-208">4,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-209">4,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-210">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-212">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-213">744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="f-214">505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" sign="-" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="f-215">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-216">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-217">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-218">854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-220">901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-221">655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-222">1,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-223">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-224">32,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-225">20,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-226">4,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-227">2,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:fixed-zero" scale="3" id="f-228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="f-229">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-230">4,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-231">2,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-232">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-233">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of taxes withheld on vested restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-234">239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from common stock issued under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-236">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-237">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-239">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-240">667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-241">525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on note payable obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-242">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:fixed-zero" scale="3" id="f-243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock in public offering, gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-245">69,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of issuance costs related to public offering</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f3e435c2ed49ca95de1a1d4a150248_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafc0c73bd74d46db9cc4fcd7cc90df81_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-247">4,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of deferred offering costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28979da435ba4d15844df6906e3d40bc_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie987a93eb70f4bd9b8928b29b52988fc_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-249">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-250">489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-251">64,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-252">36,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-253">41,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-254">99,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63a7f83cab04fd3bd0a7651465bc919_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-255">57,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-256">62,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-257">99,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-258">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-259">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment purchased under finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="f-260">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-261">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment purchased under notes payable obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="exdx:EquipmentPurchasedUnderNotesPayableObligations" scale="3" id="f-262">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="exdx:EquipmentPurchasedUnderNotesPayableObligations" format="ixt:fixed-zero" scale="3" id="f-263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs incurred, but not paid, in connection with capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-264">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-265">685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred offering costs reclassified to equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="exdx:DeferredOfferingCostsReclassifiedToEquity" format="ixt:fixed-zero" scale="3" id="f-266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="exdx:DeferredOfferingCostsReclassifiedToEquity" scale="3" id="f-267">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i5f5950d7f59540fa871ae1a67d589208_121"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exagen Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 1. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="f-268" continuedAt="i50f7d7a8a9e34cabaf01a997e4f675d3" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i50f7d7a8a9e34cabaf01a997e4f675d3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc. (the Company) is a commercial-stage diagnostics company dedicated to helping patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&#160;31, 2022, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-269">62.4</ix:nonFraction> million and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-270">255.5</ix:nonFraction> million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div></ix:continuation><div id="i5f5950d7f59540fa871ae1a67d589208_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 2. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-271" continuedAt="i091797383a05414d97bb6707243bd6e2" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i091797383a05414d97bb6707243bd6e2" continuedAt="i80eca7b9c28e419b9b5efc5c5036286c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the estimated incremental borrowing rate for the determination of the Company's operating lease right-of-use (ROU) assets, the recoverability of its long-lived assets and the goodwill impairment test. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="f-272" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. We have not experienced any losses on our cash or cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-273" continuedAt="ief116f51e17a4f95b63a2e5ce65aaf4d" escape="true">For each significant payor and customer, </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i80eca7b9c28e419b9b5efc5c5036286c" continuedAt="ib036f60af6a44835a9073d4e682b84c7"><ix:continuation id="ief116f51e17a4f95b63a2e5ce65aaf4d"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iad59c59cd12b4a74a51934e1011397ea_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-274">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e44acb2196c43dcb02a146b459fd4fe_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-275">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05aa9d3d5e8b4de399a58f24519f3448_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-276">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia584bf6fcda64608a116c549a02cfe67_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-277">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id47cdbd9f44c4293adf1dcb7a5ebea10_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-278">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c26ce8e296543d08e3fb5c648736bdd_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-279">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0bd5830dbe3d44b5a5396e5d707e5405_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-280">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1d5e4c6540b4d67906da80434e50044_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-281">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ded0e51d34d43b0ba062a85bc1cb346_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-282">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2022 and 2021, approximately <ix:nonFraction unitRef="number" contextRef="i3ae2b104191742ba8131e5c71bd9cbf0_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-283">84</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ibf7a3a01918e4ff8a94493a359671d39_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-284">81</ix:nonFraction>% of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is dependent on key suppliers for certain laboratory materials. For each of the years ended December&#160;31, 2022 and 2021, approximately <ix:nonFraction unitRef="number" contextRef="i0e981b26af96420cad2acd4d9d106893_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-285"><ix:nonFraction unitRef="number" contextRef="i4c3582c593ea48d582cab27bc402f10f_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-286">96</ix:nonFraction></ix:nonFraction>% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disaggregation of Revenue</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-287" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908968ff669f4aff969761449a9d8cdb_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-288">18,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88583c8fbed94b7f9798fc8421e0b721_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-289">27,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6955e97d9d4394a14813f7a52619d2_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-290">17,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481bde6d9dff47b0a38b570d9228c1c4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-291">9,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ab3e04c8cc4b3ba4e0900905568215_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-292">7,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164771fb3f1d463cbd018cef7d6365d8_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-293">9,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17536183b1b2446e830e5aa438b46c6e_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-294">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0719a3c05f2d48efb32f13d66e6f6d52_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-295">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3334b98a65be47a890ddcf70cd5ede5b_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a730aad2275470c92cce95e1567059c_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-297">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-298">45,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-299">48,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-300" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib036f60af6a44835a9073d4e682b84c7" continuedAt="i5e448ac4e29d48e9823e8eb8b213b895"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">deposit with this financial institution as collateral for the balances borrowed on these credit cards ($<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-301">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="f-302">0.1</ix:nonFraction>&#160;million at December&#160;31, 2022 and 2021, respectively). The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-303" escape="true"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-304" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-305">62,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-306">99,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-307">200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-308">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-309">62,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-310">99,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-311" continuedAt="i7c461a1b18b84b1495eab1e6b84540f8" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i7c461a1b18b84b1495eab1e6b84540f8">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:f-312">three</span> and <ix:nonNumeric contextRef="ie9c0d3ddc18741dc8fecde8d57850025_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-313">five years</ix:nonNumeric>. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.</ix:continuation> </span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-314" continuedAt="id4ab8ffb292348b48e3e30f4524b6820" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets (see Note 5). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We amortize all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets (excluding goodwill), into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test offered by us or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company recorded an impairment charge to fixed assets totaling $<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-315">0.4</ix:nonFraction>&#160;million (see Note 3). The impairment charge was classified within research and development expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5e448ac4e29d48e9823e8eb8b213b895" continuedAt="i413519e328364df0a92ff7af6fcbcf5f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="id4ab8ffb292348b48e3e30f4524b6820">During the year ended December 31, 2022, the Company recorded an impairment charge to goodwill totaling $<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-316">5.5</ix:nonFraction>&#160;million (see Note 3).</ix:continuation></span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-317" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company categorizes leases at their commencement as either operating or finance leases. Effective January 1, 2022 upon the adoption of Accounting Standards Codification (ASC) 842, the Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="exdx:ClinicalStudyPolicyPolicyTextBlock" id="f-318" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Studies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-319" continuedAt="i8da81e95b37243bdade745ebde760bd2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2022 and 2021 was a net revenue decrease of $<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-320">2.4</ix:nonFraction> million and a net revenue increase of $<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-321">0.7</ix:nonFraction> million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i413519e328364df0a92ff7af6fcbcf5f" continuedAt="i686221ad315c426397781d40c083a1cf"><ix:continuation id="i8da81e95b37243bdade745ebde760bd2" continuedAt="idb244626d1334260b933af44c8b2743b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janssen Promotion Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement, effective August 31, 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Janssen Agreement, as amended, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for that quarter over a predetermined baseline. The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit. The Company recognized no co-promotion revenue and $<ix:nonFraction unitRef="usd" contextRef="i94b61d4be67742429ba95efb0a3804d7_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-322"><ix:nonFraction unitRef="usd" contextRef="i0fb69c732f42466ca2a71e8f7eaca6ac_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-323">1.2</ix:nonFraction></ix:nonFraction> million in co-promotion revenue during the years ended December 31, 2022 and December 31, 2021, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were included in selling, general and administrative expenses and were expensed as incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the terms of the termination, the Company received $<ix:nonFraction unitRef="usd" contextRef="i8aa77feb77bd465da489e3faf3b36c72_I20211231" decimals="-5" name="exdx:ContractWithCustomerTerminationConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-324">0.6</ix:nonFraction>&#160;million in consideration (which was earned in the year ended December 31, 2021) and the Company was restricted until May 31, 2022 from promoting any other biologic or Janus kinase inhibitor used for the treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent. The restriction no longer applies.</span></div></ix:continuation><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-325" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-326" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-327">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-328">1.7</ix:nonFraction> million for the years ended December&#160;31, 2022 and 2021, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div></ix:nonNumeric><ix:continuation id="idb244626d1334260b933af44c8b2743b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i1c7294c3cf4640d08c8b4195febb6caf_D20220101-20221231" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="f-329">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic404d905bd0c456cb113003341a477fa_D20210101-20211231" decimals="-5" name="us-gaap:CostOfRevenue" scale="6" id="f-330">2.1</ix:nonFraction> million, for the years ended December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:EmployeeStockOwnershipPlanESOPPolicy" id="f-331" continuedAt="if80ce715f0be4441b4c994c1c41ff4e6" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i686221ad315c426397781d40c083a1cf" continuedAt="i98073e1707f243b4b0530859bf564896"><ix:continuation id="if80ce715f0be4441b4c994c1c41ff4e6"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the U.S. Treasury yield in effect at the time of grant. The dividend yield is <ix:nonFraction unitRef="number" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-332">zero</ix:nonFraction>, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over <ix:nonFraction unitRef="installment" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" format="ixt-sec:numwordsen" scale="0" id="f-333">four</ix:nonFraction> years from the date of grant or, for grants to new hires, date of hire.  Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div></ix:continuation><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-334" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-335" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-336" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the years ended December&#160;31, 2022 and 2021, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-337" continuedAt="ic19efb25b5664eada50f82ab0a5e1233" escape="true">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i98073e1707f243b4b0530859bf564896" continuedAt="id52a3036615e45b78750b561d9d460aa"><div><ix:continuation id="ic19efb25b5664eada50f82ab0a5e1233"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec3e133c80b243bc90f00f9a090a04ab_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-338">409,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if07865aaa84345d4855d746dc2002ad2_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-339">409,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id44e1098fa6e44dea992cd186d3949fe_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-340">1,421,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac4677048384433e8e79ba780e14863f_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-341">2,014,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i325c9bd99922498897b3b864e4d0b736_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-342">1,036,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4edbe79ab016482daa691291ec25282b_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-343">415,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iced52d7820074956a7e81f9bc4bcfa12_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-344">58,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55b44a6651b94f84bcc98d5253339f34_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-345">20,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-346">2,925,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-347">2,858,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-348" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, <ix:nonFraction unitRef="segment" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-349">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-350" continuedAt="id7733314816a431e922bd7ae13e334bf" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which was issued to provide relief to companies from restating comparative periods. On January 1, 2022, the Company adopted ASU 2016-12, using the modified retrospective transition method. Periods prior to January 1, 2022 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company adopted the new lease standard using a cumulative effect to accumulated deficit and there was no impact to accumulated deficit upon adoption. The Company elected the package of practical expedients, which among other things allowed the Company to carry forward its historical lease classification. As part of the adoption, the Company recorded operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i02725e3aa13240f183a18c6bf2fc237a_I20220101" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-351">6.4</ix:nonFraction>&#160;million, operating lease ROU assets of $<ix:nonFraction unitRef="usd" contextRef="i02725e3aa13240f183a18c6bf2fc237a_I20220101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-352">5.9</ix:nonFraction>&#160;million, adjusted for deferred rent and lease incentive obligations of $<ix:nonFraction unitRef="usd" contextRef="i02725e3aa13240f183a18c6bf2fc237a_I20220101" decimals="-5" name="us-gaap:DeferredRentCredit" format="ixt:num-dot-decimal" scale="6" id="f-353">0.5</ix:nonFraction>&#160;million previously included in other non-current liabilities and accrued and other current liabilities, pertaining to its office and laboratory space operating leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 326, Financing Instruments-Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which included an amendment of the effective date for nonpublic entities. For non-emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023 and the impact of the provisions of this standard on its Consolidated Financial Statements is expected to be immaterial.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt&#8212;Debt with Conversion and Other Options </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Subtopic 470-20) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Subtopic 815-40): </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounting for Convertible </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><ix:continuation id="id52a3036615e45b78750b561d9d460aa"><ix:continuation id="id7733314816a431e922bd7ae13e334bf"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition.  The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures.</span></ix:continuation></ix:continuation></div><div id="i5f5950d7f59540fa871ae1a67d589208_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 3. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" id="f-354" continuedAt="i71ff2020b0554000a16aff3c91b8c45e" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="i71ff2020b0554000a16aff3c91b8c45e" continuedAt="id0c96b189e2e49c3a6b9bf5a672e5a00"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-355" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-356">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-357">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="f-358">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="f-359">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:PrepaidMaintenanceAndInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-360">2,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="exdx:PrepaidMaintenanceAndInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-361">2,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="f-362">236</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="f-363">490</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-364">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-365">3,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-366" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b340fe912a484a884f93b38698848e_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-367">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if22a684f953449cfa60a7dc422eceef9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-368">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee2541dd1dc4aa3be549ad1f58851d2_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-369">5,136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc49921e5ab4d61aab13248e2b13794_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-370">4,361</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374c17c705bf414b91e482b616596378_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-371">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43bdad8afb4f45c6a1b22e9de4e0c1cd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-372">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f33d2414c044d385a05e4a4d691a0f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-373">5,223</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4b77c71742400abbf82a14977b7937_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-374">1,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fea4a51c8774db69325270c6310d222_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-375">1,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34154d30661d4701b9a9dcb4ea066485_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-376">1,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-377">13,321</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-378">8,656</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-379">5,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-380">3,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-381">8,197</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-382">4,772</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation and amortization expense for the years ended December&#160;31, 2022 and 2021, was approximately $<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-383">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-384">0.9</ix:nonFraction> million, respectively. At December&#160;31, 2022 and 2021, the gross book value of assets under finance leases was $<ix:nonFraction unitRef="usd" contextRef="i8ee2541dd1dc4aa3be549ad1f58851d2_I20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="f-385">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5dc49921e5ab4d61aab13248e2b13794_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="f-386">2.5</ix:nonFraction> million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of Long-Lived Assets and Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-387">0.4</ix:nonFraction>&#160;million related to previously capitalized equipment used in research and development activities that were halted in the fourth quarter of 2022. The Company based the fair values of these assets on their anticipated disposal values, which is considered a Level 3 measurement. The impairment charge was classified within <span style="-sec-ix-hidden:f-388">research and development expenses</span> in the accompanying statements of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that the sustained decrease in its market capitalization constituted an indicator of impairment and as a result, instead of performing a qualitative test, the Company chose to proceed directly to performing a quantitative test during the fourth quarter. The Company determined the fair value of the reporting unit using the discounted cash flow (DCF) method, which is considered a Level 3 measurement. In applying the DCF </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id0c96b189e2e49c3a6b9bf5a672e5a00"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">method, cash flows are estimated for a five-year financial forecast developed by management. A terminal value, which represents the value of additional cash flows into perpetuity, is also calculated. Cash flows are then discounted to present value at a discount rate commensurate with their risk. Based on this analysis, the carrying value of the reporting unit was in excess of the fair value and the goodwill was fully impaired. During the year ended December 31, 2022, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-389">5.5</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-390" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-391">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-392">5,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrued and Other Current Liabilities</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-394" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-395">2,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-396">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-397">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-398">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="f-399">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="f-400">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="f-401">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="f-402">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="f-403">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="f-404">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-405">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-406">587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="f-407">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-409">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-410">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-411">5,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-412">6,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5f5950d7f59540fa871ae1a67d589208_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 4. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="f-413" continuedAt="icc681f3506ed40c3a80cdd800b246631" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="icc681f3506ed40c3a80cdd800b246631" continuedAt="i797cd1ec806242c09e8ce81e6383132b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 Term Loan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended, pursuant to which the Company has borrowed $<ix:nonFraction unitRef="usd" contextRef="i21484a6d0a4a4221bf3a14d5f4de561a_D20170901-20170930" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-414">25</ix:nonFraction>&#160;million. At December&#160;31, 2022, <ix:nonFraction unitRef="usd" contextRef="iedb996e521c541bab8a8ad9236459639_D20220101-20221231" decimals="INF" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="0" id="f-415">no</ix:nonFraction> additional amounts remain available to borrow under the 2017 Term Loan. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, the Company executed the Second Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the 2017 Loan Amendment is <ix:nonFraction unitRef="number" contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-416">8.0</ix:nonFraction>%, of which <ix:nonFraction unitRef="number" contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130" decimals="INF" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="f-417">2.0</ix:nonFraction>% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2024, after which interest accrues at an annual rate of <ix:nonFraction unitRef="number" contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-418">8.0</ix:nonFraction>%. The Company has estimated the effective interest rate of this loan to be approximately <ix:nonFraction unitRef="number" contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-419">8.5</ix:nonFraction>%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the 2017 Loan Amendment will be repaid in <ix:nonFraction unitRef="installment" contextRef="ib914810c44274f05a6e9bda17b3ab8ba_D20211101-20211130" decimals="INF" name="exdx:DebtInstrumentNumberOfMonthlyInstallments" format="ixt-sec:numwordsen" scale="0" id="f-420">twenty-four</ix:nonFraction> equal monthly installments commencing in December 2024. Upon repayment of the final installment under the 2017 Loan Amendment, the Company is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="i1e65613bdd30464bac5bfc957856d90a_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-421">1.0</ix:nonFraction> million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For the years ended December&#160;31, 2022 and 2021, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="i147c9ab0d4e64ff080edac66d8c4f23b_D20220101-20221231" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="f-422">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i42e935f3a72e40e2b02e056b012588be_D20210101-20211231" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="f-423">0.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 2017 Loan Amendment requires a prepayment premium of <ix:nonFraction unitRef="number" contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="f-424">2</ix:nonFraction>% of the aggregate outstanding principal. The prepayment premium decreases by <ix:nonFraction unitRef="number" contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130" decimals="2" name="exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" scale="-2" id="f-425">1</ix:nonFraction>% on each of November&#160;1, 2023 and 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 2017 Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i797cd1ec806242c09e8ce81e6383132b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling <ix:nonNumeric contextRef="iedb996e521c541bab8a8ad9236459639_D20220101-20221231" name="exdx:DebtInstrumentCovenantRevenuePerformancePeriod" format="ixt-sec:durwordsen" id="f-426">twelve-month</ix:nonNumeric> basis, commencing with the quarter ending December 31, 2022. The consequences of failing to achieve the performance covenant may be cured if, within <ix:nonNumeric contextRef="iedb996e521c541bab8a8ad9236459639_D20220101-20221231" name="exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" format="ixt-sec:durwordsen" id="f-427">sixty days</ix:nonNumeric> of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The 2017 Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130" decimals="-5" name="exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" scale="6" id="f-428">2.0</ix:nonFraction> million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2022, the Company was in compliance with all covenants of the 2017 Loan Amendment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon an event of default in any of the 2017 Loan Amendment covenants, the repayment of the 2017 Loan Amendment may be accelerated, and the applicable interest rate will be increased by <ix:nonFraction unitRef="number" contextRef="i1e65613bdd30464bac5bfc957856d90a_I20221231" decimals="3" name="exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" scale="-2" id="f-429">4.0</ix:nonFraction>% until the default is cured. Although repayment of the 2017 Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the 2017 Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2022 Equipment Notes Payable</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, the Company purchased laboratory equipment using notes payable. At December&#160;31, 2022, the total notes payable balance related to this financed equipment was $<ix:nonFraction unitRef="usd" contextRef="ie483ad8f564a42bb865b2050775ce979_I20220531" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-430">0.8</ix:nonFraction>&#160;million, with $<ix:nonFraction unitRef="usd" contextRef="ie483ad8f564a42bb865b2050775ce979_I20220531" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-431">0.2</ix:nonFraction>&#160;million classified within borrowings-current portion and $<ix:nonFraction unitRef="usd" contextRef="ie483ad8f564a42bb865b2050775ce979_I20220531" decimals="-5" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-432">0.6</ix:nonFraction>&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to a <ix:nonFraction unitRef="number" contextRef="ie483ad8f564a42bb865b2050775ce979_I20220531" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-433">5.28</ix:nonFraction>% effective interest rate and will mature on October 1, 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future Minimum Payments on the Outstanding Borrowings</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-434" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-435">1,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-436">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-437">16,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-438">14,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:LongTermDebtIncludingUndiscountedInterest" format="ixt:num-dot-decimal" scale="3" id="f-439">36,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="f-440">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:LongTermDebtUndiscountedInterestAmount" format="ixt:num-dot-decimal" scale="3" id="f-441">7,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-442">28,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-443">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-444">28,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5f5950d7f59540fa871ae1a67d589208_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 5. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-445" continuedAt="id0eb6f1e144642d89bd64dd572419229" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="id0eb6f1e144642d89bd64dd572419229" continuedAt="i787cc9190e7c49d4ac2b8f5fa67bc54a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company adopted ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, as of January 1, 2022. Prior period amounts have not been adjusted and continue to be reported in accordance with the Company's historic accounting under ASC 840, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Leases</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i787cc9190e7c49d4ac2b8f5fa67bc54a" continuedAt="ifbdfbb41655a4d3e93c7d12332384595"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office and laboratory spaces in Vista, California, under leases that expire in April 2027, with an option to extend portions of the leases for additional <ix:nonNumeric contextRef="ib88c7c3974194380b44ecb42d60b8720_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-446">5-year</ix:nonNumeric> periods. The Company has not included the optional renewal periods in the measurement of the lease liabilities because it is not reasonably certain that the Company will exercise these renewal options. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective on August 23, 2021, the Company entered into a sub-lease agreement for an additional office space in Carlsbad, California. The sub-lease commenced in October 2021 and expires in April 2027. The sub-lease agreement provides for monthly base rent of $<ix:nonFraction unitRef="usd" contextRef="i2a8200bdcb0146bdbcb050345834cae4_I20210823" decimals="0" name="exdx:OperatingLeaseMonthlyBaseRent" format="ixt:num-dot-decimal" scale="0" id="f-447">66,021</ix:nonFraction> which began on October 1, 2021, and such amount increases by approximately <ix:nonFraction unitRef="number" contextRef="ifef633a201de4e788ff9e9950032906f_D20210823-20210823" decimals="2" name="exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" scale="-2" id="f-448">3</ix:nonFraction>% annually beginning October 1, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determines if a contract contains a lease at inception or modification of a contract. The Company discounts their lease obligations using its incremental borrowing rate at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Finance Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from <span style="-sec-ix-hidden:f-449">three</span> to <ix:nonNumeric contextRef="idbb89d0248f64893ad1ad1c6b9502e58_I20221231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durwordsen" id="f-450">five years</ix:nonNumeric> and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Finance Leases Balances and Costs</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="f-451" continuedAt="i070c09c137b2431a9780caced416dcb6" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-452">4,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-453">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-454">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-455">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-456"><span style="-sec-ix-hidden:f-457">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-458">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-459">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-460">Other non-current liabilities</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-461">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-462">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-463">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-464">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-465">2,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-466">165,000</ix:nonFraction> for the year ended December&#160;31, 2022. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifbdfbb41655a4d3e93c7d12332384595" continuedAt="ib44496c8901c48638074f8268d87215c"><ix:continuation id="i070c09c137b2431a9780caced416dcb6"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-467">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-468">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-469">667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-470">4.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-471">1.94</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-472">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-473">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-474" escape="true"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-475" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2022 are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-476">1,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-477">828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-478">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-479">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-480">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-481">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-482">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-483">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" scale="3" id="f-484">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:FinanceLeaseLiabilityToBePaidDueAfterYearFour" scale="3" id="f-485">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-486">6,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-487">1,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-488">1,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-489">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-490">5,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-491">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-492">1,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-493">700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-494">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-495">848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disclosures Under ASC 840</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="f-496" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Minimum annual lease payments under non-cancelable operating lease arrangements as of December 31, 2021 are as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ending December 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-497">1,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" format="ixt:num-dot-decimal" scale="3" id="f-498">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" format="ixt:num-dot-decimal" scale="3" id="f-499">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" format="ixt:num-dot-decimal" scale="3" id="f-500">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" format="ixt:num-dot-decimal" scale="3" id="f-501">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="f-502">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-503">7,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, rent expense was $<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-5" name="us-gaap:LeaseAndRentalExpense" format="ixt:num-dot-decimal" scale="6" id="f-504">0.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisition-related liabilities</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib44496c8901c48638074f8268d87215c"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the acquisition of the medical diagnostics division of Royalty Pharma Collection Trust (Royalty Pharma) (formerly known as Cypress Bioscience, Inc.) in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition, for which the obligations no longer exist at December&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has ongoing royalty payment obligations with Royalty Pharma of <ix:nonFraction unitRef="number" contextRef="i41c305776f9f4df98a125ab8c0085264_I20221231" decimals="3" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="f-505">2.5</ix:nonFraction>% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i935801f568bd44c0858bb0fa7df69e4a_I20221231" decimals="-5" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="6" id="f-506">1.2</ix:nonFraction> million (including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i935801f568bd44c0858bb0fa7df69e4a_I20221231" decimals="-5" name="exdx:AdvancePayment" format="ixt:num-dot-decimal" scale="6" id="f-507">0.1</ix:nonFraction> million) and (ii) the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Licensing Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from <ix:nonFraction unitRef="number" contextRef="i4befc2bf4a164a518ddb3977c94dc56e_I20221231" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="f-508">1.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6b6b2af557a44f209ce9709fa784684e_I20221231" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="f-509">7.0</ix:nonFraction>% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying statement of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute (AHN) to obtain an exclusive license to AHN's patent rights in certain inventions, pursuant to which the Company paid AHN an initial license fee of $<ix:nonFraction unitRef="usd" contextRef="i26007b31f51c41faa8926d8811c70043_D20210501-20210531" decimals="-5" name="exdx:LicenseAgreementInitialLicenseFee" scale="6" id="f-510">0.4</ix:nonFraction> million. In addition, under the terms of the exclusive license agreement, the Company is required to pay the greater of royalties in the low single digits on net sales of diagnostic tests using the assigned patents or a flat annual minimum royalty amount, pending approvals and commercialization.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, the Company entered into an exclusive license agreement with Queen Mary University of London (QMUL) to obtain an exclusive license to QMUL's patent rights in certain inventions, pursuant to which the Company paid QMUL an initial license fee of $<ix:nonFraction unitRef="usd" contextRef="i05cdd06cb9f34748beee2062757859f1_D20211101-20211130" decimals="-5" name="exdx:LicenseAgreementInitialLicenseFee" scale="6" id="f-511">0.4</ix:nonFraction> million. The Company is obligated to make a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="i05cdd06cb9f34748beee2062757859f1_D20211101-20211130" decimals="-5" name="exdx:LicenseAgreementOneTimePayment" scale="6" id="f-512">0.1</ix:nonFraction> million relating to the first commercial sale of the licensed products. In addition, after the first <ix:nonNumeric contextRef="i51903aede478415aba514640200f634b_D20211101-20211130" name="exdx:LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid" format="ixt-sec:durmonth" id="f-513">18</ix:nonNumeric> months of commercial sales under the terms of the exclusive license agreement, the Company is required to pay royalties in the high single-digits on net sales of testing products using the assigned patents, pending approvals and commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supply Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="f-514">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-5" name="us-gaap:PurchaseObligationDueInSecondYear" scale="6" id="f-515">6.9</ix:nonFraction> million for the years ended December 31, 2022 and 2023, respectively, with a <ix:nonFraction unitRef="number" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="2" name="exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage" scale="-2" id="f-516">15</ix:nonFraction>% annual increase thereafter for unconditional minimum purchase commitments through the year ending December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Obligations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into a master research collaboration agreement with AHN, pursuant to which the Company is required to pay AHN a collaboration fee of $<ix:nonFraction unitRef="usd" contextRef="ie067d973b59240a7840114c391ab933c_D20210501-20210531" decimals="-5" name="exdx:CollaborationAgreementAnnualCollaborationFee" scale="6" id="f-517">0.4</ix:nonFraction> million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $<ix:nonFraction unitRef="usd" contextRef="i0458f36c4a244111a45add1871029a6d_D20220101-20221231" decimals="-5" name="exdx:CollaborationAgreementCollaborationExpenses" scale="6" id="f-518">0.4</ix:nonFraction> million for the year ended December&#160;31, 2022. Collaboration expenses under the AHN collaboration are included in research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingencies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters will have a material effect on its financial position or results of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i5f5950d7f59540fa871ae1a67d589208_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 6. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="f-519" continuedAt="i103bcd9a173645808c83169c8a3820cf" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i103bcd9a173645808c83169c8a3820cf" continuedAt="i8171d4b884644f4d94ad13997b456f5f"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-520" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair values of the Company's long-term borrowings are determined by Level 2 inputs and are based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2022, the 2017 Term Loan had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="if7b2218400d14228b5ea985e6aa0008f_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-521">28.3</ix:nonFraction>&#160;million and a fair value of $<ix:nonFraction unitRef="usd" contextRef="if7b2218400d14228b5ea985e6aa0008f_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-522">26.9</ix:nonFraction> million. The estimated fair value of the 2017 Term Loan, which uses Level 2 fair value inputs, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's long-term borrowings as of December 31, 2021 approximated their fair values as the interest rate and other terms were that which were available to the Company at the time. See footnote 3 for discussion of recorded impairment charges related to long-lived assets and goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-523" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd84100c8b24959976b0a199271ea74_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-524">29,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d9ffdc3698e4888aa538e6a0986c347_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-525">29,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib300e2ee7d144ad286aacd3426594ffd_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba04ed946a3b41b5b8dd12ccca532017_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3950a651de784404bcb5123100be8933_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-528">30,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546dd718a1fe4f519ecd16edbb19413d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-529">30,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113a047163aa40aebcdd5ca09836f93a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba30848a1ca43d389206c0ad496522d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2462525bac435e95ff90467072cf52_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-532">59,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629348dc384e428cb5f8def2819ad0bb_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-533">59,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80eea195a57448589f21c7f4808d74e7_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia259598962414ddea394a3f3fe518c30_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01b77c5ef314817b937c1edcfce3899_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-536">95,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6adbdf0f555c4b13ba58f5c4786bdff4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-537">95,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b5adcc18404940a217b0bebcaf1387_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1435ec1361f4450385ff04cd5684f711_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-539">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i8171d4b884644f4d94ad13997b456f5f">The fair value of the Company's money market funds is based on quoted market prices.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div id="i5f5950d7f59540fa871ae1a67d589208_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 7. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-540" continuedAt="ica914f59dc714176bc264720992868ab" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="ica914f59dc714176bc264720992868ab" continuedAt="i26fdbeed7856459a9e693019a24709a9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shelf Registration Statement</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i26fdbeed7856459a9e693019a24709a9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $<ix:nonFraction unitRef="shares" contextRef="i9573d9982b2e49e9bd110183aaa2cbc6_D20201110-20201110" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="f-541">150.0</ix:nonFraction> million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 25, 2021, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="i3ca40d7976f44613b2feab35b0c59a82_D20210325-20210325" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-542">4,255,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic5d838eb19db44f7922ca98f01e9cf77_I20210325" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-543">16.25</ix:nonFraction> per share. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i3ca40d7976f44613b2feab35b0c59a82_D20210325-20210325" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-544">64.7</ix:nonFraction> million, after deducting underwriting discounts, commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="ic5d838eb19db44f7922ca98f01e9cf77_I20210325" decimals="-5" name="exdx:StockIssuanceCosts" scale="6" id="f-545">4.4</ix:nonFraction> million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">At The Market Sales Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2022, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="icfe5ad06e42c406da92d33ef14794240_D20220915-20220915" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-546">50.0</ix:nonFraction>&#160;million. The Company is not obligated to sell any shares of Company common stock in the offering. As of December&#160;31, 2022, the Company has not sold any shares of its common stock pursuant to the Sales Agreement</span><span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Exchange Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 22, 2021, the Company entered into an exchange agreement (the Exchange Agreement) with an investor and its affiliates (the Exchanging Stockholders), pursuant to which the Company exchanged an aggregate of <ix:nonFraction unitRef="shares" contextRef="i06fde84d2c1f410483f0af8e4b52b90b_D20210622-20210622" decimals="INF" name="exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants" format="ixt:num-dot-decimal" scale="0" id="f-547">804,951</ix:nonFraction> shares of the Company's common stock owned by the Exchanging Stockholders for pre-funded warrants (the Exchange Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i06fde84d2c1f410483f0af8e4b52b90b_D20210622-20210622" decimals="INF" name="exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants" format="ixt:num-dot-decimal" scale="0" id="f-548">804,951</ix:nonFraction> shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4c096e88d4fa4f49adc92daf85a0d949_I20210622" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-549">0.001</ix:nonFraction> per share. The Exchange Warrants do not expire and are exercisable at any time except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than <ix:nonFraction unitRef="number" contextRef="i06fde84d2c1f410483f0af8e4b52b90b_D20210622-20210622" decimals="4" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="f-550">4.99</ix:nonFraction>% of the Company's common stock, which percentage may change at the Exchanging Stockholder's election to any other percentage upon 61 days' notice to the Company. The Company recorded the retirement of common stock exchanged as a reduction of common shares outstanding and additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity and the fair value of the Exchange Warrants was recorded as an increase to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="if2b9bbb8d0ca4fd6a3ced6fba0c92324_I20221231" decimals="INF" name="exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-551">none</ix:nonFraction> of the Exchange Warrants have been exercised. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Outstanding Warrants</span></div><div style="margin-top:9pt"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-552" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab6f88ec0238452293973853113c2d9b_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-553">237,169</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab6f88ec0238452293973853113c2d9b_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-554">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica716265618d4d869aae1d9174b631a7_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-555">67,086</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica716265618d4d869aae1d9174b631a7_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-556">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96869c44a89140f9a1329238fc14fd52_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-557">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96869c44a89140f9a1329238fc14fd52_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-558">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93961cbee5f14ee69a98afa1d0336147_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-559">83,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93961cbee5f14ee69a98afa1d0336147_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-560">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4585060a7ed43049f692210d99fcdb0_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-561">20,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4585060a7ed43049f692210d99fcdb0_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-562">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86f954890ee9407f84dc9c97b645549a_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-563">804,951</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i86f954890ee9407f84dc9c97b645549a_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-564">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-565">1,214,059</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="INF" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" format="ixt:fixed-zero" scale="0" id="f-566">no</ix:nonFraction> warrants to purchase common stock were exercised.</span></div></ix:continuation><div id="i5f5950d7f59540fa871ae1a67d589208_145"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 8. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-567" continuedAt="i549e9b9553384923850643b6905e0d0e" escape="true">Stock Option Plan</ix:nonNumeric></span></div><ix:continuation id="i549e9b9553384923850643b6905e0d0e" continuedAt="i7eea30a72d3443aa8a36756b59c7dfd1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Incentive Award Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire <ix:nonNumeric contextRef="i4a3014a9e6354ea58eedd096ea6a7280_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-568" continuedAt="ic5d42f0d8f004c07bcb6577c2d3bf24d">ten </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7eea30a72d3443aa8a36756b59c7dfd1" continuedAt="ie3dee243bbef41878375286f2c2d1380"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ic5d42f0d8f004c07bcb6577c2d3bf24d">years</ix:continuation> after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally <ix:nonNumeric contextRef="i4a3014a9e6354ea58eedd096ea6a7280_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-569">four years</ix:nonNumeric> from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) <ix:nonFraction unitRef="number" contextRef="ia487f414d26048018d3c769a149ec0a9_I20221231" decimals="2" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" scale="-2" id="f-570">4</ix:nonFraction>% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="ia487f414d26048018d3c769a149ec0a9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-571">1,452,435</ix:nonFraction> shares remained available for future awards. Under the evergreen provision, on January 1, 2023, an additional <ix:nonFraction unitRef="shares" contextRef="ie94d37f040ba4631af4999316806f239_I20230101" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-572">661,999</ix:nonFraction> shares became available for issuance under the 2019 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i2578607c562a474a803e1e324447c4d6_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-573">20</ix:nonFraction>% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i2578607c562a474a803e1e324447c4d6_I20221231" decimals="2" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" scale="-2" id="f-574">1</ix:nonFraction>% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i2578607c562a474a803e1e324447c4d6_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-575">413,425</ix:nonFraction> shares of common stock remained available for issuance under the ESPP. Under the evergreen provision, on January 1, 2023, an additional <ix:nonFraction unitRef="shares" contextRef="if21529de837840bdaee22e04f99761a1_I20230101" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-576">165,500</ix:nonFraction> shares became available for issuances under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Options</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-577" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-578">2,014,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-579">12.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-580">7.87</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-581">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-582">63,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-583">5.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-584">245,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-585">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-586">257,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-587">16.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-588">152,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-589">13.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-590">1,421,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-591">12.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-592">7.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-593">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-594">1,421,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-595">12.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-596">7.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-597">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-598">1,129,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-599">12.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-600">6.89</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="f-601">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date fair value per share of employee options granted to employees during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-602">2.74</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-603">8.83</ix:nonFraction>, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-604">2.40</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-605">11.63</ix:nonFraction> per share at December&#160;31, 2022 and 2021, respectively. The intrinsic value of options exercised for the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="f-606">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-607">0.1</ix:nonFraction> million, respectively. As of December&#160;31, 2022, total unrecognized compensation cost related to option awards was $<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-608">1.8</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-609">1.1</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-610" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i834b1c4afb9e43a6897a5a3065173ce5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-611">415,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i834b1c4afb9e43a6897a5a3065173ce5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-612">16.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i834b1c4afb9e43a6897a5a3065173ce5_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-613">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-614">1,076,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-615">5.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-616">100,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-617">16.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-618">355,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-619">11.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-620">1,036,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-621">7.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-622">2,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie3dee243bbef41878375286f2c2d1380"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, all of the outstanding restricted stock units are unvested. The fair value of restricted stock units vested in the year ended December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="f-623">0.7</ix:nonFraction> million. <ix:nonFraction unitRef="shares" contextRef="ie9eb3d3b204543ea8d7fc8ac766d9865_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-624">No</ix:nonFraction> restricted stock units vested in the year ended December 31, 2021. The weighted average grant date fair value for restricted stock units granted during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-625">5.89</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie9eb3d3b204543ea8d7fc8ac766d9865_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-626">16.53</ix:nonFraction>, respectively. As of December&#160;31, 2022, total unrecognized compensation cost related to restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-627">6.0</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-628">3.3</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stock Options</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-629" continuedAt="i86656b86b5a04944a62c03022abea2e4" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of employee stock options was estimated using the following assumptions in the Black-Scholes options pricing model to determine the fair value of stock options granted:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-630">54</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-631">56</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-632">60</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-633">3.4</ix:nonFraction>%<ix:nonFraction unitRef="number" contextRef="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-634"></ix:nonFraction> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-635">0.8</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-636">1.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-637">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-638">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieff44339e8e5422491a24b075e89a412_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-639">5.5</ix:nonNumeric><ix:nonNumeric contextRef="i1fe07b69e3094708af8420871a48901b_D20220101-20221231" xsi:nil="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="f-640"></ix:nonNumeric> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0da55bae29084ecfb396a149ffd03213_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-641">5.5</ix:nonNumeric>-<ix:nonNumeric contextRef="i12f9febfdc354a78a3d5c5696fe66007_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-642">6.1</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Stock Purchase Plan</span></div><ix:continuation id="i86656b86b5a04944a62c03022abea2e4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-643">45</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-644">57</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-645">45</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-646">60</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-647">0.6</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-648">3.3</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-649">0.1</ix:nonFraction>%<ix:nonFraction unitRef="number" contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-650"></ix:nonFraction> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-651">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-652">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-653">0.5</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-654">0.5</ix:nonNumeric></span></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation expense related to the ESPP for the years ended December&#160;31, 2022 and 2021 was less than $<ix:nonFraction unitRef="usd" contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-655">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-656">0.2</ix:nonFraction> million, respectively. As of December&#160;31, 2022, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was less than $<ix:nonFraction unitRef="usd" contextRef="i2578607c562a474a803e1e324447c4d6_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-657">0.1</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-658">0.2</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-659" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5697bc9dcbcd4e158253d63ad580c6ca_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-660">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044ff56a8a6462daa0d36da9aa8bb53_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-661">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc29ebe03b724500a8ea2d0e5fd353d0_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-662">3,860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24fe3864155b4460a854467dbba00699_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-663">3,943</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if008ef2237244062a2ec402f2b90b70e_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-664">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abc7ffcaf3c49cba83cdb2a71ec0edf_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-665">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-666">4,704</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-667">4,728</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-668" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common stock reserved for future issuance consists of the following at December&#160;31, 2022:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b91b506545f4d24947576347cff021d_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-669">1,214,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2377d69c61584e0298f5a9998d400497_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-670">1,421,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock reserved for issuance upon vesting of outstanding restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-671">1,036,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for grant under the 2019 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe36546577a1446c8e1f0db960eceda1_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-672">1,452,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2578607c562a474a803e1e324447c4d6_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-673">413,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-674">5,537,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i5f5950d7f59540fa871ae1a67d589208_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 9. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-675" continuedAt="i5684840bfaaf45f18b6fb10c80be7388" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i5684840bfaaf45f18b6fb10c80be7388" continuedAt="i65fa1eacba3f4bbf94f45c8880f197f1"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-676" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-679">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-680">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-681">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-682">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-683">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-684">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-685">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-686">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-687">306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-688">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision (benefit) for income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-689">282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-690">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-691" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-692">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-693">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-694">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-695">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-696">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-697">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-698">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-699">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-700">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-701">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-702">23.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-703">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-704">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-705">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2022 and 2021 are shown below (in thousands). A valuation allowance has been established as realization of the Company&#8217;s deferred tax assets has not met the more likely-than-not threshold requirement. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-706" continuedAt="i2c6a912e479947cab0cf7989fe5715a2" escape="true">If the Company&#8217;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i65fa1eacba3f4bbf94f45c8880f197f1" continuedAt="id03e6927e47c4876a4c681eeb2c2a86a"><div style="margin-top:9pt"><ix:continuation id="i2c6a912e479947cab0cf7989fe5715a2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-707">29,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-708">22,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-709">2,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-710">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" scale="3" id="f-711">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" format="ixt:num-dot-decimal" scale="3" id="f-712">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-713">2,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-714">1,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-715">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-717">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-718">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-719">1,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="exdx:DeferredTaxAssetsLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalization of research and experimentation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" format="ixt:num-dot-decimal" scale="3" id="f-721">2,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" format="ixt:fixed-zero" scale="3" id="f-722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-723">39,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-724">27,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-725">38,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-726">27,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-727">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-728">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing and acquisition-related liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" format="ixt:fixed-zero" scale="3" id="f-729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="3" id="f-730">335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-732">521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-733">1,206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="exdx:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="f-734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="3" id="f-735">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="3" id="f-736">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-737">1,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-738">1,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-740">307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-741" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2022 and 2021, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-742">27,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63a7f83cab04fd3bd0a7651465bc919_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-743">20,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-744">11,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-745">6,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-746">38,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-747">27,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2022 and 2021, the Company had federal NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="f-748">118.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="f-749">89.4</ix:nonFraction> million, respectively. At December&#160;31, 2022 and 2021, the Company had state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="f-750">87.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="f-751">61.0</ix:nonFraction> million, respectively. Approximately $<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-752">43.5</ix:nonFraction> million of the federal tax loss carryforwards will begin to expire in 2023, unless previously utilized. The federal NOL carryforwards generated in after December 31, 2017 of $<ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="f-753">74.9</ix:nonFraction> million will carryforward indefinitely. The Company&#8217;s state tax loss carryforwards will expire in 2030, unless previously utilized. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2022, the Company's deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to taxation in the United States and in various state jurisdictions. The Company&#8217;s tax years for 2003 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any material accruals for, and did not recognize any, material interest or penalties in these financial statements in any period presented. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id03e6927e47c4876a4c681eeb2c2a86a"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uncertain Tax Positions </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2022 and 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-754"><ix:nonFraction unitRef="usd" contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-755">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.</span></div></ix:continuation><div id="i5f5950d7f59540fa871ae1a67d589208_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 10. <ix:nonNumeric contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-756" continuedAt="ic499706156d749098cb3b926c538d665" escape="true">401(k) Plan</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ic499706156d749098cb3b926c538d665">The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For the years ended December&#160;31, 2022 and 2021, the Company made contributions to the Plan at <ix:nonFraction unitRef="number" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-757">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-758">3</ix:nonFraction>% of qualified employee compensation, respectively. For the years ended December&#160;31, 2022 and 2021, these contributions totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-759">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-760">0.5</ix:nonFraction> million, respectively.</ix:continuation></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex231-2022bdoconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i84040f9ea5874c9f8927de3280a32664_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exagen Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vista, California</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-250015) and Form S-8 (Nos. 333-233878, 333-256014 and 333-264867) of Exagen Inc. of our report dated March&#160;20, 2023, relating to the financial statements, which appears in this Annual Report on Form 10-K. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BDO USA, LLP</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;20, 2023</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>xgn311-123122.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0ca38735bec040ff89b4e732fa50196c_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, John Aballi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Annual Report on Form 10-K of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;20, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Aballi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>xgn312-123122.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifa98a63e39a54a1785f44cd2cbe230d6_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Kamal Adawi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Annual Report on Form 10-K of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;20, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>xgn321-123122.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i27172bd8481d43e29742ae99ff348067_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:201%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying annual report on Form 10-K of the Company for the fiscal year ended December 31, 2022 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; March&#160;20, 2023</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Aballi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:16pt"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying annual report on Form 10-K of the Company for the fiscal year ended December 31, 2022 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; March&#160;20, 2023</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:16pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>exdx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b2849c68-b5c1-4aba-9f81-ca2d321b51be,g:62e4697b-763f-43ad-abbd-d704ff1dbc1d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exdx="http://www.exagen.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exagen.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.exagen.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.exagen.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.exagen.com/role/BalanceSheets">
        <link:definition>0000003 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperations" roleURI="http://www.exagen.com/role/StatementsofOperations">
        <link:definition>0000005 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofStockholdersEquity" roleURI="http://www.exagen.com/role/StatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofStockholdersEquityParenthetical" roleURI="http://www.exagen.com/role/StatementsofStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.exagen.com/role/StatementsofCashFlows">
        <link:definition>0000008 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.exagen.com/role/Organization">
        <link:definition>0000009 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.exagen.com/role/OtherFinancialInformation">
        <link:definition>0000011 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.exagen.com/role/Borrowings">
        <link:definition>0000012 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exagen.com/role/CommitmentandContingencies">
        <link:definition>0000013 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exagen.com/role/FairValueMeasurements">
        <link:definition>0000014 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exagen.com/role/StockholdersEquity">
        <link:definition>0000015 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlan" roleURI="http://www.exagen.com/role/StockOptionPlan">
        <link:definition>0000016 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exagen.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://www.exagen.com/role/A401kPlan">
        <link:definition>0000018 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.exagen.com/role/OtherFinancialInformationTables">
        <link:definition>0000021 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.exagen.com/role/BorrowingsTables">
        <link:definition>0000022 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://www.exagen.com/role/CommitmentandContingenciesTables">
        <link:definition>0000023 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exagen.com/role/FairValueMeasurementsTables">
        <link:definition>0000024 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exagen.com/role/StockholdersEquityTables">
        <link:definition>0000025 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanTables" roleURI="http://www.exagen.com/role/StockOptionPlanTables">
        <link:definition>0000026 - Disclosure - Stock Option Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.exagen.com/role/IncomeTaxesTables">
        <link:definition>0000027 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.exagen.com/role/OrganizationDetails">
        <link:definition>0000028 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>0000031 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000032 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails">
        <link:definition>0000033 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPrepaidExpensesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails">
        <link:definition>0000034 - Disclosure - Other Financial Information - Prepaid Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPropertyandEquipmentDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails">
        <link:definition>0000035 - Disclosure - Other Financial Information - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>0000036 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationGoodwillDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails">
        <link:definition>0000037 - Disclosure - Other Financial Information - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedLiabilitiesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails">
        <link:definition>0000038 - Disclosure - Other Financial Information - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails">
        <link:definition>0000039 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFutureMinimumPaymentsDetails" roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails">
        <link:definition>0000040 - Disclosure - Borrowings - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>0000041 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLeaseBalancesDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails">
        <link:definition>0000042 - Disclosure - Commitment and Contingencies - Lease Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails">
        <link:definition>0000043 - Disclosure - Commitment and Contingencies - Costs Associated with the Company's Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails">
        <link:definition>0000044 - Disclosure - Commitment and Contingencies - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails">
        <link:definition>0000045 - Disclosure - Commitment and Contingencies - Future Payments Under Operating And Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" roleURI="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1">
        <link:definition>0000045 - Disclosure - Commitment and Contingencies - Future Payments Under Operating And Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails">
        <link:definition>0000046 - Disclosure - Commitment and Contingencies - Minimum Annual Lease Payments Under Non-cancelable Lease Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails">
        <link:definition>0000047 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000048 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" roleURI="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails">
        <link:definition>0000049 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanNarrativeDetails" roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails">
        <link:definition>0000050 - Disclosure - Stock Option Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockOptionActivityDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails">
        <link:definition>0000051 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanRestrictedStockUnitsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails">
        <link:definition>0000052 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanFairValueAssumptionsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails">
        <link:definition>0000053 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockBasedCompensationExpenseDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails">
        <link:definition>0000054 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails">
        <link:definition>0000055 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>0000056 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails">
        <link:definition>0000057 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000058 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangeInValuationAllowanceDetails" roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails">
        <link:definition>0000059 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000060 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://www.exagen.com/role/A401kPlanDetails">
        <link:definition>0000061 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exdx_TwoSuppliersMember" abstract="true" name="TwoSuppliersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" abstract="false" name="OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" abstract="false" name="IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CowenEquityDistributionAgreementMember" abstract="true" name="CowenEquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ContractWithCustomerTerminationConsiderationReceivable" abstract="false" name="ContractWithCustomerTerminationConsiderationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationJan192026Member" abstract="true" name="ExpirationJan192026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" abstract="false" name="DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_AHNCollaborationMember" abstract="true" name="AHNCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_LongTermDebtIncludingUndiscountedInterest" abstract="false" name="LongTermDebtIncludingUndiscountedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_EquipmentPurchasedUnderNotesPayableObligations" abstract="false" name="EquipmentPurchasedUnderNotesPayableObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OtherOfferingMember" abstract="true" name="OtherOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_LicenseAgreementInitialLicenseFee" abstract="false" name="LicenseAgreementInitialLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IncentiveAwardPlan2019Member" abstract="true" name="IncentiveAwardPlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" abstract="true" name="CommonSharesAvailableForGrantUnderThe2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_AVISECTDTestMember" abstract="true" name="AVISECTDTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" abstract="false" name="ExchangeAgreementNumberOfSharesExchangedForWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_ExpirationApr12026Member" abstract="true" name="ExpirationApr12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_JanssenSIMPONIMember" abstract="true" name="JanssenSIMPONIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_ExpirationDec72025Member" abstract="true" name="ExpirationDec72025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" abstract="false" name="DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" abstract="false" name="IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantRevenuePerformancePeriod" abstract="false" name="DebtInstrumentCovenantRevenuePerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_OperatingLossCarryforwardsNotUtilized" abstract="false" name="OperatingLossCarryforwardsNotUtilized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeDomain" abstract="true" name="RentalPropertyByTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ExpirationMar312026Member" abstract="true" name="ExpirationMar312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_PrepaidMaintenanceAndInsuranceContracts" abstract="false" name="PrepaidMaintenanceAndInsuranceContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExchangingStockholdersMember" abstract="true" name="ExchangingStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_LicenseAgreementOneTimePayment" abstract="false" name="LicenseAgreementOneTimePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AdvancePayment" abstract="false" name="AdvancePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentPaidInKindLoansIssued" abstract="false" name="DebtInstrumentPaidInKindLoansIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AlleghenyHealthNetworkResearchInstituteMember" abstract="true" name="AlleghenyHealthNetworkResearchInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_BlueShieldMember" abstract="true" name="BlueShieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_UnitedHealthcareMember" abstract="true" name="UnitedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OfficeMember" abstract="true" name="OfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CollaborationAgreementAnnualCollaborationFee" abstract="false" name="CollaborationAgreementAnnualCollaborationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CollaborationAgreementCollaborationExpenses" abstract="false" name="CollaborationAgreementCollaborationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_Term2017Member" abstract="true" name="Term2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_StockIssuanceCosts" abstract="false" name="StockIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeAxis" abstract="true" name="RentalPropertyByTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exdx_QueenMaryUniversityOfLondonMember" abstract="true" name="QueenMaryUniversityOfLondonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_LongTermDebtUndiscountedInterestAmount" abstract="false" name="LongTermDebtUndiscountedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PrometheusLaboratoriesIncMember" abstract="true" name="PrometheusLaboratoriesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_AccruedLiabilitiesClinicalStudyCurrent" abstract="false" name="AccruedLiabilitiesClinicalStudyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DeferredOfferingCostsReclassifiedToEquity" abstract="false" name="DeferredOfferingCostsReclassifiedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ClinicalStudyPolicyPolicyTextBlock" abstract="false" name="ClinicalStudyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid" abstract="false" name="LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" abstract="true" name="ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_EquipmentNotesPayableMember" abstract="true" name="EquipmentNotesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_InnovatusLifeSciencesLendingFundMember" abstract="true" name="InnovatusLifeSciencesLendingFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exdx_DebtInstrumentNumberOfMonthlyInstallments" abstract="false" name="DebtInstrumentNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" abstract="true" name="CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ReceivableBenchmarkMember" abstract="true" name="ReceivableBenchmarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_Government1Member" abstract="true" name="Government1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_OperatingLeaseMonthlyBaseRent" abstract="false" name="OperatingLeaseMonthlyBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentStatedInterestRatePaidInKind" abstract="false" name="DebtInstrumentStatedInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_AccruedPurchaseGoodsAndServicesCurrent" abstract="false" name="AccruedPurchaseGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationSep72024Member" abstract="true" name="ExpirationSep72024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" abstract="false" name="PurchaseObligationAnnualIncreaseInCommitmentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_RoyaltyObligationPercentageOfSales" abstract="false" name="RoyaltyObligationPercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_JanssenPromotionAgreementMember" abstract="true" name="JanssenPromotionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ClientMember" abstract="true" name="ClientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>exdx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b2849c68-b5c1-4aba-9f81-ca2d321b51be,g:62e4697b-763f-43ad-abbd-d704ff1dbc1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheets" xlink:type="simple" xlink:href="exdx-20221231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_62570d21-271a-44d8-a6bc-a6e8d082f97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b8e6fee2-8d88-4fd4-b477-44c41d7654da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62570d21-271a-44d8-a6bc-a6e8d082f97e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b8e6fee2-8d88-4fd4-b477-44c41d7654da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dea9721a-274c-4be7-a8f8-ca6d3c1f7346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62570d21-271a-44d8-a6bc-a6e8d082f97e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dea9721a-274c-4be7-a8f8-ca6d3c1f7346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2a640aac-73fe-40a1-a9ac-2090e85e5af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62570d21-271a-44d8-a6bc-a6e8d082f97e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2a640aac-73fe-40a1-a9ac-2090e85e5af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_257e322c-8ac9-4418-b534-07604fe30970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62570d21-271a-44d8-a6bc-a6e8d082f97e" xlink:to="loc_us-gaap_LiabilitiesCurrent_257e322c-8ac9-4418-b534-07604fe30970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2dc2cf9-a886-4381-8801-560e444d7976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62570d21-271a-44d8-a6bc-a6e8d082f97e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2dc2cf9-a886-4381-8801-560e444d7976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93f19296-307e-42f3-9f95-6b3199b34508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0c2b9c5f-55d5-4f9f-aa12-8f85d079fadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f19296-307e-42f3-9f95-6b3199b34508" xlink:to="loc_us-gaap_PreferredStockValue_0c2b9c5f-55d5-4f9f-aa12-8f85d079fadc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_932777a8-0a0d-4d95-8325-f3299a687b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f19296-307e-42f3-9f95-6b3199b34508" xlink:to="loc_us-gaap_AdditionalPaidInCapital_932777a8-0a0d-4d95-8325-f3299a687b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffc5916b-13dd-4619-a98d-4c883573ff81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f19296-307e-42f3-9f95-6b3199b34508" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffc5916b-13dd-4619-a98d-4c883573ff81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fddb776e-b8b3-47b3-8870-0b64e2c8d1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f19296-307e-42f3-9f95-6b3199b34508" xlink:to="loc_us-gaap_CommonStockValue_fddb776e-b8b3-47b3-8870-0b64e2c8d1ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_72266c6d-3727-4441-b32b-f43c64cf8499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_219f3f93-14af-4703-829f-05ab36b7371f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_72266c6d-3727-4441-b32b-f43c64cf8499" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_219f3f93-14af-4703-829f-05ab36b7371f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7a462ac9-ff23-471b-8437-83e9ddf31bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_72266c6d-3727-4441-b32b-f43c64cf8499" xlink:to="loc_us-gaap_AssetsCurrent_7a462ac9-ff23-471b-8437-83e9ddf31bd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9cf6a977-387b-450c-b45f-08efd8d19e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_72266c6d-3727-4441-b32b-f43c64cf8499" xlink:to="loc_us-gaap_Goodwill_9cf6a977-387b-450c-b45f-08efd8d19e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7c218cb4-245b-4018-91d8-453fba803479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_72266c6d-3727-4441-b32b-f43c64cf8499" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7c218cb4-245b-4018-91d8-453fba803479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e98794a4-6aa6-4a08-a25d-304e4ad00088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_72266c6d-3727-4441-b32b-f43c64cf8499" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e98794a4-6aa6-4a08-a25d-304e4ad00088" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b82ec3f2-81a5-4d3c-b728-24eb726cf32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c0904e41-3848-4899-b3cc-b36cf57298ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b82ec3f2-81a5-4d3c-b728-24eb726cf32e" xlink:to="loc_us-gaap_AccountsPayableCurrent_c0904e41-3848-4899-b3cc-b36cf57298ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c0b99320-b72e-42f0-af48-85ee62509c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b82ec3f2-81a5-4d3c-b728-24eb726cf32e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c0b99320-b72e-42f0-af48-85ee62509c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f2aa184-f02d-45f9-81b8-37a0bdbf97ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b82ec3f2-81a5-4d3c-b728-24eb726cf32e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6f2aa184-f02d-45f9-81b8-37a0bdbf97ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_59b79bbd-b8b3-458d-b9f6-ed5e50546114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b82ec3f2-81a5-4d3c-b728-24eb726cf32e" xlink:to="loc_us-gaap_LongTermDebtCurrent_59b79bbd-b8b3-458d-b9f6-ed5e50546114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aa0d879-0de2-41d4-94e9-a577c2a69730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b93b4a52-6156-4e9c-a526-b119bbe5fb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aa0d879-0de2-41d4-94e9-a577c2a69730" xlink:to="loc_us-gaap_StockholdersEquity_b93b4a52-6156-4e9c-a526-b119bbe5fb7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_059dfdf6-df3f-4f4c-b4e6-b1fa83aa6788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aa0d879-0de2-41d4-94e9-a577c2a69730" xlink:to="loc_us-gaap_Liabilities_059dfdf6-df3f-4f4c-b4e6-b1fa83aa6788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_99ac2824-4f76-45a8-8d9a-cd13ce42295f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aa0d879-0de2-41d4-94e9-a577c2a69730" xlink:to="loc_us-gaap_CommitmentsAndContingencies_99ac2824-4f76-45a8-8d9a-cd13ce42295f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ba6ec868-88d3-454e-af24-153a40b3defa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5404daaf-7691-4722-a85a-46ec84f9a9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ba6ec868-88d3-454e-af24-153a40b3defa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5404daaf-7691-4722-a85a-46ec84f9a9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e65b4314-7a07-41ab-affd-061634178723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ba6ec868-88d3-454e-af24-153a40b3defa" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e65b4314-7a07-41ab-affd-061634178723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_e35c9d18-a364-4abf-af4d-fb3e0cccc5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ba6ec868-88d3-454e-af24-153a40b3defa" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_e35c9d18-a364-4abf-af4d-fb3e0cccc5ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofOperations" xlink:type="simple" xlink:href="exdx-20221231.xsd#StatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_50e00758-32ae-45c6-8426-c73be01b626b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5e6dc479-b7ae-4187-92d1-be2ce41793d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_50e00758-32ae-45c6-8426-c73be01b626b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5e6dc479-b7ae-4187-92d1-be2ce41793d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5f55e9c8-cffb-4da7-8f26-d53185faf4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_50e00758-32ae-45c6-8426-c73be01b626b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5f55e9c8-cffb-4da7-8f26-d53185faf4c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f6a196d3-562b-45cf-9cee-7560cc1b52ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_50e00758-32ae-45c6-8426-c73be01b626b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f6a196d3-562b-45cf-9cee-7560cc1b52ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c1841031-034e-455a-877f-59f1dbe33249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_50e00758-32ae-45c6-8426-c73be01b626b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c1841031-034e-455a-877f-59f1dbe33249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_de4f6a9c-cb29-4e79-9007-41b115003dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4c0f7388-c86d-4281-9426-535f32e51b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_de4f6a9c-cb29-4e79-9007-41b115003dd8" xlink:to="loc_us-gaap_CostsAndExpenses_4c0f7388-c86d-4281-9426-535f32e51b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c739a9b3-1db7-4c71-aa82-d9d00bf0444a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_de4f6a9c-cb29-4e79-9007-41b115003dd8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c739a9b3-1db7-4c71-aa82-d9d00bf0444a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_874cf58c-f83d-4132-abcd-3e81923cd899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fba9bb61-9efb-4d15-b096-3aec797f935f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_874cf58c-f83d-4132-abcd-3e81923cd899" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fba9bb61-9efb-4d15-b096-3aec797f935f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d934c8cf-ce22-4a66-9b08-3e4d0457a2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_874cf58c-f83d-4132-abcd-3e81923cd899" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_d934c8cf-ce22-4a66-9b08-3e4d0457a2b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9c332d6d-0c96-4fe1-a78a-364a45501e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_59eae90d-fb90-43c8-926c-a661083d5efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_9c332d6d-0c96-4fe1-a78a-364a45501e30" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_59eae90d-fb90-43c8-926c-a661083d5efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2ed9c4ab-b936-4505-b533-2f18c0113bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_9c332d6d-0c96-4fe1-a78a-364a45501e30" xlink:to="loc_us-gaap_OperatingIncomeLoss_2ed9c4ab-b936-4505-b533-2f18c0113bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a3887370-615c-4b61-bc39-c8ecc62abd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_9c332d6d-0c96-4fe1-a78a-364a45501e30" xlink:to="loc_us-gaap_InterestExpense_a3887370-615c-4b61-bc39-c8ecc62abd17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20221231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2baa8a-f892-4650-8be0-cde7421c961a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6fa73864-49e2-4436-9c7d-63c839929721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2baa8a-f892-4650-8be0-cde7421c961a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6fa73864-49e2-4436-9c7d-63c839929721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_0cda1743-87e8-457d-822f-b72707b5d101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2baa8a-f892-4650-8be0-cde7421c961a" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_0cda1743-87e8-457d-822f-b72707b5d101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_593e24f8-5b15-4d00-8aea-489a2919734b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2baa8a-f892-4650-8be0-cde7421c961a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_593e24f8-5b15-4d00-8aea-489a2919734b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_84eccfe0-658b-4897-971f-6098dd000fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2baa8a-f892-4650-8be0-cde7421c961a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_84eccfe0-658b-4897-971f-6098dd000fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a32b7d24-aa72-41cd-9d85-9f5aebd96e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2baa8a-f892-4650-8be0-cde7421c961a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a32b7d24-aa72-41cd-9d85-9f5aebd96e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_14c60a05-eeb8-43b3-ae3b-9e7a74d09b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2baa8a-f892-4650-8be0-cde7421c961a" xlink:to="loc_us-gaap_ProceedsFromStockPlans_14c60a05-eeb8-43b3-ae3b-9e7a74d09b2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0768b6d6-0710-4f58-b099-603eb8a09473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2baa8a-f892-4650-8be0-cde7421c961a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0768b6d6-0710-4f58-b099-603eb8a09473" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_0c6fbffc-8529-4a44-8293-e14e347a0009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2baa8a-f892-4650-8be0-cde7421c961a" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_0c6fbffc-8529-4a44-8293-e14e347a0009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40834a35-d9ca-4f8e-9ef6-1bfcbc0eae01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80b8ef20-6413-45ee-9b33-af64a9fa452c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40834a35-d9ca-4f8e-9ef6-1bfcbc0eae01" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80b8ef20-6413-45ee-9b33-af64a9fa452c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1d4a94e-3aac-4431-b56d-9288bd828254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40834a35-d9ca-4f8e-9ef6-1bfcbc0eae01" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1d4a94e-3aac-4431-b56d-9288bd828254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ded6e4f-5abb-4ca6-955a-be5b77dbcaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_40834a35-d9ca-4f8e-9ef6-1bfcbc0eae01" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ded6e4f-5abb-4ca6-955a-be5b77dbcaef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c975ca6a-0ea0-4331-a54a-18d478f78474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_74210d6a-cf6d-4fc7-b677-026c127bd4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c975ca6a-0ea0-4331-a54a-18d478f78474" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_74210d6a-cf6d-4fc7-b677-026c127bd4ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9f616e05-927c-478e-8a5a-c5016d25d26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c975ca6a-0ea0-4331-a54a-18d478f78474" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9f616e05-927c-478e-8a5a-c5016d25d26a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_dfef168a-e66d-425c-a31d-136f61e714ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_dfef168a-e66d-425c-a31d-136f61e714ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense_69f9b2f6-be69-4eda-88e7-a2e51d9f1328" xlink:href="exdx-20221231.xsd#exdx_NonCashLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_exdx_NonCashLeaseExpense_69f9b2f6-be69-4eda-88e7-a2e51d9f1328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6f803569-f1a2-43e4-8e33-fc910e3271a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6f803569-f1a2-43e4-8e33-fc910e3271a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_977d1602-aaac-40e8-bd15-680650b326cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_PaidInKindInterest_977d1602-aaac-40e8-bd15-680650b326cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_87312e51-7a25-4d20-b173-f59d195fdb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_87312e51-7a25-4d20-b173-f59d195fdb28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c5a82cee-5218-495b-b539-19b8d7b9e7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c5a82cee-5218-495b-b539-19b8d7b9e7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d59c2e69-7293-4eaa-9f78-e338ef065770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_ShareBasedCompensation_d59c2e69-7293-4eaa-9f78-e338ef065770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ddac670f-54ac-4d82-9c51-68abc7944904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ddac670f-54ac-4d82-9c51-68abc7944904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_4a1afaba-aa58-4828-a7ca-affcc0d033f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_4a1afaba-aa58-4828-a7ca-affcc0d033f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42d8eb10-7574-4cb1-b376-6fb55ebaddea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_NetIncomeLoss_42d8eb10-7574-4cb1-b376-6fb55ebaddea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2cafb9d5-46b2-400b-a3a1-565f45e7b7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2cafb9d5-46b2-400b-a3a1-565f45e7b7b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_9cce6959-aa83-4c13-97bb-6abde26fdd32" xlink:href="exdx-20221231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_9cce6959-aa83-4c13-97bb-6abde26fdd32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_42c7a7df-bdbb-41e9-8f76-08bab290f063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_42c7a7df-bdbb-41e9-8f76-08bab290f063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_164df721-6c86-4dd2-92ea-6bb55c55b347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_164df721-6c86-4dd2-92ea-6bb55c55b347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d355a6bf-40d0-4d1c-953b-8c110c897712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d355a6bf-40d0-4d1c-953b-8c110c897712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_73fb6c16-ee73-4313-9a74-e0f894884285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_78f0a81a-3dff-45d1-bd2f-78344a46e30d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_73fb6c16-ee73-4313-9a74-e0f894884285" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_066a345b-1267-46e7-aa92-0a2d570aa915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3536bc53-2ab3-458d-a3fb-4b1c51bb05c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_066a345b-1267-46e7-aa92-0a2d570aa915" xlink:to="loc_us-gaap_RestrictedCash_3536bc53-2ab3-458d-a3fb-4b1c51bb05c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b393e800-e08d-4547-ab01-dc511c99df27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_066a345b-1267-46e7-aa92-0a2d570aa915" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b393e800-e08d-4547-ab01-dc511c99df27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationPrepaidExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_def3f432-7f92-42ab-b24e-8b1470ffc8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d5517a33-9a23-4958-b60f-f109835443f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_def3f432-7f92-42ab-b24e-8b1470ffc8f1" xlink:to="loc_us-gaap_OtherAssetsCurrent_d5517a33-9a23-4958-b60f-f109835443f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_083825d0-fc37-4b1e-9ec7-aa7d42e869b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_def3f432-7f92-42ab-b24e-8b1470ffc8f1" xlink:to="loc_us-gaap_PrepaidRoyalties_083825d0-fc37-4b1e-9ec7-aa7d42e869b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_f44b4097-1296-4beb-99d3-97ab62bc70f6" xlink:href="exdx-20221231.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_def3f432-7f92-42ab-b24e-8b1470ffc8f1" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_f44b4097-1296-4beb-99d3-97ab62bc70f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_01f63155-d258-48ed-8b08-b1aea188dc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_def3f432-7f92-42ab-b24e-8b1470ffc8f1" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_01f63155-d258-48ed-8b08-b1aea188dc2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_92e0e096-1319-4c80-b62e-c5fb26c14a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bbd9b496-97b7-45d9-a64f-62deceaf5146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_92e0e096-1319-4c80-b62e-c5fb26c14a2e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bbd9b496-97b7-45d9-a64f-62deceaf5146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cf4b97d5-4113-49ce-ac31-8de20d4710a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_92e0e096-1319-4c80-b62e-c5fb26c14a2e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cf4b97d5-4113-49ce-ac31-8de20d4710a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b0c2e7ae-73a8-41b1-a090-411d0e657744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_b81e0e7a-37a1-43ce-a09c-feec1af62845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b0c2e7ae-73a8-41b1-a090-411d0e657744" xlink:to="loc_us-gaap_AccruedSalariesCurrent_b81e0e7a-37a1-43ce-a09c-feec1af62845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_e29dc3d5-06cc-4ce9-bc0a-86c2b6da0e51" xlink:href="exdx-20221231.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b0c2e7ae-73a8-41b1-a090-411d0e657744" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_e29dc3d5-06cc-4ce9-bc0a-86c2b6da0e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_c5b88c14-f4ed-4572-91ec-847fc7b3d464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b0c2e7ae-73a8-41b1-a090-411d0e657744" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_c5b88c14-f4ed-4572-91ec-847fc7b3d464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_6920b5ba-e52c-4ff2-8fed-5f6b14c4b056" xlink:href="exdx-20221231.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b0c2e7ae-73a8-41b1-a090-411d0e657744" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_6920b5ba-e52c-4ff2-8fed-5f6b14c4b056" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_1854a040-7b22-48b1-9ac6-7b2df422c658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b0c2e7ae-73a8-41b1-a090-411d0e657744" xlink:to="loc_us-gaap_InterestPayableCurrent_1854a040-7b22-48b1-9ac6-7b2df422c658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_7647deec-9786-4ce8-9c53-6ead46cc1e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b0c2e7ae-73a8-41b1-a090-411d0e657744" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_7647deec-9786-4ce8-9c53-6ead46cc1e8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_82de76b2-db04-4e59-b019-7f1d67a7b7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b0c2e7ae-73a8-41b1-a090-411d0e657744" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_82de76b2-db04-4e59-b019-7f1d67a7b7ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_ff75cd43-313d-4329-845a-c26601459d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b0c2e7ae-73a8-41b1-a090-411d0e657744" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_ff75cd43-313d-4329-845a-c26601459d92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#BorrowingsFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_2bda0575-5739-406a-a0e8-de57ac703932" xlink:href="exdx-20221231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_77492ff4-99a8-4a72-b715-6d0f7541e0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_2bda0575-5739-406a-a0e8-de57ac703932" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_77492ff4-99a8-4a72-b715-6d0f7541e0c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dbed3af0-104e-4516-b38c-7f81c3c52fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_2bda0575-5739-406a-a0e8-de57ac703932" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dbed3af0-104e-4516-b38c-7f81c3c52fb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c89dc3c7-82b8-4d08-a7c7-c1fbd359b76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_2bda0575-5739-406a-a0e8-de57ac703932" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c89dc3c7-82b8-4d08-a7c7-c1fbd359b76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c59e22c4-f1c1-483b-9730-1d970fc5f285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_2bda0575-5739-406a-a0e8-de57ac703932" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c59e22c4-f1c1-483b-9730-1d970fc5f285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7f13e947-d82d-4523-b33c-c7d11cf38be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_49e09bba-0125-4b29-9cac-aef4cce0c0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7f13e947-d82d-4523-b33c-c7d11cf38be3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_49e09bba-0125-4b29-9cac-aef4cce0c0c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_a7495204-11ad-404f-a79a-97f57bc2e200" xlink:href="exdx-20221231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7f13e947-d82d-4523-b33c-c7d11cf38be3" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_a7495204-11ad-404f-a79a-97f57bc2e200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_3df080f7-112d-4449-a0f2-4e7de22871fc" xlink:href="exdx-20221231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7f13e947-d82d-4523-b33c-c7d11cf38be3" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_3df080f7-112d-4449-a0f2-4e7de22871fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9897a9d4-0dd6-4d40-ad0f-a31b337ad377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_abbda494-d0e3-4b08-bc5f-ab1a2df64296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9897a9d4-0dd6-4d40-ad0f-a31b337ad377" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_abbda494-d0e3-4b08-bc5f-ab1a2df64296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_3e29039c-0157-459c-a1a3-1a401359cad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9897a9d4-0dd6-4d40-ad0f-a31b337ad377" xlink:to="loc_us-gaap_OperatingLeaseExpense_3e29039c-0157-459c-a1a3-1a401359cad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ddae7400-bf76-4bf2-994d-2570896798a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_9897a9d4-0dd6-4d40-ad0f-a31b337ad377" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ddae7400-bf76-4bf2-994d-2570896798a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e928cc45-f918-4d9b-8cdc-7772d1534563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_46274b85-ea70-40e7-aae2-a65c1653b817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e928cc45-f918-4d9b-8cdc-7772d1534563" xlink:to="loc_us-gaap_FinanceLeaseLiability_46274b85-ea70-40e7-aae2-a65c1653b817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_ebb03f90-6379-424d-b239-20fa70795d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_e928cc45-f918-4d9b-8cdc-7772d1534563" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_ebb03f90-6379-424d-b239-20fa70795d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_573209a7-3204-4d78-95d5-d5c0951e4047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c2f4da1f-097e-4488-a942-bbc465b412a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_573209a7-3204-4d78-95d5-d5c0951e4047" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c2f4da1f-097e-4488-a942-bbc465b412a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_884e0143-492e-43d5-a5d5-c52ec2444f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_573209a7-3204-4d78-95d5-d5c0951e4047" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_884e0143-492e-43d5-a5d5-c52ec2444f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_478e290d-fb40-4266-a9dd-085ca4ca2efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_573209a7-3204-4d78-95d5-d5c0951e4047" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_478e290d-fb40-4266-a9dd-085ca4ca2efb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_4a543a0d-0ad8-4f9b-be85-97198ce02058" xlink:href="exdx-20221231.xsd#exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_573209a7-3204-4d78-95d5-d5c0951e4047" xlink:to="loc_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_4a543a0d-0ad8-4f9b-be85-97198ce02058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_57ca4c4e-ab3c-4d03-a00a-ba9862d8dc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_573209a7-3204-4d78-95d5-d5c0951e4047" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_57ca4c4e-ab3c-4d03-a00a-ba9862d8dc97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6f51278d-0ce2-4109-bd41-69d032cfd98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd01c43e-4df7-4aae-ab55-27d051118521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_6f51278d-0ce2-4109-bd41-69d032cfd98a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd01c43e-4df7-4aae-ab55-27d051118521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d546f28-58f8-4e01-88cd-6d7cc6e01720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_6f51278d-0ce2-4109-bd41-69d032cfd98a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d546f28-58f8-4e01-88cd-6d7cc6e01720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_7c575389-0f5a-4f91-81ad-0359f209c628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ad8cd0b5-8307-489d-b5e3-34d1c5bb183b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_7c575389-0f5a-4f91-81ad-0359f209c628" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ad8cd0b5-8307-489d-b5e3-34d1c5bb183b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0ea01558-b7f5-447f-9a47-45370a0998e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_7c575389-0f5a-4f91-81ad-0359f209c628" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0ea01558-b7f5-447f-9a47-45370a0998e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_89db9983-9402-428d-895e-79b296820d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_10287075-dd44-4354-b49c-ab969cbd58b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_89db9983-9402-428d-895e-79b296820d6c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_10287075-dd44-4354-b49c-ab969cbd58b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_05c2d782-512d-4709-8442-10f0087e3de3" xlink:href="exdx-20221231.xsd#exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_89db9983-9402-428d-895e-79b296820d6c" xlink:to="loc_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_05c2d782-512d-4709-8442-10f0087e3de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a2cfc06f-caea-46e3-84e6-22efc2d9ea13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_89db9983-9402-428d-895e-79b296820d6c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a2cfc06f-caea-46e3-84e6-22efc2d9ea13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_e2001b79-cc56-4572-bcca-7882a68a8f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_89db9983-9402-428d-895e-79b296820d6c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_e2001b79-cc56-4572-bcca-7882a68a8f1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a4dec06e-1ab9-4742-a2b3-5cb4a4c9ae1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_89db9983-9402-428d-895e-79b296820d6c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a4dec06e-1ab9-4742-a2b3-5cb4a4c9ae1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e18137da-4e6e-4c43-b9d9-0dac5c2e33c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7352e7b9-e120-4b38-9429-f1218b3cc499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e18137da-4e6e-4c43-b9d9-0dac5c2e33c9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7352e7b9-e120-4b38-9429-f1218b3cc499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f0402be9-38d1-4e2d-a3af-476aca5fea69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e18137da-4e6e-4c43-b9d9-0dac5c2e33c9" xlink:to="loc_us-gaap_OperatingLeaseLiability_f0402be9-38d1-4e2d-a3af-476aca5fea69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_579f43ef-c246-4bfc-bb4e-00b4f1bfc1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1208153a-5333-4738-b21d-869489aad544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_579f43ef-c246-4bfc-bb4e-00b4f1bfc1ce" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1208153a-5333-4738-b21d-869489aad544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_b77002ec-37cd-4eac-a711-444072605fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_579f43ef-c246-4bfc-bb4e-00b4f1bfc1ce" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_b77002ec-37cd-4eac-a711-444072605fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_30de447e-d1f8-4f93-97de-2a1857d8d486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_579f43ef-c246-4bfc-bb4e-00b4f1bfc1ce" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_30de447e-d1f8-4f93-97de-2a1857d8d486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_874b49f4-1e66-4bf2-ae92-1e8e43e0881b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_579f43ef-c246-4bfc-bb4e-00b4f1bfc1ce" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_874b49f4-1e66-4bf2-ae92-1e8e43e0881b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_779e3c23-4d3a-4d5f-a272-6aa6a289d421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_579f43ef-c246-4bfc-bb4e-00b4f1bfc1ce" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_779e3c23-4d3a-4d5f-a272-6aa6a289d421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_d9ad804e-f046-4f65-a0fd-a70002174770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_579f43ef-c246-4bfc-bb4e-00b4f1bfc1ce" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_d9ad804e-f046-4f65-a0fd-a70002174770" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_20583424-a2fe-4cc5-951b-278ca22f2e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b05aecca-751a-44e0-b3a4-b54e54fcaf77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_20583424-a2fe-4cc5-951b-278ca22f2e11" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b05aecca-751a-44e0-b3a4-b54e54fcaf77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bf430746-d7ad-4e63-b4c8-ac27975fc633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_25ee3665-27f7-4d34-a432-c8976ce00522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bf430746-d7ad-4e63-b4c8-ac27975fc633" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_25ee3665-27f7-4d34-a432-c8976ce00522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fd4fb1d8-500e-49cf-b130-b1cb8f3a56d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bf430746-d7ad-4e63-b4c8-ac27975fc633" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fd4fb1d8-500e-49cf-b130-b1cb8f3a56d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ada99e44-4bcd-43c2-b31c-031b7b903415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ad2c92cf-0a4a-4db9-91b1-98ab3cb6b4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ada99e44-4bcd-43c2-b31c-031b7b903415" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ad2c92cf-0a4a-4db9-91b1-98ab3cb6b4fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bbe64319-3954-4933-9128-20bf0ab7767b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ada99e44-4bcd-43c2-b31c-031b7b903415" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bbe64319-3954-4933-9128-20bf0ab7767b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9393dbce-af6e-4fd2-b5e7-bee6fedd81a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_18471642-d6a0-42ad-861a-18f91946c228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9393dbce-af6e-4fd2-b5e7-bee6fedd81a8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_18471642-d6a0-42ad-861a-18f91946c228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5c3af244-bfb9-47e8-8052-78bd12066cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9393dbce-af6e-4fd2-b5e7-bee6fedd81a8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5c3af244-bfb9-47e8-8052-78bd12066cea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0dd5aacd-379f-46fe-a63d-a2b039721917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f4beaab2-65d3-4ec3-a6db-bf12b3f871cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0dd5aacd-379f-46fe-a63d-a2b039721917" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f4beaab2-65d3-4ec3-a6db-bf12b3f871cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_593ef14c-88b1-42b5-b082-52da97ca1909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0dd5aacd-379f-46fe-a63d-a2b039721917" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_593ef14c-88b1-42b5-b082-52da97ca1909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_bb88b01e-590f-4d47-897d-bb0a2fdedf09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0dd5aacd-379f-46fe-a63d-a2b039721917" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_bb88b01e-590f-4d47-897d-bb0a2fdedf09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f03bb3b8-4ff1-4a73-93b6-92e034e35954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0dd5aacd-379f-46fe-a63d-a2b039721917" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f03bb3b8-4ff1-4a73-93b6-92e034e35954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_53dcc033-f657-45fd-9d64-9d75ecf2d095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0dd5aacd-379f-46fe-a63d-a2b039721917" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_53dcc033-f657-45fd-9d64-9d75ecf2d095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dc20792d-627a-4ca0-b811-7c49538139ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0dd5aacd-379f-46fe-a63d-a2b039721917" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dc20792d-627a-4ca0-b811-7c49538139ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_42cc4674-1c23-4161-b7d6-ff29a3c6f555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_ea0ab6d5-5396-4fbc-82a6-7af9bc63c163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42cc4674-1c23-4161-b7d6-ff29a3c6f555" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_ea0ab6d5-5396-4fbc-82a6-7af9bc63c163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_c42892e0-2e3c-40c1-a7b6-afc7ae9fe3ca" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42cc4674-1c23-4161-b7d6-ff29a3c6f555" xlink:to="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_c42892e0-2e3c-40c1-a7b6-afc7ae9fe3ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9891eeb8-3575-45b5-ae96-0efe825c12b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42cc4674-1c23-4161-b7d6-ff29a3c6f555" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9891eeb8-3575-45b5-ae96-0efe825c12b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_77febcfa-acfa-4edd-ae17-e072e6f43f9d" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_42cc4674-1c23-4161-b7d6-ff29a3c6f555" xlink:to="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_77febcfa-acfa-4edd-ae17-e072e6f43f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c7d5c807-6a27-41f4-8721-4b0433513ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a156c2c7-e8ff-48fe-87e9-de1870c9e0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c7d5c807-6a27-41f4-8721-4b0433513ae5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a156c2c7-e8ff-48fe-87e9-de1870c9e0b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_60d3e66a-a46d-4e94-b4d5-2d750f15f464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c7d5c807-6a27-41f4-8721-4b0433513ae5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_60d3e66a-a46d-4e94-b4d5-2d750f15f464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_7eee807c-b14c-4aaa-a7a0-15bdc9f2e324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5950bf6a-6613-4619-becd-931a02c1d509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_7eee807c-b14c-4aaa-a7a0-15bdc9f2e324" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5950bf6a-6613-4619-becd-931a02c1d509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8c318b93-ffec-42dd-904a-a3139449b26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_7eee807c-b14c-4aaa-a7a0-15bdc9f2e324" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8c318b93-ffec-42dd-904a-a3139449b26f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e18cd53d-ea4d-424c-ba2a-96a91fa2095c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_504476fc-742b-4d1f-832b-2f01343d0e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e18cd53d-ea4d-424c-ba2a-96a91fa2095c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_504476fc-742b-4d1f-832b-2f01343d0e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5521d8f8-28dc-4bd6-b6f0-f95b5b685c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e18cd53d-ea4d-424c-ba2a-96a91fa2095c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5521d8f8-28dc-4bd6-b6f0-f95b5b685c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_91e2b5f2-c7e6-406e-803b-24d4411d2ad9" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e18cd53d-ea4d-424c-ba2a-96a91fa2095c" xlink:to="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_91e2b5f2-c7e6-406e-803b-24d4411d2ad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_876fcb59-c5c6-410b-b78b-c99170539c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e18cd53d-ea4d-424c-ba2a-96a91fa2095c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_876fcb59-c5c6-410b-b78b-c99170539c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0c1540be-07d5-4bc1-88cc-41aaac16910a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e18cd53d-ea4d-424c-ba2a-96a91fa2095c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0c1540be-07d5-4bc1-88cc-41aaac16910a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3a0188a6-2994-45ca-8ad3-1bb2e4d71e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e18cd53d-ea4d-424c-ba2a-96a91fa2095c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3a0188a6-2994-45ca-8ad3-1bb2e4d71e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_dd62224a-6f18-4dba-b27d-b681ba4f63b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e18cd53d-ea4d-424c-ba2a-96a91fa2095c" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_dd62224a-6f18-4dba-b27d-b681ba4f63b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsLeaseLiability_4560da1a-76fc-4793-9d02-e7b018478b7c" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e18cd53d-ea4d-424c-ba2a-96a91fa2095c" xlink:to="loc_exdx_DeferredTaxAssetsLeaseLiability_4560da1a-76fc-4793-9d02-e7b018478b7c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>exdx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b2849c68-b5c1-4aba-9f81-ca2d321b51be,g:62e4697b-763f-43ad-abbd-d704ff1dbc1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20221231.xsd#StatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="extended" id="i69bd20f5ad8e468cace8ceba7035c789_StatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5a4648b6-f34c-41d6-884a-567cbffd30d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5a4648b6-f34c-41d6-884a-567cbffd30d5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d8cb33e2-57f3-4064-8ff7-72ffc4904d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d8cb33e2-57f3-4064-8ff7-72ffc4904d52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac18f194-1383-40d4-af04-a88346a4a232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockholdersEquity_ac18f194-1383-40d4-af04-a88346a4a232" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf482c02-56c3-4e98-9962-fedd9344c3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf482c02-56c3-4e98-9962-fedd9344c3ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_46f360cc-d304-4dbe-84f5-3a2228a1e744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_46f360cc-d304-4dbe-84f5-3a2228a1e744" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5e68f4d1-372f-4366-8067-ba18264136be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5e68f4d1-372f-4366-8067-ba18264136be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1db7647a-50fc-4b6a-9534-fc78f67afee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1db7647a-50fc-4b6a-9534-fc78f67afee3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e510317b-bdd8-4e77-9470-8f2b10a45975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e510317b-bdd8-4e77-9470-8f2b10a45975" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_7120c705-3d78-42fa-9ecd-6b6445254f22" xlink:href="exdx-20221231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_7120c705-3d78-42fa-9ecd-6b6445254f22" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_fd978dd6-86e0-491b-a1e0-fd8d76ab75d3" xlink:href="exdx-20221231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_fd978dd6-86e0-491b-a1e0-fd8d76ab75d3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_83aedd7e-6feb-4964-9c5f-bb9a054491d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_83aedd7e-6feb-4964-9c5f-bb9a054491d7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6e788bc6-3623-48dd-b81f-d3dc7f05cd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6e788bc6-3623-48dd-b81f-d3dc7f05cd51" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60026db7-9605-4da2-a0ba-bb076c8995dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60026db7-9605-4da2-a0ba-bb076c8995dc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_be0ab0b8-d334-44d9-b04c-e75b28b74bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_be0ab0b8-d334-44d9-b04c-e75b28b74bde" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_35714bf0-8e1e-4ea0-b133-49270d5561d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_35714bf0-8e1e-4ea0-b133-49270d5561d6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_bc41de65-321f-4977-ba46-c9998b53d25b" xlink:href="exdx-20221231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_bc41de65-321f-4977-ba46-c9998b53d25b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_5be4b06a-08b0-4f04-aa94-e26f42e4f9f8" xlink:href="exdx-20221231.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_5be4b06a-08b0-4f04-aa94-e26f42e4f9f8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87ab50f6-2d9f-4ae6-9ea1-5ebb21b925cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_NetIncomeLoss_87ab50f6-2d9f-4ae6-9ea1-5ebb21b925cc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ad0861c2-e372-467c-9870-493352d19adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0d38e2e-981d-403c-ad82-8472f9b8e3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a675418e-418f-4805-a273-65364cd80056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5a4648b6-f34c-41d6-884a-567cbffd30d5" xlink:to="loc_us-gaap_StatementTable_a675418e-418f-4805-a273-65364cd80056" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d462c6a3-8e9d-4ba0-ab97-3b4db3429f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a675418e-418f-4805-a273-65364cd80056" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d462c6a3-8e9d-4ba0-ab97-3b4db3429f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d462c6a3-8e9d-4ba0-ab97-3b4db3429f5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d462c6a3-8e9d-4ba0-ab97-3b4db3429f5f" xlink:to="loc_us-gaap_EquityComponentDomain_d462c6a3-8e9d-4ba0-ab97-3b4db3429f5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d462c6a3-8e9d-4ba0-ab97-3b4db3429f5f" xlink:to="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3532d832-7105-4319-b5d4-5143f7633d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:to="loc_us-gaap_CommonStockMember_3532d832-7105-4319-b5d4-5143f7633d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_90a9c6d5-e7a6-40c5-8065-5cfb5c4c8502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_90a9c6d5-e7a6-40c5-8065-5cfb5c4c8502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d7e6dd02-86a5-4576-8e00-644853710ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:to="loc_us-gaap_RetainedEarningsMember_d7e6dd02-86a5-4576-8e00-644853710ea8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20221231.xsd#StatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended" id="i7e6abfa2150a425b8b173999a96d2d57_StatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e0b0b05-4329-4377-83ef-6e29c180eeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:to="loc_us-gaap_NetIncomeLoss_4e0b0b05-4329-4377-83ef-6e29c180eeb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_927aa7ba-d083-420e-b643-263d6846b1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_927aa7ba-d083-420e-b643-263d6846b1f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b74c202f-0213-4701-8a70-bfb7a64a3477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b74c202f-0213-4701-8a70-bfb7a64a3477" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_c81eb4af-55bf-4c65-af9a-6a57dbc7714e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_PaidInKindInterest_c81eb4af-55bf-4c65-af9a-6a57dbc7714e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_97ade2e6-3900-4487-bc9e-f413830058a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_97ade2e6-3900-4487-bc9e-f413830058a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense_f202e866-51fb-4ee6-95b8-f9da98829f0e" xlink:href="exdx-20221231.xsd#exdx_NonCashLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_exdx_NonCashLeaseExpense_f202e866-51fb-4ee6-95b8-f9da98829f0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_08d4ea15-6850-4750-a48d-1667d0adce01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_08d4ea15-6850-4750-a48d-1667d0adce01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e7434187-dee1-4d50-aaf4-3538bb88dcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e7434187-dee1-4d50-aaf4-3538bb88dcab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7eba0f77-8991-423c-90fa-61174def1ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_ShareBasedCompensation_7eba0f77-8991-423c-90fa-61174def1ed3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d92509fd-40a7-4e21-b41f-d31a6f69d7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d92509fd-40a7-4e21-b41f-d31a6f69d7b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dee51940-278e-430d-993a-8d04c4826b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dee51940-278e-430d-993a-8d04c4826b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_058a1fe4-5aff-4066-b120-71b1b73024ef" xlink:href="exdx-20221231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_058a1fe4-5aff-4066-b120-71b1b73024ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_49508046-0f7c-4305-9f7c-857d7cca06f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_49508046-0f7c-4305-9f7c-857d7cca06f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_af798070-335f-421b-b5ec-e5d6c04e9088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_af798070-335f-421b-b5ec-e5d6c04e9088" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_428de4b0-758c-4387-b6bd-86cf2afc05ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_428de4b0-758c-4387-b6bd-86cf2afc05ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fe773549-8784-4a0e-9244-3bea9749e1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fe773549-8784-4a0e-9244-3bea9749e1cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4326ea2c-0d66-4bfd-bb13-229b6b283a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4326ea2c-0d66-4bfd-bb13-229b6b283a06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84d8f16a-a856-4fdc-9a12-eed927e9815d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84d8f16a-a856-4fdc-9a12-eed927e9815d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_90fce929-f119-4d1a-b72c-3f95bfe77a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_90fce929-f119-4d1a-b72c-3f95bfe77a93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38a779bf-af63-43d2-ab5d-990231c634f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38a779bf-af63-43d2-ab5d-990231c634f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_adbd16b6-c1a2-42d3-9879-65de1972e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_adbd16b6-c1a2-42d3-9879-65de1972e13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7ffdf360-4a84-4fa4-8b2c-bf6917599ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7ffdf360-4a84-4fa4-8b2c-bf6917599ff0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d371875c-70b4-46ef-827f-7cb8f94b5e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d371875c-70b4-46ef-827f-7cb8f94b5e26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5d506b13-aa8f-4d13-a0fd-27a8dbb17662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5d506b13-aa8f-4d13-a0fd-27a8dbb17662" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4c1c00d8-7f0e-4b4d-ba45-a58f439b1475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_4c1c00d8-7f0e-4b4d-ba45-a58f439b1475" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_a3b83c3a-a7fa-4bbb-8522-682d55ddd885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_a3b83c3a-a7fa-4bbb-8522-682d55ddd885" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_76d61c61-df71-47aa-9c17-7b1ab5a5ca89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_76d61c61-df71-47aa-9c17-7b1ab5a5ca89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_70804ecd-1f9d-440f-83af-ac9a9c87d17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_70804ecd-1f9d-440f-83af-ac9a9c87d17d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4a30c33-554b-491d-8ec5-4963fcb02aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4a30c33-554b-491d-8ec5-4963fcb02aad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19a064b7-1506-41c4-bb9b-e9da7ee75740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19a064b7-1506-41c4-bb9b-e9da7ee75740" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef73de66-f2a2-416c-b451-e3ff648aab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef73de66-f2a2-416c-b451-e3ff648aab6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_819b2879-e070-412a-9237-cad430ce55e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_de62a7ab-212a-4f08-80a1-865d2a6368ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_de62a7ab-212a-4f08-80a1-865d2a6368ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b8bb42c9-b1dd-4b38-8178-aaf8eb80c3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_de62a7ab-212a-4f08-80a1-865d2a6368ec" xlink:to="loc_us-gaap_InterestPaidNet_b8bb42c9-b1dd-4b38-8178-aaf8eb80c3ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_78d9ff26-b17d-4f74-b94f-64008c00f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_78d9ff26-b17d-4f74-b94f-64008c00f17d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_04541a6e-0931-4f8b-a172-75181ad824c1" xlink:href="exdx-20221231.xsd#exdx_EquipmentPurchasedUnderNotesPayableObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:to="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_04541a6e-0931-4f8b-a172-75181ad824c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c05ed1b-b268-41a3-9eec-83ffcf4a8949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c05ed1b-b268-41a3-9eec-83ffcf4a8949" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_eb3fd37f-98c1-4c6c-9a4f-720aee3e6175" xlink:href="exdx-20221231.xsd#exdx_DeferredOfferingCostsReclassifiedToEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:to="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_eb3fd37f-98c1-4c6c-9a4f-720aee3e6175" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_86004103-e8a8-4e1c-81f7-d7e6d39f0bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_StatementTable_86004103-e8a8-4e1c-81f7-d7e6d39f0bb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_88eae0e4-36e8-4cce-8a31-aa871afedf14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_86004103-e8a8-4e1c-81f7-d7e6d39f0bb7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_88eae0e4-36e8-4cce-8a31-aa871afedf14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88eae0e4-36e8-4cce-8a31-aa871afedf14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_88eae0e4-36e8-4cce-8a31-aa871afedf14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88eae0e4-36e8-4cce-8a31-aa871afedf14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d17f381e-e9c1-4294-9194-816d284d8243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_88eae0e4-36e8-4cce-8a31-aa871afedf14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d17f381e-e9c1-4294-9194-816d284d8243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PublicOfferingMember_3f190b2b-42a1-4550-96c6-e5ece7e207f6" xlink:href="exdx-20221231.xsd#exdx_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d17f381e-e9c1-4294-9194-816d284d8243" xlink:to="loc_exdx_PublicOfferingMember_3f190b2b-42a1-4550-96c6-e5ece7e207f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherOfferingMember_192f2281-d7e0-45d2-9b68-e3778cb88b83" xlink:href="exdx-20221231.xsd#exdx_OtherOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d17f381e-e9c1-4294-9194-816d284d8243" xlink:to="loc_exdx_OtherOfferingMember_192f2281-d7e0-45d2-9b68-e3778cb88b83" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended" id="i297125687d254e7d8302e69ec283deb0_SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f34ca8d2-2ed0-49ed-a58b-e73b3ac86a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b523cd9e-1d52-441d-a933-48986d97ee1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f34ca8d2-2ed0-49ed-a58b-e73b3ac86a2a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b523cd9e-1d52-441d-a933-48986d97ee1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f34ca8d2-2ed0-49ed-a58b-e73b3ac86a2a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f693be69-da9c-455a-9cdd-70d8a1d33929" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:to="loc_srt_MajorCustomersAxis_f693be69-da9c-455a-9cdd-70d8a1d33929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f693be69-da9c-455a-9cdd-70d8a1d33929_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f693be69-da9c-455a-9cdd-70d8a1d33929" xlink:to="loc_srt_NameOfMajorCustomerDomain_f693be69-da9c-455a-9cdd-70d8a1d33929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f693be69-da9c-455a-9cdd-70d8a1d33929" xlink:to="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_b5b4f234-f654-425a-b4ae-a06a583ee2b5" xlink:href="exdx-20221231.xsd#exdx_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:to="loc_exdx_MedicareMember_b5b4f234-f654-425a-b4ae-a06a583ee2b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_199e6e68-bb21-4c6c-aab5-6c86b6ceea93" xlink:href="exdx-20221231.xsd#exdx_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:to="loc_exdx_MedicareAdvantageMember_199e6e68-bb21-4c6c-aab5-6c86b6ceea93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_b8a87682-fa2e-43d7-a9aa-89f779cc20f5" xlink:href="exdx-20221231.xsd#exdx_BlueShieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:to="loc_exdx_BlueShieldMember_b8a87682-fa2e-43d7-a9aa-89f779cc20f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_a2647a54-0047-4808-9aa0-35dd08cbf460" xlink:href="exdx-20221231.xsd#exdx_UnitedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:to="loc_exdx_UnitedHealthcareMember_a2647a54-0047-4808-9aa0-35dd08cbf460" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d60e0e49-0853-443d-b7c3-c91f01cf075f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d60e0e49-0853-443d-b7c3-c91f01cf075f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d60e0e49-0853-443d-b7c3-c91f01cf075f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d60e0e49-0853-443d-b7c3-c91f01cf075f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d60e0e49-0853-443d-b7c3-c91f01cf075f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbf42c9-16f9-41c7-80ab-815a8715e0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d60e0e49-0853-443d-b7c3-c91f01cf075f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbf42c9-16f9-41c7-80ab-815a8715e0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_eb703a86-c7e1-4288-b0c1-9e2f8755f174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbf42c9-16f9-41c7-80ab-815a8715e0aa" xlink:to="loc_us-gaap_SalesRevenueNetMember_eb703a86-c7e1-4288-b0c1-9e2f8755f174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_1da8decf-6f3c-4c3e-8969-77a520d6e3d7" xlink:href="exdx-20221231.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbf42c9-16f9-41c7-80ab-815a8715e0aa" xlink:to="loc_exdx_ReceivableBenchmarkMember_1da8decf-6f3c-4c3e-8969-77a520d6e3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0fe2d217-1fe5-474d-bf44-a16f3e79da9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0fe2d217-1fe5-474d-bf44-a16f3e79da9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0fe2d217-1fe5-474d-bf44-a16f3e79da9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0fe2d217-1fe5-474d-bf44-a16f3e79da9d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0fe2d217-1fe5-474d-bf44-a16f3e79da9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_63d18051-98f7-4a6d-8eb2-dc03ac3699d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0fe2d217-1fe5-474d-bf44-a16f3e79da9d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_63d18051-98f7-4a6d-8eb2-dc03ac3699d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6ffa325e-2dee-4be5-86fb-e6826029d35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_63d18051-98f7-4a6d-8eb2-dc03ac3699d8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6ffa325e-2dee-4be5-86fb-e6826029d35a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i5ceab8e788024813b69507c756d4c456_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_407303e7-2390-4d1d-bb36-b749f782a40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_407303e7-2390-4d1d-bb36-b749f782a40e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_9374e067-b3cb-4f67-8692-bcd470ac4447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_RestrictedCash_9374e067-b3cb-4f67-8692-bcd470ac4447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4f5bb82a-43d1-4dfc-a574-a140af04a517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4f5bb82a-43d1-4dfc-a574-a140af04a517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_384e61a2-5810-4a66-b44e-5e4ee983b80c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_384e61a2-5810-4a66-b44e-5e4ee983b80c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f07150e3-6d9a-4ee7-b846-6caa3e6f1b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f07150e3-6d9a-4ee7-b846-6caa3e6f1b6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dae4d362-3fe0-4418-bc9e-33dded6a76f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dae4d362-3fe0-4418-bc9e-33dded6a76f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6548f36-5798-4856-bc4e-327b2b419d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6548f36-5798-4856-bc4e-327b2b419d0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ContractWithCustomerTerminationConsiderationReceivable_908e000e-a61d-44e7-95ca-5a6b53600b66" xlink:href="exdx-20221231.xsd#exdx_ContractWithCustomerTerminationConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_exdx_ContractWithCustomerTerminationConsiderationReceivable_908e000e-a61d-44e7-95ca-5a6b53600b66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_45d10efe-d2e3-457e-87ce-ee28a026e24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_AdvertisingExpense_45d10efe-d2e3-457e-87ce-ee28a026e24b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c18004fb-c816-4ac1-b7f2-20f74393ada5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_CostOfRevenue_c18004fb-c816-4ac1-b7f2-20f74393ada5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b841420f-525c-48ba-9a08-982f477a8134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b841420f-525c-48ba-9a08-982f477a8134" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_4707ebe1-4c0b-4f22-bcd8-08a3cf99f302" xlink:href="exdx-20221231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_4707ebe1-4c0b-4f22-bcd8-08a3cf99f302" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b7eec0ac-efc3-43e4-b42f-aa5efd26c8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b7eec0ac-efc3-43e4-b42f-aa5efd26c8b4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a2e78787-8103-4541-84a3-f95771a3a930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_OperatingLeaseLiability_a2e78787-8103-4541-84a3-f95771a3a930" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa0e9d23-9ad9-48ab-bc78-3f126b521458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa0e9d23-9ad9-48ab-bc78-3f126b521458" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCredit_fa478dd9-ede2-4720-a53c-ac11b0e48fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_DeferredRentCredit_fa478dd9-ede2-4720-a53c-ac11b0e48fc2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_160f7014-ef9a-4efb-81e2-767790591559" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_srt_CounterpartyNameAxis_160f7014-ef9a-4efb-81e2-767790591559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_160f7014-ef9a-4efb-81e2-767790591559_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_160f7014-ef9a-4efb-81e2-767790591559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_160f7014-ef9a-4efb-81e2-767790591559_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b145e99-5825-4921-ad95-3cc8a60c829b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_160f7014-ef9a-4efb-81e2-767790591559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b145e99-5825-4921-ad95-3cc8a60c829b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_372574fc-a090-4a2a-9294-f32f52bf0599" xlink:href="exdx-20221231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b145e99-5825-4921-ad95-3cc8a60c829b" xlink:to="loc_exdx_JanssenSIMPONIMember_372574fc-a090-4a2a-9294-f32f52bf0599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df5aac16-9775-4769-878d-16b365bcaf01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df5aac16-9775-4769-878d-16b365bcaf01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df5aac16-9775-4769-878d-16b365bcaf01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df5aac16-9775-4769-878d-16b365bcaf01" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df5aac16-9775-4769-878d-16b365bcaf01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d1d3dc4-6e01-4334-823d-e2d91190de90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df5aac16-9775-4769-878d-16b365bcaf01" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d1d3dc4-6e01-4334-823d-e2d91190de90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_41b5cbe9-04ea-4785-832f-5d1c53acb5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d1d3dc4-6e01-4334-823d-e2d91190de90" xlink:to="loc_us-gaap_SalesRevenueNetMember_41b5cbe9-04ea-4785-832f-5d1c53acb5f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d6f2e57a-b1d7-4677-a6f6-9e96acf12fa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_srt_ProductOrServiceAxis_d6f2e57a-b1d7-4677-a6f6-9e96acf12fa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6f2e57a-b1d7-4677-a6f6-9e96acf12fa3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d6f2e57a-b1d7-4677-a6f6-9e96acf12fa3" xlink:to="loc_srt_ProductsAndServicesDomain_d6f2e57a-b1d7-4677-a6f6-9e96acf12fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67e74161-0918-482a-b220-a4606b7965ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d6f2e57a-b1d7-4677-a6f6-9e96acf12fa3" xlink:to="loc_srt_ProductsAndServicesDomain_67e74161-0918-482a-b220-a4606b7965ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_c814f753-9a8c-43a7-b0ad-e0ca0244b2a8" xlink:href="exdx-20221231.xsd#exdx_AVISECTDTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67e74161-0918-482a-b220-a4606b7965ff" xlink:to="loc_exdx_AVISECTDTestMember_c814f753-9a8c-43a7-b0ad-e0ca0244b2a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_32b38f0a-a689-4486-8556-8ad6503eca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67e74161-0918-482a-b220-a4606b7965ff" xlink:to="loc_us-gaap_ShippingAndHandlingMember_32b38f0a-a689-4486-8556-8ad6503eca3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_722e7019-ed8a-4e51-8095-01d511b73916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_722e7019-ed8a-4e51-8095-01d511b73916" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_722e7019-ed8a-4e51-8095-01d511b73916_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_722e7019-ed8a-4e51-8095-01d511b73916" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_722e7019-ed8a-4e51-8095-01d511b73916_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8b12bb03-1fec-4c47-9f66-f346cb54933d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_722e7019-ed8a-4e51-8095-01d511b73916" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8b12bb03-1fec-4c47-9f66-f346cb54933d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_ba3e8cbc-d9c5-478d-8b09-1d5cc315ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8b12bb03-1fec-4c47-9f66-f346cb54933d" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_ba3e8cbc-d9c5-478d-8b09-1d5cc315ef7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_63873920-a356-4d82-80c2-212260c9d959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8b12bb03-1fec-4c47-9f66-f346cb54933d" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_63873920-a356-4d82-80c2-212260c9d959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3678217-3f85-4728-a648-b618f198cd45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_srt_RangeAxis_f3678217-3f85-4728-a648-b618f198cd45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3678217-3f85-4728-a648-b618f198cd45_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f3678217-3f85-4728-a648-b618f198cd45" xlink:to="loc_srt_RangeMember_f3678217-3f85-4728-a648-b618f198cd45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e20360c7-d46a-41ee-ae1d-6b8f38974e1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f3678217-3f85-4728-a648-b618f198cd45" xlink:to="loc_srt_RangeMember_e20360c7-d46a-41ee-ae1d-6b8f38974e1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b080e444-1fbe-4cf0-848e-7def6bfadede" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e20360c7-d46a-41ee-ae1d-6b8f38974e1c" xlink:to="loc_srt_MinimumMember_b080e444-1fbe-4cf0-848e-7def6bfadede" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_43c10c3f-88ee-4959-92a3-a02ae2431adc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e20360c7-d46a-41ee-ae1d-6b8f38974e1c" xlink:to="loc_srt_MaximumMember_43c10c3f-88ee-4959-92a3-a02ae2431adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_833a320d-03e9-4270-94b8-eabf2913db3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_833a320d-03e9-4270-94b8-eabf2913db3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_833a320d-03e9-4270-94b8-eabf2913db3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_833a320d-03e9-4270-94b8-eabf2913db3b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_833a320d-03e9-4270-94b8-eabf2913db3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efedb02c-42a2-4ec7-b26f-0202648cba3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_833a320d-03e9-4270-94b8-eabf2913db3b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efedb02c-42a2-4ec7-b26f-0202648cba3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenPromotionAgreementMember_65a3fd36-5a1e-439f-bfaf-c7d8ba649745" xlink:href="exdx-20221231.xsd#exdx_JanssenPromotionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efedb02c-42a2-4ec7-b26f-0202648cba3c" xlink:to="loc_exdx_JanssenPromotionAgreementMember_65a3fd36-5a1e-439f-bfaf-c7d8ba649745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_6b520706-6f49-4cf2-a3b8-626537f91060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_6b520706-6f49-4cf2-a3b8-626537f91060" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6b520706-6f49-4cf2-a3b8-626537f91060_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_6b520706-6f49-4cf2-a3b8-626537f91060" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_6b520706-6f49-4cf2-a3b8-626537f91060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_617dfa9e-c565-41ed-844d-7611222fb344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_6b520706-6f49-4cf2-a3b8-626537f91060" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_617dfa9e-c565-41ed-844d-7611222fb344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoSuppliersMember_8555a0a4-0d78-4e05-bbe9-e312fd7a7553" xlink:href="exdx-20221231.xsd#exdx_TwoSuppliersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_617dfa9e-c565-41ed-844d-7611222fb344" xlink:to="loc_exdx_TwoSuppliersMember_8555a0a4-0d78-4e05-bbe9-e312fd7a7553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_64a95abb-9d9f-486b-92ba-e915f7076625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_64a95abb-9d9f-486b-92ba-e915f7076625" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_64a95abb-9d9f-486b-92ba-e915f7076625_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_64a95abb-9d9f-486b-92ba-e915f7076625" xlink:to="loc_us-gaap_TypeOfAdoptionMember_64a95abb-9d9f-486b-92ba-e915f7076625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1de85812-26f7-4000-aea3-d575ef3cb19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_64a95abb-9d9f-486b-92ba-e915f7076625" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1de85812-26f7-4000-aea3-d575ef3cb19a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_c24f7a55-fab9-4127-b068-48767e684839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1de85812-26f7-4000-aea3-d575ef3cb19a" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_c24f7a55-fab9-4127-b068-48767e684839" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e90376-4f34-4ea9-bfea-eed28b57424f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e90376-4f34-4ea9-bfea-eed28b57424f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_35e90376-4f34-4ea9-bfea-eed28b57424f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e90376-4f34-4ea9-bfea-eed28b57424f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_35e90376-4f34-4ea9-bfea-eed28b57424f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_79cf2f5a-9565-4c41-8d2b-a3645981b8cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e90376-4f34-4ea9-bfea-eed28b57424f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_79cf2f5a-9565-4c41-8d2b-a3645981b8cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_166d1882-8537-44f3-96b3-8ea4809be76f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_79cf2f5a-9565-4c41-8d2b-a3645981b8cf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_166d1882-8537-44f3-96b3-8ea4809be76f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended" id="i021b1ef8914d42a3822788a7415ac50c_SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_39cf7527-f741-4f4b-936d-91eca5835e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6602605-1fde-4b03-807e-59960da103bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39cf7527-f741-4f4b-936d-91eca5835e2a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6602605-1fde-4b03-807e-59960da103bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ab9da3de-d9ef-4da7-a44f-c628958a5db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39cf7527-f741-4f4b-936d-91eca5835e2a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ab9da3de-d9ef-4da7-a44f-c628958a5db5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_01ab098a-bd23-423e-9d51-0d298b4e5edf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab9da3de-d9ef-4da7-a44f-c628958a5db5" xlink:to="loc_srt_MajorCustomersAxis_01ab098a-bd23-423e-9d51-0d298b4e5edf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_01ab098a-bd23-423e-9d51-0d298b4e5edf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_01ab098a-bd23-423e-9d51-0d298b4e5edf" xlink:to="loc_srt_NameOfMajorCustomerDomain_01ab098a-bd23-423e-9d51-0d298b4e5edf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_01ab098a-bd23-423e-9d51-0d298b4e5edf" xlink:to="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommercialMember_62c5bb17-563a-4848-9b84-11250de3d3e1" xlink:href="exdx-20221231.xsd#exdx_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_exdx_CommercialMember_62c5bb17-563a-4848-9b84-11250de3d3e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_c5d76417-5784-4fc8-aaf6-8835a0dbc637" xlink:href="exdx-20221231.xsd#exdx_Government1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_exdx_Government1Member_c5d76417-5784-4fc8-aaf6-8835a0dbc637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_d3f02b5c-c15c-4f8e-a5ec-a89b9bac3950" xlink:href="exdx-20221231.xsd#exdx_ClientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_exdx_ClientMember_d3f02b5c-c15c-4f8e-a5ec-a89b9bac3950" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_b90d3caa-e05c-4940-97a2-0f240b7a285d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_us-gaap_OtherCustomerMember_b90d3caa-e05c-4940-97a2-0f240b7a285d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_9077b611-99a8-4ca8-9cac-4cf50ac0bc25" xlink:href="exdx-20221231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_exdx_JanssenSIMPONIMember_9077b611-99a8-4ca8-9cac-4cf50ac0bc25" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended" id="if94c2e6ca36f44e2b012bf612f373341_SummaryofSignificantAccountingPoliciesSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_030c6222-908b-4a00-a5c5-ea4bff886b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b06b0e8a-d09d-4927-88ef-b7546bb78ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_030c6222-908b-4a00-a5c5-ea4bff886b2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b06b0e8a-d09d-4927-88ef-b7546bb78ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0394d66b-c170-425e-aa4c-89e47a1f0eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_030c6222-908b-4a00-a5c5-ea4bff886b2e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0394d66b-c170-425e-aa4c-89e47a1f0eb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b38bce64-beed-44f0-ba46-8dacd83f8354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0394d66b-c170-425e-aa4c-89e47a1f0eb1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b38bce64-beed-44f0-ba46-8dacd83f8354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b38bce64-beed-44f0-ba46-8dacd83f8354_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b38bce64-beed-44f0-ba46-8dacd83f8354" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b38bce64-beed-44f0-ba46-8dacd83f8354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b38bce64-beed-44f0-ba46-8dacd83f8354" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3bb0e574-43f2-4d13-8c31-ec0f12f04a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:to="loc_us-gaap_WarrantMember_3bb0e574-43f2-4d13-8c31-ec0f12f04a03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_cf2a1149-adf6-460f-b20d-e47a6d72639d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:to="loc_us-gaap_StockOptionMember_cf2a1149-adf6-460f-b20d-e47a6d72639d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a37b372f-689a-4105-b428-26f9b1989548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a37b372f-689a-4105-b428-26f9b1989548" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b79555ee-6953-4e9b-aff9-441c54d84d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:to="loc_us-gaap_EmployeeStockMember_b79555ee-6953-4e9b-aff9-441c54d84d4a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="extended" id="i8d2aeda454db4e1aa000d5654330dc19_OtherFinancialInformationPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4e815b9f-54b8-4a39-a825-cd4acbf055dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4e815b9f-54b8-4a39-a825-cd4acbf055dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8eb4ee0a-7840-4d84-a52e-43cbfa7eac97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8eb4ee0a-7840-4d84-a52e-43cbfa7eac97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9b49f03f-6955-4fc7-bd31-d0c8429a1484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9b49f03f-6955-4fc7-bd31-d0c8429a1484" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f60abffb-13f0-4f7a-aa4d-da070f85c446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f60abffb-13f0-4f7a-aa4d-da070f85c446" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_90674098-4737-442c-bf3b-bc1baf865638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f60abffb-13f0-4f7a-aa4d-da070f85c446" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_90674098-4737-442c-bf3b-bc1baf865638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90674098-4737-442c-bf3b-bc1baf865638_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_90674098-4737-442c-bf3b-bc1baf865638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90674098-4737-442c-bf3b-bc1baf865638_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_90674098-4737-442c-bf3b-bc1baf865638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_28561651-2c00-4fb8-9c60-5f1c4391de6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_28561651-2c00-4fb8-9c60-5f1c4391de6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_5fe89b9a-7e3c-4f51-a750-c984c572e1bd" xlink:href="exdx-20221231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_exdx_LaboratoryEquipmentMember_5fe89b9a-7e3c-4f51-a750-c984c572e1bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_0c676241-a0c4-4c1a-bd43-00122e1bbd93" xlink:href="exdx-20221231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_0c676241-a0c4-4c1a-bd43-00122e1bbd93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8c614287-9f75-4e7a-aeb8-3a46def921cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8c614287-9f75-4e7a-aeb8-3a46def921cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_33442e20-9deb-4ad1-a98d-384c14eb0676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_us-gaap_ConstructionInProgressMember_33442e20-9deb-4ad1-a98d-384c14eb0676" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended" id="ie86a6b15fd7340e08d3a46c5ea78c5cd_OtherFinancialInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7f5b322d-0a1e-482c-865b-5777ad0288f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7f5b322d-0a1e-482c-865b-5777ad0288f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_d92f8fe2-fec1-4fc9-962c-2f9775276694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_d92f8fe2-fec1-4fc9-962c-2f9775276694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3eee632c-8fd7-4462-ae11-ad63a83422e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3eee632c-8fd7-4462-ae11-ad63a83422e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_47117af1-507d-4330-b16d-3007a64ca27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_47117af1-507d-4330-b16d-3007a64ca27c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a439963a-af08-43a8-8cff-209ae53c621a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a439963a-af08-43a8-8cff-209ae53c621a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb0130c5-10c8-438e-ac9a-f9e8f3fe5aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb0130c5-10c8-438e-ac9a-f9e8f3fe5aa2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e0d48c4-0d22-42b0-9669-4abe4b5ff2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb0130c5-10c8-438e-ac9a-f9e8f3fe5aa2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e0d48c4-0d22-42b0-9669-4abe4b5ff2b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6e0d48c4-0d22-42b0-9669-4abe4b5ff2b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e0d48c4-0d22-42b0-9669-4abe4b5ff2b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6e0d48c4-0d22-42b0-9669-4abe4b5ff2b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9518e419-7910-4d9e-8587-e863f1d663a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e0d48c4-0d22-42b0-9669-4abe4b5ff2b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9518e419-7910-4d9e-8587-e863f1d663a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_fcbf5d45-53b5-4e7b-ad62-9c28f15b474b" xlink:href="exdx-20221231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9518e419-7910-4d9e-8587-e863f1d663a5" xlink:to="loc_exdx_LaboratoryEquipmentMember_fcbf5d45-53b5-4e7b-ad62-9c28f15b474b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i500f6585a3ad4a98a4ebeca229929e89_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7c22024d-3ee4-484f-b41e-19de05e82569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7c22024d-3ee4-484f-b41e-19de05e82569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee7ab00d-87a7-4891-a2fc-b91bd0addd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee7ab00d-87a7-4891-a2fc-b91bd0addd32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_056a2f22-6a05-4262-8c7f-7346730773cf" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_056a2f22-6a05-4262-8c7f-7346730773cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0fabc58a-4575-44e2-a4c9-2ca57d35a014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0fabc58a-4575-44e2-a4c9-2ca57d35a014" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_62232591-b3bb-4de2-a54a-280f42fdc5bc" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_62232591-b3bb-4de2-a54a-280f42fdc5bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_e11ad23f-2d9f-4b9f-8103-49697e5ae11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_e11ad23f-2d9f-4b9f-8103-49697e5ae11b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_6e761314-a005-407d-9f1f-3225cdb72efb" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_6e761314-a005-407d-9f1f-3225cdb72efb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_6ec50a98-6b77-4323-a273-7304215a3421" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_6ec50a98-6b77-4323-a273-7304215a3421" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_c9b76ac7-6e72-41fe-93aa-2ea52783e468" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_c9b76ac7-6e72-41fe-93aa-2ea52783e468" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_749b5087-3e46-4dca-97b3-17322fb4e1c8" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_749b5087-3e46-4dca-97b3-17322fb4e1c8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_7c85811b-fefa-4b41-af48-841a4294f593" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_7c85811b-fefa-4b41-af48-841a4294f593" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_79ce7fea-a042-4d65-aed6-698d534f6b52" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_79ce7fea-a042-4d65-aed6-698d534f6b52" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_4c82a29f-c1ce-4123-bda9-9e61623090ae" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_4c82a29f-c1ce-4123-bda9-9e61623090ae" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f6ec59f2-22bb-427d-92d2-a82f11b2740d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_NotesPayable_f6ec59f2-22bb-427d-92d2-a82f11b2740d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_7d824209-cfb4-4ead-9609-8a20fae0416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_NotesPayableCurrent_7d824209-cfb4-4ead-9609-8a20fae0416e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_570e444e-5601-41a9-9c24-c0d9a4b1c3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_LongTermNotesPayable_570e444e-5601-41a9-9c24-c0d9a4b1c3fa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5a3d31e5-ac1b-4139-ba5a-e8ccd66e610c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:to="loc_us-gaap_DebtInstrumentAxis_5a3d31e5-ac1b-4139-ba5a-e8ccd66e610c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a3d31e5-ac1b-4139-ba5a-e8ccd66e610c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5a3d31e5-ac1b-4139-ba5a-e8ccd66e610c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a3d31e5-ac1b-4139-ba5a-e8ccd66e610c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e106ccad-02bc-49ba-94db-80fcebb94297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5a3d31e5-ac1b-4139-ba5a-e8ccd66e610c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e106ccad-02bc-49ba-94db-80fcebb94297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_b1b9dd86-76b9-4e41-a848-dd2c58a0ed95" xlink:href="exdx-20221231.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e106ccad-02bc-49ba-94db-80fcebb94297" xlink:to="loc_exdx_Term2017Member_b1b9dd86-76b9-4e41-a848-dd2c58a0ed95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember_06641dee-fd65-4cfc-93f9-9bc3c4948a65" xlink:href="exdx-20221231.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e106ccad-02bc-49ba-94db-80fcebb94297" xlink:to="loc_exdx_EquipmentNotesPayableMember_06641dee-fd65-4cfc-93f9-9bc3c4948a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6241c137-b0e4-4895-a007-74b486cd1f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6241c137-b0e4-4895-a007-74b486cd1f3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6241c137-b0e4-4895-a007-74b486cd1f3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6241c137-b0e4-4895-a007-74b486cd1f3d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6241c137-b0e4-4895-a007-74b486cd1f3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ae7aa11-ebd4-4dc7-90bd-a753f4ef36f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6241c137-b0e4-4895-a007-74b486cd1f3d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ae7aa11-ebd4-4dc7-90bd-a753f4ef36f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_509b90ef-a2d1-4c57-bdbd-693556473cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ae7aa11-ebd4-4dc7-90bd-a753f4ef36f8" xlink:to="loc_us-gaap_LoansPayableMember_509b90ef-a2d1-4c57-bdbd-693556473cbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_625f659d-59ec-402b-9841-cd61474d864c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ae7aa11-ebd4-4dc7-90bd-a753f4ef36f8" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_625f659d-59ec-402b-9841-cd61474d864c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_b0468fe7-3a9c-45fc-b3f8-4d11f76892bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_b0468fe7-3a9c-45fc-b3f8-4d11f76892bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0468fe7-3a9c-45fc-b3f8-4d11f76892bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b0468fe7-3a9c-45fc-b3f8-4d11f76892bf" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b0468fe7-3a9c-45fc-b3f8-4d11f76892bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ad95b3f9-3da8-42a7-97a5-67a56623e36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b0468fe7-3a9c-45fc-b3f8-4d11f76892bf" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ad95b3f9-3da8-42a7-97a5-67a56623e36e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_c4744220-b78b-4048-bc57-9a3ed7ce2ccf" xlink:href="exdx-20221231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ad95b3f9-3da8-42a7-97a5-67a56623e36e" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_c4744220-b78b-4048-bc57-9a3ed7ce2ccf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended" id="i2a9a762e500a49059c129ee68ddaa75c_CommitmentandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f2fd94dd-253a-4be7-8a25-924c1fa45ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f2fd94dd-253a-4be7-8a25-924c1fa45ac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_afb49967-1dfe-4bd8-9e35-a147e528d9dd" xlink:href="exdx-20221231.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_afb49967-1dfe-4bd8-9e35-a147e528d9dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_d441209d-e22a-4ea1-9a7b-53eb1b13edb5" xlink:href="exdx-20221231.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_d441209d-e22a-4ea1-9a7b-53eb1b13edb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_6f8e07a4-5710-4604-a06e-8a0afec1990c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_6f8e07a4-5710-4604-a06e-8a0afec1990c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_7e68a4ae-fce6-441b-b1f1-44bc3bf6162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_LeaseAndRentalExpense_7e68a4ae-fce6-441b-b1f1-44bc3bf6162d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_819e1ecd-17eb-48ec-b80c-56bb54095476" xlink:href="exdx-20221231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_819e1ecd-17eb-48ec-b80c-56bb54095476" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_c6c5ce55-fc1f-4271-a554-f8ea761e16ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_c6c5ce55-fc1f-4271-a554-f8ea761e16ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_a27fdaa2-93d4-4f35-9c2b-2292177038b5" xlink:href="exdx-20221231.xsd#exdx_AdvancePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_AdvancePayment_a27fdaa2-93d4-4f35-9c2b-2292177038b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee_1828c64c-d313-4731-9d84-daa4769b89c9" xlink:href="exdx-20221231.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_LicenseAgreementInitialLicenseFee_1828c64c-d313-4731-9d84-daa4769b89c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementOneTimePayment_d162f4e5-f7ad-459c-8424-c0390606dee3" xlink:href="exdx-20221231.xsd#exdx_LicenseAgreementOneTimePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_LicenseAgreementOneTimePayment_d162f4e5-f7ad-459c-8424-c0390606dee3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid_1797179e-6c45-46c8-b7fe-90accd9a1fc5" xlink:href="exdx-20221231.xsd#exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid_1797179e-6c45-46c8-b7fe-90accd9a1fc5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_6aa0adbd-411c-4c56-acd3-030e4b89ca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_6aa0adbd-411c-4c56-acd3-030e4b89ca30" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_bb4ddafe-a455-4797-b01f-519d48e11dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_bb4ddafe-a455-4797-b01f-519d48e11dc3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_b27ee191-12e1-4e03-9a52-97ea012423f8" xlink:href="exdx-20221231.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_b27ee191-12e1-4e03-9a52-97ea012423f8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_413ebd9c-5497-4f6e-982d-0cd7785a379f" xlink:href="exdx-20221231.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_413ebd9c-5497-4f6e-982d-0cd7785a379f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_5b9389e7-1688-449e-a180-04f215e18a26" xlink:href="exdx-20221231.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_5b9389e7-1688-449e-a180-04f215e18a26" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_9821b1fd-a9c4-4287-abf8-886e44a5bfa7" xlink:href="exdx-20221231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_exdx_RentalPropertyByTypeAxis_9821b1fd-a9c4-4287-abf8-886e44a5bfa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_9821b1fd-a9c4-4287-abf8-886e44a5bfa7_default" xlink:href="exdx-20221231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exdx_RentalPropertyByTypeAxis_9821b1fd-a9c4-4287-abf8-886e44a5bfa7" xlink:to="loc_exdx_RentalPropertyByTypeDomain_9821b1fd-a9c4-4287-abf8-886e44a5bfa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_f3672a1b-fda0-4558-8464-4e715f8bb9ba" xlink:href="exdx-20221231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exdx_RentalPropertyByTypeAxis_9821b1fd-a9c4-4287-abf8-886e44a5bfa7" xlink:to="loc_exdx_RentalPropertyByTypeDomain_f3672a1b-fda0-4558-8464-4e715f8bb9ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_33528b5b-4b23-4bd8-92e5-433a08324844" xlink:href="exdx-20221231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_f3672a1b-fda0-4558-8464-4e715f8bb9ba" xlink:to="loc_exdx_OfficeAndLaboratoryMember_33528b5b-4b23-4bd8-92e5-433a08324844" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_37f2589d-17be-48b3-8b4d-9bf4c46c7a87" xlink:href="exdx-20221231.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_f3672a1b-fda0-4558-8464-4e715f8bb9ba" xlink:to="loc_exdx_OfficeMember_37f2589d-17be-48b3-8b4d-9bf4c46c7a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3231686-220d-4c7e-b327-fab3048a6751" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_srt_CounterpartyNameAxis_c3231686-220d-4c7e-b327-fab3048a6751" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3231686-220d-4c7e-b327-fab3048a6751_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c3231686-220d-4c7e-b327-fab3048a6751" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3231686-220d-4c7e-b327-fab3048a6751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c3231686-220d-4c7e-b327-fab3048a6751" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_a620082e-18f1-48a7-906e-8b0d56d05b74" xlink:href="exdx-20221231.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_a620082e-18f1-48a7-906e-8b0d56d05b74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_60ee5edf-6d9c-47e3-8db8-3c9716be0e91" xlink:href="exdx-20221231.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_60ee5edf-6d9c-47e3-8db8-3c9716be0e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_QueenMaryUniversityOfLondonMember_d28495d6-5a23-4fc0-b452-baae6740956a" xlink:href="exdx-20221231.xsd#exdx_QueenMaryUniversityOfLondonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:to="loc_exdx_QueenMaryUniversityOfLondonMember_d28495d6-5a23-4fc0-b452-baae6740956a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cc262aaf-dd21-4a4b-81fe-292698b4ad04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_srt_RangeAxis_cc262aaf-dd21-4a4b-81fe-292698b4ad04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc262aaf-dd21-4a4b-81fe-292698b4ad04_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cc262aaf-dd21-4a4b-81fe-292698b4ad04" xlink:to="loc_srt_RangeMember_cc262aaf-dd21-4a4b-81fe-292698b4ad04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13ecc417-d967-4984-abc5-a29c8dcce283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cc262aaf-dd21-4a4b-81fe-292698b4ad04" xlink:to="loc_srt_RangeMember_13ecc417-d967-4984-abc5-a29c8dcce283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0680687e-432b-4a66-8d8b-790f73b4b6a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13ecc417-d967-4984-abc5-a29c8dcce283" xlink:to="loc_srt_MinimumMember_0680687e-432b-4a66-8d8b-790f73b4b6a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ff834362-a612-48a3-9a31-9ff3bc3af888" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_13ecc417-d967-4984-abc5-a29c8dcce283" xlink:to="loc_srt_MaximumMember_ff834362-a612-48a3-9a31-9ff3bc3af888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7ef9b47-2514-4162-b34e-9c0713b58389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7ef9b47-2514-4162-b34e-9c0713b58389" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c7ef9b47-2514-4162-b34e-9c0713b58389_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7ef9b47-2514-4162-b34e-9c0713b58389" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c7ef9b47-2514-4162-b34e-9c0713b58389_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7b797b03-14fe-434a-af52-bd6a0d225c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7ef9b47-2514-4162-b34e-9c0713b58389" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7b797b03-14fe-434a-af52-bd6a0d225c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_528149bb-3037-425b-b53d-70d64e2e40ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7b797b03-14fe-434a-af52-bd6a0d225c32" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_528149bb-3037-425b-b53d-70d64e2e40ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1e7b3284-d752-42a0-b28a-14112b758b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1e7b3284-d752-42a0-b28a-14112b758b44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e7b3284-d752-42a0-b28a-14112b758b44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1e7b3284-d752-42a0-b28a-14112b758b44" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e7b3284-d752-42a0-b28a-14112b758b44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d9e569c-d680-4646-89cb-ae766bd5d621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1e7b3284-d752-42a0-b28a-14112b758b44" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d9e569c-d680-4646-89cb-ae766bd5d621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_d8391553-bd0b-4d7b-ba4b-235872642388" xlink:href="exdx-20221231.xsd#exdx_AHNCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d9e569c-d680-4646-89cb-ae766bd5d621" xlink:to="loc_exdx_AHNCollaborationMember_d8391553-bd0b-4d7b-ba4b-235872642388" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_5f38449d-86d9-499a-a415-5da107271a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_us-gaap_LeaseContractualTermAxis_5f38449d-86d9-499a-a415-5da107271a41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_5f38449d-86d9-499a-a415-5da107271a41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_5f38449d-86d9-499a-a415-5da107271a41" xlink:to="loc_us-gaap_LeaseContractualTermDomain_5f38449d-86d9-499a-a415-5da107271a41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_10ef29ba-62d0-4827-a6ca-5667f147ff8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_5f38449d-86d9-499a-a415-5da107271a41" xlink:to="loc_us-gaap_LeaseContractualTermDomain_10ef29ba-62d0-4827-a6ca-5667f147ff8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_d0125fe3-34cf-4c68-bc0c-e53595c0873e" xlink:href="exdx-20221231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_10ef29ba-62d0-4827-a6ca-5667f147ff8c" xlink:to="loc_exdx_OfficeAndLaboratoryMember_d0125fe3-34cf-4c68-bc0c-e53595c0873e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_6b554224-7d26-45e2-9702-ea8dcdf4cbb2" xlink:href="exdx-20221231.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_10ef29ba-62d0-4827-a6ca-5667f147ff8c" xlink:to="loc_exdx_OfficeMember_6b554224-7d26-45e2-9702-ea8dcdf4cbb2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i50115495b7184210b7972f33f5b20da1_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_46a637f5-2d29-4e79-babf-f073379b30fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:to="loc_us-gaap_LongTermDebt_46a637f5-2d29-4e79-babf-f073379b30fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_e3b324ff-5e63-400d-b18e-007c51542831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:to="loc_us-gaap_DebtInstrumentFairValue_e3b324ff-5e63-400d-b18e-007c51542831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_c54f59dc-74a3-49be-a95f-18c344360700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_c54f59dc-74a3-49be-a95f-18c344360700" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3eefdcce-0a19-4621-a753-f9f9ce7ae386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c54f59dc-74a3-49be-a95f-18c344360700" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3eefdcce-0a19-4621-a753-f9f9ce7ae386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ef1a746c-0c2c-4143-a8f7-6c2252162fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c54f59dc-74a3-49be-a95f-18c344360700" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ef1a746c-0c2c-4143-a8f7-6c2252162fd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25544aa2-f78a-4cd3-ae1b-e0e7fbe6841e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25544aa2-f78a-4cd3-ae1b-e0e7fbe6841e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_25544aa2-f78a-4cd3-ae1b-e0e7fbe6841e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25544aa2-f78a-4cd3-ae1b-e0e7fbe6841e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_25544aa2-f78a-4cd3-ae1b-e0e7fbe6841e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b082c2a-7be2-4f59-aafb-4875b6a7881e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25544aa2-f78a-4cd3-ae1b-e0e7fbe6841e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b082c2a-7be2-4f59-aafb-4875b6a7881e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48552ab7-c421-4693-885c-005fb7f72458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b082c2a-7be2-4f59-aafb-4875b6a7881e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48552ab7-c421-4693-885c-005fb7f72458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_139942b0-4d25-4f6d-b611-ff4e95391fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_139942b0-4d25-4f6d-b611-ff4e95391fa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_139942b0-4d25-4f6d-b611-ff4e95391fa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_139942b0-4d25-4f6d-b611-ff4e95391fa6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_139942b0-4d25-4f6d-b611-ff4e95391fa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_139942b0-4d25-4f6d-b611-ff4e95391fa6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1aa9f226-a7e7-4402-a6b7-b9ec44acc8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1aa9f226-a7e7-4402-a6b7-b9ec44acc8ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b69031e4-0e66-47c6-853d-e3f671981252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b69031e4-0e66-47c6-853d-e3f671981252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a899dc8a-8f78-451c-befd-8654fa671905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a899dc8a-8f78-451c-befd-8654fa671905" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3e283565-cdbe-48e5-99c3-9ce883c50d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3e283565-cdbe-48e5-99c3-9ce883c50d28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e283565-cdbe-48e5-99c3-9ce883c50d28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3e283565-cdbe-48e5-99c3-9ce883c50d28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e283565-cdbe-48e5-99c3-9ce883c50d28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84c08f3f-0107-4122-99b0-e12ed17203a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3e283565-cdbe-48e5-99c3-9ce883c50d28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84c08f3f-0107-4122-99b0-e12ed17203a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b1ea9992-0335-433c-854f-eba7bdac0cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84c08f3f-0107-4122-99b0-e12ed17203a2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b1ea9992-0335-433c-854f-eba7bdac0cf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_25f861e2-9e5e-4d26-b424-72be6d04fd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84c08f3f-0107-4122-99b0-e12ed17203a2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_25f861e2-9e5e-4d26-b424-72be6d04fd9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7f07d44a-e6c3-4d9e-b2ba-03cd02f37b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_7f07d44a-e6c3-4d9e-b2ba-03cd02f37b1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7f07d44a-e6c3-4d9e-b2ba-03cd02f37b1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7f07d44a-e6c3-4d9e-b2ba-03cd02f37b1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7f07d44a-e6c3-4d9e-b2ba-03cd02f37b1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ab7fee0-5409-4877-a4e0-0305e75cd51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7f07d44a-e6c3-4d9e-b2ba-03cd02f37b1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ab7fee0-5409-4877-a4e0-0305e75cd51e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_4982f39b-aa4c-4e5a-b0fd-59df77465b3c" xlink:href="exdx-20221231.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ab7fee0-5409-4877-a4e0-0305e75cd51e" xlink:to="loc_exdx_Term2017Member_4982f39b-aa4c-4e5a-b0fd-59df77465b3c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i051fc241719b48a2b60077d7a9a15fcc_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d48aab6-7b8b-4741-9e04-0276bf197754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d48aab6-7b8b-4741-9e04-0276bf197754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5d289678-15f1-4166-9e0f-d686d5d0c338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5d289678-15f1-4166-9e0f-d686d5d0c338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87f4efc2-94f6-4d1b-9511-461fd9368d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87f4efc2-94f6-4d1b-9511-461fd9368d66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_4657cb22-42b7-4e92-93e6-0360ef75f1a7" xlink:href="exdx-20221231.xsd#exdx_StockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_exdx_StockIssuanceCosts_4657cb22-42b7-4e92-93e6-0360ef75f1a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_6e414e77-d87b-4494-9444-d90e9b0e8698" xlink:href="exdx-20221231.xsd#exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_6e414e77-d87b-4494-9444-d90e9b0e8698" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b71a813f-a5f8-4b78-8ad3-d7ff3ec81c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b71a813f-a5f8-4b78-8ad3-d7ff3ec81c5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_f5bf5719-0bfb-4fc1-9d85-121e68b42619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_f5bf5719-0bfb-4fc1-9d85-121e68b42619" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_e73d0909-e6b8-424a-aaa3-e53d03540236" xlink:href="exdx-20221231.xsd#exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_e73d0909-e6b8-424a-aaa3-e53d03540236" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_4a9d6005-5ba1-4ff0-b2bd-e0a125b22be4" xlink:href="exdx-20221231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_4a9d6005-5ba1-4ff0-b2bd-e0a125b22be4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_36d9a64f-28a6-4a17-8bd6-a529d30ef951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_36d9a64f-28a6-4a17-8bd6-a529d30ef951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_36d9a64f-28a6-4a17-8bd6-a529d30ef951_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_36d9a64f-28a6-4a17-8bd6-a529d30ef951" xlink:to="loc_us-gaap_EquityComponentDomain_36d9a64f-28a6-4a17-8bd6-a529d30ef951_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ac9c782f-4e10-4a67-93b0-522900cb57b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_36d9a64f-28a6-4a17-8bd6-a529d30ef951" xlink:to="loc_us-gaap_EquityComponentDomain_ac9c782f-4e10-4a67-93b0-522900cb57b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2c075ad9-3d30-4c28-b956-18b70dd3a9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ac9c782f-4e10-4a67-93b0-522900cb57b1" xlink:to="loc_us-gaap_CommonStockMember_2c075ad9-3d30-4c28-b956-18b70dd3a9a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf899809-0979-442d-a0c5-f0fb8dddb921" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:to="loc_srt_CounterpartyNameAxis_bf899809-0979-442d-a0c5-f0fb8dddb921" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf899809-0979-442d-a0c5-f0fb8dddb921_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bf899809-0979-442d-a0c5-f0fb8dddb921" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf899809-0979-442d-a0c5-f0fb8dddb921_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cb6acf0-9216-4034-9a55-ad43ee77a343" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bf899809-0979-442d-a0c5-f0fb8dddb921" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cb6acf0-9216-4034-9a55-ad43ee77a343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangingStockholdersMember_d96faa35-63e7-4bfc-bf8d-b74a238eba3a" xlink:href="exdx-20221231.xsd#exdx_ExchangingStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cb6acf0-9216-4034-9a55-ad43ee77a343" xlink:to="loc_exdx_ExchangingStockholdersMember_d96faa35-63e7-4bfc-bf8d-b74a238eba3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_01586c07-ab56-4243-b1ed-8b24bad96c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_01586c07-ab56-4243-b1ed-8b24bad96c0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_01586c07-ab56-4243-b1ed-8b24bad96c0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01586c07-ab56-4243-b1ed-8b24bad96c0d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_01586c07-ab56-4243-b1ed-8b24bad96c0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e39c3935-2bae-48b7-ab9a-fb3b188684c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01586c07-ab56-4243-b1ed-8b24bad96c0d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e39c3935-2bae-48b7-ab9a-fb3b188684c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember_b3f8d2c5-ad64-408a-b7dc-bb0e480b55c9" xlink:href="exdx-20221231.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e39c3935-2bae-48b7-ab9a-fb3b188684c8" xlink:to="loc_exdx_CowenEquityDistributionAgreementMember_b3f8d2c5-ad64-408a-b7dc-bb0e480b55c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="extended" id="i395b2ff3fa174782baf4a43655336952_StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f0f73b13-0e42-4e4f-996a-aeb4b3eaa153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0c64184f-2191-474f-9891-35ec2b7867d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0f73b13-0e42-4e4f-996a-aeb4b3eaa153" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0c64184f-2191-474f-9891-35ec2b7867d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a1d33e09-2af6-4672-8b54-a9cce688281d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0f73b13-0e42-4e4f-996a-aeb4b3eaa153" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a1d33e09-2af6-4672-8b54-a9cce688281d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2180bf92-3d6d-4447-92ac-41b644107653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0f73b13-0e42-4e4f-996a-aeb4b3eaa153" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2180bf92-3d6d-4447-92ac-41b644107653" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6fe5a06a-0403-4c75-981b-09ee31c8d863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2180bf92-3d6d-4447-92ac-41b644107653" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6fe5a06a-0403-4c75-981b-09ee31c8d863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6fe5a06a-0403-4c75-981b-09ee31c8d863_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6fe5a06a-0403-4c75-981b-09ee31c8d863" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6fe5a06a-0403-4c75-981b-09ee31c8d863_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6fe5a06a-0403-4c75-981b-09ee31c8d863" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_da4e7b40-bc72-43d0-98af-06d795a81e7b" xlink:href="exdx-20221231.xsd#exdx_ExpirationJan192026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationJan192026Member_da4e7b40-bc72-43d0-98af-06d795a81e7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_11d543e2-4126-4f62-8e0e-aeb0d002ce95" xlink:href="exdx-20221231.xsd#exdx_ExpirationMar312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationMar312026Member_11d543e2-4126-4f62-8e0e-aeb0d002ce95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_8e679489-90e0-47c1-84bd-8b88a9fd3a6c" xlink:href="exdx-20221231.xsd#exdx_ExpirationApr12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationApr12026Member_8e679489-90e0-47c1-84bd-8b88a9fd3a6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_88c42062-d23b-492f-a475-e5c9cb9cbcbf" xlink:href="exdx-20221231.xsd#exdx_ExpirationSep72024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationSep72024Member_88c42062-d23b-492f-a475-e5c9cb9cbcbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_483ee9fd-8d0b-4dbc-bcf1-e19c810a9f40" xlink:href="exdx-20221231.xsd#exdx_ExpirationDec72025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationDec72025Member_483ee9fd-8d0b-4dbc-bcf1-e19c810a9f40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_cda2abf4-fe04-4f44-bd39-374a1a2b12b2" xlink:href="exdx-20221231.xsd#exdx_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_NoExpirationMember_cda2abf4-fe04-4f44-bd39-374a1a2b12b2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended" id="icd7ce58af0d6419c91d202b02119842e_StockOptionPlanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dba9f867-3beb-488e-84df-5f41a122d180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dba9f867-3beb-488e-84df-5f41a122d180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfd62bfb-4059-41da-bac1-83af94c829e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfd62bfb-4059-41da-bac1-83af94c829e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_15c9585c-4dbf-41a7-8f0d-720971be4533" xlink:href="exdx-20221231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_15c9585c-4dbf-41a7-8f0d-720971be4533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e53f45c3-371a-44f2-ad2d-25907e02c6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e53f45c3-371a-44f2-ad2d-25907e02c6d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_0a75203e-dd37-4d55-bd08-2c304b44d2bd" xlink:href="exdx-20221231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_0a75203e-dd37-4d55-bd08-2c304b44d2bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_34c14753-791b-4140-ba45-18fb2e9ec979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_34c14753-791b-4140-ba45-18fb2e9ec979" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f60052b-f6d0-414a-9934-92e3473cdb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f60052b-f6d0-414a-9934-92e3473cdb26" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a4f0222-7593-4910-b4db-fb1cdfe3aa85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a4f0222-7593-4910-b4db-fb1cdfe3aa85" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b46de53f-b887-406f-a173-ee9c44f31897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b46de53f-b887-406f-a173-ee9c44f31897" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_106dce59-5d23-4d43-b92c-5ef1ec942cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_106dce59-5d23-4d43-b92c-5ef1ec942cf2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_6688429d-e790-4a2c-b3e1-f1578be45b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_6688429d-e790-4a2c-b3e1-f1578be45b59" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a0bbafca-6f01-4912-bd03-1bef2b9dad86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a0bbafca-6f01-4912-bd03-1bef2b9dad86" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_da6e0ba7-9e1e-43c0-8850-015644d2ba98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_da6e0ba7-9e1e-43c0-8850-015644d2ba98" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f36b73c0-8859-4a20-873c-5f72786c6c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f36b73c0-8859-4a20-873c-5f72786c6c4e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c0562a6-f204-4def-b3eb-dd145743c279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c0562a6-f204-4def-b3eb-dd145743c279" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_07b786a1-c32b-4421-9b8b-a1c795474b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_07b786a1-c32b-4421-9b8b-a1c795474b56" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6811f074-775e-4ffe-a122-cc7f175c0a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:to="loc_us-gaap_PlanNameAxis_6811f074-775e-4ffe-a122-cc7f175c0a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6811f074-775e-4ffe-a122-cc7f175c0a86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6811f074-775e-4ffe-a122-cc7f175c0a86" xlink:to="loc_us-gaap_PlanNameDomain_6811f074-775e-4ffe-a122-cc7f175c0a86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_465de480-d4b9-4f94-a601-5eee3d4cccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6811f074-775e-4ffe-a122-cc7f175c0a86" xlink:to="loc_us-gaap_PlanNameDomain_465de480-d4b9-4f94-a601-5eee3d4cccc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_9bd17c01-1a30-43f4-ab24-dac34a732b44" xlink:href="exdx-20221231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_465de480-d4b9-4f94-a601-5eee3d4cccc2" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_9bd17c01-1a30-43f4-ab24-dac34a732b44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_65b040c8-783b-4aea-aa65-75dd143159e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:to="loc_us-gaap_AwardTypeAxis_65b040c8-783b-4aea-aa65-75dd143159e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65b040c8-783b-4aea-aa65-75dd143159e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_65b040c8-783b-4aea-aa65-75dd143159e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65b040c8-783b-4aea-aa65-75dd143159e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_65b040c8-783b-4aea-aa65-75dd143159e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9f51e75f-9058-48b8-840c-230fa270dd06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9f51e75f-9058-48b8-840c-230fa270dd06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_989d7cba-af90-4216-8a58-83c0966e06cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:to="loc_us-gaap_EmployeeStockMember_989d7cba-af90-4216-8a58-83c0966e06cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_10ff4d69-454d-4f48-a7f2-bdc782eaf3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_10ff4d69-454d-4f48-a7f2-bdc782eaf3c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a69a6685-1b51-4ca5-9cd7-d395572a37e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a69a6685-1b51-4ca5-9cd7-d395572a37e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a69a6685-1b51-4ca5-9cd7-d395572a37e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a69a6685-1b51-4ca5-9cd7-d395572a37e8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a69a6685-1b51-4ca5-9cd7-d395572a37e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fbde0e8c-f08b-47e1-bfb7-0f2cb2979306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a69a6685-1b51-4ca5-9cd7-d395572a37e8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fbde0e8c-f08b-47e1-bfb7-0f2cb2979306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_494c984a-4859-4514-a675-50a05f6e14f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fbde0e8c-f08b-47e1-bfb7-0f2cb2979306" xlink:to="loc_us-gaap_SubsequentEventMember_494c984a-4859-4514-a675-50a05f6e14f9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended" id="i5f38193605ee4956a00fe3d3fb0053ae_StockOptionPlanRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_539953b4-17ad-4119-b03a-d3a9f22a1e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_539953b4-17ad-4119-b03a-d3a9f22a1e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_713f1111-15cd-4470-8650-4345ace2563d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_713f1111-15cd-4470-8650-4345ace2563d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70d253ae-fab5-4cc1-a4ed-319bf37707b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70d253ae-fab5-4cc1-a4ed-319bf37707b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_00f41b33-9952-4ab5-b85b-a1ddc115fd71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_00f41b33-9952-4ab5-b85b-a1ddc115fd71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d4e6d5d-0c87-4547-af7a-669c30a58734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b7c22b16-3034-47c1-95ea-cbad1187034c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b7c22b16-3034-47c1-95ea-cbad1187034c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cc5aba5b-3cde-49a3-86d1-48b5640d2031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cc5aba5b-3cde-49a3-86d1-48b5640d2031" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f424690d-a813-4c0e-8bcd-180200bb6cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f424690d-a813-4c0e-8bcd-180200bb6cbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1c292905-a8a1-4333-89df-0fc191a3480d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1c292905-a8a1-4333-89df-0fc191a3480d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16576a7d-9d11-421b-8790-e86714bc07a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4896bc9d-3177-44c0-b252-21ee8ec4d4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4896bc9d-3177-44c0-b252-21ee8ec4d4e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_406ab73d-e57a-43d3-b638-be9195035f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4896bc9d-3177-44c0-b252-21ee8ec4d4e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_406ab73d-e57a-43d3-b638-be9195035f52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6de0a93-8e20-4569-b014-66fac01e853e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6de0a93-8e20-4569-b014-66fac01e853e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e1856633-51ad-4ff4-ae85-3e9e40b8ec26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6de0a93-8e20-4569-b014-66fac01e853e" xlink:to="loc_us-gaap_AwardTypeAxis_e1856633-51ad-4ff4-ae85-3e9e40b8ec26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1856633-51ad-4ff4-ae85-3e9e40b8ec26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e1856633-51ad-4ff4-ae85-3e9e40b8ec26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1856633-51ad-4ff4-ae85-3e9e40b8ec26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24d0cb5d-94ee-4729-bba0-fb1ce5870a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e1856633-51ad-4ff4-ae85-3e9e40b8ec26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24d0cb5d-94ee-4729-bba0-fb1ce5870a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e92e24e1-23d5-426f-8b27-d8806424a702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24d0cb5d-94ee-4729-bba0-fb1ce5870a4d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e92e24e1-23d5-426f-8b27-d8806424a702" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended" id="i12fd7085927248aca7e812b0d11edac6_StockOptionPlanFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_aed85f58-87fc-4f9f-b9c9-732bbb740fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_aed85f58-87fc-4f9f-b9c9-732bbb740fea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_46c5aa8b-e9f1-45cb-8ff8-eeff90b3e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_46c5aa8b-e9f1-45cb-8ff8-eeff90b3e3f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_586eb51d-b756-486e-8ece-246e831c49a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_586eb51d-b756-486e-8ece-246e831c49a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_acc99d30-ee23-4d00-a8ea-fdc3cbbb1826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_acc99d30-ee23-4d00-a8ea-fdc3cbbb1826" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80777dfa-1b94-45b6-a22f-1e759bc7cc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80777dfa-1b94-45b6-a22f-1e759bc7cc7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7a90c207-71ad-4f11-b293-81645d4553a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7a90c207-71ad-4f11-b293-81645d4553a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38fd4453-5cba-459b-8333-d86109ef6169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38fd4453-5cba-459b-8333-d86109ef6169" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8bfb0a67-7554-48c8-8d1b-d6cd675b2b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38fd4453-5cba-459b-8333-d86109ef6169" xlink:to="loc_us-gaap_AwardTypeAxis_8bfb0a67-7554-48c8-8d1b-d6cd675b2b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8bfb0a67-7554-48c8-8d1b-d6cd675b2b81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8bfb0a67-7554-48c8-8d1b-d6cd675b2b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8bfb0a67-7554-48c8-8d1b-d6cd675b2b81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f91ea6a5-b0e2-44da-a50b-2478cd81ee9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8bfb0a67-7554-48c8-8d1b-d6cd675b2b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f91ea6a5-b0e2-44da-a50b-2478cd81ee9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e9564a4c-5187-4d9a-bf0f-be4154e21f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f91ea6a5-b0e2-44da-a50b-2478cd81ee9f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e9564a4c-5187-4d9a-bf0f-be4154e21f40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_877c8588-70d9-4b6f-8838-5403fda605d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f91ea6a5-b0e2-44da-a50b-2478cd81ee9f" xlink:to="loc_us-gaap_EmployeeStockMember_877c8588-70d9-4b6f-8838-5403fda605d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a33d7668-c32a-482c-a9dd-dae54761296b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38fd4453-5cba-459b-8333-d86109ef6169" xlink:to="loc_srt_RangeAxis_a33d7668-c32a-482c-a9dd-dae54761296b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a33d7668-c32a-482c-a9dd-dae54761296b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a33d7668-c32a-482c-a9dd-dae54761296b" xlink:to="loc_srt_RangeMember_a33d7668-c32a-482c-a9dd-dae54761296b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e7a4847-c697-4008-80cf-7998e5ef485c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a33d7668-c32a-482c-a9dd-dae54761296b" xlink:to="loc_srt_RangeMember_7e7a4847-c697-4008-80cf-7998e5ef485c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f00dc955-d6d5-43fa-b76d-b2b8fdd4e1eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7e7a4847-c697-4008-80cf-7998e5ef485c" xlink:to="loc_srt_MinimumMember_f00dc955-d6d5-43fa-b76d-b2b8fdd4e1eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c604956e-0d7b-42cf-9c6b-f8820f421477" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7e7a4847-c697-4008-80cf-7998e5ef485c" xlink:to="loc_srt_MaximumMember_c604956e-0d7b-42cf-9c6b-f8820f421477" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended" id="i7c4e12602c97479498a881cbad55acbd_StockOptionPlanStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49062c13-324d-4269-9210-bd1a2754ef51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5f1034eb-0f5e-4f13-b3ef-2a5ccaa9546a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49062c13-324d-4269-9210-bd1a2754ef51" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5f1034eb-0f5e-4f13-b3ef-2a5ccaa9546a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cafa3b0-e1c4-4f6d-bb57-904c95fd9040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49062c13-324d-4269-9210-bd1a2754ef51" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cafa3b0-e1c4-4f6d-bb57-904c95fd9040" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a83f5cc5-5664-476b-bba1-bb3e0b8ae91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cafa3b0-e1c4-4f6d-bb57-904c95fd9040" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a83f5cc5-5664-476b-bba1-bb3e0b8ae91f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a83f5cc5-5664-476b-bba1-bb3e0b8ae91f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a83f5cc5-5664-476b-bba1-bb3e0b8ae91f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a83f5cc5-5664-476b-bba1-bb3e0b8ae91f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a83f5cc5-5664-476b-bba1-bb3e0b8ae91f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_4b29c8e7-74ad-4fa2-bfe8-cb1bae370862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:to="loc_us-gaap_CostOfSalesMember_4b29c8e7-74ad-4fa2-bfe8-cb1bae370862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_913b70af-e233-401e-94df-044ea7d721f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_913b70af-e233-401e-94df-044ea7d721f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f51103b8-1110-4e9e-9726-f156d33e99be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f51103b8-1110-4e9e-9726-f156d33e99be" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanCommonStockReservedForFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="extended" id="i46683431a13d49d19392b9cc39c54844_StockOptionPlanCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d8c3a07-bfad-4d3d-a756-7c6557ae968e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f4676c53-a0f8-4dca-90c3-1b1bec3d50f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d8c3a07-bfad-4d3d-a756-7c6557ae968e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f4676c53-a0f8-4dca-90c3-1b1bec3d50f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d1c426e-a1ba-48a6-b9c6-2802d796b167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d8c3a07-bfad-4d3d-a756-7c6557ae968e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d1c426e-a1ba-48a6-b9c6-2802d796b167" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_745e519d-d5f6-4ba1-b3d1-5929e850f219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d1c426e-a1ba-48a6-b9c6-2802d796b167" xlink:to="loc_us-gaap_AwardTypeAxis_745e519d-d5f6-4ba1-b3d1-5929e850f219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745e519d-d5f6-4ba1-b3d1-5929e850f219_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_745e519d-d5f6-4ba1-b3d1-5929e850f219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745e519d-d5f6-4ba1-b3d1-5929e850f219_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_745e519d-d5f6-4ba1-b3d1-5929e850f219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_37753c4d-237c-4d24-bd57-08ba627c85ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_us-gaap_WarrantMember_37753c4d-237c-4d24-bd57-08ba627c85ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29a2f712-11fe-4576-8e85-909f5e17e705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29a2f712-11fe-4576-8e85-909f5e17e705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2cbfd0a4-3ff6-4927-898a-976bf0ed1657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2cbfd0a4-3ff6-4927-898a-976bf0ed1657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_cbe2af65-92e1-40f2-bd61-aebf0a8a4552" xlink:href="exdx-20221231.xsd#exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_cbe2af65-92e1-40f2-bd61-aebf0a8a4552" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5ccc9b2d-032c-4c3e-9df0-bab4fc9666be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_us-gaap_EmployeeStockMember_5ccc9b2d-032c-4c3e-9df0-bab4fc9666be" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>exdx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b2849c68-b5c1-4aba-9f81-ca2d321b51be,g:62e4697b-763f-43ad-abbd-d704ff1dbc1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_exdx_PublicOfferingMember_c86857eb-ed6e-464a-a572-c5a5ac945ef2_terseLabel_en-US" xlink:label="lab_exdx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_exdx_PublicOfferingMember_label_en-US" xlink:label="lab_exdx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_exdx_PublicOfferingMember_documentation_en-US" xlink:label="lab_exdx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PublicOfferingMember" xlink:href="exdx-20221231.xsd#exdx_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PublicOfferingMember" xlink:to="lab_exdx_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c70cd22-2978-4d5c-b88d-957b71ddf504_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b87b08c-912f-4062-8c13-2279dabb4b22_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1ca00810-cc76-4a34-a42d-fe6aade75693_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_303d79b4-9ccc-4e66-930a-0b014e22623b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_d9a4634d-84f6-4da8-8698-0ab5c9dcb63a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, right-of-use asset, after accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_4d2a1ae8-1249-44bd-99c1-1009703e770f_terseLabel_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_label_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund [Member]</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_documentation_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:href="exdx-20221231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:to="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_3977b4e6-afd7-4432-b79f-c79a3ca68b15_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis" xlink:href="exdx-20221231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeAxis" xlink:to="lab_exdx_RentalPropertyByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_82bb3bb9-d4a3-453a-8451-f98f28265daa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_775134e0-a2a5-409b-b9e0-b2c1cc64fbbd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6ae0afdf-a969-4a35-94b1-a343d2f7292f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_7d734660-e55d-40b9-9486-868674622bdb_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly installments</link:label>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Installments</link:label>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:to="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4c26b352-45fc-4d97-915b-a1de224e6fa3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_1179ec27-4ecd-410d-8ab0-0587939e54ff_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_07cb71a6-aa78-4ab3-b277-a6cc4e84cba4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_bdffa50a-b994-4dde-b664-2cb215236bb2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_02005277-dcdb-41ad-a002-29b1086e7278_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_eda36c58-99d4-4b1e-a2ec-f459c8cdfdd1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_fd28dd9d-820d-4536-a068-af3af9b94625_negatedLabel_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis differences in fixed and intangible assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_label_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_documentation_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:to="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c1df93ac-7db3-4336-938f-af5beed6c03f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ContractWithCustomerTerminationConsiderationReceivable_1e840d08-7831-4fd0-b497-53175dba398b_terseLabel_en-US" xlink:label="lab_exdx_ContractWithCustomerTerminationConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of agreement</link:label>
    <link:label id="lab_exdx_ContractWithCustomerTerminationConsiderationReceivable_label_en-US" xlink:label="lab_exdx_ContractWithCustomerTerminationConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Termination, Consideration Receivable</link:label>
    <link:label id="lab_exdx_ContractWithCustomerTerminationConsiderationReceivable_documentation_en-US" xlink:label="lab_exdx_ContractWithCustomerTerminationConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Termination, Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ContractWithCustomerTerminationConsiderationReceivable" xlink:href="exdx-20221231.xsd#exdx_ContractWithCustomerTerminationConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ContractWithCustomerTerminationConsiderationReceivable" xlink:to="lab_exdx_ContractWithCustomerTerminationConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb0e2eda-9a56-45c9-802d-dba13cd0a8f1_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f3ec969b-6ccc-42fd-a0b5-9dd8ebecbe07_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_451bc196-6b84-404d-bbb2-203c4ea2df88_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_BlueShieldMember_38e28e32-6dca-4c17-87a2-a024efc8ad4f_terseLabel_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:label id="lab_exdx_BlueShieldMember_label_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield [Member]</link:label>
    <link:label id="lab_exdx_BlueShieldMember_documentation_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember" xlink:href="exdx-20221231.xsd#exdx_BlueShieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_BlueShieldMember" xlink:to="lab_exdx_BlueShieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_f5681e6d-9339-4bcb-bb1e-a7c42ce4ffe4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e8d41ad1-993a-4406-802c-62e8dda73697_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_22eee045-31e2-4b2c-95cd-1e02f7610a17_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0e7a2e87-e718-43fa-8712-22e69aedcf35_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f834777d-8583-47b2-a8a4-08cdb98f0c1f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_e1d4a491-a4ba-4686-b711-2991b96bd67b_terseLabel_en-US" xlink:label="lab_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:label id="lab_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="exdx-20221231.xsd#exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_cadc1c80-54cd-41c6-af1f-12a3525a395c_terseLabel_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_label_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_documentation_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:href="exdx-20221231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:to="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_25eb8cab-5971-454d-b430-3e7a75ce2de0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_26269462-5504-4b8c-b78b-74495a6b33c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d14cd612-6b29-4b8a-bb50-a3e372031cff_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_a91168a9-4b5e-4b4d-9057-6057f6e05aaf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_7216c581-b209-4081-831e-7ca02685f146_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0f4395a7-30e5-476c-b32a-e598f28f0567_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d5a94611-5da9-461d-b6db-8539f21fbf81_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d314e1f3-0b88-460e-bb96-2a4afcbb46ae_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCredit_552ffc4b-1a26-40bf-a1c9-47d124391631_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent credit</link:label>
    <link:label id="lab_us-gaap_DeferredRentCredit_label_en-US" xlink:label="lab_us-gaap_DeferredRentCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCredit" xlink:to="lab_us-gaap_DeferredRentCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_67a90d6e-2b5d-4250-9040-e15782aa86e6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_817013cd-6758-4c3a-a8b0-4d4b36e9553c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ffa35f86-4ed8-487c-9799-904cfadd3882_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6dc158e4-1d0e-4763-b437-a845ec14e27d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0ca6cb89-d4be-44d1-98d3-dfbe53e723a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6b80c008-459e-4ead-b0c7-27f1a75c7bc6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e664244e-31c1-46f0-88c8-409b9b3c0411_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_a87fc640-b959-41ec-bdac-06c6af3c4ac4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JanssenPromotionAgreementMember_f29a36b6-1f9e-4018-8867-65bcbafe4bfb_terseLabel_en-US" xlink:label="lab_exdx_JanssenPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Promotion Agreement</link:label>
    <link:label id="lab_exdx_JanssenPromotionAgreementMember_label_en-US" xlink:label="lab_exdx_JanssenPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Promotion Agreement [Member]</link:label>
    <link:label id="lab_exdx_JanssenPromotionAgreementMember_documentation_en-US" xlink:label="lab_exdx_JanssenPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Promotion Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenPromotionAgreementMember" xlink:href="exdx-20221231.xsd#exdx_JanssenPromotionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JanssenPromotionAgreementMember" xlink:to="lab_exdx_JanssenPromotionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e4897a0d-172a-46d0-8678-b66b76bff657_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_225a82a4-0a32-4ad4-b44f-7154c8afa557_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_55352192-6a92-4333-8721-cc6c108a95bc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_cae901e7-4035-43a9-83dd-5623a3e5bfb1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_bbbc6702-cc24-47d5-a9e6-4734e64c4e6b_terseLabel_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchases of goods and services</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_label_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:href="exdx-20221231.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:to="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f89834bf-569b-4374-8950-ddd2627b9353_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d20c0904-5bed-401b-adc6-fae98615ba02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_976c2275-4cb8-42db-8b01-f810be059ad7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_442db4a2-fea8-4626-81fc-b9ca1795f093_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_65555531-cda8-4bc8-9285-48062cd69cdc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to stock purchase</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5716d6e8-a31a-4774-a89e-ef15bc5e40ee_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_6cd5e410-d528-489a-9d20-a51014ade5d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7534bc69-2cfc-45bd-a0c2-77b5fa44c320_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_61950086-4178-4c7b-9c85-d1ad50cdf846_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_02d217cd-7105-41d2-b814-942a781f2f8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_4859888e-b698-437e-9d25-d99be18b8588_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_91543464-f439-4295-9a55-9eea37ceebf0_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain" xlink:href="exdx-20221231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeDomain" xlink:to="lab_exdx_RentalPropertyByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_1d0fa559-1d70-48ee-adee-d6f90febe447_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_7d291a4c-f6bf-4ed6-af6f-2d44f956a3af_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for future issuance under ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b44f2c84-f81d-4d07-a976-2699a9ba68b5_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_fba5732d-0b68-491b-930d-f1bcc4d8d188_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind loans issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_label_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:to="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5d54ca17-0999-49bd-b678-56c63f389056_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationSep72024Member_d084dde9-49fa-44f5-a9f5-b99c14a6e349_terseLabel_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration September 7, 2024</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_label_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_documentation_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member" xlink:href="exdx-20221231.xsd#exdx_ExpirationSep72024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationSep72024Member" xlink:to="lab_exdx_ExpirationSep72024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1cbc0736-ec9b-4ec4-ac44-1cfe2737a619_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_47765184-6887-485f-b725-f5d81958f16e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_352be5d9-9159-45b0-9b8b-5f84cf4ca758_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c3d45a7e-912f-44fa-93fc-445f3b322d24_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50a21b2b-0930-4398-948a-b802d5bdf997_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_b77a72c5-73ab-4ec2-8cfd-834f941f1ba5_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeMember_13107ffa-5f09-44f2-b7ae-1134be64b209_terseLabel_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:label id="lab_exdx_OfficeMember_label_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office [Member]</link:label>
    <link:label id="lab_exdx_OfficeMember_documentation_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember" xlink:href="exdx-20221231.xsd#exdx_OfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeMember" xlink:to="lab_exdx_OfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_732815c5-f0ab-48ee-a845-12f4e7b80eb0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8e52625b-8c88-4516-b287-347dab525e1e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_474bb30a-1ae2-433d-81a2-062e9edb3eda_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationMar312026Member_5365e834-b446-4490-8120-cbf341225db2_terseLabel_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration March 31, 2026</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_label_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member" xlink:href="exdx-20221231.xsd#exdx_ExpirationMar312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationMar312026Member" xlink:to="lab_exdx_ExpirationMar312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_6eb7ad8e-0948-4baf-863e-2a498f6df0d9_terseLabel_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial license fee</link:label>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_label_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial License Fee</link:label>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_documentation_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee" xlink:href="exdx-20221231.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LicenseAgreementInitialLicenseFee" xlink:to="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c882fb19-c2c5-4dab-a3db-a381c35966b3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_5270ce6c-c547-4176-a3de-2c8da7148fdc_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_327a712d-7ab5-4a9f-bfec-a49075867ba4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_648b85a6-468d-4cd5-946f-2627a18ac07b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b9b6b94-fa52-4ed1-8d4d-08407a2b0a58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_61830455-2020-4014-936d-1b47eefdf359_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock in public offering, net of issuance costs of $4,435</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fddf4866-6ac4-4661-b158-30f92c4e28ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_708696f8-23ee-4889-87d0-4a67119f416f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of RSUs vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c0ad9c8e-5dff-4072-9d52-1dad0bf3180e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_380abe0a-bbad-4f56-b14c-269c162ed4b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_395c9d8a-989b-4cf2-8e35-f48bcb4518ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_aa822f28-318a-41b0-b06b-d357e1e19c5b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Shipping and Handling Costs</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_450efb3c-ab3e-4339-b1e2-329ec66c95fa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b57d0145-4a15-495e-9349-8d9fd8e556a1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareMember_83c5ddc6-9ff7-4e32-af3d-db025ff87a36_terseLabel_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_exdx_MedicareMember_label_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_exdx_MedicareMember_documentation_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember" xlink:href="exdx-20221231.xsd#exdx_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareMember" xlink:to="lab_exdx_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3720b494-0b00-4700-87e9-0b0198d556a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise&#160;Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_193e9d41-fe88-4169-88f6-8a278d423c92_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e342591-1888-4c09-af23-ffc172301d1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_dd0efed2-1bea-4df8-9f8f-7fa13a60269a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_789b87b2-3b13-4da1-bb5e-9b74358cfadd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a264dc01-b42f-44e8-b459-81a558feb015_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b93153c5-d65d-434f-b122-74e044d34fe9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0932870c-b91f-4597-923b-0fabd7a2e689_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4e8598fc-a31b-4e55-a4b5-518194fdde0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_510fc19a-fb92-4523-87fa-99831a127052_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_1a79bca8-18c8-4f7d-953f-24d9e736f21a_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_6583d334-a2fd-4efc-9eee-af1ef4815cfe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f7cf916e-6cf0-482a-82bb-c505764e68ed_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d66490dd-5615-4d0c-9718-721d96fb4d12_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_05583446-cc91-4652-8548-fb4c9d34f90c_terseLabel_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Studies</link:label>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_label_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Study, Policy [Policy Text Block]</link:label>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Study, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:href="exdx-20221231.xsd#exdx_ClinicalStudyPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:to="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_7bbe5146-2bf0-46cd-bae3-d9eca3f5f300_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationDec72025Member_ab13881c-15a3-40e3-b593-a919b643cad2_terseLabel_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration December 7, 2025</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_label_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_documentation_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member" xlink:href="exdx-20221231.xsd#exdx_ExpirationDec72025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationDec72025Member" xlink:to="lab_exdx_ExpirationDec72025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3a7f964f-117e-4b2a-8308-31672e1840ed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_WeightedAverageRemainingLeaseTermAbstract_38f25712-0330-4545-bbb5-615686255ce7_terseLabel_en-US" xlink:label="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_exdx_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_exdx_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:href="exdx-20221231.xsd#exdx_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7d5f9597-9b7a-4cd7-a181-888b7ec92c0b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_20622183-a4df-4fdc-aedc-2b9a44e60913_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d323a867-948e-43ba-81b5-8ae83344c320_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_8d94867e-d8d6-4c21-8a18-cd3825784df1_negatedLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:href="exdx-20221231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:to="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_1c31f95b-d932-4535-8460-ce3c58b31e50_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_b4add990-a825-476f-990d-e197b5b724fa_terseLabel_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_label_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark [Member]</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_documentation_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember" xlink:href="exdx-20221231.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ReceivableBenchmarkMember" xlink:to="lab_exdx_ReceivableBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_5ebfc10a-7a1d-4a98-804d-b6cce0514a54_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e66ce3df-e6ae-4fd1-ab16-16cb81eccaf7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_82eca066-2b47-4432-a14a-e25e03a4af4e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_d1c17acc-e86a-49f5-8bec-24c19f273be4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing and acquisition-related liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_UnitedHealthcareMember_6683b050-da8b-4b05-b4ec-684f7ce90a77_terseLabel_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_label_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_documentation_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember" xlink:href="exdx-20221231.xsd#exdx_UnitedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_UnitedHealthcareMember" xlink:to="lab_exdx_UnitedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_976d5345-b2cc-4c0b-a314-fe81b2055a00_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_e67bca16-77a0-4b3d-95b6-475d8ba8d757_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_97d52f18-5c70-417f-bee6-3c3773c40867_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2da2f840-d15e-42a3-93bf-74ca9affaae9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_deb7c0a4-b886-444b-b073-e4b80c3480db_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_dd729eb3-fd30-4730-906b-a6a0e2c3276e_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_21e655c4-f8f9-408d-8e04-aacd43a21986_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_12dea68e-2a83-48b0-9617-19fc07bbfdad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b5012534-d18e-4f28-9048-c87ec56bbca3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8806db7c-1d7b-4c3e-b5b3-a19df6843837_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_a018194b-4644-4b92-89ee-caf022ef9015_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_48d7f986-e030-49f4-b8f9-dcd169b2763f_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a1dbe4b2-e5e7-4095-8fb3-98dcdc0829a8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_59bb1b90-9a26-457d-a0a0-c3ac67f74a43_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_28652acd-71a1-4057-acf5-ac2b9722549e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e3ff45c2-f441-48bc-9c1a-f5042745800f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_f1f22c97-607e-426e-b6f2-22907b79c38e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_be4b470d-3168-4c0b-bb37-7c16a00a894d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligations, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_33b1170d-8143-45cc-a17b-ce1b2c0afce5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Reserved For Future Issuance</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ba5018fc-3f26-4bf6-aa7a-ed95646120f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions, Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_08aa60ca-065e-42fa-8e33-b89078c66db3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8afacb1a-9281-454d-9b75-e9892b5c2d2f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_cf21b1ad-e206-4cf7-baef-64a203825255_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51f6659c-8ce9-4f73-8997-e97077827812_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e9757cab-7cd9-40cf-9898-0e1baa51bab7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f28b5b7-a1d1-462e-b009-04cac75e88b6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, cost not yet recognized, remaining weighted average vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_0b9db1dc-52a1-4c04-bf1b-c50ff4e05d7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_a80dcf3b-f888-4df3-b719-ca0cacd3c0d4_terseLabel_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_label_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc. [Member]</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_documentation_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember" xlink:href="exdx-20221231.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrometheusLaboratoriesIncMember" xlink:to="lab_exdx_PrometheusLaboratoriesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cd5447a9-835d-4bfc-aa45-2bac862197e6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8016299d-c7f9-4b7c-8a5e-4ade63f1a8c9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2826e9e4-2259-4b45-860e-1e4489afb9bc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_22f722e9-e60f-4988-904b-81c29066a261_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d6014c3e-3d66-4e41-afa5-fee623c9c899_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_4b63be57-ae16-49a7-b637-0fe5e7f66865_terseLabel_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Award Plan</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_label_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019 [Member]</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_documentation_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member" xlink:href="exdx-20221231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncentiveAwardPlan2019Member" xlink:to="lab_exdx_IncentiveAwardPlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4e3b1586-d0ca-48ce-bbf3-f6fcb163ffe9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1263000f-8479-4d59-bc66-b26005410fed_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4164d486-0c2c-4f13-8457-54ca32a3e9b8_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_7dc2398c-e9b7-4838-8d5c-5e5750670371_negatedTerseLabel_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_label_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_documentation_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:href="exdx-20221231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:to="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_27f75680-363a-41d5-b414-5a9790b34dd0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_67ba23be-8500-4b67-8c19-45eabd280ced_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_726eccf2-32fc-4dc8-90ee-e3bf8d2a7c1c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_62c2ac05-f16a-47a6-a02c-493daebbcecc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d4ebe35a-40e8-4095-bd60-6ad8c08559ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_9bedbcc7-74c5-44ef-9fc3-0fed8088b352_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_3dce63d5-4d03-4039-b39b-915d0bad034d_terseLabel_en-US" xlink:label="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_label_en-US" xlink:label="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Information, Operating and Finance Lease Payments [Abstract]</link:label>
    <link:label id="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_documentation_en-US" xlink:label="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Information, Operating and Finance Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:href="exdx-20221231.xsd#exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:to="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5a4ce037-2097-4320-ad52-c75575f657ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9047d369-1ced-4f07-9cb9-28481aebf0b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_87817f3d-7c92-43e3-b4f8-85c9c3fc0724_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dde513e3-1936-4841-b372-d7395c882542_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_f58f606b-9ccd-41c7-82be-3acb0e9c20dd_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind, interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_label_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:to="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_5ca3debd-2b4d-42e5-89af-c827cbb89918_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_7e717e47-3431-42c8-b951-87f1272ae69e_terseLabel_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_label_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_documentation_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:href="exdx-20221231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:to="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_a5032322-c2bf-4e3b-a2b6-fa0fd73bafdd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_da88a701-8252-4a2b-9940-c51014a72620_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_440bf234-b7eb-41f9-9bd3-e8288727c6e9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, percentage of ownership after transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7e90621c-f424-4617-a53a-1636ab30ccfe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2baf726-595b-437b-98d1-2d69c1e7fd15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_31f6435d-6bd0-46ca-abdb-e388b5547c9a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_80a96cfb-453c-4b0a-a2db-be1f5ba692f6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance upon vesting of outstanding restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c03f716d-f5b9-4b71-8759-97960577ec44_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_cd78bfa8-af72-4fb1-b5a8-078901e53d2a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f656741a-7e6f-40b8-a27b-3e361c9ebf75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9f5450a0-8292-4eeb-8b72-b5d4bb4f59f0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_14ef6397-781c-4576-bf45-b04c7cf46dc6_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund liability</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_107b6070-7032-434e-b9d8-485969571393_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_b1913f38-acb3-4538-91d2-24d663a6e62c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f9e72b6d-e8e6-4f34-a78a-7463a98d263e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_20d3470b-6a10-4213-8dca-7d579e16e10a_terseLabel_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid maintenance and insurance contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_label_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_documentation_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:href="exdx-20221231.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:to="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_80f08c41-3978-4f2b-b612-202079f3bdc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_98f6e8ce-632a-4186-8c56-0ed56f03c2a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, fee incurred upon payment of final installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f52b42c0-3d06-4822-adc7-e0dd2527d62a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6581947c-35f8-45e4-a3ed-4a02fc916a78_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_faa6458b-1539-4d95-97b8-3484e22bd6e1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2a0fde56-bfd1-488b-8efd-9c61037890be_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_c4ff8324-6c24-4307-98c1-088ab6d76a81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_838405fb-8fba-4889-b4c4-5ed0f8a71bdd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b9743d52-9fe9-4bf2-8f2a-0ad2333179f0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a037580e-427b-4524-aca2-28787aabdd11_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_60bc69a7-8872-496d-b36b-54755133c1e4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_acce8c70-1f91-4f4f-aa49-a3c1f9b1cae7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b9b6d232-2182-42fe-b9a6-76f3bdbd0918_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_5a3c5e02-f173-4f3e-bef5-730534c63886_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, collaboration expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_label_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:href="exdx-20221231.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:to="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_27ac036e-1702-4a9f-a395-9c36be3b9293_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_eee4d5f1-1695-46bb-89f0-7575107787fd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0203705a-faca-4099-8007-7a695bd1ad71_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6af41a8c-d5f3-4a59-9ebb-7675ece6106e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_21b2c3aa-73ae-4792-a808-08c98774c510_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment purchased under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a8435f3-baf5-4a3d-b942-bd400ac6bfd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_a27f99ee-27b0-4d2f-a3f9-56f106f9950e_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in number of shares authorized (in shares)</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:href="exdx-20221231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_ac435cf0-63fb-4218-b33b-b6fe1d4427d3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_541386fb-5a33-4335-87c7-6dd405bbd495_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLossCarryforwardsNotUtilized_c043eb29-8fbd-409f-a133-c5de9fa0324d_terseLabel_en-US" xlink:label="lab_exdx_OperatingLossCarryforwardsNotUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax attribute carryforwards cannot be utilized under IRC Section 382</link:label>
    <link:label id="lab_exdx_OperatingLossCarryforwardsNotUtilized_label_en-US" xlink:label="lab_exdx_OperatingLossCarryforwardsNotUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Utilized</link:label>
    <link:label id="lab_exdx_OperatingLossCarryforwardsNotUtilized_documentation_en-US" xlink:label="lab_exdx_OperatingLossCarryforwardsNotUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLossCarryforwardsNotUtilized" xlink:href="exdx-20221231.xsd#exdx_OperatingLossCarryforwardsNotUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLossCarryforwardsNotUtilized" xlink:to="lab_exdx_OperatingLossCarryforwardsNotUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d92a7ae4-ef2b-4b34-9957-6585799f9133_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cf15937d-4c95-4a2d-9ea4-d71eb519582d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_5d2be566-7704-4d64-a2dd-1c2496702787_terseLabel_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory [Member]</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember" xlink:href="exdx-20221231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeAndLaboratoryMember" xlink:to="lab_exdx_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c143a182-a8f7-44c9-a8fd-1e83ec0c8d7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_721880f7-3b6d-488b-ba96-6ba752c39dc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8d6b4ecc-4915-4da0-a877-97e07a5bebf7_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7e31c381-32e6-4cb0-9811-242f36ec5980_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_734d95c1-71c1-4a34-8fe4-d4cb8c4b376b_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d1c2fe38-75e8-417b-b38e-52205b8a7fb3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b3487ad8-564a-4877-8594-526687450449_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Employee payroll deduction percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_54013f52-a3c7-43cf-9fb4-768d8f64fb72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_a53958eb-b585-4f08-beea-7ff45ae56de2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3291f219-1ee2-4da4-9e29-b16c71ea5fb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that remain available for future awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e0d85041-3098-4e7d-9ce8-caf7d422ed1d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1161fed0-38ca-4a8e-94c0-b259d050e6d2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_761cb028-6211-40e5-9a5c-021d3a4a0f95_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8bc831f7-5d92-47f9-afeb-fbdc791ae643_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4084ebe3-cb92-4ead-8211-85e92d9cd162_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_a59105fc-5d30-4c99-b44d-8d2bd72490c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_1e80a27a-847f-49fa-904d-fcbfc9030250_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture&#160;and&#160;fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_95c04144-199e-4477-9d6a-d3b3cbfa727c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_d7377deb-9766-4d3d-bd2f-c96528dbe814_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:href="exdx-20221231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2c574f8b-95b6-434a-b8d5-1f1d67aa4b76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_15100f43-95a6-4b67-8c33-d577a43fe516_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligations, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_17b6b8cf-11e3-4bad-883e-99efaf8b5d53_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_fcca0ba8-9cbd-451d-b8ae-7367322216d5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified employee compensation contribution, amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_4f5e5831-9823-4608-b2f8-9bb52a88efca_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, annual increase in base rent payment percentage</link:label>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_label_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Increase In Base Rent Payment, Percent</link:label>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Increase In Base Rent Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:href="exdx-20221231.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:to="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_38cd3ae0-3def-40e2-9036-0fa87f298ddb_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_53e07aed-d9ea-4904-8c61-6b9543660809_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_6ea290f8-e701-4203-a3e4-6e9ee8f6ee5f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_923a8009-b3e6-4c75-ad91-3ad86770c790_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_21a0edb6-8a81-4767-8576-6071c54fdb9e_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a6b4139c-050b-41e9-ba52-b388be900f9e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_11ba2870-6972-4179-84d6-3bb8f38351b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3163a520-ec57-4863-b6f9-0b4d308a7909_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5ecc132c-f3fe-456c-92d4-57c86b9cf575_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_1512a5bf-4b73-476c-8e2b-aeb97e50fe1a_terseLabel_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:href="exdx-20221231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f2b52e13-b9a4-483d-8560-034412d6b464_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_21dbe5bf-0bd2-4742-873a-4012f4f6d28f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AuditInformationAbstract_label_en-US" xlink:label="lab_exdx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_exdx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_exdx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AuditInformationAbstract" xlink:href="exdx-20221231.xsd#exdx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AuditInformationAbstract" xlink:to="lab_exdx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_98f38529-2d33-4882-903c-d5e1588e0538_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_dea14fb5-c320-44f6-8101-58af0c5f45f6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_47c1a5b5-7eba-4784-a82f-d45324a34f6f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_02ce2989-3320-4a91-9811-a542db854930_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3d6d94f9-31f3-4155-b306-01e89222329a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_46d358a4-4ae5-4ead-bd33-b60817fb2e6e_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment on finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_9e915514-d658-44c9-8504-3938fbbd711e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash out flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9a546047-b467-449a-b968-737ec91c1b6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1c55cfe1-7e56-4b5c-b56d-be47ea5c55eb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_de9f5a53-d119-4d28-b86b-145edfa8ff2e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxAssetsLeaseLiability_d602863b-5988-4086-b68b-2152b45628d0_terseLabel_en-US" xlink:label="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsLeaseLiability" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxAssetsLeaseLiability" xlink:to="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_04078264-5596-4fdf-a72b-37e2af44da3b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_ca7ce720-0b12-4eaf-8d4c-a5fecdb8311c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_885c56c8-4547-4946-813b-899f8da6b444_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_d6e6a839-de7f-44b5-a95b-1458663946aa_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_d431da5d-7608-4555-82e2-0ac2538191b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_c308083f-ecb9-4a03-92b1-ba2fef02636d_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2b9cfd16-3ca8-4577-a510-76019b68f5a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_1359e0cf-825d-4e99-ace6-6169adf8a018_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_b28e1a7b-e71b-4473-8e7f-753fc9447ff8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_de265606-3f70-4016-bb15-ca199242332e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_28568e6b-a11c-4dda-948a-37c33a6fc2d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ac51148a-6697-456d-8640-95ab73130a00_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b2b13963-a331-4b54-a535-79d640cf1ba3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_68b80d59-6d0e-4fcc-a6ed-81d924641ff0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_0393692e-ff0d-4c0c-8d21-6b2083045750_terseLabel_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_label_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute [Member]</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_documentation_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:href="exdx-20221231.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:to="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_15d00f72-65c2-457c-a88f-6fc4ded51ab0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_493636b1-e748-4244-9241-5e37802d38fe_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_be7f4836-c338-4559-83a8-46d9060995fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_bc59e03b-e631-4407-af76-2570559242e7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_94607b79-f7c4-42ed-a6de-2cfa53bd7cde_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Recently Adopted Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_WeightedAverageDiscountRateAbstract_0eed968a-3933-4c2b-8c86-11b1ca02a443_terseLabel_en-US" xlink:label="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_exdx_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_exdx_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageDiscountRateAbstract" xlink:href="exdx-20221231.xsd#exdx_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_WeightedAverageDiscountRateAbstract" xlink:to="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9e1409f8-572b-4542-b985-7e354d59ad7b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_723939be-2cb4-4204-86e4-813cba3cfb98_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8b9575dc-8c41-4dea-8174-88c51a6e0c8a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e0e8250b-35d2-423f-9f74-80e342be1a36_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_7b631732-d542-4fb3-a8a0-783e0483953a_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_28e50cc3-bfa1-4153-beb9-6b980827a1ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_bc2da33f-fb0f-40ae-adf7-8df75cff0c71_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d4ef79ed-1626-4478-bb2f-a15b9fe9b312_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_df57587b-aab1-41aa-9cb8-a8bd4fb9c10b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_e22a1ec5-8a86-43e1-9cbc-356321da8048_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CommercialMember_b2a13551-749a-4953-ae76-0a5e0c312609_terseLabel_en-US" xlink:label="lab_exdx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_exdx_CommercialMember_label_en-US" xlink:label="lab_exdx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_exdx_CommercialMember_documentation_en-US" xlink:label="lab_exdx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommercialMember" xlink:href="exdx-20221231.xsd#exdx_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CommercialMember" xlink:to="lab_exdx_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Term2017Member_e26f9e68-be0a-4d0a-b9e3-02fc8bc52ba5_terseLabel_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term loan</link:label>
    <link:label id="lab_exdx_Term2017Member_label_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017 [Member]</link:label>
    <link:label id="lab_exdx_Term2017Member_documentation_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member" xlink:href="exdx-20221231.xsd#exdx_Term2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Term2017Member" xlink:to="lab_exdx_Term2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d3ba9c5-c169-423b-ab36-9ea4fd813f9a_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7fc19005-6c3c-49ab-b23c-3b53dbd227e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8d600b61-eafd-4852-a167-258d84fd958e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) for income tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_fbaba0ad-0244-4026-ac66-b5b098e498a7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_265a9838-f5fd-48d5-87da-624825d8ecf4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6d6b8529-4fe4-46d3-a451-d36d5491dcb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2b6a91b0-84c0-4411-bc66-1dcbf7758581_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at the end of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_0c3a3a90-4b5d-458e-9ab6-749665ce64ed_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cea9c03e-3df5-4f7a-802f-59f11501822d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_886c2f2d-9a0b-404f-b3c7-fdca113d0e83_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_37c3882c-bb59-4110-a03a-b4bc6533fcc4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b464094a-b46c-4140-a5b2-94c034e09214_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_bf064a82-bf60-4aa1-897a-c39bb227ad52_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0eb4c102-eb13-4a7a-8412-4a914d79ff04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_e2839e0c-8f5a-4920-9b5e-6c5ee40c1ad6_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_45951f09-346d-492d-b739-f8c59147bbbe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_54c50249-6026-4d0c-a1f4-cfb8ec5909d5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_34437b3d-c233-4470-83db-9fceaf47be4a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_71c8678c-fbfb-42d6-b14e-f83de9efe184_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ed82c3c1-d6cc-4287-8f9b-f4de6461f906_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_606dccd9-0ccb-48f5-a0eb-b368d95779a1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a7c752d5-97d1-4844-ac38-b15ba6eeba7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_99263295-ad77-4d64-ae35-4ce54c881600_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f121edcf-00c7-4188-b8a2-a050b3694a9f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_89614ef6-5760-426e-a69c-692eb3a84c74_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_cb1e2f55-e751-4b15-ba61-9cd22ce484b7_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, covenant, number of days to cure covenant if performance measure is not met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:to="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_a3bc3222-20e7-4ab6-ab6c-6f81db7f2cde_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0e65e52-5fbb-46de-bc95-fc3194fa2a85_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_cebf1e71-3062-4235-a1a2-5f03fcde83ee_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e44e1ee1-8924-415d-a8e9-5a02353c5978_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_969fc031-7f2a-4025-a57d-74d5a535d7cd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2022 and December 31, 2021; 16,549,984 and 16,164,994 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b5e53988-de6d-444b-af49-083f0ced8bdf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_07ae11ce-10d5-4211-b8da-15c38d312600_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d44193c2-22a4-4539-a945-363f05254bb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_39873588-0bc5-40bf-9fad-450befb70d23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f96ea7ec-5620-4eb3-aede-95ff7c963da1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0755ed27-a241-4c27-85ec-7136f0e415b7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_bfda345a-f804-4f10-a883-f6897607f976_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_5e6d6b65-e6e2-4070-8c54-e604f5bcd51c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68b192eb-5471-4aa6-a4d4-9230d3e97c68_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34b9986f-320d-4196-ad93-536ca1f7f49c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e01a5ac-81e9-4852-afe2-1ad87af35d2a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_d92f647b-0174-4fcb-9289-1e7403ecf895_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4e32e1d3-66f0-4441-8c93-879a2b5cbb04_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ba52d456-d857-4747-a21c-cf84a445afa4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock warrant in exchange for retirement of common stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_534d55b8-99ef-4d20-8125-fbe59fb1a9df_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_004710f4-80e7-4a88-a9bf-648e32b48170_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2ff205c6-41e4-48a8-a5db-ea70071110f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_cc64ab78-6667-4e19-a5e5-2bc3c2f9574e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6d63d05f-113b-4f7a-abb4-b38ed3756e3b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_2a96d4c8-b11f-4e6e-b16b-6d93b2fe05dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_120d7b27-74ba-4c06-a14e-093db885883d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_852192b5-d970-4b52-8241-f10e7059f1cc_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, due in next twelve months</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7c63550f-e6de-4422-ad45-d01a767c51a7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred, but not paid, in connection with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_fa76ddaf-900e-41dd-a6e9-6469d1551b46_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified employee compensation, employer matching contribution, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_035294b7-52d1-40af-9bb2-0fe0c0f5f459_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_74d083d9-d343-437f-8a42-f8248306e3c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_81f77007-b4fa-4ef4-9a78-dd753bf3caab_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_4742f42a-734f-47bc-9d4e-93e9dccda17c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations, current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_3e440ef2-8dfa-4448-8a6d-28a95d217810_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_df74f7f6-4417-4fb8-8eb1-bbbe2c37fe48_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals, reserves and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AHNCollaborationMember_31040a9d-a7fe-4791-b46d-c1cd97ee23b6_terseLabel_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_label_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration [Member]</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_documentation_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember" xlink:href="exdx-20221231.xsd#exdx_AHNCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AHNCollaborationMember" xlink:to="lab_exdx_AHNCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8f382f08-e88f-4540-8c2b-bf1cadcdba74_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_40b56b82-26c1-4a14-b627-eb574398bdf5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_09b37061-2fca-45d6-a3cf-106c8826b747_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_0bfa66b4-6c5e-447e-913b-605c4cc3616a_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_deb9b006-8fcb-41d3-8225-b58764cbbc11_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_241ab419-8550-4c39-9398-decbadb6d815_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_9492f925-46e6-4063-83ce-7a09b0fa79e6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal net operating loss carryforwards, carryforward indefinitely</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_be26609f-d1a9-4660-8243-55849e55fe2c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRoyalties_7fd0ae85-750c-447e-b21a-c38fd521c477_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid product royalties</link:label>
    <link:label id="lab_us-gaap_PrepaidRoyalties_label_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRoyalties" xlink:to="lab_us-gaap_PrepaidRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a1b855fd-fdad-4983-be86-0e4275831e44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term&#160;(Years) and Aggregate Instrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_27464695-588a-417f-8728-9e76b981bbb2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4c2a7a46-c7dd-4d3d-b084-cfc07e2dfeee_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCustomerMember_ff6d3c08-9913-4ab1-81ac-8746a1de7447_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCustomerMember_label_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCustomerMember" xlink:to="lab_us-gaap_OtherCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_6767714f-a6f9-4c0c-a146-ac48302b164b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_cb2ba651-47b7-4606-898e-de1df4b7ae7c_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, minimum unrestricted cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_b3af0369-42c7-4958-897b-a096f455d35c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment on note payable obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ee14094f-621c-41c1-b054-c15c2d6d2c31_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_0d64a7a8-30cb-4e86-b928-83fe8fc8bd47_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, due in second year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_76d57ca4-ac11-4cfa-8710-c22ea560cb67_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_43097418-53a2-4169-b9ea-fe7fd2c64669_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5f123e2-7718-474f-985a-9b879737250e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b946768d-39dc-4fda-b390-0fd6b2b3e543_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_55a1eeff-6911-48b0-87a3-20a1aee59cf8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_ad19ee48-19d7-4c7a-a39c-ce5a9fb750c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b97256b4-4ed4-49bf-8e72-4d8b8b5ba818_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f3b2bad1-10ed-4802-bc5a-a60e7c505298_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_558c1ea1-2c99-4282-95c2-bde6b93e3cd1_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_40a58c32-ab62-4309-b3f4-dee725467c51_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8e82706a-1e14-45d2-9513-4c8b847437ea_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_3e5caf07-1127-4333-a777-bffbb7821ea6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash out flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Government1Member_cffce0cb-da7b-43e8-8e8f-6366ceb694b8_terseLabel_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_exdx_Government1Member_label_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1 [Member]</link:label>
    <link:label id="lab_exdx_Government1Member_documentation_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member" xlink:href="exdx-20221231.xsd#exdx_Government1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Government1Member" xlink:to="lab_exdx_Government1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ec5268a0-9229-46c4-a3b2-5a7586a297b8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8998fef6-6b0f-4500-bde0-3cf9a01b17fa_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock option grants issued and outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d4cf4af1-aa39-4cff-a69a-9d7ef5a00f87_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_feb6ef57-4558-4744-889f-ae5802334bc6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f699aa8e-c780-4d32-a3a2-293fd98eb757_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a714e5ff-bcb5-43b9-a598-6ea7d40aac0b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_538c6e39-dbda-4fde-8e21-00c5219a2019_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_354fec27-4034-4875-9691-d5ef2779844f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_eee28f7f-2bd8-4f04-8a2a-4b51b7504153_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_0365bbfd-d68a-4d94-bfe4-0182cabf0002_terseLabel_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment purchased under notes payable obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_label_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Notes Payable Obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_documentation_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Notes Payable Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:href="exdx-20221231.xsd#exdx_EquipmentPurchasedUnderNotesPayableObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:to="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_8e5ffccf-ffd3-419c-9d1b-495e126e970f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_2e21eacc-a757-4f64-bc0f-254716cf5e6f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in public offering, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ccf0ab1c-a123-4026-b036-99bcb8cca97b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_9dc0ea63-53ff-40ef-8747-43b163eb19f3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d3646bb8-c40c-4d16-aaaa-23ab646e3411_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_66e615b6-caa7-477f-bc87-6d11c6b4ad37_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_25d84a82-bf1e-48b2-959d-2a6ae0441dec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_cdabc4bc-3b42-4a46-82a2-14125f55ba11_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_c29fd2eb-7a86-44e9-b468-87ab276e7dde_terseLabel_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_label_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:href="exdx-20221231.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:to="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_68afeb02-804c-4062-94c3-5daaaea98138_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_46c746e7-248a-41ac-a956-b6f10132d0a3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8715b059-ef1f-43f9-a925-d527a3ba01b9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7403b192-c385-44f5-8dcd-55a9e97effa0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d2ff8c1c-3516-49b5-bb66-18e0753e2d2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_69729161-1c3a-4db9-974c-49a5c82774ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TwoSuppliersMember_f4ce24e2-8377-4b13-92d7-39b290577e67_terseLabel_en-US" xlink:label="lab_exdx_TwoSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Suppliers</link:label>
    <link:label id="lab_exdx_TwoSuppliersMember_label_en-US" xlink:label="lab_exdx_TwoSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Suppliers [Member]</link:label>
    <link:label id="lab_exdx_TwoSuppliersMember_documentation_en-US" xlink:label="lab_exdx_TwoSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoSuppliersMember" xlink:href="exdx-20221231.xsd#exdx_TwoSuppliersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TwoSuppliersMember" xlink:to="lab_exdx_TwoSuppliersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a9748420-2ccc-429f-9bc6-98a87ad7a25b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_9cf79c39-5933-4b97-8ece-6daa049c6cb0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_5e9c1b7e-a43b-47de-afcf-92acb02f1a4d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8aac8e65-e839-4a19-a561-cd87d2dccb90_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_48b91f1a-9ede-49bf-907b-0d31dbf9acad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_061367f0-63fb-410a-badb-c5e9905bc431_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_a2738089-dc08-4cdf-8cf1-ab569edbb39c_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_20a6e678-8402-4bbf-a3d1-17767b0a9cae_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_24acd4bf-babc-4e7d-a56e-ba34360177cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareAdvantageMember_0bbc4621-ad9e-4e33-9a50-c8214b9d2624_terseLabel_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_label_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember" xlink:href="exdx-20221231.xsd#exdx_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareAdvantageMember" xlink:to="lab_exdx_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f3287c5b-77c7-44e2-988d-612bc1cbbfab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5e0e44f-6dd0-4563-bd9a-abd3f5271c33_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_302e6fc5-8ecd-44fa-bc70-7bc6db64b55d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_31a332e4-fb54-4750-8682-3ca84ece74aa_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_f9c85bad-240a-40d8-b6fd-5e57b125c2ef_terseLabel_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for grant under the 2019 Plan</link:label>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_label_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Available For Grant Under The 2019 Plan [Member]</link:label>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_documentation_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Available For Grant Under The 2019 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:href="exdx-20221231.xsd#exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:to="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_0a696142-b4fb-412b-ba13-f68328a395e3_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, covenant, revenue performance period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:to="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid_9f79bc4a-1cd3-42b6-b12f-bb20d900ab96_terseLabel_en-US" xlink:label="lab_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for royalties to begin</link:label>
    <link:label id="lab_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid_label_en-US" xlink:label="lab_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period After Commercial Sales Begin For Royalties To Be Paid</link:label>
    <link:label id="lab_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid_documentation_en-US" xlink:label="lab_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period After Commercial Sales Begin For Royalties To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid" xlink:href="exdx-20221231.xsd#exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid" xlink:to="lab_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_3a962a4d-c331-4d22-accd-e34201efcb5a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_d7cc3940-d16b-4446-8b9a-b2d5a33df284_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, prepayment premium percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_94c18e2c-3f8b-4f72-a40c-671f91a70b16_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_c99aeb92-0f2d-4a03-9cc4-0b45ed7ff6ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5230a48e-48c5-40ce-b3a4-3110be1dd492_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_30667015-56af-4ca6-a7bf-9923a6303ab5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_053c3190-f909-4901-86a2-bb8bf0b563ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_495f19b1-a501-4b10-8227-2cc4e678ab22_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_7b1ece27-a00c-4895-a81f-9d1d3db39a33_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum royalty commitment</link:label>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_label_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b350ff7d-cd85-4bdd-ae76-42780575c50e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_980092ae-c60f-45a5-bddd-2fce4566b882_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_c4b869a0-0da4-4603-8863-f862ca577de0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Finance Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_f4f07596-665d-4f6d-998f-155b33cac7c2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_8f92005c-8a73-4f01-b3f0-3f7dd915277e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_040f059a-b6c1-4647-9946-608bc79beff7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_986da9c5-4d0a-4f36-bed2-3a6f10afbe28_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a4503e42-18a4-40b1-9280-ece5b7923e0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdvancePayment_11b52736-dc7c-4c7c-b0ba-17e3cca31a0b_terseLabel_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance royalties payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_label_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_documentation_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment" xlink:href="exdx-20221231.xsd#exdx_AdvancePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdvancePayment" xlink:to="lab_exdx_AdvancePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_35ef504b-9b3b-4180-a692-ab7c4e2958d0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering, net</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_c579be79-8ff2-4117-8809-66d70505808c_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of annual vesting installments</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:href="exdx-20221231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a16d7f64-43c1-4e72-86c9-f94c99066a4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6005d956-c850-4057-9d55-84009bcc2eec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and Expected to Vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b0d5e782-4670-4bad-9952-4f07f136e7ef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_884174b4-c9f1-4e09-9024-bf73049f2175_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NonCashLeaseExpense_ba40fa5f-20b5-4925-b823-b0a164e456a5_terseLabel_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exdx_NonCashLeaseExpense_label_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_exdx_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense" xlink:href="exdx-20221231.xsd#exdx_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NonCashLeaseExpense" xlink:to="lab_exdx_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_8065b24e-06ee-4867-a491-b33120ff746c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_16d61d5f-2bd4-4ce4-b189-7a118900e496_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JanssenSIMPONIMember_332d6633-cff2-4945-bd27-35b0129f7f49_terseLabel_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_label_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI) [Member]</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_documentation_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember" xlink:href="exdx-20221231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JanssenSIMPONIMember" xlink:to="lab_exdx_JanssenSIMPONIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4bbafa91-c9b7-4831-876a-42900109570f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock in public offering, gross</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherOfferingMember_020ccfc7-d7b7-492b-8e76-1f5658372041_terseLabel_en-US" xlink:label="lab_exdx_OtherOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Offering</link:label>
    <link:label id="lab_exdx_OtherOfferingMember_label_en-US" xlink:label="lab_exdx_OtherOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Offering [Member]</link:label>
    <link:label id="lab_exdx_OtherOfferingMember_documentation_en-US" xlink:label="lab_exdx_OtherOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherOfferingMember" xlink:href="exdx-20221231.xsd#exdx_OtherOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherOfferingMember" xlink:to="lab_exdx_OtherOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42ffba40-6932-4dcf-9357-e7613cfe91c5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_baf8f2c7-4063-4b69-bfd9-ad2d196d0390_terseLabel_en-US" xlink:label="lab_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:label id="lab_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="exdx-20221231.xsd#exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9a42844c-5bd7-4e02-a06b-a639b8ad5e89_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_762aa53d-7125-440c-9da5-9d2e82abf46f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AVISECTDTestMember_c912a115-954d-49d2-be65-e46c37510e26_terseLabel_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_label_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test [Member]</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_documentation_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember" xlink:href="exdx-20221231.xsd#exdx_AVISECTDTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AVISECTDTestMember" xlink:to="lab_exdx_AVISECTDTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c4c8b8f9-0941-43f9-bb09-948cd6cd3778_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1506c64a-ea34-41ae-9daf-154ecda87a7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_edcc7918-24d1-4207-ad4e-5adabf2ddcd0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2f4d97b3-893c-4ea6-b391-1d2fe935c176_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5572cbc2-2708-4fa0-a151-ddfc20dd8cd5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_09f26e7b-7c18-418a-afa5-4bac150374ba_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_6ab37ae7-cd76-417d-bb24-2394ff263a4a_terseLabel_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember" xlink:href="exdx-20221231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LaboratoryEquipmentMember" xlink:to="lab_exdx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ac5d9a79-e6f4-4557-943c-ac61bb407718_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2022 and December 31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationJan192026Member_a586dd75-8247-451b-8129-dc5a2ccb2744_terseLabel_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration January 19, 2026</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_label_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member" xlink:href="exdx-20221231.xsd#exdx_ExpirationJan192026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationJan192026Member" xlink:to="lab_exdx_ExpirationJan192026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_d5186a10-f9f2-4068-8b5b-32c979400263_terseLabel_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="exdx-20221231.xsd#exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8790e02e-90ff-498e-a1c1-c73b23e59ac5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e98a523-5eb1-4059-ba86-834cfd741ae2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_13c1b811-17fe-44ba-83a0-06d7448b52a6_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1fab3252-05c7-474c-b0fb-d5576e37a519_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_30750617-85f8-453d-ac86-5657f1f83e1c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3f2dd302-5b80-4ef7-a99e-5aab72e11950_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9a60c396-0c4e-4436-97a8-ba74fb2396a8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_77c0030a-0922-4de2-a220-9d8d038de5f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_6b6fcf90-4bdd-48b9-bcf7-fe34dde13088_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_7d94a82b-3814-404b-bbd6-ef718bcfb271_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_531e030f-c6ea-4eca-90f2-8ed234f62aa1_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_81225525-e4ee-4d51-9587-9d7526f49705_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_5c7fdd3a-09a9-4e2a-ba3b-2da4979f1f02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_c218497f-499e-400e-ab07-3f3335622326_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_f0529e54-6362-462d-9ce6-53fc08a02fe1_terseLabel_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Notes Payable</link:label>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_label_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Notes Payable [Member]</link:label>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_documentation_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember" xlink:href="exdx-20221231.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentNotesPayableMember" xlink:to="lab_exdx_EquipmentNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_be92cd2a-7a5d-4c07-8717-c938483ed917_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, annual reduction in prepayment penalty percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_473ad77e-378a-4566-b898-5d859af4b1b8_terseLabel_en-US" xlink:label="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares exchanged for warrants (in shares)</link:label>
    <link:label id="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_label_en-US" xlink:label="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement, Number Of Shares Exchanged For Warrants</link:label>
    <link:label id="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_documentation_en-US" xlink:label="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement, Number Of Shares Exchanged For Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:href="exdx-20221231.xsd#exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:to="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_b0593e34-3f18-4f84-bf25-db40e799801c_terseLabel_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical study activity</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_label_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:href="exdx-20221231.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:to="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_57708192-b817-4446-b96a-d162d2ccce93_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_78ecef00-befc-4f9a-b9f4-71df9fdcff60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of taxes withheld on vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_37520bbf-13a7-49bc-8b6d-b283ad7992ad_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_851bb74c-5cfe-440c-8fef-9653c10e1264_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_d728f1cc-e9ef-4742-9a7a-13a767319363_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_9a9c6787-13cd-4c29-b64d-1f7e46cb7d56_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_7e80bfce-db38-452c-a141-65574063442f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_2a5cb702-dccf-4b9b-a1fd-3449e7552578_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets_391f777b-38ec-47c0-a3cc-ecdb30b5f627_negatedTerseLabel_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_920b82bb-4773-482e-9fc8-3c3f961399ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_a2bd4ccf-3beb-4c90-a11d-ca645b255a59_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dfc5c1ee-6432-4df9-800a-4bcc4a60f841_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NoExpirationMember_a653ffe9-ffc9-4400-9160-79199e90f9d0_terseLabel_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration</link:label>
    <link:label id="lab_exdx_NoExpirationMember_label_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration [Member]</link:label>
    <link:label id="lab_exdx_NoExpirationMember_documentation_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember" xlink:href="exdx-20221231.xsd#exdx_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NoExpirationMember" xlink:to="lab_exdx_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6e240ae2-aad7-4b30-b2d7-c57a41b3daec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExchangingStockholdersMember_2c743812-5217-474c-b8b8-06f2156e4985_terseLabel_en-US" xlink:label="lab_exdx_ExchangingStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchanging Stockholders</link:label>
    <link:label id="lab_exdx_ExchangingStockholdersMember_label_en-US" xlink:label="lab_exdx_ExchangingStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchanging Stockholders [Member]</link:label>
    <link:label id="lab_exdx_ExchangingStockholdersMember_documentation_en-US" xlink:label="lab_exdx_ExchangingStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchanging Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangingStockholdersMember" xlink:href="exdx-20221231.xsd#exdx_ExchangingStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExchangingStockholdersMember" xlink:to="lab_exdx_ExchangingStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClientMember_71f0e59f-56d2-4d07-bde6-14792d2198b2_terseLabel_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:label id="lab_exdx_ClientMember_label_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client [Member]</link:label>
    <link:label id="lab_exdx_ClientMember_documentation_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember" xlink:href="exdx-20221231.xsd#exdx_ClientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClientMember" xlink:to="lab_exdx_ClientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_af5aaa9d-3040-4cda-9027-f4b539090cc9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_22b631c5-ff4a-4f4d-9ce8-3b48f7b64fb8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_78981536-c193-46d1-a0e1-86662473b51c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_40ad40fb-86be-4bdd-8cf1-80c3db486c8c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_93276283-7d9f-47ca-a3b9-06cbad55b307_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_270f18b4-fb3f-4035-805e-0c188c472371_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of issuance costs related to public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_df919caf-a22a-4cce-ac5c-4828fcd5fce8_terseLabel_en-US" xlink:label="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization of research and experimentation costs</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_label_en-US" xlink:label="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_documentation_en-US" xlink:label="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:to="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ef22c6a8-4dc1-4397-944a-06d349398590_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_3ef0d7d3-da6b-4feb-b2c3-cb2a7f0d31ca_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_608b0127-6987-4781-9422-a70d6876589d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_240ea762-c508-44c5-b5c3-5b94184be8fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_26fcd1e8-3079-46bf-8279-bb77127c5186_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_603500e1-4707-4bfd-b7d1-7ab70e79ca34_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_2947999d-2664-4cf3-aba3-b4631cf4eddc_terseLabel_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in purchase commitments</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_label_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_documentation_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:href="exdx-20221231.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:to="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_294ab000-6465-4d0d-ba17-2c899874604d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross book value of assets under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_ad61e1b9-e45d-4baf-9b6b-fd571be0ded4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic&#160;testing&#160;supplies</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_34159446-c48f-46dc-a8ed-14b21a43ad7d_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_1a7ac094-be23-49b7-ac2f-c1897bff9b34_terseLabel_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</link:label>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_label_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</link:label>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_documentation_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:href="exdx-20221231.xsd#exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:to="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_2e827abd-3180-4d26-8a32-af4612d80d54_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable noncurrnet</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_9253db20-dfb1-4c19-9968-f4177da9ee41_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_9288a1c3-f4b7-400a-a6ab-2c542f67c1c9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_e1cee0cf-4192-4c2f-bec8-a20ee634c852_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, monthly base rent</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_label_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Base Rent</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent" xlink:href="exdx-20221231.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseMonthlyBaseRent" xlink:to="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ff1d2f8f-0da6-44e8-99d4-80d167dd242d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_c68bfe2c-f1f0-4097-af0c-2af7f8a22f97_terseLabel_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs reclassified to equity</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_label_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified to Equity</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_documentation_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified to Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:href="exdx-20221231.xsd#exdx_DeferredOfferingCostsReclassifiedToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:to="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_d120167b-040f-4a43-ba36-b202d5221517_totalLabel_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_label_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_documentation_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:href="exdx-20221231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:to="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_752e1270-7f85-4214-b6ff-8937650b69ae_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_645cae75-1376-4971-94cf-32d01327925d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_QueenMaryUniversityOfLondonMember_c8ac0849-c76b-4507-bcca-c6a552553402_terseLabel_en-US" xlink:label="lab_exdx_QueenMaryUniversityOfLondonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Queen Mary University Of London</link:label>
    <link:label id="lab_exdx_QueenMaryUniversityOfLondonMember_label_en-US" xlink:label="lab_exdx_QueenMaryUniversityOfLondonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Queen Mary University Of London [Member]</link:label>
    <link:label id="lab_exdx_QueenMaryUniversityOfLondonMember_documentation_en-US" xlink:label="lab_exdx_QueenMaryUniversityOfLondonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Queen Mary University Of London</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_QueenMaryUniversityOfLondonMember" xlink:href="exdx-20221231.xsd#exdx_QueenMaryUniversityOfLondonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_QueenMaryUniversityOfLondonMember" xlink:to="lab_exdx_QueenMaryUniversityOfLondonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_67e7b51c-d983-42c2-898f-db5426818c7e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1e37f704-4e58-466f-90a7-ad2ba535d06c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_857f725c-08be-4690-9ef2-be8ea7060973_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_07ab61cc-85ad-455d-9191-e8ea6154cbbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_fbe556b4-d0ae-4c6a-94cc-65bb5b658d8f_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_label_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:href="exdx-20221231.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:to="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract" xlink:href="exdx-20221231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherFinancialInformationAbstract" xlink:to="lab_exdx_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6425284-4983-4f61-8a75-51d804ed2614_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c8384ba9-e644-43b0-bd33-cf084f3a3073_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_fbd02b8c-ada6-49ea-9dab-6e5d2eecfa24_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7c94a02c-df85-41b6-8f28-dd0f2a95c339_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a4189445-d2ae-4db3-8289-6d75d5712f9e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases recorded to income tax provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_9ceac2ce-8527-4263-b213-0497804292a2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_48f106a9-e094-4a9d-b060-5ce6b496b187_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c1173b52-5cb7-4892-bbcc-915e1b0f1318_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c7242d6e-0a7d-4202-add7-58105f2e45df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b1ac98b2-6fbf-43e8-92fc-d7ac025c39ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1458750f-72df-492f-86bf-16fa68687a5b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_55f01aa1-1d46-4592-8e11-456fb789b409_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9abdfee3-6c55-4678-a399-1a15da231adf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_2d5f0801-c22a-4942-a661-87e6855e4861_terseLabel_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen Equity Distribution Agreement</link:label>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_label_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember" xlink:href="exdx-20221231.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CowenEquityDistributionAgreementMember" xlink:to="lab_exdx_CowenEquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_08729a65-7cc1-4d95-97c8-f7f53710b72c_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and marketing costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1d28cbcd-c2f1-4f6d-889f-2cd45ef6c972_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_93ae698f-e0e3-428c-a1ce-475e0ce252f9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_c9d9840d-db2a-4cc7-a137-2ca5e0fce12c_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual percentage increase in shares available for issuance under the Plan</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:href="exdx-20221231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_a1fcb16d-7f3e-4649-a57f-106bc4846200_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash out flows from interest paid on finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3206df19-2398-4bee-a159-5fc797f2105b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bd420639-4e73-4112-a8ff-d92b07505b81_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_ed09e782-5a46-4b1b-beda-332b25257f86_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid in-kind note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LicenseAgreementOneTimePayment_5584aff9-c818-449c-9539-2cb4c2c5cd98_terseLabel_en-US" xlink:label="lab_exdx_LicenseAgreementOneTimePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One time payment</link:label>
    <link:label id="lab_exdx_LicenseAgreementOneTimePayment_label_en-US" xlink:label="lab_exdx_LicenseAgreementOneTimePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, One Time Payment</link:label>
    <link:label id="lab_exdx_LicenseAgreementOneTimePayment_documentation_en-US" xlink:label="lab_exdx_LicenseAgreementOneTimePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, One Time Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementOneTimePayment" xlink:href="exdx-20221231.xsd#exdx_LicenseAgreementOneTimePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LicenseAgreementOneTimePayment" xlink:to="lab_exdx_LicenseAgreementOneTimePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationApr12026Member_76824358-8d5c-49f0-b47a-6ea14ca5521d_terseLabel_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration April 1, 2026</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_label_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member" xlink:href="exdx-20221231.xsd#exdx_ExpirationApr12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationApr12026Member" xlink:to="lab_exdx_ExpirationApr12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b580749e-236f-41b7-a983-80a12a0cb80f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_839ef2dd-263b-4663-9f79-5fc17a53f8c2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d86820bb-ec88-4776-b020-3ad91dee78f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_892b0568-9b81-48a2-9e2b-ea6241891d58_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772d4f80-b209-46f2-96f6-7651b841122e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98e43993-9182-4b40-b77f-1d75db9b01be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_98bbcbd9-3f73-4ce0-8d9e-85107d72d535_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_3d4abecf-34b2-4f3c-8b1a-767fb5e58b13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_8c40a819-eb39-4e06-ad73-202950d2ca3a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_90101c8b-f29c-4733-be80-5d999bd6505e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuanceCosts_8142a878-ae3b-4c0f-815f-91985185158b_verboseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_fa4eff3f-4485-46ac-b026-23c826e7a4dd_terseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated offering expenses for aggregate expenses</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_label_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_documentation_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts" xlink:href="exdx-20221231.xsd#exdx_StockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuanceCosts" xlink:to="lab_exdx_StockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a9ff1ad3-0f9c-4a67-8205-bb38c55aba46_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_773332ac-d8b9-4fe8-a49d-535ce365e913_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_60a7802d-1b93-4560-9aee-b986acf49f64_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_fce2a9cf-04eb-455c-8e40-b120b1689b55_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_673815ef-4c68-429f-a917-de4aa48d4574_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_9a00efd2-e1f9-4073-86fc-f0c6367c7bde_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Marketing Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_de088bfd-7f05-4682-8fa4-a1b5ed40d4e6_negatedTerseLabel_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock from vested restricted stock units and payment of employees' taxes</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_label_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_documentation_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:href="exdx-20221231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:to="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c05f7e9b-98d8-42a6-a7e9-83bf1a8994f6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_563db949-1b06-4a17-bf9e-dd819be0694f_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:href="exdx-20221231.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_d08fa98c-f850-4cac-b228-cbe05870475c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_388721d3-6c18-4723-860a-657d25e839f3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f9d0f348-3998-4bc8-9709-f1b42b85fc6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0fb3d2ce-e1c2-4242-a78a-94a1bc370e51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee options, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ab3c9f6f-0a2d-4e1a-b8cf-ec74cf40756f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_8accfde6-2280-43ec-a7ab-882f4c1d288f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6abb6436-e924-4f2e-9dc8-2d538d476c0b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c3a85b08-7167-46bc-8830-a2c7de8a1726_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d6c0f329-2522-4f22-8489-19071e3de168_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a6ecef96-6ade-4c24-bad8-acc6d72c7773_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_b61fdd72-3ccb-41b7-8e71-d066f7b90529_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_4454bba8-12ad-476e-8280-da7e3f68b106_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4a7554b0-21ba-4bec-b362-acb17f203e7a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>exdx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:b2849c68-b5c1-4aba-9f81-ca2d321b51be,g:62e4697b-763f-43ad-abbd-d704ff1dbc1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_270da178-3103-4494-85ad-8928ad334124" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_DocumentType_270da178-3103-4494-85ad-8928ad334124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_169c5177-ab9b-44dc-ba73-d270dec0e791" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_DocumentAnnualReport_169c5177-ab9b-44dc-ba73-d270dec0e791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f476e846-eaa3-4780-a5bf-fab53f0fda42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_DocumentPeriodEndDate_f476e846-eaa3-4780-a5bf-fab53f0fda42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_28fab6b5-804a-4d68-be7d-249ebf0b3359" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_CurrentFiscalYearEndDate_28fab6b5-804a-4d68-be7d-249ebf0b3359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e3cae4bf-7f83-47ce-8ac2-80462c0cd73e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_DocumentTransitionReport_e3cae4bf-7f83-47ce-8ac2-80462c0cd73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eca91fad-f523-4d35-a1ba-64bd2c0553a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityFileNumber_eca91fad-f523-4d35-a1ba-64bd2c0553a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_08c3a262-9d37-451a-b253-6883b9443e9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityRegistrantName_08c3a262-9d37-451a-b253-6883b9443e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d33fef40-c535-4fd2-a4ab-93cde684a33d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d33fef40-c535-4fd2-a4ab-93cde684a33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7aedaf65-138b-425f-a430-8a448a23866e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityTaxIdentificationNumber_7aedaf65-138b-425f-a430-8a448a23866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_79fa226c-ffcc-4f39-83ef-2b12cd98048d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityAddressAddressLine1_79fa226c-ffcc-4f39-83ef-2b12cd98048d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6b22b999-2e66-4c18-a927-a172654886f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityAddressCityOrTown_6b22b999-2e66-4c18-a927-a172654886f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cdb9043e-6798-4fdb-918b-01fe6d20263a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityAddressStateOrProvince_cdb9043e-6798-4fdb-918b-01fe6d20263a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6e96c2ab-8328-4528-bfc6-2c67ea01745e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityAddressPostalZipCode_6e96c2ab-8328-4528-bfc6-2c67ea01745e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3d05ab71-e426-45a1-9d53-538670eeee61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_CityAreaCode_3d05ab71-e426-45a1-9d53-538670eeee61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bc0081f6-0f15-48b3-9253-536fa1dc23a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_LocalPhoneNumber_bc0081f6-0f15-48b3-9253-536fa1dc23a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_30efe874-724f-4089-a239-9a929b0939b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_Security12bTitle_30efe874-724f-4089-a239-9a929b0939b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6091b094-f10a-482f-a050-0014ae2f427e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_TradingSymbol_6091b094-f10a-482f-a050-0014ae2f427e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8a2190f6-6e77-492c-bdd3-022810033515" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_SecurityExchangeName_8a2190f6-6e77-492c-bdd3-022810033515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9d3a6c8a-6522-4b91-8bad-6a15a90030e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9d3a6c8a-6522-4b91-8bad-6a15a90030e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_1c6c74aa-c94d-4d92-98d1-e1b269ada9a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityVoluntaryFilers_1c6c74aa-c94d-4d92-98d1-e1b269ada9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0755bc3f-7dae-494b-9ba7-4a8c57b1319d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityCurrentReportingStatus_0755bc3f-7dae-494b-9ba7-4a8c57b1319d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7316f758-6a7f-4cf4-920e-1b73e4649887" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityInteractiveDataCurrent_7316f758-6a7f-4cf4-920e-1b73e4649887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e463fd1a-e1d6-460f-a3d6-1c3129b35e72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityFilerCategory_e463fd1a-e1d6-460f-a3d6-1c3129b35e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8d040aa3-3250-4574-ab47-2efae322c379" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntitySmallBusiness_8d040aa3-3250-4574-ab47-2efae322c379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e903503b-d893-431e-a944-7c992e109453" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityEmergingGrowthCompany_e903503b-d893-431e-a944-7c992e109453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_7764252f-1841-4c5b-8f2f-1e4306f8d0ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityExTransitionPeriod_7764252f-1841-4c5b-8f2f-1e4306f8d0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_a792b04c-b101-4558-b533-286075f0d82b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_IcfrAuditorAttestationFlag_a792b04c-b101-4558-b533-286075f0d82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3e2edbcf-4ac3-4b98-bf78-0ee4c5416f8f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityShellCompany_3e2edbcf-4ac3-4b98-bf78-0ee4c5416f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_443235a4-9885-4300-8eb0-77b1092bc859" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityPublicFloat_443235a4-9885-4300-8eb0-77b1092bc859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_055203af-85f2-4d2a-9f0f-83f33e5008d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_055203af-85f2-4d2a-9f0f-83f33e5008d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_794527fb-b528-4479-924e-9e8e3ccfdc0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_794527fb-b528-4479-924e-9e8e3ccfdc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_80f12a78-7d78-481f-a132-3bfe863ef8c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_DocumentFiscalYearFocus_80f12a78-7d78-481f-a132-3bfe863ef8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_66c784c2-6991-433f-870c-3d930a0b57f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_DocumentFiscalPeriodFocus_66c784c2-6991-433f-870c-3d930a0b57f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3d032354-b303-40dd-a90c-7d4abe017e1e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_AmendmentFlag_3d032354-b303-40dd-a90c-7d4abe017e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7bcd5b14-087e-4914-ac65-79b94c532519" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a59e3a19-d25c-472b-9769-ef977ab01c52" xlink:to="loc_dei_EntityCentralIndexKey_7bcd5b14-087e-4914-ac65-79b94c532519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/AuditInformation" xlink:type="simple" xlink:href="exdx-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AuditInformationAbstract_3c1d6079-1eb6-4781-91d7-42c371f0649d" xlink:href="exdx-20221231.xsd#exdx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_536f0c40-9841-42a4-85e1-32c574efa4e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_AuditInformationAbstract_3c1d6079-1eb6-4781-91d7-42c371f0649d" xlink:to="loc_dei_AuditorName_536f0c40-9841-42a4-85e1-32c574efa4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_21939a7c-3802-486d-8638-aa28851b2175" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_AuditInformationAbstract_3c1d6079-1eb6-4781-91d7-42c371f0649d" xlink:to="loc_dei_AuditorLocation_21939a7c-3802-486d-8638-aa28851b2175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_e6a970b0-7ad2-48ae-8f8d-7b66d093c222" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_AuditInformationAbstract_3c1d6079-1eb6-4781-91d7-42c371f0649d" xlink:to="loc_dei_AuditorFirmId_e6a970b0-7ad2-48ae-8f8d-7b66d093c222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheets" xlink:type="simple" xlink:href="exdx-20221231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_633cf066-c6f0-465e-b933-ccf327ee241b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_99e5a95c-0e5e-4141-8547-4961cedff06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_633cf066-c6f0-465e-b933-ccf327ee241b" xlink:to="loc_us-gaap_AssetsAbstract_99e5a95c-0e5e-4141-8547-4961cedff06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d53dc944-8469-42c5-9715-77849450fb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99e5a95c-0e5e-4141-8547-4961cedff06d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d53dc944-8469-42c5-9715-77849450fb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc9d1417-8792-4b35-a817-e554790c65af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53dc944-8469-42c5-9715-77849450fb6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc9d1417-8792-4b35-a817-e554790c65af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_24631101-d212-48e9-bd03-24e701569a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53dc944-8469-42c5-9715-77849450fb6d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_24631101-d212-48e9-bd03-24e701569a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_06e3c9eb-c21d-4c2b-9693-5d57282e1734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53dc944-8469-42c5-9715-77849450fb6d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_06e3c9eb-c21d-4c2b-9693-5d57282e1734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_56fd7268-d6d8-48da-9895-c45ba1ccd36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53dc944-8469-42c5-9715-77849450fb6d" xlink:to="loc_us-gaap_AssetsCurrent_56fd7268-d6d8-48da-9895-c45ba1ccd36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_70d971df-209c-4ac7-be30-4816247dab81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99e5a95c-0e5e-4141-8547-4961cedff06d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_70d971df-209c-4ac7-be30-4816247dab81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_63430e2a-d5ca-41e4-9e96-e71dded4dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99e5a95c-0e5e-4141-8547-4961cedff06d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_63430e2a-d5ca-41e4-9e96-e71dded4dcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bd8c95c3-8b57-44be-a27a-3fcba2001a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99e5a95c-0e5e-4141-8547-4961cedff06d" xlink:to="loc_us-gaap_Goodwill_bd8c95c3-8b57-44be-a27a-3fcba2001a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_22739013-402d-439b-a641-51b958a6f1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99e5a95c-0e5e-4141-8547-4961cedff06d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_22739013-402d-439b-a641-51b958a6f1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7f9946f0-5aba-4f49-b679-169df4f55296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99e5a95c-0e5e-4141-8547-4961cedff06d" xlink:to="loc_us-gaap_Assets_7f9946f0-5aba-4f49-b679-169df4f55296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_633cf066-c6f0-465e-b933-ccf327ee241b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8c977f06-a551-48e1-bcd3-75d39b4b3991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8c977f06-a551-48e1-bcd3-75d39b4b3991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d19033f9-349f-4f7c-b867-bab8f653041a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8c977f06-a551-48e1-bcd3-75d39b4b3991" xlink:to="loc_us-gaap_AccountsPayableCurrent_d19033f9-349f-4f7c-b867-bab8f653041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5c5f1ad-5ef0-419e-877a-3a7ab35ada68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8c977f06-a551-48e1-bcd3-75d39b4b3991" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5c5f1ad-5ef0-419e-877a-3a7ab35ada68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a9ddb5e0-4c75-41b7-a2f5-e267f98e560c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8c977f06-a551-48e1-bcd3-75d39b4b3991" xlink:to="loc_us-gaap_LongTermDebtCurrent_a9ddb5e0-4c75-41b7-a2f5-e267f98e560c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_beabc48d-c4c9-4037-a0df-d9304e3ea6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8c977f06-a551-48e1-bcd3-75d39b4b3991" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_beabc48d-c4c9-4037-a0df-d9304e3ea6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_22d30f5d-e563-4165-bad2-b0cf62a46534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8c977f06-a551-48e1-bcd3-75d39b4b3991" xlink:to="loc_us-gaap_LiabilitiesCurrent_22d30f5d-e563-4165-bad2-b0cf62a46534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9b99652e-34f4-48d4-b88f-b2a96b2cced4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9b99652e-34f4-48d4-b88f-b2a96b2cced4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e3737f8-f516-4c99-a74c-795bdd12c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e3737f8-f516-4c99-a74c-795bdd12c8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9e11af70-67c3-4047-9119-fdcc10609bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9e11af70-67c3-4047-9119-fdcc10609bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0f57a71c-ce05-4072-83cd-eb56bf7daa55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0f57a71c-ce05-4072-83cd-eb56bf7daa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_296209d9-7747-45aa-af20-a6f168bff5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:to="loc_us-gaap_Liabilities_296209d9-7747-45aa-af20-a6f168bff5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_61832d7b-6261-4df6-914a-9b8b070e8234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_61832d7b-6261-4df6-914a-9b8b070e8234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8faf4992-86d0-4454-8c75-5c9807fcb834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8faf4992-86d0-4454-8c75-5c9807fcb834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2667ada5-ed90-4edd-b9c8-e86143306031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8faf4992-86d0-4454-8c75-5c9807fcb834" xlink:to="loc_us-gaap_PreferredStockValue_2667ada5-ed90-4edd-b9c8-e86143306031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8d71e7ae-3b0b-4273-a2f8-0a7d9de1d1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8faf4992-86d0-4454-8c75-5c9807fcb834" xlink:to="loc_us-gaap_CommonStockValue_8d71e7ae-3b0b-4273-a2f8-0a7d9de1d1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d658b5c7-28f3-42b5-b1b2-2040bd65d508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8faf4992-86d0-4454-8c75-5c9807fcb834" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d658b5c7-28f3-42b5-b1b2-2040bd65d508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_97479200-beba-4d17-9afa-e0f25168a3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8faf4992-86d0-4454-8c75-5c9807fcb834" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_97479200-beba-4d17-9afa-e0f25168a3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eca05aca-bce9-40a5-9882-af99e071d39f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8faf4992-86d0-4454-8c75-5c9807fcb834" xlink:to="loc_us-gaap_StockholdersEquity_eca05aca-bce9-40a5-9882-af99e071d39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b01c01e6-fc14-4b8b-9680-04210f6aa934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02bfdc10-34c0-4394-b91f-b1cd0558124b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b01c01e6-fc14-4b8b-9680-04210f6aa934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20221231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_63f1021f-af6a-4809-bd84-23493babc60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0f1a7801-0343-4a41-a9bd-1841de8c053d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_63f1021f-af6a-4809-bd84-23493babc60b" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0f1a7801-0343-4a41-a9bd-1841de8c053d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_974c3196-33be-4e0e-9f77-764e64fb3812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0f1a7801-0343-4a41-a9bd-1841de8c053d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_974c3196-33be-4e0e-9f77-764e64fb3812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0456559d-33c9-41c7-a1ec-7519c7444b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0f1a7801-0343-4a41-a9bd-1841de8c053d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0456559d-33c9-41c7-a1ec-7519c7444b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3c2f010e-7022-48ab-9557-e494f7ace3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0f1a7801-0343-4a41-a9bd-1841de8c053d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3c2f010e-7022-48ab-9557-e494f7ace3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_13238214-8a39-4720-8f53-299401269e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0f1a7801-0343-4a41-a9bd-1841de8c053d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_13238214-8a39-4720-8f53-299401269e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f74da86c-36e2-4388-93b6-7e3d2a99521a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_63f1021f-af6a-4809-bd84-23493babc60b" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f74da86c-36e2-4388-93b6-7e3d2a99521a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_40267106-bb0b-48d6-b8f7-2284345f678e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f74da86c-36e2-4388-93b6-7e3d2a99521a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_40267106-bb0b-48d6-b8f7-2284345f678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b769ddfa-74c9-4930-b82b-bc45f4a114a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f74da86c-36e2-4388-93b6-7e3d2a99521a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b769ddfa-74c9-4930-b82b-bc45f4a114a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_27812fe9-5957-4c4e-abc6-01cb29eb701d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f74da86c-36e2-4388-93b6-7e3d2a99521a" xlink:to="loc_us-gaap_CommonStockSharesIssued_27812fe9-5957-4c4e-abc6-01cb29eb701d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9b2ac9ea-8a1d-4375-9326-d7b428386fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f74da86c-36e2-4388-93b6-7e3d2a99521a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9b2ac9ea-8a1d-4375-9326-d7b428386fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofOperations" xlink:type="simple" xlink:href="exdx-20221231.xsd#StatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f33e2e0e-c700-4734-b018-094957f3bbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f33e2e0e-c700-4734-b018-094957f3bbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2a81ec36-ffd0-472e-af07-c40aebc4fbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2a81ec36-ffd0-472e-af07-c40aebc4fbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_db31d861-f4e1-43f8-9079-8a295385b933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2a81ec36-ffd0-472e-af07-c40aebc4fbdc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_db31d861-f4e1-43f8-9079-8a295385b933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9bed732-9b27-4f6e-a6b8-792048cbc14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2a81ec36-ffd0-472e-af07-c40aebc4fbdc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9bed732-9b27-4f6e-a6b8-792048cbc14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5fe8831a-08c7-4e19-846e-cd0838469db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2a81ec36-ffd0-472e-af07-c40aebc4fbdc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5fe8831a-08c7-4e19-846e-cd0838469db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_92d1390b-fa3a-4abd-b4e3-72d006114438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2a81ec36-ffd0-472e-af07-c40aebc4fbdc" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_92d1390b-fa3a-4abd-b4e3-72d006114438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3b8ea1bf-de27-49b6-95b3-4263d34e088e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2a81ec36-ffd0-472e-af07-c40aebc4fbdc" xlink:to="loc_us-gaap_CostsAndExpenses_3b8ea1bf-de27-49b6-95b3-4263d34e088e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_15a5e041-20a8-4f2b-bd14-2c0b73d2421b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_OperatingIncomeLoss_15a5e041-20a8-4f2b-bd14-2c0b73d2421b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d410a0cb-20ed-47ae-b511-6fcffbc614ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_InterestExpense_d410a0cb-20ed-47ae-b511-6fcffbc614ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f3d17147-d67e-4157-b39e-12bd1a70b472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f3d17147-d67e-4157-b39e-12bd1a70b472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_e8811ec2-aeae-49f3-9df6-1d5dabff33d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_e8811ec2-aeae-49f3-9df6-1d5dabff33d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4dac6f5f-1750-481d-817c-f90014157b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4dac6f5f-1750-481d-817c-f90014157b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b42d8f8f-87a2-40d6-a0c3-0d5e659333cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_NetIncomeLoss_b42d8f8f-87a2-40d6-a0c3-0d5e659333cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_12090c45-cac8-4ef8-9488-5eb17b9b0c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_EarningsPerShareBasic_12090c45-cac8-4ef8-9488-5eb17b9b0c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_616b0054-3c67-49b9-b03e-0a9076852cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_EarningsPerShareDiluted_616b0054-3c67-49b9-b03e-0a9076852cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e1226ec-3029-474c-9bb6-23ce09c2d3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e1226ec-3029-474c-9bb6-23ce09c2d3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c159fc06-444f-45e2-b830-83a1b95c6dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b77c55e-f0ae-4bb9-9e38-e5c986b9f880" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c159fc06-444f-45e2-b830-83a1b95c6dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20221231.xsd#StatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_818e4087-f17a-446d-88b2-b77635589776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a675418e-418f-4805-a273-65364cd80056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_818e4087-f17a-446d-88b2-b77635589776" xlink:to="loc_us-gaap_StatementTable_a675418e-418f-4805-a273-65364cd80056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d462c6a3-8e9d-4ba0-ab97-3b4db3429f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a675418e-418f-4805-a273-65364cd80056" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d462c6a3-8e9d-4ba0-ab97-3b4db3429f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d462c6a3-8e9d-4ba0-ab97-3b4db3429f5f" xlink:to="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3532d832-7105-4319-b5d4-5143f7633d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:to="loc_us-gaap_CommonStockMember_3532d832-7105-4319-b5d4-5143f7633d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_90a9c6d5-e7a6-40c5-8065-5cfb5c4c8502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_90a9c6d5-e7a6-40c5-8065-5cfb5c4c8502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d7e6dd02-86a5-4576-8e00-644853710ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f9db7be-c095-4a7c-abb8-5117c41afb7b" xlink:to="loc_us-gaap_RetainedEarningsMember_d7e6dd02-86a5-4576-8e00-644853710ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5a4648b6-f34c-41d6-884a-567cbffd30d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a675418e-418f-4805-a273-65364cd80056" xlink:to="loc_us-gaap_StatementLineItems_5a4648b6-f34c-41d6-884a-567cbffd30d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5a4648b6-f34c-41d6-884a-567cbffd30d5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d8cb33e2-57f3-4064-8ff7-72ffc4904d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d8cb33e2-57f3-4064-8ff7-72ffc4904d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac18f194-1383-40d4-af04-a88346a4a232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockholdersEquity_ac18f194-1383-40d4-af04-a88346a4a232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf482c02-56c3-4e98-9962-fedd9344c3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf482c02-56c3-4e98-9962-fedd9344c3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_46f360cc-d304-4dbe-84f5-3a2228a1e744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_46f360cc-d304-4dbe-84f5-3a2228a1e744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5e68f4d1-372f-4366-8067-ba18264136be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5e68f4d1-372f-4366-8067-ba18264136be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1db7647a-50fc-4b6a-9534-fc78f67afee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1db7647a-50fc-4b6a-9534-fc78f67afee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e510317b-bdd8-4e77-9470-8f2b10a45975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e510317b-bdd8-4e77-9470-8f2b10a45975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_7120c705-3d78-42fa-9ecd-6b6445254f22" xlink:href="exdx-20221231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_7120c705-3d78-42fa-9ecd-6b6445254f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_fd978dd6-86e0-491b-a1e0-fd8d76ab75d3" xlink:href="exdx-20221231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_fd978dd6-86e0-491b-a1e0-fd8d76ab75d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_83aedd7e-6feb-4964-9c5f-bb9a054491d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_83aedd7e-6feb-4964-9c5f-bb9a054491d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6e788bc6-3623-48dd-b81f-d3dc7f05cd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6e788bc6-3623-48dd-b81f-d3dc7f05cd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60026db7-9605-4da2-a0ba-bb076c8995dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60026db7-9605-4da2-a0ba-bb076c8995dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_be0ab0b8-d334-44d9-b04c-e75b28b74bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_be0ab0b8-d334-44d9-b04c-e75b28b74bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_35714bf0-8e1e-4ea0-b133-49270d5561d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_35714bf0-8e1e-4ea0-b133-49270d5561d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_bc41de65-321f-4977-ba46-c9998b53d25b" xlink:href="exdx-20221231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_bc41de65-321f-4977-ba46-c9998b53d25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_5be4b06a-08b0-4f04-aa94-e26f42e4f9f8" xlink:href="exdx-20221231.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_5be4b06a-08b0-4f04-aa94-e26f42e4f9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87ab50f6-2d9f-4ae6-9ea1-5ebb21b925cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_NetIncomeLoss_87ab50f6-2d9f-4ae6-9ea1-5ebb21b925cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ad0861c2-e372-467c-9870-493352d19adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ad0861c2-e372-467c-9870-493352d19adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0d38e2e-981d-403c-ad82-8472f9b8e3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1186c24e-53c8-4cde-8e00-70bcd2880435" xlink:to="loc_us-gaap_StockholdersEquity_a0d38e2e-981d-403c-ad82-8472f9b8e3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="exdx-20221231.xsd#StatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2984089f-e2a2-4df5-b909-e95a23b936b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_7cb8c42d-c477-46ca-a158-8b06f1b19f92" xlink:href="exdx-20221231.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2984089f-e2a2-4df5-b909-e95a23b936b5" xlink:to="loc_exdx_StockIssuanceCosts_7cb8c42d-c477-46ca-a158-8b06f1b19f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20221231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1ee4d811-a068-49d6-b561-b47a055fda43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_86004103-e8a8-4e1c-81f7-d7e6d39f0bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1ee4d811-a068-49d6-b561-b47a055fda43" xlink:to="loc_us-gaap_StatementTable_86004103-e8a8-4e1c-81f7-d7e6d39f0bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_88eae0e4-36e8-4cce-8a31-aa871afedf14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86004103-e8a8-4e1c-81f7-d7e6d39f0bb7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_88eae0e4-36e8-4cce-8a31-aa871afedf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d17f381e-e9c1-4294-9194-816d284d8243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_88eae0e4-36e8-4cce-8a31-aa871afedf14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d17f381e-e9c1-4294-9194-816d284d8243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PublicOfferingMember_3f190b2b-42a1-4550-96c6-e5ece7e207f6" xlink:href="exdx-20221231.xsd#exdx_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d17f381e-e9c1-4294-9194-816d284d8243" xlink:to="loc_exdx_PublicOfferingMember_3f190b2b-42a1-4550-96c6-e5ece7e207f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherOfferingMember_192f2281-d7e0-45d2-9b68-e3778cb88b83" xlink:href="exdx-20221231.xsd#exdx_OtherOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d17f381e-e9c1-4294-9194-816d284d8243" xlink:to="loc_exdx_OtherOfferingMember_192f2281-d7e0-45d2-9b68-e3778cb88b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86004103-e8a8-4e1c-81f7-d7e6d39f0bb7" xlink:to="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e0b0b05-4329-4377-83ef-6e29c180eeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:to="loc_us-gaap_NetIncomeLoss_4e0b0b05-4329-4377-83ef-6e29c180eeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_927aa7ba-d083-420e-b643-263d6846b1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_927aa7ba-d083-420e-b643-263d6846b1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b74c202f-0213-4701-8a70-bfb7a64a3477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b74c202f-0213-4701-8a70-bfb7a64a3477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_c81eb4af-55bf-4c65-af9a-6a57dbc7714e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_PaidInKindInterest_c81eb4af-55bf-4c65-af9a-6a57dbc7714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_97ade2e6-3900-4487-bc9e-f413830058a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_97ade2e6-3900-4487-bc9e-f413830058a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense_f202e866-51fb-4ee6-95b8-f9da98829f0e" xlink:href="exdx-20221231.xsd#exdx_NonCashLeaseExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_exdx_NonCashLeaseExpense_f202e866-51fb-4ee6-95b8-f9da98829f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_08d4ea15-6850-4750-a48d-1667d0adce01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_08d4ea15-6850-4750-a48d-1667d0adce01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e7434187-dee1-4d50-aaf4-3538bb88dcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e7434187-dee1-4d50-aaf4-3538bb88dcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7eba0f77-8991-423c-90fa-61174def1ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_ShareBasedCompensation_7eba0f77-8991-423c-90fa-61174def1ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d92509fd-40a7-4e21-b41f-d31a6f69d7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d92509fd-40a7-4e21-b41f-d31a6f69d7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f42bba30-5ae9-4f27-bc60-2e8884ef836d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dee51940-278e-430d-993a-8d04c4826b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dee51940-278e-430d-993a-8d04c4826b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_058a1fe4-5aff-4066-b120-71b1b73024ef" xlink:href="exdx-20221231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_058a1fe4-5aff-4066-b120-71b1b73024ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_49508046-0f7c-4305-9f7c-857d7cca06f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_49508046-0f7c-4305-9f7c-857d7cca06f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_af798070-335f-421b-b5ec-e5d6c04e9088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_af798070-335f-421b-b5ec-e5d6c04e9088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_428de4b0-758c-4387-b6bd-86cf2afc05ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_428de4b0-758c-4387-b6bd-86cf2afc05ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fe773549-8784-4a0e-9244-3bea9749e1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cacd7f49-18c1-4f1f-857a-4c286239fc5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fe773549-8784-4a0e-9244-3bea9749e1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4326ea2c-0d66-4bfd-bb13-229b6b283a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_19f3fed8-e170-4d6b-b84c-95d2f058e7be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4326ea2c-0d66-4bfd-bb13-229b6b283a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84d8f16a-a856-4fdc-9a12-eed927e9815d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84d8f16a-a856-4fdc-9a12-eed927e9815d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_90fce929-f119-4d1a-b72c-3f95bfe77a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_90fce929-f119-4d1a-b72c-3f95bfe77a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38a779bf-af63-43d2-ab5d-990231c634f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_af3364ca-d918-4ad8-93d9-8b9ad110aa30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38a779bf-af63-43d2-ab5d-990231c634f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_adbd16b6-c1a2-42d3-9879-65de1972e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_adbd16b6-c1a2-42d3-9879-65de1972e13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7ffdf360-4a84-4fa4-8b2c-bf6917599ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7ffdf360-4a84-4fa4-8b2c-bf6917599ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d371875c-70b4-46ef-827f-7cb8f94b5e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d371875c-70b4-46ef-827f-7cb8f94b5e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5d506b13-aa8f-4d13-a0fd-27a8dbb17662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5d506b13-aa8f-4d13-a0fd-27a8dbb17662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4c1c00d8-7f0e-4b4d-ba45-a58f439b1475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_4c1c00d8-7f0e-4b4d-ba45-a58f439b1475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_a3b83c3a-a7fa-4bbb-8522-682d55ddd885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_a3b83c3a-a7fa-4bbb-8522-682d55ddd885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_76d61c61-df71-47aa-9c17-7b1ab5a5ca89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_76d61c61-df71-47aa-9c17-7b1ab5a5ca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_70804ecd-1f9d-440f-83af-ac9a9c87d17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_70804ecd-1f9d-440f-83af-ac9a9c87d17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4a30c33-554b-491d-8ec5-4963fcb02aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b089ac35-44ee-45ba-bc55-69c9223e3879" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4a30c33-554b-491d-8ec5-4963fcb02aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19a064b7-1506-41c4-bb9b-e9da7ee75740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19a064b7-1506-41c4-bb9b-e9da7ee75740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef73de66-f2a2-416c-b451-e3ff648aab6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef73de66-f2a2-416c-b451-e3ff648aab6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_819b2879-e070-412a-9237-cad430ce55e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_819b2879-e070-412a-9237-cad430ce55e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_de62a7ab-212a-4f08-80a1-865d2a6368ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_de62a7ab-212a-4f08-80a1-865d2a6368ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b8bb42c9-b1dd-4b38-8178-aaf8eb80c3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_de62a7ab-212a-4f08-80a1-865d2a6368ec" xlink:to="loc_us-gaap_InterestPaidNet_b8bb42c9-b1dd-4b38-8178-aaf8eb80c3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77b5927b-c9b8-4c8f-a61f-88970e526731" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_78d9ff26-b17d-4f74-b94f-64008c00f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_78d9ff26-b17d-4f74-b94f-64008c00f17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_04541a6e-0931-4f8b-a172-75181ad824c1" xlink:href="exdx-20221231.xsd#exdx_EquipmentPurchasedUnderNotesPayableObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:to="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_04541a6e-0931-4f8b-a172-75181ad824c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c05ed1b-b268-41a3-9eec-83ffcf4a8949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c05ed1b-b268-41a3-9eec-83ffcf4a8949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_eb3fd37f-98c1-4c6c-9a4f-720aee3e6175" xlink:href="exdx-20221231.xsd#exdx_DeferredOfferingCostsReclassifiedToEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_592fd900-cd87-4738-9ca1-af20ba3658d5" xlink:to="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_eb3fd37f-98c1-4c6c-9a4f-720aee3e6175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20221231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_52d2fea7-e6ca-4eca-a38c-5167a50a9e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_58328568-8cd5-4dc0-90d7-852f22e7a9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_52d2fea7-e6ca-4eca-a38c-5167a50a9e0d" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_58328568-8cd5-4dc0-90d7-852f22e7a9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_17266bc5-697b-4c8f-9b3f-1c5fb1ecb465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_70731f20-bcae-4399-a93c-478d108f41bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_17266bc5-697b-4c8f-9b3f-1c5fb1ecb465" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_70731f20-bcae-4399-a93c-478d108f41bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_c6ea91e5-2a40-4cce-8e6c-b7486c1dfd50" xlink:href="exdx-20221231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_95579dab-b980-4ff8-91df-1ce2be016ded" xlink:href="exdx-20221231.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c6ea91e5-2a40-4cce-8e6c-b7486c1dfd50" xlink:to="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_95579dab-b980-4ff8-91df-1ce2be016ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20221231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4426ebe0-84a3-474c-9e90-56c72b3d8a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_42a0274d-8832-445d-8cf6-4bc97fe25c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4426ebe0-84a3-474c-9e90-56c72b3d8a45" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_42a0274d-8832-445d-8cf6-4bc97fe25c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c52382a9-7f7a-4416-89df-2d8bad1f56d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c56fed39-9ace-42f1-91bd-bd2197bd6121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c52382a9-7f7a-4416-89df-2d8bad1f56d2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c56fed39-9ace-42f1-91bd-bd2197bd6121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_16590098-97b3-4ec2-99a3-8e4bf2934a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6ba5ee23-5227-4328-8109-e562a202cee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_16590098-97b3-4ec2-99a3-8e4bf2934a5b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6ba5ee23-5227-4328-8109-e562a202cee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_055dd3de-5a10-4dba-8065-286014e2c8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8289356a-7f77-4286-9854-dcc14d1cd5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_055dd3de-5a10-4dba-8065-286014e2c8c3" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8289356a-7f77-4286-9854-dcc14d1cd5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53fdf5df-f048-4298-b84d-a117fb403f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4d3eb99a-939f-4d97-81f9-481c865f598d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53fdf5df-f048-4298-b84d-a117fb403f09" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4d3eb99a-939f-4d97-81f9-481c865f598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxes" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4543af90-ad59-4f94-98c3-95845990688a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_26d7847c-0180-4ecf-83eb-6db85938657f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4543af90-ad59-4f94-98c3-95845990688a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_26d7847c-0180-4ecf-83eb-6db85938657f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlan" xlink:type="simple" xlink:href="exdx-20221231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_55141087-bbfb-4cda-a0bc-51558c79346e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5ec95033-ca7a-438a-9234-4031402d6092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_55141087-bbfb-4cda-a0bc-51558c79346e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5ec95033-ca7a-438a-9234-4031402d6092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c0439ab0-9014-4db0-b73b-d9edf7c0047a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c0439ab0-9014-4db0-b73b-d9edf7c0047a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_41cfa3a8-e796-4913-913b-5dc6525d5271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_41cfa3a8-e796-4913-913b-5dc6525d5271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2710e9ea-4fbb-4b60-a057-ab337217ece2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2710e9ea-4fbb-4b60-a057-ab337217ece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7019f17c-698a-4692-af51-6b7a6581c240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7019f17c-698a-4692-af51-6b7a6581c240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_b1a46571-4f70-489a-af00-469597641ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_b1a46571-4f70-489a-af00-469597641ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClinicalStudyPolicyPolicyTextBlock_c4532205-8ea8-4645-be24-692d6447ea12" xlink:href="exdx-20221231.xsd#exdx_ClinicalStudyPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_exdx_ClinicalStudyPolicyPolicyTextBlock_c4532205-8ea8-4645-be24-692d6447ea12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9895104e-77bd-4a6c-9cf9-b7fdcc4f6e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9895104e-77bd-4a6c-9cf9-b7fdcc4f6e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e64b2b13-6522-46eb-86fb-d0c0c09d8585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e64b2b13-6522-46eb-86fb-d0c0c09d8585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_d1dc1775-105c-42e0-bfca-52d083a7ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_d1dc1775-105c-42e0-bfca-52d083a7ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_f9d459fd-f10b-457a-b479-9a8c3067ce5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_f9d459fd-f10b-457a-b479-9a8c3067ce5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_14e894ab-bcf1-4024-a8b6-1433bab3eeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_14e894ab-bcf1-4024-a8b6-1433bab3eeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_67379a23-1fea-468d-a10c-cdf5c121168f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_67379a23-1fea-468d-a10c-cdf5c121168f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_265b2546-7826-4f20-be03-0bef2a29e3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_265b2546-7826-4f20-be03-0bef2a29e3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3eca6ade-5527-4823-805a-78f974cedc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3eca6ade-5527-4823-805a-78f974cedc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_585a0d34-f70b-465c-960d-821757b59200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_585a0d34-f70b-465c-960d-821757b59200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_35e4ba83-3b0d-4569-bbee-10ab3ce5e302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c4e2b7-f47c-4ec8-be03-65c1c99d712a" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_35e4ba83-3b0d-4569-bbee-10ab3ce5e302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4003e15d-d2e9-4d48-bdcb-3ad1a976cd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_737910e8-dcd6-4bba-ac89-ebff0486da93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4003e15d-d2e9-4d48-bdcb-3ad1a976cd18" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_737910e8-dcd6-4bba-ac89-ebff0486da93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0fa8fdba-8f4a-41d1-bf97-298374ce8194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4003e15d-d2e9-4d48-bdcb-3ad1a976cd18" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0fa8fdba-8f4a-41d1-bf97-298374ce8194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9de1964f-eb10-44a5-adc8-180e3762722c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4003e15d-d2e9-4d48-bdcb-3ad1a976cd18" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9de1964f-eb10-44a5-adc8-180e3762722c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_cb1250b3-08dc-4da1-969b-e31b8aeb2e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4003e15d-d2e9-4d48-bdcb-3ad1a976cd18" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_cb1250b3-08dc-4da1-969b-e31b8aeb2e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_dc37f02f-0596-480d-b9b8-153f93b33b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4003e15d-d2e9-4d48-bdcb-3ad1a976cd18" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_dc37f02f-0596-480d-b9b8-153f93b33b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_e7a06e31-cf49-4217-9076-7508c02eb731" xlink:href="exdx-20221231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1e7e5ed5-4828-4474-bb05-90eb4a09abe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_e7a06e31-cf49-4217-9076-7508c02eb731" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1e7e5ed5-4828-4474-bb05-90eb4a09abe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6ed74a50-da77-4bb0-82b5-da92f87dd1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_e7a06e31-cf49-4217-9076-7508c02eb731" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6ed74a50-da77-4bb0-82b5-da92f87dd1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_3cbe8a0d-adbb-4b11-82f1-7cd66013e6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_e7a06e31-cf49-4217-9076-7508c02eb731" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_3cbe8a0d-adbb-4b11-82f1-7cd66013e6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2e152c3a-84c3-41de-8581-df0ac6a72e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_e7a06e31-cf49-4217-9076-7508c02eb731" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2e152c3a-84c3-41de-8581-df0ac6a72e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20221231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9fced6bc-39c9-4a3e-a8d2-49ac0ad75060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_dd219066-c63e-429b-b5d9-3183032e98f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9fced6bc-39c9-4a3e-a8d2-49ac0ad75060" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_dd219066-c63e-429b-b5d9-3183032e98f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_562395c6-dc09-4ee4-b138-d71f7f6c6f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6035101f-a8b1-4e36-8703-3405f87e6da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_562395c6-dc09-4ee4-b138-d71f7f6c6f7f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6035101f-a8b1-4e36-8703-3405f87e6da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d435db19-c9d8-4aa6-b228-98290400fb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_562395c6-dc09-4ee4-b138-d71f7f6c6f7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d435db19-c9d8-4aa6-b228-98290400fb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_7b181310-5daa-4567-af2a-a8393e403745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_562395c6-dc09-4ee4-b138-d71f7f6c6f7f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_7b181310-5daa-4567-af2a-a8393e403745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_3e6b4acd-c10c-4518-bbb0-591a69b50a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_562395c6-dc09-4ee4-b138-d71f7f6c6f7f" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_3e6b4acd-c10c-4518-bbb0-591a69b50a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exdx-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63901c62-c910-4a1d-9b12-4eae02e30cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3edef9e4-3534-4b30-bae6-494eb72268b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63901c62-c910-4a1d-9b12-4eae02e30cd5" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3edef9e4-3534-4b30-bae6-494eb72268b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c8095b19-80c8-437d-80f1-836b18e93137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_43c987b0-8a37-40fc-bb3f-b2bb24e8984e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c8095b19-80c8-437d-80f1-836b18e93137" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_43c987b0-8a37-40fc-bb3f-b2bb24e8984e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70630aae-1ca1-4825-82e1-910f8b826e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bd02f8a2-0c82-4371-8cb9-d2f917dbac54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70630aae-1ca1-4825-82e1-910f8b826e2a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bd02f8a2-0c82-4371-8cb9-d2f917dbac54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7a01fa94-2b61-41e7-8e3e-deb02a266234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70630aae-1ca1-4825-82e1-910f8b826e2a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7a01fa94-2b61-41e7-8e3e-deb02a266234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3074b5df-3b5d-4026-9a4e-dbe9d738167a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70630aae-1ca1-4825-82e1-910f8b826e2a" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3074b5df-3b5d-4026-9a4e-dbe9d738167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9a1ac739-ab39-4cff-9ebb-a90ba3cdce70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70630aae-1ca1-4825-82e1-910f8b826e2a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9a1ac739-ab39-4cff-9ebb-a90ba3cdce70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_d7e115c1-77d0-4c4e-80a9-271023e24a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70630aae-1ca1-4825-82e1-910f8b826e2a" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_d7e115c1-77d0-4c4e-80a9-271023e24a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_343248de-91a1-474f-b03c-e9d65283a288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_91610d70-d694-4bc6-9640-7d8f13efb146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_343248de-91a1-474f-b03c-e9d65283a288" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_91610d70-d694-4bc6-9640-7d8f13efb146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0a813680-4fa9-46ef-b8f8-9a5880968c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_343248de-91a1-474f-b03c-e9d65283a288" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0a813680-4fa9-46ef-b8f8-9a5880968c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1f7c404a-8217-4f39-ad93-88f343fc0653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_343248de-91a1-474f-b03c-e9d65283a288" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1f7c404a-8217-4f39-ad93-88f343fc0653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_984c1a92-5c8c-4e4f-bade-6b4c3ef49e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_343248de-91a1-474f-b03c-e9d65283a288" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_984c1a92-5c8c-4e4f-bade-6b4c3ef49e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e632d99d-3858-4d55-a681-f9a778b4f0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32fac7fa-ae21-4712-99bf-2da3ab6f9ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e632d99d-3858-4d55-a681-f9a778b4f0ae" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32fac7fa-ae21-4712-99bf-2da3ab6f9ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0b6d7006-0281-4189-88dc-d1a0742c3dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e632d99d-3858-4d55-a681-f9a778b4f0ae" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0b6d7006-0281-4189-88dc-d1a0742c3dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_67c33353-fd81-456c-8612-9a286fbd5b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67c33353-fd81-456c-8612-9a286fbd5b37" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f693be69-da9c-455a-9cdd-70d8a1d33929" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:to="loc_srt_MajorCustomersAxis_f693be69-da9c-455a-9cdd-70d8a1d33929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f693be69-da9c-455a-9cdd-70d8a1d33929" xlink:to="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_b5b4f234-f654-425a-b4ae-a06a583ee2b5" xlink:href="exdx-20221231.xsd#exdx_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:to="loc_exdx_MedicareMember_b5b4f234-f654-425a-b4ae-a06a583ee2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_199e6e68-bb21-4c6c-aab5-6c86b6ceea93" xlink:href="exdx-20221231.xsd#exdx_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:to="loc_exdx_MedicareAdvantageMember_199e6e68-bb21-4c6c-aab5-6c86b6ceea93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_b8a87682-fa2e-43d7-a9aa-89f779cc20f5" xlink:href="exdx-20221231.xsd#exdx_BlueShieldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:to="loc_exdx_BlueShieldMember_b8a87682-fa2e-43d7-a9aa-89f779cc20f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_a2647a54-0047-4808-9aa0-35dd08cbf460" xlink:href="exdx-20221231.xsd#exdx_UnitedHealthcareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_37299eb3-e4b3-4e26-aa4a-041783c00a84" xlink:to="loc_exdx_UnitedHealthcareMember_a2647a54-0047-4808-9aa0-35dd08cbf460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d60e0e49-0853-443d-b7c3-c91f01cf075f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d60e0e49-0853-443d-b7c3-c91f01cf075f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbf42c9-16f9-41c7-80ab-815a8715e0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d60e0e49-0853-443d-b7c3-c91f01cf075f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbf42c9-16f9-41c7-80ab-815a8715e0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_eb703a86-c7e1-4288-b0c1-9e2f8755f174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbf42c9-16f9-41c7-80ab-815a8715e0aa" xlink:to="loc_us-gaap_SalesRevenueNetMember_eb703a86-c7e1-4288-b0c1-9e2f8755f174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_1da8decf-6f3c-4c3e-8969-77a520d6e3d7" xlink:href="exdx-20221231.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbf42c9-16f9-41c7-80ab-815a8715e0aa" xlink:to="loc_exdx_ReceivableBenchmarkMember_1da8decf-6f3c-4c3e-8969-77a520d6e3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0fe2d217-1fe5-474d-bf44-a16f3e79da9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0fe2d217-1fe5-474d-bf44-a16f3e79da9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_63d18051-98f7-4a6d-8eb2-dc03ac3699d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0fe2d217-1fe5-474d-bf44-a16f3e79da9d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_63d18051-98f7-4a6d-8eb2-dc03ac3699d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6ffa325e-2dee-4be5-86fb-e6826029d35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_63d18051-98f7-4a6d-8eb2-dc03ac3699d8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6ffa325e-2dee-4be5-86fb-e6826029d35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f34ca8d2-2ed0-49ed-a58b-e73b3ac86a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1f0668b-3377-4d04-9627-421d4c31d2a0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f34ca8d2-2ed0-49ed-a58b-e73b3ac86a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b523cd9e-1d52-441d-a933-48986d97ee1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f34ca8d2-2ed0-49ed-a58b-e73b3ac86a2a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b523cd9e-1d52-441d-a933-48986d97ee1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_de93ce12-faa9-4d90-82e7-788667f42bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_de93ce12-faa9-4d90-82e7-788667f42bef" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_160f7014-ef9a-4efb-81e2-767790591559" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_srt_CounterpartyNameAxis_160f7014-ef9a-4efb-81e2-767790591559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b145e99-5825-4921-ad95-3cc8a60c829b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_160f7014-ef9a-4efb-81e2-767790591559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b145e99-5825-4921-ad95-3cc8a60c829b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_372574fc-a090-4a2a-9294-f32f52bf0599" xlink:href="exdx-20221231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b145e99-5825-4921-ad95-3cc8a60c829b" xlink:to="loc_exdx_JanssenSIMPONIMember_372574fc-a090-4a2a-9294-f32f52bf0599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df5aac16-9775-4769-878d-16b365bcaf01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df5aac16-9775-4769-878d-16b365bcaf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d1d3dc4-6e01-4334-823d-e2d91190de90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df5aac16-9775-4769-878d-16b365bcaf01" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d1d3dc4-6e01-4334-823d-e2d91190de90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_41b5cbe9-04ea-4785-832f-5d1c53acb5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d1d3dc4-6e01-4334-823d-e2d91190de90" xlink:to="loc_us-gaap_SalesRevenueNetMember_41b5cbe9-04ea-4785-832f-5d1c53acb5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d6f2e57a-b1d7-4677-a6f6-9e96acf12fa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_srt_ProductOrServiceAxis_d6f2e57a-b1d7-4677-a6f6-9e96acf12fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67e74161-0918-482a-b220-a4606b7965ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d6f2e57a-b1d7-4677-a6f6-9e96acf12fa3" xlink:to="loc_srt_ProductsAndServicesDomain_67e74161-0918-482a-b220-a4606b7965ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_c814f753-9a8c-43a7-b0ad-e0ca0244b2a8" xlink:href="exdx-20221231.xsd#exdx_AVISECTDTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67e74161-0918-482a-b220-a4606b7965ff" xlink:to="loc_exdx_AVISECTDTestMember_c814f753-9a8c-43a7-b0ad-e0ca0244b2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_32b38f0a-a689-4486-8556-8ad6503eca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67e74161-0918-482a-b220-a4606b7965ff" xlink:to="loc_us-gaap_ShippingAndHandlingMember_32b38f0a-a689-4486-8556-8ad6503eca3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_722e7019-ed8a-4e51-8095-01d511b73916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_722e7019-ed8a-4e51-8095-01d511b73916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8b12bb03-1fec-4c47-9f66-f346cb54933d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_722e7019-ed8a-4e51-8095-01d511b73916" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8b12bb03-1fec-4c47-9f66-f346cb54933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_ba3e8cbc-d9c5-478d-8b09-1d5cc315ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8b12bb03-1fec-4c47-9f66-f346cb54933d" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_ba3e8cbc-d9c5-478d-8b09-1d5cc315ef7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_63873920-a356-4d82-80c2-212260c9d959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8b12bb03-1fec-4c47-9f66-f346cb54933d" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_63873920-a356-4d82-80c2-212260c9d959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3678217-3f85-4728-a648-b618f198cd45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_srt_RangeAxis_f3678217-3f85-4728-a648-b618f198cd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e20360c7-d46a-41ee-ae1d-6b8f38974e1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f3678217-3f85-4728-a648-b618f198cd45" xlink:to="loc_srt_RangeMember_e20360c7-d46a-41ee-ae1d-6b8f38974e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b080e444-1fbe-4cf0-848e-7def6bfadede" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e20360c7-d46a-41ee-ae1d-6b8f38974e1c" xlink:to="loc_srt_MinimumMember_b080e444-1fbe-4cf0-848e-7def6bfadede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_43c10c3f-88ee-4959-92a3-a02ae2431adc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e20360c7-d46a-41ee-ae1d-6b8f38974e1c" xlink:to="loc_srt_MaximumMember_43c10c3f-88ee-4959-92a3-a02ae2431adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_833a320d-03e9-4270-94b8-eabf2913db3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_833a320d-03e9-4270-94b8-eabf2913db3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efedb02c-42a2-4ec7-b26f-0202648cba3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_833a320d-03e9-4270-94b8-eabf2913db3b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efedb02c-42a2-4ec7-b26f-0202648cba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenPromotionAgreementMember_65a3fd36-5a1e-439f-bfaf-c7d8ba649745" xlink:href="exdx-20221231.xsd#exdx_JanssenPromotionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efedb02c-42a2-4ec7-b26f-0202648cba3c" xlink:to="loc_exdx_JanssenPromotionAgreementMember_65a3fd36-5a1e-439f-bfaf-c7d8ba649745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_6b520706-6f49-4cf2-a3b8-626537f91060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_6b520706-6f49-4cf2-a3b8-626537f91060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_617dfa9e-c565-41ed-844d-7611222fb344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_6b520706-6f49-4cf2-a3b8-626537f91060" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_617dfa9e-c565-41ed-844d-7611222fb344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoSuppliersMember_8555a0a4-0d78-4e05-bbe9-e312fd7a7553" xlink:href="exdx-20221231.xsd#exdx_TwoSuppliersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_617dfa9e-c565-41ed-844d-7611222fb344" xlink:to="loc_exdx_TwoSuppliersMember_8555a0a4-0d78-4e05-bbe9-e312fd7a7553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_64a95abb-9d9f-486b-92ba-e915f7076625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_64a95abb-9d9f-486b-92ba-e915f7076625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1de85812-26f7-4000-aea3-d575ef3cb19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_64a95abb-9d9f-486b-92ba-e915f7076625" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1de85812-26f7-4000-aea3-d575ef3cb19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_c24f7a55-fab9-4127-b068-48767e684839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1de85812-26f7-4000-aea3-d575ef3cb19a" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_c24f7a55-fab9-4127-b068-48767e684839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e90376-4f34-4ea9-bfea-eed28b57424f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e90376-4f34-4ea9-bfea-eed28b57424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_79cf2f5a-9565-4c41-8d2b-a3645981b8cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e90376-4f34-4ea9-bfea-eed28b57424f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_79cf2f5a-9565-4c41-8d2b-a3645981b8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_166d1882-8537-44f3-96b3-8ea4809be76f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_79cf2f5a-9565-4c41-8d2b-a3645981b8cf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_166d1882-8537-44f3-96b3-8ea4809be76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_88b4ea0a-4114-4065-af10-e8b609e9730e" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_407303e7-2390-4d1d-bb36-b749f782a40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_407303e7-2390-4d1d-bb36-b749f782a40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_9374e067-b3cb-4f67-8692-bcd470ac4447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_RestrictedCash_9374e067-b3cb-4f67-8692-bcd470ac4447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4f5bb82a-43d1-4dfc-a574-a140af04a517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4f5bb82a-43d1-4dfc-a574-a140af04a517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_384e61a2-5810-4a66-b44e-5e4ee983b80c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_384e61a2-5810-4a66-b44e-5e4ee983b80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f07150e3-6d9a-4ee7-b846-6caa3e6f1b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f07150e3-6d9a-4ee7-b846-6caa3e6f1b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dae4d362-3fe0-4418-bc9e-33dded6a76f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dae4d362-3fe0-4418-bc9e-33dded6a76f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6548f36-5798-4856-bc4e-327b2b419d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6548f36-5798-4856-bc4e-327b2b419d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ContractWithCustomerTerminationConsiderationReceivable_908e000e-a61d-44e7-95ca-5a6b53600b66" xlink:href="exdx-20221231.xsd#exdx_ContractWithCustomerTerminationConsiderationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_exdx_ContractWithCustomerTerminationConsiderationReceivable_908e000e-a61d-44e7-95ca-5a6b53600b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_45d10efe-d2e3-457e-87ce-ee28a026e24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_AdvertisingExpense_45d10efe-d2e3-457e-87ce-ee28a026e24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c18004fb-c816-4ac1-b7f2-20f74393ada5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_CostOfRevenue_c18004fb-c816-4ac1-b7f2-20f74393ada5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b841420f-525c-48ba-9a08-982f477a8134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b841420f-525c-48ba-9a08-982f477a8134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_4707ebe1-4c0b-4f22-bcd8-08a3cf99f302" xlink:href="exdx-20221231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_4707ebe1-4c0b-4f22-bcd8-08a3cf99f302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b7eec0ac-efc3-43e4-b42f-aa5efd26c8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b7eec0ac-efc3-43e4-b42f-aa5efd26c8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a2e78787-8103-4541-84a3-f95771a3a930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_OperatingLeaseLiability_a2e78787-8103-4541-84a3-f95771a3a930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa0e9d23-9ad9-48ab-bc78-3f126b521458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa0e9d23-9ad9-48ab-bc78-3f126b521458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCredit_fa478dd9-ede2-4720-a53c-ac11b0e48fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCredit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09505a01-f7fd-4f82-81f5-3c3f6b54b162" xlink:to="loc_us-gaap_DeferredRentCredit_fa478dd9-ede2-4720-a53c-ac11b0e48fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4e505118-d021-44b3-a4e3-b12964180d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ab9da3de-d9ef-4da7-a44f-c628958a5db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e505118-d021-44b3-a4e3-b12964180d38" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ab9da3de-d9ef-4da7-a44f-c628958a5db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_01ab098a-bd23-423e-9d51-0d298b4e5edf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab9da3de-d9ef-4da7-a44f-c628958a5db5" xlink:to="loc_srt_MajorCustomersAxis_01ab098a-bd23-423e-9d51-0d298b4e5edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_01ab098a-bd23-423e-9d51-0d298b4e5edf" xlink:to="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommercialMember_62c5bb17-563a-4848-9b84-11250de3d3e1" xlink:href="exdx-20221231.xsd#exdx_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_exdx_CommercialMember_62c5bb17-563a-4848-9b84-11250de3d3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_c5d76417-5784-4fc8-aaf6-8835a0dbc637" xlink:href="exdx-20221231.xsd#exdx_Government1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_exdx_Government1Member_c5d76417-5784-4fc8-aaf6-8835a0dbc637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_d3f02b5c-c15c-4f8e-a5ec-a89b9bac3950" xlink:href="exdx-20221231.xsd#exdx_ClientMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_exdx_ClientMember_d3f02b5c-c15c-4f8e-a5ec-a89b9bac3950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_b90d3caa-e05c-4940-97a2-0f240b7a285d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCustomerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_us-gaap_OtherCustomerMember_b90d3caa-e05c-4940-97a2-0f240b7a285d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_9077b611-99a8-4ca8-9cac-4cf50ac0bc25" xlink:href="exdx-20221231.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_944eb58f-2771-4dfd-9923-16970e9688d0" xlink:to="loc_exdx_JanssenSIMPONIMember_9077b611-99a8-4ca8-9cac-4cf50ac0bc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_39cf7527-f741-4f4b-936d-91eca5835e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab9da3de-d9ef-4da7-a44f-c628958a5db5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_39cf7527-f741-4f4b-936d-91eca5835e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6602605-1fde-4b03-807e-59960da103bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39cf7527-f741-4f4b-936d-91eca5835e2a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6602605-1fde-4b03-807e-59960da103bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5854b1ca-5bb0-4592-b807-cb67f9b36037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b3f7d43-ecfe-449f-8058-680db2f190c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5854b1ca-5bb0-4592-b807-cb67f9b36037" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b3f7d43-ecfe-449f-8058-680db2f190c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_04e36636-4a98-413b-b65f-692fe02ae5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5854b1ca-5bb0-4592-b807-cb67f9b36037" xlink:to="loc_us-gaap_RestrictedCash_04e36636-4a98-413b-b65f-692fe02ae5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44f8c1d4-5a7e-4ed4-8219-293d5b9b1d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5854b1ca-5bb0-4592-b807-cb67f9b36037" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44f8c1d4-5a7e-4ed4-8219-293d5b9b1d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c523aa3-35e1-4970-9786-e11579e7f5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0394d66b-c170-425e-aa4c-89e47a1f0eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c523aa3-35e1-4970-9786-e11579e7f5ba" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0394d66b-c170-425e-aa4c-89e47a1f0eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b38bce64-beed-44f0-ba46-8dacd83f8354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0394d66b-c170-425e-aa4c-89e47a1f0eb1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b38bce64-beed-44f0-ba46-8dacd83f8354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b38bce64-beed-44f0-ba46-8dacd83f8354" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3bb0e574-43f2-4d13-8c31-ec0f12f04a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:to="loc_us-gaap_WarrantMember_3bb0e574-43f2-4d13-8c31-ec0f12f04a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_cf2a1149-adf6-460f-b20d-e47a6d72639d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:to="loc_us-gaap_StockOptionMember_cf2a1149-adf6-460f-b20d-e47a6d72639d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a37b372f-689a-4105-b428-26f9b1989548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a37b372f-689a-4105-b428-26f9b1989548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b79555ee-6953-4e9b-aff9-441c54d84d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_02e5ba92-17a3-49fe-bd7d-f27f7e1c7a04" xlink:to="loc_us-gaap_EmployeeStockMember_b79555ee-6953-4e9b-aff9-441c54d84d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_030c6222-908b-4a00-a5c5-ea4bff886b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0394d66b-c170-425e-aa4c-89e47a1f0eb1" xlink:to="loc_us-gaap_ClassOfStockLineItems_030c6222-908b-4a00-a5c5-ea4bff886b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b06b0e8a-d09d-4927-88ef-b7546bb78ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_030c6222-908b-4a00-a5c5-ea4bff886b2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b06b0e8a-d09d-4927-88ef-b7546bb78ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationPrepaidExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_170a4477-3539-4ff5-9f31-649232ab443d" xlink:href="exdx-20221231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1ef30110-96cf-4037-be69-8a7d47905da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_170a4477-3539-4ff5-9f31-649232ab443d" xlink:to="loc_us-gaap_OtherAssetsCurrent_1ef30110-96cf-4037-be69-8a7d47905da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_7c08a002-0cb2-4ec5-88ff-4f420c4e46b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_170a4477-3539-4ff5-9f31-649232ab443d" xlink:to="loc_us-gaap_PrepaidRoyalties_7c08a002-0cb2-4ec5-88ff-4f420c4e46b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_c6462cbe-9fa4-4237-8f35-995560984fbb" xlink:href="exdx-20221231.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_170a4477-3539-4ff5-9f31-649232ab443d" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_c6462cbe-9fa4-4237-8f35-995560984fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_a850bfdf-7e39-438b-8cf4-8c36e5f0103e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_170a4477-3539-4ff5-9f31-649232ab443d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_a850bfdf-7e39-438b-8cf4-8c36e5f0103e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6c977f0f-4987-4d2c-9b21-3c3f04157a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_170a4477-3539-4ff5-9f31-649232ab443d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6c977f0f-4987-4d2c-9b21-3c3f04157a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_fd598011-fb0c-4f02-897b-229fd3316d18" xlink:href="exdx-20221231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f60abffb-13f0-4f7a-aa4d-da070f85c446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_fd598011-fb0c-4f02-897b-229fd3316d18" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f60abffb-13f0-4f7a-aa4d-da070f85c446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_90674098-4737-442c-bf3b-bc1baf865638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f60abffb-13f0-4f7a-aa4d-da070f85c446" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_90674098-4737-442c-bf3b-bc1baf865638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_90674098-4737-442c-bf3b-bc1baf865638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_28561651-2c00-4fb8-9c60-5f1c4391de6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_28561651-2c00-4fb8-9c60-5f1c4391de6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_5fe89b9a-7e3c-4f51-a750-c984c572e1bd" xlink:href="exdx-20221231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_exdx_LaboratoryEquipmentMember_5fe89b9a-7e3c-4f51-a750-c984c572e1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_0c676241-a0c4-4c1a-bd43-00122e1bbd93" xlink:href="exdx-20221231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_0c676241-a0c4-4c1a-bd43-00122e1bbd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8c614287-9f75-4e7a-aeb8-3a46def921cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8c614287-9f75-4e7a-aeb8-3a46def921cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_33442e20-9deb-4ad1-a98d-384c14eb0676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d49bbd85-ee14-46a2-b27b-afc6bada6b39" xlink:to="loc_us-gaap_ConstructionInProgressMember_33442e20-9deb-4ad1-a98d-384c14eb0676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f60abffb-13f0-4f7a-aa4d-da070f85c446" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4e815b9f-54b8-4a39-a825-cd4acbf055dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4e815b9f-54b8-4a39-a825-cd4acbf055dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8eb4ee0a-7840-4d84-a52e-43cbfa7eac97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8eb4ee0a-7840-4d84-a52e-43cbfa7eac97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9b49f03f-6955-4fc7-bd31-d0c8429a1484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b40685a-8b4f-4d9e-9b7e-a77f9ed12636" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9b49f03f-6955-4fc7-bd31-d0c8429a1484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_726c4516-44b7-446a-8725-19cf36166624" xlink:href="exdx-20221231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb0130c5-10c8-438e-ac9a-f9e8f3fe5aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_726c4516-44b7-446a-8725-19cf36166624" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb0130c5-10c8-438e-ac9a-f9e8f3fe5aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e0d48c4-0d22-42b0-9669-4abe4b5ff2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb0130c5-10c8-438e-ac9a-f9e8f3fe5aa2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e0d48c4-0d22-42b0-9669-4abe4b5ff2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9518e419-7910-4d9e-8587-e863f1d663a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e0d48c4-0d22-42b0-9669-4abe4b5ff2b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9518e419-7910-4d9e-8587-e863f1d663a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_fcbf5d45-53b5-4e7b-ad62-9c28f15b474b" xlink:href="exdx-20221231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9518e419-7910-4d9e-8587-e863f1d663a5" xlink:to="loc_exdx_LaboratoryEquipmentMember_fcbf5d45-53b5-4e7b-ad62-9c28f15b474b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb0130c5-10c8-438e-ac9a-f9e8f3fe5aa2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7f5b322d-0a1e-482c-865b-5777ad0288f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7f5b322d-0a1e-482c-865b-5777ad0288f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_d92f8fe2-fec1-4fc9-962c-2f9775276694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_d92f8fe2-fec1-4fc9-962c-2f9775276694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3eee632c-8fd7-4462-ae11-ad63a83422e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3eee632c-8fd7-4462-ae11-ad63a83422e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_47117af1-507d-4330-b16d-3007a64ca27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_47117af1-507d-4330-b16d-3007a64ca27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a439963a-af08-43a8-8cff-209ae53c621a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_050b95fe-2ba1-4b36-a5fb-f73f6c51d603" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a439963a-af08-43a8-8cff-209ae53c621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bd5cd44a-7557-4fc4-a8b0-c852e098cbda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_609cb8e2-922d-430e-a269-7e36f66294f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bd5cd44a-7557-4fc4-a8b0-c852e098cbda" xlink:to="loc_us-gaap_GoodwillRollForward_609cb8e2-922d-430e-a269-7e36f66294f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_86af3001-82e5-4f4a-8527-facf4ca0e93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_609cb8e2-922d-430e-a269-7e36f66294f4" xlink:to="loc_us-gaap_Goodwill_86af3001-82e5-4f4a-8527-facf4ca0e93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_44ec9495-44a9-46fb-9356-0d3734834397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_609cb8e2-922d-430e-a269-7e36f66294f4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_44ec9495-44a9-46fb-9356-0d3734834397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6709075b-a773-49ab-8738-393c43dac763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_609cb8e2-922d-430e-a269-7e36f66294f4" xlink:to="loc_us-gaap_Goodwill_6709075b-a773-49ab-8738-393c43dac763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#OtherFinancialInformationAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:href="exdx-20221231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_991b9733-feb9-4eb3-96cb-27cfae945073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:to="loc_us-gaap_AccruedSalariesCurrent_991b9733-feb9-4eb3-96cb-27cfae945073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_8819581d-9c36-4b09-81a8-9a87257c50d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:to="loc_us-gaap_InterestPayableCurrent_8819581d-9c36-4b09-81a8-9a87257c50d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_01848199-8df7-41a9-9874-79cbb1e61d9b" xlink:href="exdx-20221231.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_01848199-8df7-41a9-9874-79cbb1e61d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_66b6743b-589f-4986-94e8-d5f93fac0220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_66b6743b-589f-4986-94e8-d5f93fac0220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_0dc52ca4-9b31-4d11-9751-22de918220e1" xlink:href="exdx-20221231.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_0dc52ca4-9b31-4d11-9751-22de918220e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_4041a048-b4f6-455a-8504-a8d3c1f5826a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_4041a048-b4f6-455a-8504-a8d3c1f5826a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_6cd995f8-e508-4eb2-8915-e73ddd073978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_6cd995f8-e508-4eb2-8915-e73ddd073978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e04cc778-2602-4c63-a9a5-c0976ee6d9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e04cc778-2602-4c63-a9a5-c0976ee6d9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9b506882-73ee-4a6a-9112-1e1895ebcf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_863ed126-77c5-4bac-8dd8-cb4195bce479" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9b506882-73ee-4a6a-9112-1e1895ebcf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_87f7adb2-ef2c-4027-a7e8-c18105292b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_87f7adb2-ef2c-4027-a7e8-c18105292b96" xlink:to="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5a3d31e5-ac1b-4139-ba5a-e8ccd66e610c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:to="loc_us-gaap_DebtInstrumentAxis_5a3d31e5-ac1b-4139-ba5a-e8ccd66e610c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e106ccad-02bc-49ba-94db-80fcebb94297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5a3d31e5-ac1b-4139-ba5a-e8ccd66e610c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e106ccad-02bc-49ba-94db-80fcebb94297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_b1b9dd86-76b9-4e41-a848-dd2c58a0ed95" xlink:href="exdx-20221231.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e106ccad-02bc-49ba-94db-80fcebb94297" xlink:to="loc_exdx_Term2017Member_b1b9dd86-76b9-4e41-a848-dd2c58a0ed95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember_06641dee-fd65-4cfc-93f9-9bc3c4948a65" xlink:href="exdx-20221231.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e106ccad-02bc-49ba-94db-80fcebb94297" xlink:to="loc_exdx_EquipmentNotesPayableMember_06641dee-fd65-4cfc-93f9-9bc3c4948a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6241c137-b0e4-4895-a007-74b486cd1f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6241c137-b0e4-4895-a007-74b486cd1f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ae7aa11-ebd4-4dc7-90bd-a753f4ef36f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6241c137-b0e4-4895-a007-74b486cd1f3d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ae7aa11-ebd4-4dc7-90bd-a753f4ef36f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_509b90ef-a2d1-4c57-bdbd-693556473cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ae7aa11-ebd4-4dc7-90bd-a753f4ef36f8" xlink:to="loc_us-gaap_LoansPayableMember_509b90ef-a2d1-4c57-bdbd-693556473cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_625f659d-59ec-402b-9841-cd61474d864c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ae7aa11-ebd4-4dc7-90bd-a753f4ef36f8" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_625f659d-59ec-402b-9841-cd61474d864c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_b0468fe7-3a9c-45fc-b3f8-4d11f76892bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_b0468fe7-3a9c-45fc-b3f8-4d11f76892bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ad95b3f9-3da8-42a7-97a5-67a56623e36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b0468fe7-3a9c-45fc-b3f8-4d11f76892bf" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ad95b3f9-3da8-42a7-97a5-67a56623e36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_c4744220-b78b-4048-bc57-9a3ed7ce2ccf" xlink:href="exdx-20221231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ad95b3f9-3da8-42a7-97a5-67a56623e36e" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_c4744220-b78b-4048-bc57-9a3ed7ce2ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cc02cd4d-177f-4b45-b81f-59681118bab0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7c22024d-3ee4-484f-b41e-19de05e82569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7c22024d-3ee4-484f-b41e-19de05e82569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee7ab00d-87a7-4891-a2fc-b91bd0addd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ee7ab00d-87a7-4891-a2fc-b91bd0addd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_056a2f22-6a05-4262-8c7f-7346730773cf" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_056a2f22-6a05-4262-8c7f-7346730773cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0fabc58a-4575-44e2-a4c9-2ca57d35a014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0fabc58a-4575-44e2-a4c9-2ca57d35a014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_62232591-b3bb-4de2-a54a-280f42fdc5bc" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_62232591-b3bb-4de2-a54a-280f42fdc5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_e11ad23f-2d9f-4b9f-8103-49697e5ae11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_e11ad23f-2d9f-4b9f-8103-49697e5ae11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_6e761314-a005-407d-9f1f-3225cdb72efb" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_6e761314-a005-407d-9f1f-3225cdb72efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_6ec50a98-6b77-4323-a273-7304215a3421" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_6ec50a98-6b77-4323-a273-7304215a3421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_c9b76ac7-6e72-41fe-93aa-2ea52783e468" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_c9b76ac7-6e72-41fe-93aa-2ea52783e468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_749b5087-3e46-4dca-97b3-17322fb4e1c8" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_749b5087-3e46-4dca-97b3-17322fb4e1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_7c85811b-fefa-4b41-af48-841a4294f593" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_7c85811b-fefa-4b41-af48-841a4294f593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_79ce7fea-a042-4d65-aed6-698d534f6b52" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_79ce7fea-a042-4d65-aed6-698d534f6b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_4c82a29f-c1ce-4123-bda9-9e61623090ae" xlink:href="exdx-20221231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_4c82a29f-c1ce-4123-bda9-9e61623090ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f6ec59f2-22bb-427d-92d2-a82f11b2740d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_NotesPayable_f6ec59f2-22bb-427d-92d2-a82f11b2740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_7d824209-cfb4-4ead-9609-8a20fae0416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_NotesPayableCurrent_7d824209-cfb4-4ead-9609-8a20fae0416e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_570e444e-5601-41a9-9c24-c0d9a4b1c3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0b816f9-94bc-4ba4-874a-5436bcfe04ab" xlink:to="loc_us-gaap_LongTermNotesPayable_570e444e-5601-41a9-9c24-c0d9a4b1c3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#BorrowingsFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dc19014d-2d3f-472a-bbf4-d386c71822ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dc19014d-2d3f-472a-bbf4-d386c71822ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0412c30c-5b35-4ca8-a289-d856a95e09ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0412c30c-5b35-4ca8-a289-d856a95e09ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8a5dec28-34c9-45bc-9f10-6a9c3d98a40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8a5dec28-34c9-45bc-9f10-6a9c3d98a40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1c0a2c50-41a8-4cff-98d2-4a7cbda28666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1c0a2c50-41a8-4cff-98d2-4a7cbda28666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_113abe7b-7194-417e-b250-0ffe38d683c6" xlink:href="exdx-20221231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_113abe7b-7194-417e-b250-0ffe38d683c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5c4d3bb5-145c-47cb-b0c2-acd3d19a4147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5c4d3bb5-145c-47cb-b0c2-acd3d19a4147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_83ecc44f-550e-4560-a24f-b2deae1e5854" xlink:href="exdx-20221231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_83ecc44f-550e-4560-a24f-b2deae1e5854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d563cedd-54e1-4912-b514-6b3a860948b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_us-gaap_LongTermDebt_d563cedd-54e1-4912-b514-6b3a860948b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f96fde7c-9e39-47d0-bc30-4a9815e0b080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_us-gaap_LongTermDebtCurrent_f96fde7c-9e39-47d0-bc30-4a9815e0b080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ea37b037-c40e-4208-849a-fc98ad989d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd903bdc-3431-473d-9089-85da4cbb8f7a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ea37b037-c40e-4208-849a-fc98ad989d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24a221a0-67ab-43d1-b7cc-ce7dbe2bee55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24a221a0-67ab-43d1-b7cc-ce7dbe2bee55" xlink:to="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_9821b1fd-a9c4-4287-abf8-886e44a5bfa7" xlink:href="exdx-20221231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_exdx_RentalPropertyByTypeAxis_9821b1fd-a9c4-4287-abf8-886e44a5bfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_f3672a1b-fda0-4558-8464-4e715f8bb9ba" xlink:href="exdx-20221231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeAxis_9821b1fd-a9c4-4287-abf8-886e44a5bfa7" xlink:to="loc_exdx_RentalPropertyByTypeDomain_f3672a1b-fda0-4558-8464-4e715f8bb9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_33528b5b-4b23-4bd8-92e5-433a08324844" xlink:href="exdx-20221231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_f3672a1b-fda0-4558-8464-4e715f8bb9ba" xlink:to="loc_exdx_OfficeAndLaboratoryMember_33528b5b-4b23-4bd8-92e5-433a08324844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_37f2589d-17be-48b3-8b4d-9bf4c46c7a87" xlink:href="exdx-20221231.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_f3672a1b-fda0-4558-8464-4e715f8bb9ba" xlink:to="loc_exdx_OfficeMember_37f2589d-17be-48b3-8b4d-9bf4c46c7a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3231686-220d-4c7e-b327-fab3048a6751" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_srt_CounterpartyNameAxis_c3231686-220d-4c7e-b327-fab3048a6751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c3231686-220d-4c7e-b327-fab3048a6751" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_a620082e-18f1-48a7-906e-8b0d56d05b74" xlink:href="exdx-20221231.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_a620082e-18f1-48a7-906e-8b0d56d05b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_60ee5edf-6d9c-47e3-8db8-3c9716be0e91" xlink:href="exdx-20221231.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_60ee5edf-6d9c-47e3-8db8-3c9716be0e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_QueenMaryUniversityOfLondonMember_d28495d6-5a23-4fc0-b452-baae6740956a" xlink:href="exdx-20221231.xsd#exdx_QueenMaryUniversityOfLondonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8641ca53-2170-437f-a7a0-136a81e1f6a0" xlink:to="loc_exdx_QueenMaryUniversityOfLondonMember_d28495d6-5a23-4fc0-b452-baae6740956a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cc262aaf-dd21-4a4b-81fe-292698b4ad04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_srt_RangeAxis_cc262aaf-dd21-4a4b-81fe-292698b4ad04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13ecc417-d967-4984-abc5-a29c8dcce283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cc262aaf-dd21-4a4b-81fe-292698b4ad04" xlink:to="loc_srt_RangeMember_13ecc417-d967-4984-abc5-a29c8dcce283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0680687e-432b-4a66-8d8b-790f73b4b6a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13ecc417-d967-4984-abc5-a29c8dcce283" xlink:to="loc_srt_MinimumMember_0680687e-432b-4a66-8d8b-790f73b4b6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ff834362-a612-48a3-9a31-9ff3bc3af888" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13ecc417-d967-4984-abc5-a29c8dcce283" xlink:to="loc_srt_MaximumMember_ff834362-a612-48a3-9a31-9ff3bc3af888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7ef9b47-2514-4162-b34e-9c0713b58389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7ef9b47-2514-4162-b34e-9c0713b58389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7b797b03-14fe-434a-af52-bd6a0d225c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7ef9b47-2514-4162-b34e-9c0713b58389" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7b797b03-14fe-434a-af52-bd6a0d225c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_528149bb-3037-425b-b53d-70d64e2e40ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7b797b03-14fe-434a-af52-bd6a0d225c32" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_528149bb-3037-425b-b53d-70d64e2e40ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1e7b3284-d752-42a0-b28a-14112b758b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1e7b3284-d752-42a0-b28a-14112b758b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d9e569c-d680-4646-89cb-ae766bd5d621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1e7b3284-d752-42a0-b28a-14112b758b44" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d9e569c-d680-4646-89cb-ae766bd5d621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_d8391553-bd0b-4d7b-ba4b-235872642388" xlink:href="exdx-20221231.xsd#exdx_AHNCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7d9e569c-d680-4646-89cb-ae766bd5d621" xlink:to="loc_exdx_AHNCollaborationMember_d8391553-bd0b-4d7b-ba4b-235872642388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_5f38449d-86d9-499a-a415-5da107271a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_us-gaap_LeaseContractualTermAxis_5f38449d-86d9-499a-a415-5da107271a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_10ef29ba-62d0-4827-a6ca-5667f147ff8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_5f38449d-86d9-499a-a415-5da107271a41" xlink:to="loc_us-gaap_LeaseContractualTermDomain_10ef29ba-62d0-4827-a6ca-5667f147ff8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_d0125fe3-34cf-4c68-bc0c-e53595c0873e" xlink:href="exdx-20221231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_10ef29ba-62d0-4827-a6ca-5667f147ff8c" xlink:to="loc_exdx_OfficeAndLaboratoryMember_d0125fe3-34cf-4c68-bc0c-e53595c0873e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_6b554224-7d26-45e2-9702-ea8dcdf4cbb2" xlink:href="exdx-20221231.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_10ef29ba-62d0-4827-a6ca-5667f147ff8c" xlink:to="loc_exdx_OfficeMember_6b554224-7d26-45e2-9702-ea8dcdf4cbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_5644cfe7-c075-49a0-88e0-e586cb9795c2" xlink:to="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f2fd94dd-253a-4be7-8a25-924c1fa45ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f2fd94dd-253a-4be7-8a25-924c1fa45ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_afb49967-1dfe-4bd8-9e35-a147e528d9dd" xlink:href="exdx-20221231.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_afb49967-1dfe-4bd8-9e35-a147e528d9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_d441209d-e22a-4ea1-9a7b-53eb1b13edb5" xlink:href="exdx-20221231.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_d441209d-e22a-4ea1-9a7b-53eb1b13edb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_6f8e07a4-5710-4604-a06e-8a0afec1990c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_6f8e07a4-5710-4604-a06e-8a0afec1990c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_7e68a4ae-fce6-441b-b1f1-44bc3bf6162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_LeaseAndRentalExpense_7e68a4ae-fce6-441b-b1f1-44bc3bf6162d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_819e1ecd-17eb-48ec-b80c-56bb54095476" xlink:href="exdx-20221231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_819e1ecd-17eb-48ec-b80c-56bb54095476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_c6c5ce55-fc1f-4271-a554-f8ea761e16ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_c6c5ce55-fc1f-4271-a554-f8ea761e16ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_a27fdaa2-93d4-4f35-9c2b-2292177038b5" xlink:href="exdx-20221231.xsd#exdx_AdvancePayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_AdvancePayment_a27fdaa2-93d4-4f35-9c2b-2292177038b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee_1828c64c-d313-4731-9d84-daa4769b89c9" xlink:href="exdx-20221231.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_LicenseAgreementInitialLicenseFee_1828c64c-d313-4731-9d84-daa4769b89c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementOneTimePayment_d162f4e5-f7ad-459c-8424-c0390606dee3" xlink:href="exdx-20221231.xsd#exdx_LicenseAgreementOneTimePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_LicenseAgreementOneTimePayment_d162f4e5-f7ad-459c-8424-c0390606dee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid_1797179e-6c45-46c8-b7fe-90accd9a1fc5" xlink:href="exdx-20221231.xsd#exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid_1797179e-6c45-46c8-b7fe-90accd9a1fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_6aa0adbd-411c-4c56-acd3-030e4b89ca30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_6aa0adbd-411c-4c56-acd3-030e4b89ca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_bb4ddafe-a455-4797-b01f-519d48e11dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_bb4ddafe-a455-4797-b01f-519d48e11dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_b27ee191-12e1-4e03-9a52-97ea012423f8" xlink:href="exdx-20221231.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_b27ee191-12e1-4e03-9a52-97ea012423f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_413ebd9c-5497-4f6e-982d-0cd7785a379f" xlink:href="exdx-20221231.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_413ebd9c-5497-4f6e-982d-0cd7785a379f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_5b9389e7-1688-449e-a180-04f215e18a26" xlink:href="exdx-20221231.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_56ca08df-2ff4-4b78-9467-8b16304cc200" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_5b9389e7-1688-449e-a180-04f215e18a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesLeaseBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_763c253c-3935-467f-aa7e-add6cfec3bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_763c253c-3935-467f-aa7e-add6cfec3bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_d174a4dc-c60b-4fc3-90b2-3e4172a5fe75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_d174a4dc-c60b-4fc3-90b2-3e4172a5fe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3ee04adf-ccf1-48a8-95ef-31580279874f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3ee04adf-ccf1-48a8-95ef-31580279874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_46a5e8f3-a96a-49f8-b809-4a1f64af3c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_46a5e8f3-a96a-49f8-b809-4a1f64af3c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_51c9dbd0-b833-43cd-b9c7-de0f65f1329d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_51c9dbd0-b833-43cd-b9c7-de0f65f1329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_94ffd02a-59f0-4fbb-9af4-dd78991502c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_94ffd02a-59f0-4fbb-9af4-dd78991502c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_100b0b17-64c8-4f2c-9ce4-139fd544a578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_100b0b17-64c8-4f2c-9ce4-139fd544a578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6c8e91a8-9d59-4688-9e4f-19935e1d64d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6c8e91a8-9d59-4688-9e4f-19935e1d64d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1ebf7292-6697-46be-9bd4-e691a40652cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ee5b8-2412-424c-ba36-ea4281a3c4fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1ebf7292-6697-46be-9bd4-e691a40652cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f6b7bd0-4740-4de4-af13-f53a5078bcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_7226dcfc-2e7f-4268-a29a-4ee46468c665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f6b7bd0-4740-4de4-af13-f53a5078bcc2" xlink:to="loc_us-gaap_OperatingLeaseExpense_7226dcfc-2e7f-4268-a29a-4ee46468c665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_4591d02f-060e-40d9-9ddc-1fc56bbd7f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f6b7bd0-4740-4de4-af13-f53a5078bcc2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_4591d02f-060e-40d9-9ddc-1fc56bbd7f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_6cb9a3c2-cb9b-40a8-9174-e622ef2f7108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f6b7bd0-4740-4de4-af13-f53a5078bcc2" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_6cb9a3c2-cb9b-40a8-9174-e622ef2f7108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9ba1ec6b-3143-4c28-a9f2-f6c690045f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f6b7bd0-4740-4de4-af13-f53a5078bcc2" xlink:to="loc_us-gaap_LeaseCost_9ba1ec6b-3143-4c28-a9f2-f6c690045f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_7f87ed16-918d-46cf-a084-ae3100a985f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f6b7bd0-4740-4de4-af13-f53a5078bcc2" xlink:to="loc_us-gaap_VariableLeaseCost_7f87ed16-918d-46cf-a084-ae3100a985f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d30f4b4d-274b-48b7-9808-94e8c68e4ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_a481cd45-6a6c-4432-8e64-0bd8dd873c61" xlink:href="exdx-20221231.xsd#exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d30f4b4d-274b-48b7-9808-94e8c68e4ced" xlink:to="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_a481cd45-6a6c-4432-8e64-0bd8dd873c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0b17cddb-43ee-4cbd-ab97-179fbb37ee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_a481cd45-6a6c-4432-8e64-0bd8dd873c61" xlink:to="loc_us-gaap_OperatingLeasePayments_0b17cddb-43ee-4cbd-ab97-179fbb37ee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_12477195-cc80-4ed4-9002-bc211b6b36e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_a481cd45-6a6c-4432-8e64-0bd8dd873c61" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_12477195-cc80-4ed4-9002-bc211b6b36e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_2a0d4d2d-89e7-4b6e-9e63-9a7f767f96cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_a481cd45-6a6c-4432-8e64-0bd8dd873c61" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_2a0d4d2d-89e7-4b6e-9e63-9a7f767f96cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_00b9ff3c-973a-4bb6-8d87-aff1a0a60271" xlink:href="exdx-20221231.xsd#exdx_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d30f4b4d-274b-48b7-9808-94e8c68e4ced" xlink:to="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_00b9ff3c-973a-4bb6-8d87-aff1a0a60271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0cc11c2b-0896-495c-9d63-9280ee3d7235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_00b9ff3c-973a-4bb6-8d87-aff1a0a60271" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0cc11c2b-0896-495c-9d63-9280ee3d7235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_213daecc-76a8-4df3-948f-41d57b6d8a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_00b9ff3c-973a-4bb6-8d87-aff1a0a60271" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_213daecc-76a8-4df3-948f-41d57b6d8a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageDiscountRateAbstract_a2570831-2e86-431a-a031-f283d2cb1bb7" xlink:href="exdx-20221231.xsd#exdx_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d30f4b4d-274b-48b7-9808-94e8c68e4ced" xlink:to="loc_exdx_WeightedAverageDiscountRateAbstract_a2570831-2e86-431a-a031-f283d2cb1bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6dc8c4d0-bf32-4f42-a5ec-357f9536cf93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageDiscountRateAbstract_a2570831-2e86-431a-a031-f283d2cb1bb7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6dc8c4d0-bf32-4f42-a5ec-357f9536cf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_385ddd31-9fbe-4ead-bac1-21c7fed25448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageDiscountRateAbstract_a2570831-2e86-431a-a031-f283d2cb1bb7" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_385ddd31-9fbe-4ead-bac1-21c7fed25448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1830fa05-50d1-42c0-b013-83aaed09a9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1830fa05-50d1-42c0-b013-83aaed09a9b4" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b81584fc-5e0c-4871-b3a1-44311b33b7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b81584fc-5e0c-4871-b3a1-44311b33b7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_db484eb1-1e9d-42db-bed5-94b53bbd4536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_db484eb1-1e9d-42db-bed5-94b53bbd4536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3129a005-fc1c-4d5c-a1d1-904cee3b610d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3129a005-fc1c-4d5c-a1d1-904cee3b610d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4309b409-4a1f-44e1-bd82-a3ecd2eeb474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4309b409-4a1f-44e1-bd82-a3ecd2eeb474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_d33b1e4f-1e69-4e61-bad8-cb4adea9f2c0" xlink:href="exdx-20221231.xsd#exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_d33b1e4f-1e69-4e61-bad8-cb4adea9f2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f46be453-128b-43b2-8638-c28ab7565fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f46be453-128b-43b2-8638-c28ab7565fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7549a84f-3b1f-4a82-b752-b84e9d243729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7549a84f-3b1f-4a82-b752-b84e9d243729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_247d9668-3f7a-47a1-9952-90b0ecd419d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_us-gaap_OperatingLeaseLiability_247d9668-3f7a-47a1-9952-90b0ecd419d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_eb5166cb-233b-4c4c-97b8-c5d7151d0aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_eb5166cb-233b-4c4c-97b8-c5d7151d0aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_441540a5-76cf-4493-b842-e3a25f8aeb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36f11730-cfa5-4e42-93fa-2305114de2b9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_441540a5-76cf-4493-b842-e3a25f8aeb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1830fa05-50d1-42c0-b013-83aaed09a9b4" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_9177be4c-9c08-4b68-bd23-986d2c0bbd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_9177be4c-9c08-4b68-bd23-986d2c0bbd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_5016baf6-d6a5-4723-9704-af3d986ad615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_5016baf6-d6a5-4723-9704-af3d986ad615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4be6bc96-4e08-4eb9-abe1-88245ec606ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4be6bc96-4e08-4eb9-abe1-88245ec606ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_373068fe-b0b6-4901-8984-e0e8817f5d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_373068fe-b0b6-4901-8984-e0e8817f5d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_f2cb4949-1de8-4218-b156-b292bb37b910" xlink:href="exdx-20221231.xsd#exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour_f2cb4949-1de8-4218-b156-b292bb37b910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8b17440f-b499-4787-aa47-cc75e9b7e4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8b17440f-b499-4787-aa47-cc75e9b7e4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_23641860-0772-4815-bf12-1b0adb25e4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_23641860-0772-4815-bf12-1b0adb25e4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5b913b95-1126-4b60-94c4-1cc40bfd2f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_us-gaap_FinanceLeaseLiability_5b913b95-1126-4b60-94c4-1cc40bfd2f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_91724925-4307-415d-b189-024c141f1203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_91724925-4307-415d-b189-024c141f1203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_26150dc2-dd67-4bc9-a9e5-71f8ec162845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5456448b-d8a8-461b-8c75-1779a99ae3f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_26150dc2-dd67-4bc9-a9e5-71f8ec162845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bee4b89c-9a66-458f-8117-c272ea04467c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4d91de8e-ea20-4ee0-9cc5-2b3ee5a7e348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bee4b89c-9a66-458f-8117-c272ea04467c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4d91de8e-ea20-4ee0-9cc5-2b3ee5a7e348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_33bfe150-3a4f-4c65-a79f-71c6ffeb388b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bee4b89c-9a66-458f-8117-c272ea04467c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_33bfe150-3a4f-4c65-a79f-71c6ffeb388b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_e2a83d9e-de6a-4fdd-93e6-ee8b7b8aa9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bee4b89c-9a66-458f-8117-c272ea04467c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_e2a83d9e-de6a-4fdd-93e6-ee8b7b8aa9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4f2c8295-67ac-4359-8d6b-cf7ae77d8c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bee4b89c-9a66-458f-8117-c272ea04467c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4f2c8295-67ac-4359-8d6b-cf7ae77d8c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5e85dba0-a263-48a1-9156-21d68feb11f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bee4b89c-9a66-458f-8117-c272ea04467c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5e85dba0-a263-48a1-9156-21d68feb11f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_55e8dba4-3a49-427f-a8c4-31968996ebcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bee4b89c-9a66-458f-8117-c272ea04467c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_55e8dba4-3a49-427f-a8c4-31968996ebcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b7496bb9-e5e9-41b4-88c8-d9680c617496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bee4b89c-9a66-458f-8117-c272ea04467c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b7496bb9-e5e9-41b4-88c8-d9680c617496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6e15d9cc-3b5e-47f3-8bea-f146c9aba988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6e15d9cc-3b5e-47f3-8bea-f146c9aba988" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25544aa2-f78a-4cd3-ae1b-e0e7fbe6841e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25544aa2-f78a-4cd3-ae1b-e0e7fbe6841e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b082c2a-7be2-4f59-aafb-4875b6a7881e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25544aa2-f78a-4cd3-ae1b-e0e7fbe6841e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b082c2a-7be2-4f59-aafb-4875b6a7881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48552ab7-c421-4693-885c-005fb7f72458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b082c2a-7be2-4f59-aafb-4875b6a7881e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48552ab7-c421-4693-885c-005fb7f72458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_139942b0-4d25-4f6d-b611-ff4e95391fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_139942b0-4d25-4f6d-b611-ff4e95391fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_139942b0-4d25-4f6d-b611-ff4e95391fa6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1aa9f226-a7e7-4402-a6b7-b9ec44acc8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1aa9f226-a7e7-4402-a6b7-b9ec44acc8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b69031e4-0e66-47c6-853d-e3f671981252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b69031e4-0e66-47c6-853d-e3f671981252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a899dc8a-8f78-451c-befd-8654fa671905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_30c42195-ec8d-4dd6-9509-9f5d87337ea7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a899dc8a-8f78-451c-befd-8654fa671905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3e283565-cdbe-48e5-99c3-9ce883c50d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3e283565-cdbe-48e5-99c3-9ce883c50d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84c08f3f-0107-4122-99b0-e12ed17203a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3e283565-cdbe-48e5-99c3-9ce883c50d28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84c08f3f-0107-4122-99b0-e12ed17203a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b1ea9992-0335-433c-854f-eba7bdac0cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84c08f3f-0107-4122-99b0-e12ed17203a2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b1ea9992-0335-433c-854f-eba7bdac0cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_25f861e2-9e5e-4d26-b424-72be6d04fd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_84c08f3f-0107-4122-99b0-e12ed17203a2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_25f861e2-9e5e-4d26-b424-72be6d04fd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7f07d44a-e6c3-4d9e-b2ba-03cd02f37b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_7f07d44a-e6c3-4d9e-b2ba-03cd02f37b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ab7fee0-5409-4877-a4e0-0305e75cd51e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7f07d44a-e6c3-4d9e-b2ba-03cd02f37b1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ab7fee0-5409-4877-a4e0-0305e75cd51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_4982f39b-aa4c-4e5a-b0fd-59df77465b3c" xlink:href="exdx-20221231.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ab7fee0-5409-4877-a4e0-0305e75cd51e" xlink:to="loc_exdx_Term2017Member_4982f39b-aa4c-4e5a-b0fd-59df77465b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_623f115d-355f-43cb-9f0f-f4ae6a54b2ba" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_46a637f5-2d29-4e79-babf-f073379b30fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:to="loc_us-gaap_LongTermDebt_46a637f5-2d29-4e79-babf-f073379b30fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_e3b324ff-5e63-400d-b18e-007c51542831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:to="loc_us-gaap_DebtInstrumentFairValue_e3b324ff-5e63-400d-b18e-007c51542831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_c54f59dc-74a3-49be-a95f-18c344360700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_af2e48da-0706-45c6-abc4-b10148cd60d1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_c54f59dc-74a3-49be-a95f-18c344360700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3eefdcce-0a19-4621-a753-f9f9ce7ae386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c54f59dc-74a3-49be-a95f-18c344360700" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3eefdcce-0a19-4621-a753-f9f9ce7ae386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ef1a746c-0c2c-4143-a8f7-6c2252162fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c54f59dc-74a3-49be-a95f-18c344360700" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ef1a746c-0c2c-4143-a8f7-6c2252162fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e37d7968-2201-4e8e-acfa-f19f1bd8b80f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e37d7968-2201-4e8e-acfa-f19f1bd8b80f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_36d9a64f-28a6-4a17-8bd6-a529d30ef951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_36d9a64f-28a6-4a17-8bd6-a529d30ef951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ac9c782f-4e10-4a67-93b0-522900cb57b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_36d9a64f-28a6-4a17-8bd6-a529d30ef951" xlink:to="loc_us-gaap_EquityComponentDomain_ac9c782f-4e10-4a67-93b0-522900cb57b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2c075ad9-3d30-4c28-b956-18b70dd3a9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ac9c782f-4e10-4a67-93b0-522900cb57b1" xlink:to="loc_us-gaap_CommonStockMember_2c075ad9-3d30-4c28-b956-18b70dd3a9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf899809-0979-442d-a0c5-f0fb8dddb921" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:to="loc_srt_CounterpartyNameAxis_bf899809-0979-442d-a0c5-f0fb8dddb921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cb6acf0-9216-4034-9a55-ad43ee77a343" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bf899809-0979-442d-a0c5-f0fb8dddb921" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cb6acf0-9216-4034-9a55-ad43ee77a343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangingStockholdersMember_d96faa35-63e7-4bfc-bf8d-b74a238eba3a" xlink:href="exdx-20221231.xsd#exdx_ExchangingStockholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cb6acf0-9216-4034-9a55-ad43ee77a343" xlink:to="loc_exdx_ExchangingStockholdersMember_d96faa35-63e7-4bfc-bf8d-b74a238eba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_01586c07-ab56-4243-b1ed-8b24bad96c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_01586c07-ab56-4243-b1ed-8b24bad96c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e39c3935-2bae-48b7-ab9a-fb3b188684c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01586c07-ab56-4243-b1ed-8b24bad96c0d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e39c3935-2bae-48b7-ab9a-fb3b188684c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember_b3f8d2c5-ad64-408a-b7dc-bb0e480b55c9" xlink:href="exdx-20221231.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e39c3935-2bae-48b7-ab9a-fb3b188684c8" xlink:to="loc_exdx_CowenEquityDistributionAgreementMember_b3f8d2c5-ad64-408a-b7dc-bb0e480b55c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d2ff23c0-5c63-4533-8379-876a56751b0a" xlink:to="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d48aab6-7b8b-4741-9e04-0276bf197754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d48aab6-7b8b-4741-9e04-0276bf197754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5d289678-15f1-4166-9e0f-d686d5d0c338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5d289678-15f1-4166-9e0f-d686d5d0c338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87f4efc2-94f6-4d1b-9511-461fd9368d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87f4efc2-94f6-4d1b-9511-461fd9368d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_4657cb22-42b7-4e92-93e6-0360ef75f1a7" xlink:href="exdx-20221231.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_exdx_StockIssuanceCosts_4657cb22-42b7-4e92-93e6-0360ef75f1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_6e414e77-d87b-4494-9444-d90e9b0e8698" xlink:href="exdx-20221231.xsd#exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_6e414e77-d87b-4494-9444-d90e9b0e8698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b71a813f-a5f8-4b78-8ad3-d7ff3ec81c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b71a813f-a5f8-4b78-8ad3-d7ff3ec81c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_f5bf5719-0bfb-4fc1-9d85-121e68b42619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_f5bf5719-0bfb-4fc1-9d85-121e68b42619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_e73d0909-e6b8-424a-aaa3-e53d03540236" xlink:href="exdx-20221231.xsd#exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_e73d0909-e6b8-424a-aaa3-e53d03540236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_4a9d6005-5ba1-4ff0-b2bd-e0a125b22be4" xlink:href="exdx-20221231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1232ad0d-fd9a-4d46-921c-36be654c866e" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_4a9d6005-5ba1-4ff0-b2bd-e0a125b22be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ef07209d-f7ef-478e-a4e0-d441783d3f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2180bf92-3d6d-4447-92ac-41b644107653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef07209d-f7ef-478e-a4e0-d441783d3f39" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2180bf92-3d6d-4447-92ac-41b644107653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6fe5a06a-0403-4c75-981b-09ee31c8d863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2180bf92-3d6d-4447-92ac-41b644107653" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6fe5a06a-0403-4c75-981b-09ee31c8d863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6fe5a06a-0403-4c75-981b-09ee31c8d863" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_da4e7b40-bc72-43d0-98af-06d795a81e7b" xlink:href="exdx-20221231.xsd#exdx_ExpirationJan192026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationJan192026Member_da4e7b40-bc72-43d0-98af-06d795a81e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_11d543e2-4126-4f62-8e0e-aeb0d002ce95" xlink:href="exdx-20221231.xsd#exdx_ExpirationMar312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationMar312026Member_11d543e2-4126-4f62-8e0e-aeb0d002ce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_8e679489-90e0-47c1-84bd-8b88a9fd3a6c" xlink:href="exdx-20221231.xsd#exdx_ExpirationApr12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationApr12026Member_8e679489-90e0-47c1-84bd-8b88a9fd3a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_88c42062-d23b-492f-a475-e5c9cb9cbcbf" xlink:href="exdx-20221231.xsd#exdx_ExpirationSep72024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationSep72024Member_88c42062-d23b-492f-a475-e5c9cb9cbcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_483ee9fd-8d0b-4dbc-bcf1-e19c810a9f40" xlink:href="exdx-20221231.xsd#exdx_ExpirationDec72025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_ExpirationDec72025Member_483ee9fd-8d0b-4dbc-bcf1-e19c810a9f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_cda2abf4-fe04-4f44-bd39-374a1a2b12b2" xlink:href="exdx-20221231.xsd#exdx_NoExpirationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_101284c6-da26-45ec-8d1d-8d5ec753e29d" xlink:to="loc_exdx_NoExpirationMember_cda2abf4-fe04-4f44-bd39-374a1a2b12b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f0f73b13-0e42-4e4f-996a-aeb4b3eaa153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2180bf92-3d6d-4447-92ac-41b644107653" xlink:to="loc_us-gaap_ClassOfStockLineItems_f0f73b13-0e42-4e4f-996a-aeb4b3eaa153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0c64184f-2191-474f-9891-35ec2b7867d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0f73b13-0e42-4e4f-996a-aeb4b3eaa153" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0c64184f-2191-474f-9891-35ec2b7867d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a1d33e09-2af6-4672-8b54-a9cce688281d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0f73b13-0e42-4e4f-996a-aeb4b3eaa153" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a1d33e09-2af6-4672-8b54-a9cce688281d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f06cda8-b878-427c-8867-ee81b77100e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f06cda8-b878-427c-8867-ee81b77100e3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6811f074-775e-4ffe-a122-cc7f175c0a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:to="loc_us-gaap_PlanNameAxis_6811f074-775e-4ffe-a122-cc7f175c0a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_465de480-d4b9-4f94-a601-5eee3d4cccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6811f074-775e-4ffe-a122-cc7f175c0a86" xlink:to="loc_us-gaap_PlanNameDomain_465de480-d4b9-4f94-a601-5eee3d4cccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_9bd17c01-1a30-43f4-ab24-dac34a732b44" xlink:href="exdx-20221231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_465de480-d4b9-4f94-a601-5eee3d4cccc2" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_9bd17c01-1a30-43f4-ab24-dac34a732b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_65b040c8-783b-4aea-aa65-75dd143159e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:to="loc_us-gaap_AwardTypeAxis_65b040c8-783b-4aea-aa65-75dd143159e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_65b040c8-783b-4aea-aa65-75dd143159e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9f51e75f-9058-48b8-840c-230fa270dd06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9f51e75f-9058-48b8-840c-230fa270dd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_989d7cba-af90-4216-8a58-83c0966e06cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:to="loc_us-gaap_EmployeeStockMember_989d7cba-af90-4216-8a58-83c0966e06cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_10ff4d69-454d-4f48-a7f2-bdc782eaf3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_103ea58f-c10e-4455-9c71-fcc76bb5cb35" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_10ff4d69-454d-4f48-a7f2-bdc782eaf3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a69a6685-1b51-4ca5-9cd7-d395572a37e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a69a6685-1b51-4ca5-9cd7-d395572a37e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fbde0e8c-f08b-47e1-bfb7-0f2cb2979306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a69a6685-1b51-4ca5-9cd7-d395572a37e8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fbde0e8c-f08b-47e1-bfb7-0f2cb2979306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_494c984a-4859-4514-a675-50a05f6e14f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fbde0e8c-f08b-47e1-bfb7-0f2cb2979306" xlink:to="loc_us-gaap_SubsequentEventMember_494c984a-4859-4514-a675-50a05f6e14f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb150387-fefa-4b38-98d5-ead8f2a6b916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dba9f867-3beb-488e-84df-5f41a122d180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dba9f867-3beb-488e-84df-5f41a122d180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfd62bfb-4059-41da-bac1-83af94c829e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfd62bfb-4059-41da-bac1-83af94c829e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_15c9585c-4dbf-41a7-8f0d-720971be4533" xlink:href="exdx-20221231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_15c9585c-4dbf-41a7-8f0d-720971be4533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e53f45c3-371a-44f2-ad2d-25907e02c6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e53f45c3-371a-44f2-ad2d-25907e02c6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_0a75203e-dd37-4d55-bd08-2c304b44d2bd" xlink:href="exdx-20221231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_0a75203e-dd37-4d55-bd08-2c304b44d2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_34c14753-791b-4140-ba45-18fb2e9ec979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_34c14753-791b-4140-ba45-18fb2e9ec979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f60052b-f6d0-414a-9934-92e3473cdb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f60052b-f6d0-414a-9934-92e3473cdb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a4f0222-7593-4910-b4db-fb1cdfe3aa85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a4f0222-7593-4910-b4db-fb1cdfe3aa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b46de53f-b887-406f-a173-ee9c44f31897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b46de53f-b887-406f-a173-ee9c44f31897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_106dce59-5d23-4d43-b92c-5ef1ec942cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_106dce59-5d23-4d43-b92c-5ef1ec942cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_6688429d-e790-4a2c-b3e1-f1578be45b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_6688429d-e790-4a2c-b3e1-f1578be45b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a0bbafca-6f01-4912-bd03-1bef2b9dad86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a0bbafca-6f01-4912-bd03-1bef2b9dad86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_da6e0ba7-9e1e-43c0-8850-015644d2ba98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_da6e0ba7-9e1e-43c0-8850-015644d2ba98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f36b73c0-8859-4a20-873c-5f72786c6c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f36b73c0-8859-4a20-873c-5f72786c6c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c0562a6-f204-4def-b3eb-dd145743c279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c0562a6-f204-4def-b3eb-dd145743c279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_07b786a1-c32b-4421-9b8b-a1c795474b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18c85f5-360d-44fa-bf17-a6c0c3a0772b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_07b786a1-c32b-4421-9b8b-a1c795474b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f665551-0fdb-4ea7-91d4-72ca6d330a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f665551-0fdb-4ea7-91d4-72ca6d330a1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1c06a4ec-e85d-4e7a-9f86-10634e95d05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1c06a4ec-e85d-4e7a-9f86-10634e95d05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_82ecdba0-c9fc-4dc0-a8a5-96953e544ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_82ecdba0-c9fc-4dc0-a8a5-96953e544ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1efc736e-bc0f-495b-9b47-92e6961f759b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1efc736e-bc0f-495b-9b47-92e6961f759b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c7286542-ef1d-4829-8cad-3b156fa681b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c7286542-ef1d-4829-8cad-3b156fa681b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_486d2733-c81e-4dbc-bc67-8d478c1b4d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_486d2733-c81e-4dbc-bc67-8d478c1b4d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_834342aa-91f9-4854-95ef-176035a59249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_834342aa-91f9-4854-95ef-176035a59249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8c81a255-d1cd-4b8e-9824-3da2b88bed06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8c81a255-d1cd-4b8e-9824-3da2b88bed06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_eed490a6-66fc-4355-9e66-0fbf8c06c102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0c39ad7d-0624-4d31-8418-e1297ad03f50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_eed490a6-66fc-4355-9e66-0fbf8c06c102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f665551-0fdb-4ea7-91d4-72ca6d330a1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5feed478-72d2-41ee-8bf0-e25ea8942fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5feed478-72d2-41ee-8bf0-e25ea8942fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7b1f2dd9-07a5-4977-afe8-2002c32f2736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7b1f2dd9-07a5-4977-afe8-2002c32f2736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ea326205-9a7f-40c2-995b-5ac347c2d762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ea326205-9a7f-40c2-995b-5ac347c2d762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_413f0bdb-dbff-47e2-b88c-4f3280c4ef82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_413f0bdb-dbff-47e2-b88c-4f3280c4ef82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c48f8f00-7172-400d-9567-dc05b137da1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c48f8f00-7172-400d-9567-dc05b137da1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1964c12d-25dc-45df-a7c8-a0f2c94c6fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1964c12d-25dc-45df-a7c8-a0f2c94c6fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_492a322d-efd1-4ba6-a94a-dfc587c38b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_492a322d-efd1-4ba6-a94a-dfc587c38b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98a69208-7696-41ec-be75-737f24892055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f74dfdbb-3f74-473e-a208-68acf7514cd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98a69208-7696-41ec-be75-737f24892055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7ff35a2-69a2-44ec-9e79-98f190de350a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f665551-0fdb-4ea7-91d4-72ca6d330a1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7ff35a2-69a2-44ec-9e79-98f190de350a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019b4773-07a5-4784-8817-c82b2aea5519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7ff35a2-69a2-44ec-9e79-98f190de350a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019b4773-07a5-4784-8817-c82b2aea5519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1b8066e0-5ea8-4c42-8176-0f8bda1aee21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7ff35a2-69a2-44ec-9e79-98f190de350a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1b8066e0-5ea8-4c42-8176-0f8bda1aee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9115fcef-99b2-40a5-9773-f8fde1e5e736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7ff35a2-69a2-44ec-9e79-98f190de350a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9115fcef-99b2-40a5-9773-f8fde1e5e736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1119cd6b-51a4-406b-befe-9dd4a397528b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7ff35a2-69a2-44ec-9e79-98f190de350a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1119cd6b-51a4-406b-befe-9dd4a397528b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4d775f59-2b85-4099-a9b7-77fce5a8e27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7ff35a2-69a2-44ec-9e79-98f190de350a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4d775f59-2b85-4099-a9b7-77fce5a8e27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0bf15e31-615b-446e-aada-bd9ab7a2559a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a7ff35a2-69a2-44ec-9e79-98f190de350a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0bf15e31-615b-446e-aada-bd9ab7a2559a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9fce526-7215-4161-ac26-33a42c9e37af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6de0a93-8e20-4569-b014-66fac01e853e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9fce526-7215-4161-ac26-33a42c9e37af" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6de0a93-8e20-4569-b014-66fac01e853e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e1856633-51ad-4ff4-ae85-3e9e40b8ec26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6de0a93-8e20-4569-b014-66fac01e853e" xlink:to="loc_us-gaap_AwardTypeAxis_e1856633-51ad-4ff4-ae85-3e9e40b8ec26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24d0cb5d-94ee-4729-bba0-fb1ce5870a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e1856633-51ad-4ff4-ae85-3e9e40b8ec26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24d0cb5d-94ee-4729-bba0-fb1ce5870a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e92e24e1-23d5-426f-8b27-d8806424a702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24d0cb5d-94ee-4729-bba0-fb1ce5870a4d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e92e24e1-23d5-426f-8b27-d8806424a702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6de0a93-8e20-4569-b014-66fac01e853e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_539953b4-17ad-4119-b03a-d3a9f22a1e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_539953b4-17ad-4119-b03a-d3a9f22a1e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_713f1111-15cd-4470-8650-4345ace2563d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_713f1111-15cd-4470-8650-4345ace2563d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70d253ae-fab5-4cc1-a4ed-319bf37707b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70d253ae-fab5-4cc1-a4ed-319bf37707b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_00f41b33-9952-4ab5-b85b-a1ddc115fd71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_00f41b33-9952-4ab5-b85b-a1ddc115fd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d4e6d5d-0c87-4547-af7a-669c30a58734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e884da49-4337-4913-bcb2-5b8ed229684d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d4e6d5d-0c87-4547-af7a-669c30a58734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b7c22b16-3034-47c1-95ea-cbad1187034c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b7c22b16-3034-47c1-95ea-cbad1187034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cc5aba5b-3cde-49a3-86d1-48b5640d2031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cc5aba5b-3cde-49a3-86d1-48b5640d2031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f424690d-a813-4c0e-8bcd-180200bb6cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f424690d-a813-4c0e-8bcd-180200bb6cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1c292905-a8a1-4333-89df-0fc191a3480d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1c292905-a8a1-4333-89df-0fc191a3480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16576a7d-9d11-421b-8790-e86714bc07a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891f767c-39c0-4e7c-b727-2c8624abc84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16576a7d-9d11-421b-8790-e86714bc07a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4896bc9d-3177-44c0-b252-21ee8ec4d4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_768c686a-81da-47d2-adbb-aa6c2fb85333" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4896bc9d-3177-44c0-b252-21ee8ec4d4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_406ab73d-e57a-43d3-b638-be9195035f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4896bc9d-3177-44c0-b252-21ee8ec4d4e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_406ab73d-e57a-43d3-b638-be9195035f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_071379d9-7c2f-418d-bc2c-ae8846186cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38fd4453-5cba-459b-8333-d86109ef6169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_071379d9-7c2f-418d-bc2c-ae8846186cda" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38fd4453-5cba-459b-8333-d86109ef6169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8bfb0a67-7554-48c8-8d1b-d6cd675b2b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38fd4453-5cba-459b-8333-d86109ef6169" xlink:to="loc_us-gaap_AwardTypeAxis_8bfb0a67-7554-48c8-8d1b-d6cd675b2b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f91ea6a5-b0e2-44da-a50b-2478cd81ee9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8bfb0a67-7554-48c8-8d1b-d6cd675b2b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f91ea6a5-b0e2-44da-a50b-2478cd81ee9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e9564a4c-5187-4d9a-bf0f-be4154e21f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f91ea6a5-b0e2-44da-a50b-2478cd81ee9f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e9564a4c-5187-4d9a-bf0f-be4154e21f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_877c8588-70d9-4b6f-8838-5403fda605d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f91ea6a5-b0e2-44da-a50b-2478cd81ee9f" xlink:to="loc_us-gaap_EmployeeStockMember_877c8588-70d9-4b6f-8838-5403fda605d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a33d7668-c32a-482c-a9dd-dae54761296b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38fd4453-5cba-459b-8333-d86109ef6169" xlink:to="loc_srt_RangeAxis_a33d7668-c32a-482c-a9dd-dae54761296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e7a4847-c697-4008-80cf-7998e5ef485c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a33d7668-c32a-482c-a9dd-dae54761296b" xlink:to="loc_srt_RangeMember_7e7a4847-c697-4008-80cf-7998e5ef485c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f00dc955-d6d5-43fa-b76d-b2b8fdd4e1eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7e7a4847-c697-4008-80cf-7998e5ef485c" xlink:to="loc_srt_MinimumMember_f00dc955-d6d5-43fa-b76d-b2b8fdd4e1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c604956e-0d7b-42cf-9c6b-f8820f421477" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7e7a4847-c697-4008-80cf-7998e5ef485c" xlink:to="loc_srt_MaximumMember_c604956e-0d7b-42cf-9c6b-f8820f421477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38fd4453-5cba-459b-8333-d86109ef6169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_aed85f58-87fc-4f9f-b9c9-732bbb740fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_aed85f58-87fc-4f9f-b9c9-732bbb740fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_46c5aa8b-e9f1-45cb-8ff8-eeff90b3e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_46c5aa8b-e9f1-45cb-8ff8-eeff90b3e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_586eb51d-b756-486e-8ece-246e831c49a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_586eb51d-b756-486e-8ece-246e831c49a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_acc99d30-ee23-4d00-a8ea-fdc3cbbb1826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_acc99d30-ee23-4d00-a8ea-fdc3cbbb1826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80777dfa-1b94-45b6-a22f-1e759bc7cc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80777dfa-1b94-45b6-a22f-1e759bc7cc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7a90c207-71ad-4f11-b293-81645d4553a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba099094-7c44-4835-af83-a0e4c925da79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7a90c207-71ad-4f11-b293-81645d4553a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_883f3b7d-cffa-4af5-89d1-a9c50535f991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cafa3b0-e1c4-4f6d-bb57-904c95fd9040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_883f3b7d-cffa-4af5-89d1-a9c50535f991" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cafa3b0-e1c4-4f6d-bb57-904c95fd9040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a83f5cc5-5664-476b-bba1-bb3e0b8ae91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cafa3b0-e1c4-4f6d-bb57-904c95fd9040" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a83f5cc5-5664-476b-bba1-bb3e0b8ae91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a83f5cc5-5664-476b-bba1-bb3e0b8ae91f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_4b29c8e7-74ad-4fa2-bfe8-cb1bae370862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:to="loc_us-gaap_CostOfSalesMember_4b29c8e7-74ad-4fa2-bfe8-cb1bae370862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_913b70af-e233-401e-94df-044ea7d721f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_913b70af-e233-401e-94df-044ea7d721f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f51103b8-1110-4e9e-9726-f156d33e99be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f512df19-59af-448d-8284-c46f6811b8bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f51103b8-1110-4e9e-9726-f156d33e99be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49062c13-324d-4269-9210-bd1a2754ef51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cafa3b0-e1c4-4f6d-bb57-904c95fd9040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49062c13-324d-4269-9210-bd1a2754ef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5f1034eb-0f5e-4f13-b3ef-2a5ccaa9546a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49062c13-324d-4269-9210-bd1a2754ef51" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5f1034eb-0f5e-4f13-b3ef-2a5ccaa9546a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#StockOptionPlanCommonStockReservedForFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b3819da-4b95-4392-8eec-4ced06f6eb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d1c426e-a1ba-48a6-b9c6-2802d796b167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b3819da-4b95-4392-8eec-4ced06f6eb7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d1c426e-a1ba-48a6-b9c6-2802d796b167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_745e519d-d5f6-4ba1-b3d1-5929e850f219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d1c426e-a1ba-48a6-b9c6-2802d796b167" xlink:to="loc_us-gaap_AwardTypeAxis_745e519d-d5f6-4ba1-b3d1-5929e850f219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_745e519d-d5f6-4ba1-b3d1-5929e850f219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_37753c4d-237c-4d24-bd57-08ba627c85ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_us-gaap_WarrantMember_37753c4d-237c-4d24-bd57-08ba627c85ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29a2f712-11fe-4576-8e85-909f5e17e705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29a2f712-11fe-4576-8e85-909f5e17e705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2cbfd0a4-3ff6-4927-898a-976bf0ed1657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2cbfd0a4-3ff6-4927-898a-976bf0ed1657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_cbe2af65-92e1-40f2-bd61-aebf0a8a4552" xlink:href="exdx-20221231.xsd#exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_cbe2af65-92e1-40f2-bd61-aebf0a8a4552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5ccc9b2d-032c-4c3e-9df0-bab4fc9666be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dde8a-471c-47ec-b031-c59cffb30593" xlink:to="loc_us-gaap_EmployeeStockMember_5ccc9b2d-032c-4c3e-9df0-bab4fc9666be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d8c3a07-bfad-4d3d-a756-7c6557ae968e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d1c426e-a1ba-48a6-b9c6-2802d796b167" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d8c3a07-bfad-4d3d-a756-7c6557ae968e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f4676c53-a0f8-4dca-90c3-1b1bec3d50f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d8c3a07-bfad-4d3d-a756-7c6557ae968e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f4676c53-a0f8-4dca-90c3-1b1bec3d50f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43745b0b-26a3-4474-980b-c0aa16019be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_e185b1f9-df7f-4f92-b41c-a2e0a4f3f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43745b0b-26a3-4474-980b-c0aa16019be5" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_e185b1f9-df7f-4f92-b41c-a2e0a4f3f8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3d89cec3-808b-4c60-88df-3ca4718d248a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_e185b1f9-df7f-4f92-b41c-a2e0a4f3f8e4" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3d89cec3-808b-4c60-88df-3ca4718d248a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_39c6a9e5-111f-43b3-8aa7-04d4566e92c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_e185b1f9-df7f-4f92-b41c-a2e0a4f3f8e4" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_39c6a9e5-111f-43b3-8aa7-04d4566e92c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b93d3f4e-ff01-4bb7-b9a3-cc03b322e4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_e185b1f9-df7f-4f92-b41c-a2e0a4f3f8e4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b93d3f4e-ff01-4bb7-b9a3-cc03b322e4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_22405a7a-6a6b-46d9-a679-1d9370a119f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43745b0b-26a3-4474-980b-c0aa16019be5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_22405a7a-6a6b-46d9-a679-1d9370a119f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_aff3a894-9705-41be-9c50-ffc67581aa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_22405a7a-6a6b-46d9-a679-1d9370a119f1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_aff3a894-9705-41be-9c50-ffc67581aa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ee7313b2-ec17-47a0-8386-3d9ee227b795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_22405a7a-6a6b-46d9-a679-1d9370a119f1" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ee7313b2-ec17-47a0-8386-3d9ee227b795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fdd73f92-c925-462e-9da9-cea0d92444b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_22405a7a-6a6b-46d9-a679-1d9370a119f1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fdd73f92-c925-462e-9da9-cea0d92444b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92bfe2a3-41e3-498b-afd1-fe2633b164a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43745b0b-26a3-4474-980b-c0aa16019be5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92bfe2a3-41e3-498b-afd1-fe2633b164a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2484491d-004e-4f9a-a17a-db647f36dee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_38d7b27a-72aa-46e3-bc58-de0a903f689a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2484491d-004e-4f9a-a17a-db647f36dee5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_38d7b27a-72aa-46e3-bc58-de0a903f689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_cdcd4589-6584-4c26-a97a-057fdaa0f29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2484491d-004e-4f9a-a17a-db647f36dee5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_cdcd4589-6584-4c26-a97a-057fdaa0f29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_900cba46-79c7-45ab-9a44-145a0f31eb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2484491d-004e-4f9a-a17a-db647f36dee5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_900cba46-79c7-45ab-9a44-145a0f31eb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_409b9837-6525-47bb-8da8-a1afdedf2b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2484491d-004e-4f9a-a17a-db647f36dee5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_409b9837-6525-47bb-8da8-a1afdedf2b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_12584661-5f10-43a2-9010-9abf8ab23ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2484491d-004e-4f9a-a17a-db647f36dee5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_12584661-5f10-43a2-9010-9abf8ab23ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ecb93e98-e7b5-4248-8b16-1a5740edab51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2484491d-004e-4f9a-a17a-db647f36dee5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ecb93e98-e7b5-4248-8b16-1a5740edab51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_13348781-1350-4ce2-a3fe-27490b986620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2484491d-004e-4f9a-a17a-db647f36dee5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_13348781-1350-4ce2-a3fe-27490b986620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5cc908bb-ac4f-48d7-ab43-9089f2bbd7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5cc908bb-ac4f-48d7-ab43-9089f2bbd7d6" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5089f285-465f-4d47-b450-117f5fc29b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5089f285-465f-4d47-b450-117f5fc29b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4c3845b9-ac41-4e25-a840-a7af44f065ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4c3845b9-ac41-4e25-a840-a7af44f065ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_29aeedb3-6437-4b18-85e4-f0e011b6b5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_29aeedb3-6437-4b18-85e4-f0e011b6b5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f5fe8849-ec7b-470f-b36f-116f92354707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f5fe8849-ec7b-470f-b36f-116f92354707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_25881e15-02c7-4823-bfbe-b82cd581c6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_25881e15-02c7-4823-bfbe-b82cd581c6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d19d51d0-7e62-4bd5-9199-4803b02426e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d19d51d0-7e62-4bd5-9199-4803b02426e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsLeaseLiability_fb2d987c-51eb-4311-a428-c3fd5110653d" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_exdx_DeferredTaxAssetsLeaseLiability_fb2d987c-51eb-4311-a428-c3fd5110653d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_af52e170-dcf1-4aaf-a736-39b9f318f2bf" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_af52e170-dcf1-4aaf-a736-39b9f318f2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_82f2410c-27e8-40ff-9ab2-5840d4beee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_82f2410c-27e8-40ff-9ab2-5840d4beee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_66bde75d-84d4-48aa-abfd-e1ec57cf3d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_66bde75d-84d4-48aa-abfd-e1ec57cf3d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_63eb9880-8809-4014-8361-531b61917167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_1d1fcffa-4509-4dfa-8c3c-d1df991c0930" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_63eb9880-8809-4014-8361-531b61917167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_93da2ee8-db06-4af8-a61f-421bdfec2732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5cc908bb-ac4f-48d7-ab43-9089f2bbd7d6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_93da2ee8-db06-4af8-a61f-421bdfec2732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_a9ce5b7d-ba7a-48d2-929c-6bfd64d8b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_93da2ee8-db06-4af8-a61f-421bdfec2732" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_a9ce5b7d-ba7a-48d2-929c-6bfd64d8b2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_17d6c9cc-90e2-4f58-8b0f-0cb184344be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_93da2ee8-db06-4af8-a61f-421bdfec2732" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_17d6c9cc-90e2-4f58-8b0f-0cb184344be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_492a3db5-a227-4637-a168-753a115634c5" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_93da2ee8-db06-4af8-a61f-421bdfec2732" xlink:to="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_492a3db5-a227-4637-a168-753a115634c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_b42498c9-49fb-4921-8213-befa13ccd647" xlink:href="exdx-20221231.xsd#exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_93da2ee8-db06-4af8-a61f-421bdfec2732" xlink:to="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_b42498c9-49fb-4921-8213-befa13ccd647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ff4bbbf6-53e2-42e8-b05b-8f5576d17342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_93da2ee8-db06-4af8-a61f-421bdfec2732" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ff4bbbf6-53e2-42e8-b05b-8f5576d17342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_fd08d776-0970-4774-91dd-1ade82611d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5cc908bb-ac4f-48d7-ab43-9089f2bbd7d6" xlink:to="loc_us-gaap_DeferredTaxLiabilities_fd08d776-0970-4774-91dd-1ade82611d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxesChangeInValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ba77bd0a-0a82-4bfa-8136-3b13d8e34530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_fd04fcf2-415c-4177-b38b-9e3068e1883b" xlink:href="exdx-20221231.xsd#exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba77bd0a-0a82-4bfa-8136-3b13d8e34530" xlink:to="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_fd04fcf2-415c-4177-b38b-9e3068e1883b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_379c7fc1-1fd0-489b-b107-8f9a39cd2c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_fd04fcf2-415c-4177-b38b-9e3068e1883b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_379c7fc1-1fd0-489b-b107-8f9a39cd2c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c668daf6-145a-45dd-80df-a43b1db960fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_fd04fcf2-415c-4177-b38b-9e3068e1883b" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c668daf6-145a-45dd-80df-a43b1db960fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f4d02c6f-dd52-4490-b6cb-461cabb2d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_fd04fcf2-415c-4177-b38b-9e3068e1883b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f4d02c6f-dd52-4490-b6cb-461cabb2d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5efdf6d3-3931-47e6-a949-16b2424a2ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_79537b3e-c71b-4235-b0c9-9337255b63e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5efdf6d3-3931-47e6-a949-16b2424a2ab9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_79537b3e-c71b-4235-b0c9-9337255b63e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a6627371-326a-4ced-a6cb-07065065c298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5efdf6d3-3931-47e6-a949-16b2424a2ab9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a6627371-326a-4ced-a6cb-07065065c298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_2b09513c-b570-4c9d-9145-5903896a38dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5efdf6d3-3931-47e6-a949-16b2424a2ab9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_2b09513c-b570-4c9d-9145-5903896a38dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_053923d6-3fcb-4915-bba1-dc7f15148ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5efdf6d3-3931-47e6-a949-16b2424a2ab9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_053923d6-3fcb-4915-bba1-dc7f15148ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLossCarryforwardsNotUtilized_c9f4a789-8f66-4055-afea-e2b9477dbd82" xlink:href="exdx-20221231.xsd#exdx_OperatingLossCarryforwardsNotUtilized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5efdf6d3-3931-47e6-a949-16b2424a2ab9" xlink:to="loc_exdx_OperatingLossCarryforwardsNotUtilized_c9f4a789-8f66-4055-afea-e2b9477dbd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_addd0a4e-7b45-47a9-8345-c19e06f2ea33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5efdf6d3-3931-47e6-a949-16b2424a2ab9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_addd0a4e-7b45-47a9-8345-c19e06f2ea33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="exdx-20221231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_436544da-6563-44ef-8106-7a805c31a350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_13b15802-7264-43d8-955e-d5c10cb9c4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_436544da-6563-44ef-8106-7a805c31a350" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_13b15802-7264-43d8-955e-d5c10cb9c4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_3d8aaf02-a510-41be-be96-cea938a71ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_436544da-6563-44ef-8106-7a805c31a350" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_3d8aaf02-a510-41be-be96-cea938a71ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>exdx-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exdx-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "1 8H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W3_@Z[SO^
M OT\4?\ N(K\?Z_8#_@ZZ^_\!>/X?%'_ +B:\?\ ^#7_ )_;^\6 C/\ Q:'4
M/_3KI=?K61X[^SN$(XGEYN7F=KVO[[ZV?Y'Y=G&%^O<3NA>W,TKVO;W5TT/S
M?HK^P+RX_P#GFOY4>7'_ ,\U_*O+_P"(@R_Z!_\ R;_[4]/_ %(_Z?\ _DO_
M  3^/VBO[ O+C_YYK^5'EQ_\\U_*C_B(,O\ H'_\F_\ M0_U(_Z?_P#DO_!/
MC[_@@?\ \HG/A3Q_%KO_ *?;^OL,]::N ,"G5\#BZ_UK%5*UK<\G*V]KMNU^
MI]MA:/U;#0I7ORI*^U[*UP_"CC%%>'_MH_MC^'OV4]#T72(;-;WQ9XNN)+7P
MO93QL+=3'L\RXG<8Q''YJ?NPP>1G55V@O)'SOS,\?CL)E>%EB<3-1A'=OS:2
M7FVVDEW=CV\'VI217SSXB_:[\1?!?0=#^(/QROO#\GAS4HA_:,V@V\OGV!8C
M$Q5I9#)&O.Y%&_!RNXKL?W"P\-6-OXCN_%QO+J>ZO((X56:Y8PVT*Y.R*/[J
M%F8L[XWR'8&8K%$L:C)2V,\+F6&QLG"B]59M/1I-73MV?3T/)_VVM7_:*\-_
M 7Q=X_\ @Y\3-)\'MX8T6]U/[5)H(U.ZOH[>W2<*AE=(;1BT<\3;HKD%&1U*
M-E1\[_\ !'?]MO\ :*_:;\9>-O"/QX\5WWB)+#3;.[TO4!H]K;P6)\R5)(G:
M"*/+RY1D#9X@DQC!S['_ ,%7_C=8_!C]B3Q8JW,"ZEXJ@'A[2[>ZMY9%F-T"
MLX'EXV.MJ+EU9B%#HH.XD(WB7_! OX3:SX:^$'C3XR:C]HB@\4:S;V&GV\UB
MT:R16229N(Y"<2HSW,D7RKA6MF&XDD+G+F]JDGZGYSFF*QLO%#!83"UI<BIR
ME5BI-QM9J-XWM>]ME?5,_0"BBBM3]6"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@D#K7@_[
M6?\ P4&^#O[)GBWP]\+M3\)^+_'/CGQ2LDVD?#_X;Z(-4UAK- Y>]> R1B.W
M!1EWLP+%7V!A%*8[ITZE67+!7?\ EN9U:T*,>:;LCWBBOFGQ=_P4Y^%_P8^(
M&E^"/VK_ ()?$;X/VNM^1%I/C#QOI-C-H$UU-*T<5F^H:7>7D%O.0DTI6=HU
M2*%Y'9%*EOI/[1!_ST%5.C4IV<H[[=GZ,F&(H5-I>O=?>?C]_P '7?\ K/@+
M_N^*/_<37C__  :_$_\ #?WBS_LD.H?^G72Z]@_X.N_]9\!?]WQ1_P"XFO'_
M /@U^S_PW]XL_P"R0ZA_Z==+K]&P_P#R0;])?^EGP.*_Y+)>J_\ 24?O)111
M7YH?H@4444 ?/_[??_!0_P"%G_!.GP;H/Q$^,OPW\9ZQHNO:I)IT>H>$[*SF
M6TNA&94BF%Q=0$&1%E9-@<?N)-Q7Y=WS[\(/^#D3_@GY\5_B7H_PWU#2?'?A
M"/6+P6R^(O%VE6$&FV3L#L-Q+#>RM$C-M3S"FQ"P:1D0.Z_9W[0GP,\ ?M-_
M!3Q-\!?B?IWVC0_%6CS6%[MAB:2#>OR7$/FHZ+/$X26)RK;)(T<#*BOY@OVS
M_P!DKXF?L2_M$^(?V?OB=I=XDFEWDCZ+JMU9B%-:TTR.MMJ$05Y%V2JN2H=S
M&XDB8AXW4?7<-Y7E.<0G1JMJJMK/==[>75'RN?9EFF55(U*=G3?=;/LWY]#^
MK'/%?#?_  6R_9S^+7Q<\#^!OB?\(=$U#5[[PCJ5U#<:/I-J9KN2.Z$)$\:J
M=[^6UNH9$5FVRESA(W8<_P#\$$O^"E]Y^V'\$9/V>_C#XCOK_P")7P_L%:YU
M?5KR.6;Q!I;2LL5SD!9&E@S%;S,X8L3#*TLCSN$^^-'NKS4=*M[[4='FL9IH
M5>2QN)$:2 D9V.49D+CH=K,N<X9AAC\WF&!K8'$SPU96<7OWZIKR>YIFF P/
M&/#\\).34:J6JWBTTU\TTC\,/AGHW[8W[;>NVOP3\&66I:K'%<QV^H74D+I9
MZ8K;R)+N4*1"H$4A .7<QE45WPI_<OP[H=CX8\/6/AS3O.6WT^SCMX/M%P\L
MFQ%"C<[DL[8 RS$DGDDFKR111ME(U'T6O%/V^/VLK']CS]G74OBA#:P76M74
MR:?X9L;I9#'<7TH8J7*#A$C265@2F\1% ZLZFN&,?9Q;N?/\-\,X/P^RW$XW
M%XJ55M)RG+2T8WLDKM]=KN[Z'P'_ ,%?_P!H'7OVF_VIM#_9.^$\W]H6OAW4
M(M.CM[>\18]0UZY=8RA;SO*/E!DA!D$;12/<JQVG-?IC^SA\&='_ &=_@;X7
M^#&A2PRPZ!I,5M)=0VODBZGQNFN/+W-L,LIDD(W-@N>3UK\[?^"(/[.FK_$_
MXPZ_^V-\1+FZOO[$GGM-)O;ZX:26\U:Y3-U<._F[V9(9-I\Q&5S>;@V^,XI_
M\%MO^"VY^$O]K_L;?L;^+/\ BKOWEIXX\<:;<?\ ( _ADL+.13_Q^]5EF4_Z
M+RB'[1N:U[,IRW%9KBE3HK5]>B7=^7Y]-3P^")-PQ7%>8Z3Q,K4X]53B[12_
MQ6]+).Y]4?MR?\%E/V+_ -@[Q2WPV^(OB'5O$7C&,0->>$_"-BEQ<V,4T;O'
M+<22R101 A4/EF0S[9XI!$8W#U^=GQ0_X.E/VH-7\017/P6_9N\">']+6T5;
MBS\375[K%P]QO?=(LT$EFJH5* 1F-B"K'>0P5?SW_9S_ &9?CO\ M;?$R'X0
M?LZ_#B\\3^()+.:Z:SM98H4@MX@-\TLTSI%"@)5 TCJ"\D: EW13^K7[-G_!
MK=X*A\+M?_M@?M"ZM<:S,O[O2_AN(H;6R822#)N;VWD:Y#Q^4V/(@\MMZYD&
M&K]!J93POD--+&RYZCZ:W]4ELO7Y,^@AF7$6=5&\*N2'R2]&WN_3YGS9I?\
MP<I_\%';#Q7=>(;JV^'][9W"XBT&Z\,2K:6W&,HT=PDY]?GE;D^G%>Q? /\
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MG_"-Z]?:/'JEK8_\(WJ5YYEH\LL2R;[6VE09>"5=I8,-N2,$$^^5^#?_  =
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M+VRG5F6>>%0FVV<$AB<E>""2/L[_ (.NCE_@+C^[XH_]Q-?G3^PC^PC\7O\
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M4UZVMYNW8^1XLR^%;!_68KWX;VZIZ6?I>_WGE/\ P:_$_P##?WBS_LD.H?\
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MN($3Q37L=TDN&*O:KM )#I_1![&MN-LSG"K#+Z+M&*3:6E^R]$E?MKY&7".
MC.G+&U%>3;2O^+]6].^@M%%%?GY]R&>:Y7XQ_!SX:?M _#'6O@Y\8O!]GKWA
MO7[-K;5-+O%)25,@A@00T<B,%=)$(>-T5T9652.JH&?6G&4H24D[-:IKH1.$
M:D7&2NF?RM?MU_L<^/\ ]@_]I;7OV=/'M]_:']F^7<Z-KT>GRV\.L:?,NZ&Y
MC60?[T<@5G1)H9HQ(_EEC[#_ ,$%.?\ @K'\*/\ >US_ -,-_7W'_P '2_P&
M\/WOPD^&G[3EL;.WU32_$DWA>\6/3$^T7]O=6\MW#ON 0VRW:SGV1$,,WLC
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MH$%I-JWC'5M/\G[19Z;!M5C$)6 +R3206ZL%D,9N!(8W2-UK^ESX0?"'X;?
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M /"@U3_Y74?\0O\ ^W[_ -%8^$?_ (4&J?\ RNK]Y/PHQ[5\O_KAGG\R_P#
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MX->?^3"?&'_97M0_]-6EU^DE?FW_ ,&O/_)A/C#_ +*]J'_IJTNOTDKP<_\
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MZNG>$_$VL*=OB2$K^X@GN.GVT$&(-)M-P?*&Z6>1M_U/_P %,O\ @F/\*O\
M@I3\,]+\->+/$MUX;\3>&[B6;PQXIL[;[1]D$NP3PRVY=!-%((T.-R.K1H5<
M#>K_ ,]7[6O[%O[1?[$OQ*N/AI^T%\/;S2Y/M4T6E:W'"[Z;K4<>PF>RN"H6
M=-LL3$<21^8JRI&^4'TV%Q66\6Y:L-B'RUH[/K?NNZ?5?\!GSV(P^/X8QSKT
M5S4I?=;L^S71G]5^21D#-+^%?S5_LB_\%I_V^OV.=$M_!7@[XFV_BGPS9V_D
MZ?X9\=6KZA;6:B..*-895DCN(8XTB54@2985RQ$>237U9\./^#J7XNZ7X9:V
M^+?[(?AO7-8\YC'?^'?%%QI=J(_X5,$T-VQ8<Y;S0#Z"OG<3P7G5&7[N*FNE
MFE^#M^I]!A^+<KK17.W%^:;_ !5S]J,<YQ7SE_P4%_X*;?LX?\$]/ %UJ?Q'
M\0P:KXQN-/\ /\-> -/NP-0U-F9DC=N&^S6Q='W7$@V@12!!+(HB;\@/BQ_P
M<A?\%(?B1X:7P_X9O/ _@>;[2))=6\*>&Y'NI8]CJ83_ &A/=1JA+!MR(L@:
M-<.!N#>'_LD_L:_M??\ !5;X^7MMH&LZEK5X56?QA\1/&.H7%Q!8QJ@2/[1<
MOODEF946.*$;G8+G"QQR21]6#X0EAHNOF<U"G'5I/5_/I?RNWLCEQ7%'UBU'
M+XN4Y:)M:+T7_#6/,_BKXE^.G[1VI>+?VL?BGK%UX@N+KQ+:6WB7Q#>74>X7
MUY#<R6L*QY#+'Y-A<*BQKY426ZQC8/+4_0G_  04_P"4L?PH_P![7/\ TQ7]
M?9/_  6R_9%^%_[#_P#P2#^&7[/WPLL8?)T[XL6$NK:L+413:QJ#Z3J?GWLV
M"27<J  6;9&D<:G9&H'QM_P0221_^"L/PK9(V8*-<9B%^Z/["U 9/IR0/QKZ
MI9A3S#AO$U*<>6"C.,5Y*-E_71:'S+P-3 Y[0IU)7DY1<GYMIO\ KJ?T/_%W
MX7^$OC;\*_$GP>\>VTDNB^*M$NM*U2.&3;(;>XB:)RC8.UPK$JV,J0#VK^7_
M /:N_9L^-?\ P3X_:HU3X4^(KC6-)UCPOK OO"7B>%&LI-0M$G8V6K6KQ2/Y
M>_RPXV2,T,BO&S"2)P/ZI?>OE/\ X*A_\$K/A1_P4E\!V*ZEK/\ PC/CKP^&
M'AOQA;VGG;868&2SN8MR^? WWE^8/%)\Z':TL<OP?#.=1RK%.G6_A3WZV?1V
M_!^1]OQ!E,LRPZG1_B0VZ77:_P"*\SE_^"3'_!6SX0_MR?"70?A[X^\<6NF_
M&#3;..RUW0M4N((9M?GB@+/J-BJ+&DRR)%)-)#$@:W*R*4\L1RR?:E?RL_M*
M?LH_M4?\$^/C5'X;^*_A?6/"^L:3K#2^&/%FF-/'::A);-%*EYIUZ GF;/,@
MDW(5DA9U618Y 4'U%^R[_P '&O[=/P+TG2_"'Q5MM#^)^BV,L:2W'B*.2WUA
M[5(DC$"WL)"LWR;S/<0SRLSN79LC'KYCP@\1_M.624X2U2O^3VMY.UO,\K+^
M*/8+V&81<91T;M^:WOZ7/Z!,YZ45^/8_X.NFQ_R88/\ PZ'_ -ZZ\E_:(_X.
M;/VQOB-#=Z1^S_\ #CPQ\-[.XAA$&H2*=:U2UD5PSLDLZI:E7 V;7M6*JS8;
M=M9?(I<'Y]4GRRIJ/FY1M^#;_ ]2IQ3D].-XU'+R2=_Q21^DW_!5G_@JQ\-/
M^"<GPT73=,2S\0?$[Q!9L_A+PE)(=D*9*?VA>["&CM48, H*O<.C1QE0LTT/
M\_/PV\ ?&K]N;]J*Q\%:+,VL>./B5XLDDNM0N(6"-=7,K37-Y.((V*1(#+/*
MR(0D:.P7"XK>^#7[/O[9O_!1_P",]PG@30_%7Q$\37DT":_XHUJ]FN8[5?)8
M1/?7UPQ6%?*MF6/S7!<0^7&&8*A_>?\ X)3_ /!*;X:?\$Y/AJVI:G)9^(/B
M=K]FL?BWQ;'&=D*9#_V?9;P&CM58*2Q"O<.BR2!0L,,/TG-EO!^!E",E/$27
MW=KKHE][?X?/*./XHQL9M.%&+_X?U;^Y'N7[)?[-O@G]D+]G+PG^SA\/&DDT
MOPKI8MQ=3,^^[N'=IKFY8,S;#+/)+*4!VH9-J@*J@?C%_P '01_XS^\)X_Z)
M#I__ *==4K]XR,C:*_!S_@Z R/V_O"?/_-(M/_\ 3KJE>#PC4G4X@C.3NWS-
MONVM3V^**<:>2<D59)Q279+8^P/^#7G_ ),)\8?]E>U#_P!-6EU^DE?FW_P:
M\_\ )A/C#_LKVH?^FK2Z_22O*S[_ )'5?_$STLB_Y%-+_"%%%%>0>L%?@W_P
M= G_ (S^\)_]DAT__P!.NJ5^\E?@W_P= G_C/[PG_P!DAT__ -.NJ5]3P;_R
M/(>DOR/FN+/^1._5'L'_  :B?ZSX]?[OA?\ ]RU?L)7X]_\ !J)_K/CU_N^%
M_P#W+5^PE8<6?\E!6^7_ *3$UX9_Y$M+Y_FPHHHKYT^@/FS_ (*$?\$N_@)_
MP4D/A'_A=WB_Q?I)\&?VA_9G_"*ZA:P>;]K^S>9YOVBVFW8^RQ[=NW&6SG(Q
M\W?\0O/[!/\ T6'XO?\ @^TK_P"5U?I(,'F@Y[5Z&'S?,\+25.C6<8K9)]W?
M\V>;7RK+\55=2K33D]V_+3\C\V_^(7G]@G_HL'Q>_P#!_I7_ ,KJ/^(7G]@G
M_HL'Q>_\'^E?_*ZOTDHK?^W\Z_Y_R^\S_L/*?^?43\T[_P#X-?OV&HX%?3/B
MO\6)I/.C#+<>)-,C7RRZB1LC2VRRIN95P S *64$L(]=_P"#9C_@G?X7T:Z\
M1^)/CM\5;#3[&VDGOKV\\2:1%#!$JEGD=VTX*B*H)+$@  DU]2?\%+OB7^T5
M\%/@GI/QL_9VTAKZZ\*^)$OO$5JZ/) ^E_9+J*4SQ(Z/+"LDD3MM.4V"4X6-
MF7X!UGXJ_P#!27_@K--!X(T'0/)\*QRI#JD>C6\MAH:R)+&S274TDCM-(GF1
M2>2'D8*BO'"6!8S4XCSB.GMY-^K/@^),\R/(<7+ T\#*KB)).$8Q;4K]>;HD
M]^Q5^/G[2?AGX2?!'1?^"7'[ 'B7Q#KG@G1[JZT^^\333)<ZAXDFNKV:9[&!
MK>*,/!YL[1EHT!G&U%S'N:?[*_X)B_\ !,?2/V7])M_C-\9+&WOOB+?6Y\F
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MG]E4T?*_+3T6AT^VI:KF6F^JT.SS35('%?)?[ ?_  4;\&?M'GXV2_$GXY>
M<>!_B=XB3P^EAKEK'M\'6(MUAU:3]\Q:V)=V:[.(B6X(&!7M?[/'B?QAHG[,
M'A_Q[^T3\:O"7B/4O^$=_M;Q!XX\/>7:Z)+ ZM<>?!(6V&UCA90+@E1(D?FE
M8]Y1=*V'K4).,U9JRMKU1G1Q5*M%2B[IIOIT=M3TNBO/_A;^U7^S%\<?$$WA
M3X+?M'>!?%^J6]JUW<:;X7\766H7$5NKHC3-'!*S! TB*6(P"ZC.2,['B3XT
M?!_P=KU[X3\6_%7PWI>J:7X<E\0ZEINH:Y;PW%II$;E)-1EC=PT=JK JT[ 1
MJ006!%8RA4C*S3].II[:FUS75N]SJ*.]<7\)OVBOV?\ X]?;Q\#OCGX0\9'2
M_*_M1?"GB6UU'['YF_R_-^SR/Y>_RWV[L;MC8S@U\[_M#_\ !23X;_#G]M[X
M2?!GPQ^TW\+[;PC-)XJC^,C:CXOTU)-&FL[:%+."1Y)U-M,;R1D,1'F-LD^7
M$;E=:.%KUJCA%.Z3;NGT5_R6AG5Q="E34Y25FTE\VE^I]>?44@.3Q2\8W"OB
MWX1?$[]N7]M;XE_&'7/@Q^TWX=^&OACX??%K4O ^FZ#J'PUCUV>=].AMEFNF
MN#=V^!++([K'M8H#MW-C)*-!UDVY**5KMWMO9+1-_@.M75*459MRV2MTU>[2
M/M+\*,XZFO.?A-I_Q1^"_P ,-7U;]J[]HK0?%$FGS7&H7'BE?#47AZST[34@
M0LLR&YF4+&4FD:9G4!7P0 F3-\+OVJOV8?CCX@F\)?!;]H[P+XNU2WM&NY]-
M\+^+[+4+B*W5T1I6C@E9@@:1%+$8!=1G)%1*G+5QU2ZI.WXI?C8OVT-%+1OH
MVK_G^1Z!F@9K/\3>)?#O@[P_?>+/%_B&STG2=+M9+K4M2U*Z2"WM((U+/++(
MY"HBJ"Q9B  "2<5S?PE_:*^ 'QZ;4%^!WQP\(>,SI/E?VI_PBOB6UU#['YN_
MR_-^SR/Y>_RY-N[&[8V,[3B>6HXN23MU=M$4ZD(R2;5WLNIVE%9.E>.?!>M>
M*-5\$:-XNTN\UK0X[>36M'M=0CDNM/2<,T#3Q*Q>(2!'*%@ X1BN<&K&J>)?
M#^B:CINEZQKUG9W6L7C6FDV]U=)')>W"PR3M%"K$&1Q##-(57)"1.V,*Q"]Z
M]K?UO^17-'<O4 FN#^(_[3W[-GP<\5VO@7XM_M">"?#&N7UO'/8Z/XB\66=C
M=7$3NT:2)%-(KNK.CJ& (+(P'((KM+Z_LM,LYM1U"[CM[>"-I)IYI J1H!DL
MS'@  9)/ %.49QLVGKMIOZ$QJ1=TFM-_(L$X&: <UY_\+?VJ_P!F'XY:_-X2
M^"_[1_@7Q=JEO:-=SZ;X7\7V5_<1VZNB-,T<$K,$#2(I8C +J,Y(KK?%OB[P
MKX"\.7OC+QSXGT_1='TVW:?4-5U:]CM[:UB7K)))(0J*.[,0!1R2C+E::?9K
M44:E.4>9--=[Z&GFCVKP?XR_MK?"'4/V4OBW\7OV7OCSX(\6ZQX!\ :GJJ2>
M'_$%IJD=E=)97$MKYZP2-M#R0G"MC?L8#.#CT3]G/6_B=XC_ &?? OB+XTZ9
M]A\97_@[3+GQ99M;B(V^I/:QM=1[!PFV8N-O;&*J5&I&GS25M;6>FMB(XBG4
MJ<D7?2]UMVW.TP*/<"N3^.GQ(;X/?!?Q9\6(M*6^D\->&[[4TL6F\L3M;P/*
M(RV#M#;<9P<9S@UXC\&E_;V^)GP/T#XUZ-^T5X%N+SQ#X4M]6L?#NJ_#F=+<
M37%LLJ0/<PWX<*&<*9%C)P-WEG[ASZ['%BLSCA\4L/"$IR:<FE;1+2[NU>[V
M2N]#Z:)&<&BO ?V/OVHOB7\4O%GC;X"?M#>#]+T3XA_#R\@&L?V'=;]/U*UN
M5:6WN;8.[2*#'MWJ^2N^,DJSM%'V'P?^,]G-\!E^,GQA^*?@EK.:\O9I]=T'
MQ%'/HUM;_;9(X(H[QTB638GEQN[!290XP. #XA83-L'C*4:D&TFI-W5FN5I2
M33LTT]&CTX\\8HKG?AY\5?AI\7-(D\0_"WQ_HOB.P@NC;S7F@ZI%=113!58Q
MEHF90P5E8J3D!E/<5E_$#]HSX _"G6X_#OQ/^-7A/P]J$UNMQ%8ZYXBMK69X
M2S*) DKJQ0LCJ& P2K#L:>M[V.R6*PL::JN:47L[JS.VHSFJ]I?VFH6L=Y8W
M,<\,D:M%-$P974C(8$<$$<@BN)\3_M/_ +-_@7Q7-X$\:_'KP?I.M0/&L^DZ
MEXFM(+B-G570-&\@8%E96&1R&!'!%&H5,5AZ,5.I-)/9MI)_,[[-&:R-5\=>
M#-%\1Z3X0UCQ;IMKJVO>=_8FFW%]''<:AY*!YO(0D-+L0AFV@[0<G I?&?C?
MP?\ #OPY<>,/'WBO3M#TFT9/M6J:M>QV]O#N<(NZ20A5R[*HR1DL .2*5C25
M:CRN7,K+?5::7U[:._H:Q-%<S\1/C#\)_A#9VVI?%/XE:#X;M[N0QVL^N:O#
M:+,X&2JF5U#$#G R<5>\&>.O!OQ#\,V_C/P%XLT[6M)NMYM=3TF\CN()=KE&
MVO&2IPRLIP3@J0>0:>I,<1AY5'34US)7:NKV[V-BC@BN)_X:*^ G]D:;X@/Q
MK\*?8=9M[V?2;S_A(K;RKR&S#-=R1/OVNL"JQE921&%);;@UU6AZYHWB?1;3
MQ+X<U>WO].OK>.XL;ZSG62&XA=0R21NI*NC*0P8$@@@BBS"GB:%:5H34MGHT
M]+)]/)ES&.E-)'0UE^%O''@SQN-0;P7XLTW5AI.I2:?JG]FWT<_V2\CQYEM+
ML)\N5-R[HVPRY&0,UXG^UC\8_C9X>^/WPC_9Y^#?BK2= E^(4NN-J&NZIH9U
M!K9;"U2=42$31*0Y9@26R,*0>"&ENR.7&YA0P.%]O*\DW&*M9MN4E%)7:6K:
MU;LNK/H'@CY32GTS7S%\=/&'_!0/]F7P!+\5[7Q'\/?B5H?A^WFU#Q78R>'[
MG0]0^QQ;7;[-(+N>%B(_-<EE!41_*LS,%KV_X>?&/P7\1/ 'A'XAVNHC3[?Q
MIIMO=Z%9ZI+''<3&:U-T(0H<AI1"KNR(6P(W()52:9GA\VH5L1+#SBX3BD[2
M25TW9---Q>NCLVUUW1UPZY I 1T%>0>._CB/'DW@.W_9F^.GP]NGUKQ>GVY;
MO6HY_P"UM)ME9]0AL1"6\RY12C<<(,ERH(SZ3X+\:^#_ (B^&;;QCX#\5:?K
M>DWF_P"RZII-Y'<6\VURC;9(R5;#JRG!."I!Y!HUL=-'&8?$573@[VL[W5GH
MGI9]$U?U1KT$X&:R-*\=>"]<\1:MX0T;Q9IMWJV@^3_;6F6U]')<6'G(7A\Z
M-26BWH"R[@-P&1D5S7AG]I[]G+QSXIA\"^#?CWX/U36YI)$ATG3?$UK/<R-&
MK,X6-7+$JJLQP. I)X!H+EB\+"RE-*[:5VM6G;OWT]3O#GM16/J_CGP7X?\
M$FD^$-=\6Z;9ZMKGG_V+IMU?)'<7_DH'F\F-B&EV(0S;0=H.3@5@_#_]H[X
M_%?7)/#/PQ^-GA/Q%J$<#3R6.B>(;:ZE6($ R%8G9@H+*"V, L/44!+&86-1
M0E.*E>R5U=NR=K=[-?>CMJ***#H/S1_9_N_^"A7Q-_;/_:F_:8_8HT;X.6NF
MZM\3X?!.K67Q0U+59)DNO#EDEHMQ"+&$+Y<PG\PJS%@?D_AWO<_:1\ ?M?\
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M6PIWH&0X#DCSNIXM6IF6%SZM7AA95%.,(QDG!15G)N_-)26LM;1=TE:YY/\
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M)GPQ^-NF^(H)/"?PI^/SVOA_QW>7PGO'\$M?S:<[O(1N"OYBPM%&JJ888B$
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M\;X(-:=CGCD.(I2K4'3E)2M&,KP:Y>5+5RO)-.[>C;?O6=V>,ZQX+UG]I/\
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(H4444&<C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exdx-20221231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exdx-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1)V17AI9@  34T *@    @  0$2  ,
M   !  @      !H !@$#  ,    !  8   $:  4    !    : $;  4    !
M    < $H  ,    !  (   (!  0    !    > ("  0    !   1]0
M  !@     0   &     !_]C_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!#
M 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X * # 2$  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M"/+B'.3NQ@]/E-9\A95<HK]'"E>,'$N3_P#J]:DU-/3@!=7W(+%T)QV^1?\
MZ]7?^6W_  &@"G Q.KW2GHH&.3Z+4FH9-LH"D_OH^@Z?..: &ZMQI=RP4$B-
MN#WX-06X 6_ &%#, /3Y10!HO]^+_>_H:ISG_B;6XQ_RR8Y_X$M %6+)U;[H
M'^DR?B/+'ZU;A/SWHW9Q..W3Y5H O50L5^T12O(\I83RK_K&' =@.,^@% #;
MJ-X["ZGBEE$BQ2*N7) P3SSWI]XA>!D!P6MI "__  'K0!'&RC3F?Y706BGY
M#D,,-T]13M&+'2K0MM&8$("9P 1P!DD]/6@!NIO()8E1F4&.4Y!. 0O&:N6A
M)LX26W$QJ=WKQUH J:MDP!02 0V?FQVK*D.]9#@%BK@G'M-CO_A0!JZ<4^UW
MRKNW;T+9Z?<'3\JO?\MO^ T 4K<8UJ[.TC*KSV/ I^J9^QC !/FQ]1G^(4 +
MJN/[+N,YP(VS@X['O4$ 8?VAN[LQ'&/X1^= &@_WXO\ >_H:K3!O[2@(#;0A
MR>V<K0!3B&=5!&<"XDSW_@'Y5:@QYE]C.?/&?^^5H O5F:,<Q7@]+N;_ -#-
M %N*(%F<NQ!W*4)^7[QYQZU7U56:TN%0$L;68 #J3@4 +81G['%%("I^RQJP
MQC'!JQ;0K;1K A8K&BJI8Y.!ZF@"IJ%Q+#=1K'NQY$K^Q( QFK=B[26%O(Y)
M=HU+9'?% %/6<"!6*AE4.2"#C[O>LV63B0CYB ^"#D])>* .CC_U2?[HI/\
MEM_P&@"E;D'6;O&.%7.!ST6KDT$=PBK(,A6#CG&"#D&@".]C:6UDC0*6=2H#
M=,D'K[56>.*R2<M(<SY/S'JQ&,#\J +23QW"Q21-N0N1GW (/ZBI).B_[PH
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MQ,+]<]9I#_Y$;_&@#6AC/F-)YCXRR[.-OWCSTSFFW,*W#^0^=DD,B-CT.T4
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MH'8$G\ZD<2&2.6-5.%((9L=<>Q]* %C63S7>15&5  5L],^P]:7>JRL">PH
M7S$]?TIP8-T- &=K#A8DR>H? W8S\M9DK'#GH<.!GO\ ZW\Z -RWQYK$'DJ,
M^G0=ZF_Y;?\  : $/_'PONK?S%5$TJ%%4!W. @Y _A8MZ=R: $.F0JA4._SH
M8B<#H23Z>],FTZ,1R_.W7S>@Z@8 Z>U ":.I33;=2FW$TG&,?Q/6C)T7_>%
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M(W@2X5(P\J+N9%QD#I^')_.@"OJX+0HH(&0P)+;?X367*V]'W9.%?D C/$M
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MM858#W)/^%6Z ,F\>XDM/,90 K2!@C<;>0OU/2J$J!4ECC!**CE@!T!$O]:
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M\]/"'_?NZ_\ BJ ._HK@-OQ1_P">GA#_ +]W7_Q5&WXH_P#/3PA_W[NO_BJ
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M?PYF\*ZA%\2?$>M17?B'3].N+'4[32_)EAFG5'!,-E&X.#P5<<U[50 4444
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M\FW,KRD%F+L2[DL268DDGO73T453;D[LE)+1!1112&%%%% !7 ?"7_7>.?\
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ME]JTT18!L327)95(^7* +TZT4_>J\KV5G_7^?W)A4TI76_\ 7]6_(_1.O/\
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M!:WFYXQO('G;\E@,9(%?8>BZ+I_AS2;32]*LK?3=-LXEAM[2UC$<4,:C 55
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M]WK]^H4445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[$BAS\H8H<=\]*]/_9UTW4-)^&%G:ZA8S6!CGF\B.XA:"1H=YV,T+,?*)'\
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M?%?XDS_#/2K2^3PQJ'B.WN+B.U86$UNACDDD2.)2)I$SN=P.,XP<XJ7X=_$
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M HHHH \9_:,T>R\11^'M-G\'^&O&=T[7$\5IXBU=]/$*(@,DB%8)=P QNR%
MXYYJ']FW6+>]\(6*>%_"_@W1_#+7-T+AO">N?;H8Y0$*G(MX][N2V[." JG+
M;N+/[17A_P"'^LVVA'QSXND\'B6273[>:'4$M&O8I@HFM6+ Y1PJ[L8(P,,*
M[KP/X>\.Z#/X@;P]+#(;F_#7L<$JNL$R011"+ ^YMCCC^7KSGO13TYOZ[?HU
M\_D$]>7^N_\ P?ZN>6ZUHND^)/V'TTO7=:C\.Z1=>!H(KG591E+5#9IF1AW
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M5%]-/FDKOY_+T(C9OF6S_+M\BY\97U=/A?XC.@W^H:5JYM2+>]TNP%]<P,2
M7C@) D8#/RY^G-?-G[,NDV_]I>;X2^+_ (7UK5YY@^L#4?#4R:[=A6PZS-<7
MGG*<AE&5VJ0<#C%?6/BK^V_^$?O?^$<^P_VV4Q:G4]_V<-D<OL^8@#/ Z^HZ
MUX1X0_8\@9=#F^('BJ[\82Z-?OJEC86ENFGV5K<-.T^Y0F9GP[GAY6& .*B&
MD[^G]>?II?JRYZPMZ_U_P>FNAZ?XV_Y*=\./^OB__P#21Z9KOQM\":/\5-/^
M&>K:U;VGBW5+'[;::?<HRBXB+,F%<C:6)1ODSDX/%/\ &W_)3OAQ_P!?%_\
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MEG<ZA<)*L*8O[^:ZVB.-8UV^8QVY"@MC[S$DY)S2IZ0E?O\ BM?R83^)>G_
M_-/[C=HJ"]OK;3;=I[NXBM8%^]),X11]2:=:W4-[ DUO-'/"XRLD;!E(]B*
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M]G!8VR?=AMXUC0?0 8KXQD\"_M3_ +/HQX;\1VOQ7\-P\K:ZE\UVJ^GSG?\
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MXC^%'A+PW_:DZ:=J.I^&=7:>^T\W<L6TWD1@C1PTGE;F5B5))&02:FG\:O\
MU_+^._\ P4E53X-/Z[_\#_@7/:?&W_)3OAQ_U\7_ /Z2/7R[^W?KVCZ'\4?
M'_"/:SXVLOB5+-&MW:>!3<2WDND 3G/DX,#?OMH^<9.3V''U%XV_Y*=\./\
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MTYKRSP_^T#^T%^TMKVL:O\+K_0O#?A_3Y2EKI5]);FYN0.06#JS$D=3\JC.
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M4EM_.F:U,9BB/E0HHC_=)D 9//->M45*T=U_74K=6.!\;?\ )3OAQ_U\7_\
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M&5!4''KUKTGX#_$:;XL>";?Q0M_;WNFWT4+6WEZ5/82(WDH90RRNV07)*E>
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MO8FB5R+@D*SA5) )P>E*G[TH=5S+R^U_7K\PJ>[&?1\K_P#2?Z]$?8E%%%,
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M;BUGEEN#(8;0K(IF:VG\OS,@;BN0N3@' )HA[L^;S7_ ];:ORON$_>AR^O\
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M/#C#$<#0_:4\#6%Q9+XRU+Q'+HFD:=;QV^K6L-@+J34+<744T<$0R"DK2HJ
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MSC&3P35#X+ZE\'/#<;>&?AOX@\.W$UPQN'L].UA+RXE*H%W,3(SMM55')X
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M3+^T/9:SK/\ PC6E:#I/B'4K^YFG??HVO2Z/!"B("3//&#G.0%4@Y.?2L?\
M9@L?%/A^^\:Z-K7@EO#EG#J0F75+K7)M3N=1F:W@+.\LJ@R  [0X(4; H7Y2
M:*6\_3\FG^K^8ZFT/)_G?_)?(]%^!_\ R17P!_V+^G_^DT==M7$_ _\ Y(KX
M _[%_3__ $FCKMJ!!1110 4444 %-8[5)QG Z>M.HI/8#X"\#R:=X;^,7A'Q
M$?"WPWM;GQ"UK?6&BV?AX1:K&+B\D@<Q7'F%FFA5?-D;RP,!Q\O6OOVOE:Z\
M1,WQ6TK3/#7[0$7B;Q);:O%'>^%KI-'5WM/-_?PI(EL) R+D[02QV$<$Y'U3
M51_@Q]7]VEO^'ZZA/^+)^G_!^_>WF?)_Q@T^RN/C9KTWBOX:ZE\1)733+/PU
M%<Z'-J.E6T$CA;MRP1HHI Q=F9L':B<XKUGX%^$Y/ NI^/="L;"YTSPA::PG
M]AVLZLL<4;6T+3+ &Z0B4OM ^4'<!P*]7HI1]U6]?S3_ $_$)>\[^GY6/D7]
MH+PG\1O&?Q0U'2]"D\1I(P\_3&BAB;2%MTL9& 9I4:-9S>!%YPQ1L?=S7H/[
M,.C:E9_\).NL^'M6TW['>1IIUSXDLK.._>-X$:4>9:CRW3S"P&#D<@]!5C]J
M7Q1;Z'8>#=/UGQ+<>#O".KZNUOK6M6MRUK(D*V\LJ0B=>8A)(B*6!!QD @FN
M0^#%YI>E^+? %_X#O];;PKXO@U,7.CZIJL^I1(ELV([V)YG=H]S!5.&VL)EX
MR,T4]+KY?/?Y77ZO1!4U<7_7;Y_\,MSVKX@?\C9\-/\ L8)O_35J%2?%#P#X
M(\<:#YWCK1--UG2M*$EZ#J<"RI;[5)>09'&%!YJ/X@?\C9\-/^Q@F_\ 35J%
M5OBY\2O!O@C2X=*\827;V^O1SVJ6=EIUU>R7"!,2C9;QNP 5QD\=>M1+;^MR
MX?$K[?IU*O@7X _"[P;J5GXB\*>"]#TF^V&2WO["S2-]KKR0P'=3^M=WK>BV
M'B32+S2M4M(K_3KR)H+BUG4-'+&PPRL#U!%><?##]HCX=_$*_P!.\/\ A6_O
MWEDM7DLX[K1KVTCDAAVJVR2>%5;;E00"37?>+?%>E^!O#.I^(-;N39Z3IL#7
M-U.(VD*1J,D[4!9OH 36E2UM?A\^QE3OI_-Y=SR'PW^SC\"?$5UJZ:?\-?#O
MFZ/>MIMP6TQ%VR*B.0IQR,2+79_%:%+=? L4:A(T\262JJC  "R  5QMK^UU
M\(M/O;V&*[U6PG9TN+POX5U* *TGR++,QM@%W;,;F(^[UXKM/BYRW@C_ +&:
MS_\ 09*->5?UK;7\1Z7?]:=#T"BBBD,X'QM_R4[X<?\ 7Q?_ /I(];VK_#[P
MQX@\2:9XAU/P]I>H:[I8(L=2NK2.2XM0>OER$;EZGH>]8/C;_DIWPX_Z^+__
M -)'KOJ/,/(J:7I-EH>GPV.G6D%A90C$=O;1B.-!G. H&!R3^=6Z** "N)U7
M_DM7A?\ [%_5O_2G3:[:N)U7_DM7A?\ [%_5O_2G3: .VHHHH **** .%^.>
MFC6/A#XKLFU:TT..:Q=9;^_N?L]O%'QO\R7^!2N5+=@:\ _9U\/^!['X_P"N
M7'@36?A[!I&RZEAL_"6KPS7E[!(ELJK+;Q* D<+1N0V6.9?X<G/U?J=U9V>G
MW$VH2PP62(3-)<L%C"]]Q/&/K7-7G@OPSIOC31_%#"#2]5AAETR!HV2%;D3%
M6\MA@>808\J.Q+$"B'NU.;NFOO\ ^#;\0E[T.7L[_P!?+]"IJ/\ R7+P_P#]
MBYJ7_I38UW5<+J/_ "7+P_\ ]BYJ7_I38UW5 !63XJ\*:/XWT&[T37]-M]7T
MB[4+/9W<8DBE ((#*>#R!^5:U8'CKQUHOPW\,W.O^(+F2TTRW>.-Y(;>2X<M
M)(L:*L<:L[$NZ@!03S2=K:C5[Z'G/AG]F_X'Z@XU71/ /AF1[:Z>$7-O8("D
MT$K(PSCJKHP^HKV6O"O!?[2_PBL;P:#HMSJUB]QJGE/'<>'=3AC2\NY?,VR2
M2P!8R[S _,0/G';%>ZU6O*GT)TN_ZTZ'A]U^SW\#]4\=W>BW'PY\/SZX;8:O
M,\FFH=RR2NF\MCEBRMFO6_"_A72/!6AVNC:#IUOI.E6H(AL[6,)'&"2QP!TY
M)/XUY W[7/PB76(YDN]5FU"Y1[>*YM_"NI2-<)&Q++'(ML=Z*23\I(YS7KOA
M'Q9I?CKPSIOB#1+DWFDZC"MQ;3M&\9=#T)5P&4^Q -*/P*VWX=;?@.7QN_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>9_#/_DJ/Q?\
M^PS8_P#IKM*],KS/X9_\E1^+_P#V&;'_ --=I0!Z97E_QB_9_P##WQEN[&XU
M;4]8TJ2&WEL;C^R;P6XOK.1D:2UFRIW1L8USC!ZX(R:]0KY[_:FTWP3K%]H%
MIKO@?Q1X]\3213#2]-\.2W<"A<KN:::.2.*--VWYI&SUP#42=FG;7_@/^O2Y
M4>NO]?U^)[!X=\#Z-X9U[6=6T]#'=ZJMO',N_P"1(X(_+B1%_A4 G\2:Z2O@
M/X"?!W4O#?Q ^&^E2?#[Q;H/C30=3N+KQ)XBNK^YGT>>T\F<1I#*\ICE+&2
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MMVN89PHFM7+ Y20(N0,-\O!%=-X5\$Z3X.FU=]*B\G^TKE;F= ?E5EACA55
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MO^7W-!/^)?NOR2L=I1112 :RJXPRAA[C- 55QA0,=.*=10!Q/Q _Y&SX:?\
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MJ7]]\/-;?PYK7C3P=H.K27NM>'?#[G[7,XB/V2X$0=//2&8!C'N_B5MK;"*
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M10 5P'PE_P!=XY_[&:Z_] BKOZX#X2_Z[QS_ -C-=?\ H$5 '?T444 %%%%
M'SW^UA\.+CXD2^&;.Q?PS+?K;ZDL=OXGED6- T*YNH0B-MEA(5A(<;02,_-Q
MT7[,A;4/"NNZ[)XDT'Q+/K.JM=32>&YS-90.L$,)17/)8^4'8D#)DZ=ZY+]K
MZ;0+>3PPWB)M7L["2VU&%KC1YC'+>;HX_P#B6C"-DW) '8_NS@@UVW[/?VK[
M#XK.I^&HO#&L?VJ@O+6TNFN;8L+.V">4YC3A8]B$!<!D;DT4OM^GZK_@>?RL
M%3[']?U^7;6]NC^!_P#R17P!_P!B_I__ *31UVU<3\#_ /DBO@#_ +%_3_\
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MO;F6YLW$<.G+&T[./F4(LKHC'('RLR@C()%>#_"7P[JN@^,7\8:O\/O&4GC
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M;4444 <%=?\ )=],_P"Q;N__ $JMZ[VN"NO^2[Z9_P!BW=_^E5O7>T %%%%
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M@-R \A"HYQFO5:\@_9C\(Z;I/PVTW7(_"MAX9US5X U^;+3%T]KO8[K%-)
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MGV?Z[_U]QV7P/_Y(KX _[%_3_P#TFCKMJXGX'_\ )%? '_8OZ?\ ^DT==M0
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M)=F>@4445)1P/C;_ )*=\./^OB__ /21Z[ZN!\;?\E.^''_7Q?\ _I(]=]0
M4444 %<3JO\ R6KPO_V+^K?^E.FUVU<3JO\ R6KPO_V+^K?^E.FT =M1110
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M=I(V\$D9.,G2HHH **** "BBB@ K@/A+_KO'/_8S77_H$5=_7 ?"7_7>.?\
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M2-78'S[.QO&NXHSN.-LICC+9&#]P=<5\3>$['1;?QQH'Q$,G@F6]U+Q0MJ/
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M_/B3!  %?1M:;0A'M?\ &4G^NGE8F_-.3]/_ $E+^O,****@H**** "BBB@
MHHHH *S?$TEU%X<U5[*?[->+:RF"80F;RW"':WECE\'!VCKTK2K'\9:;%K7A
M'6]/G>>*&ZL9X'>U0O*JM&RDHHY+8/ '4U%2_([&E.W.K]SP+X0^,/\ A+?'
MMKJ5A\4?&WBNQTZ%K.^TN^T."&W:XE=%4L8K./:%PQ/.X=SMW ]O^T7;"_\
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M^+_#[:5<M?2:IX3@TJ.SF#Q>5^^6R@+EP9!L!XVY/%>S_%S[_@C_ +&:S_\
M09*TELG_ %NS.-[N_P#6B/0****@LX'QM_R4[X<?]?%__P"DCUWU<#XV_P"2
MG?#C_KXO_P#TD>N^H **** "N)U7_DM7A?\ [%_5O_2G3:[:N)U7_DM7A?\
M[%_5O_2G3: .VHHHH **** ,'QYJ']D^#=9O/[3TO1O)M7?^T-;3=96^!]^8
M;TR@[_.OUKYM^$?BX>*_VC]%?_A.? OC+R= OE#?#^T\I8<RP<7A^T3?*?\
MEGROS!N#7T!\7_%5QX(^&7B/7+2TAOKJSM&>*"ZSY)8X4&3'.P9RV.P->-_
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M_P @KP7_ -CAHW_I4M>H5Y?\?/\ D%>"_P#L<-&_]*EKU"LC0**** "BBB@
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MB^9)L****104444 %%%% !1110 4444 %9'C"\@T_P )ZU=71B6V@LII)3-
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M;CMXIK>=8($P$AD=0I14;<3EMQ;H0:*>CGZ?K'^K]-NH5-H>OZ2^XZ?X'_\
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M\OZ[?U_6E2VCZG/_ +5&D7VJW.E21:;I\UG91),UQ-H<&J7#[KJ&.2.-)0<
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MALMM &:TG\$7N]/SV\U_PUS.&\NF_P"7X/\ X<M?"/08-)\0:C<^%]8N=5\
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MV?X)6<7]KKX@V:(B_P!JHQ9;O]T/WH)))#=<DDG/4US_ ,;-'^(OB#5=-LO
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M0;&1<, 4V;<86BE]M>7ZJ_RV^;]0J;0?K_P/GH_DD=A\#_\ DBO@#_L7]/\
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MIJT$@HHHK(T"BBB@ KX2\/?\GQ?M,_[_ (;_ /36E?=M?"7A[_D^+]IG_?\
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M+]Z[A(>/T^7KG'0UP7[+>K:7JEGXO&FQV-R;?48XYM7T_P 0W6NQ7I\A"/\
M2[CYR4!V[ 2%_&IAO/T_5%2VCZ_H=7\0==\77'C;1?"WA:]TW0S=V5Q?SZMJ
M=D]V,1O$@ABC62,;CYFXL6. .ASD5M \2:[K7@OQMI_B,6<^IZ+/-I[:AI\+
MPV]X/(CD$B1LS%"/,VLNYL,AY].$_:PN=?U;4/"&@>'[8ZC)'<-J]Y:6]I<2
M3K#&K1B42131;</(N &#$@%?NUUOPX_MZ7X&W5YKOB6#Q6+VU>[L;^&T:W;[
M*\8,:2!B69AS\QP>F<D$DIZQ;?G^>C_-=G9O<*FDDE_PWE^3^:Z'KU%%% !1
M110 4444 %%%% !7 ?"7_7>.?^QFNO\ T"*N_K@/A+_KO'/_ &,UU_Z!%0!W
M]%%% !1110!Y9\>H?AQ<:7I*?$;PW)XDLQ.S6D4>@7.J^5(%Y;;!%(4X.,D#
M-<5\(;'X$VOCJQ/@CP%-H7B$B0P7C>#+_3PF4._,TMNB+E<CEAG.*W?VIO&>
MI> /!]IK=KJGBC1["U>1[VZ\,Q:4Y5,#;YO]H';@GA1'\Q)QZ5S_ .S[\1O$
MGCB30+J2/Q_JNAW2SS#6=<@T)+6561=BO]CDW@H48 *N=SD-T&"GJY6Z?Y!4
MT4;]?\SU7X'_ /)%? '_ &+^G_\ I-'7;5Q/P/\ ^2*^ /\ L7]/_P#2:.NV
MH *\/_:.\2ZAH>J>%K>Y\3:QX)\%W(NCJFO:'9K/.DRB/R(6=HI1#&X,I+[>
MJ*-PSS[A7)_$+XH>%_AA8VEQXFU(62WDIAMH(X9+B>X<#)$<4:L[X')PIP.M
M2^ERHGD7P'\;/JWQ(GTGPUXXU[XC>#1IDEQ=:CK5HH%C=B6,11Q7"PQ"3>C2
MDH=Q7RP<C.*]*^.VL>(-!^%VL7OAEKB+4XV@!N+2U^U3V\!F19YHX<'S'2(R
M.%P<E1P>E.\!?&OPE\1M5ETW09-2>ZBB,["\T6\LTV@@</-$BDY(X!S75>)/
M$FE^#]!OM:UJ^ATW2K*,RW%U<,%2-1W)_P YS53^%7_K7Y>GIU)A\6G]?UN?
M*^@_$.SM/%'AV+P%\7?%WQ"UJZU.V@O-"U2RCF@>U:0"XDE*VL9MS'&6<-N4
M94#!SBOKJO*=#_:8^'^O:M9:?I]QK$ES>2K#"S>'-0CC9F.!F1H H'/WB<>]
M>KU7V;?UTT_KN3]K^O/^OD?&:?$.V;[9<>./C1XT\&>.$N)P_AVQTV)(+5A(
MPCC@@-HYN$VA<-N??G.>>/I_X2ZQKOB#X9^&=2\36S6>OW5A%+>PO$8F$A49
M)0_<)ZE>Q..U<GJO[3WPVTS5KRP;5;S4+BSF:WGDTO1;V^B213AD\V&%T+*1
M@@'@C!KTGP_KMIXFT6RU6P,K65Y$)HC/ \+E3TRC@,I]F -3'X--=OZ^?J5+
MX_O_ *^1\[?&#QA]A^*FK6'C+XB^(_AOX:AMK9M&.BVJ)!?EE)F>2Y:"3+J_
MR^7N7 P<'.:[G]G#Q7JGBC2?$?G:SJ7BCP]9Z@(=%\0:O9"UN+Z#R49\@1QA
MPDA=1($ 8#OC)Z#QY\=/!'P[UJ/1]<U.0ZL\(N/L-C87%],D9) =T@C<HI(.
M"P&<'%:_@'XD:%\2M/N+S0'O'M[>7R7^VZ=<63!L \+-&A(P>H!%$-G;7_A_
MZ7]6">ZOI_PW]/\ JYQ'[2'B'5] T;P[]FUK5/#'A^XU$Q:WKNC60NKJRM_)
MD*%08Y BM($5I-AV@]LY'#?"#QTEW\4M'TKP;\1?$7Q*\/7%O</K']LVJ/#I
M^U 89$N5@CP[/\OEDMD$D ;:]U\>?$+P[\-=#&J^)=1CTZR>5;>/<C2/-*V=
ML<<: L['!^503P?2N=\%?'KP9X\UZ+1]%EU5KZ56=5NM!OK2/"C)S)+"J#CL
M3S1#=VU_X;^G_5PGLKZ?\/\ TOZL:'Q _P"1L^&G_8P3?^FK4*X#]JBYD;3?
M#FFZIJ5[H7@:^N9DUW5M/TU+V2$+'F%"'BE6-'?.9"AQM RN[-=_\0/^1L^&
MG_8P3?\ IJU"K?C[XF:!\-K6TFUY[Y(KIV2/[%IES>DD#)R((W*]>IQ4RLUJ
M5&]]#Y^_9M_X1WPY\3$T7X9^(+WQ9X0N=/GGU::XTF&&*RG1HQ!LN8K>$.S[
MI 8R7("Y^7O[U\8X]<E^%?BI?#4;2Z]_9TWV..-59VDVG 4-P6/;/&<5B^!O
MVBO 'Q \8-X5T/5+D^(!:M>_8+S2KNS<PJP4N/.B0$98#\:[W7M;M?#>C7FJ
M7QE6SM(FFE,$#S/M R=J("S'V4$U<W[BOVW^_P#+;Y$PTEIWV^X^;=>\;_$/
MXG7FMZ_X"O/%?A_1M$M-/BM=-O\ 0(K9M1O&N'^U*RW=N9BJ1>6"R%1G."<5
M[#\7/O>"/^QFL_\ T&2N9O/VOOA=ILEJM]K&IZ<+J>.VADO?#^H0(TCL%1=S
MP  DD#DUTWQ<^_X(_P"QFL__ $&2GT\OZ_JW0GKO_6W]=V6?C9J>O:/\*_$=
MYX9B>76HK;,/E6WVAU4L!(Z1?\M&5"[!,'<5 P<XKY,\-VO@+P?XJT?5?ACX
MWU?Q7X\GU"VBETJXT"V_TB-YE6X\[R[*-[<+&7;?N3:5YST/VYKFN:?X:T>]
MU75;R'3]-LXFGN+JX<)'%&HRS,3T %>9:5^U!\.M7O[6UL;O5YI;J18H9%\.
M:B(W+$!3YGV?;M.?O9QWS4PTJ76^G]?,J?P6>VO]?(W?&W_)3OAQ_P!?%_\
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M/X#TC3[/X%6E_:BUGNKW0+?[1?6L A6YV0 *VP ;1C/&!C-%/X)-;?\ !?\
M7JQR^)(]7HHHH **** "BBB@ HHHH *X#X2_Z[QS_P!C-=?^@15W]<!\)?\
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M1&]N6R<JK?/NPY:<9  %>A?&ZSN]2\/Z;9VFC)J\D]\ ?.U^?1H8 (Y&WO/
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M%H9'!1KN99) \O49WM\H0$Y!KL/BQ;BZ\ ZG&=.U[50P3_1/#-]]BOW^=?\
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M1#2?,_ZTT_X/R*EK#E%\;?\ )3OAQ_U\7_\ Z2/7?5P/C;_DIWPX_P"OB_\
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M>:T21J(V-RRJH$:9RI)Y).3FBGO*_P#6SM\[7]5YA/:-OZW_ "_7R.S^!_\
MR17P!_V+^G_^DT==M7$_ _\ Y(KX _[%_3__ $FCKMJ "BBB@ HHHH ****
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M_P#]BYJ7_I38UW5 !6/XNT?4->\/7=CI6LS>'[^8*(M1MX(IGAPP)(2160Y
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M "),W_8:UC_TY7- '<T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$OHQ(][I>IK=VL?]AS:Q"[^5+'B6WB(8KM=B&##:P4^QVG?DC_774RA;F?\
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MMUN$_B7]=%_6O7RL=_117,ZQ\2_"GAZ\EM-4\0:?IT\6/,6ZG6,)D9&2V *
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M[L1E59GWD+M4Y]#P'[*%C!K$%F+#7_'6@PZ3;PW*>%M8&EBTEM9?,6)U^RP
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M0!ZE17EO_" _$[_HJ\7_ (34'_QRC_A ?B=_T5>+_P )J#_XY0!ZE17EO_"
M_$[_ **O%_X34'_QRC_A ?B=_P!%7B_\)J#_ ..4 .^/G_(*\%_]CAHW_I4M
M>H5Y%=_!_P 8^(-0T1_$?Q&_M;3=-U.VU3['#H<-N99('#H"X<D#(&>*]=H
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M+6VGE_7K>W]:GHG[-JV\?@O58BNK#78M6G36VUN2W>Y:]VIN)-O^ZV[/*V[
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MVFW('F0[V1LJP965E(96#*"&4@@@$&E+^''Y_A)WM_G;5W=BD_WDF^_Z+?\
MR[:'Q;X+\0:/X@\3>&$GT#QAH_AWP[-I^B7<37NG26[NNH2"R\[;^^95N5(_
M=8R%0MGD5]S7$ZVMO+,_W(U+MCT R:^*?"?BSX=:M-X=CUOX=>%X-1TN^TI-
M ^R:J9]0@AEU!XE61V02?:(9D,CQY8$,V6ZY^V6 8$$9!X(--W=+W>[_ $?W
M]_NZ _XKYM[+^ON/AOQ!\3)OB#X@>WTWPCXLT37/$%Q8^);:XTG4M,<A192K
M&R_:/E0M;1ON5@=K!<=2:^N?A+)HLOPN\)/X<2:/06TJV-@EP<RB'REV!_\
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M>[_,*XG5?^2U>%_^Q?U;_P!*=-KMJXG5?^2U>%_^Q?U;_P!*=-K,T.VHHHH
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M_P#A/?\ W30!WE%<'_PC/Q!_Z'G2_P#PGO\ [IH_X1GX@_\ 0\Z7_P"$]_\
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MM)\(_';6KC7YBEMY2)#JT-U,8K5?*4_9[E5/E*-Q=EW#(+9_BS0!W4.K>(O
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MVG+6ZR.D1ESC'F.%P3UZ55_9RCM[KPK=W4LWB:\U(W9>>7Q39PP2)(44'R!
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M_/<,"(OM-T&:Z!Z$P,H-13_B:>7]>?W:?,J?\/[_ .OZW^1[9XV_Y*=\./\
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MMV1R*F6Q4=T?,NH>%_AE?:MX;MK7]GZ\^'6H_P!N:?-:Z]_PC^DVIADCN8Y
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M\*_BCXDB\/>'?%L4^N3(TD&GWMI<6,TZJ,MY2W$:&3 Y(7/ )Z UZQ0!YO\
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M&!P.<5SL>J>)-!2SN=::TU**\N(K<P:;:NC6S2.%!W,YWHN1N8A> 3CM78T
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M3IM=M7$ZK_R6KPO_ -B_JW_I3IM9FAVU%%% !1110 4444 <+J/_ "7+P_\
M]BYJ7_I38UW5<+J/_)<O#_\ V+FI?^E-C7=4 %<%\;OARWQ8\ OX:VVLEO<:
MA83W,-YGRI;>*[BEFC. <[HT=<="3@X%=[12M>UQWML?,\O[$OA'1]7U'5O#
MF@:%IFI'Q'IFK:;-';&)K&W@:V,\2, <%_*F/'!,G/<U]+GI2T4_L\O3_@)?
MH+K<^7_#/["W@J./P?<^(?#?A_4-1L([LZR_V;S/[1EE^XY9@"2IYY'>O;/@
MSX(N?AM\+?#7A>[DADN-*M%MF:V),?!. N0#@# Z=J[2BGLK+8'J[O<\5^(7
MP#U+Q%JNLZOH>M:=9:IJ.KV>IJ^J::;J.)8;1K9HV42(74ABP&0 2>N:]-\"
M^%8O O@O0O#D$\EU#I-C#9)/+C=((T"!CCN<5NT4H^ZFEU_1602]YIOHK?C<
M**** .5\=^!(_&]QX9DDN%A&BZO'JHCDB\Q)MD<B;",C!_>;@W."H.*XWX$_
M!34?A3)J5SJVLVFK7=Q;6^GPK8V1MHX[:!I6CWY=S)*?.;+\# 4 #%>N44+W
M;V_K;_('[V_]6;?YLX*Z_P"2[Z9_V+=W_P"E5O7S-^T?X1^(?Q)\8>/M'\/_
M  _^&5QINFB'5(&\4+)+J.J7"6F%N8XT^1MF3$/-&,K@\5],W7_)=],_[%N[
M_P#2JWKXF_:H^'&I:'\=O&/B>W\5?"C0EU*!GDE\5:W-'JOV2333:2PF%(SN
MBS^\5!G+*#WQ6-3?Y/[^G^?_  ;&U/?^MNI]K_ AO'#?"GP\WQ%ATJW\5FV3
M[3#HZ,D*# VJ5;HX&-P7Y0<XXKOZXCX)ZMH^L?";PG)H?B&V\5:?!IMO;+JU
MK('6X:.-49CSPV1RIY!X/-=O796_BR]3CH_PXA1116)L%%%% !7Q!X/^,7A'
MX6_MM_M00>*;^\LAJ#^&C!]CL[F<G9I:[OF@1BOWAU(S^=?;]?"7A[_D^+]I
MG_?\-_\ IK2@#W<_M>?"1C ?[=UC]SPO_$HU/G_>_=?-_P "S0O[7GPD5IV_
MMW6,S##9TC4L#_='E?+_ ,!Q6+10!L-^US\(VABB_M[6=L9RI&E:F&/U;RLM
M^.:M+^UI\+3<-<+JVMEG7;_R!-3*8XZ+Y.T'CJ!7.U[QX0G^T>%],?\ Z8*O
MY#']* /)?^&JOA7]E\C^UM?V;MV?['U7?G_>\K=CVSBI#^UE\+3<)/\ VKKF
M]%V@?V)J>W'/5?)P3SU(S7MU% 'S;\-?&'@KXO?M)>([S1M1U^673O#NDSPJ
M9M2T^-V6[U'S!+&Q19E&^+:D@91N?:.7KOOC7\+O$/C+5O"'BGP=JNF:;XM\
M*7%Q-91ZY:O<6%RD\)AE201LKHVT@K(AR""""&-:&A_\G#>-?^Q6T'_TKUBO
M1* /GN+X7_%[XE^*_"=U\3=3\$Z=H/AK5HM<@M/"=O=R75U=1(ZQJTUP0(XQ
MYA+!4+,!MR 37T)110!P7QJDT&/P63XCNO$EGIOVB/\ >>%C?B\W\X'^A R[
M>N?X>F:\\_9IN=#G\7>.U\,^*/%.NZ/&MD#8^+3JIN;"8K(653?*#L==C87)
MSG)QM ]"^-FK?V+X)-S_ ,)%KWA?_2(U^W^'-'_M2ZYS\OD_9Y_E/=MG&!R*
M\W_9G6]U#QYX^UJXU/Q/XFM+J'3X;;Q!XGT9M)ED"";=;I 8( P0MN\P1C/F
MXR=M%/>7]=OZZ?YD]E_77^N_^7T-1110 4444 %%%% !1110 4444 %%%% !
M1110 5Y5X-U+5])^%%_<Z)HT>OWR:UJV+&2[%J'0ZG<[L2%2 0,D X!]17JM
M<)\'V5? MR6&5&L:R2,9X_M*ZJ)_"QQW/BKP_>MKDG@>-[7Q!X9\&WCV.CV>
MHZSX=>Z81PZC]HM4M[BUD=!DD1K-(%!7#8/4_HA7PUH=OXEO] \/75ZVM>'_
M (#ZEJEI/96D-W:7LUI&;I&MDE)B66" RB,%5>5D#8RH''W+6W_+M+S?KT>O
MG<F7\1OT_"ZT^21\]?M6^/O&/@V&$>']<;PO8QZ'JFIC4%L([K[3>6T:R16K
M&162-63S7/&6\L@$8K1_9/U&'4-!\:&*[L=3E3Q#)]HU/1_EL+V5K>!VEA0%
M@A^;#J&(\Q9#WP.6_:ZGUNWU[1IM.M/&.H0PZ+J$UO!X:AN);=;Y6@,)NHXN
M)T<>9&8W###D[>I'H'[-OBB[\3>'?$.;*XM=%L]8DATB2ZTEM,>2V,44A4P%
M$(V2221[MHW>7GDY)BCM)^3_ /2U_5MK6;U'4WBO/_VW^O.][:'SY^W+XA\,
MVOCC5(+VWU?2M1L?!Z7=SX@TF:-Y"&U*+[%;+:O\L\AN(B02PVY/7->V_L81
MZ%'\!].?1+K6;MY;Z]EU.3Q!$L5\-0:X<W2S(ORHPDW#"\8Q7 ?M6_"?Q/X_
M^+?A37-+^#>B_$*R\.VJ7<5_>Z^VFW#7 F+"!0,JZKM23]XI7)X/45T?[#VJ
M7\?PYU+P[J'PWUWX?7&E:C<M)_;%Q]J%]))<2EY%G)S(V1\S8 .05R"**/\
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M#)+"JR2KN,.0Y#"0,HX)KZFT736TG31;M=376&=P\Y4E S$A!M51M4':.,X
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M ^$O^N\<_P#8S77_ *!%0!W]%%% !1110 4444 <3\#_ /DBO@#_ +%_3_\
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M]*=-K,L[:BBB@ HHHH **** .%U'_DN7A_\ [%S4O_2FQKNJX74?^2Y>'_\
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MD @G)SD] ,5U- !1110 4444 %<!\)?]=XY_[&:Z_P#0(J[^N ^$O^N\<_\
M8S77_H$5 '?T444 %%%% !1110!Q/P/_ .2*^ /^Q?T__P!)HZ[:N)^!_P#R
M17P!_P!B_I__ *31UVU !1110 4444 %%%% !1110 4444 %%%% '$_$#_D;
M/AI_V,$W_IJU"NVKB?B!_P C9\-/^Q@F_P#35J%=M0 4444 %>?_ !<^_P""
M/^QFL_\ T&2O0*\_^+GW_!'_ &,UG_Z#)0!Z!1110!P/C;_DIWPX_P"OB_\
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M^%]F+37-/UZT:XF,4NE7+W%K N\CR(Y'.YE0@CG&#D   "L+XV?'R3X:^,M
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M#)+(Y9F8]SSCGL .U:E5=+U*'6--MKZV\SR+B-94\V-HWP1D95@"I]B,U:H
M**** "BBB@ K@/A+_KO'/_8S77_H$5=_7 ?"7_7>.?\ L9KK_P! BH [^BBB
M@ HHHH **** .)^!_P#R17P!_P!B_I__ *31UVU<3\#_ /DBO@#_ +%_3_\
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M6)R=HKI-<LYM0T\P6]\VG3-)&PG49("NK,,9'4 K^-7U8-]T@_0T <5\0/\
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M[.6FG&Z>_P#27X(*XG5?^2U>%_\ L7]6_P#2G3:[:N)U7_DM7A?_ +%_5O\
MTITVLC4[:BBB@ HHHH **** .%U'_DN7A_\ [%S4O_2FQKNJX74?^2Y>'_\
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M%:V\<*V=HQ:& *H 1#M7*C& <#@=!7S2OQ)\,ZYXTTM]4TFZTP2:C$X^SZM
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MY:7%F_B<74MR(HX_"^FI>2L2I/[W?#*L<8QDM@'H!DG!I? ^ZU^^M=5N-?\
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M[;XX6=]J7A_3;.PTZ6_EGO@I9?$MUH,<"B.1M\EQ; R$<;0@4@EAG&,CSGX
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MZ*** "BBB@ HHHH XGX'_P#)%? '_8OZ?_Z31UVU<3\#_P#DBO@#_L7]/_\
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M1=*AN"=.A\*:@MS#-&$C\QR%BC P[;<X^H'!/I6HRK#I]U(T0G5(F8Q,0 X
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MNO\ T"*@#OZ*** "BBB@ HHHH XGX'_\D5\ ?]B_I_\ Z31UVU<3\#_^2*^
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MKC?[4\?_ /0M>'?_  ?3_P#R'74:7)>S6$+ZA!!:WI'[V&VF,T:GT5RJD_\
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M_#?_ *:TK[NKX2\/?\GQ?M,_[_AO_P!-:4 >M[1QR>/>C:.>3S[TZB@!NP8
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MNO\ T"*@#OZ*** "BBB@ HHHH XGX'_\D5\ ?]B_I_\ Z31UVU<3\#_^2*^
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M._UVST.\NM(N+9I-2T_[4C6TCJK^4=ZF.7('S?,,=0<"I^TEW_R;_0I;-O\
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MBMH/_I7K%>B4 %%%% !13694&6(4>YI%FC8X#J3Z B@!]%%% !1110 4444
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MT\(_]^[K_P"*J_H*^/1JT']M/X<.F?-YHL$N!-]T[=NXX^]C.>V:0SKZ***
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M)RS$FO7ZZJC3:MV7Y(Y:::CKW?YA7$ZK_P EJ\+_ /8OZM_Z4Z;7;5Q.J_\
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M/7MW7[0OA3Q!XVTW0[/P??65OXFTZ];488[C439N%^SS1"176*1L!Y%)&W#
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M)Y_&E'2[_K:WX?GJ-ZG(^-O^2G?#C_KXO_\ TD>N^K@?&W_)3OAQ_P!?%_\
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MG>0:A:PW5K,EQ;S('CEC8,KJ1D$$=11'^'&WE^2_K\@?QO\ KJ_Z_,FHHHH
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M[\8%:31=*BM1<KK$NI1)ID]M/'"8+@H^'9Y$D4+LW@Y1\[L!22*TK+WFO/\
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MW,5O#<VMG%!+%:_ZI&5 "%]JH_$]$F\$W]N]O?7:W#1P>1IL%O-,Y>15 "W
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M^OII^_1].NH&C-C]E'EOFVVH&*YVH2[R$&(C>>:]7U8@:7>$W/V,>2^;@?\
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M>'O^3XOVF?\ ?\-_^FM*^[:^$O#W_)\7[3/^_P"&_P#TUI0!Z[1110 4444
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MHZE<::L< _X5[?:I=NV6VK'J49\F%L_=+*?+/S'BB=G**7];_/[M2H)^]?\
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M110 5P'PE_UWCG_L9KK_ - BKOZX#X2_Z[QS_P!C-=?^@14 =_1110 4444
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M/J[+X4S^5XF=/^>ENR_D5/\ 2@#:T/\ Y.&\:_\ 8K:#_P"E>L5Z)7G>A_\
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M_P"QFNO_ $"*N_K@/A+_ *[QS_V,UU_Z!%0!W]%%% !1110 4444 <3\#_\
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M444 %%%% !1110 5\)>'O^3XOVF?]_PW_P"FM*^[:^$O#W_)\7[3/^_X;_\
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MFMLUVWEIB3:J("-NT @=!@DD&JWQDT>RUSPI#;:E).FGB[C>?[+HXU24J V
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MP)AN_5_F>9?![5-(;X@"RT^VT>[/]FS-'=:5XNN=:%FBR1#R1%*@6!&RN-A
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M5K'PGXAC\*Z_+&/LVK36RW"P$,"QV-QRH(R0<9S@XQ42V*CNCY_^'>D^"_\
MA:EEXLTOQ;\3+U-/M5L6T_7K+6@DDD\Z*C$SQ*&0$\K@@<.2 N:^H[^S34+&
MXM9'ECCGC:)GAD:.10PP2K*05//!!R*\-_9S\+ZCH>K:M<:YI=S?ZS)"(Y?%
MG_"3MK%O>X;_ %:*^PP$'YMBQ*@]37K/Q!CU.;P'XDCT4R#67TVY6R,+;7\\
MQ-Y>T]CNQ@U=1J-*V]D_U?K]XJ:YJO:[7Z(\^TO]G]O"/C[PUK^@^+/%$MI9
MR3+J.G:WXEO[^WN8GA95(CEE9=ZOL()XQNXS@CV&OGFZ\-_M$:]X)M=/;7O!
MND7S00-]MAAO/M,4B;6RQ\S:QRN&!X8$CH:^@;;S1;Q"<HT^P>88P0I;'.,]
MLU<E;2^QG%\UI6W1+1114%A1110 4444 %%%% !1110 4444 %<-\&?^1)F_
M[#6L?^G*YKN:X;X,_P#(DS?]AK6/_3E<T =S1110 5%<6L-Y$\4\,<T;C:R2
M*&!'H0:EHH ;'&L:*B*$11@*HP /2G444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6/XR%PWA#7!:W-O971L9Q%<W0!AB?RVP[@@@J#R>#P*V*SO$
M4T-MX?U.:YW_ &>.UE>3RY_(;:$).)-R[#C^+<,=<CK6=3X'Z&E/XUZG@_P1
MD\)>'?&4MSH7CG3]9CU+3X8]6CDU!+JXEU NB1,K! 0N"R8R!RN%&*]!^._B
MJT\)^$(KFXU;7]+D:<^4OAN&&6[GV122.H$J,H4(CN2<?<Z]CX5\+[7PY\2/
M'%KJ7ANW^(.BZIIB0NHU'Q9-<QRP/<Q,\OE37;^;%MC() *$-QE@M>X?'C1]
M8U3P]ITFCZ78:N]O<3":WOYU@79+:SP9WGH TJ[L$,5W <UK4O[--;Z_GI\O
MR6G0SI<JFT]O^!_7S]2;X":M>ZSX#::_UJ^UR9+^YC6?5;=(+R-!(2D4RHBK
MO52!E1@C!!.<UXE^T9XFT[P_\3->O/(L[74['1K6;_2/'6HZ'/J8W3%8H+>W
M^68J<@'J6D"U[G\#/"=QX(\!1Z/<3V5V+>YF\N[LNEPA;(D<Y.7))R22>F>:
M^?OCA-XW^'OC0#0O%NL1Z#;W2LMM?+;7$LLLT=Q.(;9VM)' )A$2[F<[I .
M!1*W/&WE^0J=^65_/\[GU1X1N-:NM!@EU^TL[+46R3#8W$D\87^'YG1&SCKD
M5Y;H_P 2/BSK'AW29A\,TM]0EDA-Q)=7\<4?E^8!*1&6\Q#LW8SD@XR#7KNB
MVLUGIZK/=W-Y([/+ONP@=0S%@GR*HPH.T<9P!DD\UX]X1_:"N/$'Q3TWPF+G
MP=JT5X;H.WAS7FOKJU\I2P::+R5"*2-I);AB!SFG]NW]:"7\.YZ!\6-B^!KR
M9CL:WD@N(Y/['FU8QR)*C(PMH?WCD$ _+TQGH*\^^!MUXQ\1^*/$&LZA=VHT
M3SXX5EE\)W.CW6H 0C#$3R[U",2N2F& X->E?$;PG+XW\+OH\=TUK%-<VSW&
M'9/-@29'EB+*00'167C^]Z5R?[/WPKU3X3^&[W3-1N[:2*25#;VMG++)%$JH
M%+@R<AG(W,H 4'IGDF8:<U_ZV_KY%2V1Q?[4WB+Q=H]UI1\-Z[+X;M+>)9KZ
M^<(8"DEU#!C!A<[E\PL3G@#[ISQZ!X=:\N_@VVIW\NH&[U'2H[J2WU'9YENQ
MMU#)\L:=P6.5!RQX'0/^(_@SQ9XHUS3_ .Q?$0T;19(#;:BJ,RSJGFHY> C@
M.RH8]S?=#$CFM6?3[_2OA6UEJE__ &IJ5OI?E7%[MV^?((\,^/<\T4]*;3WO
M^K_X 2UE=?UHO^":GC>6>#P7K\EM=/8W":?<-%=1QF1H6$;8<* 2Q!YP.3BO
MB3P%<>.$ATK3O#'AKXFZ8UX^AZA%<:S/.UO#>K*RZB9I)I3N@EA8-L(P6Y"J
MV*^X/%LR6_A7699=0;28DLIF;4$&6M@$),H'JOWOPKX2\[2?%DNFZ1K,GQBT
M?19#I%^/$M_XE,D9CGNMMM-+;K<%XEE>%@#M)3<I(6BG?VNG]W\W_5NMNMM'
M4_A:^?\ [;_PWE?I?7] Z*H:#HZ>']%LM-CN;J\2UB6)9[Z=IYY !C+R,<LW
MJ35^F]]"5YA1112&%%%% !7 ?"7_ %WCG_L9KK_T"*N_K@/A+_KO'/\ V,UU
M_P"@14 =_1110 4444 %%%% '$_ _P#Y(KX _P"Q?T__ -)HZ[:N)^!__)%?
M '_8OZ?_ .DT==M0 51U30M-UR%H=1T^UOXFVYCN85D4[6W+P1V/(]ZO44 (
MJA5  P!P *9-;Q7*A9HDE4'(#J" ?7GZU)10!4TO2;+0[&*RTZS@L+.(8CM[
M:,1QKWX4# JT0&!!&0:6BC?<"A9Z#ING7L]Y:Z?:VUW<*J33PPJKR*HPH9@,
MD <#/2K]%% %"XT'3+J^M[V;3[6:\MV9X;B2%3)&S !BK$9!( !(]!5^BB@"
MGJ6CV&M6[V^H65O?02(8WBN(ED5E)!*D$<@X''L*LPPQV\*11(L44:A41!@*
M!P !V%/HH XGX@?\C9\-/^Q@F_\ 35J%>6_%#Q9X@U3QM<Z=%I-[/8Z>[)(=
M/NM4@E@B/E!976T;]\'+L5PI($;#U*^I?$#_ )&SX:?]C!-_Z:M0J3XF>*]?
M\%Z*^JZ/HFGZO:VZA[O[9J,EJT2;E!8!8)-RJ"S$G& O>I>Z;V*6UD7OAM=0
MWOP_\.3V^G-I$$FGPLE@^[= "@^0[@&R.GS 'UYIWQ O=/L?"MT^I_;C;2/'
M"(],FDAN9)'D58TC>-E8%G*CA@.>3C-9GPM^($WQ"T[4[I[?34BL[S[+%=:1
MJ!OK6Y'EHY9)3''G!<J< X*GFK/Q2C\[P;<JVFR:I#Y]N9H8?,\U8Q,A>2/R
MR'WHN77:=V5&.:N>KN^OZDQ\CS/X*^'-=C\7W#WDNK64&DM<13VVKZ_>7MS<
M"9@\'F0N[PH%0X#QR/DCMR*[CXN??\$?]C-9_P#H,E1_!W2;O2++4Q>Z2^G2
M74L=RLEQ?37D\BL@Q')),[NS1C"GG;S@ 8J3XN??\$?]C-9_^@R4/HB5U9L>
M-M)\.LMKK>N:5)J+Z<V83;V<MU*-Q''EQ*S,,A3T(! /&,US?PK\5?#Z28:;
MX,TR71EU-'U%8AH5SI\-P$$<;2*9(D4D Q@XYZ5T?Q(\57'@_P ,MJ%N;6%C
M/% UW?$BVM%=PIFEP1\B@Y/([9('(X[X'Z;HU[-J^L6;6NHW%O<2646J:;>3
MRZ?-&XCE<VT4DKI"-YVLL9QNCZ\8"AN^W_#?JU_6U2Z=S<\;?\E.^''_ %\7
M_P#Z2/7?5P/C;_DIWPX_Z^+_ /\ 21Z[Z@ HHHH *XG5?^2U>%_^Q?U;_P!*
M=-KMJXG5?^2U>%_^Q?U;_P!*=-H [:BBB@ HHHH **** .%U'_DN7A__ +%S
M4O\ TIL:[JN%U'_DN7A__L7-2_\ 2FQKNJ "O&_CMI?BSQ%>6NDZ-I=MJ=C+
M")(XKZPANK1IU+EO.\S[A"B/:1C)=NO;V2L+QI?76F>'[B[M-7TS0FAP[WNK
MPF6W1>^X"6/';G=^%1+HWT*CU2ZG-_!.SU+3/"UW8ZCX>B\.?9KUT@MHK2"V
M\R,HC>84@D>/)9G&5;G:,X.:[V=@L,A:3R5"DF3CY>.O/''O7D?P4^(GBOQW
M=0/JDEE>Z=_9WFW%S9:+<644=UO4>7%-)-(EPF/,^:/(^4<\UZIK 1M)O1+;
MM=1F!]T"?>D&TY4>YZ?C5U6U'F\ORT_2_P"1--+FY?,\!TCQ+XJUCQX--T#Q
M?XDUZRDGM;NWNKJTTZWM39AT%SNWV\<LJD;MKP!A^\3YA7T57B/P?F34/$^G
M7"S:YJFGPZ9);:==7[P&"UP(#-"GEPQLP!,:!Y"Q)B<<8)/MU6URI(E.^H44
M45!04444 </\7$T>?PN;;5M4U32I+@M%9R:-<727)F*-C8ELPDDVC+;<$?+D
M]*P?@7H>I6\-YK%SJ/VFPO+>"W@A76[S4U,D32"64FY :)V+!3&!QY?))Z7/
MC1:ZM)#H=SHL.HC4+>>7RKK2D1YHG:%E12)$= CL0&=E(4<\=:VOA3HNH>'_
M  ='9:J&;4DNKEKBX<C-T[3N3/@ !=^=VT  9P!1'[3_ *_K_@:=42V2_K^M
M/SUZ.E=?\EWTS_L6[O\ ]*K>N]K@KK_DN^F?]BW=_P#I5;UWM !1110 4444
M %%%% !7PEX>_P"3XOVF?]_PW_Z:TK[MKXU^+7[!OC?QK\>O&?Q*\'?'2[^'
MQ\3&S-QI=OX>6[4?9[6.W7<[7*A_N,WW!C?CG&: .ZHKR4?L _&U1./^&L-5
M_?<M_P 4G%Q_N_Z7\OX8H/[ /QM*PC_AK#5<0G*_\4G'D_[W^E_-^.: /6J*
M\G'[ OQN$TDG_#6&J;I!@C_A$8MH^@^U8'X5&?\ @G_\;#;K#_PUCJVQ6W _
M\(I'N_%OM>2.>A- 'KE%>4?\,#?&[[1Y_P#PU?J>_;MQ_P (A#M_[Y^U8S[X
MJ(?\$_\ XV"W>'_AK'5MC-N)_P"$4CW?@WVO(''0&@#WGX(S>9\7/&B_\\_#
MNB+_ .3>KG^M>YUX%^S?^S-X@^"^H:CK'BSXGZI\1=>NXDM?M,EFNGP"W0NT
M:/"KOO96EE(<MQYAX]??: "N(^,7@.?XD^"6T")H&@GOK.2\M[EF6*YM8[F-
MYX6*@G#QJRXQ@YP>":[>BCL!\_\ [/?P%U'X3^./$M\ND:'X<T*=[N*VM=$D
M.;Y9+R2>&::,1HD;11,(E W'!/(  KZ HHIWT4>PNKEW"BBBD,**** "BBB@
M HHHH **** "BBB@ HHHH *X;X,_\B3-_P!AK6/_ $Y7-=S7#?!G_D29O^PU
MK'_IRN: .YHHHH **** "L[Q%8W^J:%?VFEZDVC:C-"R0:@L*S&W<CA]C?*V
M/0\5HUQ7QI\>7/PP^%?B3Q19VL=Y=:;:F6**=BL6XD*&D(Y"+G<Q'\*FIEL[
ME1NY)(\(U'3/C+9?%B[\(K\9YFMX?#;:X+D^'++<7$YB\O&WI@9S7N'P%\4Z
MEXX^"?@7Q#K$RW.K:IHMI>74RH$#RO$K,P4<#))X%>%>!_BUXXT_XP1Z-XJU
MSPKXOM=0UE?#RIIFEFUNA&^G)?>?$WG2;X 7*LK#H5;=SBOJ;2=)LM!TNTTW
M3;2&PT^TB6&WM;>,)'%&HPJJHX  &,"M(W4->O\ P7^4HKY=S-M.>G]:)?G&
M3^9;HHHJ2@HHHH **** "BBB@ HHHH **** "LKQ79V^H>%]8M;Q();2:SFC
MF2ZE,43(4(8.XY5<9R1T'-:M<W\0= U7Q/X5O--T?4++3KJX4HS:E8F\MY(R
M"&CDB#H2K ]F!J)ZQ:+@[239XQ\-?BUHOB+XA:1I\&N?#V_\0+I_V*RAT7Q7
M)?S-:K)&TP"F( OM56Y.X[>3@$UUG[2WAQ/$'A?0I7$4G]GZJET+>Y\.3:[!
M-^ZE3;);1.A(^?(8GY2!WJ#X-^ ?%WA_Q5<7_CG_ (FFK161M;75K.ZB^PI"
M74F**W6*-HB2BGYO-.%QYAH_:BLTOO!^EHWAK3?%$D5W-<QVVMQ--8HT5G<2
M;I8@/WF0A50<#<RG.0*NHTH)_/\ \FO_ ,%^=R:46Y.*[6_"W_ ]"]\ ?%FG
MWVAR:%:62V]Q8O(TS:?X6N-$L0V[E%CE9P'&>1O)/7 KS_\ : \8MH'B+Q=<
MOXD\3V]WI&BQ7>DVGAVPOKBWM9]LS%KOR+=XR&*H0)6(V@\+U/:_LNZ%X?T_
MP#=:EH7A;2/#3:E?2R7#:+;>3;7A5L++&"H/ED9V@Y YP2.39^(7PW\:>*O$
MFI'2O%2:+H=Y:H2(0PN%GCCE6-.A4Q%Y%=NYV;>AJJE[Q[Z?E_7_  Y-)IW?
M2_Z_U_PQZ/X;UJ/Q#X?T_4X5G6.Z@651=6TEM)R/XHY &0^S &OE_P""VM>+
M?%/Q<TN7Q2_B[4KBQNKIX8[_ $;[%86,3P2 _OA90^:RL!'CS&#;U<#Y<CZO
MA5HX8U=M[JH#,!C)QUQ7S/I/Q<L;'XN"QL/&?CC7Y--:7^V?#EYX?>7RXY%/
ME.OE6JNN' P6;!4]^*-/:Z>?]?TON$K^RU\OZ_I_>>S?&:W%U\.-7B:[O+(,
M(\SV%E=WDR_O%^[%:,LS?\ (P.3QFO/_ -FC1KL1ZY/>MJUU;6=[MTV^U&VU
M*P,Z/#'YF;>]F=_E8$!B O=>]=;^T)$UW\(]6*7UKIZA[:1VU"YEMH94$\9:
M%VB5I,2 &/:HRV_'>O/_ -EV\U2\FUB[T>+PR/!5Y<K(MII.JW<CZ<PA4;5@
MGMD*[SASRHPP(!Y)FGO/^NQ4MHOS(?VN;7Q//-X<;08M<DM5$WVGR)KD:5U7
M NXK,&ZDXS@+^[QNW'I7K%JJ1_!R!8Q:J@T=0!8QO'!_JA]Q7^8+Z!N?6O+?
MVK/#HUB33KF>TU'58[6!9;>RM["^N+=)8[J&1WD-JC[2T2.@R,\G'4UZ)X9F
M6X^ >ERIJ<FM(^@Q,NHRJRM< PC]X0WS GK\W/KS13_AR]?\_P"D$_C7I_D=
MQK=K;7VC7]M>VYN[.:WDCGMU4L98RI#* .3D9&!ZU\X0_ CPQ#I7A'Q3/??$
M"]T18-+LE\,3VY:61(KIY;07D8B\[; T_(9@ L8+[L9KZ<HH7NRYEY?A?_/3
ML#]Z/*_/\;?Y?,**** "BBB@ HHHH *X#X2_Z[QS_P!C-=?^@15W]<!\)?\
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MFD0LH8@<@;AEL<U'\)O$D/BSP+I>HV>F?V1ITD,8M;4I+&40(N05ECC8 -N
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MO7>UP5U_R7?3/^Q;N_\ TJMZ[V@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 5P'PE_P!=XY_[&:Z_] BKOZX#X2_Z[QS_ -C-=?\ H$5 '?T444 %%%%
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MUPUN@&PYW2J"4'JP&1U[5H5S_P 0K?[7X!\2P?8FU+S--N4^QH2&GS$P\L$
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M/B;_ -"CX3_\*FZ_^5U']L?$W_H4?"?_ (5-U_\ *ZC_ (4SX?\ ^@AXL_\
M"QU?_P"2J/\ A3/A_P#Z"'BS_P +'5__ )*H /[8^)O_ $*/A/\ \*FZ_P#E
M=1_;'Q-_Z%'PG_X5-U_\KJ/^%,^'_P#H(>+/_"QU?_Y*H_X4SX?_ .@AXL_\
M+'5__DJ@ _MCXF_]"CX3_P#"INO_ )74?VQ\3?\ H4?"?_A4W7_RNH_X4SX?
M_P"@AXL_\+'5_P#Y*H_X4SX?_P"@AXL_\+'5_P#Y*H R_%7COXA>#_"^L:]?
M^$/"[6.EV<U].(?%%RSF.)"[;0=.&3A3@9K4_MCXF_\ 0H^$_P#PJ;K_ .5U
M<3\0='^#?A42Z'XV\=W&CB_MF#Z?KGQ!U"#[1 ^4;*27@W(?F4\8/(K1\&Z+
M\,/B+]J/A7QSJ?B46NW[1_9/Q U*Z\G=G;NV7AVYP<9]#0M=@>FYTO\ ;'Q-
M_P"A1\)_^%3=?_*ZC^V/B;_T*/A/_P *FZ_^5U'_  IGP_\ ]!#Q9_X6.K__
M "51_P *9\/_ /00\6?^%CJ__P E4 ']L?$W_H4?"?\ X5-U_P#*ZC^V/B;_
M -"CX3_\*FZ_^5U'_"F?#_\ T$/%G_A8ZO\ _)5'_"F?#_\ T$/%G_A8ZO\
M_)5 !_;'Q-_Z%'PG_P"%3=?_ "NH_MCXF_\ 0H^$_P#PJ;K_ .5U'_"F?#__
M $$/%G_A8ZO_ /)5'_"F?#__ $$/%G_A8ZO_ /)5 !_;'Q-_Z%'PG_X5-U_\
MKJE^&^A>(-+OO%NH>(;73;*XUK5$OXX-,OI+M(U6SMK?:7>&(YS;[ON_Q8[<
MQ?\ "F?#_P#T$/%G_A8ZO_\ )54? NECPS\5/%FBVM]JMSIL>CZ5>1PZIJMS
M?F.62;4$D96GD=EW+#&" <?*.* +?C;_ )*=\./^OB__ /21Z[IKB*.5(FD5
M9),E$+ %L=<#OU%<+XV_Y*=\./\ KXO_ /TD>O#_ /@HE>:#9?"6QDECUH>/
M$N=_A2[\/PW+7EO<AD\UD:$?+^[)X?@^]3*7+8N,>9V/JZBODO\ 9,^-'Q3\
M4^-KOPIXF\-^)-3\'0633V/C3Q)H3:/=NP*@0RQ9*RD@\2*$SMY7FOK2M)1M
M9]S*,KW\@KB=5_Y+5X7_ .Q?U;_TITVNVKB=5_Y+5X7_ .Q?U;_TITVI*.VH
MHHH **** "BBB@#A=1_Y+EX?_P"Q<U+_ -*;&NZKA=1_Y+EX?_[%S4O_ $IL
M:[J@ KB?BMX9UGQ-I.CC0HK&>^T_5[34O*U"Z>VB=87W%=Z12$$\#[O>NVKS
MKXN:?_;.L?#K3)+W4[*SO?$,D=R-+U*XL7F1=+OY C20.C%=Z(VW.,HIQP*
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MINO_ )74?\*9\/\ _00\6?\ A8ZO_P#)5'_"F?#_ /T$/%G_ (6.K_\ R50
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MWQ)JNDOI,VJHVX'?:,S;'& 25;!W=!7T=6DH\IFI7OY!1114E!1110 4444
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MSP["_P!FM_\ 5QY@!VK\S<#MR?K7)_M,S7<-QH[V^C:WJD2PS&1M)U76[-4
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MT8:#@?NF"!DX^ZRUZ#6]3231E'X4%%%%04%%%% !7 ?"7_7>.?\ L9KK_P!
MBKOZX#X2_P"N\<_]C-=?^@14 =_1110 4444 %%%% '$_ __ )(KX _[%_3_
M /TFCKMJXGX'_P#)%? '_8OZ?_Z31UVU !7GOAG_ )+?X\_[!.C_ /H=[7H5
M>>^&?^2W^//^P3H__H=[0!Z%1110 4444 %%%% !1110!X7^TSKW@Z^T6\\'
M:G;:E>>(K^R%S ^BZ!-JT]BBR9CGD2)&Q'YB="1NPP'>KG[._A2\D_M/Q_J&
ML:'JTWB2TM(;;_A'-.>RM$MH3*5)21V?S"TTF[=C& N.*XOX]>)IO#7Q/U*\
M\+^(K[0/%O\ 96G6+65O96UX=8\^YN%MHH8I73$B-YI,FX(%?Y@<<>L?L^1Z
M=%\'_#J:7]O\A4E$O]J>7]I-QYS^>9/+)3=YOF?<^7TXQ13^%R^7Y_I:_KYH
M)_$H]/\ @+]=O3NF>B4444 %%%% !1110 5P>B_\ER\8?]B[HO\ Z4ZI7>5P
M>B_\ER\8?]B[HO\ Z4ZI0 WQM_R4[X<?]?%__P"DCUY=^UIX>UG7=>\"'PGX
MSTOPEXPCCU2.S;6()9(1;O; 7-PK)Q')"F&5W^7+8[UZCXV_Y*=\./\ KXO_
M /TD>OGG_@HAILGB32?".BZ?H<FHZQ)#JE]]J35Y=."64%L'N[<M&K&3SDPN
MPC!Q651V6O\ 7_ [^1K23<K(]7_9.TJYTCP+JT,?C\?$GP]_:;?V-K;:J-2F
M:W$,0=9)O[WG"8[<G:& S7MM?.'[#UWH6H> _$]UH^AGPO=3:RKZAH<,\4UK
M9R_8[;8+=XU :-HO*?)&[+MNYKUWXKR>/(?"9D^',?A^;Q&LZ$1>)&F2U>+G
M>H:++!^F#@CUKIJWBU?M'\EV.:C[T=//\V=E7$ZK_P EJ\+_ /8OZM_Z4Z;7
M@4WQV^.-A\7/A9X9\8?#^Q\&Z7K.M2VEWJVFZO#J%MJ""TGD$2H4$L1W(K9_
MV<9YQ7ONJ_\ ):O"_P#V+^K?^E.FU'2_R_+_ #+OKR^5_P U^AVU%%%(8444
M4 %%%% '"ZC_ ,ER\/\ _8N:E_Z4V-=U7"ZC_P ER\/_ /8N:E_Z4V-=U0 5
MPGQ%_P"1P^%W_8QS?^FC4:[NN$^(O_(X?"[_ +&.;_TT:C0!W=%%% !114%_
M?6^EV-Q>7<R6UI;QM---(<*B*"68GL  32;25V-)MV1\I?'1OB'XH^)]YX>B
M\#&S\(-M":CH5[IBZMK'R@L!)<S*UN@.5^5"YQD.M>Y? GPO8^#OA[:Z5IW@
MB;P#;0RR'^RKFXBN)68G)F>2.20.SGDLS%CWKX\^*4GPU\>:]?:S:^(/ >J^
M)-1UJXECU#Q!=R6EU9VDMF(K=LM"75K>0B147:.4?<N_-??6E0/:Z79PR7!O
M)(X41K@]92% +_CU_&G3O&GKY?E?\-NW8F;YIZ>?^7X_?W+=%%% PKSOQ_\
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MBLRPHHHH *X#X2_Z[QS_ -C-=?\ H$5=_7 ?"7_7>.?^QFNO_0(J ._HHHH
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MH\P(K6UAL;6*VMH8[>WA4)'%$H544#   X  J6BB@ HHHH **** "N ^$O\
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M%% !1110!\<?&#7K+7/C5JWA;2G\1Z%X@>2/_3_$7CO4-"TJ<E%.;*WBE)G
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MIJ^PQ?;UMD$^PXRN_&[!P.,]JU:C2R_K^M!ZW?\ 7]:A1112&%%%% !1110
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MFQKNJYVZ\,SW'Q"TSQ")8Q;VNEW=@T1SO+2S6[JP[8 @8'ZBNBH *X3XB_\
M(X?"[_L8YO\ TT:C7=USGC3P'IOCRWTZ+4)K^V?3KO[;:W&FWLMI-%+Y4D1(
M>-@<%)I%(Z?-0!T=%>>_\*5TW_H9?&7_ (4U[_\ '*/^%*Z;_P!#+XR_\*:]
M_P#CE 'H5%>>_P#"E=-_Z&7QE_X4U[_\<H_X4KIO_0R^,O\ PIKW_P".4 >A
M45Y[_P *5TW_ *&7QE_X4U[_ /'*/^%*Z;_T,OC+_P *:]_^.4 >A45Y[_PI
M73?^AE\9?^%->_\ QRC_ (4KIO\ T,OC+_PIKW_XY0!Z%7G?C_\ Y*A\+O\
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M10!Q/_"WM"_Y\/%'_A)ZK_\ (U'_  M[0O\ GP\4?^$GJO\ \C5VU% '$_\
M"WM"_P"?#Q1_X2>J_P#R-1_PM[0O^?#Q1_X2>J__ "-7;44 <3_PM[0O^?#Q
M1_X2>J__ "-1_P +>T+_ )\/%'_A)ZK_ /(U=M10!Q/_  M[0O\ GP\4?^$G
MJO\ \C4?\+>T+_GP\4?^$GJO_P C5VU% '$_\+>T+_GP\4?^$GJO_P C4?\
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MAY9'FB?("= !&>OJ*]&HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@_A!#
M'<^ [J&5!)%)K&LHZL."#J5T"#7>5PWP9_Y$F;_L-:Q_Z<KFDTFK,-CSJ/\
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5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exdx-20221231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exdx-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X12P17AI9@  34T *@    @  0$2  ,
M   !  @      !H !@$#  ,    !  8   $:  4    !    : $;  4    !
M    < $H  ,    !  (   (!  0    !    > ("  0    !   4,
M  !@     0   &     !_]C_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!#
M 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X * # 2$  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M27QVV=P<J,;N6&0/D[CTH CL<2BY9PI,<GRD+C_EFO/UYIL__'V/^OQ/_1=
M%V\?RK&XDX^2-FYZ<"EM,&TA;=N+1J2_][CK0!SX=OM2ATQ\Z_B2Z>U:=M:L
M]II[ON1H>2KCGD8_K0!6N#G59%(Z.,'V_=UJ-_Q[7'_ OY4 23?ZL?[R_P Q
M5"R=6NE"L"5>Y# 'I^\% %I_]1)_US/]:IEA]NG7(W?:XSC/./+6@"\.B?\
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M;W<@9L*A\N>5 ,=C(F>/Q- %K[3(0RE% ,DB=.P4D'ZFJ"WLK-<,43<#'-M
M_B,8X^G% %]YW#X\N,XGC&2O7).3_A56RNI'C3Y%(-MM/']W>!_*@"=;V8QE
M_+3<8HI/N]V'/?H*<US+YNS8NTETZ=@F1^M "+>S&$R&.//V42\+QNP>/I6?
M%<&9-SHC!)+@ <X_U\1S^9H OV\I%RT:QHJM<?,0.>-O\ZNJY.J.FU< *0V.
M3D-Q].* )+R=XFA10,2,5;/IM)KGY[V6:WE9MJ'*R94'@F,_X4 3P-(-4MPT
MDJH6&T9.''D]_P <]>]5O-?R+/\ >NH)M,_,<G=)@@GCKTH OW0)UA@2%!=,
M=.>8^:UXX?)MXXRQ<I@;FZGF@"EJ7_'Y;GY1CN<_WEJVW_'M<?\  OY4 .N(
MT=/F16R0IR.Q(R*S+"V5;QF;#"26X<*5Z8=1_3- %YXT\F0[%SL9LX[\\UG_
M &91JEP_&PSQQ^7MXQL% &D(T.PE%.92>GINQ6=IMN(K9@Q#G[*K@D=-Q<X_
M6@#1$,6]AY:8WA<;>P7@4QHTV9V+GRF.<=\8S0 ^2WB<-&4 5@$^48^7'2LB
MPLD^UA&8E9'NGQT(Q*F.?^ T ::V\<2[E7YF9')//)(SCTZ5-M'G;L#<7QG'
M/W: '3PI*%9LYCRRX/?!']:P[B!;*9Y8VPJ3(JJ1G&(R?QZT 7K=HKZ=9G",
M]J T952-NY.>_H:+*6*]*AT@<!%D $>,$,<'J>XXH K78<:Q\H;ED).['&Y/
M_K_E6HLKO<3QD?+&4P<>O)H JZB$^U6[,<\8"_\  EY_ XJTW_'M<?\  OY4
M ,O99(U^3;PN[GU!&._2LNRN9C<2<)F.:=5X[&12>_N: +S2RE'7Y,99?PVD
M^O7-9ZW,[7]P"$XDCDX'\6P>_3B@#0\Z8;>$XE'ZEL]_\^]4=.N)I( 6"#-N
M%/'93(!W]J +HN)R&;"9PK_B1]>E#2R_=PFW:R_AMSZ]<T +]HGVEL1[O+W_
M / OSZ5GV-Q+]O/RK\DURB\?PF://X\F@"^T\H5<A -P!^@/'>I8)9))EW;=
MI"MD CDJ?6@">=V7:J[?F#9SUZ=JP;N2>YDDAPJ[GC8$ _>,9% &C8PR6_G^
M:2=ZH%X/9<'M3-,MIK5\S,3^Z"<*>H)_QH AN,C5Y.4&YX\9/) ,=:,9'VNZ
M'/WD/3V'^% $-^N;R!L]%(QNQ_$O^%66_P"/:X_X%_*@"MJ;E5<!5.(6;YO]
MY?TK-M4F265@"-]Q+MZ<KYB _P!>M %TL^&W '+R 9[#:<8K.C$WGW$ZJ "8
MMN,8W>7GZ^E &BSLK8V@XG0?F35+3DFCA4,,9M]V..A,A'3ZT 6E:<H>N3'&
M?Q(Y[4YC+YG^S\_Y;..U ";IS#DYS]G!_P"!=^U4K19([[<RC#W-P5SCIYT8
MSQ]#UH O_/((U(PK.0V/][ J>%0E]Y8!RBJ-Q[\'_"@"6[/[R/Y WRN?TKG[
ME)F260!4#", \8W>42??O0!<\B20.(D)5DM<8;C ;YL?A5_5X)KBVA2%-Q%S
M"S#_ &0X)/Y4 4+HK_;1ZA@Z#ID=8Z<)TGUF)H]Q1GR#Z_(OZ<T 6M1S]KMA
M@D'T'3YEJTW_ ![7'_ OY4 0ZANV-M8#Y#_$!W%4XSM$1)(.^<9 S_RV% $Q
M;*MAN-S@YX_A/YU55L13LS9Q.A)'S?\ +,>G6@"WSE06'$J]2/5JKQ' C&2/
M]"3M_LO0!)YF5;YVY1#]WU'UI6;YL;C_ !C&W_8^M  9 8R=[?ZD-G;Z]^O^
M?6H8@?M5OM!)WW/3_KX2@"R"=\0R?]8/?O4X_P"0BW3M]>AH DN<[DQTPV>?
M;]:S@,^2'7K<Q@J1_P!,AQB@!\ME]HN[R)&$64APVWH 2<#_ #WK6H PKH#^
MV6;:2=Z X/O'4-D/],L]CGRLG !(7A%QQW[]: -#42/M=N.<]1CI]Y:MM_Q[
M7'_ OY4 5]13<K?,HS$1R?\ :%54 (BR3]^<\?\ 784 2, %/7[[]?\ =:JR
M &WE'.#,G3_KD* +3*68,"O,Z'GZFH8?^6?7_CR3_P!!>@"154*W+<1H/R'T
MI6 W]6S\_P#Z!0 ;5$1 +X\@#\/RZU B[KFW''^LN#S_ -?"4 6E #0X).)/
M3U;-3@_\3%Q@<8YQST- $UQ'N ?=C8K=O45EQC MQD'%S'RO0_NA0!?U*9[>
MQ>2,X8%0#]2!5N@# FE6YOMREB/.08R%QAEX/K4-B2+VT*[0K,>",G[B]#VH
M OW$KR2V<C+L9TR5[CYEXJ\W_'M<?\"_E0!!J&[:V$#?NR>5SSE>*JQ([>4L
M?#;Y_;CSAG]* )F#HK;R?F9\=^-IJJN]TFVDEVN$VD\'/EC% %HB3?A5/^N4
M9 ZC+9YJ&!794*]!91YY]GQ0!,L-Q@J2=VU%^]_%CGO0T<V=V?EPS=>VW'\Z
M #R;C9M.XMY07AOXL?YYJK'_ ,?-N-N[Y[GC'_3PE %I [^6P)VK)\V3_M8%
M3@?\3%CD=N._0T 69?\ 4O\ [IK'\Q5BBE8@*+B-B1T \H4 7[Z3.G-+&N_(
M5E!3.>1VK)76KL:FT $4B-J M%#978HC+DY[G':@"2*T@ 6<3IYOF E"XQC>
M"3^2YJ&R8)<6K'RQSEV/4?*/RY'Z4 :JM&)(V^TPX6)D(WCDDC'\J<\R>7,B
MRVYWYP3+CK^% $SW%NR@?:(NH/WQV.:HVS>7=9DD@$:F4AA*"3O?<./I0!9D
M-M(F#<19 .T[QP2"/ZU355CNBJ/!Y!E20-YPR $"XQ^% %\30#;_ *1%PY;[
MX[Y_QJG9G8C+-) G[A(AB4-DC=D_K0!<\Z#<3]HBY;=]\>F*:9("FW[1%]PK
M]\4 /,\&[/VB+J#]\5EQ1L;E2\MNL<;RL&$H);=*KCCZ"@"^AMTCVK<1?>#'
MYQ_>R:4-;BY,WVF/G'&\=@?\: )7N+=D9?/BY&/OBLBXC?RQ#'+;E0ZD2&7'
M\&WI]?TH MW $VDBU2[MUFV*I9F!7C&:I-IL;ZHEW]NM45;O[1A%&X_NRA!)
M/?CGCI0!_]G_VP!#  ," @," @,# P,$ P,$!0@%!00$!0H'!P8(# H,# L*
M"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_VP!# 0,$! 4$!0D%
M!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!3_P  1" ,V!#,# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M_#UHFGZ#IMM'81:5'#;1QK80D%+8!0!&N!C"]!CCBL_XA?\ (@^)O^P9=?\
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M>IT4IU'.4*EM+;>=RKI>H1ZMIUM>1*RQ3QB15< , 1GG%6JQ?!G_ "*>D?\
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MOVHOAM\=/$&JZ'X-UV;4=6TN%;B\M+C3;JT>*-CA2?.C3.3Z5ZM7RW^P_P"
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M!R3MS@ U]2U\J?#?_E(U\8O^Q/T?_P!#:@"U_P +_P#VE?\ HU%?_#C:;_\
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M\5-+\067B7P\/"WC#PUJ)TO5],CN!<0K)Y:2))%( -R.CJPR,CD&O-/V#_\
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MTMM4D:60RF:'[=;!1;A"J#-QOQNP:ROK;^O\S2VES[/HK'\'ZIJNM>%=)O\
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M06U;Q#<^'X)-$MWGUJ*[6"6WPBGS/-?(!R.K9'K3E[M[]!1]ZUNIZK17QO\
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M"56217/&P@Y[<U$Y*,7)[%PBYR45NSU"WMXK6".""-888U")'&H554#   Z
M"I*^:_@%\;/B'XV\0:/IUSI+>+_"MQ:>;<^,ETJ;15MI/+W!/*F)%SEOEWPX
M7OBO=[QV'CG24RVTZ=>D@'Y>);7K[\G'XUM*+B]3&,E)71J7NFVFI+$MW;0W
M2Q2+-&LT8<(ZG*L,]".QJS7SO^UAXV;X<GPUK.G?$>;P?K,]_;6(TW9'>0W=
MN\P$LALRIDE9%).8BK<8S74? 'XE>.OB!_:Z^*O"K:;IMKY?]G^(&MY+ :IG
M.XBQF)F@Q@'YR<[N.E1#WTVNC:_+_-?ET+E[K2?6W]?UZGF7QD_Y2%?L[_\
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MQQXJ\:^$QI5PUW'K'AF'2[>RF5XA#B1;.#>6!D 13QMR>*]C^-__ "1?Q_\
M]B_J'_I-)7SWX=TGP-??$#1/$FG^,OBK.OAV">YN+75K'7-MP&:(  RQ*",C
MF, [@>F%KZ$^-QS\%?'Q_P"I?U#_ -)I*U?PK^NIE'=_UT,/]H8:4GA/3;C5
M/$&I>&A;Z@DD%_I>BQZI,LFQP (WMYPO!/SA01C&><'#_9K\3:]XBN?&(O\
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M'UP:]7_9ET/1?".A7FFZ9KOBC7GU":XUA9?$=M?1&.*2ZFVH!<J-KCD,.&;
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M_O/-^4?O/[W'7\:BG_"3_K9:?+^O+2I_$?S_ #M?Y]#@O *AK[XE@K*X.OR
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MR:=X=MKO5+;31J%Q;6KV\0EDAA*L&=0,\CH#CG%>R_MA?\FH_&'_ +%+5/\
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M9]Y^-$4<'P0\=Q1(L<2>';]451@ "V< "KM:*CVLODEI^%OQU9G>[NNM_O\
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M]6D_Y+S;_P#8M2?^E25I)N7O/=_+[UT].A,5RW2Z?UOU]>IY_P#&3XP-X/\
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M( K6][;KC<JG!5CE0<\5Z/\ $K_D/?#K_L8__;"\KSKX[?"_5O%7Q,T;7HO
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MNE68NY;=YF"31R[_ #<1V\8D,F"QDE"XP"!OI[6"\O\ +Y^NUMNACM2D_/\
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MD2O&+B-;D#R)2(W4@$\9+8KZJKYT_::UX:+KFGR0W\UI?Q+;309O[".%7$Y
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M^RSV$/VF[D\R:7;/$-SM_$QQDGN31#X'?>_]?H.7QZ;6.DKB_C9_R1GQ[_V
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MV.*_89\'WVFZ'XK\6Q>%K#P%X3\63VM_HGA?3=16]AMXU@"O.'0;%,IVG:O
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M?%/@NUBM+8>'4M+>TLD,)B19!"#)(=H.&D?G!.*[SXZ?\GU?LO\ _7GXJ_\
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M2>F3UKT7Q_\ \C9\-?\ L8)O_35J%;-Z?U_7];&:WT_K^OZ9VU%%%04%%%%
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M6 GA53YFO=4KV5E>4N;1=EL?-6N9_P"'CWAP]O\ A%9OY/4G_!0__DGWP_\
M^QQL?_0):^HVTNR;4%OS9P&^5=@N3$OF!?0-C./:O/OCQ/%'X6LHSI>FZE=2
M78:W?58XWBM62-W:8"1D7<JJV,LHR>O:NJGB+UJ4K?"K?F:U<-:A5C?XG?\
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M<#\2M _:?^#_ (>FUZ/XD:9JF@VO[W46TG0+(7%O$/O2B%H%#A1R0&S7VO\
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MS?6$%_I.AW0TZSTOPWJEB+N"5H0\SRW<**$&Q-L:EN6SN.*]V^-__)%_'_\
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M)FO-/O\ [+8JL<VDOYEIY9),:Q/@;T5"JAR 6VY/)JSI/_):/%7_ &+^C_\
MI3J=4OV?8-*A^#?A@Z'J;ZSI<UNUQ#?O9O9^=YDC.S+ X#1IN8[5/1<#GK5W
M2?\ DM'BK_L7]'_]*=3KHJ7YY7[F-/X58\:^('_#-W_":ZS_ ,)1X'M+_P 0
M_:&^W73^#;NZ,DO=C*MNRO\ 4$UZ_P#!>Q\#6G@M)?A[HT&A^'[F=Y!;P:8^
MGAI =K,8G1&!^4<D<X%>+?$321-XXUI_^$;^-UUNN6/G:!KGDV+^\*?:UVIZ
M#:/I7MOP9@^S> ;*,6?B6PP\G[CQ==?:-0'SG[[^9)D>GS'C%9T_@^1=3X_F
M<4G@?3O'6B^/(-0U*_T4V'BJ>_@U33)5CN+1TMX@70LK+]QG4@J00QXKPG0/
M#.J64?AGXCZ%X#:V\':/#!K%II"^+YUU*^M(+?R$O9+ Q&W:0PE3C>'.%&X'
MBOJ#X;VD6H-\0[6=-\$_B&YBD7U5H( 1^1KFO"'[,.G>$;>]A_X3/Q5JT<NA
M/X<M!J$]LW]GV;;?EA*0*=PVK@ONZ5,>:+;CZKU2>_SY5Z7>Z1?NR24MMGZ-
MK]+OUMW9O?%[5[7Q!\"]7U2QE\ZRO;"*Y@D'\4;LC*?Q!%<'^T)^TU+\-[^3
M2=#;[+>64R)?:C?Z'<W]DI:!I_)!@D1A((E,ISD;0>^!7=?%O1;7PY\"-5TF
MQC\JRL=/AM8(\YVQH451^0%<5\>/ O@G0]=B\4ZY:Z_XAN]9F^P6_@_2I%:/
M5+Q[62#S AV[76W,@+F1455R>0#55+<WN;7T_3[]O4BG?E]_>W_#_P!=C1^!
M/C_X@?$/4KFYUK4?#YTNQ<P7FGQZ!?:;J$4C('C)6XE.%*L&SMY!ZY!KLI/^
M2\V__8M2?^E25YS^SS=:?X+\6:QX;U'PYXO\*>(M>QJ44?BS4X]4%VD,:1,(
M+I)9<E%V9C=LC.0,5Z-)_P EYM_^Q:D_]*DJY6TMM_5_Q(C?6^YYC;:%X]\+
M_&+Q0^G^ SJ-OXB\1VEQ/XNDN;1HDTE8(4>W,;R"8%-DH 5",MGN:]&^"/@N
M]\"Z3XELI[%=*T^?Q!>W>F:?&ZLMO:NX*@!20H9@\@4=/,QQTKT:BHC[D4EV
MM\O=_P#D?Q?<N7O._G?YZ_Y_@NQPW@=6D\2_$Y4;8[:]&%;T/]E6&#7B?PG\
M%>,K3P:G@/Q#\+EM?#MOH%ZFK375S93C7=39H]LB%92X,G[YBT@7!9<D8KV_
MP!_R-GQ*_P"Q@A_]-6GUVU0XJ5T^JM^?^?WV[%*7+9KH[G*_"G1=5\-_#'PG
MI6NR^?K5CI5K;7DF_?NF2)5?YN_(//>OFWQHOC=_A#\+$\*W'B:V27P\8K>3
MPU&'VZBPMQ;FY^5@(0AGR6&T'D\[:^O*\ U*/6I?V,;2/P^E])J;^'K50NEJ
MQNS$1&)A"%^8R>5YFW'.<8YK2I)RDZC[W\OZ_+<FG'E2@O0P_@#K'CRP^+%Q
MX:\17OB+5[6"QO3>WFJO9368ECN(EM?L[V_[Q2T+MN$P!)&<9!KV+XC?\C%\
M.?\ L8F_]-U[7SKI?@7PY>:3+K?PZ^%-YX)U?0->TNUT34ET*?3;^\A>2'[4
M;C>BO)#M:4.SY4XSG.#7T5\1O^1B^'/_ &,3?^FZ]I_95]UIZ];_ (_@2MW;
MK_PWZ'SS^U-\2IKSQ%J&@7_@KPQXPTC1KE1%INK3RI>/(+"2\>= BL/+\N-H
MAQ]XDYXQ74?LHZ#\/-:O];UC0?"GA*PU[1+A;-M5\)WQO;21)8$DPDI53N ?
M:RXX(Z\\=3^T BVGB7P3'I,NF>&/$?B"]DTI_&,UE!)=V%HEO+/(D+R*0'?R
M]H#94;B<'%<O\';IO!/C7PU'HOBF\\7^%?&QOT+ZO9VL5[#=68(,HDMXH_,C
M(C9,."0=F#@XJ:6E_P"M?^"M/PV*J:\O]?U_3W*7QY_Y/J_98_Z]O%G_ *00
MUXU^W18^#KCXF:O9ZWX"^'-[JNHZ9''!X@\2>-$TV]3,957^S[=VU#T.?FVU
M[+\>?^3ZOV6/^O;Q9_Z00UXE^U+XLA^%'[2WB_7H+KP:#J6F6(NXO%7A#4M5
M$7E1MB19H(]B@AL$!L?*,@&L9V;BGY_D_P"M#:G=*37]:H^VO@C9R:?\'/ ]
MK+?Z?JDL&BV<;7NDA1:3D0J-\.T ;#C(P!Q7BO[!_P#R#_CS_P!E=\2?^C8J
M]X^%^I-K'PW\+7[?9-USIEM,?L%K);6_S1J?W<4GSQISPK<@8!KP?]@__D'_
M !Y_[*[XD_\ 1L5=E9MU9-]V<E*RIQ2[(]4^+OP[\2>+-<\(Z[X4U32-+UC0
M9[APVM6$EY#)'-%L9=B2QD'H=P.>/0G.%\(/AG\2/ ?BG6[W6_$7A74=+US4
M9-3OX=-T6>VF\UHDC41L;EE50(TSE23R2<G->J>*K+4-2\+ZQ::3="QU2XLY
MHK2Z;I#,R$(YX/1B#^%6='@N;72;*&\F%Q>1P(DTPZ.X4!F_$Y-8Q]UMK^K_
M /#(UEJDOZT_X=F7X@!_X2'POA01]KFR3U'^C2]*XGQQ\%-5\1>-K[Q+H/Q"
MUOP9<7]A%I]W!I=M9R),L;2%'/G0N0X\Q@"".*[7Q"!_PD7A;*DG[7-@CH/]
M&EZTGC3PV?%%MID"ZG)IK6>I6NH%H^LJPR!S&>1\K8P?Y4FE)I/O^#T?X=!W
M:3M_75?B<Y\&OA3J'PDT--&F\9:IXGTNW@CM[*WU"UM8OLRKGD-#$C,3D9+D
M],]S6OJ6@V/BCQ!XFTG5;..]TR^T>TM[B&0<2(TEV&4_@?UKK%D63[K!OH<U
M@V0'_"?:R=IS_9EC\W8_O;OC_/K52][XA1]W8^2;WX0P?$U8[+2+;P3X<\-Z
M?KE]H_AVV\0Z7<:IJ&HW4,DCW,CW7VE)(]TD$K#!9L)N)Z"O:-<\=3_$3]F/
MQ#J][9)IVI+;7=E?6L4GF1QW-O,\$P1L#<N^-B#CH173Z?\ L]^!=+\>CQC:
MZ7=1:XMW-?J?[3NC;)<2JRR2K;&7R59@[Y(3^(GJ:J?%#POIG@SX!^)])T>U
M^R6$5G.ZQ[V<[G<N[%F)))9F)).<FB+M!)_T^OW_ .5K"DES-K^EK_P/Q.Z\
M7>'8?%GA^ZTNXOK_ $V*?;NNM,NWM9TPP/RR(0R],<'H2*Y;P#\'_#OP^UN[
MUFVU#5]8UBYMQ:&^US5Y[Z5(0V[RT\UR$4MR=H&2!GH*K_M#^![CXE?"76_#
MEG;6-_/<F"5K#4)/+BNHXYXY)(2^"4WJC*' ^4L#VKYU^!?PO^&7Q"^-FM7*
M?#7P9H2:/IL,;Z19S6VI2)=+,668M"ICA91E<;M[9!(&T4J>L[;;_=;^E^=D
M.>D+_P!;K_A_EIJ?2WQQ_P"2;WG_ %^6'_I;!7EO[5&D^+]>UW0M-T5_$:V%
M[;_9H#H<*R6ZW;74(9KP,K*(Q 92K.-H()^]MKU+XX?\DWO/^ORP_P#2V"L[
M]I/Q/J'A#X.ZUJ.G:B^C2>;:V\^JQJ"UA;RW,<4]P,@C,<;N^2.-N>U1+=/M
M^NGZ_+<J.MTNO]?UWV/*?V<?!_BG0?B#+IGBO0-6DC@TQIIM3UFRL#;&^2=5
M4V<MLH8(8R3B3#< XSNKV[Q__P C9\-?^Q@F_P#35J%?.7A.\\*::]GXJ^%?
MB/Q!J)L_%EAX>N9;KQ!<ZI:Z_'.(3.Q2:1U#(LSMO0*5,+=N*^C?'_\ R-GP
MU_[&";_TU:A6VO(O+3\I?E)&?VWYZ_I^:?\ F=M1114%!1110 5Y3\?)_'./
M!-GX#OUTZ_O-;,=W-/:?:+=H%L[F3RYQC*QO)'&I8$$;A@YX/JU%)JX^_P S
MP3PS\3/%VL>.O!/ABS\ :YX.@T]YX]?AFLH_[)2W6W81_9[I>'_>B+8$P=I;
M<HQ@>NW@/_"=:0=HQ_9M[\W<?O;7C_/I6]6!>8_X3S1SM.?[,O?F[#][:<?Y
M]*J]R3?HHHI#/E+XR?\ *0K]G?\ [ GB'_T0M=K\6OVI[3X*_$FQ\/>*? _B
M)]&U2,MIWB#1[=;^.8HF^</!&3,@C').UN.:XKXR?\I"OV=_^P)XA_\ 1"UY
MS^V1I_B?4_C2NK:Q;?%.Y\#^&;(W-G_PK_3K6 1&2'%RQO6E$IRH*LH48&<'
MO6<I<K7]+;J:1CS)_P!/Y'V'\,?BQX.^,.@OK/@O7;/7=/23R97M20T,@ )2
M1" R-@CY6 /-> _\$Z?^2<?$[_LI&O?^C4KUG]FSX=^!_ ?PPTV[\":--I&F
M^((HM8F^UW37-S/)+&IWS2EWW/C&2&(]*\F_X)T_\DX^)W_92->_]&I714CR
MR<>WY]?Q,(2YH\W?\NGX'U=1116984444 %%%% !1110 4444 %87C+P;8>.
M-'_L^_,L8619X;BW8++!*IRKJ2",CT((/(((.*W:*:;B[H32DK,Y'P+\-=.\
M"S7]W%<7&IZI?$&YU"\$2R. 20H6)$C09).%49)).3S77444Y2<G=BC%15D%
M%%%24<9XX\1Z+X3UO0KW7/%,FBP32M;Q:>PB\B[<@C+DQEP%+*<AE .W/6ND
MT/6M.\0Z;'?:5=P7UE(659K=PR$JQ5AD=PP(([$&O&?VK/#]MK&@:/+<^,M,
M\&1J]Q:O/JFHPV*7"2QX:,221/DX7. !T!S\HKI/V:IENOA)83B2.YDEO+UY
M;R&X-Q'=R&ZEWSI)M0.LARP(4### Q1'5/R"6EO/_@GSUI<.@>)/CC;Z/=Z7
M<6MO>:O<SV^FZ?XOU:&\M)S-=)+<"W2=8T_U6]@BJ%6X7!.>?J+XFVZ0^#TA
M%SXCMTCEC42>'0TU[@ CDD,2/4G\Z\SU?5O@K8_$+3M73QK;6'B2#5RK);ZQ
M)*LT[%XVADB+L@&YCV&TJ.178_M!:M%I_@^QMVEEBFO;](HC#J%W8XVQR2.S
M2VK*ZJL<;L><84]3@5%^6C'U^73^O^ 7;FK-KM\^O]?\&YQ/P9LX]:^+DVMV
M.I^+M1M=.TNZTNY7Q7;O&\,[36[A4S&H^ZF2"<D%2..:P;S08- ^*ECIU\9[
M?1YO%?\ :$%\WA21;E[N25I%C.H^;L\LL=@/E@E,)GO7?_LT:@NI>$9YK.TC
MM+9KJ5KQ9I[R:[:X98F5I'NLR-F)E.6)XV >@R9/CY?1^*_+O7T"+2U\1-H3
M:/(\@U*':Y473,?EV[0)<;0-A!WYXK?X9TX]5;\9)_F]/DV9?%";Z/\ R:_)
M._S/>JHZYI$/B#1-0TNY+K;WUO);2-&VU@KJ5)!['!JW#,EQ$DL;K)&X#*ZG
M((/0@T^HU3*/ES_AW?\ #7_H)>)?_!E_]C5JR_8C^$7PY6;Q-?:;J7B)M+C:
MZ6'4[PS1_(-P^3@-TZ-QZU],TR:&.XA>*5%DBD4JR,,A@1@@UW?7L2]'4=O4
MY_J]):J*/-/@K\:(/BU'JT*:;#ITVF^42MK=_:H'C<R*I5]B<YB?@ KC!5F!
MKTZN<\$_#S0/AU8W%IX?L6LX+B7SI?,N)9V9L8'S2,S8 X"@X'8"NCKEJN$I
MMTU9&T;V][<Q?!G_ "*>D?\ 7K'_ .@BMJL7P9_R*>D?]>L?_H(K:K(H*^=_
MVE&N7\06,.GVT[ZDT4'DRVDNI&=3Y_\ !' GDN<9XD8 _P 6%KZ(KYH_:$M;
M.^^*.FM+K5QIMW8VUO=QW!2?RK.,"[\QD,; &5@ X!&#]GP3C +C\<?4'\$O
M0]G^+RW+?"_Q.+.ZELKK[!+Y=Q"TBNC;>"#'\X_X#\WI@\UQW[/.L"XTF_M&
MTFXTZ874@<-+>SJK(L88,]T RM\X^7V/H:[GXFVMM??#W7X;N2&*W:S?=+<3
M-#&F!D,74$K@@'(!Z=*\N_9IGNWN->CL=-T=-"BF2.35;"^N+@WTWE(3(#)$
M@8Y9M[9^]^BC\4O3]12^&/J/^,6L^+O^%@:3IMFEK<^'Y+FTC;39;6.47.6+
MM)([.&C"E%P1C! /S9 KU_Q1_P @V'_K^L__ $IBKYS_ &C-:TZ3XM>'=!:"
MU?5+FXTZ2.0Z7:F10+H-_P ?DDH:'A6Q\AS@A<DU]&>*/^0;#_U_6?\ Z4Q4
MHZPOYO\ 0;^.WDC7KB_C9_R1GQ[_ -@"_P#_ $GDKM*XOXV?\D9\>_\ 8 O_
M /TGDI@:_@3_ )$?P]_V#K?_ -%+6[6%X$_Y$?P]_P!@ZW_]%+6[0 4444 >
M6_M/?\D*\5?]<X?_ $?'7J5>6_M/?\D*\5?]<X?_ $?'7J5 !1110!\[_M#:
MYIVC:\]O=?'H?#W4;JW66QT6YM]+EA1P"J2L+B!I-I;N7 ZX(KVCX?R:M)X%
M\//KLBRZTVGP&]D5T</-Y:[R&154@MDY4 >@KYP^-/C*3X8_%#QA):ZUX;TK
M_A([&V6>/Q?I]R?.*1F("R:,$79PP!MQA@V3T:OH/X2Z/%X=^%OA'2X7NI(K
M/2;6W1[Z$PSD+$H!>,\HW'*GITHI_!)^:_\ ;K_IZ^5@G\<5Y?Y?U_PYG>&/
M^2P^._\ KQTO^5S7@NF^)+#X>^(]0L[#XE?$*UTF/5[B[?1H?A]<SVZ%YVDE
MBCE%@Q,98M@JQZY!Z5[UX8_Y+#X[_P"O'2_Y7->">,O#_BCP'XNC\2:IH.HC
M06UZ"-[J/XK:LRQI-=*B2-9F$(5RZYB!(P<=.:4;^TCYZ?BOE]X2^!_UT?S^
MXTOVXO%VG^./V#_B=J^EK>K9S:<%4:A83V4N5N8P<Q3(CCD=UY[4W]J[4KV#
MX&_#?3-*@U2\UG6=3T_3[*UTCQ')H<TLCV[G!N%1OE !)5L#CKD &W^WEH</
MAW]A?XH6%O-=7$4>G[A)>W+W$IW74;'+N2Q +8&3P  .!65^V0UA??LW^!]"
MU.TT'['KNH:=ISZOXE#_ &+2-T+-]J9D=&5AMV*=R\OR<5-36R7>/YK\RX=;
M]I?DSS;]FJU^(K?%Z;PW=^%]?AC\*ZS!/K-QJ7Q)EU(PB6U?RSY9A FC*N3L
MR/F7G&*]*\:_\I,OAQ_V3_4/_2FJW_!/K3]&\(V?Q$\&Z-_PC.K1:+J-L7\4
M>%VD>#5#+#OQ(\DDA,D>"I <@;ATYJSXU_Y29?#C_LG^H?\ I371/9+R3^](
MPCNW\OQ?^9]85\C#XM:WXP_X1S5M=\1>$-5T^_\ $]M9CP#':,NI6<BW@2-A
M,)RS30E1*X,07"MT'-?75?$UQHK^,O'7V;3OCCX5L/BU)J41NK+1['3EFCC2
MY!EACF,1FD98E8%&8Y((88S64?XL?5?FOZOTW-9?PY?UT?\ 7F?;->*Z'XNN
M_ /[,NJ>(["T2^O-+MM2NHH),[&9;B8C=CG:.IQS@&O8[&&6VL;>&>X:[GCC
M5)+AE"F1@,%B , D\X''->2^$Y]4MOV<[V71+W3]-U5(=1:WO-5/^BP,+B;]
MY+_LKU.>..:FII%V'3UDKG)?#?Q9?ZI\9_#=IK?BSPG\1;JXT>]N[74/#MH;
M>72EW0!PP$\JM%+E0&;#93ODX]8^-_\ R1?Q_P#]B_J'_I-)7SS\%O"]GK?Q
M-TZ_^'?QLT;6].L?.EU_3M$T_3K=[G)C\O>D$0+J2'&]CD9^4Y)KZ&^-_P#R
M1?Q__P!B_J'_ *325J_A7]=?Z_,RCNR;XG>+?"O@_08;OQ= UQISSK&B)ILM
M^?,(8@^7%&[#@'YL8]^:Y[X?_'/X?>)M6MO#WAK[?!<3;FB@;P_>V</ +-EY
M(%0< ]3S7EOQ]^!/BGXD?%*2:RM[B"PN[> 1>)(M6:W33(XHKC?"T2NK-OF:
M!\J"#MY(VC/5?LN^'?$?AV3Q/#JL,%OI!^R"RCMO$<NMHTRHZW,@EE ="S!"
M4(QW&2344_>4G+^OZ_K34NI[K27]?U_6NAW_ ,2O^0]\.O\ L8__ &PO*SOB
ME\1OA]X-U2SM_%]I)<WDL1>%H]"N-0PF<$;HH7"\]B0:T?B5_P A[X=?]C'_
M .V%Y7S5KO[-OC77/'&MZC_9TT#6UY<7AN)/$\]I%X@$M\)53,+%X-EKF'+)
MWVC*\U.O.H]/Z_KOY%:<K?\ 7]?U<^F/AS\6O"OQ(^U6WAJ2]9;%$+I=:3=6
M2JIR%"^=$@/0\+G%>%_#?_E(U\8O^Q/T?_T-J]F^ .C^(?#_ ,,[+3_%$)MM
M6@N;M1;G4#?F&W-S(;=//;YI (M@#-AL#D U\_Z9I&JZ]^W?\=M/T/6W\-ZQ
M<>"-)2UU9+=+@VLFYMK^6_RO@]CUJY^[MJ1'5V9CZE^U/\1]=\9:K\)_#!C@
M^*MUXLO(-^I:4_V/0]#C.8KIB %EWH%*G<<ER/2O:_ OC;Q'\0OV4]3UKQ9:
M1VFOR:5J<%R886ACG\KSHEF1&Y59%0. ?[U?.?B?X4_&M?B5;W?Q2U:Z^+_A
M..ZB$5AX/UZ+0UMPK#Y[BRVH9B#@X$QQSP:^U?B@ OPQ\6@# _L>\X_[8O3@
MK4E?5_Y)+Y7W?=MN[Z$G>H[:+?[VW_PW9)*V]_)?^"?W_)F?PH_[ Z_^C'KZ
M#KY\_P""?W_)F?PH_P"P.O\ Z,>OH.I&%<1I?_):_$W_ &+VE?\ I3J-=O7$
M:7_R6OQ-_P!B]I7_ *4ZC0!\G?%R+PY:Z%\:-1C^&^J>+_$,.I7EQ!XUBTJ$
MOI\D:(0B3R2B0?9RI"E!MX'OG[0\'ZU)XB\,Z;J4VGWNE27$*NUGJ*JL\?LX
M5F&>_!/6OE7XC?$36])\4^,_.\=>(M'\:VFH21>'?!-II,<ECJ<&%\D$&W9I
MA-D[Y!(-F3]W;7U_"SM"AD78Y4%E'8XY%$/X4?1?E_5^JZA4_BOUE^?]6Z/H
M><^$&5?^%J,]PUH@UN8M<1@EHA_9]KEA[CK^%?*_AG4M#\%V/P6U7P]\(=>M
M-32_@BN/$UCI-O;3:Q'):3!CO,WF.)3MD(E],]<5]6^!I+B*Z^)SVD:S72Z]
M(88VZ,XL+3:#[$XKP?X1_$+5K[Q?X%@M_'GB+Q1XGOYMOBCPKJ>DQPVNDKY$
MC2,H6W1K?RI0J+EVW@X^;.:*?\7_ ,!_!O\ #OT77I8G_"?I+\OS[=7TZGKG
M[7[;OV3_ (P'!7/A'5#@]1_HLE>?3:9X?U;]B7X6P>)?A[J?Q-TS^P-$8Z'I
M,:O-O%G'B7#2(,+SGGO7H7[87_)J/QA_[%+5/_262O)O%7A>V\7?L/\ PAL[
M[0O%'B?3H]+T">ZT7PFP%S>Q+:QDQN3)&?*/&[# ]*SGLO5?FC2GO\G^1@_L
MIGP[\-?B3XQC\(?"WQ;X2M-?O-+MY] O+2V!TP&.?-VS"X>3R24Y!  )^4')
MKM?CI_R?5^R__P!>?BK_ -(H*\^_9P^%O@KP)\7)/&GA[X(_$+PG>7DMKH\$
M6L$-#8JZ3^;<Y-RY9.%#;L[25VCDUZ#\=/\ D^K]E_\ Z\_%7_I%!71+X5_7
M;3[M?G;H8+XG_7]=OE?J?4-%%%9EG$^/_P#D;/AK_P!C!-_Z:M0KRK]H3XM>
M,_"OB"_M= USP_X4TC1H=*GOM0URQ:Y$HO;UK<MGSHUCCB5"S$DDD@97K7JO
MC_\ Y&SX:_\ 8P3?^FK4*P?C3\98?A7;E]1\ ^)/%&D&.-YK[28;22WC9I0B
M(XFG1MVXJ>%(^8<U+W7J4MF:/[/U]#JGP?\ #EW;Z=;Z7%/')((;/?Y#DRN3
M+'O);9(<R+DGAQUIS:Q9>'_BEXWU/4;F.ST^S\,Z5<7%Q*<)'&L^ILS$^@ )
MIGPT^,"?$'7M9T.?PGK_ (1U32K>WN9+778[=2\4QE5&0PS2#&87')'2J/B/
MPG;^._&WQ%\.W4LD%OJOA/3;-YHL;D#S:FNX9XR,YY]*NI?5HF%KI2^9Y3J?
M[;D;>)+C3]#L?".H6GGB&VFU#Q9]AGDSC&^%[4F-N5RI/&Y<]17T9X,U+7=6
M\/P7/B/1K?0=59F$EC:WOVQ$ )VD2;$SD8/W>*^/?B-X2T#1KCQ)H-WX^\57
M_CF]AN8_$>H>$?"3W]M'!<QQ!8[B)(IA#A(8SA9%D(+'@$8^Q?!OB/2?%OA?
M3-7T*_BU/2;J%6M[J$_*ZCCZ@@@@@\@@@\TXV]FGN_Z_K[]-"97Y[;?U_7X=
MSF_A5_Q_>//^QEN/_1,%=[7!?"K_ (_O'G_8RW'_ *)@KO:DHX'X\?\ )(_$
MO_7NO_HQ:9\6/AOJ_CBX\,ZGX=\00>&]>T"]DN[:ZN]/^VPLLD$D+HT7F1DY
M63((88(I_P >/^21^)?^O=?_ $8M=]2W&>5>#_@M?Z))X#GUCQ*VMW?AG^T)
MI)A:&(W=Q=%OGYD8HB*\BA,MU7GBM>3_ )+S;_\ 8M2?^E25WU<#)_R7FW_[
M%J3_ -*DJF[DG?4444AG$^ /^1L^)7_8P0_^FK3Z[:N)\ ?\C9\2O^Q@A_\
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M8?\ I;!7>,H88(R/0UP?QQ_Y)O>?]?EA_P"EL%=[0 U8U48"J!G/ KB_'_\
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M-/NXSF1X6:.V3;,OEE]I*N-K>C"B/O/^NUPEHK_UN>Q^#/\ D4](_P"O6/\
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M;Z=%)I<:SBW>ZAVJ%D+K;,FX;OG8#C-?3]%3'W;^OZ)?I^+*E[UEY6_/_/\
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M>CU"'Q?=>+DEN)$6Y$C7#6.S<=Z@Y3G[WM7W+\4./ACXM!Z_V/=_^B'K\O\
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MM1_MG5I]3N8FB9XU@\^8!BB'<!A0.21G.3UND_\ ):/%7_8OZ/\ ^E.IU4^
M=QJMU\(O#C:W<O=ZD(721YKA+B8*)&")+(A*M*J!5<@GYE;FK>D_\EH\5?\
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M ,S?O/,Y-94OMQ6UOUBOU_X!I4^R_P"MG_D>L^(1_P 5%X6^3=_I<WS?W?\
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M8-)^.'PAT#Q1I.HIJ@DMTANYH[-[51<JB^8HC;.T GL6'H37S+^Q-_R#9/\
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MJTWW_K?]3Y\^'/B[1->^.G@&>P^*EG\59)[*^ F5+2'4=.7RE+?:!;(@\EB
MOER(&5PI!/(KZXKX>^&G@72?$WQON_#VLZ5J?C32Y+JX:6V\9:6UW+I=J+6"
M6WN$O)8]Z2-*TD93S#[!=AK[?C18T5%&%48 ]!5OX(ONK_?K_7](A?$UV_K^
MOZ8ZBBBH+"BBB@#P_P#:BM]#M['PAK7B"PT35].TO4W>33?$!2.UG5X)(_\
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M<\,*^F_%#:,GAO4O^$A^Q#03;NM]_:.W[-Y)!#B3=\NS&<YXQ7QI8_"GX?\
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M-=/\;O\ DBWC_P#[%_4/_2:2GTV_K3^OF+KN=M1114E'"_$K_D/?#K_L8_\
MVPO*[JN%^)7_ "'OAU_V,?\ [87E=U0 5\J?#?\ Y2-?&+_L3]'_ /0VKZKK
MY4^&_P#RD:^,7_8GZ/\ ^AM0!Y9\:/&$?CH>*]>G^$_A^'X=:#XJ33KWQ)97
M\5MXA%S!>1H]U"/*./WA^Z6W,I//-?:OQ0Y^%_BTCI_8]W_Z(>OSD_:!L_#G
MAOXZZCXX?6/@WKNM6_B6!&T.W^V2ZJQ^TK&"]JET(I;A 0263JIK]'/B@<_#
M'Q:?^H/=_P#HAZ=/_=X/^KVC_7X!4_C27]6N_P"O/?0\D_X)_?\ )F?PH_[
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M/C2/Q-Y7Q7U[XG?9S;Y_MKPX=)^QYW_<S#'OW8YZXVCIFLKXZ?\ )]7[+_\
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MJ2@#OJ*** .)\ ?\C9\2O^Q@A_\ 35I]=M7$^ /^1L^)7_8P0_\ IJT^NVH
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MFL';@?V;8_-Z_O;OC_/K714^-^IC#X4;]<'\=_\ DCOBW_KP?^E=Y7!_'?\
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MA_Z6P5WM !7$^/\ _D;/AK_V,$W_ *:M0KMJXGQ__P C9\-?^Q@F_P#35J%
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M@PG6(%AM]2^PM:74L[K;WV[<N1"0_ .[Y\@$\5] _!#^W?\ A4/@_P#X287
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MWKB-+_Y+7XF_[%[2O_2G4: .WHHHH X3X9_\ASXA_P#8QM_Z16E=W7"?#/\
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MBUWU<#\>/^21^)?^O=?_ $8M=]0 5P,G_)>;?_L6I/\ TJ2N^K@9/^2\V_\
MV+4G_I4E '?4444 <3X _P"1L^)7_8P0_P#IJT^NVKB? '_(V?$K_L8(?_35
MI]=M0 5POP+_ .2,^"?^P1;?^BUKNJX7X%_\D9\$_P#8(MO_ $6M '=5PWQ&
M_P"1B^'/_8Q-_P"FZ]KN:X;XC?\ (Q?#G_L8F_\ 3=>T =S1110!\N?'G_D^
MK]EC_KV\6?\ I!#7@O[6RV$G[2FIV<FF>)/&GA6XN+"77_#^GZ= ]L=16RF%
MHAE>96D B!E,(7!*CY@37O7QY_Y/J_98_P"O;Q9_Z00UWWQ"^ ?PT^+>L:]I
M^I3RKK%Y<V=_J4.F:J\%SOAB>.%F"-N0&.1E)&-PQ6<HN35OZ_K?U2-(R24K
M]OZ_R]#JO@/#IUO\$_ D6D:E-K&EIHEFMK?W*%)+B,0KM=ER=I(QD9..E>-?
ML'_\@_X\_P#97?$G_HV*OI#P_H.G^%="T_1M*M4LM,T^WCM;6VC^[%$BA54?
M0 5\W_L'_P#(/^//_97?$G_HV*NBI)3G*2ZLYZ<7&"B^B.V_:2\&RZ\OA;6Y
MO#VE^,]&T.YFEO?#FL7,<$%QYD>R.8&4&)GC.<*^!\Y(((%:'[-_@^]\)^%=
M8DGTBP\,Z?JNJ2:AIWA[3+A9[?38&CC7RU9 $^9T>0JGR@R'&:Y_X[:I\+]:
M\3^'F\:^*/#$VG>&[N;[?X;U::.<S32P8A_T?)+2KD%5*DD.2.<5M_LV:7IE
MAH/B>XT#3+S1/#=]K<MSI>F7.ER:=';PF&)?W,,@#*C.KO\ =49=L#N<Z?VO
M3]8_GOUT1I4^S_7?^OG]_>^(L'Q%X6!W _:YL%?^O:7K7S-\;-'\8^$]<@BU
M_P",EEK/AIHV<^%[[6(/#%_<(6//VN%-TN!\H4>2#CEN]?3?B _\5%X7^?;_
M *7-\O\ >_T:6O!/C!XEGT7XL:I-X<^'OAWQ%J'_ !*=-U34O$6H-!N,SRBW
MBA40R8"AF+/P/F'#8XSENO-V^_\ X/\ 5RU\,OO/7/@3XS\+^./A;H-_X0:%
M='2V2%+2.[2Y:T8*,Q.ZNX+#(S\QSG/>M^RQ_P )]K/WMW]F6.?3_6W?^?RK
M!^ \?A__ (5+X9N/#&D+H>CW5FD\5B"&,98<@O\ Q\Y&[N *W[,_\5YK W9_
MXEMC\OI^]N^?Q_I6\_B9C'X4;]<'\=_^2.^+?^O!_P"E=Y7!_'?_ )([XM_Z
M\'_I4%E+]H>?6;?X4ZF^AKJ379GM5E&CVBW5[]G-Q&)_(C964R>67P2I /-<
M!^SKKOBOQ)K'V;6=!UBTT>PT^2":\U_1X[&2ZN$O&^S2J-BEG: *SX 4,%P
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M_P"2,^/?^P!?_P#I/)0!K^!/^1'\/?\ 8.M__12UNUA>!/\ D1_#W_8.M_\
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MP5]ILY+590(S]H%NY)?)#,Q!!SVP:^X/BC_R3'Q=_P!@>\_]$/3IZ8>#[_\
M#Z=M[6N[62"I_&EY?\-\]KWMK>YY)_P3^_Y,S^%'_8'7_P!&/7T'7SY_P3^_
MY,S^%'_8'7_T8]?0=( KB-+_ .2U^)O^Q>TK_P!*=1KMZXC2_P#DM?B;_L7M
M*_\ 2G4: .WHHHH X3X9_P#(<^(?_8QM_P"D5I7=UPGPS_Y#GQ#_ .QC;_TB
MM*[N@#R#]L+_ )-1^,/_ &*6J?\ I+)7D'C:S\-WG["7PH_X2GQ$WA?3HM'T
M*5-07P^NM%919IM'V=HI1SS\VWC'45Z_^V%_R:C\8?\ L4M4_P#262O-=0\5
M:[X3_8K^$-SH/C/0OA_+/I&@VUSX@U\1-%:V[6L?F,B2D(\F!PI//-9SV7JO
MS7H:0W?H_P F1?L0^/-=\7:UX_LI?%^L^//"&G?84T;6]2T!-(B)9'\Z%(A#
M&Q*$+D],%< =[OQT_P"3ZOV7_P#KS\5?^D4%<G^SSXJU_P#X79J.I:S^TSX=
M^(WA2XCM-.M=/LH[2+[5>R+,5C6.-SY+C;D;<F3!S]VNL^.G_)]7[+__ %Y^
M*O\ TB@KHEJD_P"OZZ^C1A'1M?U_7ZW/J&BBBLRSB?'_ /R-GPU_[&";_P!-
M6H5SNL>//B=>:G<Q>'/A?9O8P2M&EYXE\0)8F;:<;XTAAN#M..-^TXZ@5T7C
M_P#Y&SX:_P#8P3?^FK4*X?X@> Y_BE\9SHOB2]U^T\%6>AQ7=I;:3?W%A!=W
M;3R+-YTT#(Q*(L.V,L!\['!QPM>9)?UI?]!Z<K;_ *UM^IW'@/Q?XJUJ\GL?
M%'@B;PS<QQ^:MW;ZA%>V4W(!5)!MDW<Y^:)1CH31I/\ R6CQ5_V+^C_^E.IU
MS/P=\/ZGX)\<>,_#,%[K6I>#;.*RGTR?6YY;EX9I!+Y\$5Q*2\L:A86Y9MI=
MESQ@=-I/_):/%7_8OZ/_ .E.IU3MI8G6[N=M1112&<%\*O\ C^\>?]C+<?\
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M->6?MG^%/^$X_:%\*)X6^%>LZSXBTF&9]3\16EZ-!AE62 "V4:B&#,T3?,5
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MBG3K_P"*VGWWV&TAO-!TWQAHL1N-=5E(:"":V:W#2B0;,!&(W*2O-$=)>O\
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M6;KXP66BS:;XEU'P_)'9.EKIMI<-9S3"<-F6=("B*-O(,B]%)X->Z^*.-+@
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M1-<EY)%0D+O61,'.3L/I7HND_P#):/%7_8OZ/_Z4ZG7%_LT>!K/P/INM10^
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M+$!;=SPQ0R CY20>A#^(OD_N?]:=KA/^&UZK[U^%^_1GL_[1.NRZ#\,;F1#
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M^U:CJLEB5S)^]C3$%S(Q^1P 0,?+R12:Q:V</[.=S;Z+8)X0TY=!V06.LHD
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M^)7_ &,$/_IJT^NVH *X7X%_\D9\$_\ 8(MO_1:UW5<+\"_^2,^"?^P1;?\
MHM: .ZKAOB-_R,7PY_[&)O\ TW7M=S7#?$;_ )&+X<_]C$W_ *;KV@#N:***
M /ESX\_\GU?LL?\ 7MXL_P#2"&O-/VQ/ =W\1_VA/"R>#?A#K_B'Q%H\,KZI
MXBT^Y.APR+)!BV4:B"&9HF^8J <#CG.*]+^//_)]7[+'_7MXL_\ 2"&N&_;
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MA;2M(M[R^-SXUO=$MY8Y&E"K#%;QOD_NVW2' &5'->^>(2/^$B\+98@_:YL
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M**@H^4OC)_RD*_9W_P"P)XA_]$+7U;7RE\9/^4A7[.__ &!/$/\ Z(6OJV@
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M9ZFOG36OA]\>_%<NJ7%Y>^!]/M-0THZ')X>,MW>6*1G<6O!E(\RG<5\LIC:
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M[&EL)0$;;_K=YMCL# ;_ #%.6V]=M75A&6B:5_+;?SW7XZF-TJ4G'5I_?O\
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M4M;M !1110!Y;^T]_P D*\5?]<X?_1\=>I5Y;^T]_P D*\5?]<X?_1\=>I4
M%%%% !1110!P7AC_ )+#X[_Z\=+_ )7-=[7!>&/^2P^._P#KQTO^5S7>T ?.
M?_!1+_DRSXJ_]@U/_2B*O<O!?_(FZ#_UX6__ *+6O#?^"B7_ "99\5?^P:G_
M *415[EX+_Y$W0?^O"W_ /1:T ;5?)WC7_E)E\./^R?ZA_Z4U]8U\G>-?^4F
M7PX_[)_J'_I30!]8T444 %<#\"_^28Z9_P!=[S_TJFKOJX'X%_\ ),=,_P"N
M]Y_Z534 =]7$_&__ )(OX_\ ^Q?U#_TFDKMJXGXW_P#)%_'_ /V+^H?^DTE
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M38T:Q"W("M@!FQ\Y-?67C_\ Y&SX:_\ 8P3?^FK4*\)_:>\>>&]*^(UWIWQ
M\0ZAI?A?3?#BZGINA:?JDNFMKMZTLRO'YL3*[E%BB C#8S+D@\5'VX_UTO\
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M/_2V"N]H *XGQ_\ \C9\-?\ L8)O_35J%=M7$^/_ /D;/AK_ -C!-_Z:M0H
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M ,I,OAQ_V3_4/_2F@#ZQHHHH *X'X%_\DQTS_KO>?^E4U=]7 _ O_DF.F?\
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MAX8)][!X.*^/?@#X?U8>,3_9OQ!$WBW4X6N!KGC#X?7L-[JL"D%C!/<7(&P
M@^7'M"@@A *^L_BNNBM\,/%J^)#,OA\Z5=#4#;@F06_E-YA0#G=MSCWKY?\
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M8Z9_UWO/_2J:N^K@?@7_ ,DQTS_KO>?^E4U '?5Q/QO_ .2+^/\ _L7]0_\
M2:2NVKB?C?\ \D7\?_\ 8OZA_P"DTE ';4444 <+\2O^0]\.O^QC_P#;"\KN
MJX7XE?\ (>^'7_8Q_P#MA>5W5 !7RI\-_P#E(U\8O^Q/T?\ ]#:OJNOE3X;_
M /*1KXQ?]B?H_P#Z&U 'SKX\UKP''\:;[Q/?? ;PW=>&9-8OY)-:N-8DCU*Y
MDM;Z*VN+A(?N;O.F!6/.6"GI7WCX@\%:'X!^#?C'3?#^GQZ9826&HWC0Q$X,
MLJ222-R3R68G\:^0?&$/C_Q/X_E2Q^#.FRWO@G7M0UA[W5?#C-!>":^C6WCL
MF4@/))&/.DFYVLN3C%?;7Q0S_P *Q\79&#_8]W_Z(>BGIAZ?]=OZ^7:P5-:T
M_7]7^CW\^]SR3_@G]_R9G\*/^P.O_HQZ^@Z^?/\ @G]_R9G\*/\ L#K_ .C'
MKZ#H *XC2_\ DM?B;_L7M*_]*=1KMZXC2_\ DM?B;_L7M*_]*=1H [>BBB@#
MA/AG_P ASXA_]C&W_I%:5W=<)\,_^0Y\0_\ L8V_](K2N[H \@_;"_Y-1^,/
M_8I:I_Z2R5K_ +-7_)N?PK_[%32O_2.*LC]L+_DU'XP_]BEJG_I+)6O^S5_R
M;G\*_P#L5-*_](XJ /2*^7OCI_R?5^R__P!>?BK_ -(H*^H:^7OCI_R?5^R_
M_P!>?BK_ -(H* /J&BBB@#B?'_\ R-GPU_[&";_TU:A7;5Q/C_\ Y&SX:_\
M8P3?^FK4*[:@ KB=)_Y+1XJ_[%_1_P#TIU.NVKB=)_Y+1XJ_[%_1_P#TIU.@
M#MJ*** ."^%7_']X\_[&6X_]$P5WM<%\*O\ C^\>?]C+<?\ HF"N]H X'X\?
M\DC\2_\ 7NO_ *,6N^K@?CQ_R2/Q+_U[K_Z,6N^H *X&3_DO-O\ ]BU)_P"E
M25WU<#)_R7FW_P"Q:D_]*DH [ZBBB@#B? '_ "-GQ*_[&"'_ --6GUVU<3X
M_P"1L^)7_8P0_P#IJT^NVH *X7X%_P#)&?!/_8(MO_1:UW5<+\"_^2,^"?\
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M.59&4_0@U\L>(OV6M+TSXIR-X4^&/A.WTR^U31]1M=?M(;6V?1Q:S(]PBQA
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M8_G6X9S%E!@#]X",!313U;OY_DOZ^;[:$](W7]?U^GF?0O@S_D4](_Z]8_\
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M .BEK=H **** /+?VGO^2%>*O^N</_H^.O4J\M_:>_Y(5XJ_ZYP_^CXZ]2H
M**** "BBB@#@O#'_ "6'QW_UXZ7_ "N:[VN"\,?\EA\=_P#7CI?\KFN]H ^<
M_P#@HE_R99\5?^P:G_I1%7N7@O\ Y$W0?^O"W_\ 1:UX;_P42_Y,L^*O_8-3
M_P!*(J]R\%_\B;H/_7A;_P#HM: -JOD[QK_RDR^''_9/]0_]*:^L:^3O&O\
MRDR^''_9/]0_]*: /K&BBB@ K@?@7_R3'3/^N]Y_Z535WU<#\"_^28Z9_P!=
M[S_TJFH [ZN)^-__ "1?Q_\ ]B_J'_I-)7;5Q/QO_P"2+^/_ /L7]0_])I*
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MQ_9M[GU_UMK_ )_*D4;U%%% 'RE\9/\ E(5^SO\ ]@3Q#_Z(6OJVOE+XR?\
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MQXC=^$/&O@OQM93P>!;O7/#VE^(+C5+>?3[*RCU*<RM*2SW)O273]Z>#$C,
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M_P"P/>?^B7KJ*Y#XQ?\ )(_&_P#V [[_ -)WH \K_P""?W_)F?PH_P"P.O\
MZ,>OH.OGS_@G]_R9G\*/^P.O_HQZ^@Z "N(TO_DM?B;_ +%[2O\ TIU&NWKB
M-+_Y+7XF_P"Q>TK_ -*=1H [>BBB@#A/AG_R'/B'_P!C&W_I%:5W=<)\,_\
MD.?$/_L8V_\ 2*TKNZ /(/VPO^34?C#_ -BEJG_I+)6O^S5_R;G\*_\ L5-*
M_P#2.*LC]L+_ )-1^,/_ &*6J?\ I+)6O^S5_P FY_"O_L5-*_\ 2.*@#TBO
ME[XZ?\GU?LO_ /7GXJ_](H*^H:^6/CA_R?O^S+_V#_$__I'%0!]3T444 <3X
M_P#^1L^&O_8P3?\ IJU"NVKB?'__ "-GPU_[&";_ --6H5VU !7$Z3_R6CQ5
M_P!B_H__ *4ZG7;5Q.D_\EH\5?\ 8OZ/_P"E.IT =M1110!P7PJ_X_O'G_8R
MW'_HF"N]K@OA5_Q_>//^QEN/_1,%=[0!P/QX_P"21^)?^O=?_1BUWU<#\>/^
M21^)?^O=?_1BUWU !7 R?\EYM_\ L6I/_2I*[ZN!D_Y+S;_]BU)_Z5)0!WU%
M%% '$^ /^1L^)7_8P0_^FK3Z[:N)\ ?\C9\2O^Q@A_\ 35I]=M0 5POP+_Y(
MSX)_[!%M_P"BUKNJX7X%_P#)&?!/_8(MO_1:T =U7#?$;_D8OAS_ -C$W_IN
MO:[FN&^(W_(Q?#G_ +&)O_3=>T =S1110!\N?'G_ )/J_98_Z]O%G_I!#7U'
M7RY\>?\ D^K]EC_KV\6?^D$-?4= !7R_^P?_ ,@_X\_]E=\2?^C8J^H*^6_V
M!_\ D$_'7_LK?B/_ -&14 ?4E%%% '/>(?\ D8O"WR;O]+F^;^[_ *-+70US
MWB$C_A(_"V2P/VN; '0_Z-+UKH: "L"R_P"1\U@[<?\ $LL?F]?WMWQ_GUK?
MKG[+'_"?:SR<_P!F6.1V_P!;=T =!7!_'?\ Y([XM_Z\'_I7>5P?QW_Y([XM
M_P"O!_Z4 =Y1110!P7QQ_P"2;WG_ %^6'_I;!7>UP7QQ_P"2;WG_ %^6'_I;
M!7>T %<3X_\ ^1L^&O\ V,$W_IJU"NVKB?'_ /R-GPU_[&";_P!-6H4 =5K%
MG-J&DWEK;WLNFSS0O&EY"J,\#$$!U#JRDCKA@1QR#7SYX0O]1T#]H#1]"@^,
M+>/?M%M=?VQHL]OIJ7%LR(##*[6UNC@9!7:Q'4')Q@^T?%"XT.U^&_BB7Q*)
M6\/+IMP=06!G61H/+;>%*$,&*Y P0<FOFK]E[5)_!?C_ /X0JQTS7O"/A9'E
MMK;1_$%AI\I,ZV\=P(TN;20.KB*17(F60D;AOR"*=/6H_)?Y_P!?Y:!/2"]?
M\OZ\O,^O****0!1110 5@7G_ "/FCG;G_B6WOS>G[VUX_P ^E;]8%YC_ (3W
M1^3G^S+W [?ZVTH WZ*** /E+XR?\I"OV=_^P)XA_P#1"U]6U\I?&3_E(5^S
MO_V!/$/_ *(6OJV@ KX9_8F_Y!LG_98O$W_I#<U]S5\,_L3?\@V3_LL7B;_T
MAN: /N:BBB@ HHHH **** "OB/\ : ^'MGKOQ:UR7Q+\,]'\-^'9FC8^.U\/
M'Q!<WOR*"S)&?]%*XV[I8W7"YK[<KXP\2?"/7_C;\5_B->:5H?@X6^DZR-,:
M75[G5!/,PM8)-Y$-PJ 8E X4=*SWJ*W1-_BE^J_R9=[1=^Z_5_H>H_LF_!_X
M1_#72-9U'X7ZU!XBDU9H_P"TM2AO8Y=[)NVJ8H@L<.-S?*J+[]*]^KY?_95\
M!O\ "OXL?$/PQ=^'?#.E:E_9VF:C-?>'6NV^TB5[I563[1(YROE'&,?>KZ@K
M>3O9HQBK-I_UU"BBBH+"BBB@ HHHH ^=?VP-6NM+M?#/V6_DLBZ7X<+(4)4P
M!2T6'7=<?-LB7GF0GC;FNZ_9MF>;X36(DDE9X[V^A,<DGF"#;=RKY2/O?>B8
MVJVXY"CIT'/?M0+X@^R>&I-#MY[E[>>:Y58[BT@1;E$!MVD:X905W;@57DAB
M?X:[KX-2:M-X LY-9D22Z>>X:,++#(R0F=S"CM#^[+K'M!*\9!Y/6B&TOZ[?
M\'^M!S^S_7?^OTZGQGXR6]L?$FK,EO:2>#=2@UE8GGTRVGU 6L5XSWLZR/=H
M$F5W.P^6S,H3<"5KZ8_:6GNK7P3X:N=&NI-.U>+4XVT_5Y'54LY/L\WS2AXW
M5@Z[H@K+RTJ\@X->+>)H/$$?C#5[VT\!V-YJMQ>W5Q=13> 7F1+J*8BQ1;H;
M1*)E)9I\L$/)*9Q7TQ\7[V:Q\!O=,VI6QCDC>9M)O;:UDC'?,EPRQA<]><],
M5GK]7BD[?\/?^OOV:*_Y?-O7?\K?UW^3.3_9/U9_$'PUNM4N+K^U-0O=2DGN
M]6299(;^4QQYDB*(BA0-L>U5P&C89)R3P%UKUA<?M$02/J^I^(K&35/+A37+
M:Y6PL9EE$)6U>-Q%E905#20DE^/-KO\ ]G3Q-K][;ZMIFKZ=KTNGK<R7.EZW
MJD]G<)/;E8L1^9;2,I*LS $  A3SD&O)V\.ZM;_&JWU2[TF*QMM/\2R-(MU<
M&.TE6XNOD=$-P$.V.-9L["3/. %!S71O7I:65E\ME\OTZ&&JH3UN[_?N_G_5
MSZ3^+5C>:E\,/%5KI^J1Z+>2Z;.L6H33F!(#L/S-(.4 [L.5Z]J^7O!/Q0N/
MB7XW\->'])OO#>@6VEZC:'3H+;Q#,UU;0QA3<0[1&$N_/13M!<X4[CR*^E_C
M=_9!^$/C#^WOM7]C_P!F3_:?L.WS]FP_ZO=\N[.,;N/7C-?.^G_:[KQHMWXH
M_MK4K:/7M%T_4=6C6QMTCNHMLMK;>2A+%%ENDWRH<L3@?(#6=/\ BI?X?S_X
M.WG;J:5/X=_\7Y'U_1110 C*&&",CT--6)%.0B@^H%/HH Q?!G_(IZ1_UZQ_
M^@BMJL7P9_R*>D?]>L?_ *"*VJ "OE[]J#^Q;CQY80^)M,O_ !1IZ:>DEEIF
MC2H)[.;S) \\RE<^6P" ,6P#&WR]Z^H:^</CY?7FG_$A7L/%D/P[>32X1+JU
MV[>7J8$LN+=%*% T>2=P._\ ?#C%1+=?UT9<=G_75'H>GWUU'^S[#=WR0^);
ME=$\UX].ODMTNL1Y"I.-BKD8&\;1U( Z5E_L[K;ZIH=SJGV1M/NEF9!8^??2
M_9U=(V*F2YQYV=JD.B!<'Y<Y)+H[.QO/V9%M[C2=5L;*310&L;+$MZN1GY#.
MH#.3\P,H YRP'-97[-,1T2;Q#HW]E^(H$1HI4U'Q!<Z=)YX" >7&+([ $&.W
M\0!/05J_XL_ZZLQ7P0_KH8/QQ\,Z?:_%33_$5Z==CM7:QM[D:?>:;'!(#.%4
M.DJ&X(R5SY;#.!CD5[UXH_Y!L/\ U_6?_I3%7S_\8FTJ'XW6=W<374>LP_V>
MNG7MO9A[:Q)E8R"Y;82V]>G)VCGY/O'Z \4?\@V'_K^L_P#TIBJ(_!\V4_C?
MHC7KB_C9_P D9\>_]@"__P#2>2NTKB_C9_R1GQ[_ -@"_P#_ $GDIC-?P)_R
M(_A[_L'6_P#Z*6MVL+P)_P B/X>_[!UO_P"BEK=H **** /+?VGO^2%>*O\
MKG#_ .CXZ]2KRW]I[_DA7BK_ *YP_P#H^.O4J "BBB@ HHHH X+PQ_R6'QW_
M ->.E_RN:[VN"\,?\EA\=_\ 7CI?\KFN]H ^<_\ @HE_R99\5?\ L&I_Z415
M[/\ #+_DF_A/_L$VG_HE*\8_X*)?\F6?%7_L&I_Z415[/\,O^2;^$_\ L$VG
M_HE* .EKY.\:_P#*3+X<?]D_U#_TIKZQKY.\:_\ *3+X<?\ 9/\ 4/\ TIH
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M: -^N#^._P#R1WQ;_P!>#_TKO*X/X[_\D=\6_P#7@_\ 2@#O**** ."^./\
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MZ4UM-<LFC.+NKGUC125X7\,/VJM'\7:.I\4VL'@769X9;JPM]5O%6VU"W5F
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MQY8SWFD?;6MH9/*,EYI]Q:;C@'*><B[UY^\N1[U\\?'#_D_?]F7_ +!_B?\
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M(&I?$+1=6FUC1K?0M4TO5;C2KFUM;TW<6^(CYDD,<9(.[NHI1]Y77:_RT_\
MDE]XY>[OWM\]?\G]Q)X _P"1L^)7_8P0_P#IJT^NVKA_ TGE>)OB:^TMMUZ(
M[1U.-*T_BO.O^&DM7U3PGX"N_#GAW2=;UWQ+IMSJ<VGSZRUJEE% BM("RP2L
M6!<)@J/F!&:F4E%-OI_P?\F4HN3LCWVN%^!?_)&?!/\ V"+;_P!%K6S\/?%G
M_">> O#GB7[+]B_MC3K>_P#LV_?Y7FQJ^S=@9QNQG Z5YQH?CE_AM^RSX?\
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MPC/:J;N 1QP)#(;AQ%$!#$7#[V^4G<H. H>]447MI?[]?PO\QRT@Y+?7\O\
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MCQ#%',(X=J.L+J8E*ECNYY'. .<C]K[P"GPQ_P""=OC[PTE_-JC6.DCS+V9
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M_P!=?^!Y^16\!V_VJ\^)D&V-O,UZ1-LR[D.;&T&&'<>M><6GQ3^!>K:/X?\
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MZ_ [;P-\0O"_Q(TI]2\*:YI^NV2/Y4DUA.L@C<<[7 Y5O8X-9FD_\EH\5?\
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M'^?6M)6OH9QO;4\TM/CA\._A3J&K^'?%'C+PEI.J)J5S<FSL&\OR(Y9#(IN
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MQ!OM#L_%TG@S3-#TW4[74WFT6.XENY6MY5D18_,VK#N*@$Y8[2P[YKT#Q_\
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M<?Y]*T>R_K^OZ]%GU;_K^OZ\W\^?M77GAWP7X[\.>+?%VC^&?&.D_8)=/MM
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M)O\ TAN:^YJ^&?V)O^0;)_V6+Q-_Z0W-/?5@?<U%%%( HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /F;P-KGQ'?XJ+97-U?1Z7)JTCW#:EJ5BZ-
M&LERK(D*.TJJT9MBJX!5HR2>3GV+XK_#6+XF:1IUI+=0VWV&\%V%NK87$,G[
MN2,JZ$C) D+*<_*RJ><8KP33YM6U[XQ>'_$%_HWABP\*R>*+JVL-0TW2DBUA
M[B,7"8G8SMB-BC[F"[CP2J G'L_QXTB35O#NCL;6ZU33[;589K_2;:&67[=;
M[75HV6+D@%@^""I**",'-1RJ5**EW_R_JW^95W&K)KM_\E^??_(N_!7X8O\
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MCD<;><<D<BO"?BUXBT6'XOZW9_$CQ[XA\#:!!:6IT&/3;^?3K6[#*QGD::(
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M&C6CZ7I(LU3KEMXFD#@C'ITKPKX=_P#*2CXN?]B7I7_HRM'H9H^LJY#XQ?\
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M3?\ (-D_[+%XF_\ 2&YH ^YJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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MIMI8&3 <VL"Q[L=,X S7R]\._P#E)1\7/^Q+TK_T97UE7R;\._\ E)1\7/\
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M);R0X.>F/,W=#TK;T[PEH>CW0N;#1["RN "!+;VR(P!ZC(&:UJ* /ESX\_\
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M(X.,D=9V>W7^OO\ \F$M(-K?^OZ_R/0_^"B7_)EGQ5_[!J?^E$5=]HOQ$L?
MOP\\$C4--UJZ@GT>V/VC2M*GOECQ"G#K"KN,Y_NXX-<#_P %$O\ DRSXJ_\
M8-3_ -*(JS?B9>:/!\/_ (=Q7NI^'--OY-"B%O)JOBJX\/W:_NHANAGA5C@$
MC@C!.*B4K6*BKW/H/PEXST?QQIK7^BW9NK=)#$^Z)XG1P 2K(X#*<$<$=Z^:
M?&O_ "DR^''_ &3_ %#_ -*:^@OA#>?;OAAX7E;5K779O[.@674K*Y:YBN)
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MKV!]:]/KY_N)KE?V7VM[*_U;3;^^NY+"VN-$ECANA+-J+1H$DD4K&"6 +XR
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MSC'O725R'Q-^)%C\,]#MKVZL+[6+R]NDL;#2M+B62YO+APQ$:!F51\JLQ9F
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MH2O,XD\]TD\QY3$<1@>:<[E?;\N*W_CY#JDWPYG.DK)Y\=Y:R326MK%<W,4
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M )_U_3'+227?_@?U_2.XKB_C9_R1GQ[_ -@"_P#_ $GDKM*XOXV?\D9\>_\
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M ,YB8KD@9['_ &5Z5%+^%9[K_@J_^?F7/X[_ -=_Z\B?X@?\C7\-?^Q@F_\
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M[CAN,9J7\2_K^O\ *Y4=F>D_"75-2UKX;^'KS5[!-,U&2U7S;2.(1+'@D !
MS!> #@,0,\$CFN5\=7&KVOQ(U6;0(EGUR/P;=/8Q, 0TXG4QC!(!^;'6M/\
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M6Z:;.XMU_M+Q5-I[O=!;6&-%06;% $1$&0#G'+%L@=Q\1O\ D8OAS_V,3?\
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M7AC6_P#A=WA237+==0U_3_$-P)+YO!S1WAM-LPBE_M*$+;NC)L+@J""W #
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M!@E$L<B-'( )LCY@5QP#@UZ]XA _X2+PM\I8_:YL$=O]&EKPW]H#P=I>L?$
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M[_)A+56_K?\ K^KIG@S_ )%/2/\ KUC_ /016U6+X,_Y%/2/^O6/_P!!%;5
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MFLNKS@7EOK$CVFIE9;BW=+BR$JJI:2(LKA7Q\A;&ZG_'G_D^K]EC_KV\6?\
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MXA_]$+3[IK_Q1\2-)NK;QAKD-[;^)+JWL;[7/#MF^F_+)*LMK;R+%YT;;4V
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MXV8P^%'UC1116985P/P+_P"28Z9_UWO/_2J:N^K@?@7_ ,DQTS_KO>?^E4U
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MQ:[ZN!^/'_)(_$O_ %[K_P"C%KOJ "N!D_Y+S;_]BU)_Z5)7?5P,G_)>;?\
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M_P F9_"C_L#K_P"C'KZ#KY\_X)_?\F9_"C_L#K_Z,>OH.D 5Q&E_\EK\3?\
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M <3X _Y&SXE?]C!#_P"FK3Z[:N)\ ?\ (V?$K_L8(?\ TU:?7;4 %<+\"_\
MDC/@G_L$6W_HM:[JN%^!?_)&?!/_ &"+;_T6M '=5PWQ&_Y&+X<_]C$W_INO
M:[FN&^(W_(Q?#G_L8F_]-U[0!W-%%% 'RY\>?^3ZOV6/^O;Q9_Z00UWU]\!;
MO4/BOI/C"6^\. :=?O>)+'X=":F4977R3=B;!7YAG,9/RYR#S7 _'G_D^K]E
MC_KV\6?^D$-?4="T:EU0/5./1A7RW^P/_P @GXZ_]E;\1_\ HR*OJ2OEO]@?
M_D$_'7_LK?B/_P!&14 ?4E%%% '/^("?^$B\+X8 ?:YLCU_T:6N@KG_$ /\
MPD7A?"AA]KFR?3_1I:Z"@ K LR?^$\U@;@1_9ME\O<?O;OG_ #Z5OU@68/\
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M?QL_Y(SX]_[ %_\ ^D\E &OX$_Y$?P]_V#K?_P!%+6[6%X$_Y$?P]_V#K?\
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M]F7_ +!_B?\ ](XJ^IZ^6/CA_P G[_LR_P#8/\3_ /I'%0!]3T444 <3X_\
M^1L^&O\ V,$W_IJU"NVKB?'_ /R-GPU_[&";_P!-6H5VU !7$Z3_ ,EH\5?]
MB_H__I3J==M7$Z3_ ,EH\5?]B_H__I3J= ';4444 <%\*O\ C^\>?]C+<?\
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M_P"ORP_]+8*[V@ KB?'_ /R-GPU_[&";_P!-6H5VU<3X_P#^1L^&O_8P3?\
MIJU"@#MJ*** "BBB@ HHHH *P+S'_">:/PV[^S+W![?ZVT_S^=;]8%X?^*\T
M@;L?\2V]^7U_>VO/X?UH WZ*** /E+XR?\I"OV=_^P)XA_\ 1"U]6U\I?&3_
M )2%?L[_ /8$\0_^B%KZMH *^&?V)O\ D&R?]EB\3?\ I#<U]S5\,_L3?\@V
M3_LL7B;_ -(;F@#T_P"*7@?QMKG[0&N:_P"%;O5K&_T7PM87.D+Y\L>FW]R+
MJZ,UI,N?+?S(PBDD%DW*PQ5WX2^(-1\7_':ZUK1]'\9Z%H-UH\C>(+'Q1#<Q
M6L6I>9$(5M5FXW!!-O,'[LC8>2:F^)7B2;P/\<KC6_$VG^+M3\--H,=KHB^&
MK2[O(8KIGE%R)8;<$B5E,.R1Q@ '# YKGOV<? OQ \%^*?!,FM7_ (LN=,U'
MPYJ$^JVNO:G+?+;70N8#:*QD9MDODL^5!QD-Z44NG;WOO?.]?DEIWY7ZJIO+
M_MW[DH_K^OR]7_:<L]5U#]GWQ_;:'%>3:O+I$Z6L>G!S<-(5X$>SYMWICFO%
M_'5MK/P[\+:SX$UFW\?>(-)EC6_\(:YX<:\N;^VN-A'V.XFB);Y)#E6G.QD;
M#$[*^@?C1'XEF^%GB5/"#R1^(VM&%FT+(LN[(W",O\HD*[@I;C<1FOEG4M-\
M#-H]P/#GAGXXQ>/3$WV6X=M<687./E:2::3[*5W8SN)CQGC%9/>6^RVWZ[>:
MZ/H_)LU7V7YO?;IOY=UU5^J1]?> UUE? _AY?$6W^WQI]N-0V8V_:/+7S<8X
M^]NZ5NUB^"UUF/P?H:^(FC?7UL8!J#0XV&X\M?-*XXQNW=*VJZJO\26V[VV^
M7D<]/X(^G7<*X#]H"WU*Z^!?Q!AT>.ZEU:30+Y+2.R#&=I3 X01A?FW9QC'.
M:[^N5^*D?B&7X:^)T\).(O$S:=.-.<E1B?8=F"WR@YZ9XSC/%<U36$EY'32=
MJD7YH^<M6L]4^&/@RX\&^);?Q]XA\)ZE8P7VA:GX?>]NM5TV]"#?9R2Q$R@;
M]KHTAV89D8X4"OHOX3KX@C^&'A1?%F?^$F&EVXU+=C/VCRU\S..,[LYQQG-?
M*4VG> #I;"#PQ\=/^$X\KY;C?KGVG[1C[WGF3[+C=_M>7[8KZS^&,?B*'X<^
M&4\6NLGBA=.MQJ;(00;GRQYGW>/O9Z<>E=+=^=]VO3KMW[-]N6^IRQ7+R+LG
MZ]-^W?UOT./\27_QKCUR^70=&\"SZ,)#]EEU#5;N.=H^Q=5MV4'V!-:'P+TO
MXAZ+X/>R^)%QH]_K,=Q*T5]H]S+*)86=F4/YD:$,@8+QG(4'BOFSXJ:SXD\/
MZUJND>*]-^(NJ6>J>+_M&H3>&8+RYM[G1 LHMX+9[7/V?86B\U/D=]K\MD5[
M=^S+INHZ?8^*O+L_$&F^"Y-11O#MEXH>9KZ*#R4$N1,QE2,R[BBR'<!G@# K
M*G[T6_+_ .1?WZV^3[&M325O/_-?I?T:/:Z*** "BBB@ HHHH ^3]<T/QKJ_
MQAU\_#F^F\#02LL)FU36XGMYKM993/-'IW[[>'!3KY#':3D=3[;\6;KPW9^$
M-+LO&WAZ/QK'>7<-M'IJ:8EY]HN0C-O6!L@8".V?X0#SQFO&;A;/6OVB-'L]
M.6WN-3T_79+N[AM_#"V<\4/ER@R->,Q++EES@9?/&,UZ7^T!X0\9^*M-@_X1
MFRTW54M]LT4%Q>SV%U:W"DC[1!-"REFV,R^66C!R07 )%2OX4?7_ "?^:5M+
M^FE/^++T_P"!^B;ZV]=6? ]OA_-JNKGP9\-AX*N;8O:WEQ_84.GDN"I,3%,$
MGYE;!X((/I5?6OB_XJT?XBQ:)+H,<.C7&I+8P:A-9781BQPA,@3RQD\ YP20
M.M;7[//ANX\+^!)K>^35$U2:^EGO?[7B*SF9@NX[C-,9%P!AO-DX&-V  /!-
M>^V>(/C,$@\87=O/_;XDM7NM/U.YTE7CNQ&(PKWOD[P1L#"%4$GW2#@UK:]6
MG"^]OTO;\;&>U.<_ZZVO^%S[#LOM'V.#[6(Q=;%\T0DE-^/FVYYQG.,U/2+G
M:,G)[TM24%%%%( HHHH Q?!G_(IZ1_UZQ_\ H(K:K%\&?\BGI'_7K'_Z"*VJ
M "BBB@#C?C')80_"WQ-)J:32Z>ED[31V^W<ZCG;\Q"X/0[CC!.>*\V_9YSX,
M\0:GX:O;&WM;S6/.UFW_ +/O(9X%A5D381&JE6 D3YB"&P?FX KU'XJ37-O\
M-_$LMG?V^EW*6$S)>7;JD47RG)9F5@.,\D$#T/2O"?V7UT>W\=W\7AC2+[PS
MITE@\E[8ZU+&;B\F\R/9/"H7=Y:@N"V0N77Y>]$-:C7E_G_E^G4)?"GY_P"1
M6_:CN;N\^*'A^."R\.W:Z9ILTZMJDLDWE2O)'L:X@6RG"QXCDPQ92<OAD(R?
M?([R74? F@W4[V,DTS:=([Z8Y>U9C-"28F(!*?W3Z8K \:> &U[QI#>:5KVI
M:&]S%Y.M-I=W$C&)$<PEDD1\')*[EVG!Z\#&Y:VNDV/P_P##]OH3K)HL3:<E
MDZN7#0B:'8=QY;(QR>M$-(.+[_G?^OD$M9)^7^1V%<7\;/\ DC/CW_L 7_\
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M_8Q_^V%Y7=4 %?)OP[_Y24?%S_L2]*_]&5]95\F_#O\ Y24?%S_L2]*_]&4
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MMQ_Z)@KO:X+X5?\ ']X\_P"QEN/_ $3!7>T <#\>/^21^)?^O=?_ $8M=]7
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M'^C2]*Z"N>\0@?\ "1>%LJ6/VN;!]/\ 1I:Z&@ K L\_\)YK'"[?[-LL'O\
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M'^7G ZUXS#XPAL_A[J/BGP5!XXTF\T6Y^SZUX426"]ET_:F]BUO<R,IC"%6
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MIMWJV@ZAI"7M[IZ#*B:U>5V)4%BI4"5=Q QG%?3GPK_X1[_A6?A8>$CGPO\
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MHC\+:V_X?^OF$OB2?];'<UQ?QL_Y(SX]_P"P!?\ _I/)7:5Q?QL_Y(SX]_[
M%_\ ^D\E &OX$_Y$?P]_V#K?_P!%+6[6%X$_Y$?P]_V#K?\ ]%+6[0 4444
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MU]-^"K^SU+PW:SV'B%?%-L2X&JK)#)YQ#$'F%53((*\ =.>:^2K3Q99^"_\
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M&#(I#;P1D-Z^]*/P)C>]CRW1M>E\+:;\7-8@M/M\]AK$UREKO*>:R:?:L$W
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M1PW%RUO&-Z %F=8W( '^R:];KQ;PW>7%A^SMX#FA\1Q>%(!::>+K5)9($\J
MJN\*9U9-QX R._%2^GJOS0^C]'^1TG@OX@>*=:\06VGZ_P"%K/1H+A+XQS6N
MI27+!K:=8OF5[>/ <-N4Y/ Z5<^(W_(Q?#G_ +&)O_3=>U1^'/B30M6UF6'3
M?BFOCB?R6;[#]JT^0H%8!I +>)&X. <G'/K5[XC?\C%\.?\ L8F_]-U[5OH2
M)\0O&_B#PS?0VF@>'K7793IUWJ,GVJ^>VP(3$!&FR&7<S>9P./N]ZN^!?%6M
M>()M3MM<T6VT:[L_)95M+Q[E)%D3=]YHHR".01@_6L/XI:RNCZ]I$FH>/X?
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M/PUXDL[*.\N)9M)U\+<6RP8+0RQR1",3[22$\W)V/P,5R?[0&M6?AO\ ;P^
MVK:A+Y%A8^'?$ES<2A"VR-+968X ). #T%=);ZUXI\1>/M%BUN'2?&/@G7K^
M8Q6:Z9#=6MHJ32^5*MPA(5O*$,G[S)8LX&TC%)7<TE_7;^OQ0W:,')]/Z?\
M7X'T?I]XNHV%M=HK(D\2RJKC# , 0#[\U\0_L3?\@V3_ ++%XF_](;FON7IP
M.!7PU^Q-_P @V3_LL7B;_P!(;FJ=KZ$QO97W.I_:(UZ\TC]H"XN+&;6O#.G:
M;X?L;G7_ !+X;U"-+F*UENKB.-Y+6:&6*:.)E9F; =5=B,@$5UWPLT&Y\%_M
M"S6/B>^U3Q=JFI:+-<>'O%&HZK'<[K))(/M$7V>*"&.W8N\+94-O 'S<8KH=
M:U2QF_:"\0VZZ!I[65GX8@_X2C6-2NI"6LF:Z:&"*W"E7P5F9V..&QSVY?X'
MZ3X.\%_&"&U\/>'HQIOB3P^=2\.:^NM75\S:?&T!>W\FX_X]5W3HRI&=I YP
M5Q2H[I?XOQYONV^?O;CJ]?\ MW_VW[]_.WN['I'[3>HVND?L_P#CZ^O=,CUB
MVMM)FF:QEE:)92HR!O3YD.0"&7D$ BOG$>'_ !IX@^'OB6UG\7^,K[6O#;!-
M>\$WWB*UMXIK-HS)O@ODL1/(DD?W2S(20RLP(-?2W[16I:1I?P1\8SZ[I+Z[
MI36+0S::DY@-SO(18S(.4!9E!8=!DUY+\9/">C^+M%0^(/#NCZM\4-)T,7^H
MZ+8:_>Z=!<:6)'#Q&XC4>>F5("2KM+9R%!S6,M.9ORW^;O;KIOY:Z&L=>7Y_
MHM^GEYVW/?OAS?Z3JGP^\,WF@VQLM$N-,MI;&V*X,4#1*8TQVPI _"NBK!\!
M:UI_B/P/X>U72;;[%I=]I]O<VEML">5$\:LB8' PI P/2MZNNM_$EZLY:7\.
M/H@K@?C]?6FE_ [Q_>W^G1:O9VVA7L\MA,[(EPJPNQ0LO*YQC(Y'45WU<+\=
MM3TC1_@OXWO-?T^35M%BT>Z^V6$4AC:XB,;!HPX(*[@<;NV<URU?X<O1G52_
MB1]4?+GASP_XZ\6>!=;TN/QGXQC\4:-!!/=>#KKQ';16]U8RIO22#4!8FX*.
M@906(8.K*S#&ZOJOX,ZEHFK_  E\'7OANQ;3- GTFVDL;)_O00F)=B'DY(&!
MG/.*\4^(G@W3/''A71=/U_P_H\WQ2M-$>[@T73_$-]812:8LJ+) UY$H:1-K
M(-KJ5+'.,9->X?"77M*\4?"_PGJ^AV']E:->Z7;3V=AM ^SQ-&I6/ X^48''
MI74_MV[K_P!N6_7;SLU(Y8WM"_;_ .1>W3\+JVY\J:'=ZEJWQF\5Z?;>(/$O
MPTT#4_%%_I-C>:!J-O-9W6I1@2.LT%U;2?9Y)0693&VUF5N QY]B_9;M6T7_
M (3C1-8LKJ/QM8:I'_;FH76J'43J#/ C03+-Y<>%\O:HC$:!-I&.YY[2;CP=
MXDT/XCQ^)] T[2/AW>>+'LTGEOKB2\N]6-TL#3D*,V^9@@0HV1C=\HKJ?V9+
M6Q\.1^-/"B^'8]"US1M47^TYH]5FU07[2PI)'.;F<"5F,952K\KMP.,5E2T@
ME_=7_MOW;[=N71;FM76I)K^9_G+[_-][Z]#VZBBB@ HHHH **** /D+1?AOX
MB\%_&S1;O6[."#0KG7V6VN+&VMXR9-]Y+"7?[0TAR)Y%)V98  XKLOVJM/UO
MQ%J7AO2)++6CX2>99KB_\/6D]Q=6\NV56;$39&%9 -RE2'<X)4"G>(O%/ASX
M=_$B[O(O@-=MX@$-]JBZ]86^D)+<0PE1/.)#<K)SYJG#88[NG6NG^.D-UXX^
M&.B7NFV]]=6-Q/#=7&FVXF\RY@DA<!7\D%OE9TDQRI,8!X.:R>E*+2O9_GIK
M]SU\O(TWJRN[737W:Z?>OO\ ,D_9ATG^POA_>V$=A?V=I;ZG-';3:K9RVMY=
MQ!4"S3)+SN(&T$8&U%X7H/$M3^('@;0?BY'K&K:AX2TQK+Q3/I[Z!<ZY/%>6
M[M-\U[)$TPAQN43[3%@;BP?>>?9/V4&O4^&,UMJ'GP7-KJ$ENVGW#3L;';'&
M#$&G59""<R#*@#S,*, &L?6/CAXFF\:2^'M'L?!K7@U46,:WFJW&YU$N&4NM
MMY0F,8+>6)"P/&#C%=4D_;0:=W9?^V_I^=ULCGCK1DFK*[_7^OE;J>\V=Y;Z
ME9P7=I/'<VLZ++%-"P9)$89#*1P00<Y%34B\* 0 <=!TI:S]"SA/CI9W>I?"
M3Q-:65E_:,L]KY3VWV5;IFA9@)=L+*PD81ER%*G) &#TKY]^$/PITK2_BOH'
MB;PSX-72=--]/:6:R^%8+(IIL5F4:[EF-NDJ3RW!^4%@60GY,9-?1OQ>TG5M
M>^&?B+3M#:X75KFU:*W:TN#;RAB1]V0,I4XSR"#7E_A_X(ZSX4^(UOJUA>>(
M9=/A\2!T2\\37EU%_9ATPJP:*6=E;_2B3@@MG!'%*GI4;\OUM^OW<WE9RUA;
MU_+_ ('WV\SZ HHHH Q?!G_(IZ1_UZQ_^@BMJL7P9_R*>D?]>L?_ *"*VJ "
MBBB@"CK9F&DW9M[R'3YA&2MU<1^9'%_M,NY<C\16'I/PX\)Z#XNF\0:;H]E8
M:]<P/'--:KY9E5F0NS(#@DE$RQ&> ,U7^+=E=ZKX%U'3K72K_5_MB&!X]+E@
M2YC4@XDC\]EC8JP4[6(!]^E>=_!?P?K5CXR.K:I;^,' @NLS>(VTZ*!9;B1)
M)C%';%I/F:->'.U0#MZT1^+^NP2TC_7]?U]\7QX^-'B+X?\ BJVTJRFTVTTV
M>V6026J)J&K.Q)#".R::)B  ,,@F).?DKU*2X:\\%Z-.TMS.TLNGN9;R#R)W
M)GB.9(]J[&/=<#!XP*\2^-7B33+'XS0Z?=>%;PW=Q9VT<.NZ.M]:W+%I3\LE
MW H01J-_RR/@$Y/!KW35(XX?#.G1Q7+WL:7-BJW$CAVD N(AN+#J3ZT0^!^O
M^82^/3M_D=%7%_&S_DC/CW_L 7__ *3R5VE<7\;/^2,^/?\ L 7_ /Z3R4 :
M_@3_ )$?P]_V#K?_ -%+6[6%X$_Y$?P]_P!@ZW_]%+6[0 4444 >6_M/?\D*
M\5?]<X?_ $?'7J5>6_M/?\D*\5?]<X?_ $?'7J5 !1110!XM\1_B/_PB/Q&L
M+/5M.L]92WB?4M/AT^X*:D25,!C2V;(G;#L>&7C^'BO4/!EG:Z?X1T:VL;>X
MM+.*TB6&WO%*S1IM&%<'HP'!'K5*+PUIVEZO<RP7RV.IZI>"\=HX;9)IUC50
MT6?+RZ8').7 ;[PXQTU$=()/?^ORO;Y7Z@_B;6W]?\/\S@O#.?\ A<'CO'!^
MPZ7C/TN:\Z_X3VTU;QQKOAW7M%CU?4C<6VC3W'AF8S2"--LZ336Q&Z",&<@M
MN?[IYKT3PVN_XO>/%/0V&EC]+FMGPOX;T_PRMII>F7JQII]OLGLH(;>(2,^"
MLTB1QKM;Y&QMVJ=S<' P1^*[V_K_ (;Y@_A:_K^O\CQC_@HE_P F6?%7_L&I
M_P"E$58_Q.^'NK^+?AWX+OK#1=)O['3]!LIY6NM"AU2>5]T"L@C;]X0L)D<"
M+#$K@$' .Q_P42_Y,L^*O_8-3_THBK!^+D&JR_#7P1<V.DQ+:V'AZUFN-;>_
MO+![=7:")E2XMF!CVJYE9FW#"'Y2,UG/=?UT9<>O]=4>M_L]?#Y/A_\ #O2X
MHDU#3X[NRM96T:^N'E6PD$0#HF\DH">2G !'0'->.^-?^4F7PX_[)_J'_I37
MT#\';NXO_A1X/N;N>XNKJ72;9Y9[K=YLC&)<LVXDDGKDDYZU\_>-?^4F7PX_
M[)_J'_I3714^-F,/A1]72!S&XC95?!VLPR >Q(R,_G7@6E^/+'Q%XTU'0]9T
M5=1U5]1MK"XNO#<YN!&;642Q37$) :W0L_7+CU->]W5N+JVEA8X61"A. >HQ
MT((/X@BL/PSH-AX?%OIVF7JI!IMLMM+I\$4$:;CAA*ZQHNUR >!M7YC\O3&<
M?BN]OZ_X;Y^1;VTW_K_A_EYG0UY=\,9KVW^"MO-I\MI%=12WDBM?*6A(%W*2
M&P01D C/;.<'I7J->6_##P[:^*O@WIVG7JJ]J]Y/(Z/#'*K[+Z1]I6167!VX
MZ9&<@@X(F5VK(:M?4PO@KXXT?X@76DSP:#/;7213ZJM]IUQ]MTU9+DAY8C<!
M5_> N?D*C&#7<_&__DB_C_\ [%_4/_2:2NDT6.'R[B:UO_MMG+)^Z1/+\J *
M AC0HHX#*2=Q)!)&<8 YOXW_ /)%_'__ &+^H?\ I-)6DK=$2KZW*WQJ\37/
MA'P;+J2C2Y=/WI:WD&J7#6RM',ZQ;A. PCV[\G*-D#MUJ+X2:OIGB3^T-3L-
M'U#2W2&WT]I+I<P7$<(<H]O(.)4_>-\XZ\<"NH\0:#IE[?:?K&IF 1Z2)9D:
MXBB9$)49?>ZED*@=59>O.:TM+MWM-/@B>\EU!E7FZF"!Y/<[%5?R J8Z7\_Z
M_P _O'+6WE_7^1Q_Q*_Y#WPZ_P"QC_\ ;"\KGOC-XV/A/6M"M]2@TN^TB]G6
M:*&:\-I=+-;D2@1Y#+,6*J GR<\9.:Z'XE?\A[X=?]C'_P"V%Y6IJ?AK3H]8
MO-4:]73M4U&**QAO%AMQ-&5W$+&[1DL3D_*Q8<< <TM;JP=&)\.)K.[\*PWU
MCINH:3%?3SWC6>JPF*XCDDE9W#(>GS$D>Q%?,WABW>[_ ."AOQKABMH;R5_
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MRV\ZRS7UQ;PPVT370D9OFD5(P<!CPRX)*C<6YSTU):12_K^KW&]_Z_KL>>^
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M7$32R-(ZNI^Z=SGBLS2?^2T>*O\ L7]'_P#2G4Z[:N)TG_DM'BK_ +%_1_\
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MP]7T_3O%MW?:#K6@PZEIB00S%KZW66WF9FD!0!@02NP$_P"^*WU4(H50%4#
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M3=QZ#>BZB@)@B !?8A;<59ON\;MH)VT4OM]_^"OR"IO!]/\ A_\ AR_\<?\
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MZ;F SC)Q7GW[)>M6^M>$-8>VT33]$2&\2&6.S^S>9+*(4WR2^1)(N3\I +9
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M5R,[& SG'%3)7*B]2I^S'_PCTFBZK<>&M2FU*PE6S.7^S%(2(%'E!H$52RC
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MQPWR +@]MH QC  JG\3+N>TO-+;^W==T>S*2[UT'13?R2/E-I8_9Y@B@;N,
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MLAPHW9D;Y<DU:_:/\:0>"_#/AG6S'I_G0ZNLUK)J]P]M%'*+:=E! &XLP!0
M\ OD],5P<7A=/$WA?QUJD]GXBU/XCZ?J-W!;7NGZG(/WIF<6HMBLHB6)%\L.
MAQC:V]22<]G^T+8&;X;^&[C7)=/N)+'4+>>[T^ZNI;5-1D\IU,,;PH\F[<V\
M*JG=LP1@DU+^!-::Q_3\O3M\K7Q.^MU)?=_G?OW.O^#_ ,3E^*WAN[UB*VC@
MMDO'@MY89#)'<1[4=74E1R-^QAR R,,FO/\ 3_!7Q3C^()NGU5;31;;6GN !
M=H8[JVEG9W!C$>0$@6.-5R#YCN^3U-_]F+P?I&G^']3\0626*W&HWT^V"QO9
M[I;&+*_Z,SS*K;@REB&12I?:!@"O*OB98Z?=?$ Z/9:SHNNZM=>((@--'C?4
M!J$3F<."UK&Q5%0XRH "H">U:Z*K"RUTT^[[_P OS,E=TI)OOK]_W'V#14%C
M]H%C;BZ$:W7EKYHA)*!\<[2>2,^M3U+&<K\4O%$_@SX?ZUK%HRK?6\.+7?;_
M &@-.S!(E,?F1[LNRC&]>O45X'X/UWQ)J/QVT7_A+=/\,7=U9W']F2:UI_A7
MR)8;Y[)K@VB7)U&1QB,\MY3(2-O!Y'MOQPO+;3_A+XHN+S2X]9@CLV)L9+AK
M=93D;1YJ@M&<X.Y1D$9'(KQ'X;3WWAGXA:/I.H^!M+MH[#Q#/I7]I)XJO=1G
M%Y/8&[>Y*30*)6*8CWNVY02!\O!5/^)\OUM^OWV^;E_#^_\ *_Z?=?KM]3T4
MUI%7AF4'W-"R(QPK*3[&@#'\&?\ (IZ1_P!>L?\ Z"*VJQ?!G_(IZ1_UZQ_^
M@BMJ@ HHHH Y7XG>&[[Q=X+O](L!;/)= )(EU(T:LF><.%;:PX()5AQ@CFM%
MO#-G-XHM/$!>0WMM92V,:J1Y>R1XW<G R3F).^!SQS6;\5H[F;X<^(([..^E
MN7M&5(M,4M<R9_@C^9?F(XSN&,YR,5YK^S#I?B3PPWBK0]9\+:KX>T^*[%Q8
M?;9XI83&X/RH4FD^;@%L?*#[YR1^+T_X;\A2V7]>9M^,/BUIO@_QYJ&B6VER
M:GXLO([-;+33>[&O%/FEI%1LK'%$JL7D ZX!YVYZU->3Q5X%T/68[>6TCU"3
M3[I;>8 /&'GB;:V.XS7C/Q(\5Z_X<^+ME9W?BV75-(6ZMRVAVD7V">&.20MY
MKSQH[RQIA5('E+R S,37O?BCC3( /^?ZS_\ 2F*B/PW??[OZ_KL.7Q6-BN+^
M-G_)&?'O_8 O_P#TGDKM*XOXV?\ )&?'O_8 O_\ TGDH U_ G_(C^'O^P=;_
M /HI:W:PO G_ "(_A[_L'6__ **6MV@ HHHH \M_:>_Y(5XJ_P"N</\ Z/CK
MU*O+?VGO^2%>*O\ KG#_ .CXZ]2H **** /GCQ3I?AKQ1\2M1T-?AYX>\7W#
M:E ^H7_G22W-L1Y;YE=K8QH5"J?*\[)7H.<5[]IRRII]LL\,-M,L:AX;=BT:
M''W5.!D#MP/I7B'C+1/$U]\6])U7^S?.CCO3#;K#IR$+"DEM\[W0'F)E'N&^
M^%)C"[6Z'WBB/\*(2^-G >'<'XN>/@W"_8-+SSCM<]^U>9?"_2M \1^(],O-
M#^&WAEX-*1GM?$EC<2-&7!"9\U[1/.8C<=Z%_F')&<UZ;X<9E^+GCTHNYQ8:
M7A?4XN:XCX6Z'XDLOB=+J.J:=Y<M[:+/>RQZ<EK%$SPQML$B8\TB0R)AR[ +
MG*_Q$?B_KSL$OA,G_@HE_P F6?%7_L&I_P"E$5>S_#+_ ))OX3_[!-I_Z)2O
M&/\ @HE_R99\5?\ L&I_Z415[/\ #+_DF_A/_L$VG_HE* .EKY.\:_\ *3+X
M<?\ 9/\ 4/\ TIKZQKY.\:_\I,OAQ_V3_4/_ $IH ^I]4N%L]-NYW>2)(H7=
MGB +J I.0"""?J*^?_@!J^K?\)_?V6N6XOIYK5Y+35KR\>XOC&$MY2L@W&-,
MBYC)$2HF5( .*]\UK6M-\/Z?)>ZM?6NG62D*]Q>2K%&,G !9B!R:Y+3?'_PT
MM=2EN+#Q%X7BO[H)$\MO>6XEFV@*BDALM@8 %$-)-^5@E\-CNZ\0T>XN8?V=
M8H[&\OK&^NKR6TMIM/9$E\V34'1!N<$*I+ ,PY"DE2#BO;Z\G^&'BKP]X;^%
MNBKK^K:;IB37-X8AJ%Q'$'*W<IRN\C)!P>.G%)ZZ,:T=T5OV:M8NM2\,ZC%J
M.GVEIJD<L<D\]K<2W!N!)&&1GDE9W+ <?,Q/'0#%=7\;_P#DB_C_ /[%_4/_
M $FDJ?PKXP\"23KI7AO6O#[33.\JV6F7,)9V.69MB'D]23BH/C?_ ,D7\?\
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M_P#I/)7:5Q?QL_Y(SX]_[ %__P"D\E,9K^!/^1'\/?\ 8.M__12UNUA>!/\
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MU49S@41UE;T_/]?T#I<]"KS+X3ZI#HOP>LKZ>WN+F*&>[+):6[SRX-W*"51
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M/.2"HZC//L"0+?\ KJ#V_'[CCOVPO^34?C#_ -BEJG_I+)6O^S5_R;G\*_\
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M'RD8&,5%+X?/E7R5X^[ZK3S]UEU/B_[>?S^+WOGJ_F>U4444 %%%% !1110
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MJJ$YS\RJH.1Q7G.I6/P[TGXGZ?-=^%_$5OJ7]K%+>[:&[&F&[F<-O(W>3S(
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M_8]SIPD+S)&D+!Y2Y4H#*K!3'G(^]@8KO_"/AR#P?X7TG0[9S);Z=;1VL;,
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MP5(S4MJZN4E>YZKX%\*_\(;X;ATPW"W,BRS3R210B&/?)(TC!(\G8@+D!<G
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M/J'VFVL[_5C<WLX7<MO)^]D:0_(IPO08. *%\7]?UZ!+X?O_ "_JYF?MA?\
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M_GUKEO@?<ZS?>';JZU/4CJEK)*GV6X:[@N=Y"*)65X1M\MI-Q4=0.H'0=3>
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M/VA[J.$&4AT!"G#+QT7!->K_  UU"XU/PC;3W&HKJX\Z=(;Y2I::%976,OM
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M +7T_6;EX;F\D:_^W:X\<D8,C+BV>U6WSMP JMC/W<\5[XK;E!'0\\C%"^%
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M<M("O(95*=#D]*Z;P_'>S7WQ<CTV6.#46U<+;2RC*)*=(L-A;@\ XKB?V?\
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M_$W8C\3_ *[_ -?@$O@7]=5_G^O<C_;"_P"34?C#_P!BEJG_ *2R5K_LU?\
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M?J<Y\8/'GA[X>^./".HZX;>/S8+FU$U[=Q01I%)+;(Y4.#O<%D. 5^02$DX
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M'J^R;^XZ3P/XX\(Z];P:3X<\4Z7X@DL[95*V=_%<R^6F$WML)[X!/J:J^/\
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MI=?VKI&DV]WJ%[<>,=4T>U6.:2811I!9M^\<F.0EV P HR>@ZO\ 9SL[/5-
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M[_TG>I*/*_\ @G__ ,F9_"C_ + Z_P#HQZ]"U3P3\,;&XU ZAX;\-Q36MO\
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M57!N-NUXK(,X7[3* =YR-N2V!7O4,HFA210P5U# .I4\^H/(/L:Y#^U/'_\
MT+7AW_P?3_\ R'776[2M;QF=%CF*@ND;%E5L<@$@9&>^!]*2^&PWK*YY?H^C
MQ^(=+^+VERQW,T=YJ\\#1V903,&T^U&$,GR!N>-W&>O%9GPM\/ZCX-UR2270
M?&=ZUX6C-UK$ND"*V5Y6E=MMM(IP78G[K$=AUK:\(V^KW&H?$%=%O;.PNO\
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M2>/8-;TVSU2SB\37$WDWMNLR B"'Y@K \X)_.M70_!_PW;4=.FTGP_X=%[)
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M5[](%,?L/)B0?GFB.D>7Y@][E7Q%_P C#X7.S?B[FYST_P!&EK.;QQK(8_\
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M">(?_1"U]6T %?#/[$W_ "#9/^RQ>)O_ $AN:^YJ^&?V)O\ D&R?]EB\3?\
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M .@BMJ@ HHHH \Y_:&TK1M4^#?BDZY:PW-G;V4DX:9(V$3!3A_WGR@#/)/\
M#FN-_9*U+2-:\.>(=0TJZTVZ:ZO(GNO[#M(K:PCE$$:E(UC=QN&WYCN.3@\
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M:ZTCQ1KFF,L9T]?#>L1V*6^$ <2J;B%G<ODY.]<8'&#GE/\ @G]_R9G\*/\
ML#K_ .C'KW.^M9IM2TZ>._-M#;N[36X'$X*%0#SQ@D-^%(=[%#P)#K%OX3T^
M/7G9]4"MYGF,K.%W'8'*@*7";0Q7@D'%8^E_\EK\3?\ 8O:5_P"E.HUVRL&&
M0<CVKB=+_P"2U^)O^Q>TK_TIU&J>KN2M%8JPP^*6\=&V^TD^$DG;4AJ0E3+9
M79]B(ZX$F9-V/NX7/6O0:^7I-$UC3? ^MW.C8L?!$AO5U;-W&UQ<1B603316
MS1E8I/O?\M1G&2FZOIVWV_9X]A8IM&"W7&.]*/P+^OZ_J^MQOXOZ_K^NUCA/
MAZ474OB29)/)C_X2!]TF[;M'V&TR<]L>M/\ A]#XL;4+G_A)92D.GQ"PM2LB
M$:AALF\8+T++Y8VG&").,$5F^&]!B\56WQ7T:>1X8;_6IK9Y(_O*'L+5<CW&
M:72_A';ZEKR>)-=O=/UCQ+;WL,D>HV5@L'DI"K((5W/(RY+.6^;DGH.E"^+^
MOO\ E_6M@E\/]?UK_6ES-_;"_P"34?C#_P!BEJG_ *2R5K_LU?\ )N?PK_[%
M32O_ $CBK(_;"_Y-1^,/_8I:I_Z2R5K_ +-7_)N?PK_[%32O_2.*@#TBOECX
MX?\ )^_[,O\ V#_$_P#Z1Q5]3U\L?'#_ )/W_9E_[!_B?_TCBH ]B^)NFZS>
MZMISQ6.N:OH2P2+-8^'M12QN//++L=W:6(E H8863J>0>VI\,;76K72K]=6A
MO[6W:[)T^UU6Y2XNX8-B#;+(C.&.\2$9=CM(R>PZ'7+.:^M(XK>^.GR+<0RF
M51DLB2*SIUZ,H*_\"J^K!N5((]J(^ZOZ]?\ @>@/74XKQ_\ \C9\-?\ L8)O
M_35J%<[XUTC6[CQ;?376D>*-<TQEC.GKX;UB.Q2WP@#B53<0L[E\G)WKC XP
M<]%X_P#^1L^&O_8P3?\ IJU"NFOK6:;4M.GCOS;0V[NTUN!Q."A4 \\8)#?A
M2'>Q0\"0ZQ;^$]/CUYV?5 K>9YC*SA=QV!RH"EPFT,5X)!Q61I/_ "6CQ5_V
M+^C_ /I3J==JK!AD'(]JXK2?^2T>*O\ L7]'_P#2G4ZIZNY*T5C@=1T/Q@&U
M KI7BR?Q0TTWV36;?6H$TM,N3"3;F<#RU4J&!@9N#]X\GW*/=Y:[R"^/FV],
MUGPVLL6N7=X]_OM98(HDLR %B=6D+/G/5@ZC_@ K2I+2*0WO<\M\*P:G=:+\
M4H=&E2#5Y-:O%M)9,;4F-M#L)R".N.H/T-9_A?2?$%OXDTF2RT7Q=I($V=2N
M?$&M0WEM/#L;<%C%Q*5<MM(V(@&.<#@])\*^+SQX3_T,EQ_Z)@KKM'M9;&.X
M2>_-\\EQ+,C, "B,Q*QCGHH./PH6CN#UC8Y'X\?\DC\2_P#7NO\ Z,6F?%#3
M=9OK[27MK/6=4T1$F6[L= OTLKIY24\IC(TD1V "3(60'++P>S_CQ_R2/Q+_
M ->Z_P#HQ:Z[7+.:_P!/:"WOFTZ8R1L)U&2 KJS#&1U *_C2&<S\,+/6K.TU
M-=2M]2L=/,Z_V?9ZS=I=7D4>P!P\B.^X%\D9=FQU/0"O)_R7FW_[%J3_ -*D
MKO58-T(/TK@I/^2\V_\ V+4G_I4E42M#C=:T/Q7]LU=FTGQ=>ZXUQ.UAJFFZ
MW!#IT2%V,&8&N%!"J4#;X7)(;[W%>TV*SK9VXNF1[H1J)6C&%+X^8CVSFJJV
MLJ:Y+>-?DVK6ZPBS(&U7#,3)G/4@@8Q_#6C26D;#>LK_ -?TMCSSP[%>SZA\
M6H],DCAU%]85;:249193I%AL)X/ ;':N:\.Z/XE@UC2&M='\7:=>BXC.HW^M
M:W#=64T0_P!<!"+B3!89V[(DP<9VC(KLO /_ "-?Q*_[&"'_ --6GUTNEVTM
MG)?&>_-X+BY,L2L /)0JH$8YY ()_P"!41TE?^M'M\^OH$M8V_K7_+IZFC7C
MOA.TUB\_9S\&1Z+]I-Q_9UBTT5E*D5Q+  ID2)W(57*Y )(^JGD>Q5PGP-;;
M\%_!9QG&CVQP/^N8I/S&C,^'>FZU9^)RT>E^(M%T#[(XGM_$FJQW[RSET\MH
MB)YF4!1)NRP'*X'<:OQ&_P"1B^'/_8Q-_P"FZ]KJ]#U"35M%L;Z6UEL9;F!)
MGM9AAXBR@E&'J,X_"N4^(W_(Q?#G_L8F_P#3=>U;NM'T)*_Q0TW6;Z^TE[:S
MUG5-$1)EN['0+]+*Z>4E/*8R-)$=@ DR%D!RR\'M;^&%GK5G::FNI6^I6.GF
M=?[/L]9NTNKR*/8 X>1'?<"^2,NS8ZGH!U&M:C)I6GM<Q6DM\XDC3R81EB&=
M5)^@!+'V!J]4K30;UL?+GQY_Y/J_98_Z]O%G_I!#7U'7RY\>?^3ZOV6/^O;Q
M9_Z00U]1T %?+?[ _P#R"?CK_P!E;\1_^C(J^I*^6_V!_P#D$_'7_LK?B/\
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M'O#MO<LUM]FA7Q#(;B]660H?(C-H/,9,990>,C) YH7Q*VX/9WV.:_X*)?\
M)EGQ5_[!J?\ I1%7L_PR_P"2;^$_^P3:?^B4KQC_ (*)?\F6?%7_ +!J?^E$
M5>S_  R_Y)OX3_[!-I_Z)2@#I:^3O&O_ "DR^''_ &3_ %#_ -*:^L:^3O&O
M_*3+X<?]D_U#_P!*: /JN\F@M[.>6Y*BV2-FE+C*[0,G/MC-?.>B_#+PMXG\
M?VMUI/ARS\)V=\UMK,"7?A^%9[E;9XVWVL\<O[@-^ZW)(F_#$@#)Q]$ZEO\
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MPI\96GBC0VM+71+[0?[*V6AM;JUEBBVA?E,+NJ^8F!UP"/X@#1'5-KI_P/\
M/\?OJ72_]?U^GW1_$K_D/?#K_L8__;"\K/\ %'A[X9:+J-XVM>%M$6X^R2ZG
M)--I<3&9$8"0AMOS."RY'4[QZUH?$K_D/?#K_L8__;"\KD/CEXLT^S\7>%-+
MN-#;7);9I=5$7V>ZSF(H%"/$C*Q.\DH^5)5=VW@B'NOZ_KN4NO\ 7]=CU;P[
MHNEZ%I<4&D:7;Z/9O^]^RVT"PJK, 3E5& ?7Z5\P?#O_ )24?%S_ +$O2O\
MT97TUX1\30>,?#MGJ]O:7MC'< G[/J-LUO/&02I#(PR.0>>AZ@D'-?,OP[_Y
M24?%S_L2]*_]&5I+?4B.Q]95R'QB_P"21^-_^P'??^D[UU]<A\8O^21^-_\
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MUW_I?@#UU_K^NIE>(<?\)'X6R&)^US8(Z#_1I>M<OK/Q6L+?Q5>:';Z;#?\
MBVUNUL[#3VG59Y8WACE>X.03'  2"^#DQXY.!74>(3_Q47A;Y]O^ES?+_>_T
M:6O,/BK)XMMM2U5H;_Q?I^GRSV\5O>:)!I1M[:-O+4LPE)N&PQ<L0.AX4@<K
MK;^N@^C9ZUX4UX>*/#FGZJ+:2S^UQ"0P2_>0]QGOST/<8-5;/'_">ZR<'/\
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M-,-DA=OW0;=@U-#7\?\ V[^O*T=KV*K:?A_[;_7SEO8^C_!G_(IZ1_UZQ_\
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M_P GU?LL?]>WBS_T@AKZCH *^6_V!_\ D$_'7_LK?B/_ -&15]25\M_L#_\
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MI-8TRWTC38;,Q/'#<K.EQ<;P1)'\H8*%W [L'+#CC)C\?_\ (V?#7_L8)O\
MTU:A6CV7]=7_ %^>IFMW_71';4445)04444 %%%% !6#>9_X3O2.%Q_9M[GU
M_P!;:_Y_*MZL"\ _X3S1SMR?[-O?F]/WMKQ_GTH \F^/>I:%I-]J$>O)XJG6
M_L/*A71_$,5DJJ%8/Y4!NXFE<9W'Y&S@ 9Z5[5H=A#I>CV5I;O/)!#$J(US,
M\LA4#@L[$LQ]R37CGQFM[33]5UV6?4IK"PU;3H[?5';PI>:F$A7>-T5Q%A(B
M ['Y@X4@-@<Y]MMU5;>)48L@4 ,W4C'4T1^%^H2^)?UV/E;XR?\ *0K]G?\
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MHPB4G<QPX*\?,<\UE)*4XQ?6_P!UG=?,UBVHRDNEO_2E9_)GN.@?L:^,X5^
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M3?PG_P!@FT_]$I7C'_!1+_DRSXJ_]@U/_2B*O9_AE_R3?PG_ -@FT_\ 1*4
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M/_)]7[+'_7MXL_\ 2"&OJ.@ KY;_ &!_^03\=?\ LK?B/_T9%7U)7RW^P/\
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MX>^']+UJ#5K738XKZW@%M"X9BL2 $#:A.U3AF&X#.#C..*Q?CO\ \D=\6_\
M7@_]*[RN#^.__)'?%O\ UX/_ $I#.\HHHH X+XX_\DWO/^ORP_\ 2V"NWNT:
M2UF19?(=T*K)_=)'!_"N(^./_)-[S_K\L/\ TM@K1^)4NA?V!%;:]HB^(X;N
MX6"WTO[,D[7$Q#%0JOA00 QW,0  3D5,MK%1WN=#I,+VNFVEM-=?;9X8422X
M/!E8  N1VR>?QKE/'_\ R-GPU_[&";_TU:A7$? 'X9:9X9O)M1LX+.PDTZW;
M1/L,&CI8W,0!C?%TZ2.L\FT1$.N%(8D9W5V_C_\ Y&SX:_\ 8P3?^FK4*TEW
M[_U^6IG'33L=M1114E!1110 4444 %8%X1_PGNCC<0?[,O?E['][:<_Y]:WZ
MP;PG_A.](&1C^S;WCO\ ZVU_S^- 'SMXZ\9ZYK>K:Q=:AX;O]1TJSCDBN(+"
MZU:-05:7%M)#;DHS,D8RY381*N>,;OJ*U8/:PLJ>4I12$_N\=*X3XG>/-?\
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MYC;SGPA6,97'7G(YR4]-7Y_/IKWWNO-(*FNGI\MMOU\FSU:OSS_:?_:9\1>
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M:Z?!I<TH%O>3ZEI>I7=\KM-)<.8BUP/W>&WOL3C]Z3U)IQMSRMV)=W35]_\
MACE_CQK^CZ?\?([%=6\8^![R;1[*/5O%7AM[5K1;>:YFBMDNDG1RN)!(!,BY
M7S.2!78_#O0?"?@_XO:+X2AT+7-%U;PYH%U;:+>7TT<MMJUG)- ]S,KJS,91
M*(RP<*WSDX(-=3J_P]T#Q/\ %;Q/_:NDZI>KK7A>#2[UYXE_LV6W6><^6K?>
M\[,K$CLNTCFF_#GX!VG@#Q,NNW7BGQ%XMOK:Q;3-..O7$4@L+5F5FCCV1H6+
M&-,N^YR$7FE3]U*_][_VY+\_1IRZZLJ:MV_N_E%O]?-673;N/!G_ "*>D?\
M7K'_ .@BJ'Q.\!VWQ.\%7WAN]=4L[QX#-YD7F*Z1S)(R%<C(8)MZ]ZO^#/\
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M9/\ DO-O_P!BU)_Z5)7?5P,G_)>;?_L6I/\ TJ2@#OJ*** .)\ ?\C9\2O\
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MGZ/^OZNG/X%Z_JCZ=K(\4?\ (-A_Z_K/_P!*8JUZR/%'_(-A_P"OZS_]*8J
M->N+^-G_ "1GQ[_V +__ -)Y*[2N+^-G_)&?'O\ V +_ /\ 2>2@#7\"?\B/
MX>_[!UO_ .BEK=K"\"?\B/X>_P"P=;_^BEK=H **** /+?VGO^2%>*O^N</_
M */CKU*O+?VGO^2%>*O^N</_ */CKU*@ HHHH **** ."\,?\EA\=_\ 7CI?
M\KFN]K@O#'_)8?'?_7CI?\KFN]H ^<_^"B7_ "99\5?^P:G_ *415[/\,O\
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M 'E?_!/[_DS/X4?]@=?_ $8]?0=?/G_!/[_DS/X4?]@=?_1CU]!T %<1I?\
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M\^6J?]^H_P#XY1_PT3X;_P"?+5/^_4?_ ,<HHH /^&B?#?\ SY:I_P!^H_\
MXY1_PT3X;_Y\M4_[]1__ !RBB@ _X:)\-_\ /EJG_?J/_P".4?\ #1/AO_GR
MU3_OU'_\<HHH /\ AHGPW_SY:I_WZC_^.4S_ (:"\+DY.G:EG_KA%_\ '***
M '_\-$^&_P#GRU3_ +]1_P#QRD_X:(\-]?L.J9_ZXQ?_ !RBB@!?^&B?#?\
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MRBB@ _X:)\-_\^6J?]^H_P#XY1_PT3X;_P"?+5/^_4?_ ,<HHH /^&B?#?\
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M]1__ !RBB@ _X:)\-_\ /EJG_?J/_P".4?\ #1/AO_GRU3_OU'_\<HHH /\
MAHGPW_SY:I_WZC_^.4?\-$^&_P#GRU3_ +]1_P#QRBB@ _X:)\-_\^6J?]^H
M_P#XY1_PT3X;_P"?+5/^_4?_ ,<HHH /^&B?#?\ SY:I_P!^H_\ XY1_PT3X
M;_Y\M4_[]1__ !RBB@ _X:)\-_\ /EJG_?J/_P".4?\ #1/AO_GRU3_OU'_\
M<HHH /\ AHGPW_SY:I_WZC_^.4?\-$^&_P#GRU3_ +]1_P#QRBB@ _X:)\-_
M\^6J?]^H_P#XY1_PT3X;_P"?+5/^_4?_ ,<HHH /^&B?#?\ SY:I_P!^H_\
MXY1_PT3X;_Y\M4_[]1__ !RBB@ _X:)\-_\ /EJG_?J/_P".4?\ #1/AO_GR
MU3_OU'_\<HHH /\ AHGPW_SY:I_WZC_^.4?\-$^&_P#GRU3_ +]1_P#QRBB@
M _X:)\-_\^6J?]^H_P#XY1_PT3X;_P"?+5/^_4?_ ,<HHH /^&B?#?\ SY:I
M_P!^H_\ XY1_PT3X;_Y\M4_[]1__ !RBB@ _X:)\-_\ /EJG_?J/_P".4?\
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M'_\ '*/^&B?#?_/EJG_?J/\ ^.444 '_  T3X;_Y\M4_[]1__'*/^&B?#?\
MSY:I_P!^H_\ XY110 ?\-$^&_P#GRU3_ +]1_P#QRC_AHGPW_P ^6J?]^H__
; (Y110 ?\-$^&_\ GRU3_OU'_P#'**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441314640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 16, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXAGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0434866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1261 Liberty Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vista<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">560-1501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,825,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2023 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441316816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440163264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,391<span></span>
</td>
<td class="nump">$ 99,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">9,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,143<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">72,611<span></span>
</td>
<td class="nump">112,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">8,197<span></span>
</td>
<td class="nump">4,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,885<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">86,221<span></span>
</td>
<td class="nump">123,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,046<span></span>
</td>
<td class="nump">2,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,040<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Borrowings-current portion</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">5,347<span></span>
</td>
<td class="nump">6,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,623<span></span>
</td>
<td class="nump">9,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">28,778<span></span>
</td>
<td class="nump">27,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">4,493<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">867<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">43,761<span></span>
</td>
<td class="nump">38,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2022 and December 31, 2021; 16,549,984 and 16,164,994 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">297,970<span></span>
</td>
<td class="nump">293,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(255,527)<span></span>
</td>
<td class="num">(208,140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">42,460<span></span>
</td>
<td class="nump">84,936<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 86,221<span></span>
</td>
<td class="nump">$ 123,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075442615264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">16,549,984<span></span>
</td>
<td class="nump">16,164,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">16,549,984<span></span>
</td>
<td class="nump">16,164,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441137792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 45,563<span></span>
</td>
<td class="nump">$ 48,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">24,214<span></span>
</td>
<td class="nump">20,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">52,018<span></span>
</td>
<td class="nump">44,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">9,876<span></span>
</td>
<td class="nump">7,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill Impairment</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">91,614<span></span>
</td>
<td class="nump">72,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(46,051)<span></span>
</td>
<td class="num">(24,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,448)<span></span>
</td>
<td class="num">(2,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(47,669)<span></span>
</td>
<td class="num">(26,676)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">282<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,387)<span></span>
</td>
<td class="num">$ (26,851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (1.68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (1.68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used to compute net loss per share, basic (in shares)</a></td>
<td class="nump">17,082,348<span></span>
</td>
<td class="nump">15,972,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</a></td>
<td class="nump">17,082,348<span></span>
</td>
<td class="nump">15,972,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441353488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 41,839<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 223,115<span></span>
</td>
<td class="num">$ (181,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock in public offering, net of issuance costs of $4,435</a></td>
<td class="nump">64,709<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">64,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock in exchange for common stock warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(804,951)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of common stock in exchange for common stock warrant</a></td>
<td class="num">(12,775)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(12,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrant in exchange for retirement of common stock</a></td>
<td class="nump">12,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Exercise of common stock warrants</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,851)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">16,164,994<span></span>
</td>
<td class="nump">16,164,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 84,936<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">293,060<span></span>
</td>
<td class="num">(208,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares', window );">Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue', window );">Issuance of stock from vested restricted stock units and payment of employees' taxes</a></td>
<td class="num">$ (239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">245,186<span></span>
</td>
<td class="nump">245,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 4,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,387)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">16,549,984<span></span>
</td>
<td class="nump">16,549,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 42,460<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 297,970<span></span>
</td>
<td class="num">$ (255,527)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441001568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 4,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075439374256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,387)<span></span>
</td>
<td class="num">$ (26,851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(306)<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">967<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived assets impairment</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill Impairment</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,704<span></span>
</td>
<td class="nump">4,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">3,577<span></span>
</td>
<td class="num">(744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(505)<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(854)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">901<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(1,402)<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(32,144)<span></span>
</td>
<td class="num">(20,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,318)<span></span>
</td>
<td class="num">(2,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Purchase of other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,318)<span></span>
</td>
<td class="num">(2,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of taxes withheld on vested restricted stock units</a></td>
<td class="num">(239)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from common stock issued under Employee Stock Purchase Plan</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payment on finance lease obligations</a></td>
<td class="num">(667)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payment on note payable obligations</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock in public offering, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">69,144<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(489)<span></span>
</td>
<td class="nump">64,683<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(36,951)<span></span>
</td>
<td class="nump">41,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">99,542<span></span>
</td>
<td class="nump">57,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">62,591<span></span>
</td>
<td class="nump">99,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">1,732<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Equipment purchased under finance lease obligations</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_EquipmentPurchasedUnderNotesPayableObligations', window );">Equipment purchased under notes payable obligations</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Costs incurred, but not paid, in connection with capital expenditures</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredOfferingCostsReclassifiedToEquity', window );">Deferred offering costs reclassified to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs related to public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,407)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_OtherOfferingMember', window );">Other Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs related to public offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredOfferingCostsReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Reclassified to Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredOfferingCostsReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EquipmentPurchasedUnderNotesPayableObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equipment Purchased Under Notes Payable Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EquipmentPurchasedUnderNotesPayableObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense and Current Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=exdx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_OtherOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=exdx_OtherOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075446427024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc. (the Company) is a commercial-stage diagnostics company dedicated to helping patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&#160;31, 2022, the Company had cash and cash equivalents of $62.4 million and had an accumulated deficit of $255.5 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075445008352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the estimated incremental borrowing rate for the determination of the Company's operating lease right-of-use (ROU) assets, the recoverability of its long-lived assets and the goodwill impairment test. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. We have not experienced any losses on our cash or cash equivalents.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2022 and 2021, approximately 84% and 81% of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is dependent on key suppliers for certain laboratory materials. For each of the years ended December&#160;31, 2022 and 2021, approximately 96% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disaggregation of Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">deposit with this financial institution as collateral for the balances borrowed on these credit cards ($0.2 million and $0.1&#160;million at December&#160;31, 2022 and 2021, respectively). The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,542&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:f-312">three</span> and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets (see Note 5). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We amortize all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets (excluding goodwill), into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test offered by us or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company recorded an impairment charge to fixed assets totaling $0.4&#160;million (see Note 3). The impairment charge was classified within research and development expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company recorded an impairment charge to goodwill totaling $5.5&#160;million (see Note 3).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company categorizes leases at their commencement as either operating or finance leases. Effective January 1, 2022 upon the adoption of Accounting Standards Codification (ASC) 842, the Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Studies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2022 and 2021 was a net revenue decrease of $2.4 million and a net revenue increase of $0.7 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janssen Promotion Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement, effective August 31, 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Janssen Agreement, as amended, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for that quarter over a predetermined baseline. The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit. The Company recognized no co-promotion revenue and $1.2 million in co-promotion revenue during the years ended December 31, 2022 and December 31, 2021, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were included in selling, general and administrative expenses and were expensed as incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the terms of the termination, the Company received $0.6&#160;million in consideration (which was earned in the year ended December 31, 2021) and the Company was restricted until May 31, 2022 from promoting any other biologic or Janus kinase inhibitor used for the treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent. The restriction no longer applies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $3.0 million and $1.7 million for the years ended December&#160;31, 2022 and 2021, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and totaled approximately $2.7 million and $2.1 million, for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire.  Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the years ended December&#160;31, 2022 and 2021, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,014,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,925,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,858,956&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which was issued to provide relief to companies from restating comparative periods. On January 1, 2022, the Company adopted ASU 2016-12, using the modified retrospective transition method. Periods prior to January 1, 2022 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company adopted the new lease standard using a cumulative effect to accumulated deficit and there was no impact to accumulated deficit upon adoption. The Company elected the package of practical expedients, which among other things allowed the Company to carry forward its historical lease classification. As part of the adoption, the Company recorded operating lease liabilities of $6.4&#160;million, operating lease ROU assets of $5.9&#160;million, adjusted for deferred rent and lease incentive obligations of $0.5&#160;million previously included in other non-current liabilities and accrued and other current liabilities, pertaining to its office and laboratory space operating leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 326, Financing Instruments-Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which included an amendment of the effective date for nonpublic entities. For non-emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023 and the impact of the provisions of this standard on its Consolidated Financial Statements is expected to be immaterial.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt&#8212;Debt with Conversion and Other Options </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Subtopic 470-20) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Subtopic 815-40): </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounting for Convertible </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition.  The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440927360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,321&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,656&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation and amortization expense for the years ended December&#160;31, 2022 and 2021, was approximately $1.6 million and $0.9 million, respectively. At December&#160;31, 2022 and 2021, the gross book value of assets under finance leases was $2.8 million and $2.5 million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of Long-Lived Assets and Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company recorded an impairment charge of $0.4&#160;million related to previously capitalized equipment used in research and development activities that were halted in the fourth quarter of 2022. The Company based the fair values of these assets on their anticipated disposal values, which is considered a Level 3 measurement. The impairment charge was classified within <span style="-sec-ix-hidden:f-388">research and development expenses</span> in the accompanying statements of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that the sustained decrease in its market capitalization constituted an indicator of impairment and as a result, instead of performing a qualitative test, the Company chose to proceed directly to performing a quantitative test during the fourth quarter. The Company determined the fair value of the reporting unit using the discounted cash flow (DCF) method, which is considered a Level 3 measurement. In applying the DCF </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">method, cash flows are estimated for a five-year financial forecast developed by management. A terminal value, which represents the value of additional cash flows into perpetuity, is also calculated. Cash flows are then discounted to present value at a discount rate commensurate with their risk. Based on this analysis, the carrying value of the reporting unit was in excess of the fair value and the goodwill was fully impaired. During the year ended December 31, 2022, the Company recorded an impairment charge of $5.5&#160;million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrued and Other Current Liabilities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441019072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 Term Loan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended, pursuant to which the Company has borrowed $25&#160;million. At December&#160;31, 2022, no additional amounts remain available to borrow under the 2017 Term Loan. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, the Company executed the Second Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the 2017 Loan Amendment is 8.0%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2024, after which interest accrues at an annual rate of 8.0%. The Company has estimated the effective interest rate of this loan to be approximately 8.5%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the 2017 Loan Amendment will be repaid in twenty-four equal monthly installments commencing in December 2024. Upon repayment of the final installment under the 2017 Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For the years ended December&#160;31, 2022 and 2021, the Company issued PIK Loans totaling $0.6 million and $0.5 million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 2017 Loan Amendment requires a prepayment premium of 2% of the aggregate outstanding principal. The prepayment premium decreases by 1% on each of November&#160;1, 2023 and 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 2017 Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, commencing with the quarter ending December 31, 2022. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The 2017 Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2022, the Company was in compliance with all covenants of the 2017 Loan Amendment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon an event of default in any of the 2017 Loan Amendment covenants, the repayment of the 2017 Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the 2017 Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2022 Equipment Notes Payable</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, the Company purchased laboratory equipment using notes payable. At December&#160;31, 2022, the total notes payable balance related to this financed equipment was $0.8&#160;million, with $0.2&#160;million classified within borrowings-current portion and $0.6&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to a 5.28% effective interest rate and will mature on October 1, 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075444889648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company adopted ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, as of January 1, 2022. Prior period amounts have not been adjusted and continue to be reported in accordance with the Company's historic accounting under ASC 840, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office and laboratory spaces in Vista, California, under leases that expire in April 2027, with an option to extend portions of the leases for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liabilities because it is not reasonably certain that the Company will exercise these renewal options. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective on August 23, 2021, the Company entered into a sub-lease agreement for an additional office space in Carlsbad, California. The sub-lease commenced in October 2021 and expires in April 2027. The sub-lease agreement provides for monthly base rent of $66,021 which began on October 1, 2021, and such amount increases by approximately 3% annually beginning October 1, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determines if a contract contains a lease at inception or modification of a contract. The Company discounts their lease obligations using its incremental borrowing rate at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Finance Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from <span style="-sec-ix-hidden:f-449">three</span> to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Finance Leases Balances and Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-453">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-456"><span style="-sec-ix-hidden:f-457">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-460">Other non-current liabilities</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $165,000 for the year ended December&#160;31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2022 are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,040)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disclosures Under ASC 840</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Minimum annual lease payments under non-cancelable operating lease arrangements as of December 31, 2021 are as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ending December 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, rent expense was $0.9&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisition-related liabilities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the acquisition of the medical diagnostics division of Royalty Pharma Collection Trust (Royalty Pharma) (formerly known as Cypress Bioscience, Inc.) in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition, for which the obligations no longer exist at December&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has ongoing royalty payment obligations with Royalty Pharma of 2.5% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $1.2 million (including an upfront payment of $0.1 million) and (ii) the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Licensing Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying statement of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute (AHN) to obtain an exclusive license to AHN's patent rights in certain inventions, pursuant to which the Company paid AHN an initial license fee of $0.4 million. In addition, under the terms of the exclusive license agreement, the Company is required to pay the greater of royalties in the low single digits on net sales of diagnostic tests using the assigned patents or a flat annual minimum royalty amount, pending approvals and commercialization.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, the Company entered into an exclusive license agreement with Queen Mary University of London (QMUL) to obtain an exclusive license to QMUL's patent rights in certain inventions, pursuant to which the Company paid QMUL an initial license fee of $0.4 million. The Company is obligated to make a one-time payment of $0.1 million relating to the first commercial sale of the licensed products. In addition, after the first 18 months of commercial sales under the terms of the exclusive license agreement, the Company is required to pay royalties in the high single-digits on net sales of testing products using the assigned patents, pending approvals and commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supply Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $6.0 million and $6.9 million for the years ended December 31, 2022 and 2023, respectively, with a 15% annual increase thereafter for unconditional minimum purchase commitments through the year ending December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Obligations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into a master research collaboration agreement with AHN, pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $0.4 million for the year ended December&#160;31, 2022. Collaboration expenses under the AHN collaboration are included in research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingencies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters will have a material effect on its financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441019072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair values of the Company's long-term borrowings are determined by Level 2 inputs and are based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9 million. The estimated fair value of the 2017 Term Loan, which uses Level 2 fair value inputs, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's long-term borrowings as of December 31, 2021 approximated their fair values as the interest rate and other terms were that which were available to the Company at the time. See footnote 3 for discussion of recorded impairment charges related to long-lived assets and goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The fair value of the Company's money market funds is based on quoted market prices.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440983760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shelf Registration Statement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 25, 2021, the Company completed a public offering of 4,255,000 shares of its common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, after deducting underwriting discounts, commissions and other offering expenses of $4.4 million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">At The Market Sales Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2022, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0&#160;million. The Company is not obligated to sell any shares of Company common stock in the offering. As of December&#160;31, 2022, the Company has not sold any shares of its common stock pursuant to the Sales Agreement</span><span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Exchange Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 22, 2021, the Company entered into an exchange agreement (the Exchange Agreement) with an investor and its affiliates (the Exchanging Stockholders), pursuant to which the Company exchanged an aggregate of 804,951 shares of the Company's common stock owned by the Exchanging Stockholders for pre-funded warrants (the Exchange Warrants) to purchase an aggregate of 804,951 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.001 per share. The Exchange Warrants do not expire and are exercisable at any time except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 4.99% of the Company's common stock, which percentage may change at the Exchanging Stockholder's election to any other percentage upon 61 days' notice to the Company. The Company recorded the retirement of common stock exchanged as a reduction of common shares outstanding and additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity and the fair value of the Exchange Warrants was recorded as an increase to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of December&#160;31, 2022, none of the Exchange Warrants have been exercised. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Outstanding Warrants</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2022, no warrants to purchase common stock were exercised.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075444110272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
<td class="text">Stock Option Plan<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Incentive Award Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of December&#160;31, 2022, 1,452,435 shares remained available for future awards. Under the evergreen provision, on January 1, 2023, an additional 661,999 shares became available for issuance under the 2019 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of December&#160;31, 2022, 413,425 shares of common stock remained available for issuance under the ESPP. Under the evergreen provision, on January 1, 2023, an additional 165,500 shares became available for issuances under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Options</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,014,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(245,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(257,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,129,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date fair value per share of employee options granted to employees during the years ended December&#160;31, 2022 and 2021 was $2.74 and $8.83, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock was $2.40 and $11.63 per share at December&#160;31, 2022 and 2021, respectively. The intrinsic value of options exercised for the years ended December&#160;31, 2022 and 2021 was $0.6 million and $0.1 million, respectively. As of December&#160;31, 2022, total unrecognized compensation cost related to option awards was $1.8 million, which is expected to be recognized over a remaining weighted-average vesting period of 1.1 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,076,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(355,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, all of the outstanding restricted stock units are unvested. The fair value of restricted stock units vested in the year ended December&#160;31, 2022 was $0.7 million. No restricted stock units vested in the year ended December 31, 2021. The weighted average grant date fair value for restricted stock units granted during the years ended December&#160;31, 2022 and 2021 was $5.89 and $16.53, respectively. As of December&#160;31, 2022, total unrecognized compensation cost related to restricted stock units was $6.0 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.3 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stock Options</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of employee stock options was estimated using the following assumptions in the Black-Scholes options pricing model to determine the fair value of stock options granted:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56%-60%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4% </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8%-1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5 </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5-6.1</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%-57%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%-60%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6%-3.3%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1% </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation expense related to the ESPP for the years ended December&#160;31, 2022 and 2021 was less than $0.1 million and $0.2 million, respectively. As of December&#160;31, 2022, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was less than $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.2 years.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,704&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,728&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common stock reserved for future issuance consists of the following at December&#160;31, 2022:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock reserved for issuance upon vesting of outstanding restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for grant under the 2019 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,537,524&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441002128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision (benefit) for income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2022 and 2021 are shown below (in thousands). A valuation allowance has been established as realization of the Company&#8217;s deferred tax assets has not met the more likely-than-not threshold requirement. If the Company&#8217;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalization of research and experimentation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,882&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing and acquisition-related liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,031)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2022 and 2021, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2022 and 2021, the Company had federal NOL carryforwards of approximately $118.4 million and $89.4 million, respectively. At December&#160;31, 2022 and 2021, the Company had state NOL carryforwards of $87.0 million and $61.0 million, respectively. Approximately $43.5 million of the federal tax loss carryforwards will begin to expire in 2023, unless previously utilized. The federal NOL carryforwards generated in after December 31, 2017 of $74.9 million will carryforward indefinitely. The Company&#8217;s state tax loss carryforwards will expire in 2030, unless previously utilized. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2022, the Company's deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to taxation in the United States and in various state jurisdictions. The Company&#8217;s tax years for 2003 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any material accruals for, and did not recognize any, material interest or penalties in these financial statements in any period presented. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uncertain Tax Positions </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2022 and 2021, the Company had no unrecognized tax benefits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441002128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) PlanThe Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For the years ended December&#160;31, 2022 and 2021, the Company made contributions to the Plan at 4% and 3% of qualified employee compensation, respectively. For the years ended December&#160;31, 2022 and 2021, these contributions totaled approximately $0.9 million and $0.5 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441197920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. We have not experienced any losses on our cash or cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:f-312">three</span> and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets (see Note 5). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We amortize all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets (excluding goodwill), into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test offered by us or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company recorded an impairment charge to fixed assets totaling $0.4&#160;million (see Note 3). The impairment charge was classified within research and development expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded.</span></div>During the year ended December 31, 2022, the Company recorded an impairment charge to goodwill totaling $5.5&#160;million (see Note 3).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company categorizes leases at their commencement as either operating or finance leases. Effective January 1, 2022 upon the adoption of Accounting Standards Codification (ASC) 842, the Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ClinicalStudyPolicyPolicyTextBlock', window );">Clinical Studies</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Studies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Shipping and Handling Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2022 and 2021 was a net revenue decrease of $2.4 million and a net revenue increase of $0.7 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janssen Promotion Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement, effective August 31, 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Janssen Agreement, as amended, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for that quarter over a predetermined baseline. The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit. The Company recognized no co-promotion revenue and $1.2 million in co-promotion revenue during the years ended December 31, 2022 and December 31, 2021, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were included in selling, general and administrative expenses and were expensed as incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the terms of the termination, the Company received $0.6&#160;million in consideration (which was earned in the year ended December 31, 2021) and the Company was restricted until May 31, 2022 from promoting any other biologic or Janus kinase inhibitor used for the treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent. The restriction no longer applies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and totaled approximately $2.7 million and $2.1 million, for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $3.0 million and $1.7 million for the years ended December&#160;31, 2022 and 2021, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire.  Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the years ended December&#160;31, 2022 and 2021, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Recently Adopted Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which was issued to provide relief to companies from restating comparative periods. On January 1, 2022, the Company adopted ASU 2016-12, using the modified retrospective transition method. Periods prior to January 1, 2022 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company adopted the new lease standard using a cumulative effect to accumulated deficit and there was no impact to accumulated deficit upon adoption. The Company elected the package of practical expedients, which among other things allowed the Company to carry forward its historical lease classification. As part of the adoption, the Company recorded operating lease liabilities of $6.4&#160;million, operating lease ROU assets of $5.9&#160;million, adjusted for deferred rent and lease incentive obligations of $0.5&#160;million previously included in other non-current liabilities and accrued and other current liabilities, pertaining to its office and laboratory space operating leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 326, Financing Instruments-Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which included an amendment of the effective date for nonpublic entities. For non-emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023 and the impact of the provisions of this standard on its Consolidated Financial Statements is expected to be immaterial.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt&#8212;Debt with Conversion and Other Options </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Subtopic 470-20) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Subtopic 815-40): </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounting for Convertible </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition.  The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair values of the Company's long-term borrowings are determined by Level 2 inputs and are based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9 million. The estimated fair value of the 2017 Term Loan, which uses Level 2 fair value inputs, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's long-term borrowings as of December 31, 2021 approximated their fair values as the interest rate and other terms were that which were available to the Company at the time. See footnote 3 for discussion of recorded impairment charges related to long-lived assets and goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ClinicalStudyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Study, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ClinicalStudyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441248832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</a></td>
<td class="text">For each significant payor and customer, <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,542&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,542&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,014,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,925,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,858,956&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075445198592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,321&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,656&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,772&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440927360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075444178320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-453">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-456"><span style="-sec-ix-hidden:f-457">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-460">Other non-current liabilities</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $165,000 for the year ended December&#160;31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2022 are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,040)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Summary of Finance Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2022 are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,826&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,040)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Minimum annual lease payments under non-cancelable operating lease arrangements as of December 31, 2021 are as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ending December 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440987344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440985760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075444135632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,014,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(245,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(257,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,129,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.89</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,076,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(355,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions, Stock Options</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of employee stock options was estimated using the following assumptions in the Black-Scholes options pricing model to determine the fair value of stock options granted:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56%-60%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4% </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8%-1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5 </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5-6.1</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%-57%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%-60%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6%-3.3%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1% </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,704&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,728&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Common Stock Reserved For Future Issuance</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common stock reserved for future issuance consists of the following at December&#160;31, 2022:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock reserved for issuance upon vesting of outstanding restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for grant under the 2019 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,537,524&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441628032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision (benefit) for income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">If the Company&#8217;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalization of research and experimentation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,882&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing and acquisition-related liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,031)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2022 and 2021, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075439343520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,391<span></span>
</td>
<td class="nump">$ 99,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 255,527<span></span>
</td>
<td class="nump">$ 208,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441399872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Major Payers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Receivable Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Receivable Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Receivable Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember', window );">United Healthcare | Receivable Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_BlueShieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_BlueShieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438799824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived assets impairment</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill Impairment</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">(2,400)<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">45,563<span></span>
</td>
<td class="nump">48,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising and marketing costs</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual vesting installments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 5,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 4,885<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exdx_JanssenPromotionAgreementMember', window );">Janssen Promotion Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ContractWithCustomerTerminationConsiderationReceivable', window );">Termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Supplier Concentration Risk | Two Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | AVISE CTD Test | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember', window );">Blue Shield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ContractWithCustomerTerminationConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Termination, Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ContractWithCustomerTerminationConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exdx_JanssenPromotionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exdx_JanssenPromotionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exdx_AVISECTDTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440180912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 45,563<span></span>
</td>
<td class="nump">$ 48,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">18,975<span></span>
</td>
<td class="nump">27,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_Government1Member', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">17,687<span></span>
</td>
<td class="nump">9,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_ClientMember', window );">Client</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">7,928<span></span>
</td>
<td class="nump">9,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Blue Shield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_Government1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_Government1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075444135600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,391<span></span>
</td>
<td class="nump">$ 99,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 62,591<span></span>
</td>
<td class="nump">$ 99,542<span></span>
</td>
<td class="nump">$ 57,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441102032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,925,262<span></span>
</td>
<td class="nump">2,858,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">409,108<span></span>
</td>
<td class="nump">409,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">1,421,235<span></span>
</td>
<td class="nump">2,014,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">1,036,208<span></span>
</td>
<td class="nump">415,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">58,711<span></span>
</td>
<td class="nump">20,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441816864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Prepaid Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Diagnostic&#160;testing&#160;supplies</a></td>
<td class="nump">$ 1,795<span></span>
</td>
<td class="nump">$ 1,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepaid product royalties</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PrepaidMaintenanceAndInsuranceContracts', window );">Prepaid maintenance and insurance contracts</a></td>
<td class="nump">2,072<span></span>
</td>
<td class="nump">2,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid and other current assets</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="nump">$ 3,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidMaintenanceAndInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Maintenance and Insurance Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidMaintenanceAndInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438417232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 13,321<span></span>
</td>
<td class="nump">$ 8,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(5,124)<span></span>
</td>
<td class="num">(3,884)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,197<span></span>
</td>
<td class="nump">4,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture&#160;and&#160;fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">5,136<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">5,223<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,382<span></span>
</td>
<td class="nump">$ 1,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438387584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived assets impairment</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Selling, general and administrative expenses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill Impairment</a></td>
<td class="nump">$ 5,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Gross book value of assets under finance leases</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075444103696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 5,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">(5,506)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441086736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</a></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">$ 4,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AccruedPurchaseGoodsAndServicesCurrent', window );">Accrued purchases of goods and services</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AccruedLiabilitiesClinicalStudyCurrent', window );">Accrued clinical study activity</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations, current portion</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Refund liability</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 5,347<span></span>
</td>
<td class="nump">$ 6,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedLiabilitiesClinicalStudyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Clinical Study, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedLiabilitiesClinicalStudyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedPurchaseGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase, Goods and Services, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedPurchaseGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438618032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Loan payable | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentNumberOfMonthlyInstallments', window );">Number of monthly installments | installment</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Term loan, fee incurred upon payment of final installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentage', window );">Term loan, prepayment premium percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction', window );">Term loan, annual reduction in prepayment penalty percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod', window );">Term loan, covenant, revenue performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet', window );">Term loan, covenant, number of days to cure covenant if performance measure is not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance', window );">Term loan covenant, minimum unrestricted cash balance</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease', window );">Term loan covenant, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Paid in-kind note | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentPaidInKindLoansIssued', window );">Term loan, paid in-kind loans issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember', window );">Equipment Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable noncurrnet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Revenue Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantRevenuePerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPaidInKindLoansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid In Kind Loans Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPaidInKindLoansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage, Annual Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440340256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future Minimum Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">16,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">14,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LongTermDebtIncludingUndiscountedInterest', window );">Total</a></td>
<td class="nump">36,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">(158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LongTermDebtUndiscountedInterestAmount', window );">Interest</a></td>
<td class="num">(7,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">28,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Borrowings-current portion</a></td>
<td class="num">(190)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 28,778<span></span>
</td>
<td class="nump">$ 27,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtIncludingUndiscountedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Including Undiscounted Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtIncludingUndiscountedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtUndiscountedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Undiscounted Interest Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtUndiscountedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075437828448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 23, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid', window );">Period for royalties to begin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, due in next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase obligation, due in second year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage', window );">Annual increase in purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeAndLaboratoryMember', window );">Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OperatingLeaseMonthlyBaseRent', window );">Operating lease, monthly base rent</a></td>
<td class="nump">$ 66,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent', window );">Operating lease, annual increase in base rent payment percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember', window );">AHN Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CollaborationAgreementCollaborationExpenses', window );">Collaboration agreement, collaboration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Future minimum royalty commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AdvancePayment', window );">Advance royalties payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember', window );">Allegheny Health Network Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CollaborationAgreementAnnualCollaborationFee', window );">Collaboration fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember', window );">Allegheny Health Network Research Institute | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LicenseAgreementInitialLicenseFee', window );">Initial license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_QueenMaryUniversityOfLondonMember', window );">Queen Mary University Of London | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LicenseAgreementInitialLicenseFee', window );">Initial license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LicenseAgreementOneTimePayment', window );">One time payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementAnnualCollaborationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Collaboration Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementAnnualCollaborationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementCollaborationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Collaboration Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementCollaborationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LicenseAgreementInitialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Initial License Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LicenseAgreementInitialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LicenseAgreementOneTimePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, One Time Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LicenseAgreementOneTimePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Period After Commercial Sales Begin For Royalties To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Increase In Base Rent Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Annual Increase In Commitment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=exdx_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=exdx_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_QueenMaryUniversityOfLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_QueenMaryUniversityOfLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075439338400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Lease Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 4,885<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease, right-of-use asset, after accumulated amortization</a></td>
<td class="nump">$ 1,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1,040<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations, current portion</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">$ 4,493<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">$ 848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075445628608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Costs Associated with the Company's Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 1,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease assets</a></td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">2,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438831072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash out flows from operating leases</a></td>
<td class="nump">$ 1,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash out flows from interest paid on finance leases</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash out flows from finance leases</a></td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Information, Operating and Finance Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438719824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Future Payments Under Operating And Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">6,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">5,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">4,493<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(700)<span></span>
</td>
<td class="num">$ (587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">$ 848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, to be Paid, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440227136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Minimum Annual Lease Payments Under Non-cancelable Lease Arrangements (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 1,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">1,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">1,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">1,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 7,927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438314688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 28,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">59,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">29,438<span></span>
</td>
<td class="nump">$ 95,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">30,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">59,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">29,438<span></span>
</td>
<td class="nump">95,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">30,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | 2017 Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">28,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">26,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438636544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Nov. 10, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Estimated offering expenses for aggregate expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember', window );">Cowen Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering, net</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_ExchangingStockholdersMember', window );">Exchanging Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants', window );">Number of shares exchanged for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of stock, percentage of ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,255,000<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in public offering, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Estimated offering expenses for aggregate expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange Agreement, Number Of Shares Exchanged For Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_ExchangingStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_ExchangingStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441348960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">1,214,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member', window );">Warrant expiration January 19, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">237,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member', window );">Warrant expiration March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">67,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member', window );">Warrant expiration April 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member', window );">Warrant expiration September 7, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">83,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member', window );">Warrant expiration December 7, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">20,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember', window );">No expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438338512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Employee options, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Common stock, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="nump">$ 11.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,704<span></span>
</td>
<td class="nump">4,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Annual percentage increase in shares available for issuance under the Plan</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum Employee payroll deduction percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to stock purchase</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized', window );">Increase (decrease) in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Common stock, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="nump">$ 16.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Grant date fair value of RSUs vested</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted (in dollars per share)</a></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="nump">$ 16.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Annual percentage increase in shares available for issuance under the Plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards</a></td>
<td class="nump">1,452,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized', window );">Increase (decrease) in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438628944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">2,014,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(245,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(257,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(152,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="nump">1,421,235<span></span>
</td>
<td class="nump">2,014,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">1,421,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable (in Shares)</a></td>
<td class="nump">1,129,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise&#160;Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 12.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">16.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">13.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending balance (in dollars per share)</a></td>
<td class="nump">12.94<span></span>
</td>
<td class="nump">$ 12.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">12.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 12.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term&#160;(Years) and Aggregate Instrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 1 month 2 days<span></span>
</td>
<td class="text">7 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 5,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and Expected to Vest, Aggregate Intrinsic Value</a></td>
<td class="nump">483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438608224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 11.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Ending balance (in dollars per share)</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="nump">$ 11.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">415,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">1,076,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards released (in shares)</a></td>
<td class="num">(100,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards canceled (in shares)</a></td>
<td class="num">(355,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="nump">1,036,208<span></span>
</td>
<td class="nump">415,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 16.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted (in dollars per share)</a></td>
<td class="nump">5.89<span></span>
</td>
<td class="nump">$ 16.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Awards released (in dollars per share)</a></td>
<td class="nump">16.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Awards canceled (in dollars per share)</a></td>
<td class="nump">11.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Ending balance (in dollars per share)</a></td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="nump">$ 16.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,487<span></span>
</td>
<td class="nump">$ 4,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438212400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="nump">57.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438617280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,704<span></span>
</td>
<td class="nump">$ 4,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,860<span></span>
</td>
<td class="nump">3,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 631<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075441756944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock Option Plan - Common Stock Reserved For Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">5,537,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,214,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock option grants issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,421,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Common stock reserved for issuance upon vesting of outstanding restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,036,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember', window );">Common shares available for grant under the 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,452,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Common shares available for future issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">413,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075445438176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(137)<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(169)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(306)<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income tax</a></td>
<td class="num">$ (282)<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075445254656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefits</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Non-deductible expenses</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">23.90%<span></span>
</td>
<td class="nump">24.60%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075438746512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 29,789<span></span>
</td>
<td class="nump">$ 22,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves', window );">Accruals, reserves and other</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Interest expense</a></td>
<td class="nump">2,236<span></span>
</td>
<td class="nump">1,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Indefinite lived assets</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,374<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts', window );">Capitalization of research and experimentation costs</a></td>
<td class="nump">2,047<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">39,979<span></span>
</td>
<td class="nump">27,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(38,567)<span></span>
</td>
<td class="num">(27,158)<span></span>
</td>
<td class="num">$ (20,596)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Financing and acquisition-related liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Indefinite lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(1,206)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets', window );">Basis differences in fixed and intangible assets</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="num">(1,412)<span></span>
</td>
<td class="num">(1,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Fixed Assets And Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075445442720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Change In Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward', window );"><strong>Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the beginning of the year</a></td>
<td class="nump">$ 27,158<span></span>
</td>
<td class="nump">$ 20,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases recorded to income tax provision</a></td>
<td class="nump">11,409<span></span>
</td>
<td class="nump">6,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the end of the year</a></td>
<td class="nump">$ 38,567<span></span>
</td>
<td class="nump">$ 27,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In The Valuation Allowance For Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075444104112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 118,400,000<span></span>
</td>
<td class="nump">$ 89,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">87,000,000.0<span></span>
</td>
<td class="nump">61,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Federal tax loss carryforwards, subject to expiration</a></td>
<td class="nump">43,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Federal net operating loss carryforwards, carryforward indefinitely</a></td>
<td class="nump">74,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140075440996080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Qualified employee compensation, employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Qualified employee compensation contribution, amount</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>exdx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exdx="http://www.exagen.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exdx-20221231.xsd" xlink:type="simple"/>
    <context id="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic71131a0a18a4dcdba1f5f3a771db49c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8d55c3bc4e324e6b94b5e0875b9eefff_I20230316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="ia586976f14c945e092ffa77bf6eea0a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia42d222f98d840eb9ce09d6de69b0abd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac2e346101f544b3b8c12fb87ac0784e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91db90b0b71948a3a7ed62f79644090a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15bf116298a3437e8f5fc8227e8b9962_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia63a7f83cab04fd3bd0a7651465bc919_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i786ad5d8770443b192b64cc933e5cec3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied976c8e24054ecbbc5ea323afd116ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i447883be0ca142b2aba0ad1f554359cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5688532efb274edc8b634de1ed329963_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie09435be4441486fb5d942d843092a49_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibaf731ab91df4cce9e68b8a2e71e2969_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2f4d5cd9295462fbea62e01ed3d1ff3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie7a1b430e1df4dbb8fe1a520a779c20d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i641ab5447323466db021f35839754d97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1f3e435c2ed49ca95de1a1d4a150248_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iafc0c73bd74d46db9cc4fcd7cc90df81_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28979da435ba4d15844df6906e3d40bc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:OtherOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie987a93eb70f4bd9b8928b29b52988fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:OtherOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad59c59cd12b4a74a51934e1011397ea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e44acb2196c43dcb02a146b459fd4fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05aa9d3d5e8b4de399a58f24519f3448_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia584bf6fcda64608a116c549a02cfe67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id47cdbd9f44c4293adf1dcb7a5ebea10_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c26ce8e296543d08e3fb5c648736bdd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0bd5830dbe3d44b5a5396e5d707e5405_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1d5e4c6540b4d67906da80434e50044_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ded0e51d34d43b0ba062a85bc1cb346_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ae2b104191742ba8131e5c71bd9cbf0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibf7a3a01918e4ff8a94493a359671d39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0e981b26af96420cad2acd4d9d106893_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c3582c593ea48d582cab27bc402f10f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i908968ff669f4aff969761449a9d8cdb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i88583c8fbed94b7f9798fc8421e0b721_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c6955e97d9d4394a14813f7a52619d2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i481bde6d9dff47b0a38b570d9228c1c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8ab3e04c8cc4b3ba4e0900905568215_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i164771fb3f1d463cbd018cef7d6365d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17536183b1b2446e830e5aa438b46c6e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0719a3c05f2d48efb32f13d66e6f6d52_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3334b98a65be47a890ddcf70cd5ede5b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a730aad2275470c92cce95e1567059c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i91bdb390f427408ea87ff211d239efb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie9c0d3ddc18741dc8fecde8d57850025_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94b61d4be67742429ba95efb0a3804d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0fb69c732f42466ca2a71e8f7eaca6ac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8aa77feb77bd465da489e3faf3b36c72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:JanssenPromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c7294c3cf4640d08c8b4195febb6caf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic404d905bd0c456cb113003341a477fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec3e133c80b243bc90f00f9a090a04ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if07865aaa84345d4855d746dc2002ad2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id44e1098fa6e44dea992cd186d3949fe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac4677048384433e8e79ba780e14863f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i325c9bd99922498897b3b864e4d0b736_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4edbe79ab016482daa691291ec25282b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iced52d7820074956a7e81f9bc4bcfa12_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i55b44a6651b94f84bcc98d5253339f34_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02725e3aa13240f183a18c6bf2fc237a_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ie0b340fe912a484a884f93b38698848e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if22a684f953449cfa60a7dc422eceef9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ee2541dd1dc4aa3be549ad1f58851d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5dc49921e5ab4d61aab13248e2b13794_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i374c17c705bf414b91e482b616596378_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43bdad8afb4f45c6a1b22e9de4e0c1cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24f33d2414c044d385a05e4a4d691a0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a4b77c71742400abbf82a14977b7937_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fea4a51c8774db69325270c6310d222_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34154d30661d4701b9a9dcb4ea066485_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21484a6d0a4a4221bf3a14d5f4de561a_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="iedb996e521c541bab8a8ad9236459639_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i11758bdfae5647bb9010a004bb8ab441_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="ib914810c44274f05a6e9bda17b3ab8ba_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i1e65613bdd30464bac5bfc957856d90a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i147c9ab0d4e64ff080edac66d8c4f23b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42e935f3a72e40e2b02e056b012588be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie483ad8f564a42bb865b2050775ce979_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="ib88c7c3974194380b44ecb42d60b8720_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a8200bdcb0146bdbcb050345834cae4_I20210823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-23</instant>
        </period>
    </context>
    <context id="ifef633a201de4e788ff9e9950032906f_D20210823-20210823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="i3aa1b564f2bd4571b6af808180440a8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idbb89d0248f64893ad1ad1c6b9502e58_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41c305776f9f4df98a125ab8c0085264_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i935801f568bd44c0858bb0fa7df69e4a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4befc2bf4a164a518ddb3977c94dc56e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b6b2af557a44f209ce9709fa784684e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26007b31f51c41faa8926d8811c70043_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i05cdd06cb9f34748beee2062757859f1_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:QueenMaryUniversityOfLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i51903aede478415aba514640200f634b_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="ie067d973b59240a7840114c391ab933c_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i0458f36c4a244111a45add1871029a6d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if7b2218400d14228b5ea985e6aa0008f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9cd84100c8b24959976b0a199271ea74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d9ffdc3698e4888aa538e6a0986c347_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib300e2ee7d144ad286aacd3426594ffd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba04ed946a3b41b5b8dd12ccca532017_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3950a651de784404bcb5123100be8933_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i546dd718a1fe4f519ecd16edbb19413d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i113a047163aa40aebcdd5ca09836f93a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3ba30848a1ca43d389206c0ad496522d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d2462525bac435e95ff90467072cf52_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i629348dc384e428cb5f8def2819ad0bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i80eea195a57448589f21c7f4808d74e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia259598962414ddea394a3f3fe518c30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id01b77c5ef314817b937c1edcfce3899_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6adbdf0f555c4b13ba58f5c4786bdff4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50b5adcc18404940a217b0bebcaf1387_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1435ec1361f4450385ff04cd5684f711_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9573d9982b2e49e9bd110183aaa2cbc6_D20201110-20201110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-10</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="i3ca40d7976f44613b2feab35b0c59a82_D20210325-20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="ic5d838eb19db44f7922ca98f01e9cf77_I20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="icfe5ad06e42c406da92d33ef14794240_D20220915-20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:CowenEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="i06fde84d2c1f410483f0af8e4b52b90b_D20210622-20210622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-22</startDate>
            <endDate>2021-06-22</endDate>
        </period>
    </context>
    <context id="i4c096e88d4fa4f49adc92daf85a0d949_I20210622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="if2b9bbb8d0ca4fd6a3ced6fba0c92324_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab6f88ec0238452293973853113c2d9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica716265618d4d869aae1d9174b631a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96869c44a89140f9a1329238fc14fd52_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i93961cbee5f14ee69a98afa1d0336147_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4585060a7ed43049f692210d99fcdb0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86f954890ee9407f84dc9c97b645549a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a3014a9e6354ea58eedd096ea6a7280_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia487f414d26048018d3c769a149ec0a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie94d37f040ba4631af4999316806f239_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2578607c562a474a803e1e324447c4d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if21529de837840bdaee22e04f99761a1_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i834b1c4afb9e43a6897a5a3065173ce5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f089a1558114e6cba9e97065369d2c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9eb3d3b204543ea8d7fc8ac766d9865_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieff44339e8e5422491a24b075e89a412_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1fe07b69e3094708af8420871a48901b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0da55bae29084ecfb396a149ffd03213_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12f9febfdc354a78a3d5c5696fe66007_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5697bc9dcbcd4e158253d63ad580c6ca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4044ff56a8a6462daa0d36da9aa8bb53_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc29ebe03b724500a8ea2d0e5fd353d0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i24fe3864155b4460a854467dbba00699_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if008ef2237244062a2ec402f2b90b70e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0abc7ffcaf3c49cba83cdb2a71ec0edf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b91b506545f4d24947576347cff021d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2377d69c61584e0298f5a9998d400497_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe36546577a1446c8e1f0db960eceda1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonSharesAvailableForGrantUnderThe2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>exdx:installment</measure>
    </unit>
    <unit id="segment">
        <measure>exdx:segment</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-32">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-34">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-35">0001274737</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i91bdb390f427408ea87ff211d239efb8_D20220101-20221231"
      id="f-312">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-388">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i3aa1b564f2bd4571b6af808180440a8c_I20221231"
      id="f-449">P3Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      id="f-453">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      id="f-456">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      id="f-457">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      id="f-460">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-4">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-6">001-39049</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-7">EXAGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-9">20-0434866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-10">1261 Liberty Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-11">Vista</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-13">92081</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-14">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-15">560-1501</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-16">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-17">XGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-25">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-26">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ic71131a0a18a4dcdba1f5f3a771db49c_I20220630"
      decimals="-5"
      id="f-29"
      unitRef="usd">61500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8d55c3bc4e324e6b94b5e0875b9eefff_I20230316"
      decimals="INF"
      id="f-30"
      unitRef="shares">16825696</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-31">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2023 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-36">243</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-37">BDO USA, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-38">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-39"
      unitRef="usd">62391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-40"
      unitRef="usd">99442000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-41"
      unitRef="usd">6077000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-42"
      unitRef="usd">9654000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-43"
      unitRef="usd">4143000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-44"
      unitRef="usd">3638000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-45"
      unitRef="usd">72611000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-46"
      unitRef="usd">112734000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-47"
      unitRef="usd">8197000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-48"
      unitRef="usd">4772000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-49"
      unitRef="usd">4885000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-50"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-51"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-52"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-53"
      unitRef="usd">528000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-54"
      unitRef="usd">433000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-55"
      unitRef="usd">86221000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-56"
      unitRef="usd">123445000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-57"
      unitRef="usd">3046000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-58"
      unitRef="usd">2492000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-59"
      unitRef="usd">1040000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-60"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-61"
      unitRef="usd">190000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-62"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-63"
      unitRef="usd">5347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-64"
      unitRef="usd">6826000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-65"
      unitRef="usd">9623000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-66"
      unitRef="usd">9318000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-67"
      unitRef="usd">28778000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-68"
      unitRef="usd">27478000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-69"
      unitRef="usd">4493000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-70"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-71"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-72"
      unitRef="usd">306000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-73"
      unitRef="usd">867000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-74"
      unitRef="usd">1407000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-75"
      unitRef="usd">43761000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-76"
      unitRef="usd">38509000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      id="f-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      id="f-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-81"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-82"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-83"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-84"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-85"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-86"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-87"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-88"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-89"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-90"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-91"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-92"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-93"
      unitRef="shares">16549984</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-94"
      unitRef="shares">16549984</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-95"
      unitRef="shares">16164994</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-96"
      unitRef="shares">16164994</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-97"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-98"
      unitRef="usd">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-99"
      unitRef="usd">297970000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-100"
      unitRef="usd">293060000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-101"
      unitRef="usd">-255527000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-102"
      unitRef="usd">-208140000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-103"
      unitRef="usd">42460000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-104"
      unitRef="usd">84936000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-105"
      unitRef="usd">86221000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-106"
      unitRef="usd">123445000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-107"
      unitRef="usd">45563000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-108"
      unitRef="usd">48299000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-109"
      unitRef="usd">24214000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-110"
      unitRef="usd">20588000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-111"
      unitRef="usd">52018000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-112"
      unitRef="usd">44541000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-113"
      unitRef="usd">9876000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-114"
      unitRef="usd">7237000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-115"
      unitRef="usd">5506000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-116"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:CostsAndExpenses
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-117"
      unitRef="usd">91614000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-118"
      unitRef="usd">72366000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-119"
      unitRef="usd">-46051000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-120"
      unitRef="usd">-24067000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-121"
      unitRef="usd">2448000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-122"
      unitRef="usd">2625000</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-123"
      unitRef="usd">830000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-124"
      unitRef="usd">16000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-125"
      unitRef="usd">-47669000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-126"
      unitRef="usd">-26676000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-127"
      unitRef="usd">-282000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-128"
      unitRef="usd">175000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-129"
      unitRef="usd">-47387000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-130"
      unitRef="usd">-26851000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="2"
      id="f-131"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="2"
      id="f-132"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="2"
      id="f-133"
      unitRef="usdPerShare">-1.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="2"
      id="f-134"
      unitRef="usdPerShare">-1.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="0"
      id="f-135"
      unitRef="shares">17082348</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="0"
      id="f-136"
      unitRef="shares">17082348</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="0"
      id="f-137"
      unitRef="shares">15972256</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="0"
      id="f-138"
      unitRef="shares">15972256</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac2e346101f544b3b8c12fb87ac0784e_I20201231"
      decimals="INF"
      id="f-139"
      unitRef="shares">12652308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iac2e346101f544b3b8c12fb87ac0784e_I20201231"
      decimals="-3"
      id="f-140"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91db90b0b71948a3a7ed62f79644090a_I20201231"
      decimals="-3"
      id="f-141"
      unitRef="usd">223115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15bf116298a3437e8f5fc8227e8b9962_I20201231"
      decimals="-3"
      id="f-142"
      unitRef="usd">-181289000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia63a7f83cab04fd3bd0a7651465bc919_I20201231"
      decimals="-3"
      id="f-143"
      unitRef="usd">41839000</us-gaap:StockholdersEquity>
    <exdx:StockIssuanceCosts
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-144"
      unitRef="usd">4435000</exdx:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231"
      decimals="INF"
      id="f-145"
      unitRef="shares">4255000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231"
      decimals="-3"
      id="f-146"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231"
      decimals="-3"
      id="f-147"
      unitRef="usd">64705000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-148"
      unitRef="usd">64709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231"
      decimals="INF"
      id="f-149"
      unitRef="shares">804951</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231"
      decimals="-3"
      id="f-150"
      unitRef="usd">1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231"
      decimals="-3"
      id="f-151"
      unitRef="usd">12774000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-152"
      unitRef="usd">12775000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231"
      decimals="-3"
      id="f-153"
      unitRef="usd">12775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-154"
      unitRef="usd">12775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231"
      decimals="INF"
      id="f-155"
      unitRef="shares">11950</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231"
      decimals="-3"
      id="f-156"
      unitRef="usd">89000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-157"
      unitRef="usd">89000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231"
      decimals="INF"
      id="f-158"
      unitRef="shares">32968</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231"
      decimals="-3"
      id="f-159"
      unitRef="usd">390000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-160"
      unitRef="usd">390000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231"
      decimals="-3"
      id="f-161"
      unitRef="usd">4728000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-162"
      unitRef="usd">4728000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="ifbef6230cfcd4d44a4e1aa944ae0eab8_D20210101-20211231"
      decimals="INF"
      id="f-163"
      unitRef="shares">17719</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i5e40544c2f6543ecadfc5f7915c4d2d3_D20210101-20211231"
      decimals="-3"
      id="f-164"
      unitRef="usd">32000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-165"
      unitRef="usd">32000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <us-gaap:NetIncomeLoss
      contextRef="i786ad5d8770443b192b64cc933e5cec3_D20210101-20211231"
      decimals="-3"
      id="f-166"
      unitRef="usd">-26851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-167"
      unitRef="usd">-26851000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ied976c8e24054ecbbc5ea323afd116ad_I20211231"
      decimals="INF"
      id="f-168"
      unitRef="shares">16164994</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ied976c8e24054ecbbc5ea323afd116ad_I20211231"
      decimals="-3"
      id="f-169"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i447883be0ca142b2aba0ad1f554359cd_I20211231"
      decimals="-3"
      id="f-170"
      unitRef="usd">293060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5688532efb274edc8b634de1ed329963_I20211231"
      decimals="-3"
      id="f-171"
      unitRef="usd">-208140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-172"
      unitRef="usd">84936000</us-gaap:StockholdersEquity>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares
      contextRef="ie09435be4441486fb5d942d843092a49_D20220101-20221231"
      decimals="INF"
      id="f-173"
      unitRef="shares">64064</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue
      contextRef="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231"
      decimals="-3"
      id="f-174"
      unitRef="usd">239000</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-175"
      unitRef="usd">239000</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie09435be4441486fb5d942d843092a49_D20220101-20221231"
      decimals="INF"
      id="f-176"
      unitRef="shares">245186</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie09435be4441486fb5d942d843092a49_D20220101-20221231"
      decimals="-3"
      id="f-177"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231"
      decimals="-3"
      id="f-178"
      unitRef="usd">60000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-179"
      unitRef="usd">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie09435be4441486fb5d942d843092a49_D20220101-20221231"
      decimals="INF"
      id="f-180"
      unitRef="shares">75740</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231"
      decimals="-3"
      id="f-181"
      unitRef="usd">385000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-182"
      unitRef="usd">385000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i150e0be1fe4d46eaa3e06e8cd42bbd17_D20220101-20221231"
      decimals="-3"
      id="f-183"
      unitRef="usd">4704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-184"
      unitRef="usd">4704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ibaf731ab91df4cce9e68b8a2e71e2969_D20220101-20221231"
      decimals="-3"
      id="f-185"
      unitRef="usd">-47387000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-186"
      unitRef="usd">-47387000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia2f4d5cd9295462fbea62e01ed3d1ff3_I20221231"
      decimals="INF"
      id="f-187"
      unitRef="shares">16549984</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia2f4d5cd9295462fbea62e01ed3d1ff3_I20221231"
      decimals="-3"
      id="f-188"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7a1b430e1df4dbb8fe1a520a779c20d_I20221231"
      decimals="-3"
      id="f-189"
      unitRef="usd">297970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i641ab5447323466db021f35839754d97_I20221231"
      decimals="-3"
      id="f-190"
      unitRef="usd">-255527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-191"
      unitRef="usd">42460000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-192"
      unitRef="usd">-47387000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-193"
      unitRef="usd">-26851000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-194"
      unitRef="usd">1557000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-195"
      unitRef="usd">948000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-196"
      unitRef="usd">161000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-197"
      unitRef="usd">279000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-198"
      unitRef="usd">551000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-199"
      unitRef="usd">540000</us-gaap:PaidInKindInterest>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-200"
      unitRef="usd">-306000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-201"
      unitRef="usd">148000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <exdx:NonCashLeaseExpense
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-202"
      unitRef="usd">967000</exdx:NonCashLeaseExpense>
    <exdx:NonCashLeaseExpense
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-203"
      unitRef="usd">0</exdx:NonCashLeaseExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-204"
      unitRef="usd">397000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-205"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-206"
      unitRef="usd">5506000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-207"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-208"
      unitRef="usd">4704000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-209"
      unitRef="usd">4728000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-210"
      unitRef="usd">-36000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-211"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-212"
      unitRef="usd">-3577000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-213"
      unitRef="usd">744000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-214"
      unitRef="usd">505000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-215"
      unitRef="usd">-521000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-216"
      unitRef="usd">47000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-217"
      unitRef="usd">167000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-218"
      unitRef="usd">-854000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-219"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-220"
      unitRef="usd">901000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-221"
      unitRef="usd">-655000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-222"
      unitRef="usd">-1402000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-223"
      unitRef="usd">984000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-224"
      unitRef="usd">-32144000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-225"
      unitRef="usd">-20269000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-226"
      unitRef="usd">4318000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-227"
      unitRef="usd">2370000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-228"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-229"
      unitRef="usd">50000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-230"
      unitRef="usd">-4318000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-231"
      unitRef="usd">-2420000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-232"
      unitRef="usd">61000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-233"
      unitRef="usd">89000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-234"
      unitRef="usd">239000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-235"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-236"
      unitRef="usd">385000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-237"
      unitRef="usd">390000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-238"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-239"
      unitRef="usd">32000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-240"
      unitRef="usd">667000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-241"
      unitRef="usd">525000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-242"
      unitRef="usd">29000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-243"
      unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-244"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-245"
      unitRef="usd">69144000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ic1f3e435c2ed49ca95de1a1d4a150248_D20220101-20221231"
      decimals="-3"
      id="f-246"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="iafc0c73bd74d46db9cc4fcd7cc90df81_D20210101-20211231"
      decimals="-3"
      id="f-247"
      unitRef="usd">4407000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i28979da435ba4d15844df6906e3d40bc_D20220101-20221231"
      decimals="-3"
      id="f-248"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie987a93eb70f4bd9b8928b29b52988fc_D20210101-20211231"
      decimals="-3"
      id="f-249"
      unitRef="usd">40000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-250"
      unitRef="usd">-489000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-251"
      unitRef="usd">64683000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-252"
      unitRef="usd">-36951000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-253"
      unitRef="usd">41994000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-254"
      unitRef="usd">99542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia63a7f83cab04fd3bd0a7651465bc919_I20201231"
      decimals="-3"
      id="f-255"
      unitRef="usd">57548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-256"
      unitRef="usd">62591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-257"
      unitRef="usd">99542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-258"
      unitRef="usd">1732000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-259"
      unitRef="usd">1815000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-260"
      unitRef="usd">741000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-261"
      unitRef="usd">1111000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <exdx:EquipmentPurchasedUnderNotesPayableObligations
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-262"
      unitRef="usd">807000</exdx:EquipmentPurchasedUnderNotesPayableObligations>
    <exdx:EquipmentPurchasedUnderNotesPayableObligations
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-263"
      unitRef="usd">0</exdx:EquipmentPurchasedUnderNotesPayableObligations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-264"
      unitRef="usd">182000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-265"
      unitRef="usd">685000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <exdx:DeferredOfferingCostsReclassifiedToEquity
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-266"
      unitRef="usd">0</exdx:DeferredOfferingCostsReclassifiedToEquity>
    <exdx:DeferredOfferingCostsReclassifiedToEquity
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-267"
      unitRef="usd">28000</exdx:DeferredOfferingCostsReclassifiedToEquity>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-268">Organization&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exagen Inc. (the Company) is a commercial-stage diagnostics company dedicated to helping patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&#160;31, 2022, the Company had cash and cash equivalents of $62.4 million and had an accumulated deficit of $255.5 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-5"
      id="f-269"
      unitRef="usd">62400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-5"
      id="f-270"
      unitRef="usd">-255500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-271">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the estimated incremental borrowing rate for the determination of the Company's operating lease right-of-use (ROU) assets, the recoverability of its long-lived assets and the goodwill impairment test. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. We have not experienced any losses on our cash or cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the years ended December&#160;31, 2022 and 2021, approximately 84% and 81% of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; CTD test, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is dependent on key suppliers for certain laboratory materials. For each of the years ended December&#160;31, 2022 and 2021, approximately 96% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;deposit with this financial institution as collateral for the balances borrowed on these credit cards ($0.2 million and $0.1&#160;million at December&#160;31, 2022 and 2021, respectively). The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:f-312"&gt;three&lt;/span&gt; and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment and operating lease assets (see Note 5). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We amortize all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets (excluding goodwill), into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test offered by us or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Management&#x2019;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2022, the Company recorded an impairment charge to fixed assets totaling $0.4&#160;million (see Note 3). The impairment charge was classified within research and development expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2022, the Company recorded an impairment charge to goodwill totaling $5.5&#160;million (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company categorizes leases at their commencement as either operating or finance leases. Effective January 1, 2022 upon the adoption of Accounting Standards Codification (ASC) 842, the Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical Studies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2022 and 2021 was a net revenue decrease of $2.4 million and a net revenue increase of $0.7 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Janssen Promotion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement, effective August 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the Janssen Agreement, as amended, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; for that quarter over a predetermined baseline. The Company's obligations relating to sales and co-promotion services for SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; were a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit. The Company recognized no co-promotion revenue and $1.2 million in co-promotion revenue during the years ended December 31, 2022 and December 31, 2021, respectively. The related expenses for marketing SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; were included in selling, general and administrative expenses and were expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the terms of the termination, the Company received $0.6&#160;million in consideration (which was earned in the year ended December 31, 2021) and the Company was restricted until May 31, 2022 from promoting any other biologic or Janus kinase inhibitor used for the treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent. The restriction no longer applies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $3.0 million and $1.7 million for the years ended December&#160;31, 2022 and 2021, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and totaled approximately $2.7 million and $2.1 million, for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire.  Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the years ended December&#160;31, 2022 and 2021, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,014,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,925,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,858,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which was issued to provide relief to companies from restating comparative periods. On January 1, 2022, the Company adopted ASU 2016-12, using the modified retrospective transition method. Periods prior to January 1, 2022 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Company adopted the new lease standard using a cumulative effect to accumulated deficit and there was no impact to accumulated deficit upon adoption. The Company elected the package of practical expedients, which among other things allowed the Company to carry forward its historical lease classification. As part of the adoption, the Company recorded operating lease liabilities of $6.4&#160;million, operating lease ROU assets of $5.9&#160;million, adjusted for deferred rent and lease incentive obligations of $0.5&#160;million previously included in other non-current liabilities and accrued and other current liabilities, pertaining to its office and laboratory space operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Codification Improvements to Topic 326, Financing Instruments-Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which included an amendment of the effective date for nonpublic entities. For non-emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023 and the impact of the provisions of this standard on its Consolidated Financial Statements is expected to be immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt&#x2014;Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (Subtopic 815-40): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting for Convertible &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Instruments and Contracts in an Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition.  The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures.&lt;/span&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-272">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. We have not experienced any losses on our cash or cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-273">For each significant payor and customer, &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iad59c59cd12b4a74a51934e1011397ea_D20220101-20221231"
      decimals="2"
      id="f-274"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e44acb2196c43dcb02a146b459fd4fe_D20210101-20211231"
      decimals="2"
      id="f-275"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i05aa9d3d5e8b4de399a58f24519f3448_D20220101-20221231"
      decimals="2"
      id="f-276"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia584bf6fcda64608a116c549a02cfe67_D20210101-20211231"
      decimals="2"
      id="f-277"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id47cdbd9f44c4293adf1dcb7a5ebea10_D20210101-20211231"
      decimals="2"
      id="f-278"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0c26ce8e296543d08e3fb5c648736bdd_D20220101-20221231"
      decimals="2"
      id="f-279"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0bd5830dbe3d44b5a5396e5d707e5405_D20220101-20221231"
      decimals="2"
      id="f-280"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id1d5e4c6540b4d67906da80434e50044_D20210101-20211231"
      decimals="2"
      id="f-281"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9ded0e51d34d43b0ba062a85bc1cb346_D20210101-20211231"
      decimals="2"
      id="f-282"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3ae2b104191742ba8131e5c71bd9cbf0_D20220101-20221231"
      decimals="2"
      id="f-283"
      unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibf7a3a01918e4ff8a94493a359671d39_D20210101-20211231"
      decimals="2"
      id="f-284"
      unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e981b26af96420cad2acd4d9d106893_D20220101-20221231"
      decimals="2"
      id="f-285"
      unitRef="number">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4c3582c593ea48d582cab27bc402f10f_D20210101-20211231"
      decimals="2"
      id="f-286"
      unitRef="number">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-287">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i908968ff669f4aff969761449a9d8cdb_D20220101-20221231"
      decimals="-3"
      id="f-288"
      unitRef="usd">18975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88583c8fbed94b7f9798fc8421e0b721_D20210101-20211231"
      decimals="-3"
      id="f-289"
      unitRef="usd">27499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c6955e97d9d4394a14813f7a52619d2_D20220101-20221231"
      decimals="-3"
      id="f-290"
      unitRef="usd">17687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i481bde6d9dff47b0a38b570d9228c1c4_D20210101-20211231"
      decimals="-3"
      id="f-291"
      unitRef="usd">9221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8ab3e04c8cc4b3ba4e0900905568215_D20220101-20221231"
      decimals="-3"
      id="f-292"
      unitRef="usd">7928000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i164771fb3f1d463cbd018cef7d6365d8_D20210101-20211231"
      decimals="-3"
      id="f-293"
      unitRef="usd">9288000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17536183b1b2446e830e5aa438b46c6e_D20220101-20221231"
      decimals="-3"
      id="f-294"
      unitRef="usd">973000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0719a3c05f2d48efb32f13d66e6f6d52_D20210101-20211231"
      decimals="-3"
      id="f-295"
      unitRef="usd">1091000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3334b98a65be47a890ddcf70cd5ede5b_D20220101-20221231"
      decimals="-3"
      id="f-296"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a730aad2275470c92cce95e1567059c_D20210101-20211231"
      decimals="-3"
      id="f-297"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-298"
      unitRef="usd">45563000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-299"
      unitRef="usd">48299000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-300">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-5"
      id="f-301"
      unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-5"
      id="f-302"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-303">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-304">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-305"
      unitRef="usd">62391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-306"
      unitRef="usd">99442000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-307"
      unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-308"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-309"
      unitRef="usd">62591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-310"
      unitRef="usd">99542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-311">Property and EquipmentProperty and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:f-312"&gt;three&lt;/span&gt; and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie9c0d3ddc18741dc8fecde8d57850025_D20220101-20221231"
      id="f-313">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-314">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment and operating lease assets (see Note 5). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We amortize all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets (excluding goodwill), into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test offered by us or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Management&#x2019;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2022, the Company recorded an impairment charge to fixed assets totaling $0.4&#160;million (see Note 3). The impairment charge was classified within research and development expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment exist. As the Company operates in a single operating segment and reporting unit, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing a quantitative assessment is unnecessary. If deemed necessary, a quantitative assessment compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, an impairment loss is recorded.&lt;/span&gt;&lt;/div&gt;During the year ended December 31, 2022, the Company recorded an impairment charge to goodwill totaling $5.5&#160;million (see Note 3).</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-5"
      id="f-315"
      unitRef="usd">400000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-5"
      id="f-316"
      unitRef="usd">5500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-317">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company categorizes leases at their commencement as either operating or finance leases. Effective January 1, 2022 upon the adoption of Accounting Standards Codification (ASC) 842, the Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <exdx:ClinicalStudyPolicyPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-318">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical Studies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.&lt;/span&gt;&lt;/div&gt;</exdx:ClinicalStudyPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-319">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2022 and 2021 was a net revenue decrease of $2.4 million and a net revenue increase of $0.7 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Janssen Promotion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement, effective August 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the Janssen Agreement, as amended, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; for that quarter over a predetermined baseline. The Company's obligations relating to sales and co-promotion services for SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; were a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit. The Company recognized no co-promotion revenue and $1.2 million in co-promotion revenue during the years ended December 31, 2022 and December 31, 2021, respectively. The related expenses for marketing SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; were included in selling, general and administrative expenses and were expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the terms of the termination, the Company received $0.6&#160;million in consideration (which was earned in the year ended December 31, 2021) and the Company was restricted until May 31, 2022 from promoting any other biologic or Janus kinase inhibitor used for the treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent. The restriction no longer applies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and totaled approximately $2.7 million and $2.1 million, for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-5"
      id="f-320"
      unitRef="usd">-2400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-5"
      id="f-321"
      unitRef="usd">700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94b61d4be67742429ba95efb0a3804d7_D20210101-20211231"
      decimals="-5"
      id="f-322"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fb69c732f42466ca2a71e8f7eaca6ac_D20220101-20221231"
      decimals="-5"
      id="f-323"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exdx:ContractWithCustomerTerminationConsiderationReceivable
      contextRef="i8aa77feb77bd465da489e3faf3b36c72_I20211231"
      decimals="-5"
      id="f-324"
      unitRef="usd">600000</exdx:ContractWithCustomerTerminationConsiderationReceivable>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-325">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-326">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $3.0 million and $1.7 million for the years ended December&#160;31, 2022 and 2021, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-5"
      id="f-327"
      unitRef="usd">3000000.0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-5"
      id="f-328"
      unitRef="usd">1700000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfRevenue
      contextRef="i1c7294c3cf4640d08c8b4195febb6caf_D20220101-20221231"
      decimals="-5"
      id="f-329"
      unitRef="usd">2700000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ic404d905bd0c456cb113003341a477fa_D20210101-20211231"
      decimals="-5"
      id="f-330"
      unitRef="usd">2100000</us-gaap:CostOfRevenue>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-331">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire.  Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.&lt;/span&gt;&lt;/div&gt;</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="INF"
      id="f-332"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="INF"
      id="f-333"
      unitRef="installment">4</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-334">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-335">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-336">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the years ended December&#160;31, 2022 and 2021, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-337">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,014,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,925,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,858,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec3e133c80b243bc90f00f9a090a04ab_D20220101-20221231"
      decimals="0"
      id="f-338"
      unitRef="shares">409108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if07865aaa84345d4855d746dc2002ad2_D20210101-20211231"
      decimals="0"
      id="f-339"
      unitRef="shares">409108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id44e1098fa6e44dea992cd186d3949fe_D20220101-20221231"
      decimals="0"
      id="f-340"
      unitRef="shares">1421235</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iac4677048384433e8e79ba780e14863f_D20210101-20211231"
      decimals="0"
      id="f-341"
      unitRef="shares">2014330</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i325c9bd99922498897b3b864e4d0b736_D20220101-20221231"
      decimals="0"
      id="f-342"
      unitRef="shares">1036208</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4edbe79ab016482daa691291ec25282b_D20210101-20211231"
      decimals="0"
      id="f-343"
      unitRef="shares">415325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iced52d7820074956a7e81f9bc4bcfa12_D20220101-20221231"
      decimals="0"
      id="f-344"
      unitRef="shares">58711</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i55b44a6651b94f84bcc98d5253339f34_D20210101-20211231"
      decimals="0"
      id="f-345"
      unitRef="shares">20193</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="0"
      id="f-346"
      unitRef="shares">2925262</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="0"
      id="f-347"
      unitRef="shares">2858956</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-348">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="INF"
      id="f-349"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-350">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which was issued to provide relief to companies from restating comparative periods. On January 1, 2022, the Company adopted ASU 2016-12, using the modified retrospective transition method. Periods prior to January 1, 2022 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Company adopted the new lease standard using a cumulative effect to accumulated deficit and there was no impact to accumulated deficit upon adoption. The Company elected the package of practical expedients, which among other things allowed the Company to carry forward its historical lease classification. As part of the adoption, the Company recorded operating lease liabilities of $6.4&#160;million, operating lease ROU assets of $5.9&#160;million, adjusted for deferred rent and lease incentive obligations of $0.5&#160;million previously included in other non-current liabilities and accrued and other current liabilities, pertaining to its office and laboratory space operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Codification Improvements to Topic 326, Financing Instruments-Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which included an amendment of the effective date for nonpublic entities. For non-emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023 and the impact of the provisions of this standard on its Consolidated Financial Statements is expected to be immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt&#x2014;Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (Subtopic 815-40): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting for Convertible &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Instruments and Contracts in an Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition.  The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="i02725e3aa13240f183a18c6bf2fc237a_I20220101"
      decimals="-5"
      id="f-351"
      unitRef="usd">6400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i02725e3aa13240f183a18c6bf2fc237a_I20220101"
      decimals="-5"
      id="f-352"
      unitRef="usd">5900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredRentCredit
      contextRef="i02725e3aa13240f183a18c6bf2fc237a_I20220101"
      decimals="-5"
      id="f-353"
      unitRef="usd">500000</us-gaap:DeferredRentCredit>
    <exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-354">Other Financial Information&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2022 and 2021, was approximately $1.6 million and $0.9 million, respectively. At December&#160;31, 2022 and 2021, the gross book value of assets under finance leases was $2.8 million and $2.5 million, respectively, and is classified in "Laboratory equipment" in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impairment of Long-Lived Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2022, the Company recorded an impairment charge of $0.4&#160;million related to previously capitalized equipment used in research and development activities that were halted in the fourth quarter of 2022. The Company based the fair values of these assets on their anticipated disposal values, which is considered a Level 3 measurement. The impairment charge was classified within &lt;span style="-sec-ix-hidden:f-388"&gt;research and development expenses&lt;/span&gt; in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined that the sustained decrease in its market capitalization constituted an indicator of impairment and as a result, instead of performing a qualitative test, the Company chose to proceed directly to performing a quantitative test during the fourth quarter. The Company determined the fair value of the reporting unit using the discounted cash flow (DCF) method, which is considered a Level 3 measurement. In applying the DCF &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;method, cash flows are estimated for a five-year financial forecast developed by management. A terminal value, which represents the value of additional cash flows into perpetuity, is also calculated. Cash flows are then discounted to present value at a discount rate commensurate with their risk. Based on this analysis, the carrying value of the reporting unit was in excess of the fair value and the goodwill was fully impaired. During the year ended December 31, 2022, the Company recorded an impairment charge of $5.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Refund liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-355">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-356"
      unitRef="usd">1795000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-357"
      unitRef="usd">1091000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidRoyalties
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-358"
      unitRef="usd">40000</us-gaap:PrepaidRoyalties>
    <us-gaap:PrepaidRoyalties
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-359"
      unitRef="usd">49000</us-gaap:PrepaidRoyalties>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-360"
      unitRef="usd">2072000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-361"
      unitRef="usd">2008000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-362"
      unitRef="usd">236000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-363"
      unitRef="usd">490000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-364"
      unitRef="usd">4143000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-365"
      unitRef="usd">3638000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-366">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie0b340fe912a484a884f93b38698848e_I20221231"
      decimals="-3"
      id="f-367"
      unitRef="usd">98000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if22a684f953449cfa60a7dc422eceef9_I20211231"
      decimals="-3"
      id="f-368"
      unitRef="usd">83000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8ee2541dd1dc4aa3be549ad1f58851d2_I20221231"
      decimals="-3"
      id="f-369"
      unitRef="usd">5136000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5dc49921e5ab4d61aab13248e2b13794_I20211231"
      decimals="-3"
      id="f-370"
      unitRef="usd">4361000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i374c17c705bf414b91e482b616596378_I20221231"
      decimals="-3"
      id="f-371"
      unitRef="usd">1482000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i43bdad8afb4f45c6a1b22e9de4e0c1cd_I20211231"
      decimals="-3"
      id="f-372"
      unitRef="usd">1206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i24f33d2414c044d385a05e4a4d691a0f_I20221231"
      decimals="-3"
      id="f-373"
      unitRef="usd">5223000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6a4b77c71742400abbf82a14977b7937_I20211231"
      decimals="-3"
      id="f-374"
      unitRef="usd">1151000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7fea4a51c8774db69325270c6310d222_I20221231"
      decimals="-3"
      id="f-375"
      unitRef="usd">1382000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i34154d30661d4701b9a9dcb4ea066485_I20211231"
      decimals="-3"
      id="f-376"
      unitRef="usd">1855000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-377"
      unitRef="usd">13321000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-378"
      unitRef="usd">8656000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-379"
      unitRef="usd">5124000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-380"
      unitRef="usd">3884000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-381"
      unitRef="usd">8197000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-382"
      unitRef="usd">4772000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-5"
      id="f-383"
      unitRef="usd">1600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-5"
      id="f-384"
      unitRef="usd">900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i8ee2541dd1dc4aa3be549ad1f58851d2_I20221231"
      decimals="-5"
      id="f-385"
      unitRef="usd">2800000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i5dc49921e5ab4d61aab13248e2b13794_I20211231"
      decimals="-5"
      id="f-386"
      unitRef="usd">2500000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-5"
      id="f-387"
      unitRef="usd">400000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-5"
      id="f-389"
      unitRef="usd">5500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-390">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-391"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-392"
      unitRef="usd">5506000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-393"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-394">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Refund liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-395"
      unitRef="usd">2355000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-396"
      unitRef="usd">4048000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-397"
      unitRef="usd">142000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-398"
      unitRef="usd">139000</us-gaap:InterestPayableCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-399"
      unitRef="usd">803000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-400"
      unitRef="usd">510000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-401"
      unitRef="usd">514000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-402"
      unitRef="usd">180000</us-gaap:AccruedRoyaltiesCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-403"
      unitRef="usd">162000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-404"
      unitRef="usd">254000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-405"
      unitRef="usd">700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-406"
      unitRef="usd">587000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-407"
      unitRef="usd">445000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-408"
      unitRef="usd">0</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-409"
      unitRef="usd">226000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-410"
      unitRef="usd">1108000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-411"
      unitRef="usd">5347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-412"
      unitRef="usd">6826000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-413">Borrowings&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;2017 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended, pursuant to which the Company has borrowed $25&#160;million. At December&#160;31, 2022, no additional amounts remain available to borrow under the 2017 Term Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2021, the Company executed the Second Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the 2017 Loan Amendment is 8.0%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2024, after which interest accrues at an annual rate of 8.0%. The Company has estimated the effective interest rate of this loan to be approximately 8.5%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the 2017 Loan Amendment will be repaid in twenty-four equal monthly installments commencing in December 2024. Upon repayment of the final installment under the 2017 Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For the years ended December&#160;31, 2022 and 2021, the Company issued PIK Loans totaling $0.6 million and $0.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The 2017 Loan Amendment requires a prepayment premium of 2% of the aggregate outstanding principal. The prepayment premium decreases by 1% on each of November&#160;1, 2023 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The 2017 Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, commencing with the quarter ending December 31, 2022. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The 2017 Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2022, the Company was in compliance with all covenants of the 2017 Loan Amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon an event of default in any of the 2017 Loan Amendment covenants, the repayment of the 2017 Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the 2017 Loan Amendment due beyond twelve months of the balance sheet date as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;2022 Equipment Notes Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2022, the Company purchased laboratory equipment using notes payable. At December&#160;31, 2022, the total notes payable balance related to this financed equipment was $0.8&#160;million, with $0.2&#160;million classified within borrowings-current portion and $0.6&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to a 5.28% effective interest rate and will mature on October 1, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Future Minimum Payments on the Outstanding Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2022, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Borrowings-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Borrowings-non-current portion, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i21484a6d0a4a4221bf3a14d5f4de561a_D20170901-20170930"
      decimals="-6"
      id="f-414"
      unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="iedb996e521c541bab8a8ad9236459639_D20220101-20221231"
      decimals="INF"
      id="f-415"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130"
      decimals="INF"
      id="f-416"
      unitRef="number">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind
      contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130"
      decimals="INF"
      id="f-417"
      unitRef="number">0.020</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130"
      decimals="INF"
      id="f-418"
      unitRef="number">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130"
      decimals="3"
      id="f-419"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <exdx:DebtInstrumentNumberOfMonthlyInstallments
      contextRef="ib914810c44274f05a6e9bda17b3ab8ba_D20211101-20211130"
      decimals="INF"
      id="f-420"
      unitRef="installment">24</exdx:DebtInstrumentNumberOfMonthlyInstallments>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i1e65613bdd30464bac5bfc957856d90a_I20221231"
      decimals="-5"
      id="f-421"
      unitRef="usd">1000000</us-gaap:DebtInstrumentFeeAmount>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i147c9ab0d4e64ff080edac66d8c4f23b_D20220101-20221231"
      decimals="-5"
      id="f-422"
      unitRef="usd">600000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i42e935f3a72e40e2b02e056b012588be_D20210101-20211231"
      decimals="-5"
      id="f-423"
      unitRef="usd">500000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130"
      decimals="INF"
      id="f-424"
      unitRef="number">0.02</exdx:DebtInstrumentPrepaymentPremiumPercentage>
    <exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction
      contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130"
      decimals="2"
      id="f-425"
      unitRef="number">0.01</exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction>
    <exdx:DebtInstrumentCovenantRevenuePerformancePeriod
      contextRef="iedb996e521c541bab8a8ad9236459639_D20220101-20221231"
      id="f-426">P12M</exdx:DebtInstrumentCovenantRevenuePerformancePeriod>
    <exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet
      contextRef="iedb996e521c541bab8a8ad9236459639_D20220101-20221231"
      id="f-427">P60D</exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet>
    <exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance
      contextRef="i11758bdfae5647bb9010a004bb8ab441_I20211130"
      decimals="-5"
      id="f-428"
      unitRef="usd">2000000.0</exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance>
    <exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease
      contextRef="i1e65613bdd30464bac5bfc957856d90a_I20221231"
      decimals="3"
      id="f-429"
      unitRef="number">0.040</exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease>
    <us-gaap:NotesPayable
      contextRef="ie483ad8f564a42bb865b2050775ce979_I20220531"
      decimals="-5"
      id="f-430"
      unitRef="usd">800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="ie483ad8f564a42bb865b2050775ce979_I20220531"
      decimals="-5"
      id="f-431"
      unitRef="usd">200000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="ie483ad8f564a42bb865b2050775ce979_I20220531"
      decimals="-5"
      id="f-432"
      unitRef="usd">600000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie483ad8f564a42bb865b2050775ce979_I20220531"
      decimals="4"
      id="f-433"
      unitRef="number">0.0528</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-434">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2022, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Borrowings-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Borrowings-non-current portion, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-435"
      unitRef="usd">1911000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-436"
      unitRef="usd">3205000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-437"
      unitRef="usd">16377000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-438"
      unitRef="usd">14973000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <exdx:LongTermDebtIncludingUndiscountedInterest
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-439"
      unitRef="usd">36466000</exdx:LongTermDebtIncludingUndiscountedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-440"
      unitRef="usd">158000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <exdx:LongTermDebtUndiscountedInterestAmount
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-441"
      unitRef="usd">7340000</exdx:LongTermDebtUndiscountedInterestAmount>
    <us-gaap:LongTermDebt
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-442"
      unitRef="usd">28968000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-443"
      unitRef="usd">190000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-444"
      unitRef="usd">28778000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-445">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company adopted ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, as of January 1, 2022. Prior period amounts have not been adjusted and continue to be reported in accordance with the Company's historic accounting under ASC 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases office and laboratory spaces in Vista, California, under leases that expire in April 2027, with an option to extend portions of the leases for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liabilities because it is not reasonably certain that the Company will exercise these renewal options. The Company's lease payments under each of these leases are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Effective on August 23, 2021, the Company entered into a sub-lease agreement for an additional office space in Carlsbad, California. The sub-lease commenced in October 2021 and expires in April 2027. The sub-lease agreement provides for monthly base rent of $66,021 which began on October 1, 2021, and such amount increases by approximately 3% annually beginning October 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determines if a contract contains a lease at inception or modification of a contract. The Company discounts their lease obligations using its incremental borrowing rate at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from &lt;span style="-sec-ix-hidden:f-449"&gt;three&lt;/span&gt; to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating and Finance Leases Balances and Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance leases consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-453"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-456"&gt;&lt;span style="-sec-ix-hidden:f-457"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-460"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Includes variable lease cost of $165,000 for the year ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information on leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from interest paid on finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Information regarding the weighted-average lease term and weighted average discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Disclosures Under ASC 840&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Minimum annual lease payments under non-cancelable operating lease arrangements as of December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended December 31, 2021, rent expense was $0.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Acquisition-related liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the acquisition of the medical diagnostics division of Royalty Pharma Collection Trust (Royalty Pharma) (formerly known as Cypress Bioscience, Inc.) in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition, for which the obligations no longer exist at December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company has ongoing royalty payment obligations with Royalty Pharma of 2.5% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $1.2 million (including an upfront payment of $0.1 million) and (ii) the total royalties earned through January 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute (AHN) to obtain an exclusive license to AHN's patent rights in certain inventions, pursuant to which the Company paid AHN an initial license fee of $0.4 million. In addition, under the terms of the exclusive license agreement, the Company is required to pay the greater of royalties in the low single digits on net sales of diagnostic tests using the assigned patents or a flat annual minimum royalty amount, pending approvals and commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2021, the Company entered into an exclusive license agreement with Queen Mary University of London (QMUL) to obtain an exclusive license to QMUL's patent rights in certain inventions, pursuant to which the Company paid QMUL an initial license fee of $0.4 million. The Company is obligated to make a one-time payment of $0.1 million relating to the first commercial sale of the licensed products. In addition, after the first 18 months of commercial sales under the terms of the exclusive license agreement, the Company is required to pay royalties in the high single-digits on net sales of testing products using the assigned patents, pending approvals and commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $6.0 million and $6.9 million for the years ended December 31, 2022 and 2023, respectively, with a 15% annual increase thereafter for unconditional minimum purchase commitments through the year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Collaboration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2021, the Company entered into a master research collaboration agreement with AHN, pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $0.4 million for the year ended December&#160;31, 2022. Collaboration expenses under the AHN collaboration are included in research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters will have a material effect on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ib88c7c3974194380b44ecb42d60b8720_I20221231"
      id="f-446">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exdx:OperatingLeaseMonthlyBaseRent
      contextRef="i2a8200bdcb0146bdbcb050345834cae4_I20210823"
      decimals="0"
      id="f-447"
      unitRef="usd">66021</exdx:OperatingLeaseMonthlyBaseRent>
    <exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent
      contextRef="ifef633a201de4e788ff9e9950032906f_D20210823-20210823"
      decimals="2"
      id="f-448"
      unitRef="number">0.03</exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="idbb89d0248f64893ad1ad1c6b9502e58_I20221231"
      id="f-450">P5Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-451">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance leases consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-453"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-456"&gt;&lt;span style="-sec-ix-hidden:f-457"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-460"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Includes variable lease cost of $165,000 for the year ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information on leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from interest paid on finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Information regarding the weighted-average lease term and weighted average discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-452"
      unitRef="usd">4885000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-454"
      unitRef="usd">1427000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-455"
      unitRef="usd">1040000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-458"
      unitRef="usd">700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-459"
      unitRef="usd">4493000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-461"
      unitRef="usd">848000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-462"
      unitRef="usd">1540000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-463"
      unitRef="usd">679000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-464"
      unitRef="usd">80000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-465"
      unitRef="usd">2299000</us-gaap:LeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-466"
      unitRef="usd">165000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-467"
      unitRef="usd">1262000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-468"
      unitRef="usd">80000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-469"
      unitRef="usd">667000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      id="f-470">P4Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      id="f-471">P1Y11M8D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="3"
      id="f-472"
      unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="3"
      id="f-473"
      unitRef="number">0.048</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-474">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-475">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-476"
      unitRef="usd">1446000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-477"
      unitRef="usd">828000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-478"
      unitRef="usd">1489000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-479"
      unitRef="usd">574000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-480"
      unitRef="usd">1533000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-481"
      unitRef="usd">248000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-482"
      unitRef="usd">1584000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-483"
      unitRef="usd">147000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <exdx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-484"
      unitRef="usd">539000</exdx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour>
    <exdx:FinanceLeaseLiabilityToBePaidDueAfterYearFour
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-485"
      unitRef="usd">29000</exdx:FinanceLeaseLiabilityToBePaidDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-486"
      unitRef="usd">6591000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-487"
      unitRef="usd">1826000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-488"
      unitRef="usd">1058000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-489"
      unitRef="usd">278000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-490"
      unitRef="usd">5533000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-491"
      unitRef="usd">1548000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-492"
      unitRef="usd">1040000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-493"
      unitRef="usd">700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-494"
      unitRef="usd">4493000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-495"
      unitRef="usd">848000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-496">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Minimum annual lease payments under non-cancelable operating lease arrangements as of December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-497"
      unitRef="usd">1337000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-498"
      unitRef="usd">1445000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-499"
      unitRef="usd">1489000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-500"
      unitRef="usd">1533000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-501"
      unitRef="usd">1584000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-502"
      unitRef="usd">539000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-503"
      unitRef="usd">7927000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-5"
      id="f-504"
      unitRef="usd">900000</us-gaap:LeaseAndRentalExpense>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i41c305776f9f4df98a125ab8c0085264_I20221231"
      decimals="3"
      id="f-505"
      unitRef="number">0.025</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="i935801f568bd44c0858bb0fa7df69e4a_I20221231"
      decimals="-5"
      id="f-506"
      unitRef="usd">1200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <exdx:AdvancePayment
      contextRef="i935801f568bd44c0858bb0fa7df69e4a_I20221231"
      decimals="-5"
      id="f-507"
      unitRef="usd">100000</exdx:AdvancePayment>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i4befc2bf4a164a518ddb3977c94dc56e_I20221231"
      decimals="INF"
      id="f-508"
      unitRef="number">0.015</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i6b6b2af557a44f209ce9709fa784684e_I20221231"
      decimals="INF"
      id="f-509"
      unitRef="number">0.070</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:LicenseAgreementInitialLicenseFee
      contextRef="i26007b31f51c41faa8926d8811c70043_D20210501-20210531"
      decimals="-5"
      id="f-510"
      unitRef="usd">400000</exdx:LicenseAgreementInitialLicenseFee>
    <exdx:LicenseAgreementInitialLicenseFee
      contextRef="i05cdd06cb9f34748beee2062757859f1_D20211101-20211130"
      decimals="-5"
      id="f-511"
      unitRef="usd">400000</exdx:LicenseAgreementInitialLicenseFee>
    <exdx:LicenseAgreementOneTimePayment
      contextRef="i05cdd06cb9f34748beee2062757859f1_D20211101-20211130"
      decimals="-5"
      id="f-512"
      unitRef="usd">100000</exdx:LicenseAgreementOneTimePayment>
    <exdx:LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid
      contextRef="i51903aede478415aba514640200f634b_D20211101-20211130"
      id="f-513">P18M</exdx:LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-5"
      id="f-514"
      unitRef="usd">6000000.0</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-5"
      id="f-515"
      unitRef="usd">6900000</us-gaap:PurchaseObligationDueInSecondYear>
    <exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="2"
      id="f-516"
      unitRef="number">0.15</exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage>
    <exdx:CollaborationAgreementAnnualCollaborationFee
      contextRef="ie067d973b59240a7840114c391ab933c_D20210501-20210531"
      decimals="-5"
      id="f-517"
      unitRef="usd">400000</exdx:CollaborationAgreementAnnualCollaborationFee>
    <exdx:CollaborationAgreementCollaborationExpenses
      contextRef="i0458f36c4a244111a45add1871029a6d_D20220101-20221231"
      decimals="-5"
      id="f-518"
      unitRef="usd">400000</exdx:CollaborationAgreementCollaborationExpenses>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-519">Fair Value Measurements&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair values of the Company's long-term borrowings are determined by Level 2 inputs and are based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9 million. The estimated fair value of the 2017 Term Loan, which uses Level 2 fair value inputs, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's long-term borrowings as of December 31, 2021 approximated their fair values as the interest rate and other terms were that which were available to the Company at the time. See footnote 3 for discussion of recorded impairment charges related to long-lived assets and goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificate of deposit, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of the Company's money market funds is based on quoted market prices.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-520">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement. The estimated fair values of the Company's long-term borrowings are determined by Level 2 inputs and are based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9 million. The estimated fair value of the 2017 Term Loan, which uses Level 2 fair value inputs, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's long-term borrowings as of December 31, 2021 approximated their fair values as the interest rate and other terms were that which were available to the Company at the time. See footnote 3 for discussion of recorded impairment charges related to long-lived assets and goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LongTermDebt
      contextRef="if7b2218400d14228b5ea985e6aa0008f_I20221231"
      decimals="-5"
      id="f-521"
      unitRef="usd">28300000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if7b2218400d14228b5ea985e6aa0008f_I20221231"
      decimals="-5"
      id="f-522"
      unitRef="usd">26900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-523">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificate of deposit, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9cd84100c8b24959976b0a199271ea74_I20221231"
      decimals="-3"
      id="f-524"
      unitRef="usd">29438000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d9ffdc3698e4888aa538e6a0986c347_I20221231"
      decimals="-3"
      id="f-525"
      unitRef="usd">29438000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib300e2ee7d144ad286aacd3426594ffd_I20221231"
      decimals="-3"
      id="f-526"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iba04ed946a3b41b5b8dd12ccca532017_I20221231"
      decimals="-3"
      id="f-527"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3950a651de784404bcb5123100be8933_I20221231"
      decimals="-3"
      id="f-528"
      unitRef="usd">30100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i546dd718a1fe4f519ecd16edbb19413d_I20221231"
      decimals="-3"
      id="f-529"
      unitRef="usd">30100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i113a047163aa40aebcdd5ca09836f93a_I20221231"
      decimals="-3"
      id="f-530"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3ba30848a1ca43d389206c0ad496522d_I20221231"
      decimals="-3"
      id="f-531"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2d2462525bac435e95ff90467072cf52_I20221231"
      decimals="-3"
      id="f-532"
      unitRef="usd">59538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i629348dc384e428cb5f8def2819ad0bb_I20221231"
      decimals="-3"
      id="f-533"
      unitRef="usd">59538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i80eea195a57448589f21c7f4808d74e7_I20221231"
      decimals="-3"
      id="f-534"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia259598962414ddea394a3f3fe518c30_I20221231"
      decimals="-3"
      id="f-535"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id01b77c5ef314817b937c1edcfce3899_I20211231"
      decimals="-3"
      id="f-536"
      unitRef="usd">95761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6adbdf0f555c4b13ba58f5c4786bdff4_I20211231"
      decimals="-3"
      id="f-537"
      unitRef="usd">95761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i50b5adcc18404940a217b0bebcaf1387_I20211231"
      decimals="-3"
      id="f-538"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1435ec1361f4450385ff04cd5684f711_I20211231"
      decimals="-3"
      id="f-539"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-540">Stockholders' Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 25, 2021, the Company completed a public offering of 4,255,000 shares of its common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, after deducting underwriting discounts, commissions and other offering expenses of $4.4 million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;At The Market Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 15, 2022, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0&#160;million. The Company is not obligated to sell any shares of Company common stock in the offering. As of December&#160;31, 2022, the Company has not sold any shares of its common stock pursuant to the Sales Agreement&lt;/span&gt;&lt;span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Exchange Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June 22, 2021, the Company entered into an exchange agreement (the Exchange Agreement) with an investor and its affiliates (the Exchanging Stockholders), pursuant to which the Company exchanged an aggregate of 804,951 shares of the Company's common stock owned by the Exchanging Stockholders for pre-funded warrants (the Exchange Warrants) to purchase an aggregate of 804,951 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.001 per share. The Exchange Warrants do not expire and are exercisable at any time except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 4.99% of the Company's common stock, which percentage may change at the Exchanging Stockholder's election to any other percentage upon 61 days' notice to the Company. The Company recorded the retirement of common stock exchanged as a reduction of common shares outstanding and additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity and the fair value of the Exchange Warrants was recorded as an increase to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of December&#160;31, 2022, none of the Exchange Warrants have been exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Outstanding Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December&#160;31, 2022, no warrants to purchase common stock were exercised.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9573d9982b2e49e9bd110183aaa2cbc6_D20201110-20201110"
      decimals="-5"
      id="f-541"
      unitRef="shares">150000000.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3ca40d7976f44613b2feab35b0c59a82_D20210325-20210325"
      decimals="INF"
      id="f-542"
      unitRef="shares">4255000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic5d838eb19db44f7922ca98f01e9cf77_I20210325"
      decimals="INF"
      id="f-543"
      unitRef="usdPerShare">16.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i3ca40d7976f44613b2feab35b0c59a82_D20210325-20210325"
      decimals="-5"
      id="f-544"
      unitRef="usd">64700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <exdx:StockIssuanceCosts
      contextRef="ic5d838eb19db44f7922ca98f01e9cf77_I20210325"
      decimals="-5"
      id="f-545"
      unitRef="usd">4400000</exdx:StockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="icfe5ad06e42c406da92d33ef14794240_D20220915-20220915"
      decimals="-5"
      id="f-546"
      unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants
      contextRef="i06fde84d2c1f410483f0af8e4b52b90b_D20210622-20210622"
      decimals="INF"
      id="f-547"
      unitRef="shares">804951</exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants>
    <exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants
      contextRef="i06fde84d2c1f410483f0af8e4b52b90b_D20210622-20210622"
      decimals="INF"
      id="f-548"
      unitRef="shares">804951</exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4c096e88d4fa4f49adc92daf85a0d949_I20210622"
      decimals="INF"
      id="f-549"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i06fde84d2c1f410483f0af8e4b52b90b_D20210622-20210622"
      decimals="4"
      id="f-550"
      unitRef="number">0.0499</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="if2b9bbb8d0ca4fd6a3ced6fba0c92324_I20221231"
      decimals="INF"
      id="f-551"
      unitRef="shares">0</exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-552">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iab6f88ec0238452293973853113c2d9b_I20221231"
      decimals="INF"
      id="f-553"
      unitRef="shares">237169</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iab6f88ec0238452293973853113c2d9b_I20221231"
      decimals="INF"
      id="f-554"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ica716265618d4d869aae1d9174b631a7_I20221231"
      decimals="INF"
      id="f-555"
      unitRef="shares">67086</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ica716265618d4d869aae1d9174b631a7_I20221231"
      decimals="INF"
      id="f-556"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i96869c44a89140f9a1329238fc14fd52_I20221231"
      decimals="INF"
      id="f-557"
      unitRef="shares">131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i96869c44a89140f9a1329238fc14fd52_I20221231"
      decimals="INF"
      id="f-558"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i93961cbee5f14ee69a98afa1d0336147_I20221231"
      decimals="INF"
      id="f-559"
      unitRef="shares">83778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i93961cbee5f14ee69a98afa1d0336147_I20221231"
      decimals="INF"
      id="f-560"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia4585060a7ed43049f692210d99fcdb0_I20221231"
      decimals="INF"
      id="f-561"
      unitRef="shares">20944</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia4585060a7ed43049f692210d99fcdb0_I20221231"
      decimals="INF"
      id="f-562"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i86f954890ee9407f84dc9c97b645549a_I20221231"
      decimals="INF"
      id="f-563"
      unitRef="shares">804951</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i86f954890ee9407f84dc9c97b645549a_I20221231"
      decimals="INF"
      id="f-564"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-565"
      unitRef="shares">1214059</us-gaap:ClassOfWarrantOrRightOutstanding>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="INF"
      id="f-566"
      unitRef="shares">0</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-567">Stock Option Plan&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of December&#160;31, 2022, 1,452,435 shares remained available for future awards. Under the evergreen provision, on January 1, 2023, an additional 661,999 shares became available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of December&#160;31, 2022, 413,425 shares of common stock remained available for issuance under the ESPP. Under the evergreen provision, on January 1, 2023, an additional 165,500 shares became available for issuances under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,014,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(245,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(257,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(152,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,129,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted-average grant date fair value per share of employee options granted to employees during the years ended December&#160;31, 2022 and 2021 was $2.74 and $8.83, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock was $2.40 and $11.63 per share at December&#160;31, 2022 and 2021, respectively. The intrinsic value of options exercised for the years ended December&#160;31, 2022 and 2021 was $0.6 million and $0.1 million, respectively. As of December&#160;31, 2022, total unrecognized compensation cost related to option awards was $1.8 million, which is expected to be recognized over a remaining weighted-average vesting period of 1.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,076,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(355,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2022, all of the outstanding restricted stock units are unvested. The fair value of restricted stock units vested in the year ended December&#160;31, 2022 was $0.7 million. No restricted stock units vested in the year ended December 31, 2021. The weighted average grant date fair value for restricted stock units granted during the years ended December&#160;31, 2022 and 2021 was $5.89 and $16.53, respectively. As of December&#160;31, 2022, total unrecognized compensation cost related to restricted stock units was $6.0 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of employee stock options was estimated using the following assumptions in the Black-Scholes options pricing model to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56%-60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%-57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%-60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6%-3.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock-based compensation expense related to the ESPP for the years ended December&#160;31, 2022 and 2021 was less than $0.1 million and $0.2 million, respectively. As of December&#160;31, 2022, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was less than $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Common stock reserved for future issuance consists of the following at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock option grants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance upon vesting of outstanding restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for grant under the 2019 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for future issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,537,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i4a3014a9e6354ea58eedd096ea6a7280_D20220101-20221231"
      id="f-568">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4a3014a9e6354ea58eedd096ea6a7280_D20220101-20221231"
      id="f-569">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage
      contextRef="ia487f414d26048018d3c769a149ec0a9_I20221231"
      decimals="2"
      id="f-570"
      unitRef="number">0.04</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia487f414d26048018d3c769a149ec0a9_I20221231"
      decimals="INF"
      id="f-571"
      unitRef="shares">1452435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized
      contextRef="ie94d37f040ba4631af4999316806f239_I20230101"
      decimals="INF"
      id="f-572"
      unitRef="shares">661999</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i2578607c562a474a803e1e324447c4d6_I20221231"
      decimals="2"
      id="f-573"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage
      contextRef="i2578607c562a474a803e1e324447c4d6_I20221231"
      decimals="2"
      id="f-574"
      unitRef="number">0.01</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2578607c562a474a803e1e324447c4d6_I20221231"
      decimals="INF"
      id="f-575"
      unitRef="shares">413425</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized
      contextRef="if21529de837840bdaee22e04f99761a1_I20230101"
      decimals="INF"
      id="f-576"
      unitRef="shares">165500</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-577">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,014,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(245,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(257,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(152,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,129,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-578"
      unitRef="shares">2014330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="2"
      id="f-579"
      unitRef="usdPerShare">12.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      id="f-580">P7Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-581"
      unitRef="usd">5428000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="INF"
      id="f-582"
      unitRef="shares">63000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="2"
      id="f-583"
      unitRef="usdPerShare">5.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="INF"
      id="f-584"
      unitRef="shares">245186</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="2"
      id="f-585"
      unitRef="usdPerShare">0.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="INF"
      id="f-586"
      unitRef="shares">257982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="2"
      id="f-587"
      unitRef="usdPerShare">16.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="INF"
      id="f-588"
      unitRef="shares">152927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="2"
      id="f-589"
      unitRef="usdPerShare">13.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-590"
      unitRef="shares">1421235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="2"
      id="f-591"
      unitRef="usdPerShare">12.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-592">P7Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-593"
      unitRef="usd">483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-594"
      unitRef="shares">1421235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="2"
      id="f-595"
      unitRef="usdPerShare">12.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-596">P7Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-597"
      unitRef="usd">483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-598"
      unitRef="shares">1129333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="2"
      id="f-599"
      unitRef="usdPerShare">12.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-600">P6Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-601"
      unitRef="usd">483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="2"
      id="f-602"
      unitRef="usdPerShare">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="2"
      id="f-603"
      unitRef="usdPerShare">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="2"
      id="f-604"
      unitRef="usdPerShare">2.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="2"
      id="f-605"
      unitRef="usdPerShare">11.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-5"
      id="f-606"
      unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-5"
      id="f-607"
      unitRef="usd">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-5"
      id="f-608"
      unitRef="usd">1800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-609">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-610">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,076,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(355,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i834b1c4afb9e43a6897a5a3065173ce5_I20211231"
      decimals="INF"
      id="f-611"
      unitRef="shares">415325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i834b1c4afb9e43a6897a5a3065173ce5_I20211231"
      decimals="2"
      id="f-612"
      unitRef="usdPerShare">16.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i834b1c4afb9e43a6897a5a3065173ce5_I20211231"
      decimals="-3"
      id="f-613"
      unitRef="usd">4830000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"
      decimals="INF"
      id="f-614"
      unitRef="shares">1076725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"
      decimals="INF"
      id="f-616"
      unitRef="shares">100586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"
      decimals="2"
      id="f-617"
      unitRef="usdPerShare">16.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"
      decimals="INF"
      id="f-618"
      unitRef="shares">355256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"
      decimals="2"
      id="f-619"
      unitRef="usdPerShare">11.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231"
      decimals="INF"
      id="f-620"
      unitRef="shares">1036208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231"
      decimals="2"
      id="f-621"
      unitRef="usdPerShare">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231"
      decimals="-3"
      id="f-622"
      unitRef="usd">2487000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"
      decimals="-5"
      id="f-623"
      unitRef="usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="ie9eb3d3b204543ea8d7fc8ac766d9865_D20210101-20211231"
      decimals="INF"
      id="f-624"
      unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"
      decimals="2"
      id="f-625"
      unitRef="usdPerShare">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie9eb3d3b204543ea8d7fc8ac766d9865_D20210101-20211231"
      decimals="2"
      id="f-626"
      unitRef="usdPerShare">16.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231"
      decimals="-5"
      id="f-627"
      unitRef="usd">6000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231"
      id="f-628">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-629">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of employee stock options was estimated using the following assumptions in the Black-Scholes options pricing model to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56%-60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%-57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%-60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6%-3.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231"
      decimals="2"
      id="f-630"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231"
      decimals="2"
      id="f-631"
      unitRef="number">0.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231"
      decimals="2"
      id="f-632"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231"
      decimals="3"
      id="f-633"
      unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231"
      id="f-634"
      unitRef="number"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231"
      decimals="3"
      id="f-635"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231"
      decimals="3"
      id="f-636"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibd163b7909f4413d81a3366437727ccb_D20220101-20221231"
      decimals="INF"
      id="f-637"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib4f81db922a5465e9f3809fb558290dc_D20210101-20211231"
      decimals="INF"
      id="f-638"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ieff44339e8e5422491a24b075e89a412_D20220101-20221231"
      id="f-639">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1fe07b69e3094708af8420871a48901b_D20220101-20221231"
      id="f-640"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0da55bae29084ecfb396a149ffd03213_D20210101-20211231"
      id="f-641">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i12f9febfdc354a78a3d5c5696fe66007_D20210101-20211231"
      id="f-642">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231"
      decimals="2"
      id="f-643"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231"
      decimals="2"
      id="f-644"
      unitRef="number">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231"
      decimals="2"
      id="f-645"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231"
      decimals="2"
      id="f-646"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231"
      decimals="3"
      id="f-647"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231"
      decimals="3"
      id="f-648"
      unitRef="number">0.033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231"
      decimals="3"
      id="f-649"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231"
      id="f-650"
      unitRef="number"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231"
      decimals="INF"
      id="f-651"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231"
      decimals="INF"
      id="f-652"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231"
      id="f-653">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231"
      id="f-654">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231"
      decimals="-5"
      id="f-655"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ied4ce5f51683429380905d8f6d86efab_D20210101-20211231"
      decimals="-5"
      id="f-656"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i2578607c562a474a803e1e324447c4d6_I20221231"
      decimals="-5"
      id="f-657"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i87708aeb507343ada94c216bee62d8e6_D20220101-20221231"
      id="f-658">P0Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-659">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5697bc9dcbcd4e158253d63ad580c6ca_D20220101-20221231"
      decimals="-3"
      id="f-660"
      unitRef="usd">213000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4044ff56a8a6462daa0d36da9aa8bb53_D20210101-20211231"
      decimals="-3"
      id="f-661"
      unitRef="usd">164000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc29ebe03b724500a8ea2d0e5fd353d0_D20220101-20221231"
      decimals="-3"
      id="f-662"
      unitRef="usd">3860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i24fe3864155b4460a854467dbba00699_D20210101-20211231"
      decimals="-3"
      id="f-663"
      unitRef="usd">3943000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if008ef2237244062a2ec402f2b90b70e_D20220101-20221231"
      decimals="-3"
      id="f-664"
      unitRef="usd">631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0abc7ffcaf3c49cba83cdb2a71ec0edf_D20210101-20211231"
      decimals="-3"
      id="f-665"
      unitRef="usd">621000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-666"
      unitRef="usd">4704000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-667"
      unitRef="usd">4728000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-668">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Common stock reserved for future issuance consists of the following at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock option grants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance upon vesting of outstanding restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for grant under the 2019 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for future issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,537,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8b91b506545f4d24947576347cff021d_I20221231"
      decimals="INF"
      id="f-669"
      unitRef="shares">1214059</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2377d69c61584e0298f5a9998d400497_I20221231"
      decimals="INF"
      id="f-670"
      unitRef="shares">1421235</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6f089a1558114e6cba9e97065369d2c7_I20221231"
      decimals="INF"
      id="f-671"
      unitRef="shares">1036370</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibe36546577a1446c8e1f0db960eceda1_I20221231"
      decimals="INF"
      id="f-672"
      unitRef="shares">1452435</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2578607c562a474a803e1e324447c4d6_I20221231"
      decimals="INF"
      id="f-673"
      unitRef="shares">413425</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-674"
      unitRef="shares">5537524</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-675">Income Taxes&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision (benefit) for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant components of the Company&#x2019;s deferred tax assets at December&#160;31, 2022 and 2021 are shown below (in thousands). A valuation allowance has been established as realization of the Company&#x2019;s deferred tax assets has not met the more likely-than-not threshold requirement. If the Company&#x2019;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accruals, reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalization of research and experimentation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing and acquisition-related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basis differences in fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2022 and 2021, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2022 and 2021, the Company had federal NOL carryforwards of approximately $118.4 million and $89.4 million, respectively. At December&#160;31, 2022 and 2021, the Company had state NOL carryforwards of $87.0 million and $61.0 million, respectively. Approximately $43.5 million of the federal tax loss carryforwards will begin to expire in 2023, unless previously utilized. The federal NOL carryforwards generated in after December 31, 2017 of $74.9 million will carryforward indefinitely. The Company&#x2019;s state tax loss carryforwards will expire in 2030, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2022, the Company's deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is subject to taxation in the United States and in various state jurisdictions. The Company&#x2019;s tax years for 2003 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any material accruals for, and did not recognize any, material interest or penalties in these financial statements in any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Uncertain Tax Positions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2022 and 2021, the Company had no unrecognized tax benefits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-676">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision (benefit) for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-677"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-678"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-679"
      unitRef="usd">24000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-680"
      unitRef="usd">27000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-681"
      unitRef="usd">24000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-682"
      unitRef="usd">27000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-683"
      unitRef="usd">-137000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-684"
      unitRef="usd">137000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-685"
      unitRef="usd">-169000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-686"
      unitRef="usd">11000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-687"
      unitRef="usd">-306000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-688"
      unitRef="usd">148000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-689"
      unitRef="usd">-282000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-690"
      unitRef="usd">175000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-691">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="INF"
      id="f-692"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="INF"
      id="f-693"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="3"
      id="f-694"
      unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="3"
      id="f-695"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="3"
      id="f-696"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="3"
      id="f-697"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="3"
      id="f-698"
      unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="3"
      id="f-699"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="3"
      id="f-700"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="3"
      id="f-701"
      unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="3"
      id="f-702"
      unitRef="number">-0.239</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="3"
      id="f-703"
      unitRef="number">-0.246</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="3"
      id="f-704"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="3"
      id="f-705"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-706">If the Company&#x2019;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accruals, reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalization of research and experimentation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing and acquisition-related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basis differences in fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-707"
      unitRef="usd">29789000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-708"
      unitRef="usd">22365000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-709"
      unitRef="usd">2216000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-710"
      unitRef="usd">1102000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-711"
      unitRef="usd">349000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-712"
      unitRef="usd">1055000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-713"
      unitRef="usd">2236000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-714"
      unitRef="usd">1953000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-715"
      unitRef="usd">362000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-716"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-717"
      unitRef="usd">1606000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-718"
      unitRef="usd">1407000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <exdx:DeferredTaxAssetsLeaseLiability
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-719"
      unitRef="usd">1374000</exdx:DeferredTaxAssetsLeaseLiability>
    <exdx:DeferredTaxAssetsLeaseLiability
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-720"
      unitRef="usd">0</exdx:DeferredTaxAssetsLeaseLiability>
    <exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-721"
      unitRef="usd">2047000</exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts>
    <exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-722"
      unitRef="usd">0</exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-723"
      unitRef="usd">39979000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-724"
      unitRef="usd">27882000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-725"
      unitRef="usd">38567000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-726"
      unitRef="usd">27158000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-727"
      unitRef="usd">1412000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-728"
      unitRef="usd">724000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-729"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-730"
      unitRef="usd">335000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-731"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-732"
      unitRef="usd">521000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <exdx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-733"
      unitRef="usd">1206000</exdx:DeferredTaxLiabilitiesRightOfUseAssets>
    <exdx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-734"
      unitRef="usd">0</exdx:DeferredTaxLiabilitiesRightOfUseAssets>
    <exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-735"
      unitRef="usd">206000</exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-736"
      unitRef="usd">175000</exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-737"
      unitRef="usd">1412000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-738"
      unitRef="usd">1031000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-739"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-740"
      unitRef="usd">307000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-741">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2022 and 2021, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-742"
      unitRef="usd">27158000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia63a7f83cab04fd3bd0a7651465bc919_I20201231"
      decimals="-3"
      id="f-743"
      unitRef="usd">20596000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-3"
      id="f-744"
      unitRef="usd">11409000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-3"
      id="f-745"
      unitRef="usd">6562000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-3"
      id="f-746"
      unitRef="usd">38567000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-3"
      id="f-747"
      unitRef="usd">27158000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-5"
      id="f-748"
      unitRef="usd">118400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-5"
      id="f-749"
      unitRef="usd">89400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-5"
      id="f-750"
      unitRef="usd">87000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="-5"
      id="f-751"
      unitRef="usd">61000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-5"
      id="f-752"
      unitRef="usd">43500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="-5"
      id="f-753"
      unitRef="usd">74900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia42d222f98d840eb9ce09d6de69b0abd_I20211231"
      decimals="INF"
      id="f-754"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia586976f14c945e092ffa77bf6eea0a3_I20221231"
      decimals="INF"
      id="f-755"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      id="f-756">401(k) PlanThe Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For the years ended December&#160;31, 2022 and 2021, the Company made contributions to the Plan at 4% and 3% of qualified employee compensation, respectively. For the years ended December&#160;31, 2022 and 2021, these contributions totaled approximately $0.9 million and $0.5 million, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="2"
      id="f-757"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="2"
      id="f-758"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231"
      decimals="-5"
      id="f-759"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231"
      decimals="-5"
      id="f-760"
      unitRef="usd">500000</us-gaap:DefinedContributionPlanCostRecognized>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M[HCF(]-BL^H-;*F5L17>P*OE#3ZS&#PHYODJ"-=NOAQ1JH!EU0384BO#*DR
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MP03DC52\ZI0U@HK5VT_RU 5B3P'B$074*:!3%<).(6P=W2)KW;HEBLPO!=\
M8:2U-7/1QJ;5UMZPVBSCO1+Z6Z;UU/R:E*3.*;@W%B0X U_O;\';-^_ &\!J
M\&7%&TGJ0E[.E'Z949GEG>'KK6$T8OB6YN<@A%.  H0<ZC>GJ\-#]9EV<><G
MVOF)6GOAB+V;1@A:*T"DU'Y>N/S9&L!N Z:<+N2:Y/1JHNM%4O%()_.??X)Q
M\-[EW2L9._ UW/D:^JS/;XA< ;UJ(#<7]'O#'DFIG7>NXM94TIHR-?\XCU&8
MZ9 _[KMC2V49QF@G=8 3[W!B+\X/><X;#4NW@YQJC(N23D%-E0OFUE*\#S-(
MD@%*6RB+(^P&&>U 1EZ0=X*N"2L ?=*=4U+9!I:K%16Z//=SRH4ZL@!AB,,!
M:ELHC,/4C3K>H8Z]J+]P1<H3 ,;6NQ,4P^'JVU(0HB0<B6RRPY@<B:PF(Z&>
MVXB:+%UK>E"C&9!8(%*8#3/ %L)),I*FZ0YGZL7YIT9)%*L?0$DU80!AF.&,
M+\\:?3,>VM2&DJ;1 *\M%+C!9CNPF1?LKYP7&U:6+D29YV5;.+9$% 6Q&Q$,
M>HH)_ %LJV4\4IWZP6M1.H#F$,)A. )MC_W@"77B@0;MK(L1&A:(0PRB$.-H
M!%_/6O TVBH96;"2*4;=W 5?E;Q>R]JATSU]03]_[7AA39X-*3@=#NVN&>!X
MN"ZV%,+92#^ /6]!/W$-.\+>ZCBQVKP$ SRL/8?42"^ /7=!/WE=<Z%U-%!Y
M]L(%:R[,_.S$:3,1S"R8MM 8S)ZLH)^M](*+AA8.:CT669N9HA /2<$A%:=H
MK*WU] 7]_'7(L<>0VLR4Z4%KB-0A%<*160#V! ;]#+:7!C6OAZG0,B[@2U P
MV16>68B"+A1@4C;M_B#G<J1#VA2&TB2QVK=#+,')F&L]W4$_WWW:\X?_8%G:
M;(=Q9BV)CS4/MR(](2(_(=[2)=60"Z#(TS&4R.:]84DZ1,(QUD8]-2(_-6Y9
M>S]?CB%U<>6P%AU"$ ?)"-B]W9V7DKI:/ 80.4:()!Z2N4,L3*,@&\'8TQHZ
MLBWC5<64F7&W!9;SVB0KK7.-%[S]Q!4%T3LG<*]A-Q\#YZ[T_QLZ=+ZG3(2]
M@\R]XOFW%2\+*N0O[;2OGMV[<"_U_O V_)6L'7K=\R\ZNGGL*ET:_Z?@37 >
M!% /-@+H/7E#WP,83(.@_0-R18398#9JQ07[AQ:Z,_.7IZ83:SM< -XHJ70"
MF49'%+C5F^=JH4OUY;"E3:[A4^B,M8_+NP">3/>HIWODIWM3"+P>#PD*/#'Y
M 9=U<.-IA+-IEN)60M_"&$^S# ^BV@X>_RFL4Z#-K&E[&%D^.X/LV#U;7=$A
M,]; ^_D$^>>3#T7!#+_KQFA.,,Y8#7*R9KI1.F':HP?*DBRQ$L(EI^EF+"OZ
M(07YAQ0]!#954Q)%S>RQ9#ES'@,@>Y X0U$4(2NF+L$@A7@,:3]S(/_,L24;
MZ>AH3L".,0/AV(JK+9;J:60D"\)^U@C]LX;%C&T>GPJ^,YX<<+J]_W6(.?>_
ML[V#:O,KP1]$/+!:ZGEMJ16#\T1W&[$]>-_>*+YNSZX77"E>M9<K2C1J(Z"_
M7W+-FMV-.0[?_?PQ_Q=02P,$%     @ NXIT5FY0-LG3 @  ]@H  !@   !X
M;"]W;W)K<VAE971S+W-H965T-"YX;6RM5EUOTS 4_2M60&A(T'PT3=O11F*=
M$#P@5:N 9R^Y;:PY=K#==O#KL9TL)%O:!I0^-/ZXY_@<VS>YBR,7#S(#4.@Q
MITPNG4RIXMIU99)!CN6(%\#TS):+'"O=%3M7%@)P:D$Y=0//B]P<$^;$"SNV
M%O&"[Q4E#-8"R7V>8_'K!B@_+AW?>1JX([M,F0$W7A1X!QM0WXJUT#VW9DE)
M#DP2SI" [=+YZ%^O? NP$=\)'&6CC8R5>\X?3.=+NG0\HP@H),I08/TXP HH
M-4Q:Q\^*U*G7-,!F^XG]DS6OS=QC"2M.?Y!494MGYJ 4MGA/U1T_?H;*T,3P
M)9Q*^X^.96P8.BC92\7S"JP5Y(253_Q8;40#X)\"!!4@Z L85X"Q-5HJL[9N
ML<+Q0O C$B9:LYF&W1N+UFX(,\>X44+/$HU3\0VFF"6 -H9!HJLU%L!4!HHD
MF+Y%[]%KY"*9Z5&Y<)5>T,#<I"*_*<F#$^2WD(S0V'^' B\(.N"K_G"_#7>U
MS=IK4'L-+-_X!-]:WQ 0 E*DMS5YZ/)3$H3=!":EKF6!$U@Z.F<DB ,X\9M7
M?N1]Z'(W$%G+Z[CV.C[''NMS1 =,]X"N"$,IIQ0+B0H0Y6&^[3)?,LXLHTG_
M0^R-/$_O_*'IZE)42VY8RPW/RMW8&X;P7F5<D-_ZB(SL\MYU:BWIHH8*WRM_
MS^3V"&PIGM2*)WT4$RGWE]6>I?K7:S5YX>B$E:BV$O6QHE_R4F&6$K:[Y"<Z
M(Z$4>7;%_[S[T]K/]&R>KWB>ZR_$R22?#GD: Y&UC,YJH[/!DWS6*\DO1;7D
MSFNY\V&3?/[BF@5>=Y;WB6QI]KV_'TAON$2ON%JOFV@2SN>S\)GBSD@_TJ'A
M"<6-3[H_<#Y7A'UD=T5VRG8;18FI"+]BL2-,(@I;#?5&4_T>$V615784+VR=
M<L^5KGIL,].%*0@3H.>WG*NGCBE]ZE(W_@-02P,$%     @ NXIT5B0KXP2#
M!   $1$  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RMF-MNXS80AE^%
M4!?%+I!$(G5T:AO(H8< W39(=KL712]H:VP+*XDN2=OIVW<DV9(C4>P6R$VB
MP\SP^SDD1^/I0<BO:@.@R4N1EVKF;+3>7KNN6FZ@X.I*;*'$-RLA"Z[Q5JY=
MM97 T]JIR%WF>9%;\*QTYM/ZV:.<3\5.YUD)CY*H75%P^<\MY.(P<ZAS>O"4
MK3>Z>N#.IUN^AF?0G[>/$N_<-DJ:%5"J3)1$PFKFW-#K.^95#K7%'QD<U-DU
MJ:0LA/A:W3RD,\>KB""'I:Y"</RWASO(\RH2<OQ]#.JT8U:.Y]>GZ#_5XE',
M@BNX$_F7+-6;F9,X)(45W^7Z21Q^@:.@L(JW%+FJ_Y+#T=9SR'*GM"B.SDA0
M9&7SG[\<)^+,@48C#NSHP/H.P8B#?W3P:Z$-62WKGFL^GTIQ(+*RQFC513TW
MM3>JR<HJC<]:XML,_?3\67,-F!:MB%B1W[<@>36]BER2S\_WY/V[#^0=R4KR
M:2-VBI>IFKH:AZV<W>5QB-MF"#8R!&7DHRCU1I$?RQ32UP%<Y&VAV0GZEEDC
MWL/RBOCT@C"/,0/0W;>[4PN.W\ZA7\?S1^(]E$M1 &FGDOQYLU!:X@K]RS1;
M3;# '*S:MM=JRY<P<W!?*I![<.;??T<C[P>3TC<*]DIWT.H.;-'G3["'<@<F
MC8UC7#M6)\E^'H1AY$_=_3F\P2IADTEK]8HJ;*E":S:.:[A<$WC!PTZ!NC81
MAF^9A3<*]DIOU.J-K%FX$ZK9O'(\'4V$Z&RB6<!HT$N'P<H+D\2<CKC%BZUX
MSWA"8S(NR!I*3$Q.\! A/,6C+*OV2'6(MXDRH<<#J)!Y-.FA#ZV"( RH&3UI
MT9/_6-\*N%QN:N049S<7VWI_VWB3 <DDB:,>[M H9GYLIIVTM!,K[<]"I(<L
MS\E#L>69K$!-?)/A?(9>GV]HY)GAJ-?5&<^*]TEH3+X8;$YC/?&&DTBCP7HU
MF.$T1M$(ZEE)I%;47X529"5%<<+%>FC$I(/Q+X/("VF?TV#' B\:23AE'2BS
M@CZ4&O! :1>D$9*9!@_Z&\AH%K%P!+$KC=1:@3K$K"Z21D)_,'3B>WV^H1$=
M2W17OZB]@-6)7@!^#,.1CVC^,K(F T.RXRB:]$$-=BR*XC'8KJQ1:Q4Y?64@
MH#7=X? 03UB?<6AT2>.Q7'>%B-HKT6_8=>0XI4:N:%#K<?K\).ZC&>Q8E(0C
M1SGMRA"UUZ$3',$M3=2&2[BHOO^S)7F/G[>IR',NSUY^,(IHAIB\@KN*!QH,
M9O0J&BFDM"M'U%Z/3!+2+-]I2/^/B.3;1!C,+"*Z*D7M9>I+W5A!>LGW>+:N
M@92[8H' ^ %3,RNR4ZA'"X++?8O:2&G-7.-D5CHL8S3V$N8/3S^#93B)&0M'
MMBWKZAZSU[VWT7N>9HMB-JR((XI-EF;%[EES68!<USVW0MI=J9N6K7W:]O4W
M=3?;>WZ+_7[3G7=AFA\+/G*YSK#GS&&%(;VK&,\GV?3?S8T6V[J%70B-#7%]
MN0&>@JP,\/U*"'VZJ09H?P69_PM02P,$%     @ NXIT5O"J$6?<!@  PRT
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M<'(]IT3WO=H'J!K?'UN%MMO\LK+C#=HEV/-2*3P&KN7&'T;V%U!+ P04
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MQ>S'\TEAQ/@279^OL)6+N!#GQQ:_0,BS ;ZOG8OC"P?8_:99_0M02P,$%
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M":"=&1J!-2P_$=&V6:V>7(F>=OO\I8Q/GEW?-I]*T8AE5G]DU O3!."V+K?
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M?:XN&LJX4:<:X6RH I=0 G6AS2@5E6#Q&N3:DJUK=MWK<$O!.L?I>+/8;&Z
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M\DD\#B$ #:("I9[%UKM;<NT*OK9\E,\7T97H S<P/'6/ ([ O BG9=*G[B3
MLQ<G5^%9R;ZIF/G\F^^=&1VN'[0#RM&;<-V#.__"=S@'G"_\PU%U=X1ID)V7
MFXFEG]V?I)IXDIN57!N67H75X!BY7HD4M1WASRN,F6 _ XG]3+KW7V27G2MC
MNUJ;0Q[+&X2S-$)@;Z)[P&?N,O&_RCW5ZK+.%B\HYG@KA^6=6@Z?)'9.#SE9
MM-D,A_+5 KU946_)7OD;,\;WE4-\&>9WT1UP<I.?NUILXK1>ZJ\+EVR6"R<*
MC4 E<3EY+7SJ=Q@M7F4<R6>VJ5U,0"&?=>=><94JB9]KC'#W8F(72AL[@HFB
M#6"?'B20W*./)/1NO'U/.RAH#?F(_/(D&R/YI="O#,?N!&VZ89AKR]W@@ARY
M="NZ(#QF)GOXG^$'A\<$IKW\U6=Y>9)!+[4T321BLZ$D.H'S*HTCU0X&^#O#
M!C$ 2QHIO/1=R-JX_>XG^7PVC=Q9R2.MXH-R?F"17@LYDC3*TM 0; WD;B,?
MMU.PS+D;O:KZ7S 7,$,H!7$:N-SL]WH@!1\/>\AURF&\8)D@<4.P<.:[:D.H
M,*B 6*\@WO<V<ND2SJ@U55FPWPPVYB[ZHQA[E^25&Q="C,YWG!X2Q,7I[)0$
M[$>S[/3.9_PH&GC#N4WK G+Y^PKO-#]R=-<O!<2?OSR=+4Z/M5>V)9LCU[MP
M!Z$IL*<Z=#C_0VQ^S9KD3S^]>ZQ=YU08^G)^,3L_)1L<^0+LN5#6\<F,-R/%
M'DR2/3&/4QC?'63'<"R^8WW:DKBSJIB0EHX;T7E'QY[3Z(Q!^/)H"6/;E/LE
M,.O5Z/@E-(^N ^,DN=.++^7L7;2G\;)&2V)Q'%SL/$T*1T\;$E0THF6_HMTS
M_*T=[DSS?TFGT+RM\Q;X STL@IF>#13Y WT\I+&>L5'%*/(Q/FKV$W#J200D
M\(?$7MM!HC_BXD0PL3F!"ZYV;GU::;3;+I.)1GD&CJ&T<?3Z]NYXD/E$AM)%
M37" )P.&NW+@'S!/9_^D>7J=X7"/#SQ*7L8&?>]%&DW*8AR1(_+/WQ\@Z/0/
MV$LV-DCKA!24[*H3:%R>)(5EHEL:QS1ZB?)7@7J]Y$0;NJ+Y9+K@ZTIW(7NP
MU&W3WZ_=U639H6 0V]7+?47QQ^Z(]RJ*%O?^5(-*?N7_0H\OHKET>_C[!>Y:
MK4&@& 0)1V0YQE1/D,>>X&"KBZM21OF)DZF_5/8\^@MS<+G\=_3XC_'4G?RQ
M.?]IXOY4W[7\A;KPN/R=O[<9/#;NJEK1JZ<G+R^>2>^N^X6L./^]NF73=<V&
M?T3SOVGQ 'V_:H@Y^@LF\'_ \(?_!5!+ P04    " "[BG16X"#+U30'  #^
M$0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RU6&MOX[@5_2N$-]AF
M *VMIZ-DDP!YS+0#9-'![+;]4/0#+=$V,9*H(:DXWE_?<TE)5J:.V\&B7VQ+
MNO?P/LY]R-<[I;^8K1"6O=158VYF6VO;J\7"%%M1<S-7K6CP9*UTS2TN]69A
M6BUXZ93J:A&'X7)1<]G,;J_=O4_Z]EIUMI*-^*29Z>J:Z_V]J-3N9A;-AAN?
MY69KZ<;B]KKE&_&KL']K/VE<+4:44M:B,5(U3(OUS>PNNKI/2=X)_%V*G9G\
M9N3)2JDO=/&QO)F%9)"H1&$)@>/K63R(JB(@F/&UQYR-1Y+B]/> _L'Y#E]6
MW(@'5?U#EG9[,\MGK!1KWE7VL]K]1?3^9(17J,JX3[;SLLGEC!6=L:KNE6%!
M+1O_S5_Z.$P4\O -A;A7B)W=_B!GY2.W_/9:JQW3) TT^N%<==HP3C:4E%^M
MQE,)/7O[5[L5FGV0#6\*R2OVL?&)1L2N%Q8'D-BBZ,'N/5C\!E@4LU]48[>&
MO6]*4;X&6,"RT;QX,.\^/HGX*(HY2Z* Q6$<G\!+1G<3AY=\O[OLGW<K8S5H
M\J]CGGO<]#@NE<Z5:7DA;F:H#2/TLYC=_OA#M Q_/F%U.EJ=GD+_WB2=!#MN
MZJFX?-*BY;)D[U_0"8PPC#<E\PH/G=:BL>S.&&'-*"FFDLI)%KTD]Y*%0ED;
MR]2:X3%;JPK=038;=BX;W%&=@:IY=\5  %&O #"0@#XB]BCYIE'&RH)9@2]H
MFJYM*XE#SU@47%QF[CN\C$:K6JW*KK!,JSVO+$FF(4LOQ^?4PJR@" AGN&Q,
MI]T5K'7$,"P.PHN8/L.\#T';:[_I:IPL<4HX'O.FX!E+@RA-\)T$RR2' EJO
MMGNG\?YK)]N:I%_=%N/M/QK1#YUNI.VT]WTM7^@W&769XR-/V!-?*<VMTOO)
MJ5D0D7M!LHS8@ZK;S@+X\)B@C%K;'0=N%*1YC,\X7+(G@4ZZ516B7",OSX+$
M#>#B.(%(E!%<@W+L?/.&#Q#;P"*#QXG#R;.,_:8LV-H>#TF4! D\RX-E1B<:
M<X4A4'1U5W$K2O1NY YL]],!FKQ6VLK?_8USN!:G[]AY$N0YOH^'/6 -!B?B
M$T27%RZ#%^#'XTGDOCJ0(NU2M1=<&R:H8QY)#JE3@@*VXRBH%KZ^2%2FJ/;L
M+)HO,12J:CCG+)Q?#C<"S$S3"C?UJOV<W=F3Z&3)1BO$ET8H>^95)XA,/3D[
MF*=!"U\>%:7/.(O.XGG^VH9XGAVW(?!EA>JO@"K74E"1L=DQ9LV8HZU@EJ\J
M<'(%CLS9QQHEI%UR8=J3:C8_/0&Z'!H0X?]9J7*'X]ECIXG_0XC?BK!WG<C+
MFSWL+90F.=X0-8?3BBW7&Q</A#@=_=7"4\DJZ@//$E6&M!2\E:"E_%U,V=@9
M[R[U7*Z+K3.V% B,ZHN%PB1=8[);;ME.H&BV:%5>SU=UI^V6?>VXID*#.>3!
MG/TV\8!VE-)+PWJ?2-.W!;"NSZ=R@'C.&S11V?J*D*95!@7EE4"YK82ALN_7
M8  %!J4$HUG":K  38*,]R;\9\"((9-L[Z3=G@K!.#BF#I4"OF+U<5XA+N2:
MP6;$W:U2%)K82"&2< RKY1>4Y)@#7W-DOT5[LWUFFU(6Q#B*R\1J5ZN@$5F(
MM2Z@&6"QZI(8JI]F(E&*4P8JX!.OW0!Z3:)BJV"0(X4JA LL>&5!#;KW#0[B
M/P%BY8&UK[,]?SLHTU0/ P#3AGH.H#KT=;!O0$62"]4U%(F"FRU;8TZP\\>'
M#^^04 R*\KO2_K&AGE3M!W3@C# C/"(**M.<KAW/J/-Q-)-G\9.KS/6X=^")
M@)H=6 'AU1XY;?""X ^\8][Q@:6#M5JX;8:F"-EQZ%]E*8D"D)_8@TGO,M$*
MVTF+S@1G>6449*K"SX<Y>WAM/V";:?1\T=.1_6G@)A\%&#H:;0XUO<%T[H+8
MWU>=EN;+G-V[4G6E2.?#QCUFN.=2P;5V43V552HO21.EH,$XC/X#%XC/KK$/
M/9$4UET%)GK6DYO_ISZ9'<: I^YA)?$]?<P7N,QE-=K?'_$G<S![.BK?G)3?
M+CI^-[CGE=_H'/ZW6A%F=A9DV$C&L3'QYMP]>O=?,&)@_/A#'D?QS^RN*'0G
MRB,K\I/D*UGY]CZ5>KT*5A.I/[K1#:>T?*^AZTX;!M;8:,^PS"99YE:7,,U'
M)5J%-?6C*,6NE5P>T#HT;C?]81<ER$]=>H^08"'+PX1E43C*'[;M+$I9E!^>
M%'@S01>NF+%=N1_&WYY%2SB0I?W;2+]L,+6JY,8U<Q3($"Y7#*B?BS!D67[!
M/HLU%I4QBGN6IMF8&Y\/WI\^C70<+VGI#//_,3/$F22E?6\9Y- ]]HJWF+R3
MUP)%0?\\4%+1&_SK^7AW_'/CSK_3'\3]/R._H*8PB!"(-53#^44V0P-Q_S;X
M"ZM:]X:_4M:JVOW<8FH)30)XOE;*#A=TP/B7S^V_ 5!+ P04    " "[BG16
MA.1:+F4*  #@&@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RM66MO
MW+H1_2O$-FEM0+%WU\^DC@'[)A<-FMQKW"0MBJ(?*(G:92.)"DGM>N^O[YDA
M]=B'W13H%WLE<88S9\X,9Z2;M;'?W%(I+QZKLG9O)TOOFS>GIRY;JDJZ$].H
M&D\*8ROI<6D7IZZQ2N8L5)6G\^GT\K22NI[<WO"]!WM[8UI?ZEH]6.':JI)V
M<Z]*LWX[F4VZ&[_IQ=+3C=/;FT8NU&?EOS8/%E>GO99<5ZIVVM3"JN+MY&[V
MYOZ<UO."OVFU=J/?@CQ)C?E&%Q_RMY,I&:1*E7G2(/%OI7Y294F*8,;WJ'/2
M;TF"X]^=]I_9=_B22J=^,N7?=>Z7;R?7$Y&K0K:E_\VL_Z*B/Q>D+S.EX[]B
M'=;.KR8B:YTW512&!96NPW_Y&'$8"5Q/GQ"81X$YVQTV8BO?22]O;ZQ9"TNK
MH8U^L*LL#>-T34'Y["V>:LCYVWMC(:'KA;LY]=!'=T^S*'L?9.=/R,[FXI.I
M_=*)]W6N\FT%IU#;6S/OK+F?/ZOQG<I.Q-DL$?/I?/Z,OK/>NS/6=_:DOM2+
M=]IEI7&M5>*?=ZGS%DSXUR%O@Z[SP[HH.]ZX1F;J[03T=\JNU.3VCW^874[_
M_(REY[VEY\]I_R]Q>%;VL&6#0H YNQ)?E*W$1R-K\:$6GU7C594JR\\2X9=*
M_&2J1M8;H1Y5UGJ5"RD\R90D(Q=6*>2B%T>T=EOC,3CKE]!;FY7TK1,?=:'$
MYTRK.E.X4G4..\3/;9V+#XGX^"".^K7'B9!.2*@&@Q+1M-:U$MMX(]9+G2VW
M3%MB:<I^P;P7\PLD1%DBMT_$'<*LLN!2QY]$U$;(/->4_K+$)J:MO4,IH6(E
MY$KJ4J:EHKV"5@$+H6#?PQ,"[1>SZC";SY[ C&Y^5IF!IW?D$T,&_72?P9=X
M@@6MU7XC[@Z@RJMZV>,3\05/=(U0*.>%E5X)*F9E&6WF"._8O:U#:">N3Z8O
M$V&*".H<EW2[D3J'\E??=$W_60,5>EHY0J[G@1-'#Q_^ROK=,7;UNAQPAPR0
M.4= "PC$G7K+99;9%FR0^$DPU"T4!W<*-B]X.@XUQ#3J;H15%87B$KZ+1H''
M\(5Y2J%40C:--8\L6VZ@_ +*[WC_?!"&2-XJ#D@C-TR$BJI9N4G@6:F<VPXQ
MG2..-L!J!N[5 %Q0&3S R>>\#)1OK*XSW1#YL$[NFF#J)V.VUA1A!;+&& F_
MQOW-J\*T5JCOA%XT%P^Q85F2G!.9J? CH]TAU >'(G,BOC9\E,(#WH2A0\0U
M!7FDY7D^;5-?4T)];[6E, 5P*+X#>0K%,7HQ.YD.^?J%(F;24B\D'\ZX2A79
M3!@I'T R U+J$5V(@Z)5M(LI";4[L+6.E#Q!ETKYI<E/!(YS7K)1TH)E5'GV
MJP=';#_3M7,4PCX+X#-0HTU?3$\N.P=9&#?Z"I4 )-<$@\I-(,JAL$<HD2;@
M3A\G_*QTR_[.7W91DPM4CP5GP"'&A3T.*,D5$$8? \0W8O:22*@D,A5J^PH7
M,#CK,#A_VF!-C"M+F&$!P^^ !EHE*&4=;:D-%SK75;PA^VKT@2F9[358M^&*
M%CV+6/\)*#BGO$NP.BO;/' :.4VI2 F +&^4]1%/66!7Y#S%/(,GM:1\B#J?
M 1O/493&04;9H<)1:#H<Y*."!71D>#HV%L;DHH>; %H0*6O6B.1K2BUQ[(TD
M<"/5)7E/JPTVLI1LK0WKX,1*YQ0J"'N<65X7.@MI >.=7M1\@]7;QG#14RM*
M]H0U%JVMM5L*"80H<RB=P0'@ S.]"F6!3FC8,KN8BEQN&)8"?1$64190$O 2
M4$E0;1E,D*X[OUP&M'OVT68"B12>+PRA@7,O Q1L5:>-\ P^.XUDP%Y;^I\+
MW9/Q 5TU$ #/**>@"UZ7N,$,LH1-J[BOJ$#TEBH3]K1@'H)*+@D+RG*A6*MR
MI5YQ(:7F7@/240'EMH8VCN(B=C)[Q2)X ?<=3 Y=#P&,!H-W,;W%I R4Y6$*
MRWIGP98-E?N,K=5%T@7,Z4<0IP_9CVL\4+;<N"P3MD-F:K*89C4T%7"1#]V<
MFF>&H%:4RR93*G=8@V!1;\>-34%-'>V025"PP(Q',Q$_SS9BH6IE65D!=@O*
M5HZZX^C0PEKE/U -]QC0)Q?X%I*,PL\884C2%>I<J2&<=VG7"3@ZG=J::I#5
M&5G&AJ>R9/3HH)IO'U0*[B]VJ1F3-J&F$O$(!*> +5P2K.WXS_&A.ACH$4[=
MH54&XO]&-2,H.U?48X;V/*"T[?.&JH/(M6N,8UL[D:Y.JGJ!25J,<$GI1*1>
M!K1.*;"DE_,V SQ.QWU08-%6C.B!O@;A5SG+&F)^UC+E.9]WZW17B!,^_W--
MV-3@2FQPAH69;+3GRF2R;Z2WDM^X]"UUJL.QOT)HN&8%\'<H,0PB,021'%C$
M-9%LBT-YZ*%,1IY11FV%RNK%0EEX?J2/MU".PJYKAT>]$I<>'B+ZCG%HE ;#
MUDM54VM)NH-RU# VPX5,T198TA&2J2-W'.S/3%OF@@YFP)^67 RHZ6&*@AP@
M++E$L1;4UUJJ[S+'R>.Z7F<?[2[XR2CS1&!B"'1"5WMBW7%%[5RH+$+[<;OF
M#OG-[NZ F6(4JA1AZ4RYBHM6VVM8U<)PSY,M91WYBY*,*DWV'>T(I);Z%17
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M1R4C JROE++-"VW0WNS>_!]02P,$%     @ NXIT5D!&E8\0 P    <  !D
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M(W<$D=[@5)Z8D^0ASV#$0+D,!0^N=I0&QGHXA3+XZP#'J *KR*$?,"&.F2D
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M,*B= >UOE++[B0O0?[,6_P-02P,$%     @ NXIT5O,'/6N:!0  4A$  !D
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MPM2.3@?A? SB$8!@W,\)S_+"V HOZZ@/@RF,3DG?G\'?9CMK%GIH#<)^&I5
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M8#X(S"_1UQMZ=V4K$?0./K;..JY*H?;PA1O#E;//Z;U,_%PA[+2D]^<YV&U
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M!M(:F/<;(?3SP"[0_MV1_ M02P,$%     @ NXIT5F#T?W_! @  ZP<  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULK97?;],P$,?_%2M,:$BP_&RR
MCC32UC*Q!T2U,7A /+C)M;'FV,%VVNV_QW;2J&NSJ2!>&I]]]^WGSF<[W7#Q
M($L A1XKRN3$*96J+UQ7YB546)[Q&IA>67)18:5-L7)E+0 7-JBB;N!YL5MA
MPIPLM7-SD:6\490PF LDFZK"XND**-],'-_93MR25:G,A)NE-5[!':C[>BZT
MY?8J!:F 2<(9$K"<.)?^Q30Q_M;A.X&-W!DCD\F"\P=CW!03QS- 0"%71@'K
MSQJF0*D1TAB_.TVG_TL3N#O>JE_;W'4N"RQARND/4JARXIP[J( E;JBZY9O/
MT.4S,GHYI]+^HDWGZSDH;Z3B51>L"2K"VB]^[.JP$^!'+P0$74!P;$#8!80V
MT9;,IC7#"F>IX!LDC+=6,P-;&QNMLR',[.*=$GJ5Z#B5?54E"'1-&&8YP13=
ML+8S3(D_H+F &I,"?7K472-!HM,9*$RH?*<7[^]FZ/3D'3I!A*%O)6\D9H5,
M7:6QC+B;=PA7+4+P L(,\C,4^N]1X 7!0/CT^'#_>;BKB]%7).@K$EB]\!\J
M\O-R(970K?=K*,U6-QK6-<?Q0M8XAXFCSYL$L08G>_O&C[V/0TG_)[%G)0C[
M$H2OJ6<S@E>,2T7R5E*!'K-5:\BFKBF!P8UN91,K:^Z/=>8GXU'JKG<S&W#R
MQG[O](PXZHFC5XFWC5H+7C2Y0H(_8:I>H&REXAV R-MC'' 9#Q..>L+1483F
M9E5@F@N0/B_Z[,A&6"OGS/;6(//H "CPDF"/>LC).Q_FCGON^%7N]CC4';TA
MYG8F;X0 IA"6$H:1XT.:,-XC/O2)QMXP<-(#)T<5^F]0DX.6C/PHW&,]= KC
M<+^Z[LY5;)[!+UBL]!8C"DL=YITE>H]$^[2TAN*UO9T77.F[W@Y+_1J#, YZ
M?<FYVAKFPN_?]^P/4$L#!!0    ( +N*=%9ZA96Q_@,   84   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;+5878^C-A3]*Q9=5;O2[(#Y"IDF2-U,
M1QUIJD8[N^U#U0=/<I-8"YBU33+37U\;"(3$01N)O"1\W'LX]_K8'#S9,?Y-
M;  D>DV33$RMC93YG6V+Q092(FY9#IFZLV(\)5*=\K4M<@YD62:EB>TZ3FBG
MA&96/"FOS7D\885,: 9SCD21IH2_?8*$[:86MO87/M/U1NH+=CS)R1J>07[-
MYUR=V0W*DJ:0"<HRQ&$UM7[%=S/7T0EEQ%\4=N+@&.E27AC[ID\>EU/+T8P@
M@874$$3];6$&2:*1%(_O-:C5/%,G'A[OT1_*XE4Q+T3 C"5_TZ7<3*W(0DM8
MD2*1G]GN=Z@+"C3>@B6B_$6[.M:QT*(0DJ5ULF*0TJSZ)Z]U(PX2L'\FP:T3
MW!]-\.H$KRRT8E:6=4\DB2><[1#7T0I-'Y2]*;-5-333P_@LN;I+59Z,_Y0;
MX.B!9B1;4)*@QZR2AF[Q1S3G2B]<OB&2+=%OWPN:JQ&4Z/T]2$(3\4&%?'V^
M1^_??4#O$,W0EPTKA(H5$ULJ<OH1]J(F\JDBXIXA<@^+6^3A&^0ZKFM(G_UX
M.NZFVZHE35_<IB]NB>>=P=M7?H/F"5$E=QOPSY,*1X\24O&OJ=0*VS=CZYEY
M)W*R@*FEIIX O@4K_ODG'#J_F H?"*S3!J]I@]>''G]A4HDB/Y0![+M@*KQ"
M&Y5H>@79QMCS](!L#RLZC8K"(&R".DS]AJG?R_0)A+A3J\*B2(N$2%BJR:P:
MHD1=+1>*.4D9E_2_\H*)?/6 \(#6QP"[_A%Y0Y071;Z9?="P#WK9SXT=OD$9
M&-L<G'"(\'AT1/0TR!^-7#//L.$9]O)\*'A&9<&A4IAB6QVLZ*N^:ISWO8B7
M3H:!P#K%CYKB1U=<$T9#MF$@L$X;HJ8-T:!K0G2BPW%T)-73D,@S"W7<D!SW
M+P?DA7$B&7_K)]>+<NFH# 36*1@[[9O<N:(\:_"!.C$46K<5!Z8&#RK1&NY0
M@ 'VPB.5&J)\+\1FH>+6:>#>-W@\8VE>2.7"&HHE8<%6<D<X&/D.:C"&0NO6
MWUH,[%U3M[T&YN)6#(36;47K87"_B;E8MZ=F!/N1>ZQ;0Y3KG/%;N+4LN-^S
M/('Z?-JP9(EHJBAO0;,T._]>H(O':""T;MFM \+A->4ZJ!L:"JW;BM8/X5Z?
M<;E<1Z?+K.MZQW(]C<(X.+?,MJX%]]N6&<N$Y$6U>Z"^517MM6J*6;"]4!>/
MTD!HW<);)X3'UQ3LH YI*+3N-WUKD=Q>WW&Q8&NX[O?LR?IJBHJ"X$BP]L$F
MC=XA^X/P-<T$2F"ETIS;D5K6>+7I5)U(EI?[-B],2I:6AQL@2^ Z0-U?,2;W
M)WHKJ-GZB_\'4$L#!!0    ( +N*=%9ET\B'D@,  "4+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;+56;6_;-A#^*X16#"W@1"]^BS/;0.RD;8!T
M,^IE^U#L RV=+:(4J9*4G>S7[TC)JAW+0C=D7VSR=/?PN>/=\<8[J;[J%,"0
MIXP+/?%28_)KW]=Q"AG5ES('@5_64F74X%9M?)TKH(DSRK@?!<' SR@3WG3L
M9 LU'<O"<"9@H8@NLHRJYQEPN9MXH;<7?&:;U%B!/QWG= -+,(_Y0N'.KU$2
MEH'03 JB8#WQ;L+K>1A8 Z?Q!X.=/E@3Z\I*RJ]V<Y],O, R @ZQL1 4_[8P
M!\XM$O+X5H%Z]9G6\'"]1W_OG$=G5E3#7/(_66+2B7?ED036M.#FL]Q]A,JA
MOL6+)=?NE^PJW< C<:&-S"IC9) Q4?[3IRH0!P:]_AF#J#*(7AB$O3,&W<J@
MZQPMF3FW;JFAT[&2.Z*L-J+9A8N-LT9OF+#7N#0*OS*T,]/?3 J*O&>"BIA1
M3NY%F1HVQ!?D5ZH4M7$F;V_!4,;U.Y0^+F_)VS?OR!O"!/D]E86F(M%CWR ?
MB^K'U=FS\NSHS-EA1#Y)85)-[D0"R3& CX[4WD1[;V91*^(MQ)>D&W9(%$11
M Z'YCYN'+72Z=7"[#J][!F^AL-R4>>Z0!:?"$ P3N?M6L!SKP) O#ZA.[@UD
M^J^FX)78O69L6][7.J<Q3#RL7PUJ"][TYY_"0?!+D^.O!'84AEX=AEX;.H85
M03&[RKK%&-!,*L/^=H(FSTNXH8.S?6@[12;!V-\>>G2J-#K0.2+:KXGV6XD^
M2+&YX)CN2%%K,)JP+*=,V>MJXMD_H= =#5_0+'4&!SIG2 YJDH-6DO<UI0YQ
MA!\<X1M+N$,^ D\NL(0O'C5TR-)03"^;;'*-I1W+#(A49"XSO)'4-F,L[4K^
MY>[)6,F* ]9CD8%R]].8FNT,E]B4F=ATR 8$HO#RSA/L7DR;JI_ $SY$&IJZ
MQKP5_3_FZK".[K"5^P<IDQWCV A;;WYX<O/]?C!X<?7#'[WZJYK<57M^TI7$
M^$GU3&#?1IK8M:+\V\[Q2F!'#H]JAT?_8P,=O6887@GL* QA\/V5#MK34DFM
MB9V&R);R FP]5RVJP+=3D;5[P8%PH,U5-:M..,S9Z.JDJS9I]4_ZJG\P<&"C
MV+@Y3)-8%L*4KW4MK6>]&S?AO)#/[ SH!IGO,.4 ^8FJ#1,:'5HC9' YQ$:J
MRIFLW!B9N[%F)0T.26Z9XAP+RBK@][649K^Q!]23\?0?4$L#!!0    ( +N*
M=%8.84T7E0(   L'   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;*U5
M46_3,!#^*U:8T":Q)4W;#(TTTMHRV,-$M3%X0#QXR;6QYMC!=IOQ[SG;:6BW
MMB#$2VR?[[[[OHM]3ANI'G4)8,A3Q84>!:4Q]448ZKR$BNHS68/ G;E4%36X
M5(M0UPIHX8(J'L91E(0592+(4F>;J2R52\.9@)DB>EE55/T< Y?-*.@%:\,M
M6Y3&&L(LK>D"[L#<US.%J[!#*5@%0C,IB(+Y*+CL74P2Z^\<OC!H],:<6"4/
M4C[:Q74Q"B)+"#CDQB)0'%8P <XM$-+XT6(&74H;N#E?HU\Y[:CE@6J82/Z5
M%:8<!6\#4L"<+KFYE<U':/4,+5XNN79?TGC?\T% \J4VLFJ#D4'%A!_I4UN'
MC8!>LB<@;@/BYP'[,O3;@+X3ZIDY65-J:)8JV1!EO1'-3EQM7#2J8<+^Q3NC
M<)=AG,D^F1(4N6*"BIQ13JZ%/QFVQ*?D@Y1%PS@GQU,PE'%]@L;[NRDY/CHA
M1X0)\KF42TU%H=/0(!T+&N9MZK%/'>])W8O)C12FU.2]**#8!@A11R<F7HL9
MQP<1IY"?D7[O#8FC.-Y!:/+WX;T#=/I=;?L.K[\'KZO>MUN)7SQV#57%]UV5
M\D"#W4#V)E_HFN8P"O"J:E K"++7KWI)]&Z7RO\$MJ5YT&D>'$+/QK!@0C"Q
MP,O%\4S!+K4>XMQ!V#:SRH;#*$G#U::*@WG^4<6P4S$\J*+[<ZRJ*5/8M<PN
M'1XDV=!QND/(\(7:J//88I=T[)*#[/"Z_*' R8&4GM1+CRWFGE>XT5<J4 O7
M;C7)Y5(8?RL[:]?1+UTC>V8?8Z?WC?DWC'\F;JC" Z,)ASE"1F?G6"WE6Z]?
M&%F[[O4@#?9"-RWQM0)E'7!_+J59+VR"[OW+?@%02P,$%     @ NXIT5B_]
M,T54 P  B@H  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULK99O;],\
M$,"_BI4'(9!@^9]FHXTT-B&00$P;\+Q O'"3:V/AQ'EL9UV_/><D#5WC[JD0
M;UH[OCO_[LX^WWPCY$]5 FCR4/%:+9Q2Z^;"=55>0D75F6B@QI65D!75.)5K
M5S42:-$I5=P-/"]Q*\IJ)YMWWVYD-A>MYJR&&TE46U54;M\"%YN%XSN[#[=L
M76KSP<WF#5W#'>BOS8W$F3M:*5@%M6*B)A)6"^?2O[CR.X5.XAN#C=H;$^/*
M4HB?9O*A6#B>(0(.N38F*/[=PQ5P;BPAQW^#46?<TRCNCW?6WW7.HS-+JN!*
M\']9H<N%DSJD@!5MN;X5F_<P.!0;>[G@JOLEFT'6<TC>*BVJ01D)*E;W__1A
M",2>@A\=40@&A>!4A7!0"#M'>[+.K6NJ:3:78D.DD49K9M#%IM-&;UAMTGBG
M):XRU-/99UV").]83>N<44X^U/W1,"%^32[S7+90D(^,+AEGFH$B+ZY!4\;5
M2US_>G=-7CQ[29X15I,OI6@5K0LU=S62&?MN/E"\[2F"(Q37D)^1T']% B\(
M+.I7IZO[C]5=C,<8E& ,2M#9"_\@*-\OETI+/'T_;&[V=B.[77,E+U1#<U@X
M>.<4R'MPLN?_^(GWQN;T7S+V* 3A&(+P*>O9D/G>7D.W4G#>3S##_4 "IWHG
M @]86!18<]_O-.MV,F7E/@O".)Z[]_O.3H4B+TI'H4=.1*,3T2E.X.'4@"'2
M-KC>0K*WKQ\%!VP6F?#<CA:/:/%):$TK\Q++D")B1=9"%(I@@(E))\OMX8PG
M-*D7'A!/96+?LQ,G(W%R$K$46\I-);"Q)99]HP.VJ8R?'F&;C6RSD]AR7& Y
MWEBEVV+;OQ%,;VVDLRE%<ICWJ4P01W;2="1-GR3MBPH0#IAT(I:<K;NZHEYA
MM9<2:DT:(<T7&W0Z 9IYW@'T5"9.9W;H\Q'Z_$GH6UBU>"CY\ I8XWD^V3:*
M#N_X5.9(WGWO]_/E/8G6EVHZY)__?J>LCY W36B0'$!:A'S?.U*)_+UWUC_I
MB)K;+3KH7;[_#]J?5,8XC&:'U%.I)-WSK:=V]QH%TZ5]HG+-:H6G<85JWMD,
MZX;L&Y]^HD73]0Y+H;$3Z88E-HL@C0"NKX30NXEI1\;V,_L%4$L#!!0    (
M +N*=%;LJN+/7@8  -,O   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM
M;*V:76_;-A2&_PKA#4,'I+$I?R3-' .U+6$!VB!HUNUBV 4MT[90B71)*FF
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M(Y6A@=:+>"*+7[0I^P:N@:)<*IY6P4"04E9>\7,U$8T VWLGP*D"G(\&N%6
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M7#=0]]>,R><3O3'5;D0F_P%02P,$%     @ NXIT5C$T;T6H @  %@<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULA95K;]HP%(;_BI554R>M#>0*
M78A$0=,FK1/J9?LP[8-)#L2J+YGM0/OO9R=IQ%87OA [.>]YWG-P3K*]D(^J
M M#HB5&N9EZE=7WE^ZJH@&%U*6K@YLE&2(:UV<JMKVH)N&Q%C/K!:)3X#!/N
MY5E[;R7S3#2:$@XKB53#&);/UT#%?N:-O9<;MV1;:7O#S[,:;^$.]$.]DF;G
M#UE*PH K(CB2L)EY\_'5]=3&MP$_".S5P1K92M9"/-K-UW+FC:PAH%!HFP&;
MRPX60*E-9&S\Z7-Z ](*#]<OV3^WM9M:UEC!0M"?I-35S)MXJ(0-;JB^%?LO
MT-<3VWR%H*K]1?L^=N2AHE%:L%YL'##"NRM^ZOMP( B"-P1!+PA:WQVH=;G$
M&N>9%'LD;;3)9A=MJ:W:F"/<_BEW6IJGQ.ATOA",$6VZK!'F)5H(K@G? B\(
M*'2!;@@GK&%HSGF#*?H&I@%HA9^M0*$'7H)$WP6_*# O@.(UA3YF+B4V>;JX
M\R5H3*CZ@,X0X>B^$HTR-)7YVI1@C?A%;_>ZLQN\87<)Q24*QQ]1, K&Z.%N
MB<[//OR;QC<=&-H0#&T(VKSAR38H1Q^61!54J$8"^C5?*RW-6?KM,M]!(C?$
MOE]7JL8%S#SS BF0._#R]^_&R>C3D1+"H83P6/;<="1P>>I4::NRK^@N'X=A
MFOD[!RL:6-$I5NAB=:KDD!5%L9L5#ZSX%"MRL6(':S)ULY*!E9QBQ2Y6\IH5
MAZ&;E0ZL]!0K<;%2!VL2N5F3@34YRKJOP$SLC0;I(DY>$>/PC49.!^#T.%!H
M,RY8/SUH.Q+J?FRX+$Q?'=)T&OQ_2/V#,6>_&#=8;@E7)OW&R$:7J3D2LIO"
MW4:+NIU\:Z'-'&V7E?EP@;0!YOE&"/VRL<-T^!3F?P%02P,$%     @ NXIT
M5L),E'^4!0  02L  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULQ9I=
M;Z,X%(;_BI4=K6:D;@&;?'732--6HZTTE:JV,WNQV@N7. TJX-0VZ8RT/WYM
M0C$TQ&W8@_:FA81S?%[[Q3PQGCUS\2A7C"GT(TTR>3I8*;4^\3P9K5A*Y3%?
MLTQ_L^0BI4J?B@=/K@6CBR(H33SL^R,OI7$VF,^*SZ[%?,9SE<09NQ9(YFE*
MQ<\SEO#GTT$P>/G@)GY8*?.!-Y^MZ0.[9>K;^EKH,Z_*LHA3ELF89TBPY>G@
M<W!R'A(34%SQ/6;/LG:,C)1[SA_-R>7B=.";BEC"(F524/UOP\Y9DIA,NHZG
M,NF@:M,$UH]?LG\IQ&LQ]U2R<Y[\&2_4ZG0P&: %6](\43?\^0]6"AJ:?!%/
M9/$7/9?7^@,4Y5+QM S6%:1QMOU/?Y0=40L(PCT!N S [PT@94#1<]ZVLD+6
M!55T/A/\&0ESM<YF#HJ^*:*UFC@SPWBKA/XVUG%J_H7& GVG2<[0%:,R%TR/
MD9+HXP53-$[D)_0;^G9[@3Y^^(0^H#A#=RN>2YHMY,Q3NGV3Q8O*MLZV;>$]
M;5VPZ!B1X AA'^.6\//WAP?-<$^KKJ3C2CHN\I&#I*/+;)WK#M 2BR]IX;8[
M%JVR^"EG$OWU5>=!EXJE\N^V/M@V&K8W:N[*$[FF$3L=Z-M.,K%A@_FOOP0C
M__>V'@%*UN@?4O4/<66?WW%%$W3/A8Z+LP=YA#(]K? E6L0RXGE6=M*"W2L4
M2YG3+&(HXE*U6F/;UKAHR\PMFSF>3$>3F;>IZW56U%%O6.D-G7IO6)0+H96V
ME>\,/714@9(U5 XKE4.GZS]+R90\:=,XA-0(E*RA<51I'+WMW#:%V[!1S83#
MZ9"\-J$S><?2QU7IX_>9$/V#KGC&?NK)7CSJ^VZ9ZSGW2,_ 49(OV,),Q1&5
MJ^(6+ [84QYO:&)F[S;ISF8/'5R@9(T>FE0]-.EJX FD1J!D#8W32N/4Z8+S
M?2-[A);FJ;4IGEIF'DZX>7"U=<9TQ^MX&NYX?;HS+4^'XU%07=4H/_ M5?CO
MMO$Y$RI>QA%5K'AZL#67L?H/5G:W?>@X0V5K]E2-OX*N=BXCH70"96OJM+ 5
M.%D%Q-)E$W5/$S_P_5>>=E?25:G%IL#-377O?V4;EFQS!ZV*@("G%-X'/@66
MGX*PLY5!^0DJ6U.G):C "2_[\:*,>XLOW.F[EF_A*'#3T3Y_0A.'NXR#Q[P/
M*@LLE@7CSMX&12NH;$V=%JX")]? 3-.3=Z%'RV4N]K#L%+CAR>%O>!1QEG+P
MV -E:RZ'6&C#?E>/8U#D@LK6U&F1"SM1!\3C91-OH8B[DJY*:RM<;NC:<RNT
M+;Z=N5,=/,1],!BV#(9)9RN#(A=4MJ9.BUS8O6:U%T7*N+H_=[S9!T5A2U'8
M35'[O*E/L1^,T1T3*4HXS5KE@:Y5065K]H0%,CSZ7Q:B0?D+*ENSCRQ_8?>Z
M&.QB=-E8@U F9'?V[H/%L&4Q[&:Q"R/F,I-*Y,801ZAFE OWTZF%P$;377U]
MK'%A"VJX$ZAAZ!\B[C(.OA'Z@#1B(8UTAC0""FE0V9HZ+:21_B&-[$+:ZUO
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M7SMOSHTMGZL%2)@/"0L@82$0K*6%2:V%R7>6']&:Y*MB17JX;^X2@!%T;LZ
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M5ILP7AZ*+F\DV^@SN4],2I;IRS4E,>5%!?5\R9C<WQ0-U$?39_\"4$L#!!0
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M=$@CKN0H<6VS71==;;(/.^N@7J\GTH<TPDKP6:NV7ID^%6VKQ#Q*."](]@K
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M4K(DO5P3'!*N&ZCW2\;DRXWNH#C F_X$4$L#!!0    ( +N*=%:VF__"; 0
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MM1H6I]/XJ(1^RG2<FCPJOGA&?R0FI_.0QN@*?:5,H.\TW ":2CV_YJ%$G^Y
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M8=$.,SR>@S0+\/Y*"/TX,2?&[L ?_P]02P,$%     @ NXIT5K'@?KT/ P
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M<F]P<R]A<' N>&UL4$L! A0#%     @ NXIT5IWEF [N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ NXIT
M5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "[BG16PP^3<>4'  "I,   &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ NXIT
M5B(;)%XW @  M04  !@              ("!*!   'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( +N*=%8:LHG2WP4   H9   8
M      " @942  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" "[BG16;E VR=,"  #V"@  &               @(&J&   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ NXIT5B0KXP2#!   $1$  !@
M             ("!LQL  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( +N*=%;PJA%GW 8  ,,M   8              " @6P@  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "[BG164?I]G!H"   \
M!   &               @(%^)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ NXIT5IJMUV>D"   0RH  !@              ("!SBD
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( +N*=%:M7_KS
MM04  -\,   8              " @:@R  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " "[BG162G/&=_TD  #,<   &0
M@(&3.   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( +N*
M=%;@(,O5- <  /X1   9              " @<==  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ NXIT5H3D6BYE"@  X!H  !D
M         ("!,F4  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " "[BG16\44M?@T.   T)P  &0              @('.;P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +N*=%9X:X Z:P8  (@0
M   9              " @1)^  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ NXIT5JMUDI0*!P  /!,  !D              ("!M(0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "[BG16@<M)
M^;4)  #='0  &0              @('UBP  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( +N*=%:'A@!T6@@  .45   9
M  " @>&5  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MNXIT5D!&E8\0 P    <  !D              ("!<IX  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " "[BG16.0H"\0LD  "6<0  &0
M            @(&YH0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( +N*=%:3'M;S: 4  )T.   9              " @?O%  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ NXIT5K#$YDS+!
M;0P  !D              ("!FLL  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " "[BG16.@^@O@\#  "_!@  &0              @(&<
MT   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( +N*=%;S
M!SUKF@4  %(1   9              " @>+3  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ NXIT5HL/:#\0 P  4 <  !D
M     ("!L]D  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +N*=%8>/97* 00   $8   9              "
M@:WO  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ NXIT
M5CF8N7I@!P  KC(  !D              ("!Y?,  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " "[BG16$FRP%[$#  !J$@  &0
M        @(%\^P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( +N*=%9<[Y0\J0(  " (   9              " @63_  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ NXIT5O V49>M P  ^A
M !D              ("!1 (! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " "[BG168/1_?\$"  #K!P  &0              @($H!@$
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( +N*=%9ZA96Q
M_@,   84   9              " @2 ) 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ NXIT5F73R(>2 P  )0L  !D
M ("!50T! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "[
MBG16#F%-%Y4"   +!P  &0              @($>$0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +N*=%8O_3-%5 ,  (H*   9
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M970T,BYX;6Q02P$"% ,4    " "[BG16T<XWA<<"  #S!@  &0
M    @($;+@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M +N*=%8H#1<CGP,  'L-   9              " @1DQ 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ NXIT5H1LUV I!   E!0  !D
M             ("![S0! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " "[BG16,31O1:@"   6!P  &0              @(%/.0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( +N*=%;"3)1_E 4
M $$K   9              " @2X\ 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ NXIT5LUB"KCY!0  IBX  !D              ("!
M^4$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "[BG16
M2*EMP0D$  #A%0  &0              @($I2 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +N*=%9BK&C71 <  .,O   9
M      " @6E, 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ NXIT5N[%M7HE!0  MAH  !D              ("!Y%,! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "[BG16Q>"\:4($  #,$P
M&0              @(% 60$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( +N*=%:VF__"; 0  &H8   9              " @;E= 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ NXIT5EWO#>QC
M P  =PX  !D              ("!7&(! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " "[BG169$[[)7\#  #\#P  &0
M@('V90$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( +N*
M=%:QX'Z]#P,  !\*   9              " @:QI 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ NXIT5GO:R))/ P  <@H  !D
M         ("!\FP! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " "[BG16(\6CH/@$  #P%@  &0              @(%X< $ >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( +N*=%;11K\XW (  '<'
M   9              " @:=U 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
M4$L! A0#%     @ NXIT5G.IHJV[ @  60@  !D              ("!NG@!
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " "[BG16DYHJ
M[YT"  "H!@  &0              @(&L>P$ >&PO=V]R:W-H965T<R]S:&5E
M=#8Q+GAM;%!+ 0(4 Q0    ( +N*=%8P63:Y.0,  .P3   -
M  "  8!^ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ NXIT5I>*NQS
M$P(   L              ( !Y($! %]R96QS+RYR96QS4$L! A0#%     @
MNXIT5O*7?TR3!   82@   \              ( !S8(! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( +N*=%;U29+, 0(  %XD   :              "
M 8V' 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +N*
M=%;63,"2X $  .,C   3              "  <:) 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !% $4 VA(  ->+ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>153</ContextCount>
  <ElementCount>395</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OtherFinancialInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Borrowings</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/CommitmentandContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockOptionPlan</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Organization</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Other Financial Information - Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails</Role>
      <ShortName>Other Financial Information - Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Other Financial Information - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails</Role>
      <ShortName>Other Financial Information - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Other Financial Information - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails</Role>
      <ShortName>Other Financial Information - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Other Financial Information - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Borrowings - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails</Role>
      <ShortName>Borrowings - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Commitment and Contingencies - Lease Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails</Role>
      <ShortName>Commitment and Contingencies - Lease Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Commitment and Contingencies - Costs Associated with the Company's Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails</Role>
      <ShortName>Commitment and Contingencies - Costs Associated with the Company's Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Commitment and Contingencies - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails</Role>
      <ShortName>Commitment and Contingencies - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Commitment and Contingencies - Future Payments Under Operating And Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails</Role>
      <ShortName>Commitment and Contingencies - Future Payments Under Operating And Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Commitment and Contingencies - Minimum Annual Lease Payments Under Non-cancelable Lease Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails</Role>
      <ShortName>Commitment and Contingencies - Minimum Annual Lease Payments Under Non-cancelable Lease Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stock Option Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanNarrativeDetails</Role>
      <ShortName>Stock Option Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Option Plan - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails</Role>
      <ShortName>Stock Option Plan - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option Plan - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Change In Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="exdx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/A401kPlan</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeFinanceLeaseTermOfContract1, us-gaap:PropertyPlantAndEquipmentUsefulLife -  exdx-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="exdx-20221231.htm">exdx-20221231.htm</File>
    <File>ex231-2022bdoconsent.htm</File>
    <File>exdx-20221231.xsd</File>
    <File>exdx-20221231_cal.xml</File>
    <File>exdx-20221231_def.xml</File>
    <File>exdx-20221231_lab.xml</File>
    <File>exdx-20221231_pre.xml</File>
    <File>xgn311-123122.htm</File>
    <File>xgn312-123122.htm</File>
    <File>xgn321-123122.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exdx-20221231_g1.jpg</File>
    <File>exdx-20221231_g2.jpg</File>
    <File>exdx-20221231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="653">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exdx-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 653,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 153,
   "dts": {
    "calculationLink": {
     "local": [
      "exdx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exdx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exdx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exdx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exdx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exdx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 591,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 7,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 11
   },
   "keyCustom": 47,
   "keyStandard": 348,
   "memberCustom": 35,
   "memberStandard": 34,
   "nsprefix": "exdx",
   "nsuri": "http://www.exagen.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.exagen.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Other Financial Information",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.exagen.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Borrowings",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.exagen.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitment and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.exagen.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.exagen.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.exagen.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stock Option Plan",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.exagen.com/role/StockOptionPlan",
     "shortName": "Stock Option Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.exagen.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - 401(k) Plan",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.exagen.com/role/A401kPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.exagen.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Other Financial Information (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.exagen.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Borrowings (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.exagen.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Commitment and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesTables",
     "shortName": "Commitment and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.exagen.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.exagen.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stock Option Plan (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.exagen.com/role/StockOptionPlanTables",
     "shortName": "Stock Option Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.exagen.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Organization (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.exagen.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "iad59c59cd12b4a74a51934e1011397ea_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "iad59c59cd12b4a74a51934e1011397ea_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.exagen.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i908968ff669f4aff969761449a9d8cdb_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Other Financial Information - Prepaid Expenses (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails",
     "shortName": "Other Financial Information - Prepaid Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Other Financial Information - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails",
     "shortName": "Other Financial Information - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Other Financial Information - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
     "shortName": "Other Financial Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia42d222f98d840eb9ce09d6de69b0abd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Other Financial Information - Goodwill (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails",
     "shortName": "Other Financial Information - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Other Financial Information - Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails",
     "shortName": "Other Financial Information - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i21484a6d0a4a4221bf3a14d5f4de561a_D20170901-20170930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Borrowings - Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i21484a6d0a4a4221bf3a14d5f4de561a_D20170901-20170930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.exagen.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Borrowings - Future Minimum Payments (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
     "shortName": "Borrowings - Future Minimum Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i18c46c816c6e4ea6a6e64df13f87ffed_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Commitment and Contingencies - Lease Balances (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails",
     "shortName": "Commitment and Contingencies - Lease Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Commitment and Contingencies - Costs Associated with the Company's Leases (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails",
     "shortName": "Commitment and Contingencies - Costs Associated with the Company's Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Commitment and Contingencies - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails",
     "shortName": "Commitment and Contingencies - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Commitment and Contingencies - Future Payments Under Operating And Finance Leases (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
     "shortName": "Commitment and Contingencies - Future Payments Under Operating And Finance Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia42d222f98d840eb9ce09d6de69b0abd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Commitment and Contingencies - Minimum Annual Lease Payments Under Non-cancelable Lease Arrangements (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails",
     "shortName": "Commitment and Contingencies - Minimum Annual Lease Payments Under Non-cancelable Lease Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia42d222f98d840eb9ce09d6de69b0abd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.exagen.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i2d2462525bac435e95ff90467072cf52_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia42d222f98d840eb9ce09d6de69b0abd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "icfe5ad06e42c406da92d33ef14794240_D20220915-20220915",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails",
     "shortName": "Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.exagen.com/role/StatementsofOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stock Option Plan - Narrative (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
     "shortName": "Stock Option Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia42d222f98d840eb9ce09d6de69b0abd_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Stock Option Plan - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
     "shortName": "Stock Option Plan - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia42d222f98d840eb9ce09d6de69b0abd_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
     "shortName": "Stock Option Plan - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i0b00ca98fd364b66a07fb11fff190ef1_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
     "shortName": "Stock Option Plan - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ibd163b7909f4413d81a3366437727ccb_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
     "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i5697bc9dcbcd4e158253d63ad580c6ca_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Stock Option Plan - Common Stock Reserved For Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia42d222f98d840eb9ce09d6de69b0abd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails",
     "shortName": "Income Taxes - Change In Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "iac2e346101f544b3b8c12fb87ac0784e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.exagen.com/role/StatementsofStockholdersEquity",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "iac2e346101f544b3b8c12fb87ac0784e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.exagen.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia586976f14c945e092ffa77bf6eea0a3_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - 401(k) Plan (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.exagen.com/role/A401kPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "ia42d222f98d840eb9ce09d6de69b0abd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.exagen.com/role/StatementsofStockholdersEquityParenthetical",
     "shortName": "Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.exagen.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.exagen.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20221231.htm",
      "contextRef": "i434c2cb3a6e94d76a9ae6ce5fa7c974a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 73,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exdx_AHNCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AHN Collaboration",
        "label": "AHN Collaboration [Member]",
        "terseLabel": "AHN Collaboration"
       }
      }
     },
     "localname": "AHNCollaborationMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AVISECTDTestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVISE CTD Test",
        "label": "AVISE CTD Test [Member]",
        "terseLabel": "AVISE CTD Test"
       }
      }
     },
     "localname": "AVISECTDTestMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AccruedLiabilitiesClinicalStudyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Clinical Study, Current",
        "label": "Accrued Liabilities, Clinical Study, Current",
        "terseLabel": "Accrued clinical study activity"
       }
      }
     },
     "localname": "AccruedLiabilitiesClinicalStudyCurrent",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AccruedPurchaseGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchase, Goods and Services, Current",
        "label": "Accrued Purchase, Goods and Services, Current",
        "terseLabel": "Accrued purchases of goods and services"
       }
      }
     },
     "localname": "AccruedPurchaseGoodsAndServicesCurrent",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdvancePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance Payment",
        "label": "Advance Payment",
        "terseLabel": "Advance royalties payment"
       }
      }
     },
     "localname": "AdvancePayment",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AlleghenyHealthNetworkResearchInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allegheny Health Network Research Institute",
        "label": "Allegheny Health Network Research Institute [Member]",
        "terseLabel": "Allegheny Health Network Research Institute"
       }
      }
     },
     "localname": "AlleghenyHealthNetworkResearchInstituteMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.exagen.com/20221231",
     "xbrltype": "stringItemType"
    },
    "exdx_BlueShieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blue Shield",
        "label": "Blue Shield [Member]",
        "terseLabel": "Blue Shield"
       }
      }
     },
     "localname": "BlueShieldMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow Information, Operating and Finance Lease Payments",
        "label": "Cash Flow Information, Operating and Finance Lease Payments [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In The Valuation Allowance For Deferred Tax Assets",
        "label": "Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]",
        "terseLabel": "Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]"
       }
      }
     },
     "localname": "ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number Of Warrants Exercised",
        "label": "Class of Warrant or Right, Number Of Warrants Exercised",
        "terseLabel": "Number of warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_ClientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client",
        "label": "Client [Member]",
        "terseLabel": "Client"
       }
      }
     },
     "localname": "ClientMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ClinicalStudyPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Study, Policy",
        "label": "Clinical Study, Policy [Policy Text Block]",
        "terseLabel": "Clinical Studies"
       }
      }
     },
     "localname": "ClinicalStudyPolicyPolicyTextBlock",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_CollaborationAgreementAnnualCollaborationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Annual Collaboration Fee",
        "label": "Collaboration Agreement, Annual Collaboration Fee",
        "terseLabel": "Collaboration fee"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualCollaborationFee",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CollaborationAgreementCollaborationExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Collaboration Expenses",
        "label": "Collaboration Agreement, Collaboration Expenses",
        "terseLabel": "Collaboration agreement, collaboration expenses"
       }
      }
     },
     "localname": "CollaborationAgreementCollaborationExpenses",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares Available For Grant Under The 2019 Plan",
        "label": "Common Shares Available For Grant Under The 2019 Plan [Member]",
        "terseLabel": "Common shares available for grant under the 2019 Plan"
       }
      }
     },
     "localname": "CommonSharesAvailableForGrantUnderThe2019PlanMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ContractWithCustomerTerminationConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Termination, Consideration Receivable",
        "label": "Contract With Customer, Termination, Consideration Receivable",
        "terseLabel": "Termination of agreement"
       }
      }
     },
     "localname": "ContractWithCustomerTerminationConsiderationReceivable",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CowenEquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen Equity Distribution Agreement",
        "label": "Cowen Equity Distribution Agreement [Member]",
        "terseLabel": "Cowen Equity Distribution Agreement"
       }
      }
     },
     "localname": "CowenEquityDistributionAgreementMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "terseLabel": "Term loan covenant, minimum unrestricted cash balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "terseLabel": "Term loan covenant, increase to interest rate"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met",
        "label": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met",
        "terseLabel": "Term loan, covenant, number of days to cure covenant if performance measure is not met"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_DebtInstrumentCovenantRevenuePerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Revenue Performance Period",
        "label": "Debt Instrument, Covenant, Revenue Performance Period",
        "terseLabel": "Term loan, covenant, revenue performance period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRevenuePerformancePeriod",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_DebtInstrumentNumberOfMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Monthly Installments",
        "label": "Debt Instrument, Number Of Monthly Installments",
        "terseLabel": "Number of monthly installments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfMonthlyInstallments",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exdx_DebtInstrumentPaidInKindLoansIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Paid In Kind Loans Issued",
        "label": "Debt Instrument, Paid In Kind Loans Issued",
        "terseLabel": "Term loan, paid in-kind loans issued"
       }
      }
     },
     "localname": "DebtInstrumentPaidInKindLoansIssued",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "terseLabel": "Term loan, prepayment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "label": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "terseLabel": "Term loan, annual reduction in prepayment penalty percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentageAnnualReduction",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentStatedInterestRatePaidInKind": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "terseLabel": "Term loan, paid in-kind, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentStatedInterestRatePaidInKind",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DeferredOfferingCostsReclassifiedToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Reclassified to Equity",
        "label": "Deferred Offering Costs Reclassified to Equity",
        "terseLabel": "Deferred offering costs reclassified to equity"
       }
      }
     },
     "localname": "DeferredOfferingCostsReclassifiedToEquity",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs",
        "terseLabel": "Capitalization of research and experimentation costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets",
        "label": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets",
        "negatedLabel": "Basis differences in fixed and intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right Of Use Assets",
        "label": "Deferred Tax Liabilities, Right Of Use Assets",
        "negatedTerseLabel": "Right of use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_EquipmentNotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Notes Payable",
        "label": "Equipment Notes Payable [Member]",
        "terseLabel": "Equipment Notes Payable"
       }
      }
     },
     "localname": "EquipmentNotesPayableMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_EquipmentPurchasedUnderNotesPayableObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Purchased Under Notes Payable Obligations",
        "label": "Equipment Purchased Under Notes Payable Obligations",
        "terseLabel": "Equipment purchased under notes payable obligations"
       }
      }
     },
     "localname": "EquipmentPurchasedUnderNotesPayableObligations",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement, Number Of Shares Exchanged For Warrants",
        "label": "Exchange Agreement, Number Of Shares Exchanged For Warrants",
        "terseLabel": "Number of shares exchanged for warrants (in shares)"
       }
      }
     },
     "localname": "ExchangeAgreementNumberOfSharesExchangedForWarrants",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_ExchangingStockholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchanging Stockholders",
        "label": "Exchanging Stockholders [Member]",
        "terseLabel": "Exchanging Stockholders"
       }
      }
     },
     "localname": "ExchangingStockholdersMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationApr12026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Apr 1, 2026",
        "label": "Expiration Apr 1, 2026 [Member]",
        "terseLabel": "Warrant expiration April 1, 2026"
       }
      }
     },
     "localname": "ExpirationApr12026Member",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationDec72025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Dec 7, 2025",
        "label": "Expiration Dec 7, 2025 [Member]",
        "terseLabel": "Warrant expiration December 7, 2025"
       }
      }
     },
     "localname": "ExpirationDec72025Member",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationJan192026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Jan 19, 2026",
        "label": "Expiration Jan 19, 2026 [Member]",
        "terseLabel": "Warrant expiration January 19, 2026"
       }
      }
     },
     "localname": "ExpirationJan192026Member",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationMar312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Mar 31, 2026",
        "label": "Expiration Mar 31, 2026 [Member]",
        "terseLabel": "Warrant expiration March 31, 2026"
       }
      }
     },
     "localname": "ExpirationMar312026Member",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationSep72024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Sep 7, 2024",
        "label": "Expiration Sep 7, 2024 [Member]",
        "terseLabel": "Warrant expiration September 7, 2024"
       }
      }
     },
     "localname": "ExpirationSep72024Member",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_FinanceLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, to be Paid, Due after Year Four",
        "label": "Finance Lease, Liability, to be Paid, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_Government1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government1",
        "label": "Government1 [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "Government1Member",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncentiveAwardPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Award Plan, 2019",
        "label": "Incentive Award Plan, 2019 [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "IncentiveAwardPlan2019Member",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "label": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_InnovatusLifeSciencesLendingFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Life Sciences Lending Fund",
        "label": "Innovatus Life Sciences Lending Fund [Member]",
        "terseLabel": "Innovatus Life Sciences Lending Fund"
       }
      }
     },
     "localname": "InnovatusLifeSciencesLendingFundMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares",
        "label": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares",
        "terseLabel": "Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)"
       }
      }
     },
     "localname": "IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value",
        "label": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value",
        "negatedTerseLabel": "Issuance of stock from vested restricted stock units and payment of employees' taxes"
       }
      }
     },
     "localname": "IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_JanssenPromotionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Promotion Agreement",
        "label": "Janssen Promotion Agreement [Member]",
        "terseLabel": "Janssen Promotion Agreement"
       }
      }
     },
     "localname": "JanssenPromotionAgreementMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JanssenSIMPONIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen (SIMPONI)",
        "label": "Janssen (SIMPONI) [Member]",
        "terseLabel": "Blue Shield"
       }
      }
     },
     "localname": "JanssenSIMPONIMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LicenseAgreementInitialLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Initial License Fee",
        "label": "License Agreement, Initial License Fee",
        "terseLabel": "Initial license fee"
       }
      }
     },
     "localname": "LicenseAgreementInitialLicenseFee",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LicenseAgreementOneTimePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, One Time Payment",
        "label": "License Agreement, One Time Payment",
        "terseLabel": "One time payment"
       }
      }
     },
     "localname": "LicenseAgreementOneTimePayment",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Period After Commercial Sales Begin For Royalties To Be Paid",
        "label": "License Agreement, Period After Commercial Sales Begin For Royalties To Be Paid",
        "terseLabel": "Period for royalties to begin"
       }
      }
     },
     "localname": "LicenseAgreementPeriodAfterCommercialSalesBeginForRoyaltiesToBePaid",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_LongTermDebtIncludingUndiscountedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Including Undiscounted Interest",
        "label": "Long-term Debt, Including Undiscounted Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtIncludingUndiscountedInterest",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtUndiscountedInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Undiscounted Interest Amount",
        "label": "Long-term Debt, Undiscounted Interest Amount",
        "negatedTerseLabel": "Interest"
       }
      }
     },
     "localname": "LongTermDebtUndiscountedInterestAmount",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "terseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_NoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No expiration",
        "label": "No expiration [Member]",
        "terseLabel": "No expiration"
       }
      }
     },
     "localname": "NoExpirationMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Lease Expense",
        "label": "Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory",
        "label": "Office and Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office",
        "label": "Office [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "OfficeMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Annual Increase In Base Rent Payment, Percent",
        "label": "Operating Lease, Annual Increase In Base Rent Payment, Percent",
        "terseLabel": "Operating lease, annual increase in base rent payment percentage"
       }
      }
     },
     "localname": "OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_OperatingLeaseMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Base Rent",
        "label": "Operating Lease, Monthly Base Rent",
        "terseLabel": "Operating lease, monthly base rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyBaseRent",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_OperatingLossCarryforwardsNotUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Not Utilized",
        "label": "Operating Loss Carryforwards, Not Utilized",
        "terseLabel": "Tax attribute carryforwards cannot be utilized under IRC Section 382"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotUtilized",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.exagen.com/20221231",
     "xbrltype": "stringItemType"
    },
    "exdx_OtherOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Offering",
        "label": "Other Offering [Member]",
        "terseLabel": "Other Offering"
       }
      }
     },
     "localname": "OtherOfferingMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities",
        "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_PrepaidMaintenanceAndInsuranceContracts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Maintenance and Insurance Contracts",
        "label": "Prepaid Maintenance and Insurance Contracts",
        "terseLabel": "Prepaid maintenance and insurance contracts"
       }
      }
     },
     "localname": "PrepaidMaintenanceAndInsuranceContracts",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_PrometheusLaboratoriesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prometheus Laboratories, Inc.",
        "label": "Prometheus Laboratories, Inc. [Member]",
        "terseLabel": "Prometheus Laboratories"
       }
      }
     },
     "localname": "PrometheusLaboratoriesIncMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "label": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "terseLabel": "Annual increase in purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligationAnnualIncreaseInCommitmentPercentage",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_QueenMaryUniversityOfLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Queen Mary University Of London",
        "label": "Queen Mary University Of London [Member]",
        "terseLabel": "Queen Mary University Of London"
       }
      }
     },
     "localname": "QueenMaryUniversityOfLondonMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ReceivableBenchmarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable Benchmark",
        "label": "Receivable Benchmark [Member]",
        "terseLabel": "Receivable Benchmark"
       }
      }
     },
     "localname": "ReceivableBenchmarkMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RentalPropertyByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Axis]",
        "terseLabel": "Rental Property, by Type [Axis]"
       }
      }
     },
     "localname": "RentalPropertyByTypeAxis",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_RentalPropertyByTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Domain]",
        "terseLabel": "Rental Property, by Type [Domain]"
       }
      }
     },
     "localname": "RentalPropertyByTypeDomain",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RoyaltyObligationPercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Percentage of Sales",
        "label": "Royalty Obligation, Percentage of Sales",
        "terseLabel": "Royalty obligation, percent of net sales"
       }
      }
     },
     "localname": "RoyaltyObligationPercentageOfSales",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "terseLabel": "Annual percentage increase in shares available for issuance under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized",
        "terseLabel": "Increase (decrease) in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments",
        "terseLabel": "Number of annual vesting installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exdx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs",
        "label": "Stock Issuance Costs",
        "terseLabel": "Estimated offering expenses for aggregate expenses",
        "verboseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquityParenthetical",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "terseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "terseLabel": "Exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_Term2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term 2017",
        "label": "Term 2017 [Member]",
        "terseLabel": "2017 Term loan"
       }
      }
     },
     "localname": "Term2017Member",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_TwoSuppliersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Suppliers",
        "label": "Two Suppliers [Member]",
        "terseLabel": "Two Suppliers"
       }
      }
     },
     "localname": "TwoSuppliersMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_UnitedHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Healthcare",
        "label": "United Healthcare [Member]",
        "terseLabel": "United Healthcare"
       }
      }
     },
     "localname": "UnitedHealthcareMember",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-Average Discount Rate",
        "label": "Weighted-Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-Average Remaining Lease Term",
        "label": "Weighted-Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.exagen.com/20221231",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r290",
      "r319",
      "r582",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r151",
      "r194",
      "r201",
      "r207",
      "r253",
      "r401",
      "r402",
      "r403",
      "r429",
      "r430",
      "r453",
      "r456",
      "r458",
      "r459",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r151",
      "r194",
      "r201",
      "r207",
      "r253",
      "r401",
      "r402",
      "r403",
      "r429",
      "r430",
      "r453",
      "r456",
      "r458",
      "r459",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r151",
      "r194",
      "r201",
      "r207",
      "r253",
      "r401",
      "r402",
      "r403",
      "r429",
      "r430",
      "r453",
      "r456",
      "r458",
      "r459",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r242",
      "r600",
      "r670",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r364",
      "r548",
      "r559",
      "r577",
      "r578",
      "r597",
      "r608",
      "r614",
      "r669",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r364",
      "r548",
      "r559",
      "r577",
      "r578",
      "r597",
      "r608",
      "r614",
      "r669",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r242",
      "r600",
      "r670",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r240",
      "r549",
      "r598",
      "r613",
      "r664",
      "r665",
      "r670",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r240",
      "r549",
      "r598",
      "r613",
      "r664",
      "r665",
      "r670",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r347",
      "r364",
      "r392",
      "r393",
      "r394",
      "r524",
      "r548",
      "r559",
      "r577",
      "r578",
      "r597",
      "r608",
      "r614",
      "r661",
      "r669",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r347",
      "r364",
      "r392",
      "r393",
      "r394",
      "r524",
      "r548",
      "r559",
      "r577",
      "r578",
      "r597",
      "r608",
      "r614",
      "r661",
      "r669",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r290",
      "r319",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r612"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r16",
      "r581"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r16",
      "r581"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued\u00a0payroll\u00a0and\u00a0related\u00a0expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r64",
      "r159"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r612"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r639",
      "r640",
      "r641",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r195",
      "r196",
      "r197",
      "r198",
      "r207",
      "r245",
      "r246",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r401",
      "r402",
      "r403",
      "r427",
      "r428",
      "r429",
      "r430",
      "r441",
      "r442",
      "r443",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r485",
      "r486",
      "r491",
      "r492",
      "r493",
      "r494",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r550",
      "r551",
      "r552",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r97",
      "r98",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r72",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrant in exchange for retirement of common stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Marketing Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising and marketing costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r309",
      "r488",
      "r595",
      "r596",
      "r633"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r123",
      "r136",
      "r162",
      "r185",
      "r225",
      "r234",
      "r238",
      "r249",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r444",
      "r446",
      "r469",
      "r612",
      "r667",
      "r668",
      "r719"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r155",
      "r168",
      "r185",
      "r249",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r444",
      "r446",
      "r469",
      "r612",
      "r667",
      "r668",
      "r719"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.exagen.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Costs incurred, but not paid, in connection with capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r157",
      "r579"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, fair value disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r36",
      "r41",
      "r46"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r117"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit, included in cash and cash equivalents"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r128",
      "r142"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r271",
      "r272",
      "r574",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r639",
      "r640",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r612"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2022 and December 31, 2021; 16,549,984 and 16,164,994 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r55",
      "r56",
      "r114",
      "r115",
      "r242",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r55",
      "r56",
      "r114",
      "r115",
      "r242",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r55",
      "r56",
      "r114",
      "r115",
      "r242",
      "r573",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r133",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r55",
      "r56",
      "r114",
      "r115",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r55",
      "r56",
      "r114",
      "r115",
      "r242",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r27",
      "r549"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r28",
      "r185",
      "r249",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r469",
      "r667"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r638",
      "r703",
      "r705"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r424",
      "r434",
      "r638"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r638",
      "r703",
      "r705"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r53",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Refund liability"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r183",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r303",
      "r310",
      "r311",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r124",
      "r126",
      "r135",
      "r190",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r489",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r301",
      "r468",
      "r593",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Term loan, fee incurred upon payment of final installment"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r18",
      "r119",
      "r316",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Term loan, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r18",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r190",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r489",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r20",
      "r78",
      "r81",
      "r82",
      "r83",
      "r118",
      "r119",
      "r121",
      "r132",
      "r190",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r312",
      "r489",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r120",
      "r299",
      "r314",
      "r593",
      "r594"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r638",
      "r704",
      "r705"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r39",
      "r110",
      "r425",
      "r433",
      "r434",
      "r638"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r125",
      "r134",
      "r418"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r146",
      "r718"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent credit"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r638",
      "r704",
      "r705"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Indefinite lived assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r701"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r108",
      "r702"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r108",
      "r702"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Federal net operating loss carryforwards, carryforward indefinitely"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r108",
      "r702"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Federal tax loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r108",
      "r702"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r107",
      "r108",
      "r702"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r108",
      "r702"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves": {
     "auth_ref": [
      "r108",
      "r702"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves",
        "terseLabel": "Accruals, reserves and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "periodEndLabel": "Valuation allowance at the end of the year",
        "periodStartLabel": "Valuation allowance at the beginning of the year"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails",
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r103",
      "r701"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r108",
      "r702"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "negatedLabel": "Financing and acquisition-related liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r108",
      "r702"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Indefinite lived assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Qualified employee compensation contribution, amount"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/A401kPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Qualified employee compensation, employer matching contribution, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r39",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r344",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r369",
      "r397",
      "r398",
      "r400",
      "r404",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r88",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved For Future Issuance"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r176",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r208",
      "r210",
      "r212",
      "r213",
      "r214",
      "r216",
      "r459",
      "r460",
      "r555",
      "r557",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r176",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r210",
      "r212",
      "r213",
      "r214",
      "r216",
      "r459",
      "r460",
      "r555",
      "r557",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r186",
      "r413",
      "r435"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r700",
      "r706"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedTerseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r700",
      "r706"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "negatedTerseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r700",
      "r706"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "negatedTerseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r700",
      "r706"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State income taxes, net of federal tax benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r700",
      "r706"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock options, unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r699"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to stock purchase"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan",
        "verboseLabel": "Common shares available for future issuance under ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Common stock option grants issued and outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPolicy": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.",
        "label": "Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r77",
      "r151",
      "r172",
      "r173",
      "r174",
      "r191",
      "r192",
      "r193",
      "r196",
      "r204",
      "r206",
      "r217",
      "r253",
      "r334",
      "r401",
      "r402",
      "r403",
      "r429",
      "r430",
      "r458",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r516",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r301",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r463",
      "r521",
      "r522",
      "r523",
      "r593",
      "r594",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r301",
      "r349",
      "r354",
      "r463",
      "r521",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r301",
      "r349",
      "r354",
      "r463",
      "r522",
      "r593",
      "r594",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r301",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r463",
      "r523",
      "r593",
      "r594",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r301",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r521",
      "r522",
      "r523",
      "r593",
      "r594",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r498",
      "r503",
      "r611"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r500",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash out flows from interest paid on finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r496",
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Finance lease obligations, current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Summary of Finance Lease, Liability, Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Lease obligations, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r499",
      "r505"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payment on finance lease obligations",
        "terseLabel": "Financing cash out flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails",
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease, right-of-use asset, after accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r498",
      "r503",
      "r611"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r710"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Gross book value of assets under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r508",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r507",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r247",
      "r248",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r312",
      "r330",
      "r448",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r589",
      "r644",
      "r645",
      "r646",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture\u00a0and\u00a0fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r160",
      "r264",
      "r554",
      "r591",
      "r612",
      "r649",
      "r656"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r39",
      "r265",
      "r266",
      "r267",
      "r591"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Goodwill impairment",
        "terseLabel": "Goodwill Impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails",
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofOperations",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.",
        "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r39",
      "r62",
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Long-lived assets impairment"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r29",
      "r174"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r414",
      "r416",
      "r423",
      "r431",
      "r436",
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r187",
      "r205",
      "r206",
      "r224",
      "r412",
      "r432",
      "r437",
      "r558"
     ],
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense",
        "totalLabel": "Provision (benefit) for income tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r171",
      "r408",
      "r409",
      "r416",
      "r417",
      "r422",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r632",
      "r715"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r120",
      "r130",
      "r175",
      "r222",
      "r487"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r178",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest expense"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r509",
      "r611"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Finance lease, term of contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r185",
      "r249",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r445",
      "r446",
      "r447",
      "r469",
      "r587",
      "r667",
      "r719",
      "r720"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r127",
      "r140",
      "r612",
      "r637",
      "r647",
      "r709"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r156",
      "r185",
      "r249",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r445",
      "r446",
      "r447",
      "r469",
      "r612",
      "r667",
      "r719",
      "r720"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r13",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r13",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loan payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r2",
      "r126",
      "r137",
      "r300",
      "r315",
      "r593",
      "r594"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Total borrowings, net of discounts and debt issuance costs",
        "totalLabel": "Total borrowings, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Borrowings-current portion",
        "terseLabel": "Borrowings-current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r70",
      "r190",
      "r305"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r70",
      "r190",
      "r305"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 4.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r70",
      "r190",
      "r305"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r70",
      "r190",
      "r305"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Notes payable noncurrnet"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r20",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r273",
      "r274",
      "r275",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r40",
      "r129",
      "r143",
      "r154",
      "r169",
      "r170",
      "r174",
      "r185",
      "r195",
      "r199",
      "r200",
      "r201",
      "r202",
      "r205",
      "r206",
      "r211",
      "r225",
      "r233",
      "r237",
      "r239",
      "r249",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r460",
      "r469",
      "r588",
      "r667"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofOperations",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r48",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r207",
      "r216",
      "r245",
      "r246",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r401",
      "r402",
      "r403",
      "r427",
      "r428",
      "r429",
      "r430",
      "r441",
      "r442",
      "r443",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r485",
      "r486",
      "r491",
      "r492",
      "r493",
      "r494",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r550",
      "r551",
      "r552",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Recently Adopted Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r2",
      "r126",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Notes payable current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r225",
      "r233",
      "r237",
      "r239",
      "r588"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r711"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities",
        "verboseLabel": "Lease obligations, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/CommitmentandContingenciesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r501",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash out flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/CommitmentandContingenciesLeaseBalancesDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r508",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r507",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesMinimumAnnualLeasePaymentsUnderNoncancelableLeaseArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r47",
      "r49",
      "r58",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r167",
      "r612"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Diagnostic\u00a0testing\u00a0supplies"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCustomerMember": {
     "auth_ref": [
      "r730",
      "r732",
      "r733",
      "r734",
      "r736",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer classified as other.",
        "label": "Other Customer [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r628",
      "r648"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "Paid in-kind note"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of issuance costs related to public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments of taxes withheld on vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Purchase of other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r347",
      "r348",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/A401kPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r612"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRoyalties": {
     "auth_ref": [
      "r580",
      "r590",
      "r648"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Royalties",
        "terseLabel": "Prepaid product royalties"
       }
      }
     },
     "localname": "PrepaidRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock in public offering, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Term loan borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r96"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from common stock issued under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r631"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r660",
      "r714"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r63",
      "r158"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r65",
      "r141",
      "r556",
      "r612"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase obligation, due in next twelve months"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "Purchase obligation, due in second year"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Principal payment on note payable obligations"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r100",
      "r144",
      "r727"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r627",
      "r634",
      "r728",
      "r729"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units",
        "verboseLabel": "Common stock reserved for issuance upon vesting of outstanding restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r84",
      "r139",
      "r566",
      "r571",
      "r612"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r151",
      "r191",
      "r192",
      "r193",
      "r196",
      "r204",
      "r206",
      "r253",
      "r401",
      "r402",
      "r403",
      "r429",
      "r430",
      "r458",
      "r562",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r220",
      "r221",
      "r232",
      "r235",
      "r236",
      "r240",
      "r241",
      "r242",
      "r343",
      "r344",
      "r549"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r346",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition and Shipping and Handling Costs"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r506",
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Equipment purchased under finance lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Future minimum royalty commitment"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from public offering, net"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Sale of stock, percentage of ownership after transaction"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares issued in public offering, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r242",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r591",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r46",
      "r122",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r366",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions, Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r164",
      "r165",
      "r166",
      "r218",
      "r317",
      "r318",
      "r319",
      "r321",
      "r325",
      "r330",
      "r332",
      "r597",
      "r626",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r57",
      "r114",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Awards canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, Ending balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, Ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, Beginning balance (in dollars per share)",
        "terseLabel": "Common stock, fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Awards released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum Employee payroll deduction percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares that remain available for future awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term\u00a0(Years) and Aggregate Instrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Employee options, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise\u00a0Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options exercisable (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and Expected to Vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]",
        "terseLabel": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]",
        "terseLabel": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Grant date fair value of RSUs vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r47",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r77",
      "r151",
      "r172",
      "r173",
      "r174",
      "r191",
      "r192",
      "r193",
      "r196",
      "r204",
      "r206",
      "r217",
      "r253",
      "r334",
      "r401",
      "r402",
      "r403",
      "r429",
      "r430",
      "r458",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r516",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r217",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r5",
      "r6",
      "r77",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r77",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r77",
      "r84",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r5",
      "r6",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock in public offering, net of issuance costs of $4,435"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r5",
      "r6",
      "r77",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock in exchange for common stock warrant (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r5",
      "r6",
      "r77",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Retirement of common stock in exchange for common stock warrant"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r59",
      "r612",
      "r637",
      "r647",
      "r709"
     ],
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r184",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r334",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r484",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r484",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r484",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash items:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Supplier Concentration Risk"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r247",
      "r248",
      "r312",
      "r330",
      "r448",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r644",
      "r645",
      "r646",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r195",
      "r196",
      "r197",
      "r198",
      "r207",
      "r245",
      "r246",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r401",
      "r402",
      "r403",
      "r427",
      "r428",
      "r429",
      "r430",
      "r441",
      "r442",
      "r443",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r485",
      "r486",
      "r491",
      "r492",
      "r493",
      "r494",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r550",
      "r551",
      "r552",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r407",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increases recorded to income tax provision"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r504",
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r209",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r208",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(5)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r616": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r617": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r618": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r619": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r621": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r622": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r623": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r624": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r625": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782768-158439",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=122147696&loc=SL65671395-207642",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001274737-23-000019-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001274737-23-000019-xbrl.zip
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M\_Z_'W%'^[ =25O*^=F.I<D*EKUJ7J?9E9*CE.=(TF9[#+:W_^'T\!%W>%@
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M&3-71LRS8Y>S^ EB"IO,ZIX^V.'XMK(3Y:0*C(9 <>XI.U 1V!!NDD@G?'X
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M#%'AB<IML8]-'*4\4(Q)Q>/8%=*) NG%+$XWP37_J*A O8^.)[C$<^0,7+
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M4L^3+A"6L!F37N1SVU>, S^,'6ZGSX2ZVH<_@+&ESLM<'HTG57FAK8T-H:R
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M79?[+/!5G'H1 #4![NG&MA2;3Y6/#\BGF>N7 B5Z7JPBY3/79;'#79;8H:]
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M/JOW'A[]3)V,KKN@@<^\F?98Z.R\ 6JX"0V!Y?>$LN$H2= "0(VSI@'0JAP
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M!*PJC/R62!X763FM\UE+'<O>NB9R8]%AM$8(<3LT4<H3X$I0$O3=]R!I$6@
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M;IT<&7HF^DT@;Z[:;>@&S=?84)N>!NKP9^#/,ZL;KM?ERA(-ZC$*UD>ER-\
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M&(#OXCQS*J_"X<0E?GR>P17IG>BAQS@L'NDTGUDR2VF0<:/APHO9 @+=OAZ
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M3M4SV*<]>J"_F"1 W);V5J.>HUF-D3=+2$%11@W<.V6[U&WVJ7$CJQN=R*B
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MT?LF;0-B'Y454LZ0!EJG,>Z3"^T#0;?HC'R>K:RX*68_\&'V 0-J[66.C$D
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MXRO9&#V?7.<(MD$RX.G4J2"AS+MJGK@HJ;K#[#WK9#&WRS@K%&638O*7KK8
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MX_5!I*(9Y[LFRWA  8-<"S*03,*0J>XPUL1">(@VIT-$IAZ\2R9:1^:V,%2
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M/3.5<!TYXISS,ZM;/+]][.8PX*=3XY<VE>@GH>LH *@C&3EV>1OH[HS/)>U
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MKTMH/5"DF4V,<Y;"7+4.J6\@ACR!8$$,:=N:SC75U5W"\5+Q8\268?M6TR6
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M:<\=2N+G%#_)]&TJJ'OM9<?L.$LK\WC.UI;>+7(^D:;1JJ(H:XQ*Q$WF(^G
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MMBXQ1C.8[72?DG:0A[MVD+6M73*;H72! 7UU5<S)G:++\**LA<WW5I+Y3&4
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M47Y#!UQD5ZHUV<_<B(*UZ-6!X;[/@BP83O<F(%SD"QHUNA^YIF9DLC3 X98
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M2M:Q52Z'M--)]@93F%^7DXZF@C9E<YE7VJ"I921Y4N;7C[D?;!RBXUNTUJ3
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MH[E^\ A_>W9(\<KQXR?/3XZ.LA']05O\XY =IM"FC ',\IMLZ/D(SS33H:V
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M]MZ]N6TKV1;_*JR<EUT%:2SYD612]U;)LC/Q''OL8WLFY_[U*X@$)<0DP %
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MD[?8:+]U]8%3C[/?_;!%ZD.Z"1IY4->E'YMTX558;%]\]@<A?(966QTP5HZ
M +3X())KA<PSZ@JMJ+R:*;+/64*ZB*/$-W<UM[>NT5PQ7<.UT]?7.9(GDA;/
MHDU"!UQ[S/J# (^[/X3MQ)S3+?N9W3Q<Z(SDL24+(V.4278C-KZ2JX"'2>@
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M30EE C:J@3.-Q+"[(V<8\(YAY#6/T<8'YT<AQ)P:ZA"&@[<."'UA^<4;AN?
MUQ7,1O.FQITK](D5.>;8G!$1F9R*E(#D#*M]"6FT:1W<NW_HD-F=-&&,*G18
MLVP*6#49#AX[3I/7Z]5Z1S-*6C\%]"/&@0II%+B\D:80*/=%OUE?UTW>-.0H
MJY"PURE$6Z6J_$)]]S(X*-3<"^U5W_?F."F1X&DSEZKG_RIGF9-W)$GZ=D55
MU"AVU4S.@ZU9*1T?=Q!PBZEQR\!U5Q"5URC>3A/:YX5/WW (/T@4"T3*SEUC
M&]-Y,,ZMG?JNK5L"$'U2 8\=3DXE0"FWH""X$Z4JSG-65_#L# X4AGD![&O!
M'1>HD KPR^!@A[QOR$K&8U I2>(K"$0S'$5AEJF[CO00+17LX)^]Z"H-E>05
ML3SUM:\7YSV<O"D%4(>GKYN&4:B.HZ#2/I$PTZTH)&',T[%&M7I17[5CHQ[)
M7$CV<U&? ]2RKNAKSJ!7,U<Y2GE/\G-QK(72O)4:B-6USW)"FY]UVG^8<!-1
MOH$U+>45%WP6(9FOVMXT:0Q_XY4M0SLSRV5E990MDF[OY!&Q4H:/F=TL,3PJ
M'2RLP.W%9$[CNY5TJ;^_?*NOSH>F<D;6@CX7K54=$K,[(WK4?[REA?YN1>Y3
M=7ZP*.;='Q\_"W]!@K.LZ+C_X\'1-[^R%?_/?_OVV9/C7SU"3\?AZ,GADV?T
MXK0_+??/MBA,Q$HH\>>]+2Z%O]EW^\&_B\&_2=I<S](_Z%%JNV4_ 7<R 909
M0(YO7I34"[L?U[L9UVL9^,V:?T?_W _X70PXHUC;EL6L^=0,IS&(YC-MB)N:
M2Z<ALYSP$90'LKD";2")$-(NAD,GE8).VL)UYU$E.'CLWIN6Q/^2@-;"GP]J
M".EZ(C=SJ_=#3IMS?G826.MP9^\+\*WNXGR]LJ3P(\K2TI(](2+/&7S&4\,\
MG9P2,UP>Y0;'^N<D$W%ZPGBB7+I%N?74X6'2@(5P4L[W)$9]],!0IJX./NS9
MQD4LPHV2(!C:'AD@/8!+!FN'^:P@3WW2Y4S70?\1-ADE/P>,=W0+>EEJPZ-J
M["H\7B'J;I+ AGN-P5!D+,@0*"EJ2H\:YH=8\1/! 4<R\H.RQD[NZ@^E]AR'
ML35LI+U])CB1J)+P4P@'6!4CC*2.F=#X75!>3!? 2%^#W$8H@'UJU^B2"M6C
MLF_W.Y4P<9[HAR M](R6IW(3>SCYH;ZBE9 Y*:*6_B!5#]PIDD]:BZO)OA"E
M3L9=.(0NLB8%:)E^6*\H'2(-.:RKY/_T<+)>75!7C[X+*/U+L&919P-6\:(X
M]X.GF\?/AS'P8Z ]G4ZD>[HL?'*#$I%[>(N'MWR[A[<,F0O$7D=\*"U2;C4B
M@#3PVI0;=#:8LEDOBF4]#4?VP0*8,V'4Y;,^ O[#=B( ";9MEX/FP%0HHO"K
MWI:6- AR]*& $I^5!I8QZY%T&-":'\1K"38AW'.Y-%0-MUJZ4ZGA(UR5)+()
M>AT8U29=1-KRZWZEC#32U,DYM3K=D6Q.'!&P\IC=UDWJ4G(@HVK8?D);#R1Q
M_#3<U$GFC$>V;X)IDA$$HZ4"$#P#:*29"$$5:!=;//VA%%KT1-I\G@T53GWB
MU3HX)$S+J3U6K>;0IN'=:JH&[^0Y^79@;'5YQ:.1"TG2":]]!ZT_8+V?I1P\
M4\M0PZ^9Y.?GM.(Z!Y=*D>I>UR82VE"1GFN.\[*=RNE& ]ZN\\I:@I^O9^<A
M!#_E=G1'YWVTE<>[KGS=Y^BQ".ZM"P5#4Z$)2\0=1%0IE3YF73.$"R!72>ES
MKR^?(PW+%73&B;%-H@HJ/U:LF#X^-HHF!VE(71,AJ*;>B_Q3T2<=[7PE\6/^
M.8QP&,?WQ:(LYFZ,CL>9RQ,87#$;GRCCY+8)\VS?/$+"7LD>2610<-@%H&!C
MCE\*<.3H)HG%9&$(EI @^5#.NI3"LR_@2%<\NCF'.>.>A<3V%BY*6^;J-\'0
M9)-$J>!+S-U8GX3:O=ULLWQ9799-[4,8MA7OHR/VWM7-=M*XI9T]96N8#%8M
M5&(\5D6C5<2+)'/KAONC1FMLO&(3:?%@ZKEWT$CK1?* *_'(A&O7L$9YP79V
M^,4_PG%,&1?\@<M!9=W[<T)^?%$LZ0IAKX8O+NIS5F(^MR0\U57HK.1_G2WJ
MVJMZ=,*G35Y!F$(Z:3<K5F9'X988(23YTY-II>8+9D8BWG&B5;@,=K$6#A"\
M;&&U?SRVBU=4[:,S=8W!P"I9 YD&%I>(A)L9.&I9 Y,.^4U"Z+E@@0CR;XC@
M);HX\YPH-!+UNAX*YZJ(]'V(;>1:S)"PS,\EZ<49R!*'>V;CTOY7%HDQTKP/
MC[:2%T<R#TC">(YD6D5%W'63E#V7VE;U> )OJ13/X@)1$Q1F\JTQ>8CFXVH!
M=M6>KLFP;)Q7')%2H;=<YA*'!E>8>(/$!6#J?L%H1)=IC@;8@?R$D'FA:S=7
M=XV7^%4A!$K%Y(&(O\BEQ8-3ZQEOPA#U*Q"8D/5^:.<P@:7P29CANH/V@;'\
M\>UL&\IJQ6G)D(\K_;0 : S<]S:N/=X_OI@*!,H+$#EA@\SINH%T!;6SZ'K0
M,[WP)C6LUA:.+./@=]0])(I$5\,=$_W\W(G23-)/E.#E-C&U\'8Z7:^4_^)#
M/B^$M5.834_2.,M7?XFO9+4@K=66?Q;9WG"<F]Z 7X'),[EFLP21$.,K]C#
MFDVW,S_#;SC8T8,SD@0CG,E%':P)>(I7Z%3L)&BB]UB6_^ S8..N((N!6$8A
MV%5./R';+'S7*^(+;G*A5"<NLN)V:^/7SQ=#'>(T!Q!G%U?O"<('35@2"<JC
M[R(6[(K2?Y2HZNJ.S^;C1T_B*OKCY.C;;Y&6.T"CAWV M?,4]JGWB?!MF*S+
MTV/&YY@'$K=2-OF6"5/: LELMJO&SYM-GN&WP5H5JG,5EJ/U\7W]C#X5F(G$
M90DCP7PMM0O*-"\T%G7OT+!F^+;$>#:IA!<VJG@U!:5$.#D) 1J\&8$?N3G0
M=%$VDPC&I2 RK "A/0/VCJ4U?HPLN9%M)IKL^*@L@7D>-MU.FDA@$A4MR/#K
M#F00H*);AJ/H,H_]EX41P(69I6.QPV$C>8BP>"YI,RF01Y&],X+*,?#K[6 :
MTU84KD6C'! ^*I<>_5E1WVS9,8P'J[35]"J!6Z^8M,"[(-8-GDX)Q9/G37TE
M*P]MA]*A3*:X:(3J@T':R$HOP@SR+I-ECN&)XQ&5:6 _Z= .!AA2+ #)DKD$
M1ID.GQ6:G#F[PGV9JW*%SA5VT3@M9.<OW3D,W7-A91<<H[Z.X_'#0U3G.2,:
M82*4?Q]ZICWTG'\0SXJ6['.@1>7ILDA Y14\B)?A@/P7A@S"Q9$=J\(*Y/12
M#@GS+XN!+^2\L=[CR3K,Y)7< B19C)+#5( F03@=K1C6&(OC22S>0)-Z[/>,
MMN1\!+E<.FF6]XFDQN2&%IV24RP)X!:Y,87ZI=72$P^D>XJB8LTXOQ#_:W)9
M&_=U< 6:G341!(6D,:GJ2^&(E$'+@.P_F#700C>&IB7RRBS,#LYJ$?6Y"%:Y
MI2@("PF+O-1P2*?$;V#F QWNWN"%Z-8'-W:[4D($\"$:$3BS^H48[&QM&;LS
M%JH)&V(Q($+E[D\&W^[D7-#:9EFK*3LN3MZJAE,;QL7.<.Z/<*J/@N[?B/7"
MQD@MV<#FTYX^%X<.$Z&MZ,Y4)2X$. LJ0G M*-')\F1Z@I,!!ZRT8 FLX!&+
M8^YWO&Y3<ASX:4!>RXQ?J2<S*QN0\\<P!9QDK![6U=-/@G%/=^P5*$!Y\V\,
MYD<0!_FZQ&<X&<[JBL(H_ 8UQ[I!7<:13.).;.1DKVA<I\9.T^FLFTU.AAOG
M@<<@MS?\=-%JQ;M4&ZDH['QZ419BW.,*@(/"?%!+X>RQ]"-O-V_.--L293?[
M]DR/])Z9'7QM7]QTQ<W'C_;%S8$%,Q*O/'C6"VPP:M5TXGF1YPFY:X*W1Z]@
M61@MA17PA'B6O4;A2B.'JQT$#M@69'.<0$;!3@(EQOC+<F@KQ1308)T&P_0-
MT;A([3 Z)^!6)@RZ['JQB9%(A? W%+V5E)(7=S*+AL[Y*?&Y=_$LXA (\B%<
M#"FGX>&) IK23N:?!K_GDM3'@S=/>:9.*A::8%/_FDQS.\^MTXIYRO.EA(^?
M"N]-Y;,90$&B1J0RYF*DPCG"'K&2@3*D+0IH4/**%2WRKN]=:%#'MA8LLV@$
MT1Z'\/1T3H;(^C=+:VQE81Q/="02R& .)]/]P@Y.T$Y_)IEWLOPLY=/L9$6$
M9C,"ACB[[-5*J#FD8'&9PGD&')SI"];R@K3(7GZF>L-MNRC"NW8B4R]'$SD"
M!Y0KR%=M\4?]C^\H&;O(-W\L*[P#?O2=7$O.LQ'Z AQ;_'&T[8>/V+YW3?C_
M,[VS?'R(C_[0S8:?/3XZ?/KH>.O'CPZ/MGYVW66?/3L\_O:;6UWV#WAD?NPP
M,C3"_^>KQU_%8P\0WC\>KSY/CA3([ _M ;L#1N;72A%BU&^]1V0L[NEKOA//
M*GF=&Z:/>LC. 64YD(<+?FZPT-_)IH#M6W43H DF].3?73,4A./^=0;B]@RV
M86CX$6>D0 KS^4<@LIABY&>MAG]BU![1F-UR;PUO,\?_^](I"(_S:]EW+,0_
MUQ=T1 5WH/Q9@WD_WO*=(O.RR>D%85D&2PGF1HW/G>S*'1^2_\Z7Q!(PRZ]^
MWL3?C[?DV?[>!"?\;)_6#?$S!/__0S%MP%[PSTW\_=@+;_+@7_^0_Z,@AK7B
M7WC3\]P_US2[3/W8%/<R)D=/V?'\>3LA.37NXAKW=QW>V<EO7N%=+-=_;G#O
MA]W[&"S>Y"_U99Y-WET<OCC\%S;Q_FQ__>ID\M</V>1O19-/-P1^>U5-#W\/
M5OUY0PS&S\OFT[^P17^35\PV\2YONHJP@:?UP?<U#$4V^;"N)F\(.D9YO#[(
MY%]XKY^$K?Y#77_JG6W_6B_YH:B(U/AOU-XX\.8=YY2<\AGEF:;=Y,.T9/$S
M=?;^Z9C[?NR4'XMJMIE0<-?V7OA?ZSW'?;QL\KZHBCH<?7FSS*?%NA/4\S]_
M&MR/W?+RK #K\KL0U^?HY?JUO8!?-*=VP^GP!NB]C&CIB.6TUL-@@F\(4N?U
MZ]/?@R%XWA!8^GT=!J1K"3SR\Q?"_7AA6P4:,V23'PY?'?Y)%\$=S/S]L '?
M-WGU:?*A"X[!/Y4GW?V-OR7)$[R#O.T61?"*ZU;\@-]/0/#GG& 5KP]?'TX^
MKA>+\DY"YQU]U].+O"3DT(2%QB4>X-?6/H%7U671#E((F/P_H%JX8UCY%\#F
ME=+L\*H2QJY=K!&CYZ,YSRLA]HGPYE9[J>NF4]S)+'FQ4E^,P>T1'A=!OWT<
MM**S\LN\7* XS-#H<0"6-J5B44"+6B]I0$CHQQ F8=NC:8]^:R!* ;+H\R@%
M)?6!1[S?I ;:=UU%Z)A[*Q9Y8>C8+L[J];T03[\Y?/8?PRX!XS(&K<F\6.:$
M@7S\]>&W_]'[C#[!D#P^?'KCA;@CCOKJ"NJ+%2VT8C$_T.'NL[ ^/3Y\<N-E
M?[PH*4=T?'SXS7_0OW\H:7A96OLUX03K;'+T^/ Q/CQIRSSX3X\/'^&?SQ<Y
MM^&<S-$N?:!]T^%Z=&N"1%S5Z.N!GGI.4>@#ZI4;WN5A-GE$PQE^\Q?NQO@A
MO\I+:%)I.^"[G(7?7K6+G.T;#9[^S)JV7U4S^=G)(F\_Y7+!P\D3FH)_?IAW
MLJ\HZ3S.)A]JX^5AN5>8GC>$4=I-D UW%3[B)EJ:7(@PY-"2(HTIF;7T+=OX
MEN?Q+1^\_/ G4JWGE]6&Q2-<NBD6W&-/5U.-J0_KEBRK=@&\!V%\VNC(W2#4
MRCFYU4B?BOWEIXG_?!@AAH)2#F9^;;;1E#'Y2=#Z3.\?CP#0/L=^#VW"R_HD
MR01IFQ8I%2P]"6/7&**6/!DPCFA]7:+/,B<6!](X-ID^7!C(:46\V^/DAG.G
MA[+D%-<8MU2;N44I=D<IJ\LZV##W6#+SSVMJ2B9KK'40UC*#9?&LQ=R^K..#
M5XZG3!@FS#\A+_D1KJZN#@O@L0[#N_RA5!=I-W?YAS7!Z@E&MHM[&%U=1+9<
M$92D0*O/PCC]P>C0E'"2^2-9X-Q\GP&FOS)6=#;$UIYMO<-KUH@RK+HJ$?(7
M@"<OA8=[+QYTBTD;=*.P#XEV*V;HX<:CNF+)PY:;'_?C^S/'EX7G$0W 7GVB
M1@;T2].>.>"VFKAU#L,!LU2B'&(<9X'PIC#]C%H^B;L-(J+:KK^3=BPF*CQ,
M>-_&X=LXCO9M'&,GS!();&X\2HGR@Y."YFS7G 9>2>I=77CEJ[8XYW;JN RW
M>Q"^+15]PGPSY59)F?%92:#HF!!83SWFEF1QE;[,T#&N1OXIGWK4?U!S9P??
M*PE!A[\B0?M(@RJ&.;X7&M.M#^15^._)-\8R<P+/3OW=G304$:#F#,6.^CX@
M'H64!C_RS%$I@CA&Z&J8)RG\@RS%F^)S.:U9F^K1<>9^4N7![G.K@"_=2ESR
MZ#''):)$CK9GO6Y\!N.W=[<*!\:+8#>OT B["6Y_<VXL-])Z6>M]7YC4C:2-
MLX1%3EGBDL? <U]S"7I^%1ACA;_K+X#?O$6LHPV>_;:*E)HAN(%'Q\^.)J]+
MJOAL)C_FFVSRMS(,#Z7#%V581U693[X]?O3-$5^Y"U'ABKJ$E30G;(X'7S][
M]'#R]-FC@Z.GC^1[5\59.$8*UPC4BQ\XKO+&!(1%)?,!@_F(R2)+Y.RX=Y3;
MW?7:4&'NA,EG+MR,_+=D;9UM.(A!ES/-63:VJ6/.EWJ/(&]3=^:E4T\H](3\
M$Y?<40US=G51,.V5<P:EH72)I& ]_;2;AN/$,J.[;SCF97C,9-[ 3/ ]Q3='
MCP[^.YO\CXEZC7S^/YDI;?<__>;@OUTPY6?9TA ?F"Q!,P<O/_-6Y @<W?:3
M!Q]>GC[D'1 >E8@.W<]?GC*AAHWWO.&HG96.E8TJ?,\8C&T;==@^;3$]/*\O
M^4'YVU_9LOW*ZZ#Y?4+2ES6M8<IQY$3X=;;8:.*#^^:@NQZ,"WJXF[IBGC8>
M;BQ[XQ^DU\'N%.UVHF7F'84G'UGBY>S_?%4^G3_]]NFCV=?T/T\>S?-OOC[*
MBZ/\V=>SI]^0>?G_CIY]=?UJ.Q[MSOE5=PJ<@J.3P\G[LOTT^9X)R7:ORW!;
MVO!2PBMQ?;QE"G^[K!>7Z/J]"#\*=NU<%F<3WO5P\O_JM9I%Z\ D+A;F%8?,
M5OB>RA4JFVX)G<EVVH3SQ92RN_J<326?HTP?A$[3P=;SWMK09/=V?NI:SLVQ
M:Z-CQXE!;ALF]6[^RU<1Z6$;[T793M>\IR&]"G'"$HY)=!E/ZXJK"/C.^ZC,
M\#9ZPE^%UYY3YHTI-U@3BV:"E6^5D",Y-HB7A3IN+PB-XY@)XD$R>36?1*)#
MUW,ILP ZI; P_D&<-IX_)G,#,]7'SZ[1U JQN##1&WVAV@))=/9%NHBC]Y6(
MEX*Q3-0%FIRY_YMR6HR]E-Q J@E\G&_"LN,_+XCTD8_Z1A?-AE/3.IK238P1
MZ*TZTZS%.JMPIA<Q4T;4K/-\J@0ZD>"5+P86*K^FZ4J?JOH*\[;&%_12L=EU
M5@1K42[-<AK_*[%%E\V0UD?(.FS$=]-=^+ .KT3LK,X&[J*WH&M!B2-'ET0(
M>>5U9"=%SSGY;2[ZJ.''XOW[71RLT[I58NK!2N,U%)8&K;#4DIH!]5WM;?K<
M?8/9]=]+Q*&Z"[.2<D[=8_&Y;XZ/G_WVJD7H[/FQ4 [F,+1,LS='TH+2&>0R
M?5X)5658.2ZG41B?A.QK(4TC,R DJ Q'J(5HCSATUA2DE2QB%TPG)RV508:)
M%LI*&;'GQ+6&\M<]%@3;H9E^A61/,SL0XE](Z4QF-4>90AH,%D*E.\MGQ=_7
MG$?SM/^JA=FO%V1\4!2;">4AIQ<X=Z=E->/"_ZR<;Y3F+KP ^><X6GH"IEJ]
MK$6_/5(D77O?<DZK3_6%N25"T^.Z$(4,B6U2)+K%2,1GRNSH%E5=Y5 R#P&U
MI3H$1?=:A'&7EJ80%1=Y R:_Q/(H24KT[-2=@P8 ,_C1R19&O)2B(X@_C<6E
MOUS$5.'G1-1SDY$2LGPZNL88V\#EZ-V=_:*XHY.)#I,SOX-=SI]&G22YHKY3
M*JX+7 )$E6@^B34<=,N4+TQU]2:@?2W.]\?,G4S;VW'CZ6G/.T];JD<^ZC&.
MBI4I>Y$E71E><FP_B_Q&<U&L0S ")G](24<5\Y%CSW)AYL8H03D].Z$4-]_=
M%EJQ7P\W;.-KL"!MK&G?&@#BD0=;C?N('SI?(S\"%O2EZK6C",]9#O)%%Q"=
M1T7!'G1O%^[(_;PJ!@X94P#/BB4R!.*^*2WQ8*=#='VCAD "C[%OH;0?&83-
MU//10$=\T6R?UM\ERN#X?J ,]IOL2S<9,ZT62?23J8E,O"OCDZ4=Q%!8$>5E
M/QA%2P[6]_'YG<_=B]@.06J* [/F:A@+=&!LC#AW47S6MHOK#L#HEA';/@1H
M2((A',[0<.*J-"CU,U4YZC^$K*[8NK&?^SO:MP!ND(,T)G8VSZ<,!#\CH#65
MG:"IA,Q*6:&F 8)MF1[1;4%@>YE/54G<N+/M<E#)[=D+UA'8\@.G): 1=&)"
M%(WK?3.BQ61LAES6CF/]/;6F[W,I=QHVRQ)(A+A=Y4=I@R'^QYT*2)PM\HH@
M*A[KQD&U-R>QUXS+0Y5&:?@;E*3,D@A:(/Q"!(#J,R97C\\2U5(AA,SK:^RJ
MB8%B5X[5$M:MB8IFK)*8B? B_:*@OU2Z"11]Z_1B7/.$-Y%<I%7:7VL^BF.S
M7[!W68'P[5<.D!%\3=@*\46@\6'""O4"!,Y);E#!G=QB2 N'N[<TCS@KV^F"
MU:3D&E8*GH8U0S5I ?!9;FD;^#(3);I*D"FQ@E586=ZBE=&*/:ZKL0_JR-#D
MI+^TY>?),CS@A2)&H37^^!'?6HK045Q3CGQM3O,;;#"815S.D"2D[<GI-2F_
MY%5,K$W:#8DE,Y[PMH,/F6:I'MP\X-[(1(D_>^RB:>K&5L#H0%("/Z>.$#8%
M]D)$UXY=SW*I[@'/%J+NOM_&=[6-E8[=SG=HW5P4^27EY:-VITFW$K:LIZU(
MP,NB(09W$;X=$;ADJ(+TLB4.1=FB;%"9,A/YMP=4?EXOT4F-LE:UL0/I;!-6
MC%9\*EIYN2ZGF,.T<I)$4ZAHT^D3UZH_9L/]\P4!*?8+ZV[K -ZME7IB,OO6
M[$C)WPUKC692M_:I95XB; 3IOQOP86A96U1""=)_+NJBC=-71H\ L&9[\W&'
MLTQXEN]?G&"JPX$!J;NH9T<]$&W+\M9ZCJ/IC)NY$&JX@H!L\AC#MGH\FH)E
MV/NO7WQL4R^!+PY$:.^*32P0A$L@FG$JGAT>_O2$.3?"6SASM5\>OU1BR[P5
M<DN@ETC@2=*,!]H_:KI81=\4AS0_ZT2+.02E&=Q/V)U-F/IA<FK:?G;>E];?
M3-RRE=87ZRD1&>TMT]S0@YB@?=G,<%R7?1?7V?E@7IKU*FE4MR/$M#0ORI73
MT^1' %S-E*X!V=1GDZ=@!<LFTKQT_3OL)NKQ/4!\[Z/D$ 7MSSUZ\X,4R7^K
M?O.M</#Q%[H/L+;;M>3^!FTH'(Y7*,/-_-"TI2:*Z#]6W(7V_37-C2E3CNM5
MO!J_09BD?W_R]>&327B=A2+/__WXV>&W^A> RE81\B'STY]/%_W&:0VW?BR=
M;3J]>&AHV=]"ZQ@9J?52HIA90;..^/[?CY\^/7RJCW@X>7NIK7OA0)BT!32F
M^%Z]U>=%P()C47=)QHY YU%_.':S^EI-/JM7TA:32:C4 ^ME6V 3U<QK>F^I
MIH($(!K/F:SG3?+DWK@6_%R\C\B)NJP7ZV7TJX4$BPAII>Y_^O9OKUX<''T[
MH;QSL2RGN.<OL^-ZR<B;?](S!U-!-H-\@E CC%+9COK'" /R_YMM]R\TG7N<
MZ"^ $]U-6__!7G0D\;T-;B5(KHS5V:FSCX8QTXX]J0X8;]&M5HHY;\FB\TU/
M,0"W#Q&GY>WD#0(S.:OY'^5,:Z,QA[,QJB"EBDF!G-+A8A%B\OLPJ-F$%NOP
M,;E)EK+&L4<6+ZUL>'1];A+*ET3)3JA$5+YL$+!D<Y. UQ*%B;B&TP)\9];2
MQ(L\&<1K5MCO$L_R^'[@67[5_?X^V75GFS%#SUD28*J!$)!&^+"3K6,G[DJL
M</J==19J+H5M"#85)V!$.1X697I1 :?)_?I_W ,M[R+BIN.9'3%)4]9-FJG,
M%WM(ZYV,M&0"X1S0^9DW>[#PW8QL</_#X=8UFH98%#G^5W2,9PKJ#G:D Q!F
M/^YW,N[YBO)I#=Q<K42;UR%COA_J.QGJ:=V&B^274B7'/ZW6OA_C.QECP94S
M.<ZJ*)H#9D\M9E;%^2EX(N%$;)'QWX_Z78RZI[,P$./Y.L1&]/M;,A#^ZG3#
M(X4E37*,>,>H"+CT4T%?E.8D\)KJ>Z\[ 4P2!6.(AV82#FM(G7$&1+-<_;P*
M<A7TH7X 5%LQ<U^0^@@%DGV.B@2UK:A+C<DUP2%$%IHIS>392^+UE8+[@M(9
MB_(379GJ&"023*!A2NNM*WPZ,D94>\]31 2!;CBEH+$WI\S *M" 022+F8(D
MAFA'DIH+BM%;"=$M) 87O?+*)G!G3<T(B99-.8V\)7V(_D@K@Y?%%S]--@YM
M]6PB0R:17=P1'Z_IEIL0N(PIHHCJ0P$_%M%M7*4>*75"LJO)Y3A0F/\-$*P+
M//SW'Y0:1B!TRMG"R4!_95J,>!ZI]1D[A?N.MC>T? QL:0*\@"(&TD?R).##
MF+#TA^!*JTU<#L@NTNZ:"P$Q_8_LB;J)H+;>YAJYO999&B8BY[=4N*G4!@AD
M![M2D\F 49'T'(_C@E0:8%C<BRC@6D=E&6X 7"/NR /+9II!LC/-G4[(\=8I
MTN?R-U7?<!:Y_!R::Q=7\TN#,9X$B[.8'#^EJL[1<49Z8,NB"^/\I^<GG)ZS
M1.*;>O'B,TEF$2H8;)_E.6-(BSW7\:VXCM]\_%\:-IP$PD]L^-YF%)IK!P/3
MSR-=2@V83.%F4V/[D"P]6=:DCY!*\E0.6_I=0H8B7T'X+C)2"5\5+6AM%-95
MK2PX[T\H Q;6R$7=-<7GL#6X?J3MB?9,)[/P'B7"5EIHIU(AH,K;7^JFG$$K
MXX(H:*E6AQ<NV_@F*&5L$GN!YRYZ2]?JD:=O/C!< K&Q"<Q0LBZ8VW>O3\*U
M9X7500"$"=OOC,T,G(_]*K[-*GZ]7A'SD4XB^RPR?3;,8>W^^U'VZ)NG!$S%
M\ :[6SM0&?V*UMI9L:FY "YS:*H)Y-<U==M>Y0NLROWLW'IV)@\>/3XZ_NM#
MV@E_(W;'?/+@FZ,GWSYZB$X1G&@HT7_SY-'ALV2.:!9U;JY(H2?X>."4TU(6
M\ *GK[__H-RK<4>B8J7DM;PQ'RN-ZZ!/X.GAY,3NE";(A="UW51UM5D2[)D)
MN+:XGX>3'SASD$O)N<_<18^=& #"0<))FJX7.;]Z,)-"\B8^K]UK4&6=*_5;
MO":]N%D^;<CFNE??Q2'*>I0)<VVC<;D\H;_/B;=VXZBV[=IJU,/D[??#K?<#
M\"4A]A+1KUQT7("=IKD/$V#F;([\D\[]?("JY0TFT9ZQ4<L1<QI60S@/J\F'
M(IQI6.['7SO$3#!N17G)3)2T4K&,[-9T&A*#H# ]RTEO/F;XQNO3%Z(,@_#Y
M</+713C7PTI'*P%=F_?!/+^LT?V(7Y1MY#(TJ$JX1K\/0+$T !7&=@'MFEL&
M#[E<A6O^W?AV\52@Y^1>DM@-4)!CH+ I8L&+()G\G)Z#_C81Z(!"9O"WZ44(
M#(OJO"?/TR];A\@\+Y?:X1LE@#B^-Y BXJN=#"G?CMN'EDEZ./ ANDGUSA"!
M@5;<*NK44'6V($;>7!PF]GVT@CX&53B</"\8JH/\]B61ARQ#K$(+HB5+W7&)
MDP?Y3.OYT@QM=\39W=1Y3+[0,LM[:TJR$6T'\F',E&0W&#U.=G(LH711\\(A
M>[PINGA;[-Z>D^A=8@&6#E\ZB3L5?#: 0K  %&W/ZB"]"X7W6%2"M*,[[2WP
M%UA@/;*Y0A[,WG[T;N_/F7."WKV$F4DCON3<$M=,*4:1UTB*WII9\K7QW<Q5
M_'A!A.3C8,W&8::0S_+(C#'H%$&9&+,7.7MA:"*HCI/9KC$J^)27AG1KXZ$F
M&,A53J$C$+>4W93$<)GVH298T$6^$:!I08!X<I;10VKX>_DQ#O05?+T(XQL'
MA2F.E-GI]0JEZPP6ZTM([UD]76/&1<\%IWLDRQ9*;BCAI>QQ?&SX-#J=V8LU
M-1]TX@5+3RFS'H3_VLU%]2K)=D=H(Z?_H/$:%IHQ/8P>!XJ<W.+GRUE"4,D\
MS9W'"S!]HITO/,H"T;=&7\F02YPU$27:A$4Z=M\?3EZ&F:''VG:VQH6?(NW&
MP:& $SH0%.V.69-?.5/3(=JA<S]3/4I&-?Y$7@46LH2;21B5F5\YK0_2]6VY
M)TI]A^5!#Z!YJ7%#L%"^Y$RYL*00)!VIS'H0%^X>%YCB I_\/G&!7PH"_]=B
M9-U-TWS2([S\*43'L4K,C4OP?/2U*6H^*PH*E!K$UCH.&-\DA-][FS=XFZ<?
M7_373N9TK"Q<"NMWD:^KZ057S*AV9-P;M#TF@^W1[^II2CGETOE-UK+MC_WD
MW7+R3.$^3,IEL#-"&7'.PTABPGDSO?!"\\AH]@/;+3QG7CJC)K;(+-@2'/%T
MBH?W/"-_BM*OZP;L2?H#K?N/<ZZ-FZS=M$[4D=\CYAP,$X/%(VN@PEG\!HB=
M:EUBTU!JYL:'&,FP@E,_B2&.UZHN68Z"/+#8T3\%5H=BG<FB#C%!TQMT1QDZ
M> %-D8\\ 4=C5Q("^18XW;E"03UJA(=GW'@7J?(LHJ8D%\1 2C.:.>9Z4T:;
M'$Z^7S?L!5YA00+]78%DA_$"/ &S03_.Z#" QL@21'\G63^!>72>A8O26RW4
M>0:8*9OE&TYZ89?[@DZQI!MK:W>.[_@<N<SU>"C?!J@3DG8!7FE/%ZO;$/^=
M=N?<V *8"/_\5OG9+^^?_G7)UW?3!OJ2O/2NJGO:3O->LF::K_)I6"R99R>6
MD2)BO3;12"*H@G?_PGU@6MH59;)44A8(!-/OZK?>Z+,HZ1<%FM-F3?1W85BE
M D)YD7,XTFZ+%,O5HMX4 O;QUY)9]BI10TX$/7"U@3+KB4Z[1$&$:"4FG4%X
M(%I+&XB;?"7=>WYT>!AY9/,4;I%D!5C!M\G#IY2K:6P9MQ@0VK<<B],0,E>8
MX[NT@";S/D.F="YU$T8XC,^:.J'6#0I)O/LU_\_&CQ9"G,#8,JHE6D]2D<!-
MR3E(?DR&D1 (;U-[Y79BDAS14<J)[X9PH2V1GC,W'1205^NS!?H(@Q6K:,]R
M&R(G)]9MWW?54FTB?TRC$R,_KG3I C6"M\RK+(,_KL_YQG)F.,GY0-#F=L_R
M)%@>'1N]DJ_RL2%V/=U:DTN!0*5CNQ5PC<242Z*\;,1PC2)I?<YIG(@F*E%7
MY[4NAM0")+:R['1=1@O)<WVCH1RRJ/8X;.Y+G_D-0A'KU?V1BMC-PXL&>$1^
MH^?[]!@HS+N201V/C+@<(;@SMM8\^O2/L%;S.54"=,63,2"9]$5A15+_H=)U
M]6YE(17B+_.=45'W'O)P]K?,\EB5Q.=?MTSMFUNO+J]Q<FW?[+[C]4X:3E"3
M"N:#<2;$S1).V23(L<0DB62GZX&/(YG^/4G;G<U'W17"-DWC&V=G=AE,M:9G
M1K</.!.\ HM^LI^=NYJ=V%_KVG&$LYU-)]EG[6$:ZUL:I WTRVT73)M4^GSS
M!L+"S,PWZ>^48*3GU2+=-OH#Y%**O*%00B^Y;XJ\L_DOR3NGN9/I5Z$).=95
M*B2!E/D9W^_$.[.3XN3 &4(I?I&/J5#M1_XN1Y[C7S)IP>T- 605.4F&(E)"
M&#K@3&N*',+(^SFYL]WP<TBC1GOZME!&Y>ON@HIO>U+N.YHT+1/2/KHL*D[=
M(:^"2M \2=+5U9Y7]RYWB\7.2/^(<\:IQQBY ]7%S:0[B0D?R09+%4CR9D;.
MA_H;H<$5D)7;Z6FE-WYG)-846B8J1#Y!2C!0X9[<FC,:+PB[>ML>8G';*OW@
M4 5(MP7,4RL(9V6-J6C:'IZ-IY$V/255&,87K P1Z!EFDQW57D8>E0CT:^ 0
M6:">R>R?K^9Z#UHS\=8J+;*?UB]!SL3JC4T+C:[!:;GVXDH[X0EE]TDB52=H
MCU#T",6GOT^$XK6+3O/8]Q,A-?GU=REM4I3\KBYJ4@:,;G'.(&&KBHFG3<0;
M;*Q+[E;3S2FXB6P2MGBY$'4,E.U:'+<,AB)8_:RDZM.;NBGHMSC5Q_/DW)<0
M41?1Q0>Z!?YC/)B'N=ML<E&W$+ ;+]FXIOX$=W,+2&D^*'E8,Q\C=Z90K"8X
MR=+#1!9"#N#X.VB4-=$UJ"M(W7WPZ+$1%D=4>.!P^>TYTT3JSY7$8CG5GIZP
M_JB$&Y[FOE0*?QR<)&!#LFJ63F%8;_TDOZ##:.J,P&A;O!]Y@:)LA)/1I;"_
M2"I/-Z#C=K,J."H1_,7OQII7MHF8X_W6>PU]O=A(?OM\=)CO2(O##Y(-X.$)
M_[SLM$&)YZQFT.;-&TE[]SE#%*5)KF>/R\(%BE8;C "7BSN]FA?4W%YX2$P;
M%B[UX2^+O!(VZN)S3H"%S!JI:HHTM/.8'MAZJN%PS<-<K;G/;5(1OT2+P66J
MQO[3"(W!\>3D]/WDA/N73^W),OSYE$+XYAP;BZ4%?Y2Q!E9I@,>_:6GH4-9A
MZ=55^+]")HA.G+.-BU:AWLE 7KH3@:309U5/6594?D87USKM^)2.XVH=GOLL
MG,=TUB@\UXA;DS>;<XPG;]A#++'LA:N<JY*IUP[X)]C.L7-@V**FP]C1Y\ ]
M(Q<I/A>-#$+1 @Y*C6\CI<]1XBNSD<$X545W53>?1C2@77QV'?/<3J8=WO>&
M@@]0;E*)7(7:''VV,7HK,(*M^@>T4 :5L 2U_J>EB'EQU.' KX$X(\=FW=4E
M.0&R1NR?!XW([\S"P9.C?=$@ILD51E- "<E1LSYOF?B,0(OT,.RVZ97##B#*
M/:'V8GC-QI%Z&9N9NS&B)U"0W ^G@=!E= 4='<GX;)>'B&WX:+'Q??A(,X0-
MQ>P$F2>6:)=$X0"6E I-("VS5.SFX0\/59[0!D9H+;JZ8XUH,ASP#/HCIL17
MJ.Q;G7^+< Q<#*:<ZN%AK%&W[P+;DREQG3"*9I@ LOLPC[DRZA7NHG9 ,'_.
MK3>9[3%JY5A"?(&I"3O7#$33 U[",0V=1$@D?C7NQW9B*"6ILVY=::[K0$\L
MD3]<+U>1?Q*6)^]RIF5A =4ZF5H&:%$G PO#=TJ/F%PG?M]U)DSK,,M.?<(Q
M; HEC][.7ZYN>E?C_NRT9Q;M,W2FT<%N^@$->4P,Y740'GYB]X("HX)84RZ
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MH-?3.+_!3(F-YG^4(K_G^S_E=XX=)U+  5:B+@67,<HY.) Z>V@O#@^3PZQ
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MK"2U "BZ[-WXU*0.O#9&8:[6EM5/:Z9]88NX6G<F>N#KN>U:8&>>)6I89?O
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M&"'FB-1D1E3'"@,J]R+:ZFVO[=-1DL202(&)A42S9!KF.&8VZ(0KP^] X.Q
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M%=$FAO.<,)TCB5]_=_I0>CFYJ0#@9M?TXTH9&C)C<P2??R_[0>C[#[O*02?
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M9UC_RW9K2S2LBDS/3MV3DDDNIHQ5>'^_FJE+1K2']T("1W^"&XP1FCRV<V@
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M$H4*Q>O)=>3,]>G[DY0IO/?-1R$NQ'UUK2V.!IEP8,N,6MC>#4EQ';.LH)T
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MU@;_E#.S&J.RVQ_IO%19,NBVKWTP5R132%9%%6*.1J#T7GL'])M6KZ8*,BA
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M<M>ZA=L3QK+DNK%5Q\E*W&]%"<1-5H5&QEU4)CQ#7>4"Y"(5;]Q368Y!XCK
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MW VCJ"#DLO.#I 4N"3(A8R((O572OWKJ&L)+4/P2J:0FP3P^R*@!\L")L<V
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MYV%V[CG']GC]!,?KQ.V?GK;'JSU>WV5"3_KN\6#T]#%.UKTM *DD;[8%8$J
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M:9K<PG RIX##G-)/*W9/$]?R?>S\ 4XVV?Z]+IW/+AVP:1C1+4N#:PE9TR+
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M[CQ+N2=9$("3!P=L*/X>_/%(_<2#PT/&%CTX)#M7$BZ9'"YU[T%XG'%4Z$-
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M%GL1M _9IEG"PXS"SS@5"L)[6"HY]6Y I1%0#!]0"<]:RB3X C< XX-Q*;5
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MD#%C62;'&Y="+[ 27LBO2W=]4MJ0NN2/QDNUK3=ED[(3)"^"9XR75L2%A)R
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M<D=7;(( )@S;FH/E2,>OQLV'M>&XN3[4E1>5=\[=(O*RO2.!)[\<?QF;*%)
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M.:Y=LO.39.<(.DNR<_%)S%IFY]>D&"L?DNSN/'5RW/!)+OIDF;@EF?BI,G$
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M-I'$Q!;8%L7W-+SX-\VS542S5,RK=0&]?Q4(U<[3A/ASEH5W<9)(>T%8'MZ
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MD,2+=(O*X=]F>9[=P4*+BZ;\C<T:R%(9 !>6P7_*TMOO-)^\H_Z\I< *.6G
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M8?SS\D_P3W/'A.2W<<K5-7W1^ @HZ+-YS_HU>\P;S#^,@\<U;ATU[N]CJI
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MKR\,\+,_?X/+<U3-%V8T"<1BYA&;. 63K>),@HF,*6B&S'4+^%143!U>L"N
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M%E ,;2B!_E2#Q2T:KHL(=U3%-ZDEW62;+^.XM&UHXD1KD?_*\MWRYW4F/\0
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M(7&*M8P@#ZH<*UY#4E*EFH(8(P$\@/L">?5L3JDR@86-"R4#DF=])S+%ITJ
M9TB7SA!;D18EJW@D)2P1B];OQG$P;A=D%TI$XER!^RKZ!)J+=^QPE+!3V&A.
MTEN*1]R<:Q2G),7D>CC^HHS+BATB^Y(?05PV=]/[F-<5^R3]@3^YVQ4@.HZG
M<#7-J?^ M<ST'F '[V'E\EAK&A=%!6^A")P@RZ?(@ $6.0WAZ0')0^#$K9I4
MA=P" %F_A<QGM?:$5=W'48RUI_B450"L;152'XJICQQDX*M.XUF!Z'\L\H!:
MZJOS6X@/ KXJU]^R4EJT.<2_QQ/ L<_T3OF:34CZ;-@S0?'APETZH=:_XWPN
MX&[IA9]3\N."1+#:-R2Y(P_%X)=%' 8$7CK$Y?WS75[^R<_AUHX7+\&'\>#8
M5PT[LE42V<0T7<,BGNH8H4EM5_==,W"X0@KWT/ *54"+PF4D,*GN85C*<W6#
MNM1W?5TS?!<#0()07D@9QG J*L=QL8;*@*P"K'.&DX=O&F+Q28*T4BB@I^39
M'=!!EM8- =H4H[SZXQ;:/+%<K(J(-#/P3(NJGAZ!9'7\R*:4J,3XQ\=.B]Y:
M5>(;<8/29J:"VW.QJ@TNU='J2#<%3C=AFP:&N]7*33W4=3WRW- U5>I[ :P^
MM$-J>[Y*_)"M?-7\>'+EFU@6K6WIN*UUP<79WLJG>WRTNZ&\'BG+7#I(2%$
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MN>!#+KTDZCA/YIH4'G2SC+9NR!^3 M<J"I(OS+0EN!T4.7P_?)-X*J@P@1C
M\L7Z4WQBQ]X7SVIV"D7S5MCM-D= MCT ]OZTV1#[?-V>\%E5.CL'IA/6>LSL
MP^$CMS,FDM=JV9.08V6*G0N>UY4U*M5,/7WRJ6V!O?+@VQ;YX1DWAL),A:#A
MKW,WR'!)0,V]%%Q^/5&.+:N#5ZJ#/?&K@Y^L]EWRRYB:86D>-737P#XU*L$
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M;-8\VU R'O0&:F/UE+?ORPG<DW/KK O\OC/+[=Z[D#:;!N+7KVDFVJ5[K=.
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MG7(0YE5XDTU%<?H[9#&XF_+KU>_OU6"H'1,_?9M%8EK>9%!7=?%V:8FHB(M
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MS%ISD,X)\:<JSIA/E8MIS/P*+WD1:.VO&5YM>_?IXNK7]Q/$DY,8/H7Z0,6
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M-'_5F;-*\#=K:[+JI-I!J#37WQ<$U3;X_X>$%1C-[RV;'S,CTS1CWXL\IHO
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MBBYX/88/>3=082M(J2!\OWQ[^=7RRJ\"V6M"39"<FLR.B'K#%_"[9%Z"0C3
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M"+Z/6&1:$B.@%GP;)TC_D$"(RH]Q6F6)A$=(<5G4@B*NO]MVY/4>*'B$1,7
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MN#DS._+65"J O8/A=$'M6##)Q2S.,[RQ4FK>RTZ5%.LBNL/V2)5R;YT N9@
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M/G>B7DR%+>7;^JWJ)^B-1MX&XEW13;%TY/:X1%$_EZ28BS+<TZY8)6R,")&
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MQA]:J<1R;K?#M;^-,6^.J=NZMT;A@1-[G@AUT_*8;9J^Y;N69UN&885FY*]
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M50.@5.-%'A)1.F.;U+4(]D1H'-FA&]'0I3QBOHI8GSV\:'?"BT,\E#V\2#4
M2N<(+J&IE<)Q$$?@.$Y'1P[O3/:(ALU:V"/TM&:=?G2(6JSC"=9I@OOT?R3*
M8@?MM53=7NS@=;K8&@"ELN95'+5BFQH -11-I#HI80V .H.%IACI-X(@CI*9
MZH @;-G6K8YQTE=\HBQ3Z(K)RU>\ ^&RLU?H!9$>7W:!-GC1A6B]LU>%S9"
MCF,:WLUXGL.#L+<VG<!.M*/J+<%N9[,T$)MJ5H)E_Z6&_EZVW>Q$5?V]7NY+
MUZU>[W)K5&P-[VE=UF?/N"9@4+X#&70")6';<2ER IMB1AS"7&1QDUN8$.($
M)*07[RFW^J;BH>VN@$T7Y^RGR8OTG.M C:O6<\YV-QAD;\^Y<W4^.^B,2I$
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MG:?EC7'QF9PW7<Y8/KX.2C:*X<K)-_&\^,Z, XOG;%9=>1/%P%^:;GZYG"
MP32'?Q3%N$ .#+Y5QM_@07C-"C%=)1LF^\?;ZJG1]:G19/?4Z O,?VX<0/SB
M0.$M9@J1Q:F''>"F@+C X22@KLFYCP/,7,I>J$5O7,.+##JD&FX])U?/R56U
MB%87;NO";5VXW??0AC5SZ^+S&_2@W#W1;#6;AG\0U8E%, (L_EF:YT; LNP9
M[/0GEH6]E"B>G.Q1X^A>\QA09KO4<VADDL C-D<>CL#K=OR(<LX0L_[U_K#A
M536O^V-%B[\#*;Y=I\3-2:#)XOXF3.<WY9?7^X@YR %UX(T=5Y%DK>8@S4'K
M'$1PB#&./#=T">*^%P 7A30$?]='S \E![7HYML'![G 07ALT9.;\77(0=<_
MQT-75UZ72EO6EFTPXZK.K"53BL:V8VQVE1U2J$_M:R? OC1"MP1HBOZL8Q/5
MRR"O8RB(FDKA-@BR!5SXV,C@WK+',B.4"M"R!N<-2AE4/RMQYY_+^[Q-PNJ2
MA>56_;B) \W1U")7Z-:\=J+K40&T);J6.@$+G8!L[2B<D[3>BY@[S^=5SEP[
M!</1 V6U44LVLZ3M;VG;_^KHK+=HT%%T)J:WCCV[WJ).F_A]BO.01S'0B #'
M/4K$G;A!;=T/1ZK_3YJ& O,&9A4H9Y9\$_6EQ3\UL9EHCT=/]J.U':\:>?4E
MS/>2U[J(C^+O/+SYBV=I$]G1T53B3/$O"I'>]9OK'769TH:4(H&;]38YP)'E
M1*M\7Q^=EF:8:#<WI@TC8+6Y/W J/5^DIW\J%5W1Q@0Y"E'I]3L+OW.X._ 3
MB@*59^TD**=)^/?P>YU!Y;U5=47/K7G-$[QF.8KT(-34IHQ&:$]M>WT$C+2/
M<)%V1.PAGF\466;K:" 1Z,]B 08J_CT ?:VQ0$.1_0<;9YM4\#&JH!KPD=\V
M*4 8;*VS==@4:01$5++8--VJJT7.0[?[]1'N3!\IZF9@6T5]]#6%^S1@$WEC
M:?^EW8XK[E=RSJR%N-[62L0:32UO[#E=X9#ZG<6NB5-MS=,Q<1*P<)RQZW:5
M7.N7.*_?K_F=Y_F;SEJLOD(C<'=[N#,JBJ;.D"T94Z2\W;%-Z[['N8?H:(KK
MD.+ZDOX=4!R5JL"T3QE#J)[/H)Z(;VA(((??:A_A&GR$#[QU8A#+]#4QAV&#
M:<H<J(,@*;-.?.YHZN"N\F2#,/\55PFS53-%W:A&-ZII2TOOX@3,/]&D1B3"
M6/"?15ST:+R1;1V!R-8([-(VQS7*[^XMB[7VJLO;O<TRT>]4) I:Y0<\%?/5
MFO)4]2Y?)KT:B5EH-+6L4^9;:R3$A:IA7F'T1AG)_BD3[>7FSY]F+)F+1# H
M;MG.IH5TAS<KF/W5U#< Z;Z'_.IDAD=3&]<'_0TY3JBPA/\L_BP@;HN<*X(G
MN$K^ZAC+ML9<\@8_1G_DC45H+T<(+4M$"'%#@<M%C"I-<"H$^HZFM_TF!%'1
M0;Q^,_[O+!<C2^(([I,G <_%J%5Y4\5$DV49J[;OAZ@!WHF;7,[+.:#FW;)%
MD_8.)L5I"UX=^NI/XK>G+PHFA7-*E$8]&UX]J;XKL:,3_H,3[MON\W)@X1H7
MMK;K=V;^6]OU.ND_;.KL.+C3"77*@G5DG1+HT;B 4X>.A#M42!\.P(')]NZ'
MXJIQW(>/6>CR/!247,HD1=H$+KK+;%]V'K!F:,W0UV2*;'-TC7.)  PTM,5I
M[8I>DF$WQVG7INX6LUY?F,':Y_SFQ3V\\?EC5"\4^,JWAS43<WOX\AG'?;\M
MYSC+ =S-0Y3%;.2F*<KA(A.X-_'8,V=9;O DA$^\,/M[;#S=Q<&=4<'C'C(@
MZ0RV4PY<SD1O$+F>I#X#[L</'W__:7,2W'BS%<6.P31C>*A]"XMQ$0R^?V!Q
M)K\1GOI6-CLTGG@FHL-P/.*D\JT9YDLLJ1[:JX?VZJ&]>FBO,D>IA_;JH;U;
M._UG@]9G<ZG9?0XJ*!$*&'1?I>HO& QY?=[1 /T?%>JO3B_1)7AGB>Y)$8ZK
MB&%H/KPR/J06<R+7"IB/2!1:?HB80VV34-L//-.3?(@NPX=BO P:VUY7#:<5
M2X\,);O^?NF<9SP01QB6+GMZSZ6O_9"ECW%^; -Y#5_<QY]'!:7V,6J=+[=9
MMP@-O4]N[^&(6Y?9$S&L1S3@U@,!KXT633<@-'!-&E!..*- DY2$D6E%KA-%
M/)2T:%:T>(#QUCLMVJ,I'=M*S;1YC<XD%Z-AE7 C=0KNRE-P*C2GZ<#TI3O[
MDNDDN^9PS>'##S(Y_029U,C*KU+LA^3DSY?UOIV_G*865HIH*,Z29^..A088
MMCQC,^/#Q]\W,]#"I&$/X/Q^ASN>\]FS\5_]:Q_[Y1&K5>I<3-!^N[[@7\%A
MS^$6E^1(5^0H0*BF.ZEWJ#+@\&?2JH,3:K7!XYBOKPUZHZGK[=F?Q!,\</CA
M(USEQ#B&5/(YT$$SH2A.&E_$RF^3\/<T6!-7J^.S$1R?,T&#)H\7-VF"NVCN
MV62-1H;$_5\6_K]AZ5_3W[X_Q)G47DUG@$=38DWJ%4O+BRX=N4HL2KRTP.AL
MDKR$RL@DH@@6<O%*+L ]L"UK#"<SX_#(0\8?XW21P^$MYO$,!'DX,;ZN?7F=
ME;[Q1&R0BUI-@T5SGAGK& 'X?M,9 +]]2.<'WH<UFCID4@^F+>]#GO3Z(<')
M5+UJ!)%^70DI"=QU?LE+0;7OZM9OS$+[;VQIJ@Q!TV]([?]N'"-A,-CY"I\F
M1J1F<<YE#*.B3"'N5J=8H].-8Y??,..":%EA)L[@V47X#$L!4^[;W3(RL@6E
MJRC:*R%N0.WWL%-8R!-P07X7/QA!B>-[BN=W)9;OGK,J<?]>("H2>-UG_LB3
MA5A1R(T?WW]^^]/8^,(+SK!<++57&@0+>1+RTI$E7HU<N0!<,E:A^DQOHN*5
MKY]X##1>\)<0/W!%162J/*$_!&^$AM0'>5GX;3S";0-EE[?Z[P5<>1C+$\J;
MF4A<? & %$A)<6+RJRHN%$2TM@;^'7::%,OPGXME3+Y,M@B)+>9W:28AO$8(
M]R46#Y_<8&_1HB2IN*\!+5EN:2<\LH1&JLFWZY<HTDW?$GA8P$*!D,&V$YOY
M&4[[@0-5RU.J\*2;*2E0R?" A)/"5E<9*GE5J\_Q+48-4_C&))T#/SQR0_Q$
MZ':Q*X,%0;8 P2^^H<"'AN!"B<\NERD>&*^>6*YY8[T%">:@XXI&;U(6P".R
MSYM4:O!6@4E-!486/@C?4I.Q=>3SVNV5YTGPQ!'8T8>T:$SY1IX46"XKR*CP
MIM<>+'U'M'J$^> I+N:['ZG!MPXGEJ\Q&.O&!_YD?$[O67(TV6#9CO,&VUM'
MM/;K7;8"^WWC-W[&V9\WTGAXPV9/[#D?_;Q)_T#\6Z>X?0#%-J=_\S-XM.'%
M6Q<DU7D<(@O,6^QPX@3$=2@C 75-SGT<8.92-CH_%]8@<)(+_T@"\/<94"/8
M,L:GDAQR)27&,8Y:[W[*^P_OMJW#/Y*EH! 68C6D[,7:*[2R!<D9XMO]K-P>
M39.T9L/6C=K%VJND(/?+EZFOK9:ZP^>S&-0M$%V%I60SF0V3BGO'_@JKN](=
MPNJ4AMVZ79? S1KS)SZ#[[Z'I=WEDT.T@I0\=F1[-@H=\1M!$7,=DW&342>T
M70\C]U^F<'[WGJV)SRR$P$?BAHDF1L]%.Y]XDA># S_",6<@[>89GX/W(U1R
M1>R_QGD QM4B:RCDL6G!>7#N/+P5_! 0SW,0-6T:.L1#G@LK]#U, ]MR0TKM
M[<(?@LP?__S)$%T!Z_%3]<B^6;N]N.D-=LD?0*&DF;!5#0[N4?K,P5YFCV#%
M@KT&!U'PSW_ YHHC83@Q^'_EK>7 4]DS&-G+)KG 6^":+;V:\DC+:(7P>R;&
M)R:"V/%#82M7;\V![9Z+;S86#Y7)77.=OO#L,18Y[01V/9,7GL7^0KYL%M_'
M\XEQ&X9240H&WE0ZX@U\5KH"]^Q/OO&\M&^+UVZ< .Q?B :PP3A8FWD@R#)-
M)L8[L"A;EU]M+B?<7D'Y_D_E>W?JF60AWM(M2@DW1%*$G_MV;85B8;\5-Y;]
M@\T#D(K?-OZ=9\%Z'\T;O.)/!SBLIFM^D&?3;I\G(F#ZWJ<[FEH-^P0>J-@H
M7/%:L#8T=3NP>2R!Y76JFL,JPQ/R)*<"X)JB=$UG+D; ?E[JYJ9(G#>:HGV!
MN+81\%/A5)WMC"*QL]TAWRWJ:*J[W:&CI'LHPI')_ TFTI,:[?:<M ]+=_NP
M/_MI^ R_W<WO9]/_!U!+ P04    " "[BG16W.I@+L02   HS0  $0   &5X
M9'@M,C R,C$R,S$N>'-D[5UM<^.V$?Z>7\'J2RXSU=F2?2_VQ->1Y?-5K6VY
MMB^7?LI )"2A1P$*2-I2?GT7 "&^$Z1LQ6RIS"2Q2.PN@&>YV%TLP9__MEJX
MUB/F'F'TK--[>]BQ,+690^CLK//UX;+[L?.W3S_\\/-?NMU?S^^NK MF!PM,
M?6O(,?*Q8ST1?VY]<[#WW9IRMK"^,?Z=/*)N]Y,D&K+EFI/9W+?ZA_VC]%U^
M.NE_/#ZQWW_L3M[9O>XQFJ#NR?1CKVNCOG/4[TW>]2;XK[/3]WU\_/[DPZ3[
MX?W1M'M\A)PNFDR<KO/A\'@Z[3D3N^=(IBOOU+/G>($L&!CU3E?>66?N^\O3
M@X.GIZ>W3T=O&9\=] \/>P>_7E_=RZ:=L*U+Z/=$Z]6$N[K]T8&X/4$>ULWQ
MREDEFN,5FF'ZUF8+(.CW>_VCGFXK.)$2WH1Z/J+VAK?C\ZZ_7F(OGP9N'XC;
M0LYA][#7[2<D.?Z&+"[FW8&ZV;&0[W,R"7Q\R?CB D]1X ))0'\/D$NF!#N@
M!2X6."<:Q&[[B,^P?X,6V%LB&QOGX=,/EB7 (8LEX[Y%,X13Y$UD1SWN2[*.
MI8"\8C;RI7:*EIX>4Z;] 79]3_SJBE]O5Y[3.:@N-?"Z,X26M23':93T\$J=
M'L2TLG=R<G*P$FJ6WX-<S9'MN^+/;J_?/>K5$%ND@M5EPZ^NIGN)/D2/6+T^
M:+IG]B'WL2K2!1.E_.U5[$;^8UIQ$C2!&/V[.@(];+^=L<<#!Y,JBI]N+O[(
M475$*?,EO;@27ELN"9TR=0$N"<!.-6IW>*J-5\8$YSP:\G^GB-N<N8;GZ&#)
MV1)SGV O;KXE@SG'T[..,.)=;:5^<]'D+?1$-\D(2*J>N'T )-B]BD:B:07Z
M9QT/ '"QFILF#WS)<=V! XD'"X0$^G]^_#9RZXX?2.S _?\8OH.G=8</)(22
M+48OJ!_@OD6<L\Z0@>_9L<2UKW>C(B]""E1--2_-+>K&IT/Y3\_J1DYJUY)4
M/Q^DVZ:X!!YVQO23_#NMUR%QV*2$,*40E>F2,YE+%E[44U<RH8/ (?X(3"U?
MR)Y4F]L,E7&:^\EIE@RL&(<63?DY<H7_<S_'V/>JS7>2Q#C91S##]S ].)SM
MD-Q2]&V=ZEO$821S[!/HVQ;SGJ0W@G!<"H+U)L'NIQ:!LID4CTW'L.K([E1\
M$ IHC6"\2X$1\;'8U(HXM12&>Y_9W^?,=3#W/O\>$']='XX<'D98WI?"$N?X
MHZ5X[@$*)W<+:U:'H1&Z#[6AVYL\.?-#Y,TO7?:TA<6+2(WP?"R%1S"R)*<6
M@3#F,T3)'S7<W 2%<<I/A(M+/-ME7L Q_(B3MVB>[X/% O$UV!@RHV0*SSKU
M![;- NH3.KME+K$ASJRH_=5XF;#I'::Q"1E+6Q6QMB+>EF;>(N3&8)OY):'@
MIQ+DUHX*B\F-^/0RSX[@96V8M3549)RS)]#&JG%BU-XXY?WTE$?$+9KA(5LL
MB"\61D2=(9.//J;5#50)O1&!HS0"$3,+N%D)=BW"Y!(1_@MR WR-D9@9Z;94
M@R.?U(C$<1H)P<>2C*PXIQ:!L'U(6#L,[+W+K,YMC_Q@^..EX';KHHJK;YK(
M..OO<V?=4BPLP:-%4SZB,)'X :VJ&OXX@7&J/Z2G6E%;DKQ%LSPX/NQ]KZ[2
M47/C#'],SS"0OOG^4]O4N%J\M(L8K'HLEHF3J\=BUAO]5ZNR1Y4 >$ 3]V4A
M#3F: .T_([BVWB@A;8*S,$RN@Z")B1&T.A%W&U&*HN$ZL&2HC#B4A.%MG/;B
M>+H.#$8N1EAJQ>9M!"HWTJZ#41D#(SQ5 _8V(I.-P&NY!D741DPJ1?&M!22*
MS&NCD2$U0F$.[=N(0RQDKX-!ELPX_Z7Q?ANG/KX5>H%]1-RJ?FX.H7'Z,\F
M.!?K3<BG3?-?+>"[PX^8!GBROD;_8?P6K<%PUT+K^6*,V#XG>]"U0M'69&U)
MX9:2OM>)0K!N$!>U<8]X!XJ0X6U"_^@YJ8:NM9&WQ[L0$YA=-)MQ/).]9=/P
MB=D!^@9)1EW(9#!JZ4)2NJ#1MF&O&T6(B;(Q\:]PY1^1*P(LB(7OL.=S8OO8
M$?=VH"AUQ!JU)I-OJ:4U0M1?5?E<K#<R(Q#U1]W?JU$1GO?8#C@1+QOM0%FR
MS(TJD<GUU%*)2& K(2],1-]RO$3$^;Q:8NK5A+HN4R/$F7Q16;:[:X5B+"UG
MCVP2!/FRX!JLGC""2Y%I>REXBSD;,<[DGTP8*UG2>&^D[9&.X[&=\U^=G1'3
M3"*K'--V._B%\_Z%,>>)N.[+H)CF9@0QDPTK!U'SWV,8GW5P/GB G2N")L2M
M[SQMP=>(:S;-5HIK*,F*B6HEQ-$&[W;FM83>"%DF>Q;;;6Z[^8RFXC+P87:N
M@?4B6-RBM=Q*W!*C4EXFO(XS^:X$7HJW%3*W-/=6HE>\Y;_=4U:#GQ'%3*:J
MM)B@[<]A\<Q?8>3A\#WZ>L]C39Y&1#-9) .B4HH^ F#_@"8A&#+/]P:>Q\!I
M\+$C3@@$1P+:+Q%=*X!>"NTZHHQ*4*]&2-P&X58D79V%"/*ML ,_>DI1]@J2
M1.T^6"[5\8+(U>] QWS+,56S-J#.-RS.CL3.X!%ST EY_0&+(PE?1'U>KB-&
MY<IDK S*%>]:]'YWP@4?4ZU>T$%+][ ;=C&T4:*3>_5+S*YRL[1W]94ZF(<G
MAM 9S*2*=_"+VJEM1!I5*I,@,ZA4Z%YNW$K9#6O3#ZE%84_V=NN%4/RM]PJJ
M\UMOKSR-4YXPJAM0&B!7SE "TQM&;3%YKJ@ED[<'$#0 <?U@=<=],*I6)LEK
M4"T=[ZINA>M62M&@:]VH;V&;>.]:J6VY-=>U=*64@Q'I3":XL&R[A>!D*Z^W
MK+TR\S$"E4GMYM9RMSU3D9WI;V(^0(%]=AMP>PY&1]@R1E4==^"+HZ_%6?G/
M!+2N&"/>V:K*?+RU8,MGEA9M*=FZQCR2WEZ=B"KVG_$(ES QX?DN6R>9>0%@
M__ FYCCV<V##I("^/P>R$G9&\+*%C3G@):YI$7L@$8WJ\.2-KR"G9IU9=7Y&
M*+/5ACE0QBH'U6TI8X\EHAMO<^!YP4)>?A:69?R,6&;+!'.PC#FT,1E[+$.+
M> [^@B.RW9AZLGMAA=VS3:V)L1'=3+ZUT.AVI2PK+DP7"NYQ1C3FB8)AP_P1
M.Y>,JW30"!X)$90_!^XZ_(VHY[^SFD(]X=]JF18(U4DN+;:5\,=>CQ2/!*/J
MK-K-Y?#1.,<4I-:K$]V.M1'T3+XI\7:FQ#N4)2K HYO14QY*_*GM@-]AFU&;
MN"1\A>?S=(J%*XHW;>Z07^]IWYJ[$?;REW*%&Q87)Z#?"(PK@9"YQSV)S 6>
M8LZQ S?!Z\'R_9QM*Q6?+\:H"9GLEE$3M&2I 4JV3$VWO98Q;J'G(K<^HL+Y
M596EKLN>:J_VM3@:D<[DM=*F7HJ J]9&B+61TG9$M\M=E3$PX?4^D[=*X=7N
ME-7F/,1:@&2HC"AD$E"QPQ3_WR?^YX/DYP?5[\0G"L4'"L//G4I8Q+?1?GMX
M8K($AV#N7>/%1'RF#$T\GR/;/^OX/, =^5G%LTY>2TI<N5&I6\KOOYXN,2?,
M>9 ?1W,"]8F:CN4%P);X@?CUA;-@>=91S8F/%QU+?4MM\T'84X<M$*$CN"<8
M19]=S(P@MKK&EK4[424TGG[UL%KVXJ.:(M?;#*LJN7FHZ@NAOKXU45639QT;
MN!._X@2H*Q"W@;;R=87A;TH3U$:VW%L&Z\/%KQ$]EQ^LHWZXS7R+N8U%%PLF
M8SMF.]2"I9)181YT,#M6WXBYY&SQ"_9\[.0E0@?4"0<QGGY>+%VVQN*4'##6
M,@=6.#\O*Z3.O*5TRL&3W:G4D#UAJO;.P)RJ3R@+-V;&L6Q9;B>J4C?!=H@2
M#3&";\2?#P//AS6;BTI"0J5@N.T1)_S(%GC7F#R*'A>JQ[;LMK<M.]6#SZLE
M49W]!Z*]D_YA_WTY]"4$34#[ D_\$4PDEY]S%)_,I#"G-X'HX7AZ@=;> QN*
M=-P43)NL/X4Y#NL[1MX- ]4M-ITOP_S%ITE=T405)FGP]YLA$YU@BJ0<\:+6
M38#[BM&9JET6R-AN(#;WOU('/$1Q'@)V1O ?\.^*,:W!H:GN05(MY0$!Z_"O
M!0D6X1H.GG=%Q2[E4&,2=N8'9)(MTI71KMVZBA^83]=4(ZV/ -!U+4Y8X^AC
M#]P/T>/QQ"7JO*!B-[@NFZ;Z+O)=WO$4L(1'M=QVY39MA.$BMLC7;SRFD0@(
MD1M>OL3%SVH%RJ8"EQ^'79(5=M3S".[T2)3ZS@CT?JN@SL2LJ38<EA[X31[Q
MX EQ1V0S^H>]DW+E+J=I@I87O]H?#JCTN2TGW)$;):(9.JL45\C-WCD"YV#P
MB(CLS"7C7T05HC2L#W,L !' F,*I+5@U =_!+Z/[S\.'BP?PCPQ.9$[+)HS@
M\\J6>?:-.=7>O$)#WQ;[^+K M'A]W8;7KM18BJP5  Z6O%<G_DNW;P*<L-3#
M.@B6_TJ%*XRO#0Y",4$3Q@,Q-BQ<]'YT?3N^&94/);]M$T9Q&X!;:5?SV/+;
M-F$45QBF%R?3IYO8X8&=XUM$G(L #Z80,/X;(W[) E[LQFW'K:G^2^4(4B6<
M[[ 3V JNYX:D&89-B% C*WF![0]@)=]5M:KI]DW0_!L6]:]\''DMFS""_,R=
MJ*9RB4S2J??VOE*>.+HU/!6C9D*P.MN&YAM>: M$N3V[WFC14E[;D<K7A?#D
MYE@^^%;VJ*9*%;-Y_6QRM(8QSQN"8[N&/HJ(5&2\O_JPH/V!B\=;D;JA3TK!
MCH#8!](V0.>/17&>WF<%(R__7W>GH3K?)BR"=_+$#WV8Z?E:-+^0%KMH^2BC
M:,(R(F8_@&G?9%+!+-VSJ0_ZBHTAOI&R"2.\!B?1-HXFW:H)/8\Y'H@?U8ID
M,P1-&$]XT/,UM/:Q/(Q")C0]$ Q_ZVWHXN6U,GU#3:M<^X6/@"$,$K&@6O%D
M785.GWQ>@3$B'G9N2G9MZS-Z1OY\MU%6F$*",<1?@C:I>1E-$S1=>G"9MZ1B
M)V*<KZ,FH1<H4]XZOZ:+F$!+75>>TE"L#+N0M2,?3#RX,\RWV$T:4_Q %OI$
ME,I;26FRINXC#9Q'Z0(;AI=NUE!#E\IT@,T>T7\2ZEPQ1#UEMZIF2?)I&VO.
M!JZ+9W-,UW_'R/7G8'N?&)>OSB%NS\6XA$B#+U*3R?^TP4O[^2.:W&(8!/Z<
M\=)XZT^1_=+11\U0?.@BSQM/P\5]S&6EK^YM9LDO+O6KR>:51WT._LS]G&#7
M*7]@LNT:\4SD>VE*MU["WROC]-JY(Y'BPHXR8.;HJZAU$V!4^VE5]MR:U&L=
MSTJ/06PJ5 M_,\V;,)9$K>;&M5-N:^)>69%1/29-]1/S1Y&XJC^C5',F"G@T
M=2*BS>U-_JE<PTL(FJ#CHF"W?]C[8'B;*=6J"3W?+$XJ">.5A:HY31L:PN3E
M;0<KXM7)\ZKV+X"1XY\Z$,52+]R^V+*^ZU\!QB(SN(;E]A%SC_CK\?2*4<>T
M!UJ!L F:&"]\SZMW'RS$[TIU\V7D#=58T+T%]N<X\#:FCH"K1FU#=8J)K G(
M#@*(V6L46Q:W?^T:R^P7H(8NH>![N?=^X*R' >>E":"*Y,TMJE$ESKH:2BX"
M=]@6<2F9$NP\,/42GK%(N@*'QF:)$IC)KYN&_WW *__<A46R)((WD^[PB?6U
ME"U2N"IHE=5?HCQ81*LP#N1B[QS/"+UD_(ZM(0($I=;58I7SO%OQ?OU" W4B
M!EC;ASG.'KP!O<Z\WW,';OJE*B<HW)A]'M/7MI ;]SS^%H]A0ZB,I GKUXA2
M]HA\6&/)%-_;!(L/$UUA>7#O94 -Z:VJU$T8:>J;P0/JR!<?PH5)J9OVDD7M
MOZ@:B%<09!<XLTW<J<R&&-/DMHA.V5XSZL_==:5]PAH<7GWW+^]S/P6?U="?
M(C"YA,]B^=HV,;M3D=1Y&$"H[5+S#>^9;<FML>Z4*"(#="5VX1 *QY[;MJE)
MKNBTA7.P^?,%XM_+5XH2@B8L#I%K9GY[+-FN";W_PAXQI^):K[S[.0V;T/_4
M5]+NL*#3+VJ(Q(?)A-9@\-H&,_D62KC(Z9. *AXDE*%J:E"=PN4BS%R),MJ:
MD.:3OC:86V_P#QQ''DH&H6!J0[_""1([EMJ$<N:D2WCOHUBV4ZA 5'U3T:LL
M9]&$(8>^OCXOX@MCC@@8[C%_)!!55<R_&<F;:BJB"N%[O!1O91U7K2A.MV_"
MBA9WVK=_;[$FEZ9"JW4R.O D?1)>]*6W"N9O6W9->,A5KF\==3WJX'@JLX*%
MPZY"VH0AAJ]&B]T;EMC'K_1&=3%9$Q[K3'X2_M#7PI@ML213)SPBWANB)?&1
M2_Y0\?U4UTR*A,]*#$(("D^U*]NH_A-[T-#=Q*%+C,J4;/.G:HX\*-:SYQ""
M?/KAOU!+ P04    " "[BG16,:Y="MDE  #*>P$ %0   &5X9'@M,C R,C$R
M,S%?8V%L+GAM;-U]6W-;M[+F^_X5'L_K(,;]DMK9IQPGV>,:)W;9SMEGGE@-
MH&&Q-D5Z2,J7\^NG08J*+J1$<F%1RTZE+(FBN#Z@/S2Z&XWNO__'E_/)DT\X
M7XQGTY^>BA_XTR<X3;,\GG[XZ>F?[W]C_NE__.-O?_O[_V#LOWY^^^K)+[-T
M<8[3Y9,7<X0EYB>?Q\NS)__*N/CWDS*?G3_YUVS^[_$G8.P?JS]Z,?OX=3[^
M<+9\(KE4MW\[_S%*KT.RGD63!-,0@87B!4L@LY(B&A'Q?WWXT4K4-KC(G%6%
M:06908R99<=U*2+')/+J0R?CZ;]_K/]$6. 3&MQTL?KQIZ=GR^7''Y\]^_SY
M\P]?XGSRPVS^X9GD7#W;O/OIY=N_W'G_9[5ZMP@A/%O]]NJMB_&V-]+'BF?_
M]?NK=^D,SX&-IXLE3%-]P&+\XV+UXJM9@N5JSA_$]63G.^I/;/,V5E]B0C(E
M?OBRR$__\;<G3];3,9]-\"V6)_7KGV]?WG@D?H$/./TAS<Z?U5\_^QDF%>J[
M,\3E@@"O/F#Y]2/^]'0Q/O\XP<UK9W,L/SW%+_D+/5A*(=>/_9\W/^#97R@2
M3-+%9#7H5_3SY<?4AQX+"+\L<9IQ/=3-8R:S=.--DSK1L_GF+R<0<;)Z=72Q
M8!\ /HY>C2&.)^/E&!<C*XWC60HFG0"F=?8,;$ST#_K,O2S!W9J!"GU!V%>2
M*;"(*_%<?O:S.C7/<+)<;%Y93=9JHK8\?CU=QX_D%RPXGV-^22OX'-_#EVN?
M_0<N1]&C+8B2^>P]TR5K%K5S-,ZD17;6Z R-1_< I)LCOD:1Y_/T9#;/.">E
M]/3)9ZPJY%(_K?'!/-WASLW5<?F.9XN+\_/59[+Q$L\W?U^551L>+&?]26$M
M>1I)5VJ\FDT_O,?Y^2\8EW_,INF"$$Z7HXP0G*0A2J<3TQ$= U\\J5^;51+%
M*6U;\WTKDGV((+\Q(C28\V;R?[T\P_EU(OZ%1X+5'" QIPHR^E8P"/2CY(&C
M-VB@\,8<V(UF'QZH;XP'C>:^G2[X"\J+#0[C4$F9F(<4:'BB&F1*,^XL&5BH
M>'"M.7 7Q3ZRU]^8[#O.=;OU_Q'G-.[IAU=(MN(&U==K5"2#.\E4 BDC;\G$
M)B/<>RZ8L1PU#=H%UWHK>!#4/HPPWQ@CVDJB&4'>+6?IWV>S"<WIXM?_=T&(
M1D$5$62P3'%'RDD61;Y9,,Q&1:Y05-IPWY@1=U%T'=>;^:4YMOKH_X3)!8YX
MDC$D4Y@QV9 %%@H#(,^)=F&3N0L%<FH\L"TPAF3[=I3^;8YWG?1FK'Z>\[@.
M'R9O8$P6^0OX.%["A 8GG7/@&0>>F<XT+J^D847)$,!Z%T-HS( =4(9D^#9F
M08O);\:$M[B$\13SKS"?DO)=/$_IXKQ.-69RV,9IO!R5DDP0-C*A,N&R@C1P
M\/1=\EX9LM"*%XU)\3"J(1G$C?G16"3-J/)B=GX^FUY3727GZ)Q%%GU43#OZ
MQWO'&8]6HTP^B]0Z*G0;PY!LX\8TZ#3=[7:*Q0*7BY&3TMID,U-.UI",%BPJ
M&5G1*EF=BM?M-X;5DYLX^.N/NNY?BE!4"8H)#86FDM-42MIYN8&H;'3*B=*'
M;W\;R)!LG2,DO=6C[S39C7F[\2T=:"NK6UF*K$M'1.:U<K2_8LBY*!&SZX6^
M![CPI[)F&LCY^,EM)M]_SF;Y\WA"5E,J%H)S3)&!Q$BA)A8UF=/<8\FD$P,J
MV5BTFV</R09I(-6CIK2G2,S;.F6ORY\+7 ULY)(4/D7-I#8$B0O/@LB>P*D2
MP7.E7>O]YUY 0[([6BCN9I/?C ]OYC,"M?SZ9@+3Y?-IKA;5QWK$3M__-I[6
MP\]M8)^7)6U!URWFCW-,X[5LIOGY^6R^'/_WZL<1!N^"!LTL@&4:N&<@#4T@
MUZ@A<\Y]ZT!._Z,:4FRP 3,'1H,^#QNBEYA4D<P+,.3_*U*[3GI:=4A?;2I*
M]GC(OM52.<+N2FEV,5TNWL!7B!/<C"WQ4&=3T):B27'X$(@"B0:H:%S&R> A
MMS; MB(9DL7=D0-WK++N4]_._$YI?H%YRP@3CR$HR>NX5BXQ9U (F#>(5AH>
MDFNM='>"&9)9WIX,#030]SG;!I,M$D!XS0J7F>R*$FC,T=.& 3SF6((KS?WQ
M>Q$-R;1OS(R&HN@E#6<#Q(3H0DUF7(>[C*?O0K$,LT'#C;9"Z!YS<(9]^-Z"
M"%TGO0];B&RS+6%4,LQX)B.-\8R2:9$U"QH# ^/(-P$;G.HQ#6,KIA[.E6-0
M48.1S I#=BB&1 .4ED4A2"1H2G2MCU\?&M=@[*/NO+C-_HX"Z(/\(VY"+IF6
M6RXUG;OH&GC!"J" 5^2=N.8.Z<XTV\%80^U%?^R4-SU)&R^K%UM']V(VK=LQ
M3E,%% (DZ:4F+(Y(:( LLQR I2Q40BUE,*U-H7O@#-0.:L^)5B+IZ0 C@L7D
M+3W8Y[HO:R2CG1 )HT#SJ#*6UBGJ]QQ@',%X6)S5>:4O55B?8+*:Z>4+F,^_
MTDRO3SB-YCH#%.9L$$P[*1EX TS7P>L2(!35FOO[ !O2IG@\+^Y0OKE,6H8/
M5J&,MYB0@,4)_H%7-BI:$[42FI%'XFB90Z0QE\RX%59IX;R3K5ER'YXA;9OM
MR-%, @T/!/ CC/.O7S[B=(%$W&NGS2-4)H4L/ -E=;TO5VI0([,2%?)$_QEL
MO6O>AV=(VV8[3C23P"U._/W9[6EZ13\?=U'OW1)H-JHBFY7+2,=L>M2-O1V?
MU/WJWCX0&]WA>S%;K.R92Y$M1H8CY\YXIB0@B3]9YC6Y.,FIB%Q$*VUL;EW>
MQ-#9<\8)_>K#/W%*4S>IASGY?#P=+Y9U(C_AY6-&!FU.FHS!Z.I(A7<LR"Q8
M1$DVFW!!Y=9Y ?LA&Y(QT8D?=SSJ]H)IF.:Z0/J8:N_\@I]P,EN=(5Y!*L:0
MM^]9*B4R,G<<\X5&G8T2WA328ZEU>M"]@(9D4C2E2#LQ-/3%%\O7I>:^K+Q*
MG'\:)UR\(\=R5"R(8&F;-%;6/)A46$B(S!E+.YJ(1L;63M=N-$,R*9IRHI$
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MXUP?X>MJQ;XN?\R6N+D-->(I@W!:,>^P7ETE(%[*4M/E'7?19,';5['9CN5
MNZ-WY_T4=&DBEV8LN7YS],U\3 /]6*LQK0&2F:Q0ZN*9B:)>JN T3D"H=^=
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M#XZVW%KI-F)DM O6P#U$*V.BH=J'MII#'CBDE.R^:-"; -K5"5]?[KL^_,V
MN2A6"6-8EJM< \PT5DY:2P""\#ZGYF4G=J,94EKV23:/[C)Y'*MU?:</KEWG
MZ\=TW?V<7NW7/8?7S(C=<46R]A4($CG6?BQ"B<!T\IP,"HDLF1+K)5P-LG7N
M\GUX&E2TVO[9_YS7H'N,.41-HPVN-E@R.3"PNC K,R:$8H1N':2Y']&PS-E&
M/-E2QZJ54%JVJ;\XOUC5@+Q^BD??3W#+<=[N:\:IZ!A<S7D1M;!.2,@@*<%\
M1LFS=H)#ZS!.*^R#ND#>&_L>1=*/L6W>S0+M8]/<_90>M\P]A]9HP[S[M(WE
M%'F26'M?.P5^U0:0 :_]>(3('.N5 -TZ^WXGF 8:L'[P.YC _/H0O:"UYH I
M!Z(V&L(ZQ,0*8A)0K/2ZM6^_'<F0ML8VC-BBF;I*H(UWOV5X]+XQS?F[Y47^
MN@&&,N2D2 %RFQ)I80PL)@[,VR2CS<#1B(?TR@'/&U*(IRT!^IKT7IHL7%WQ
MWB!*)GI/>RXK&NNAAY,L"$S,:U>2BRIKVUH)WH=G2"&@?O1$,VDTU19O+N;I
MC!#=3HS; +-!\F@B,#22B%N*9+X01%-L%#KIR,U^H<#]GC>DV$Y_VJ+EI#=O
M#G>9=[O!(KS1P#5G+M;^GI[&&B#9^F,N6LID3?M+]MN0''BM_ANB1D,)M/2L
MZPBO3BLV8)S5+I,)0VY^38A-Z.N52,4L NFHE 3ZUI'@'5"&="F^5\NRDPS:
MG@[L'J>7&5V]+Y0CUTRC(0.'DY?OBLC6@8LNM8Y WH]H2%?@^Z%'0XFT2YJZ
M6"QGYSA_B^5BFN^8.:4XD[)63(G:AUK)0!9.K>8GK>5"FY!#ZQ3V^Q$-Z=9[
M/RQI*)$>PV$_S^;SV>?Q],/BMXOEQ1Q_)Q_J_.)\4RBR0PALST_N'O8Z9@@=
M0UTKF[+FD[_'^?DO&)=719;_G.;+"BGX5R4G&<G1-,XPXU1@FEL@&M'FD=$X
M2(ZKL.>%R;T?V56=7'_0[T"SNEH6UUL97K6F>SG]OPCS]X0;1[0>@BQ%LQ#J
M>JFMGJ*K):LR)[IK@3RUCGX=AW0(T;$>271;%YU G,UVLH.P_D$+^?UGG'S"
MWV?3Y=EBE"-F!84SP362/R\LB\HGVGR]2"H966)KKZD3X"%$Z89*Q$["?1P^
MKM;.Y]DH^1IV3(YY6?N99;ZJ$>)8$B5F94(D _'1%>'GV1""?T-EWS&B?#S2
M_3:[F(^2"2AETJR())CVM8&>4[1<<G"\)%/:WSP\"N@0@HU#IMW!PNR%=R-R
M6!4&[5@FEY;4K52D;E5BR64A4E$^-N_L>_WYW8O!5:$NEO.+.LM_3F&=IH!7
M-0S?S/%\?'%>JQK6MU[OFENS)G1 'F($QD6MFAG)0PL)$@,L.B6R?7AJ;4IT
MA#RH@NQ'4^ENM;C3R;'-$<_UH6_3)L_/Z\\C(//:2*Z9$$"3PG6AG24 +?-B
M7$P2:=X/=@MW/V]0^4J=V='71+=GP/T;B\J%>W*G"%L=N]:!-I8BF:[U4Z7T
M3I1T, D.B T\[HEO>QJTF^T>HVXO9N?GXV559S#-]?8!X<7IZA+[JL[N8C&K
M>7:8/X^79\LSK)558?IUL3K#[A*4:_/@[C&['B:@4?;:Z@D5Q"CXX"!DS7C.
MM02-Y@PR+[6K!]'205:N=6KJU<-;9J!LR+]I80&1;%D=-,L<%>V']>H"F9,,
MH@"9B]4RM,[BO@?.$")QW61_7[Y)E[EO=X)XH^?$!HI"&<AM2606F9HW3M^!
M ,4$:"[(KTV06]-@*Y A1,#:$J#[?/>2B?:V3N#K\N=BW3[N1KFMG &=YIS%
M6N%-1]H20]"92>.X#]8%#ZU=O3VA#<I:::X?6LGD46R5]7';YIR-[*UK!9/)
M&;L^SGYLEF, ]&F[=)Z01C;,UHS'J_/0"QQAD#XE;5@)M7=##K5P6D[,.2>S
M,$J;YD4X'\+42\[M2%OI=/2&(3A>>^C46]XH&5B3A#4J>M':AML*9$A63E-V
M[)5L>Y 8^LW"ONX5_OHEX6)Q&2/ &+DJ@3.K7&!:DJ*-4@62;R',+IAL6I=4
M/PC@D,RDTS.HB=C:1<GI^8@[6KE=GP?CE.0!'%,U^J2S\ZPB8MDD'HQ S9O7
MI=T7VZGFX,XA;I)%9Q"%\>"0:>T]@Z EBS%I:Z(6$IJ?T!^)=4A:NQ?.W3FI
M.H503[X,KX[4O-?(A:ZW3R6AK->"H$Y-,A*3U%H7W[H$TZ$8AZ3F!T6YHX3X
M*%2K20.U7S:Y^YF52*ZAEM;2>LB9<6\2Z 022_/\C\,@#LNO'AC1#A5AHT.C
M^Q"^G_V,M4DH(7Q>ECB_6@\:C%9 .#EDLK4*V5H1R=0.3@2?D$M^^Y[0K@.D
M8QX_A%2.D]#H1!)Z'(VURO8TKO):(X.H:M,UKAAP#BQ"\%9FGU-X+&/UH+S=
M4]U%&Y[6.EB,/1TQ7&]K;81TGJB?R-W7@@<6LQ;,!L(E4\G!M_:J]^H^WFR$
M5[7&,A=)*S)(<G%, ]3Y-X9)E[D10G@C6Y<QO1_1D'R7%NRX_Y"EDSSZ7@5_
M-?H:N6RT+=(SXPMM!63(,N]39C:[E"S]Z&3K%I$/@AJ2RW%"IAPIE7[#DR.7
MC#/*!\:+@6HK$)2:M,25"85VD62;MU;?(V#=:'2;Q4EF4,H\&N85I\7I0V;1
MH&*J]G$Q,0JO6GM'74M@/&IP_B!6'%3^XA!)],O\:\N1(W!A:FUF5PS3VA46
M0-<S<^4X\! \GJ1"RC!5Y(D8<J0\OI6#Z-&MW?\1CJ()PL .HV]/RJF.HTGM
M1&*18D'S6JB7]GD?##(7H@S62YYMZ]H6CW(<O2V<*;CTCCOR!K,FYU 9S:*N
MN4$QV)!B-KYY,?A]L0U^7SR60WLIP*[":A,3W IM9Z2)FR2S\Y*957JSX[6H
M@)9,\,*Y=ZCR[1L[.V*!!SUV\+MC5Y[T+(E^#:O[CNV 7*?$;6$)$&J+'T4H
MT3(IL1#^@"!.G0=TS!GLJ<XI'E4)=1+>R2BV.3VI5VI$=(&E9.RZKEY,"9CS
M7H+UX(LX23K-<0=?ISJQ>/1=[5!1G99'JW@VZ(Q$<V2"=EG2I*1$04;%3(H:
M= J C\.DH1U'/#Z7#A;7Z1.R4'BA7"9UB011)ZU8#)F\Y@R)=FQ4*CU6!DBO
M<[ S?\XI(]&1I%!(SG14GN@A RM""A]52CJ<=$*ZI#\.+A7K$+8==/#71)R]
M'_X53HHF8F#*9T%S(&OW4"BD%"PD, 7!-N]XM\_AWS>25=6%/2U$\BBAO,OB
M;<^GTPN8K,#?B&#5J&3=B":U3NOJU\_G<Z _[EJMKF=$?0;ZVD]9H[C?31+N
MJ,ZWRH\(12LD1T;JU46GQ&+4R#B/N@CZ4;0O8;H?M+::<>=CK@H.2^Z%4<",
M4HK6)&GO* 69:39H'P"R:=X?XS"$0]J%^V#7_6JTJ?QZVGUW8GPY)5^OFNF+
M472.<XF)*9<R;0*U%HH3HI9#X$Y:;DK/-W_W #FD'7M 3#M2BH] MNH,KH$J
MGE%KARR+LDI_K.TT,S()PAN7?=;^\>AV!7-(<<9A$>XX29Z:<N_/<(Y08_ C
M[W34-#-,H+V\. T8)/WHD::+>R]:IY<<#')(4<@!T>U(*9Y>O]5#GO6B<"Z@
M2K6=>*:=7^=:S4,ZR2R !>E#UCUG?NZ#<DB!R@'1[5@Y/@+?QI\NE7 .D'VM
M?TN^/$U+L::6L"(_GLP!+H739!<\&M\V*(?4(V18?#M*CCV&8GZ#\?P_87*!
MOQ-R MTUD'+OYW4/@^P/MU4WRU5+\:O'UIJ3DUE]\JA>VU%::E(3I<;GDF'!
MB,BD\PFD+!)%:\6_$TSG]B&P.'L^S?5+[=CZ"29U7K>-.G(#N#H>-(+4I$;.
MH@+-HM%H=$E0FE=%VQO<D,(3;7ASIZE(+W+J4;V\G-*W^!Z^U,I^YQ]GTXIW
M5JY>OJR.]3-.L8R[M*D_[D'=%5*# 3;25+]@P?F\%KO<^NA1I-V-.]IKLJM5
M4-$J%G7R#))TP9F2K&J=[/, I.X5GM<?_VX)2Z1E\8K^8K)K^-(@*FOK%:!Z
M(R@K6H!:299\<#8AYT:V;H%T"+XAZ:Z63+I;S;DGF36SR3<(?T.:]-W82M8E
MBNR9X1QK/_/"HE"D946*OB@P-K=.W-T/V9!"IZ=@4D,Y-6S'MCH1V(4),H2
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MQ<FF7<GKY1G.R;LCK%P@,X&7VN;",1]<9C%RD(7^J#P*;W<"'E(2WX!8VD;
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M[\GAOST6-)_C/7,R+U^O_T1ZUC_^]O\!4$L#!!0    ( +N*=%;+ \N5[5@
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M7OWZUQN__Z=:_+8((?RR^/3\5V?#3;](CQ6__-_?7W](G_$$V' \F\,X7;R
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M8(JV2J:5)5..6\<B""^M%LK&7I:BCOB> )WZT-1-5IG#L&HQ$P8B1V>U(X>
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MCX_+EEVTT%.FP?KPXPW.5]LB1L<5>,N2JPU/I2<3E2?! LKBG3%%N.;929N
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M2Y8V^=AZM=T*YJG0K*U6-O!E[R#^.:)K1;9!HO/T7QHCKW:H%LQK4*P$XYP
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M7HW'DR\P/YN]'A;\D(8X3CBKZ(;C3R_/QGG=N)HV-BTE9]'Y2'N>]BQ6^R>
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MD@<5:YJ*DPZT8C*G8)A.K<NISG=P5S/4["&<AB?.8KZ\_E+WX6[:AY3)&N,
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M!40I(E(5)#:Z& 'I)2I(%1&D"F0K"$@7$%#X 2I-:J2&'ND" M(%A$!H4I,
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MYK^7;CB1?;6Q;O2BXN8>:G)QV],);:LW)=0#_?#L\IS</#OL&P-2);,13[$
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M?EDB5?)%ZLH'U^T^GIZ6\:G[PH'2]OGAG/62QWCQ_\).ENM$"A (I_><S&%
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MLL5^(!ZE5]CG=;*B\$?CI_IX)RA>[[2%K\&G#"7)_<>)7P_K&F 2&U9!/<^
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MWL+2,'=VG%)-.P).Z>F_B=V8_W F \22KO])$YK#P:25 ;$F"-*P?,#6N2:
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MJ6O @$Q_B7[6 A=WRF! T(F# %G2B\I=1<H&;>L%?>1@I0L5[Z!.N%B8O^;
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ME,(R!Q&&P'>XX7]<G!H6Y@%H#_7/S1[7P#L-ZE/#$=6Q^L\$TTV4RB/8[+J
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MHHFZN'6-2K07\5^": QYG;Z+4A@9X>_$$M<&(*?I=\FLSV,D<1M2EBV4LL+
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ME0[%<D ,\Z,_,#3H0W>X7G'C88=.:5.',CCW2[P%0W,R9HQ)HD)WNBW%Z;9
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MEPAM@'\Z8=[<(2$KJ)CW,H(W/1%/U)&G34(#]C<E<F[,:=\$A+>7MJOQF<L
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MT?]BF%AW,U"6X<M:?<)C]/'[\F8$;3(EPS979V4-/5P.2M=N!G-3-$)06M/
M):-M[=AW)%Y<Y]_U'+)P9#-SZ)T\O:*ZMA,_R*Q; (.R"FM\.-M0D)J1VGL3
M8U;<H%J%W#"(>=SQF)\3G*"!E,(3 CCH+IE.$I7)'QS]].E]R8\W JJ?/]2
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M*!=J%-FL0\./.+F03/S3=?H<:=FG^Q/B>XIUT/B#6P=X2,]U<MY:PC&^<\P
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M5KJ^@4)[;E1M5-^,<4'?Z9R,^2#^5KJ/LYONG1E8U(9DD)@I(M2"NO9.B3O
M22:(>@@4(+5XUGCS:1%Z/5\6)-3(HK8L:9[56O<SS3,4$*:7&*L([&RB'U6
M8M+Z:8UCU<KK:+2>BZB(NI7P\*OIT]15%%^ENO7I1>.:6E,3BH64DA2LM+4
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MYA#+$O]HXVFDSVH^[+#BW*VT*J:T&PV"6D*U_3?+NCJ,K6D:7B\!(X/$)IN
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ME2^"N5PXPXFWYKEPAYDY5.&BN_S(*,-,K&G2ZO?.WH'R$\TLSX_F"^D27V
MHL29X"!&F9,HY$H&T,QJ8'F4-1MQ1+_/^].N3!8#OQM =&7-ZK\ZQE,HWSW*
MVO58T*J7L'(5(@,^N>:=[;",IJ*G+<F 11DB8G+4=LOL;O;W_W'^P"/S/BZ;
MD(1I'#D$;J&N3UT]$SB !-9VVB8IQTK?LM?)?TI)8:&S;8/5UFH#7I%R1A1W
MC>ZX.03WP_GX']WC_V3ZB4>V>[ 1XM/!.#WXC$"QF 8$0K3:3W.M^'[7(96\
MJC5[H*N:D<UW*1[3F7/P ?XJNO /9OQYL)=W;S1&W*E56#]@PEE^.Q^N>FQ5
M+8>*6K@>).MBQ3]$E%]4]X(Q$#Z!5ES/%$US'LPSJ4Z+67;MLG%%4*Q:+35Z
MH!S/D<I_EUH7DE $H]WMIV4N\U*$&9PCIC%T\"A [D^"B\PHOXN]R9+E7ULF
MS?N&B91O5AN?&TX$V./DM1J;QI;!W!#)7ND?NQPC8J]Z63GD]S^G7YH%@6VM
M$"Y]C*^H1Z-69[0:3[\C)5R5G1_7%+@65$5LI*PV+4-2ILD D,X) 5>] B:Q
M#B] K)=@D<H7Y/R?(AU3*:)?J_V=3:)&N%:L]-O(YQJ(NV2 :5??PFCJWB C
M:4@9P;8M!G?E1+5NGM.V!0%'5^ZYYEEKN+FY/5F^R5#2'C]&_/7PXRMJ>![*
M'AIGC.)6X"D21Q6(QRWQ7,:MH_N#+V<)\'#?X__XOHU#5GA\..KS>:)^M,*)
MCU5V'B=[A[!P[C;_"&CMH+(Z=?;DX9&H-?.%?0(-QP\6G%-O=&PAJ<7?>GW*
MMU=ZZ:;>["D(&'PLNVN=,VY@.++M7:J$[3QBK4%FT&AP,5PK\\'L1J2858TC
M>@0D%]9D!O,M*KE3A'_A440:F6>!QPSCBQT>:U[VC_UZUD7Y8)(@Q'SJ4?72
M<0;HAIY1X#6]_V<( \#(,0))F\'7YE=ZF)2%:D BDIU 5ST?_F(N:A9* "SR
M(@L,#Q/OK+-UWGZ<TAT(L[\K,# :$TK2G4^K&;02%@HR?HO!BV2^QADL\3;B
M[Q"F-IHXFT93Y]$:XN""$;#H+4EJIA=\; ^*0-U_U"F3'J3C6@O.<Q64"R!I
MK3<Y@\I+9YSJWDWJOU@]=0R;][6:\ JU\UZ\)**Z*$/YDSO=6!['TIY*!D0T
MN/_J]=;V.VNK.E)Z.40(T1T1MXO=_W/E RU5 'U:F^]G#S:*T@\P[GR<#>X(
M9K_4^6V-S5AGM>WOHP_[OA_V_O3(TLET54F?3W>_O?%F?$PK_H*G%0=$Y,XZ
M$%'=44<^O\-U"*Y@GB:X;4FSN./>RJB#[[:-Y;+O_5YBW3U*QP)= .#2*HH+
M45_;).3"XCP/'%L>3]/YA$4A\3RD-)#"==&!X6ZQG>MFSU9L541@\S?Y/T4>
M#@9/RE'.7PD&TIN[2'-:EHR8YX456@\@A*'C-CW"/Z\C/3]>HV!OWH.BE>9T
M(@1KRH>]SEW-8WOH2TLGV_H:;0>_WISA:-*9ZZ1>6E46](#\@G4!4U;.?6H?
MC>@Y^Y(<AY,]18_**^)'Z2AVT6W!U#M/NXDB?\VM+_;_F0[VRDX=ZJ8;M,J;
M"U]LKI0&MF<=_L1\-U5R(RU38@[$MY,I^; _D#K/^0CMEEEN;MIF%VUF''9M
MG.V/A^D %8>HAE"M8)/1>?JN@D099*_557Z!EFLMO\;?%4C0I%^M=.1V[Z&9
M^:Z0U'JG<L6'B98E>7$8B'5NA!T2:$F6KE7A(\K7V73!5 LQ$F=:VU,Z$F=W
MS"$[082!SIKSJ:7'<S.RJS708+\\$M*WU-Q%+BZ217=8O"$M3<S/GUK+]W=.
MUIQ+_8=/W<O<R8,N&TJ2IOE9N+]&P5KRBD_9U=+\SQFT'6Z>8\\WU:?-=%K"
MY([*6(XL1P[Z!;LZADVD&A']1:J39O9Q80Y#8J7 [FCZY(KZ*LMGY: IH?S'
M16%[!V3 G3Q$(/3Y\R54B_]N9(69#F55M8@MM\."#BK3Z>=^\@8'3T^< D)]
M/=W.;8E#:LR4X&9-%< 5\BQSV4H[?VW3Z9@F[T5T/$CT$O]^['+J/B/:OVL8
M(M0N!QB7RM ?5,WL74D8?#8!>K297VL4]Z[,,5D1+YQPG_VCSI]<7GD)"L+&
M3)<U9="0U+9RNUP)I[Y:D<7Z:&[Y^<]66@^8A)!0K*)L-@R'CIT\MSY<F_RI
MHR%"!IA);$[\_4GX:2T3YNV>UWMK+"9WP?Y;UON$+7DN)\IT:5G :A,#<NQ@
MFZV%Q#3Q2(>"^*:"D,>S$IV:6>Z=Z[(/;B\$<[Y_SE\N1_WD2<&N.*M[UX)9
M61Y#7-Z\]>Q]$S$;WV6'-S^%B]YZ0+@9#O?'8,B!1L90KSCF/IQQ)].:&>*W
MBJN_V'QZ9, J+:VLS.T<(]&?#S\JV:0[?//*F"#MKFZAMK=+)]J2?U?.6/<$
M68<.?L!!(TN)SI@SD-7$H-[OX*4/4U*N'._*V%Q93[*37D\6<'!'<Z)+P-<V
MS>*^*"B# G^MR5AQ-B7Z_,B?[Z>KZ B[99_E\_SK)4R<V?0O_X0JFKO97UO_
M$=DUC)]1FPV>9("MU"3I$ZO/87.  !E@N00[XRA#'5S[9^#A?Y[$;B<#G($4
MF]9,-J->Q?(Q3Q]5%FQX()M^%"&C*Q=$:4"7[+Q\GLS;H!D>(JHOEY'^R+DU
MYD.NKDM]08IH23<,_' LV: -] 4#(J7L$VSX?_SI>WA7O./U-^8'G_J"QBM,
M.@H)[CL*>C*?>;SF+ :+^*GOGK$EL:'YHA_>8_D]Q6?? Y2Y6@VUKU=DU,'M
M1I0>*#,N0%1OC*?TXPZ7WW<=W93^T/'L2\:W7>V$!P,^\G84J?<"43J3I]8B
M'T!C:%[X'JEI'TD D@'\QLW (XEU,N!4F^?#>#N1\8(WBRPRGK%=;.5SP=AZ
M%TK69N(;@A!&.<:*-T4'+QYE6Z3#TX WM;1LYG=5BY<^B<C\S%1 NBS2!/]!
M>APT=--(B=^2LZW#2@SG;S*G82^V$X?I1K)+.-!>=QIK\.#NM(MY-21I!W!K
MZ?30M%K:/+?&BXMU[(N'0!V5IW<-"#Y+FR"WW18E#MQ+/[<(P7C^3&"]\XS)
MC^70F+80YG>ZMS&OEGYPC<(L"!@P=A,.D(-PC"NHG><4(,3XKK-'6[8Z+ 13
MZX@J+3)H+ALKXG@.,SSD2UUVL8+5V.)'$O;B2:5.R:=>$RDTAAEK7W/" +&,
ME+)\"IRCA!E\B";!/B>ODI"FBEM%0<*T[DEU"Z1."4N&.U/:JP/OZVK15=[E
M$&)%:BA_(*'B9)::4LUMA=W-]BX\R/RTJ?HQ&4!0"WKLDGD'M])/JE\\HY=N
MTS6/ZD;4B(_O_+R=K/[%1]B#ZU9\VUVI[:3]A598Q/QC0E*9L'.F,L$1JZ@T
MH+Z@&Z)27G?VK/45M;Z;.B7F(S_3M5L''8%4&G-JIR14ON+TGG5,P&NG><%1
M/GQXAT1HG2 LSW6B^F6==JVEGIU&9W>U5)NO?<2U[<I0QX%+W:>M$QM<FTYE
M8BL:VZM/^3TZ6Y+&HL,HO2E]X-^DK#\KW<)MH1G#$R8Q"U\0M($> UJ-0CI#
M92R&8;-SHID^WR=+3(I!#N+W#1^TG!5LLB^IVZHOJ:@/77FM]Q&P!L@&MIZ0
MHDZW"PK_$M763RL'%$RQNY<V%YB\H-0NIP=^T(B#M"FDJY@2)J;>HB9F/*!B
M@[(O@N&%W5<_;!V4GC _V$ZZA5>-!]$-#V+.NDMV>)](=P^"N1?S&;4K/@T\
MOMH PR*/JO'F'9S''P_B*"%J[69N,3SU&RR$UNUQNLK;7DSM7VLQ[P-:C2D7
M':\6G"<?R.O0="UE,*U[.,L=9I8"C]*?FZ:]KG9P-7FI2KUZ63O3J*7\HTBT
M5\==EXQSZ WX<>#9YV.=E1-4/S$*B#B.E%*F79^_ 2&:>B_&,5BZ2)IOFLTA
MH]FL7JJB#=C='^D+YVA>UV+=N>H+%SE/);HO-7IV6MT<O?!2;(:U-FT .BSC
M%\&,1ZYSOL.'EOKM#S%;RNY\9E8+G+GP@ZY*HL/HUH%Y,919 Z^O$W8L?G-"
M>5NDD.MEK4UM< ,;\-X[1T%IM5O>V%I8.!0AGE,,J6MKDY&Q8L"WS4EWC"NP
ME#4/1,KU2'VK +_@T4GAS_73T\$&+IQ =0HV6*6M)P\)6XV,&O]N=-<->$7X
ML3@85IW*VA7YHI.$6>4$3S]*BWFVR/IT]9L)WP<]Y$<A@&<D[%_Y?'=EQ-B1
M''U*6(.Z@J7$YX#G-MYB52D"30EH1'48Y*CGLIG0H A35MA"?:50]%@/ B$L
MO#5*L#Q[$B"%/T*DJGUVK-5J5'$<NVX_!!>UK4.KI=WRM7GQH8]N,=%R,LZ[
MD:HMB';"6^>&+Q079V;64$WRNNJU]^2DDMU(HNL-0Z#(W\'IN*>XDB!A1/!,
MIY7XV*$UHW-%ESUFD,U9>3IQND,^*]-++?BQ@)$7X($HRP?TT6[T4=V5OZTP
MUBYL6D^)@OPY3,1Z=H8,*(EEM2BW8M#AIN,>-T380N_8[+Z:=\R ;]OC_!2=
M>O<W/J"3<JEI9W4PVIJ"56&J)\_KS1G%I>UWGA&;QF<#+%8:KO^#!?],6(',
MHY9 \NW.I5:0-DQXC (7!LYF/KUN0$C8T)(VR3&VH="B\]3@!R#:;]HMO9^K
M:DS$+M ONI,!!O]Q^VL$"04G>!B,S1-"%_V!$;STXPHR15KN8&<H^W/%G,^I
M-XWH$F[?^MC;6R)YK7O=0BG^3,ZYRD^IW/87!-:NQ)]H/"YZJ#73KV\.E7-
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M.[#!5&^,JR2NCQ+_Y8;OJX.'D3TPNEX0:I=(-7)%/[J9T=>?1D#MF^/4M,_
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MU:#W%PH;P=Q7AZ4=06:&+>ZFQG::,AC(;_V8*WBPT4?Z<$?FU=?WB#(;/FB
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M U8 TCZY=U5H7_US5J0?;#?>26AI![\B(LR0_B;0O\"(N4.PSQ0/@-W"=L/
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M,XD'<X^#.5J5JQ@@=T045*%.?TP%DU!^KU/'J,>^:EP"3&2-O;@;DW4>IH3
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MS<*EXV*UT;]P1X;SWUIB+64X)71OE()VD5_D"_1)6HE+HRE7KV%C38).[/.
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M6J]42'Y@,2@AD&;]J(3N_8&NT:'O"U'08Q'*_L(])V+/IL<=IV^);%V[PG<
MBF7:.&H=!&$!'QST#-D$JMLPPZ<?N[ [( ,LG4Y2:T^V2ZPU'*HGBR:_-=NE
MAUD*37Y5F.L;/CP:H5]=JLG)IENZ(_GZ?B7RELC>40G7! _F)L+#P;?P&<NS
M(6*/KC;;S[+$-"8Y,K W^)R,>2SEFHVNF0BM48O%\31/K0L,[M\[)'3RZAX@
M1R7N6M@$S_0-5"'V/8HS)J,/"UFAX'(4W)GJV.NX,$V>M5)<E$T;=#%P/9/'
ME5(/4'1(&1QDC0G9_;5J[2SC6+AUA5H5B-5 D4Z\S?-I!5'VGI)&T)RA]JN4
MB_N8BCS!A.<$3'Y<:I\LJY\L[!96$S4@Y-*30S[:9<V9+*_9<L$16;0T=+\0
MB:_LN]VD89-4\X5@9U6^++P'/^HBQ;3%<I-\?##?9L/7T#O5&HA>+%V!BJ!\
M(X7<E[JG JP+3DO%L#%N_+L5/D^&8ZEFI)\RV;Q=?.E&D?.6?__%:O]L[GR
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M>&XU$%$<H-7?+=*C]5*6-^&^X]\.(#45QG_>D:P9F]J$&ZD@7_)HB3X).(0
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M7OIR>G6E3E)I:5,WI>/F++5)%9)<(>D^E7:=GJ)A0^\^8T3"@FFQPX>]/I<
MVAI%DAX.2L(2-H5]9U;HI%I!3^)^]77DOF#7GSL<N[8?[QEN\1 5 2Z<0\2N
M1.@N5;NYPTEBE&0L!97^(O>%<;[G1_7Z(ZMAE?[VE1\2(O$(*@6#,HO- .6$
M9NGO6[[$4:X[<-/[&8^O\3P42/8C1LL;426:PZ)K0)'2=4K4Z,^)<7!X$K$/
MR^>NY^TLR;[/>C2,7H5E-WW*26=WZ0HFPE(24+T9)C$X(_2A\:]FE;FN8-Z<
M4QV6X"^D']7AT)9.5Y*]O<X^KX&D)XJ;$B? Z>.)/[2G;S*6S@E-N69_V7R9
MI./$K^A./@9"Z)12/G>I@3W[>V"0"D<Z4#9XTIH30Q4'#RM0_>X7JX7&%X=[
MNYFQ=D[3S&9"'XL\4*.K5H]H(Q_D[IL/\H@YEVH602TEXKS0I]VS5NN18.4R
M;(INPQC,S<VUILE  C@[B,9G5R2:KI#] 9^1*KF>E!<UE+<$$TQ O:!]TZG,
M-=\CW%6AH\!5V ?WRM46E_IY6:A/*JB78?48:@C]"(S<T$GQI[G2QB?^G[0P
M@ED"4OZ"U^Z2GG,T9RX;Y791,&QW92@G2#: ]>G+S%MR*B6SI'K,>"*]NQPK
M'X:Q*%VO9#Z+XD%);DO^,CA\NBXD.4"<^'=#09/_82Z&^_E?>XEKN?$YU[ _
M$'0*KSV6%6G(-A1 WWYOA'4-E6J"^"*-I3\](UB ATD'K<"MO@D!I-N7  =$
M& .$&.>/BN?L'.>%?8BOS7 [FD*XI =/<J>--'C;WQ>_;W,)\,N[HE-1N=7#
MU1C@"ORD#(I=ZLK0#$-.N"U/2" H7%(V=^KNK8GWB_7<Q(7=>5&/(G\DD(-5
MN^#@Z[@$)'#<Q13C>%OO3[X[LZEA 3.VWFML\#=[D\3+^!2G=<WC!XW'R%/^
MC?*C%L)VD\BO@(6%A.+FI<^M%R)C9N?RWHAQ^(@?8U<RMEHU\"Q/BQVT#Y72
MT&9]U91Z0^&4ZY%^@^3H- 7:@? D';$C60[9_/GG/?O0/]D2TAW'9C8IWC\)
M4AIT9AQ[O'\C_RD7K=:UAYE]]SS?BB>(6[/S[;HY(:%OKA@)!A:B8(5T69 :
MDB3;S*O2-9XE\Q6[\:4ELZ]=G"ZK2E@JZ[WU6IGU0-&FK^];,_V2(6)=+K,Y
M.IIA%1XND)U5[]?Y-J]^^H.T+B'#PY6T+ATH7Z>O+^$:QB%605DX+*@ V]F9
M)D)WDI3.-@3RH/6W=GWC[W?(Q-[Y/B8WX"0!1B#"^RX.&$X+P824D5?/&=E<
MD]*/B?WE7Q(7+G-F"G,N7U(="]I9DT(>OO5?I;9^C1*)9^G)1<6.D/HIM]41
M)"??S3E6>,N^:0X=)C,01M$%KKUNU2"U<&0B8N:6W&2A_)1!&5GLE-20+"_O
MN/OY]ZL?ZJ2W<67KN7&<U"^6];NSU;H"O!=BA:OMW!M;TRK.SH-J(H2VZ=#
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M#230+W67!7&M+R]%*%!)E159ZC TY6V-!.]Q^9U:9$]5?B()J!.\ULO,G6B
M;3C%_;>-&G!&9_K0%E^,?Z=X]9B5//B;85F0)=6_I7CLE_Q'QYC/Z$IH_$)"
M+AB/07C^"9?:?__&D:CVOVP_$K"]''"1#A@#7Z1P<&\%NQ2D<IC7-$;[QW)9
M'>EBG!_)S6:39=WD.=S+6B#I1HX,FA#)D"9]<J0DVEJ?;E]OG[BS2S,B\:&_
MJZD@\9;JEE]O#=@.?7BE $'1-27++0VI?X:ZWFX.L.H-*]G=JFKD9GM_4/V
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M"C%D[<D+VSZUM1E_<DL6-J6WWPQ.C2@V#]$JJ#?\GE,#^#/WRE2<EYX^J5A
MJ'R+X2?_!RZ&8'4(3;W*)^)6D UJ$X@E20?P>%'VKS6#[4N 2DR(_/E?ZTQ7
M'P63DV0,[TEH*WT,B'HKF +]^=?@0+G+N?KW(<4&T\/K#(ZKU-RU7O>LI=XG
M-=9 '#AIMZP?H"NJ>8=AD!5=CNF7R4L:TW!Y53>/$O-;*)#H)ZZ;<]Q:[SL
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MNZ6K_+=9.EMQMT60]3X2$7UOU+ZU;LJV\K.;[02-=(,9*?H-C=S]2X#NX,W
MZ<$,D@@[2(PUY^3JA)*PV>)&:AJC4^%V,#<\^YB\AMOYX5)E6[L@Z>[K=FX
M9VGK7:<D%R62:5>':>%F<>(3PX*,H4_;Q%,Z-7]>)D5<L3F/S9BS]1/]2G1/
M[LJ0X5P'@1O-F<@@[W6"H':J4CZY8*L8\[1:$^=?/\T<M247HKL$1.'2SCX0
M;FP3-/\_VMX[JLEO[18-HF"A"=)+5$"4#M);;#014!!"$:+2B8#T ($@2&^"
M% 4A2A$% :FAM]"[M- AH9=  @(!0CBXO_/ML_?O=^^X^[MCG'\9@S?K7>]:
MSYKS67,^3_D:</L97+4-A/OT7]J>:JPG\$#<$O@OVIYO@"+QXVPRR*X(SC_*
MO$H."RE8BGV2H_O=)@$VI;%'^)Z@-?4-?%%MG6N7:[Y> OH$YHU=*OK6BU,D
M"_%<##LR'AUQSHE.><QZW1HA]>G=FWL).G1TN$SS9Y5DK8-V+'M;G52]^,Q:
M/7_BF.-6#OIK812V@69=ZT>,E'5EI8\3F.-:DO3GFQ([?+,0+UQ]P#%R4U1%
M?;X7 AZN-<*EN[02'+X[BL*??(GATQ*=,#B:?WL7^($3D])MQ7'@=X0(K]7.
M)NGKO#<8W576Y=?7>.I7LYK,D?0QZ)MH"T"'B;:JP";[>AV"[010!'8.U3'5
M+I+H1%BF[JH](+0FYS/&R:2KJ8+:9@D56 RSDY51Y8B@_W4=B;(EJY\]+R0_
M2#/+1BM5S%"=Q8R/$-M"L VAVM[8=$8T8RXI"R>&C+A>UT"T"_7X6ENI?F2:
M8.@."W[UBH@4&]56DFK^1 6Q&HPC).P<L\U "HZ2)'#RQ\[[E(J?IP$RD! 7
M4=T7/*<?5RT?6:OIXN?OF,&7W#=E9B]_&#7>Y4S-R=3D<EU\MZO"U/QRT5FN
M,9*F70ZIIIVKO97Q4J=S_17BC20'%T#L!-2A<#G4=+]?QD C1(ON&\.%:_Y2
M3]54X28C<&H<O3A:A^@=]EO;6<S,JW@8+NN?/U7)&"=YR?3]2Z^#E 1&U3R)
M<:MV)M(D&NR2,V/2_=6TWYUUV+B:=295=\>B9[ KTP>RX%SCIO5J(1I_3M4J
M5X<B-DM$^->KZTX?3A(>SJ9,(Y!5O]2O4#7]>Z/(+6C07QI/S@S\FTD$<H'D
M5$&90I8U_7Z/MCL!W'* >(&;+?E. .]QQU\1LX192NI@H-I*^?O>\I 30&T@
M)4G,CA3@ KH[E-WG;=Z&(/XRN_+?QPW5LB^0_$D^!K%A/(#X7612]*!(>> $
ML("M/27W+RN"3P?@V^HK^(][#A]Y_(UJ'9B0#F4(V?)XZ@0 G438GO+DF\7I
M=S<I3E&<[U@!A>3W;Z*#?)IV7,9CU_4)*2U.5LUL&9>)NW6#JW+.A^U1.2B$
M\+39W'V:,>3YP(B+<\PZ<JYOD ^/OY;W2J 1EY8:1GYO77'T*K90#Z_E]Y;-
MF2@6H/7)2KC-<Y_TH6) "<-])$-RH3"KJBVW,/XH;_NT__C96*O5?!K>9SBS
M(T=<,'[O^<%'J9LB\9TO:2Z:=V-^ZVR=HC)>W:S5 SG*5N<T4OWTK<^+]% X
M3P"=3_Y8$%^D 8]E)\!?_Z9"^<SXJ!!L0"@XQK3$L+<8[RMY&,LEL\MY/^Y\
MSK<)D<JRON!:>>6.H>!K;QY?L)&E$3%_+Y-D<Z0R[>!U F!2>5A]=B)56S S
M33F"W'J/&CBM,=;T L/K8*&>BZ%0'XLKRZ4J-="2S!\/[/9?65-*ZD-ZBQ?
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MJK/\8S?]0?>0QI5,U7)8GM?+5AXMT3^R*A59W;QC!G\I!T"6(B+W?^R7GP!
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MB4. 4MS#M,91-<%R-?5>_&\4^(DHP\\I29;PS.==5UD2LKS RBD<G4(^&B<
MS.[Z#@_K>TI#4<V"_WWHXG&RQ"U4ZT^G5[L<<Y@^I91FR-O'I_B[K6J^5QW3
MHM2UQN4R6:LCX" V#.6QZNB.&=L>MK;[QMEVSJ__[:9L5,%%3ME)"[7!W=*C
M FGL<K =X5U?N*_7)$0.QH[VXEI*EQU!HI%\ZV8,18XR1R)IQSHZVQL>.W([
M5R[M)<7S"YSQIKYV,4L%P%6=?WJR.02H_EA$7#JD%$ /R9M^RZTU<8SF)(8C
M"G/4K7*Q6PM!$B5F6;6#/8.9S<7X:\$'(9)W.506K&3O8V_D8VO6+32&[@^(
MPZ6\<SE$-W]W3[Z@^R7<HA+?9&,S'LWZ4FF_]Y0@2'C.@T+W?5D_T8O,6I@V
M;G$KV//+2VU]]%(JEBI\!I\&?XH5Z3X!6)^&0)3O6:7DTB+S]?P?$2,!XWDS
M,QK[KUX8O>ND[NG :DV47.$$6'V^\6*OZ-B)@AC-T;$O/T88*^G'FF5\_T*J
MT:PI3S[2*/%7@TV"!^&*-XI?;T<PY90*\W^8YQ=+SW+EH,LM G_1] 0V=K/6
M#^)^N2"*F?ISFX#)R5N+]!WL0O:T*M;S.:\;RO:*LU<1XQ'?'/EX2U)U?,CQ
M!:2U=71A^^(I-/B9Y5,[GZ"AL%M8T[C/S@XIS0B1'=ZQ>-:)[> R+:3VB6VC
M2G9J^?1^ZGWJK1, @Z7^[NF7QTX*$8MD*1#,KM7 [GVN592M40AN&^([)3?6
M,>'&,X?UUV-D/3BF#T.#KL"0:$E["I!$A2VPI+?MPV$>$_9C/B<3+83NEU\[
MNAAA&BC,E)']/(@*B%A#$59'I75D]O;FN9\49E_@?*EP%FEVL/Z8 &E!1DYX
MA>HBT06W->7W?!-]]T)\5*>;-7DZ;ZR[O5"?6LOQ=F[CV%U55Q7^[@7=V609
M38LK6AS;/P$P3CEBE.S]'?M&FX]ZWG&\VC3#J;[IT)CI"!/T2I C:',J= [^
MJ][L/]=5V.T%?5P:41'+=JCG^3E:>[^@_9M#!8:K,%<LI*"6$2!_L9]+^;;2
MMXDWV@?:'9.I()O?98-DH<(5:-:-N+Q5I=IDL_>:^3IY@M.-D3=VC->>"[Q[
M9?U,\IR<4QM;#2B"0DV0B)6!F;=7Z\7G.:3Z?9QW>L'42FUU;ILLP;L>1U(F
M8.:B4\):@?0>P$NUH^Z=KV2=&#@Z3.6P(]9ZC/3!P3.1OHJ0O&.C>O/C_0MK
M6:<?F^8$D#OEV?"?907^&::M2?EHKWKQ >>RM/&BJV65@(=[[&YFW65,6LQM
M7>N?GL_%7F MT/(U\'.4@1OED"6*B>EO9VX1$!L'<_DG #K1DN.$(\.1F5F+
MX<N<*?TQ+8P_BPW \,:,"R*IAU%SO4MQW^&2!#SES8W,0]7%O*E)\0)/P=X>
MQQ. ?/*V5D_+=T$?JV@KV3G+"Z36>:@3(]I,**3^\JKDBIH 92#MD:F*C;1T
M6V'_-9??&E)V/L)Y+>*O)0%%[J0+>2;K(!HXT/OKRCKVB'8HBVG5X;4=6U>6
M<[]D((3CJ,5Z5_8)"=*]V[#K4FE JC\!K!^2]0[_W^PLE8@)J-F@AS*$\1FT
M7HS(%YR3-=4MGH;5*N0Z>CS)AI_\?&Y4(=#6JGE;6I-UZB^-B_* G"K<.6L3
M##DXD7F_I54EMN_._*4VTZ*W&U5&T+<.&KQR?-T4.W"EW_!L1UR##PV?^'LH
M](\CFM7XREU88?GH&5&B4+B89]3(M!WNPF;M.IO)-8.$5L4I@8/[SL(7P,^L
MGR,?D[[,WR<L8V?#:_7$LNJ<;G29EU<D6S%W=56=?R;"VMG8-Q0]JMD$H3*'
ML3>M$-?,0HO]\CEV+]7@#;M9.I8XYA\;RSQX7-S.%9BGMJ6H*&LU[U6FHDP(
M;E-Z[V!\.&'N &:60\+2YM*]>'Y$34OMAWV6+>2?TA/)1$U%OZ:< $3\3><M
M>8G[K8SG80,K\60) IDK+BICWI(/$<,[H!5QUJU-;NSUO0,[GN ^#LP/LK$#
M)_RBC;JV?H1HE'#%',.X-%5C/X85"RJ-"Y5!A '9?Q\KH4T(<='+H[_-H]Y\
M@P5P&CN)*\SP+P;MWW[C<NWU%?I/G]<G9P+$_4_Q'F*LU^X$\+GSZ>"32,A(
MFO&!H$N\E%/%":# LZ'G]^EV_5SZAH@B)VZ% 7>)B-,E'F>Q^_>,PW^EP?Y'
M)5)U<)B0(K(+H;V5BR;%J\(L-B>WU^GLYD9D8=>=<RGO&.]I7F6QE" $-QJL
M@-C*8NX!PRR!)!TGFB1W.]F,CPCG[?5'9M<K8UFY$\1^3,XN'<]Q<,KB&Z[(
MX$7 )&\<MYBWJ0NC/8;-0-,G3ZQKDML^' U*G1+B[87%O0G@".BEW"+%?UZS
M/#\,O_4=%O8@UCS\59F%P:645Q]. +XKA3U>K!RJTE._Z(4AA^N4%ZK/4W8'
M=GO_46OE]&7^66SE_T&044@]7SYE#*&3U796T?7&BKP0K$PQ',+YB'MQSM-?
M$0XL3KC[ 6,OEL)Q%H,P49,F^"-C9?+]+HW?"!';*O \OX"Z*IEP(<%Z[7R3
M-8 XD)'N(.LGH=]_./1MJ"*W;_:,!Y"&-(EKAF6A3P'D LI7-7&TU#[@5@;E
MEH!: /K&9+1/?'[;RM,SU&\^78X\3*VUFP,%>AQ9F+>HB9^2-'!UAK^^43&J
M=+CV"V\B8H)%I9OI@8'1HL71I^+&)^_.^<D:'7<42?2B#BEI+"X!E@W)85U
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M@G5-UNB?U,)U=U1^;UE4KU:L8>A8=UY+"6UQ(W-5 C@*J>?(4VOOD(>V\R<
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M]@[V508+*40^]#0*!2>G>K;E\RZ5E4R2#49$<95/D\X6=L4#>#X:A7,V]JN
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MS!EV$+:7*#;48R,3RE_JR(K]W@']<5?8#R!7%#S4;5")IU48BRATP42\J<I
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M?T/!683E,%<EV_F,4I[[7+U8 P?UX2W[KW4S'S<FI-UB8B<57RZG_X9P=06
M]Y=?[?4K'LRNI$I-G@)ROY1E*[FB;SP#*!&2SJOKAZ4!(WG/'TM/=,]GZCZI
MP6\F>WCDL<4IAF<M:]<U1!E=I1V:LM1%Z94FP7_^\#B(Q#:+XJ:;DHC@1ZEK
MADU#)#$H7)A A0GZGGIPH?=9<ABL)P$HU]L3$RZ:(-JK0M6&<>^ &ID.PB64
M^_,:72V49==T&)\(^%M^G]$;EIKK3&'G4GU*(2RSPE>U6,8Y'N(*!PE:O$V&
MF*T\I]X/+C[Y\(E4FWSPE?OENQA">!\4X%"5W<K6.+PSV8]HM_K!U5=PAL?F
M3@'S?>"+N^S2V0PN<BIL8^(^8(#-$U6AXH;1O)'[,Y<$F0[U11MSUB_5:W=M
MON09[84_)KK+=0Y$UZ;>7B&S?25W#XOE!0XP. T4RQRD#Y]794\7W,9AIFIP
M:7<G1];)/U2X\--5"OOH?,UBBS6_<8GG)>U%$+I@3HB?O7AY72F]!QJ0 +C;
M1<URK#,SX$-XT%XI$>,-!DZNI!KI6#BY!P\Z"G:>TQ/\K%#F!*\!])@$XQ5#
M^-\>1(")C@>']"#W0A*-1&HI6%G_&5' 5SR8<Z52/-[V$XV\^"WU@A1@BN/Q
M^X7H[V&@<+F))J#&:D"VP""BUDW)/,]:'X=^HR>>Z24VD_LLBRENYMO*N;O;
M=NZ5%VYJL],)W*%\U4BK/#E/SD2NJ "'RY7T2R?7&A:<U(Y2RFL3DN'=$%>J
ME[ZXNW,?/M"G["#:E,\K*1)P.M,JQ<X^_M"K]0WHX>J+EJ9U<?)*/RWL&5D4
M4Q_O,!\WB5"F(P\#*QJ33P'BT_%0XCX4,6]5W_@U^;%JL7.7HN O5BRXYL%B
M]S7$6XV!JCO*%,+4^9Y\7P;"'?'0^*@J:YU?YFNI?B\T?<ZCT_:?9MU_IR,9
MM'0C]GO+'8&/7) 1DO\962P,=ZP9EIDE:FS::'TM?I.3^"E&*W__DDFRAT$+
MJRD@X07D/=%];L.H/5AHS'T+);B*DOJ*>C*&Z3.PO/I94F2FO2<4E%'XZ+8_
MU8X1C\3R*8"2A*ZH%DO;FR7]H-PO'/06>P25A/IU8,3?+]S_,N%\M$A*_:P4
MZ4.;I*7C]5UGI9&#JZY++^!1,G""?,F\\Z0"=74BA_\4X)++:HF>!LZ$:@O*
M625I#QA9G0*Z^OFP$F]DK&7[6@[D6&6Q8V:-=0IAY7FTNB+&)YO9OM^)O7-7
MNST#GA #"]?20>N$0N<9_J'R76O# 4W6@>=0V+@MBP"F/C&1?IU>XS;POE,A
M2?8,A9DR$Y/)->!Q$O.HT_^X>*L2<%*1=C](0HMMC/?ZJ(PM-'C-<3[Z'70A
M0__)(-+4^?HU-2&UIW-;@D4V>KX(P!Z4QF9P;^.!UJ [23Y(^8A'7WL$CI8<
MLX6<ZRI=_'J]'?"ZV- 3J+1 B\9<=LPPQM<D%A ]VRT(]+6\GPHFK5P:/M2P
MUN"5 %.B2D[KWU=S7<X++PH+N#F=I T-Z^*S&C]5Q*2KE.:M;IN[Z/&6BQ>E
M^9T3R>BW+'Z9I%J9^*+ERD0MN\6-H.K%HU)2S2':H+B*#TD"9L4O)/Z"_PW^
M8H.I3P&]+'CJD^@C!#E9T[H:P&*]M9';'-6_R6]9GY@7=^$%SZ!.^--FK?-I
MPC7S:Z:B761QN/QGPG*G.U5&-O,:BK<A^M'(IU#E2TNU24']KM\MO,\_-M8\
M>!+;$>,MW9!_XMK]<Z]GC\8<Z?@U;HE#?,[$_ZG9>9SICZ&^$<HJG/(+IR9T
MS; MT_24.I1908/7\7+^1&C)PL&M>Y3U5\VR8)1S*FE_6'FPJ5R/[N 5'-LS
M7T=_G=YK?KR9U@MLHI5[,=&Z4=_L=)(#5WZ.C0\[8.4,+_?/L>#1?/1^JXKX
M/!5&:OQE1<5XKC72@))B>UGXI?-^+7CG%'#-!S'^X.>F#(VE;C3$?],V/+#@
M!I7A7=.4T-1KJJOWJ B_3*((C8B)>"W.L>CB&5AW5T-5NMYZ0%B90GBC8.4E
MH[M"6@M//PO4/5,<K\P*CTM;Y=%Y8#4<EX I0M<H/.MRD,OR/+QVP7-R)X:6
MUPM3(1C-+YI+K<%!6W@UWN(0.9^]/IX+ =.[SL=C@7'BMP3--Q:BZ'2PWZ;1
ML-7?-=LB-]_WM+(+)+8B@_#N8>5PX+R>0/N^Y)3>\P)+36>J-,_WST6B6/SD
M%^, 2]EZ".3:O< )_S/0_SZ7[J2ZO[^S28Y1U\/-Q"&2F_7-YRE*^@DJQJR1
M)ZNL#6_UA?*_RSW.BV=6$N<6+65Y+NA'Q:#Y3+1]2X7.>4:2V(EKG,>!69SE
MOD1S7*_\N;E<&2[#X&H(YA*R^YS]-C,7,/Z1)$;4+X +5XZ6[TYKFH[\* YP
MWW08D[!8TGA74GPUZ_UEJ57_?!X_,KK\OH43NIP>%7@,L8QVNEX7=6/S21EC
MX\NAA/PWCZ=>7L)]SCV^/WY\[]=) 5_-FR8<M,D_R\8#[6Y=CU.I7LSF)M'8
MX;(9X,JA.QT*Z(@L'D,OJG2)3.X=18N'C4J_6QG%+PG64'0I)!H1'^P'#C4)
MX (E6/B8B*66H[<VEJHCCAW- M]U>&[,-.K;/-8?5<U1:/8]!820G^Y.(HC7
M#_[L:/N)H(D+?X6/L,&/IKU1^@V5^>13L\UNG_'-R83KO("&72/"YA4+XB\,
MT".[BBU*O$D12>2DH7N@BN_<_*0\^@56V"';!7.E?LO>R7F8&"]I_9'NQP4&
M/(Q%_.A)OEM!=@C::8L6KD%\,\/V,W5[@S[+/=D (OK&;JJ"!>LN*=-NFQ@A
M#))[Z+4Z>I:6Z<B"D+%9EK(FKF+8>#N"X1-JN$(B=BS20:S">X=9@_I#J724
MH?[M,-"-;]G-DVCB/([.J(7O8I,Y5HP%.FDZ['TH+J:.D>I<HMC>,KF:F'W_
MYN+S*R<(N5, [4/W&S(GKNCY'TM_)JPI2\$W3TK$X7SS2X-[F4)5B"AMY28&
M)T,+?0_WDM24*]4?B@#>/F*AC^Q 0;#E816QDRVJLP<;];_H;[2SSV?D3_<-
MRKQ3@#N<BZ 7,NJZ:Y+U2]3:10[D4-.U=UW^.7>.%G6JUF_NO14;[F!&%XN]
MKC#''/@%_'([9%+TV#*%H)>Y\1%R%YO"JR_0HRJ0IFZ/F50%[@28-<&]"$HH
M.J(^5L^!3F78,'5HZG;H"<TD;<,KP8^>=O?\:A2OK8PU>:YANZ-(] VRY7*=
M2"KB/M?:L:[^.H^BGJ7_IJESDM2^F6[QI>? 1MJRBT9)"D,1!.F9M2U4%F*\
M:!D/63X4/>1M_4LG!A5T"@A]0U28[53@>V6?;86737@:2#2 ;1D'*GH.M3 ^
M?^62Y! S/UHWN95^1//GN2>8V<8.]D85+)@;8P6AF9\%@E?-&%<#JE2X]5R6
MIDWI>NPB<0DWTUH<*/T$.#C*2ER;S98@^AJSR:1H<&5A7!/(T;W<F1/9,4M)
M3.LB"X[FC=*GS5L;6ZF]M.R(70R_-O'F=4^WTV(ZJACYX11@AP8298];:Q5F
M8LN0L>[7T$F"X^Y-8KRQ7L#-X3LW+_(+O?!JY-X44#(;3!DU\OF-%@-1IF=%
M3C:2VOZ?%ZF4Q?YSD\H_VBM_9^1U?YNJ HC&$;\2Q+OG^4(7">+YM,F_VOV<
MH;=CF'J^6FE>@@.T)Y?<6CCN=OK*+,U6@=X PU!77 )*)IP/DBRMS+_(EH5M
MB%EN/#[?\.X<?8\VTP?&CB!-B]0-=Y/#%!8_NRQWS'#+ 8H?OY2<VXLHU2X%
MY\?$I$.GP XSY5\T9AG.^X49]72M;U,@79#OQ[$1D226,I@+)#O*AI;XBAY9
M8K&RK#[L/5K3D.B0<"UU.FGIX:%M;<(WC5$W38LCJ]W2X;2,?K*N?C=!8,.R
M[X_U8PE59OV\E">EXKO95)A5! OT*G[*XJVGE7/PU2\UZ=8*/C.MS](XG JL
M/,M>G!@O7PW4;P.QN-C<)=K-QS/\8?S14)!OR]+?B4P=?.UK\(@1]9RZB#J!
MGDZH!.I=BT-L<PU.9$K+[8_+R;'BI]3%.NM-T@5?6/"WOZ!5M&?0"'QL5V2Q
M^E@I->WVM$:2TD-\W8N*,I.WB5,,JCQOD, FHDPAK _'%K<5$0LWR9OY=LL^
MO?M!8U87^XAJI3;<-26N+=C0-X;2YA6^=E[E/3ZKV[1VV(?'TD@A?P5=G_&D
M&?*>\UE)7FB O<A \=*;-?3>B0O3L/J)D^_N']:PPAMWYD<)FB]WU^3(WYI4
MRS!:F.O5,#%H]8<[G<GR5$S+5#>HI*Y2/4V?4Q+&-QJCB(GS8F8/B7(Y).$(
MS0;G+1^(8BE899.2]@W41"QM6<-!0\46X$I%>T:(]L,)L>.A36R%TQ,UR<XR
M7>40)QFH+[-8:EKSFV/C* ZOJI?4W]%2%5H57*K$3*P[[1D7;5-0/NB(OPS7
MJ"6<QYDWAZ<]%7.'OGT@F.VDE\9T(58'T/HV:,[/5TAL&IU!J H.:D(S%./7
M2.BP61(?J&6W[U\U=F"&X)%TC0@[PG&GI%PG!'U1UT?2:LIY'PUTJ];02'YT
M+/C:^@9F<MZKY5"UFX-E_^1/Q9LXA)-H]"0"H]OY&58SB;M0FF<M]@Z_;G-A
ME/7;J%DOK^?%[X-;4-(6QP^MEF[Y7AMG/_3*ISSKG(D]]_5E@FCKC!*>KB!C
MKJ_YT8$^?K$9E3JTFN[3^2'VR]42#TGQ];"%."F;<G->8*PMOB"FF&ZC(5KD
M7K0A=%QWF_ZZO'P"@K%W66FLV7O4+\-UN:"<*C1*I"SV'V?T;W6:E ,H7&A^
MZU!% N-X<I9=3@$KY2*4XY"?P0Q]T1L:H"V-\D-FLLSR* 8NG-%'N-*#6,QO
MI-BC+20Y48[_=TQQ!MC7V%1X\7'U)1.3036;75V!1=#/^NDK7)*%W-OWN+WZ
M :Z/K<;;04RSL.%Y=)B2:O&O4X"#B\79VT?XV(7S.:;^0X<G +G#O=,M,_3S
M?] ?+3W6@YL02^? &*[YKC3\>'MWU]DS4!N]WH!?;XCQO=U7.4<CI45Z+L=-
M?QP;9&(C=*P&6[,DROGGD#0:"!Q?B!XY IT5OTT;GDU-KS(][&.IC^P][]MX
M[IZ RAX0%^WV;8N@%^R^M=%0CAVR. 6TZA^1$Y>R* EI&R!L?'S6E1&X+KZ!
M[P*1W7+@>5E+ED!U\YMPKIS,QX_F^3]/=GER41= UJ+FR5=(+GCWKG*6/8F+
M:R]6=6E<ZZNO=GLY"WNGLU+@;%^U4PPU1HW^?@NM72M.'ZT''VG^%]-H?605
M1(]H*V+_KM/LD7'U*HO0_[#[Z2^W<2=_P@:N5(5&C5>!@)JY+OL695[$) _Z
M3.E$G<OM4LDMSV!*\Z$?N)\U!>Y[Z0EW@#D+4#6$@9<^MOFRM3)A:6'5>2AT
M8_@1T8JM#B#>$0.ET)BO_YHXA*IN".=ZHV,EZ*D64/:2Y03R_A3PFKJ]DH@9
MZ/3%YZ<BH<YBD8&FC'D$15%HBN8LQH!E8+K/KCB'=QTY#.X4.A(Z!5 );VG,
M9+]RWW,T^]>>^;]>3WA5PG_@6E#\T0;UK+[ 0BNQSO8;ME<<KM,2#2^U]+9<
M)5CN1>"*%M-:5:YJB0F@,ZN.0WCR>GXDWXG]'%.Z<ULXE%I8R=0$$2&A =$E
M)NYI]O,!-GR@EEBAJOV Q8(4_WSG]D>!HL@+7)2!3DEJ0Y)?K!/12S'P]H49
M%=7D;-.3 B7W>? YXLVVG4XRSQ!)NT WZ+-JF30-E>OGOFOP[Y>W)KENQI5]
MOZ#A96.'ES-+;CL%,'-N'F@1U'<@1W"PRX@/\.*,18;NET%D0AE#B7K5\TB<
M2%ZC5[P'L;7"FHAHOVUE/J-M)V!5PL&/7QRK\:BNVQ8C^ZP<#% 6>EBSJ%P\
M!5CL0,@(Q?+O-^#Z1T,8A(VI@V,K%R*B 97F@P6=@T'4AZ +69!K07D3K9S3
M_* 9<P$^!2;JX(]QH\O@*[LPN"Y6GT'\$X0@U=YN4FTMNSK;OB];*UN+__0"
MV6SWKF)N ?X]@IWJ\AXX-/CJ>)/VG$\3@?:Z(KK&2I,VMD"WX/W&V'W^Y/6A
M9$%S*WCY -S+QIG0B-.,(MTAJ/2U!5 E#D!DJHSTW3^N]!>O/7;W!=_)==!Z
M&ATGZ'FXO(@MT-F."3P%I)%4LE]B,89!Z(&CD3UD&'Z5E0P,5=:"./CXTIP"
M+E%4'YL_)#6&?68,B7M5Q../I,.'9V-%R$)$79,J?$'&[:8L_\C18'X7A<S^
ME%+!J!VALLHJK;-C>ORE?6FB[MR3($6^?J;-7B'_*7D2I".8E^@X_R@:]_N6
M-X^'S^R5)]^V./-G,0N5L;:PL>GW%(P:Q0(;F@)"7WL+$3-6X.V-W)\JXI/M
M/OACXSBL2&'8Z\#<#+6T)T;'G6O.?/W"\\-(EQWDQ"?7+7N"#AV;=@VY=X25
M2[=4GU8E[ :39== PXRAO5$/5QPEX,X'LX\D^_29V?D?Y4+3)Q49 ,;-AN:Q
M@D&L_HS$3./KB/CAQ;4/WC*MP7T!-6DEYL0FY\I?4QE!&G>71L]X/,,TI-(F
M^]K96]>M.^R]Y[M.%49RL6TZ 1D;U\0C?_L@&'QFV:Q@D^KXVC"D]S3M](05
M>*#4Q5??]PY71RA[KKD 5_S[NDJ[EPK<"Z8_E;0KUFQH"#79V#N.*H4Y [)9
MF/!LFG9WF-*;!29!U^\&\5(0\:7V:\O#KT_*Q'U.+ WPX2'SQW9%O3SM+@>I
MJ?MI3(\^=Y6SO]6^,@AM[ZFC>,5$ 6ZT=F^/WU@)OC!M T$)O>I\MC^ZN>X^
M7P7Q/1;MHG6^^LS\G=<.-^_[7JJDK$KH(3D U._KZ_ZB."\)C)\!)Q]61"#_
M=3#Z'TVW/T]D59#K@*_1:TU>?\R3C)-#6 !^N_\9T1R[BX*YK9P#=. :^*DL
MP:_,7RW4>4.\2@X-SR_6M%X)NWNWEU*F$WZMDL@,P94RS\53Z'V"O8ZD98N=
MZSM1NFZP]7UH,D?<3""5XX>HWWX!(2M_#DB-@?@V%$9)!]*8)6ZY-4FQOETT
MHG3/./GH.Y=U17.'R6/%ZBPZ'Q.X.K+N)M]K2 +QK3;P# W<'O/ID1:L3C%G
M>X;^M3!S^<K3<Q5^\G0_GQ:6IC0@$HP'-4X0W_? _^[FD";0?AQ!_-.GU2S6
MVGJ";.5<]OFIZ-P2"(8G?4#A80Z(G]4WZC&M&VT>:J8H]\6 RKQ5=H=$%"\;
MT=;.V0,+U3(76RC@<A((UXW<Y*9-Y'Y<JCCG^:*0LEQWQ3/'GZT%P:523N /
M$FZWN3N.$H!).R=96;LHC.:$V/D*Q:ASF]'0WM?[/904X0&^Q1WS1U&[IA)+
M1SWO6QDXGUH7;13[\0)V:'S#:++%03W+:;YUAX=?\JX5=PHW[]LM"C@$G]8!
M-;664TTV#"S*D?K<-.A^:]CIZHL=M:A'6G/<XR98?2;G8.!/]^IRER,>.9TO
M,7T>/B]:#65X>D\!\OW&9!;$&CBML-#0EN!\@K#,%OT-8EC?4'H\_ZOI/,&O
M<Y:ANK3\$8:FG\;X2YP3[VC>.:RV#J8+^MTC]<7DV^?W6G^(KI5L9P+WWQ$1
M2)<QB^!LCS)M+_^;[31R$3(7<0YV(>\Y 1^]#B*[FP.:S29J_Y@EJ@=!CG;(
M*,TN9P+]!&K" Q<?RRN-=XQCPKX@\U0./],2>Z+5=G?N)4:^3N_3B\GL8*\L
MV!%B7KRR@OAJ/CO<1X+94B8+[6-[I?9SD\9U)A8.(>"4<+%-!Z[:,P"YH8R?
M?#B*O,5ETC0B?FL)XK\PM&LY^3M)_:[]CFW8SR^)H11S,9R[V<"UFJSK@Z[5
MEI2BYC9JU]\,4+8MZC_,??DMZ!VE$=\K/5\R*CA?%W=\1E42=VJ[@.Q!$=B"
M<EN<Q!N4 -%]O@A:GJ&A(%8BR+;X]GV6;FKHPP9TW^*F%2TW]U)C]D1[9\#9
MKSJ;\1#S(Q\;#S1?/<?#UL'9G%!=AWK5JP$/X;9MT[)6"P$\5<0)?R0L=^M3
MP17'<@?W^A\]*%7BQZW+RK*Q#0O:)_ ,79S*2:*GH?C ;8I^&2SH!&:J.H[N
MI]CBG9D!"Y$G"ZW,;[M2MO5S,MT.>*G.,#$))B)6$*:7-I&%)+FSH%;Z07/C
M&I8'?&^P27$?"C'&=T=LRC"SUE;\'KN_NOIMMC?ADX%= G]5"$O>+]]7D_+<
M<FU 'J'93C$^';Q[!Y@1KH/?ZVQN7^.;E"W"KQP;L-OKIH0J*8+Z%I,FJ!(N
M8 [ O/#[^*UV:UH7E-"(W7!9EDEMO*=TO'1Y9F4WY[D?W=2+!OK40_6SY^$!
M>,=XF=]50:S6)LA\4Q_+\@M'0THBO=^3VHKNKNM+/_"#(N;1A2=6PE]0V?BS
MDTDN<_K+'IH*ROVB^L2J67KG,^X7^ G&>;1D/^X#!>GI3ERCX;6]SWO#5-KO
MA[V(1Q5MQ?HXXB_K9\N)QUB'$#QF; CJOY4D6F@?OV[QO']%D/;#&P'/YH /
MQM_Z78S=@X#9:(=9HB9<GG!'&AP>?+69X/A:W/MP>;2@;L@V7/3&8"Z#:WW4
M#,/Z<=X%2:N7]8>!Q^-==_=Z@UF(Q7 9+ETDPE%O_R[.Q-%9]L-YNE:[225'
MEN@Y=XQH"Q^#TM,9EI][NLE8"I=Q]-.FH8KUJ;:R*W4[.?<TG@"[&J<#+:OQ
M,['^)6 .TQ]#U].-J(!2&Y3"+E=O=4^HRG@%8]'0,_K1YYYX>\C";W)3!3K>
MY$X 8GV6:I'$RSN=P7R#5;IZ*J+6LG_4W2>JN;KJ$-6B8M/U[TK4%T-[C!WO
M"K.L@]A4#OXIH*UPV-E'$:T+>EUJ,5V%A33%N)IPW5G@*H. UCH+FU<+0#!!
M7F;XSZ[ V?H2:T>U]P.V3J G?L^S8].SFG-)H@2>Y?!G_CY%Y5^!*=#]")-;
M5'&)B#X-8_'6VWXLE-1WD<E*<I Y"6IBJ>9H,#MQUHP CA<>$<M)TZG[*88>
M$O!/<5/:$O\F5TO#X3M;+YNRK R<3%^J+R1"-)M'?2Q[O$]D?US/PJ[.MVE>
M<9'\WK$+,'OO#*ZF;B^W(8^-=6V9I5L6LXK8@^E=^.5NW3-:"LIV&\YN_N#7
M_U"ZV >5/?Z]F,0:"#F!Q\[^1=:QQ%<C--LA7W7"K(-7*2V!!8Q!E V/CHV'
M;KW>\4\=*[ ,#.I\HB$(C_W5.QDRU@SZRR:>:N9XR>J^U_7V&69*S/NW"8[1
M)&M\Q>IR9QIG04[";)6"0W'YRBG MJFI9CM':"':9??MMY":V%8*)#QO92BU
MYD-]YKK=Q>U2FWFK1Z6G *'2,Q"[+[$Z>V14<):L_GIKA-5WY%\5EG_=7FO2
MM@K:MFH"G26\I?Q30+ZLS/09SPLB;!F->\>'*8P.1+QN(_F+;$^:1]<_K75.
M=!.*8P*^6V%,#)U;*)K;1:J6Q;,0"_7Q-J]\REQB7]3(3CX,'QNS?"__-)>Q
MHVRCEX>B.!63PC-(J V!PB_-S?+  K;FS6+V]%F)!3M&M;6H8>&?&S6]+ML4
M7H)(G@]Z;H:2/[@"8HH,Z3W [NF$8S#FZWP,9C\QC\?,X,N(3&#>E\JX8U5T
M-?/WY<LA"R%FPE/CG\>RG\V@"[+%R Z(LRPQ?K0.K_\(*^V>D033$"^,X3I5
MKA#HL[T")2*KPW[F6OI$JJ%T6F4Z@%11FX/0[6W?5Q^>CM>3^!H(=,MMLS3Z
MV $I,I.S-/%1[K):)2B[RGVJY%SQP%- !<CLI$R%Z[>H[U$8^:LS2[&[BK.2
M7/'%83=/W9-L=O:U#V;Y,/U."W"<DE0![)5: QM&(]\MS33M&@=58MVW&O9S
MDD /([ZPZL6CD_&3RVF=R/<[R_^_31*9>G\(UDR.=5PX*[+Q4S27-LM<Q24^
MUH[NT7"=1V7]:(UDUDGX<O>9BH&V!H:]AEZT+9BN=6Z FF2(G^*[U&16!*O?
M$RV,L*K*T*AE5'5>U.KRK8L:$V"^%<U^V9*ND2LPOH3D@2OGFY\)]X%ZZKY;
MAW>^J2Y_.^Y>_S4^2="AF\<C:@$N?*P&8^OB/"F(S9MR*4=X=SXSWZ4Y]A8\
M]\@^Z;S)'&_>8WUM10CR=]79-Y9ED8G-2D=DH= +35NY/F>G9/;A681RVSH%
MZ)2O+9X",*#].P2V#B07++K3U((U!!OK:#"6 ^&HCEYY=BR>??)N[%CRRMOM
M3:X?%/+/*'ID]L[_6<Z>WZD]?4;_"H^"QF]H=]MQM08HST; ^3ZMF!V4%X.?
M_&J%*N,<I7H22ZHB0#-7L[MJG'*JWGY86#AP\(B*,3:[EQ/U'Z(2HF8[SF^C
M_?CAJ_^L$HENKOY5'F] 7;[.[8.;&E<_2WPNQ"^#VD^_7A* EJFV:OQ6Q>$K
M@JM) A+)6*@,>J4A?B *L+\T-._T[$W5L9V\T7XD9;"PKSXN/<&\2]P&WK<D
MN2'0'U2W;S7'JQ"2GA4%*#Q)H9X('FC ]4TW@IR3?1$STXV\$YTZKC@YQH'W
M?CD;E&=_OERR3+4S$C.R:T =/T$$Z8^@G?49;?3$\[XZSW /"K^T7*TUZ/H^
M'E"A5I1T_GVP>IL6AX8EP,UUFZ]:K@W-0#(FIN #QA^,^ P A3+'2I6R^ <?
M(#IJ;.WUJI)PB_:2)<6Q9#,J9,#NWS3[U#VG@$DP(PE*,)LO1Q7.\3$1(5B^
M")\[],U8Q4M@,F/TAK!]EK_FCJS.=14C03V^#"Y<XN?DO<[_D=1__!@:/(!@
M/ 4X29S'./-2$Z;1X1L"2;)-@YME3%K(]XY1:@G?/0??[;->IJ"%W47FB^1#
MC=8WI3>\<&@ N3U8\6>P"LP/&Q])EHYG6E6P?5X?/MPV=F2?1OC"LKV4RJ&Q
MQT&]3#>$ZLB)*CTN46:4-?-<(_\[A:8KX?_C1<1+B"J'9+]RN-!HN2O\DAV!
M_W?5PRR^$6&M9QGT]-O@4 -XJZ=4C+T#2A6/7M_"@[H:%C/1'9!RQ3:+=BU.
MT*7V3Z> -AFN.OE?7_H:(#$!G;+#*V##X#$S9HDV6%GY[C&=3I"1^;!W#W9D
M(4O1QWDS-T:1W9KOLJ62G,MA&G9@O;&"*#P__D9)MYQH--]56>@TYNG"A)$^
M:N>@<K&D]/DAU<U15##TMF!?'Z&6O8K^7B\L^+$6L@,-SM*<_=R5T,[M$:,1
MQ:+AU<)MM%KQKDU/=C#T8OO]US=W^42PY:9?!JN^/QV.<A+)B4KZUY&4_[7K
MD612VC]_"J!U.<JOS@5/F5OH>?&4(0(<U&XQ!";=(8[EV\,:+C3@"[Y>=@'_
M&A!ZV],0J1C\38=!Z(>&[,EF<\E-<.+VIK6B5P4T/AM^Z=@($BQ$\$W)58Z+
M*,586:NZ^NCQ0E[QS+]]WO_Y3HK[U^6#^F#E>)95$+<232GQ0'VPW+LT"/18
MUUK=S6UWVG0?8@GI4?,4[[XCD-HN^9G*[J;4AV=-^NTH5A568N0\W>W?,]QX
M5#Y+9W-G]QOI(#N#YO0CV:D<>2_7RGBE4EJ].Z< 1P_ >-"Q 2QX2)2'IF,@
M2-H( Q:4=&ZW1@V//X[)JPM1Z:][+\<HS)C4)GF),GW(=%'_>';QZ& <+Q6V
M.7Z &-C=^#1(HL,C8Y48"Z9_DZ]]'7PZ9.J_>0O]U4<WNB;$1J\/8&[[D/]&
MBV+\9TJ ?\0&B\0;<95KWUZU*2 BO0,#V7'568O>BZQ^DGEM\ISFR]J)38MO
M *_.T^!NB8X@'(@+X/#;WS"OS0@#@3[2NKR?E$\!$X_S72VK=L(2W\L;U:M2
MV7&;LG7$TY'$Q\C7P)W86.MA8ZC84OVP_?NPSZJT1>(7)ZMT*J5_+5_S_(6[
MFG*8NT@&9V</?+\ZWKPTNWRT?^C/.^Q643-XZ5SI:XK0#R\]?BB7+B!?@294
M+A*;BZT&<%#ZI9:38G+[_+2UZRY1_I;Y[B"OW%'O4OV/1^>#(&Z1/$W.C">8
MCQ=5!_XOXMX[J.EW6Q^- B+2!*0WZ2I-NG04:2(&47J)BM080B= (*("T@4$
M%!0$I @$I'<BO0E(#82:@" ]H482PF7O<_<Y9_L]]S?[[KEG[A_O3)+)YS.3
MR>=]U_.L]:SU<"VF_]9:;Y^?%-#"NTS#KQ)$3"=2*8'(4G%"4A7GR&<S#D;F
MZ1KA3:GIL]?>-!JV8O3(MD<4H1. #'*5*' "("0[0)G(FJBFZ'7SJH]YM;41
M]NP0F_7O24_CSAY_L;E(?YWF,Q<@N=,1SHC?RLW%@-$-'6KX\6K>JM3@N-!@
M.K&,9W>BS9^E/#$]&W:HR^>3*>FX*/8Q\PL>;?'R?M6+Y0F]A.^U#3\^3_R@
M$.[Q#$I5U6E]5#LHE3QX7$X9&"&;T-2$%?PZLIG/KJK[BB]IX><$+^4O@]U"
MO<TK&GL L8YY5Z"RZU^-7=-1/-*A["W9>79P70)_5N0V!UUV)3B!Q2A/,5$.
MI*1CE#M'1_=AI=J<")MG?DK4+3;"3]LDV.!_USA9Q%AFF!IZ79SFVA7U$> 4
ME.#:*R"[H:79.FR87E/$"1*1'MNY3D95QL$N82H]B2)WG:,([_DO.3;Z="MI
M/]^+TQI:,,\[+JS.7#O4J27I[9><9:^? ER8!O#J*W2=4]#3?F$".0'0G  <
M2KR)29H.?^[@/_)- ?O_++$OI$+]0\>\,H0I!>_Z8<,^3[M)%JT>-&360PK!
M_A4.-STFODI"XL\(2]Z=;K%\XD_C?0X,.GA X N]@O=HAK\T:$@RL4Z'.+83
M%"W4/B"I97:%.3U+N&.AU:]E>04^1X\33P 2T9S&(Y$1"*SL+H\1QP),?_K.
M^[X4+M8XG4UZ-*_J>J9D!E$EG[BL"37*LAYON6R0?P+X++(:>OGKC\=A9X4W
M9)ZA80QVFY.SCNK/N7J- T]_+R(^YJ?7&$8 -$*J)@WI_6LR>O8%!&>3D7NH
M#,R+K(X#,J]2-(8?U54EZ!'NIV+HB3*W[W;1^>^L/0&F7S^V-N1OWFG:760_
MKEA5/H(<MIL8X^YE!=>9N#G1O!WNC'7\;OLEEU;UQG1F9)[QK'S:0Z,%WK*H
M-)ZJW"X;E_!G>T.B[Y9^[--'_91_^H@]Z1*O5Z9/Y@<+SDW)(AB"<O'AL-\0
MBPW1 G>T3!^G;39^V;G<-L,-EZGTD:BG_]145SZ5>C'O"9P*/Y?XI>S@!! N
MV$FA'2TI\Y"2A?.6..AIG#7<R8/G[ 8"6+EOWWL>R_=H=SU3<5S0 #^[.1-$
MLQ(U=4GVP")32.$>5[C0[<&H;Z(?OBX(YCT\, G4'D=\$U>O/O;7V&[#H+ND
MS79-,E=,B BO['YA172Z<YF?2)5HW!"7,LFHRY"F?-LA R<=VM^&X5]&%C:5
M3V+TG[['ABT[.2P)G^W&GVOQQ8/"R2JX+ %W&\O(IJN+P+!,L1?C?O('HU/3
MT_:YAJ:U4X[I,#'UR.\V4K$)[U@E5ZO-RHLJH9<?E5-E!7E/:*/W?].Y26JO
M'_W.4B1+-!$FLK /1UIXW+.8R%Y88]4\CJ!7#1_P,T4:L5@)PYQ$>.?,357J
M15$JD"XQI-I@6"K#-GJ$T:I#:YS_59PHO81G;%^)Y4P82)6XL]N&.8RIFB+?
MQ+MT:7&.E55S5?7 G1RE4V(3C40VXC*7YW8')N]=Y[IH1.4FP;['_!*N'H"U
M9])4VW88TS 0]>B$5@,EAZX ^V(=;S-6>27)!R<%YJAU_<V_'7E YW9*U5=G
M\,6(2R 0V89@D8M'@? 1E85K,=1!!9%D$\4#E8FDZ6)][H?Z@XY.W0S/G[)R
M+3?G8LES"AG >BW%BA\;4/C\C$RXGU*'LP:352_/Q:DA@(#D $7#G4=S#,V1
M>9EX%<<L,#FI>_!VO&HZF$X#E>9UO2I-[GMI2]&GE6RE,3@[_CM/0.3&/E*R
MPT$(A3\H=V(<STPNG<O;GGQ9Z%7CTZ"/?2Z4Y[<8;4H$I>T?J4/75+=09>LA
M_JJ@A$RA4;;..>87HQT8F9>+]CP;:VJ0@J@)PV=^-*G<CV"O)JE"T:+/I/IT
M^A;0E@O!\]&U/$O:^+>K#DPUP]Q<31CE/!\-4OD.UH':3 &]C 1&-Z1;P0(?
M9WP+BNS@M:W=<1[U)2)%VQ8^#M;*=^7!NJD_9*;\G*<F2V>OV]1D!V,E9;G(
MDA#F^[;VNFVU::9*G^>%C<+<13-O)*9T\<A*978, _VS]BM.PP4E3#.9TH#:
M/0$HC%+^N4-;E:1G338<TY!TH6T?"-#%8]U>CRLQ/O&/N%W;;1RH\<6<+POW
M] :_ZG*#]A_#KWZ"J@\2L,UF\[= ['960P5&3D6V-FXJ-:/VW&6?:^]3KS)X
M]5AU1O:S[-#)JW:ZW,>H4% %Y4BE0-%GIR"7D7QS@;<_2E9#"6ML:TMLFD8&
MWYLHK9:^0W%0KAH9.)O&']1""V"P1!+;29Y$2PL!;C U@7GJ,XG*/8/2)X[Q
MY_:'3_O$GD;0[0,10FI"2 ZQN#U5>3W/WFI-4F[XV<:68T6Y+L1#N6-7ER-
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MIA\D1.["!B%:2\21?MWRYEV$9P/[&)KE'5[54=15UT4# "M3(1(*70\?V-G
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M7IW&-99\F,M#HQ1IL@&67X;_SO!3Z%ME8H[M:Y],:]R%,ZH>^='!Z_/DE,;
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M]4-;0H4^0XFV/Y.\@J4$4A41N6-1.S@@@W%UHOF<TX@:LB67(33];@"G0D\
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MWD3O32VBV3K\ SA^K&E/CV!ZE3NK7]O2**,:)H7. P25=3UZ556SJL)K7BY
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MPG4YK%_NI(3_H]DW+T'&ECE/1M'P3=!HX9O??010]PYLM+R]V6JDCBNI3#%
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M'ED<W\<TY<;+C)Q=4LIJ2,$:?9D@YP4_EM@1[4DR[^ANUZ<*&AV$<=9 SYT
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M1G+8\X91-OAIYG9B1K/:;CA[;^X*6GA83@2)286M+:"@E[ 2O\TY^(#)TUA
MJ8NSU#YX>770"I/S'B$[C('7E\<[KDU'*2<7'ZD0"Q$9RAG)S&E@/GLW\J%&
M@6Z^C_7LXY7KO^.62]Z3'_NZ!!-'FS)XO>H@6D")84+OEN>'ML?FZ,?KY#;3
M<G!1.79OMQ+CO__!![*6[]EQ.2_NQ^^_4R\X.198)REL4'N###T!F+B!_$8;
M;4W#C_QG6<;C=S.T&(=1ZD4R]>1G0!C4NN\92,W68VS^SKLV/M4^LX$7FNEQ
M?:>04Y+41XF"1V/(8N@3P-Q7;9S1D?<)(+<$MT&AD\/L7WVA)L34NPN[X/9=
M\.R$04X1+G/O8#]*+N($(/ X1>P4=VE.%%P[ <2*[T$/@\J[#U5V$TZ')^-@
M%%HE(8K))Q://)3IGWOS_^TTYOP_J^S29J9I"6B1<<JO;.43P*M9,V+#:>ST
M"J3??B2ZRZ4\O;GW91^T^O1-D>3D:IV&(U/]D);(T7UB<1.(Y2^*I69@Y2_%
MYJL_W@"UY3N>W_;ZU&TX=];OLR3@PS/7<U_R4#FX#<)#(AR?'/MW>LZ._6"N
M8T"G> IK;]VK]KD[T-B+E^>:ZB7O'Y*?E%;9SYRB(KX=$ZZ;@R$*)2M5=<CC
MX:1JJDSG]'BV3B\OG_Z.",VR3<+E31=QKZ0\5,:N\]";YIR+2GWT.8QDO#IF
MK=Y(&ZEA(O#!#>PN5KL):;HY??7EPN.DA2?M7MP<:T(\LR2!W8Q/;MG\*-1
MEODP#HD>]CETRL:W_2Y(&!#V\36W,5/Y_KI^RP%V* &>NCZ\?6S+PC:UFMF*
M1'!VU27'(/I=GLGNW945UA5)[HT%Q$1C]9T>\50TFA)"3@#BQZ#YE16/!B[*
MVQ/ S/(@S/33Y[PXJG]M7?Y'&W-S".^_D;6$!$@XG@#,_A=92\<4900-(*Y_
M59SF0%?,Q+>[<<J1#1'!\=9/Z?;>2_Y^XLQ#<XE,];3!JADM-A "S,.N' @6
MNI6Z61FCIP[:G#-YK,2<@4943JSMA2$0R78H:T#U+#3*,QUVGIRYH7/H8QDD
MD1+H!?8ND9[1#^L3GW"CBM2 SZ2]?%S+#2\X ;C Z%8H]&2]O.5,0JI;7?5[
M7W_-M\]+(R;ZO*6;-+LW4_-N%B3),U]IM[Y"U3!6DX$6/W+\A>8R*<2"QE<R
MR^%?>;1:"Y;2V1PF>RI>.'GQGGL%[$[W8'G'.#>4PTRY%@#&.V6D8Q_L6=8A
M7UO6]^_8J7K RYI]7*(>6F*#KU'?NR%1PY*,W0Q1(4V_#/&F[C$#CC=[%]DW
MAH*?0R0JTW"!=+5QDM9B^HD\(3U2B<U)>2;:%J:G:(47)8GOHQ50N$],BG3S
M%^B+DU;B]J3>NAL>UE;"Q\G'+9:(X;Y:0R/Q5G,>GM,U'I:CR?5>1ILE9^<$
M0+T?-+P7C]"4LZD>D%/*8C"QQ&G\]G"IO9WYX*?*U8NI"FTWOWH=Z?X2)VUG
MTQL3I\1-%-W;^KIAY!UY[E=9I.J-!$?57?A[# 3*'<)623K_/C_$B/RX)$1O
MV+'"+B/KUN#1&&+52'(S)=M,S"-W7OWA@]1[ 3LO=TW)0C@X\]$3:*P0DP2Z
MENQ6&G!_F9AXCV*S@$ 9]W1"YWONID32ZUCTAQ<;3[L?!F,/)*&MXJ/ L\5U
M'ZL'2>XG@)?008LUM1DM\1#7 :V+$[>QNVGX\P/8\S59EH,^L1MED#2COLS'
MEDX_>#KM'1O\=[9<"+XDJ#G1-ZT]2D8IF7YYUW8J1:FA<\1R9['*QBBZ3]LE
M3L^Z;>;,&U>9-IS-O7M2D].4,P4B!<<$S$PVDK@ZF_P"+6,D[<!&LLPJ ]ZZ
MD&EW0^+LPN6?US8N/AYZKBKL6_ZFU>'RP-%%7(.!P\@&6[/1X PX/NN]O*Y(
MPIOP3JWFU ".F9Q*2@X>RA8PJTO2I+QT*5Y2,WW%I5LU(HV\+#LS/-%[,?!7
MH-.W9 _5XQF+C+8;O4$9[1\E#4?0+.2O@_;#;W0&F;*,)(I%UNTL=07$I(ZL
M?2VJR77^926VK"@0K!%1[YGJMU61QM=;*"?7*G&X-FZU>0VE<FA"-K8?EO:0
M6SO2P1DIT7%*T:&,\R9^Z_CU[CT43SGKJ?GZ=;L&_4[=?KPYN=B?M#KC5X%3
M%Q R'3D*_6S;\.' ]+U,G%W^^NTA/V [>YZXNA!]0F,,X,/3ANZ6,'%MQC#^
M[I(5R[IT--;DPU.\C,1PN6<Y+7UI)_=\TO/? I5W+.,@VT<P'*;LG?ZFF\ST
M*<QD&1SL%01K$W*)@W<'C]Q*P%QU4;&X:?J5[MP)<$:Z/)]==Y.-K=23\$SS
MA )EKJ0&5;@]$9:@"!(*<#$EL43[7E8*Y;H?8P()]!A/U=-LGWVM,W=!!]X+
MI2=/-]J.ML;;&;/$:W$BB,KQ>/ &]QC9L=4R@]>R(!/1WV&.=7EOJ<#6>^F1
MSH3"K]$)H>^PIN-@G&1CO8E0R\!O=+4O+/BK?7-A!=C.K[8F$/4Y]MS57-)^
M/]6DTA6H\]X8B+0P[I3A<]'O8SYR>M(?VIPQ7#V6W:K';L[]__&W:I.H7:!G
M E(@I18/:M0@'7%MMV6KF>:51:_2BEV?!41X ZF=R7D0W?%F-03V3MM!J5]J
M0UYW8M2C5Y]4A1W]U%)V2E="6'X-9+^)W]+POX4A#^:M\GJHO<KF1?\2S;D7
M8>AS F">&.]ZG"4"*1_]3K5YTS[U%?]N^?BL;'1@^5*0N^T8.=H\B:]?>M>!
M?S@J2[%SON;,PE;>H_"X*HY&,<8(!7OXCQS>(UV21-Y(F/2 1&4ELNHU<GXN
MW0'2$G7[^F.9XM>,5]XJZR9=2"HJI0R:*FJQ_UKD+<\IMFG^F@]L_+(ZRJNH
MDK)OGBQ%N"!Z0SVNQO[1V@+RRW=H"0:?AF'8&VI+7:J3"F.A<.?L/O^E>"S9
M'#0YG :/]5E>WP&'^S[&AUK:[1/F#*X^M"E*\]N;*/4_2R>!@NUF1AC#8N57
MF/(;@PL0U\?LQZ:-5>WVYQ#UFUAVO4O.M&7T*KU;=[3NWU1:PYP) >,F'9N[
M\]WJTI,EBJ'H0 ^?AC#((_W(&JB6DQ'S\QM2X1_HYV&N3(XM(W6%<PY\#223
MCWC;IF]]CJ%YK45ZZI6T*)P/)8!1GWE8%4#HS .Q<^4=23_0&MPYZ@M$W*]Z
M%JD?0SM$Y7F'].LP;A_69#O:DLP<4&*,J>U'F976=?HH(;- @V+(6M-WMW_=
M]*1Y\Q)9,_Z"_N-8;Z@>[2GF%1?MQ:JP=OQ4A:>B&<ERC7O3[*^8X '@!\-K
MKT;>6(^Y/78<DD'5GNL SIZUR=05B%.@MMY-HE.4PX?.E5T);1\08D5,LX"G
M6-_<(]U/\<D:(\PX&17$]I3)T[[5N'U-Z^G/Z.UR%9Q<!(6/"6P^JL$!"PT-
MIFZ^%2BZFC%Z>7.-+L/(V1GV%L#]\L<,R1:#X,SQ_AIR91@"\; E=XI_2WE2
M%?S^<8PI3ZHK7E=@+M%?+7+QZO7L:);=9U'&H7)V$>K!T0.0A8A1TR$XPF6@
M7#;7D!WB*G ?KY#&R*HCD$1W5<CM! #4AFNGF&.E#BB8\@(,_Y&";&G_I&V
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MC&W,R.83<]H%Q=% T5O$A4CUR58(.,_0.^2[@Y&&@@EW(IMRG 3K9;XDNCD
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M)*2E>3'$4FEBH7#D4V<FZLEJ/.$HJLJD<KY2)XODI:/U:F[R>PH#=<JQQ.L
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MK[!/NQG\=4T)($O+ON2A,@X!5,%&RGOLN,4@+,;R?25D5"8%F%HK=/SBJ-O
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M/Y*<?<E5G)RY[\"B$/^9/<HL*5_)?Y6;B%HAU%]!)-)17[/!.EFA0$9'_LR
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MAI N!@RW"(6UNPJ;/4F D/*E_6XS>.5\<.;(^6GNMY9B9']9]7K3=RBG77R
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M#.("SBI\3]6J"R0<J8.0<4K'J:&2;5*0\+"I$W]%A:-]MG!#NW)Z$Q9= +5
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M_/W<\^M?0-RB*^4?K9)<S;6C?APBIVW35W)GGK5DLX6?ORG0AUA%2\7DM8X
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M<D@+W^/@8+\V:!G3^M&PO"#!HM@Q;:$]=#.;2O!YZ,?S0]D5\9?&D@M6U)0
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MU'5<[MGGV9>;Y]QC0?H%&)FC^^C4D2X)PQG&LTZX7(A8*PBLO\?%0;AI._N
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MHGCVW%!I>X?4B_09I[535!8[F;Y4ZO2X!'KJGZHZPD*]BAX<\,YZ+4C,J$V
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ML(AJ'='D_M1FA@M /5#P_N&7Y:7.'G@VL[_QE+&_/JH'AA('\7SW,YS1!PX
M6;B)<B)3$>KC!ZR!('$"Z@@[E>X5(AJ"K_8[VODQK-RHVOC2+OL5-\I9M+L
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M@Q8[P=TZ!A*5VVH+#4/IG=)V94H^#]",5:9 \1-:!HG97#?JL *D8VTT^[>
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M>]3X]!C$\%P+B-BU.\9T,!-GZGT+$WW U\? 1)WW[<[O+;FZCCK3UM(CWO:
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M&<STM#M7W@Z#3G_U5J_XA;O3, 4])A.4ZHLS7U)C&[G_N)99]2G>_$N\E,(
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M8QOY<H.W$@?%R+!1EMB\STM@@TD=EM.5^?ZM=H$/*O6V'\6Y^20&MZ2V9$9
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MQYD>[IA? _ZV&U+928YC*^MM%?H9LB!FW^S-5_3N<:C^+:Z%VR,@?*\[P\<
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MMG=T-*"#^"E5C.CU8OA9#B:O 5%GV?D$&+]+ 1;+\_XV5RG_,MLRW>*M+4*
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MJN=>,XDO=.O53OIMFOQ"G:E,CS&T-AI!>G&$;?$JD1#*XT[R%5>.NU-MVE_
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MOYJ*FE<=HSR1 -WO>^<G2@D,1U-U79$AQ.(32HJ!W_<J8-$B';!:JY7GB]J
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MJ1];I*25"Q>,CUY[R$,0GFPC@!OW[9#&R":*^;"+Z2?VQE+ X"V1J4@14]>
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MU8[_]-]7_5\[YX_W_R*#J(4#^C/Q\!_7EI9%(^_0,KM>._,Y_YW7KC08O:<
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M9(-[NN\GTJ<>S5N7+>$$7)T-E?DNDB+_ZNTFA'&QH4<3X=&9@>9KF"A/59X
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M8B92 !S_'U84,%X;&W;YD?=("XS0QY>G/#97^7:_X'L(/8,C'1?K!R4:O#P
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M^"AI/9.\-D;L:.@_/R8UM[P'K<_@F]G27'P^1E ^O*K),RAIR7X2V'7^=?H
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MR6DDEY^P#\>T7G%/G*H=50;?G]4("' L7ASXUCNQ9"!8)R3P@6SG+>#M63^
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M22#2O%FNP/?&7TIN^HH34L19H9.-.6> U2?%YHM_SCR@P<$)'[;#>/9QT#-
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M1^[(0L1(9RG6^5327I)LYC\>'26HOW/^Y$\+\_[D\61<S8@V;UN.X(V/F2T
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MS5!KC]92<ZPW4H-+IL]MVKE("@V;IIB7ZX;W+GK+KLF6IS4,U%@^^=EPE*F
M#3NHPX-PZ9B;V6C@A36<O0RFU0.D*$BHS? Z<LHWHJ2_R<#[X4U?]&Z<<VD1
M02!'N1SJT)UG5 "KZ#S8KU-2;(\N)SBUMBPHE!CD:HFO'__PG2%]E_%_GP>4
M&NOHY<WMDG"W=)V<KXBDK)(&O)ZW$3C)FNADG1L\,EYPNYP![@BGZ;R05^L
M5E%D7<ZZ(A7'1## .<QRCF5'^GU;3)O$"/+R1G=^Y@UZF]1RGNSGKL4)%MYF
M0*3$TL;E3*TW%$:(E&7SV(S61L6[N(G8+&D/7^ (/ ]P^41FP;L@'IQ5?9"$
M+G/6'=O>$JLY\3,N;(2#6.;47\<\3='E02$< E5G3X6G QA6B.P_B%PKT@A:
M3^AE_]37(WT6&N[G160$Z=4WIA_(DLMR46H6$41] QJ)6;>S.GFR5D^!\>-#
M*HR!PG(=)DOIZ S:$X-QL9RJX0V,7;G3S9/X+@HM'ONA<AT,/"X;#\)NF^.T
M.S^EO?-U1*:)6KXH,. 7*E]H"^J7Z Z4\-/O>]0;V:A^--$-X@':Q-&ARF'9
M^%A4W[.T ZI\Z"7S'AOQ;2M]NU_JV(1WE\TBF.KU.OVUT%,Y]3_<5U^,IAL'
M:7G/*BA%,KCF*]'31W[QH@UX2BE_"3OCMZ#6P?L%;-# $M1T[PU$N& :Y/W6
MN38E"E+59GW;Y'9@V*4O4.\3)0%65GX_FV""AN."^,65AOT$#:;,8BN:C5N"
M[5_4WXY>70\25L'63IT!VOT///T#%J3W=4@'4WP7-/:=X> S=M>[>IXGNB8)
MNW@8A1BS+7)7D-XP&?25[[@I]:'$X1OG)^Z[H%03YT!Y.2RX<Y9Y8C]KBKK#
M]^G]VMKF_/&R!9;D,3'C[J0FUKJL],^60=[;H)(S $,-\"H^L<7W>RJ:RQ\B
MBI'[Z&D,IG& GQL[)&_L<^((5*4K@V24!G1F<00(ZN2M(AG. +;,.(%WHA[4
M_@^7M:I_\-;ZA4:T?SD*5^*,+91=CTQ3W/002XDY%2]'S7:.'A;5'Y\>C/B+
MNFT*-WXK%2EHJ'<6H[*T>^W 4/N@1Y;+F^EHYD0I ,5#&R  /C:?>XNT;]P.
ME?8<WZ3IC$$&.SNK]*='[%)+B%%Q6E+F!T0Q&CR,)K_%>FV'"A:%M-L.)2%K
MNFX8!4$'V]WF!XP@TH_4I.ZM9]%,J3&ZF9@UI8?\=$GBG2QGX=4 <*<.6!.E
M!N"+N7,3*NO%NG@N^!D@"(D^E;P#?1&CW&(A@&]= %Z=(KB.*DI"'C0,OX+7
MUS?\*)?LJ*N*50ID5@J5Z]U3;'+5]I\&<1.[B=2X\F)<.X:ND\L&W0^Z*"]3
M;G<PSIS)(9+IWS%4*>IQ_4M,M!KE-8;X"39814D.Z#(SRG':\ Q MSNA1T5X
MMC^'B-J9_L6HJV)M^SN66,""YK7]+-V0QVI.VAE J[8A[5HV?\)MXX??$@+I
M"O!#B"^W$%*(4?=!BO6)M$<W%PS@%9FFLH^L'^Z*..AZQIJ* %K6+:P*".KX
M"*[NT!HNO5:X@%G:UD^+M?$WY/E]MJI6*2[^/V1Y=@9:Y4(IYKUTN:RL$%FQ
M66&@:RF-'$A@V]SPKD+F/Y%EDP[&>5,%O1VBJ%B/7:ID:KJ<S&.O884,O57X
MOELD@OUAMQO%E2H*XHG0PJ>).OUG)NW\06J1,BY#J4K78XLLLS_H7':]8$6;
M'531RL:UNJ>K).SX>.ZJ-U@#%Q#GDK>>YE@.R_]I^;VZ.<0J\O&5=M>*:_.!
M 3G%>&!+  ?>O[#G)3J&7!N[_R%NJ1F1:I^\,A@H<R7PW!O 8*VSKNKTY2.;
MA;!NK7J(X\VWCGYE^(#OP\8BOQI'G-WK%US/W_.+JU,2^/ U@\GH-DWB'-O^
M'-5 WL^ P89'#5?JV>_:7N4 UM;[0&#\CK,M[Y_<^;8P$KD%1',-QV9[0-S[
M[OIY1C%U=K]'O/Z&]#"O3":OD *9#'43KGNE66<X<FH=&(12>P>J\(@Q/9@G
M>Z0PZ=J\-[%]$2Q<%I/VY^79OQ?( [&'[=7>P!9%]A].5K%^,>*/ZRH3C*HK
M48))U&(^K<*S#9< PG^#\7M"&(@R-DX-QQ(A)C6.G)"<45V:%;:;TQ@7$V76
MC_X:Y]HU3R_?O<RV%"AG+SP(16NN(O<D\'UG@$O@.>(]-<(M<QEB*(@-BM8F
ML:YN0?(?13"%,T"(< 'II?L6Q FW8%#\(@\VWWWNF UB1?J)U/89@/.W;ZKI
MD,A8GGX&4!:/1F(+FL\ "Q^@;4DCT!4K7 J1<0))< U4N!2Y.X=_UN!\>ADA
M<09H2SL\ \3^3K(Q_)TRDM(%PNM9G %PO20R\G_RN\WO@8[$+&Z? 2J]5'XW
M=7F6_;>W<, #T=]3YDLV58^'E_40"&0LJTW#F <;C/].Q^L[GR7NH#X/\+9L
M=05*-/W1"9?AQ( @-QK BW=3@U?AH;_;FKQIE8]1S,*D%]3&*STEJ_W(Y^ 6
M1.O2)5SWUQ!,XSEVI WP O'',_P;[_'A9=VJ'\MI& [6+79!:Q^^J51I=.SL
M%_T@*H+0#6ZK5PMBAE"]=Z?A 1SK2&HB!SY,<YP I NQ3+2HKZ\8LAQ_4C3N
MN1&_&5&P\D;Y!8#VI\VGQ+WGWLX;AR>W5LX U;"()E#12L"U<:>:&=?E@6"5
MAJ9D4U/)*596>KF41$&HM[J<NIE+VJ$0ZMF2;H 6UH"8^N'YIY1T@GG;?S]M
MK.B_FS:6T8#M/^2Y4C-X)<*2^:#!?";XD5M33;5I0\5FX+47 3D-0@#A=W@2
MJ>,+:]L^85TZ XRHYIK/N&5*8KG3%_K\[XL^!)_8C)03I\$N!;-]=I+/CIX]
M4O>>Y&1,4^$K''C Q<6TC/Q3DG+_)D1D*_J&F21A^8LHQ?TI14\ILW4M_/XN
M2L _)/QWA+'/]I]B_C?9 O@R_0W%9_Q]]<H< O=0#?3*ZO&(/?M!H7_A4>C$
MB9[QU\;8F^Z"_?1JP@FEJBZS@6Q_>G^^(<%9[WQ3.F+4M!+H0KAI\2DON7([
MUK^LQ16L#4EC7)QE'YY[L5RTU.SYUW0K&9S;P3.\/VZDR]<YG&#WTN?+S]4#
MNI>.3BE52HQ*>71+Q=$E$62LWYS"\A_E]D_L#Z6PN1:>>BA#7P,IUS/)3K,@
MHI])@$Q8P:#_"<R9Z:AYY\,@KXI=E7+%L\_Q74HM7,*3Z]U(Z[BI[Q,'CMC,
MW.PI?*+!Q.;6ME6#^O[%&72M0=+4,T;K5TVRE]UV);;FTP[84:Y+*3)NK.7/
M7^1$"E'_3_M!_J'.$5<'F)"!3HL92;QQAN/&4PT7V).&^$]>-:)VMT,<G7G:
M,Y3*#T[C/<QM!^I?.Q"'&F:R'*QSG(:<=R>+UH8571 X4+L/3![H5D#LTRI9
MX>9/S1WV",ZWNQ*U6YEW@2_A0;LOGT2$-#/YVP%_*:R7/K:@$GL&>/(5:Y%$
M&Y;-G"PUPEMMJE/57R4QP-#Q^;Q'O-GM?4J8R=$N6B=P;U.K[5@@ HW$Y:X<
M9/IW!S9QE-I[4@V+3Z7WIDV^N/.2 9E<_6V:)8'2V>'TTW3[ #;K,3=[\+.Z
M&N.MY#51NV"0Z$K]>W/_[+?7>I9]TL/Y&4:B#>8ND9A#V-%1>7/-W>0R(-ZI
M,8!YNWCUP^\X?#.=+ACC:B8U7@_C;VDT;&@QXK@QJ5T@:YZBA V2GMD)>=5"
M[PU(1#7:SRLJ>N?P7""PXSPKW?*FP<D'!W1+=H>YI]Q6#KST6*BGC%7]R>=1
M?3Q;/C#&-^LF&$CA_@WR'*:5#;E;V>A,8\><Z!T[^ PW7E!731E1>,)58];-
MK]Y8N234I=$UU .K)5PM-\)GM:;15A8\<'2?>=A&76++=HX5XST6[QE+049.
M/HR4JXT+=)Z'1<BX#6#B+H+'+=MVP-63;/OJ>PN.YXL4>\0\6/1#FN9FD@V5
M0T]G L+P=*9A'0A*[ ',\17*JIF8Y>S!E2BHYP1CKX@C+_CA@C? C=,<G:)Z
M D3E/*MG#V]#V?=.]J).H3RB]X HN87+4 #Q(A[6[6QSFGTSWIZ;^N'THQ&Y
M4I=BA;=>9B?6"#<<;),-M]#.S8)7F9\V9V@[!+(W^=T8&WW?1U)4-JL'\7&W
MG<C@3E2]%WO8#-8[_1E.-+WIVK,8%"GPR'8+X?$7V*TPJ$V5H\G2\U@YZ<ME
MG*7]#P/+K^RH^AI^1U)"K>@B#2U$$C'BT0C1U4S!"5%Y4;&P^4T]C1J#T+$;
M.@F;]9<V@^C\ITZZ(]MD7),.#*"NB56[KE5[1^E:Z!CX!&[1<$\#ON[,AP*^
MAL6F373KA#64=4>ZISNR=!*YQIW<::S'.Z-,3PO.20PE:*"4:2\J',&RD/,Y
MF6)-/PCFZ#X0G?<(1B$E_ Q05=@(I?6^$*X'YD@X]**I=]#M7:;<.H#E ZU!
M@<PD.U+8GNI.7OK3.]$0B4Q_/E:;GD=UF.+ZWD+[JYP:P%*@T&1W,#J+9B\K
M',E6 [J*-\1PAQ7BHPRPB$)TSY[QEJ5;B7&#5FT.(/ET=$%$GYLIS(&^>3I.
M;-5]N_=@Q_7D_8KI[-+T(%R"H ]E6 )-Z;4>+V\RN0FIX787Z$)K-Z4Y'#4=
MZ2P^%=?7I"S%VDXJ\D?@8B:Y?-U !0N!E"9'T /@:1+$$*OWM!XGT,'#9.*=
MTLDS69?)617U^%TWV+)P>B>^6"A_\A-]!VW&^AK[6M%"GB5\_]CD-&/#[>'Q
M5Z@)&#\[:T!2(152_\,Z9P=$A6^8;C6!1Y?NF]_MN"ARO-\YJ@-&KY\4Y44,
M*Y16*5/S4E)F;UK4J@!<@%AXC?@1%J=&I/>%D>P>";I0^ST\ V31,4+1 E_.
M #M2GJ-/*1G^/LWSQV\:.O[_Y?[?7<['?"Z"%U?8@3RO46"'F@_32=@Q3=W>
MDYL6S#6 OP9E>L=KB#QHN0?3_^<U>B"N%A[N /%#;_H]^A':?*$N%6KI<J4I
M=B:^('E@*)1(U4%+>]_%_)21K 7:9K<0=RSP##J_AHK#:\N3#,BC-1T"EZDA
M5 7PA@>;YKU C!C-PM^ORR4RZ'!"A^XGG@$H#<;FAAYP4A)N9LJ> 7(\!(BT
M945G@'<CW3Q[3_+. *UCM5Y[3RG)S@ 7"V.!*QD:9X#@$GL@6A+7?<I0#,1Z
M./[?_+>YW4CJDGX=RL"'HZA$+_X0V:R)<& R.98+2U9+$_AV\0<9V_J:\%#1
MOP.Z_ 7&$*\H<PT&;F4GG8_7* 4+KK4'T>:[4TG-_I%*D:A1<GMR]W?89C.M
M]$@;?J&KQ#DG%$37RET0'W/5R/'ZSU*ECP[]T&:)EQKGFL'H[4!W9&@ 0PV6
M&'<06@.WX[<K7[JK(U\EI\%?=6\Q(R,U8E]J6/>Y%YA\["=)JAXP,0W4&";O
M3/]\E-@J]"'A%J-$0WP0E8(2DRBC$R4#^@P0!*2#W"I<8[XO$R0/+#"VIZTR
MGT:MON_F:A=V>K;&0A/\;5!YN/'YTR\ 5O+ "Z*,6Q0\,4T,.1!5;'DN&GEU
M%;>6=C.;)\G#YA:OE5EP<!#=4Z&MM]E&WB#ED3U_L2F'O1G%\[5U\,>;L?Q/
MO^0J! *>']]RA-Z^M!L#//# N^415*.ZDRV8JFMQ9MK"W46/S#4E/Q_E77/\
M7+<D0)Z@L6X1I\(A5];NX?3V?T4%M_^;AK$%&W8&'N)>5U'C\SJDO-RI[[&2
MX^X@_W=9\L#AV]PM-@JV.8%2MO^-:NS_.LZF_@-02P,$%     @ NXIT5H"Y
M .#90@0 \;L$ !0   !E>&1X+3(P,C(Q,C,Q7V<S+FIP9^RY=U@47[<N6"3)
MDI,D"0H21'(0:%!) B(H.8F 2,ZYH1%%,@@(2!"0()(E9YJ,Y)QS-T$R36R@
MP^W?-^=\=^Z9,\\S=_Z<9W97=>^GJKKV?E>MM=YW[<+.8=< ZN>J&JH 'AX>
M\ ;W ;#K]+]5_.S? 8"V-B     )[APM0(#KX>'Z_[0[P"T\@O\X<@OW=0<@
M^E<? -[CL?Z[[X;'_Q_7X , /AY ^!_'_?#Q_[-/_PCX/]J;_SCWKU_L''81
M> J0W+I%?(N(A)B8F)24A(R"GI*"G)R"A9:.BI[]#B<'^QTVMKN\#_GN<@OQ
ML+'Q2S\0>B0J(2'!R2>K(",F_U!<0NR?F^"1DI)2D%,P4U(RBW&Q<8G];S=L
M.T!# O@!.01X7  ^#1X!#1ZV&^#$S9(([U_M/P  >/@$A$2WB$E(R<AQ%]12
MXQ 3$. 3$A 1$>+ X@7AS@.$-$2T7*+*M^ATK8BYW>G%/B3\(.%Y4MG!H#=^
MS"O^UB.4E(R1B9GESKW[?/P/!"0DI:1E9.6>/E-155/7>/[JM;Z!H9&QB;6-
M[3N[]_8.GE[>/KY^_@$?/X5]#H^(C$I,^IJ<DOHM+3TW+[_@9^&OHN*JZIK:
MNOJ&QJ;.KNZ>WKX__0,3DU/3,[-S\POK,/C&YM;VWYU=Q,GIV?G%)?+J^A]<
M>  !WG^V_Q87#0X7/B$A 2'Q/[CP\'W_N8"&D(A+]!:MLBZQE3L=M]@'$OHG
M"3\J.TAYQ/6.&=YZC),Q\DJLWT/\ ^U?R/Z? 0O]?X7LW\#^)ZX%@(( YX0T
M!#0 "#C_F@X_ .WQ+DQ0V%ZC_LJ,NFB;_+ZJS:A;VB@2 /EG52SY[/2Q*P3J
MS2=>/EGJY[OX&G5'B> Z\S8/%J![9?^W+#?<O7'(YM"E5> YSV?',L5A'K_+
M/\^JV(<T1E ?KNX,_VY-<*UP(1X:&"'T7\,?7&4YA' IL?+I)7GBT:X]MQ[1
M44H;W>ZQZ@N2;[II5E5E\F.OPH\)N,9XX?WV-J[;>-*('NO@*ZDD/NEY]]=7
M_$EIGYC_IVT?Q9?R0UZ<^W%M-7CYDL:H4,R30VK_;_T;UZ\67WW5KNXW\\_P
M3)I\MX\!OR2T>Y5V$'FB9.TR 2Y5_K,OR-WKG_2ZY<L LW]5F-+2AZV^6;9+
MA<"@]P0V#F)YUH,4%)MB&FO6DI)E-TN:M/OF\<Q![=<Q8X3UGA+BID1Z3ZL)
M0MT4]?Q1);=Z_?EFR[['?!0-?1FSMG^H(XL%]L:(7W07)^+Q4JSYECYFO93;
M['YE_BNVBN?3;_D-+_D;1 +FJ$ XC38Y75 9>O#</0+5,9D-?UZ9OY"AH'HB
MI#A>;^4%)#1<]IKN!N@RY:DHC-U\!BWH$22E/0)DX#18X'Q/F5O=Z5V4Y$($
M,_^H<E3"U]J?-H^3(WI:/EE5CABF=]>YII]YJ)X 5IVA.[CYY%#2KK:X?)1V
M$1T%-4LFV+6>AY]TO!.U4@XFO7+_UWD#M=CG=4\?A-#TO3Q(T*_Q_M)[PV!,
MY^Z99?@8"_2&W%^"OA-;7\;T3TZQ^3!P&21N>[A^X2UT?_FH(9[MQO-JC)#7
MW\WYBX28<$S:"M5@TA)5H4/1SY+:\S7EUK;QN[UBH!F5)*4['H)"E9OFXFY&
MU'G$<5@ KF<_AQFKN_KXJ-8L<UL^X$SA+X'JA52BXUN&YR52)Z^SR!*0!A*/
MHET9U"C>D"3@EZN/DEZ-$3]U9TE9,)IE\1(0GTPPDK.(]K;V9S5C7A!G%3GT
M#2V\&_-]CN?C8M%9L;:#+;\T;Z_J8OD'%KXA3O\@=O?1B0KCY3[Y3G5G78H"
MS:9C?Y;^\R))GFS,$P\/M:/'OEA W\09"W#,<AZ+;"K1>QMM)MH:30:_\>Z5
MX:U:LZNU-C7IIY^MTHR8L6>U?]>GIJ3JN:=T9[QC*SJ2T?KD^?Z3.N4K]X_#
M[TR?7:S</^%X>G],\6U?=N,B(H>2_-?J2'+;R'Z9A)' LMO!P2(*5H*$<+YM
MN<O9$)")"Z0QH@,Q6CW6Q(/$J##QD[,1]TG)][D"X@*_A&F$E/;.<TB_X6_?
M9?LB>VUXST%YZNC6],+#?#V@']0671Z<=Y)#.>A&5#!^I2YN%P)J/= 64@M'
MM?\P[1\A9D:O/@=:7673'Z2ZR.=5R_:#^$$S53]#K6"Z'K>Y3FD5H3WUH($0
MJ4-RX=+2QB7JA+A6@;B4D8GG'*I.*C1DW8F-%A Y8%"]HU$W1&H@GR;^2 0J
MCSAX9;+AP+A[TQU2OHZ;/6D.Z:$[.G<IYHC]-FC[N[TT*M ,T@Y-!G@O$#7C
M2S0WW9T$^T:0L%>?>=-?QZE0A)6+4:&]Z?'>/&5[M$1OQL+PO75$%$UD(PHZ
M3ODCUC" Z W@@T<!R^QTF"9IS+"1(L?;&<-&IR_Y03#W0<QKO,("V@4P;ZB8
M&O&O*X<N+% ,.N\>(RQ$VZ%(( (;!T;?]?;I+ETV>F6P0,IX("0>9Y_F-]IE
M?XB%WAU@S@GE [AHBQY66B579UX%_<5SVHZ3:E!E-=&H^T50=#*5/:8WB@4X
MK3%0.BR@,D8TN,,AK A3[UBI%#5O]8PJ*US2%-X8;[Q'RQ^UW7AW*T2,/KGE
M):B-V/)BHL*D:[.OL*GH%1=Z;?NW#+P6D-H&+902<\KPAOC?9*,=IER1%PU8
MX -$ $BT; "M6&X)Q!:BP'V8\U%,+#V>+1:8TL "9J/GI5(&6.!3IUK'@E3,
M!3&I$FM7+F16%0O,E\AUDL!JO6)]PFM4G7SY_.^'/%Q4JALO%3 JEGEI6G2E
M(OA?S+'I=6._.7T46J0]2R<F[L5E&Y$9K(;(N1W%#_[J^JWN4FV[SLA= ^PS
MO\3VJ_?0R(8JJ>$LAV3?G;_1CDS+ YS_$+29?GJ^E0%"!<5?HW303$I,KIP#
ME0U)\8E2+@%N#YP?.7,Y+T:KYD,O&_:4V) ^-WKA6N ]9.+.@8G/3.E%>F#;
MQGM_ 7B6*J@,,&B0G;;1DY/IN$ O._S;2S2DKRLQ)UA ]+70=Y.=)[_O66P\
M(BX\(@),(.>TD%EQM$.:U<7.+(_O EQF5.9D)D3D=B06,&?% N^*I;3N$-1\
MC);I(T9? U L(,R*:8+LY^:YGJMA&M*!A#E!QK?XH:2\9[!J)W:3"R&QS* *
M&=#9_'O\&TB)Y8T=%OBA']AK/.'X_H_]=^-DSRGG/LLRP A?T(N'U<)"!_P=
MNB;PH2$J\)-?YB/'?*N]CYS$]'A%;K'W:BI_O-S_],#J"RG[CO"$^L%;#2.)
MJ)#'_.U\;+ 0T0HR+.!8+__Y:?N9Z,2"^;!P3Y&88K\4JM03Q;*K\!=_ZT>"
M-RG'MU[(@DG5*N( EX?Q<7ZMHY]D3WZZUKE--D><?+%W9#RNFK#@GV'<,I,\
M1[<ZI+MSL*/$R.IBYF\'>N_BN6HEN_-/@B^N0ZAM+KV@#GVGOYC5(;YSI$3'
M%-\/]/J)TOTY[&-OA:)?S[U59UQFT%C%K]/XJYX0[UH&L'[I/-AD"\J0^;,3
M]QTT6J ^]!/.83SZ3=5#[LI_]#GP1A2=F433-V^6T%SGSR[ $,9%L\:YHBDK
MX_0&G2LZ166EQ#C=G9C[Z-WPR%+J".B%8O+;%?KZ:9X/TC"9T)AZ9H+)GT%_
M\<^[!>\:OE6.YWUSXUNJJ0['7W%O%I;0/)4Z)/3?6RT#7*\B]Z[UKJ+WKE_>
M8E^S*JGVSU#=X.&KL][1K@;M,-H1>^[?^^9]1?7D/?Y%#M5"SF-3%]DWH 4S
MJM,=@PR,0CEHS7(@1, AJ46YLS<V@@5CE?EEL&\R_8>K[]UWG3].MI.!/FMN
MN_CN,:**FC]/'Z@ _=Q>^_1?@G_^$MXOG:70E29@6U3"\###=WH 2_\E1?F&
M$;X8FPJSI"0,@\' KEJLHLK=16=YB*\?YT (G^E\C"VJ9NEME$[S<KC"-9FG
MV>#6_ERSAM?.W'VU/262^FIFK<\RIQ>Z(N2]^QR*R=D,'6G2<CR$B6MX(Z#9
M;L^K= #J^H!)^$YO5)G[*;4LW/6TI'AC-R[#$'A &??BJ?L9+(2WY3OLO:Y2
M=XQ^]4Y-^O9V:XJCOW'=CX'^9.)0:]"Z$EW[!*7>DD1B,2.KZ@LV?P4LP'9^
MI-\R>R*$!0)V26M&ASQ\-4))X17/ :@7Z0PS+3V3EM?VMZLRO_439WA,I<<W
MUHRBK9 '#I:(*Y=@W;AMT(I)W;\]$-B+&)_<4G'Z4LA3R<-=+22<[,J20<&;
MLMZ9O!.NBQ978LJ2.+%YS/28I3H.=6J,"T#=8C,0*P6B;_, SDH$V).,[=^C
MW](+"'#IL;.O@PF^HWB:7542JJ;=,P(R <:I>UK#4[ZM,+$&$JV]NB,Q_STZ
M^T&<^RKS,*"HZ9<I80L8X"GJQJ>R"W)W]BO.T'Q+3CC,9B?I+HJ#K$G@_:Q#
M=#<G![^S\="13Q2/?Y$L-;[MTKYDR=('\@EAEW_ ;^"T)5^U=MG!.?/[\*[I
M@RRC1;(D[N*$S+=B$(X:O(#EW+;O[]QB+G(D;%_'-B=E83Y'/WC;*L!^UXW&
M!E"+H>XC+CJ4R2&;M>JM//F\^26IF<U%!P/=-(D6;.U&))STOB+F:$D'2GY]
MNM%O%AUE)L=9S )"$%7S/ZTW.&\3&ZS=\O P2)GY:*)JO_R=-*U;6IS]M-^^
MC5[@33K0,C&@.[O1:PRAS+\^'[8K&SJ N)&\X(U[08QPXD#+Y%!2R5G5?X+I
M7J>,0DZ/7GOM1>:',)*(N] CYK5"?"]RR'-A'BR_TSJA,+79 DHAJ"]IO:/(
M>KUBJZ<2^47D14IW8$LK%C@6&2VPFUO2O#@]J>B7'!#A['P7#XJ_'R)2<Q)F
M]HG C?@O%?NNT;U$C52?Y7Q!&WQ9@:#W^/[+J0[EJ]^D/&<+'3J:$P/3>,/)
MFK.D" DN8VQ>WHJ-$3.]PMCS!>184-EV'&A-"O^L!0]U8_[RD06$0GI#N!K^
M3&]LWMJ.9Y'_0N&=Q\+IV,2&WE!0"$>^))3>R_C#JD ?X]*'$$'JIV"!>,=X
M)--)#ME"1K(AWFL8HVL&>A,M*#5]7\/V#<FJ^\.5S(IO(5C H@;/JWJ]'O X
MP<OJLN\5E!.5SG:7^P5\JX,S+V]N[^THW1':+XO-@7EQIDEJOM#("WM*\6[5
M1^:OUB>OZS&B OL!CD;17@BM[,$+:Y$TS.CHE1..D>_O#,G*CLYWX%C8]^!U
M&:/Z4;U8C,)PAQF\\#OS*.=3'+N@3DBF8@1E*>,O?POXO;YWF8(W(!#;!R5&
M\>.;5M_\P2BM"F9/--Y\34LT!EY3\ "(V!5=OM56P.R$]XM,)*F!IIE50[MK
M!F>8Y?1:.FR!/DR:QI/\$1:PD>'%)?DG?RLNQG>9Y6ZGL5L7DDX$O;L?[ZX*
M_KAW(K(S#)A,>5XT6X4JG[$KVI9H_UN+4N^RUDG-$&R NHG=7\,?/WN6>/NJ
M5VD454>/)^I48M6PM+8=OP[ZKF_0_:I:REV.5FT8"PCU%9H ]2.O&=F>MZJ?
M.U30M,?8Q)_Q'F &QPBSWNFW^6Q2HU=USPO>757B) ES[^J%8@W @A?S_0"3
M+^5S?;F'"7)@_G"CWS:FL>HYB6FC#1$*]>T6@\Q0!9_CA-67:*^#\[_O\34S
M#[6\NNRR76>J0T83V0.6>LD2L(!6.',.\:#M173SGX1/QNINBP& 1CL64-@S
M"7E4'H*9?[>@L1*R=M/W<I[J;% A#ER:":A;T+CW!:/?$SS5Y3GP@6>>,^]<
MII35_Z=(,)QZY5$_E"=*TX\%WNN_!B*J=%8S$3@9$ :HMQ,I!-^<8P'OXBK
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M57R1#T1\-$,&(09-Q\"<"'QX][Y3"@IIX/R@MDZS/DLET#;P3=4BO[X>1>E
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M$1-;@I8?+:02_?7H,7U-K/EO\N[?!VQN9JV*U=RE,GQ2XGB:WYM;>8Z;%2U
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MOD3_M!H:;ISZ*N$'TTCXFY!,CW$]B-?ND,0 JZ'52G)8Q).[!AJ /AB*4#+
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MM)T-3V;=,/SV^=CK E^O10A8P<K@64I*79N&LE6?0DW<XL@1ZW[2\4$2#?"
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MDH[J/K[C&<<+5)[CB4UU! T@[-(#/N'\=YO3/-\6/##"-T2: W;9\XXV[+!
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M?O4TM:CV%4V@YC%-7-5EU%WA>JSV2L<+2@/TO5]7ZN0GX&*=6XD/]]9'1W@
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MO7./@*VQ*(KDX6I]Y843 !-X5.?8(\#QQ?\F%Q1RDXMH;;443N+:XQ$UUA,
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MC4]*)DN+ A%3E*N$8_-?N//(JUEKH2H5,:DLW,R+X5ZRW_F5 KUA/#9+:>:
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MQ507)@.)QG!>IWV\C>\)X.>Q:3,Y>33.4FKR>+U$V/L-@-D:8"CKFM%6E_.
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MWB_AH0:C_]9Q0%!R>^Z(RJ-9FB*JDY>T=?Q.Y@2PF_%H0S*2<BIEQ!S;<63
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M3_A;W?6O$#&=<K^DHD)$U-[="S:^HKS\-*6-BUR"VRN@JD[10@9H IACIQ-
M#@S95XB4(=@"FU0$*Z._0I)J-1*<SX=T]5Z]\B107[! F5<,W5;_B+_OX@,B
M5^^T+@4%)0G]6EZ]/;T\N,HQKA;FXH O*,W4.3M_\7?U''^M^9]GL[X&C86>
M1S)K'$Z^GWP5BT92/E<.B7V^_T,)#>I]I29^]Z#.<^/)DRJNL:<TL;A9-'W
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M^LAV7]F@AC]&+HID)T5BGW&IRH?2Y"LB"2/!V#456O9^"KR%OY"253OP+/#
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ME6R&?,ZPKDUUVK.7I67<"KE] A! +.'.JK0@PF6'TA@@<N%8="KV\2PE_YT
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M&Z23>LJ7YIG5[%A3F+6N*Q)D/ZD;2,9I)_;]=0N!'6IBNR2/679A)_0EOZD
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M99*^SDYA',PSA+]L\C7AWSG+TVCA]/-#?;R>@9L/8.0E2K:^9O=$Y:19LS
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MZ:3W(ZHKCEWK'4_>O+X,_MRSX)/N^LLU#J*=X)98=#S=>T1&"6?XZ ?MWJ4
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MQQ^K)=>=NS->@UX$Z@68WML[]*!@9CB<'?O*IU4P6#)W!J@U76X/&9T(\5)
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MZ$?$-LA@!Z&^^0J.T-S?Y=)TPN_4E[/?->T+<@W\2[3T&RFG]*&EL4JN9:O
M\:&'H]@4CC \B*7?@2/B/*K-X&E;Y\PXY+-;S[3]CYT72 4X:.UH:]XPH^RO
M1_6>^PH\',C>)$H4V#"<XDK82^Z\VF#A(&NH_=6-53*3^=QO0GTG%/Q/L7$<
M#5BFW"!0 >V*XL#.J^E.IK3I->Q+SV47N=W=;Z! RF@'0/0KNK&W# ^E=RBI
M>8X-!QO3Q G0[ST48:K"=2962-S3&J43#!%>Q%',R,C@L;T21&-MGH:1K=4J
MN ;8X>_=98IL@]%QSI!*//&]WV5735^<P!__GI./6HDX8S,5J)W9+?1]%PDA
M2,8V:1!I]U\,[R'9334<D#WYCN_,/[^VMT+\V,DQB>=.,F$[]P'6#)8G(69!
M736D)!=OHHYA PDS*[>9PV0,!5I&/S9[5ZKB&RU>9,L_,_/4M?\B>H3TY2SY
M'M'^W+ECWAWX\9O=F3(ML!%%2S+IP'_">2M;Y'T<3IRR/TV6M4ZH/=@&_[.X
M^8@![4<%!,%@/:GD6U3 M].;N]R-_+*JSM;A\*\B9*^]_QH"^&42W2093)?!
M7-*<%.[5+$DBG4+20@>O=+1V"!HA:!]R$R28\VC?+>_V(U3@%J):B:],"R])
MM]+P">>_F234<6?#KNAK*?%8SO!U%IEE%&U BB6RF WZO9@#*G9;WAP@0QR*
MM#C"_5@<\KJ%X@HO<O2<Y_9R"!E7G&>F3P5Z._G#:!55P]3&%A[9\,3)LSXF
MZ>V"4_8"2HI>4D3W4I9.S'*7??I#KAE1V'.5VTWY1Q?%73F%<OC&]^M?;RI0
MV+8Q89[BC*U>P LU8$:_&]@R:2E,D"B<Q7A%9G\(PM3C<->JJ6]1[M/&QTC_
M!UBV/9? O+JH-;P[3KW*0J+Y1IC,\B\Q<9G@]6>BK10FLNH(L@D\8RQ.]L%+
MLD*S*$[H6X3RPKQN^O($])-8@5MF'A#8G>=%]5Y3#"IO%Z-@G51 "^PB%<!P
MPF&9+$(669'LW=D8V5U]O[01,(&QI@)B+EUPG^5Y/K/'MUQIA- M@,(,3R(#
MV%OQX/ &1,?D@^-S3ZRR5^Z5]#69=$>^&^1OV\GRQ68'C(&W'8&<L'7]$>!N
MLO:V"QO4<J)S^AL5T,:MN$';R2LRE#NX2[-9#:;YQB%;(5YJW37?<VT;SOVM
M9;=TJ7(/G"95B.FAJ#.N%_@I$K!X4(P5(;QMFIVD/01N&MQ8^BTI+AXX=";.
M;[**-CRQ1TC^/(#F\%%/.7:N\*]Y+.8TP ?<H0(&;XGV8^P80]%7""*=/4H.
MLUM!P*M-(CX^XN7P\Z:M]/11#:#%/_-_ZJUG'SO_&C2RG\=^(7O\I^PHA0I8
MZ^\$'ZE=\- Y#9I.*AL!7LNOT"(G, NTT:K_8S560YL,T+\+8G]@[$'1E@\(
MR C)#0]Z]W8*ZZ"4O4?Q5@V]6V?YDYS]O;)>NU^Q5G%"JC^U!!,N&I6]1_[[
M)R[-@;J, ]@F4H;]SN%!K X7Y:8@&\+<6N)SMI]N"D06JD_6%<]J'H9+2WJN
MZH^G :OV=A4*6T_OH,7$RNB1^8MNP2!N9<KC1-%$,=\>IX3KW^M%PGD<^DI-
MH#!\2NR>LOJBHK)*?[N"06=G1R'-=8A*P<^.(P!-@9\4J05QU7/#[C&B[3T5
M$.*I>V=J:E''PDO14Y*URT#],=T@G2W']?C!(A*\S8NB2$1U@!DF=039CY A
MNQ.R:6+.#W<<(75V,3%+".V&E)&<UY!\R=0%!<1&/3<T80[T>]U/H,C4!\_M
M4,/([A_F\R#&)71#*[;>O%C)V7R/;=<N6%K<VY! /LUB!\IV>0Q20Y)E4)BW
M3P"9>5H5#^*##Z!(>(  5.?A0+F2UI=)TG&G$46^.6P1R+3*RT1(G)[0N/#3
M]4(<7C#J-0,SYR]VM8]!W1_453H)+A&["'82^.G(KBBI1EEXE0WB6P3ZL2IW
M%'29/_@[?W"?W,1X82,%@\3HTB0=;J#V3@)X?KG,&I%AT!U*EQG\A.6"=TVK
MW^ER@F_QPL9Z7:F G%?E^WFY@:13;!:$=V#V-C%']QP0["K<JQ2Y.L*OPMGI
MJX]FFWT?-B=LXE:W0,=OQ2H?"4K$<J1>DS>Y?_EUT&TJ@!<X'T]*H31CJ0!U
M<>]AU+4%2T:2."Q':T9^#\Y<B_*>16S0Y'TVY8R=[!QP0:1RYMQLBF(1'_'!
MU\Q3 0D[+J<1<!AQ]#)IVNC<_S9#_^H\G[G'JJ=IQS+#>,BM(@0;:V6DI%4?
M;91$$BZ18Q',F/57X7\U:'^O88 1+4&2HMD?!%MG<CH]J]'&K[,!%TY)QS4"
MZ"1('+-K^ON2I[ELA\LA)_KZ:6+2,7WDW%R^6.?R3['G(?>4& $4[N=?()&)
M=Z+5)3)D5=*HE1<[\/Q\U,(O@SUO?=;G('^ S#:[Q=!=J)%O;^J<SIM..S$N
MGI_G2FN?$;3"^5Q&E$W_88L<6XT:]]M+O8A_RAOF(AO^1&UQ#KSN06BYBBPT
MN.W(Z23#\ !W,7QFV?-)=9SQ&(M0:VSFTZCRB4>" $W.\JW_,I$N)14?2ZR
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MQYS^(/L/4(T)#MUCIWI7C_O]JXP9GEYL$5*.) G);I\K<U9^T'*:(RV<?#-
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M#>'(I8\_XQP3'M\97T=[-?\_ZC4"I!=IALC$51E,5'R_QV"0XG0J2\_VX/V
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MN$^S.11Q1GF8WG/@2QK-;[@OP'GC2MA$)E).6^?4TKX?3\I3J,Q8/@$ CK@
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M$:Q:M"O+/][M*YYWGF=@9_6E8_T">%Z2L'*$^&G78N^R^M@76*\G?+_'GYT
M!?7R'.I=GVJ60\4_0L5=2K3P6[;Q,-(6%@C(#?"YB/E?>/HUTF*1(6GL0QPK
M&P?(O&L5BJS+%RW4YW_9FNA$F0]<_2GOV7W: W[JQU8.!N^B$(O;^2O@U(EF
MCJ;_N)'[,8O*G'V$  [1X <R#%CH&YHW8_NLF&0[%J?#WQX6&^F0:J5E7?=8
MC.Z>6FX7B7EUZBH^:&A5$C.3.QZ9Z^#!"9.H$?2RN:Z!4K?\^4RBP_I66;\+
M%5? SVAZRZ,'S8F\%Z2<*+WBK":G3<Q-+G%FE;VWK)VX?8Y1YN;;"PIQ1SH
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M;]L%2**?.@6^G+_#.%8K]8_&8B/,VB Y]A9Q2%*3GM@)X!XV!U)MG@':\.*
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M**F0W?2+U1 4+A5H&7%SX]:]%);KT7.4BUQ[V;H6JJJ8=F#_=L7COM)TSQ.
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M$'5F]O1:)[M31=8#W%:5C7S&#!LC>RW.P3-,/5<^J#/PQ\7<TZC =B9$&HX
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MDY!VQ]L[12?4?GWOJL5-,DI^38:8A.7!O-^'OOXK&E"<%$ *:1IY-HP@'D<
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MX;--0<9>X6[MB\.@=$]@<Z5E:(?1\NN0<D2LXR;W]9_?'ANK-Y0665+/WRU
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MI8>"4^#W+"\;=4J""J:-MGU50>HS#9,WDFB+7D0ZUS?K_"2_/@\B>6]8K#P
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M-'HZ2U(/E$E.=Z9=2E;Q@OUNGUK.,!::[< NU9+*-\IT\U&0M3Y#W*4W:RJ
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M)SXR;-2F/\M]W#^UI0I./-_K0VIK][LV_IXS&8Z2K!&:O?])U_*SLOJ5Q>'
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M:Y]4PN<C'BC,Y1>\F_94$O[69C3H1=TOKZ_[F''K"X!>U^GK=8 ?6+P%QJ7
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M.7)0LH_FV\%-.W38C:-PFVY[^<I!6="C+BCM@G U7YSN<Y=7_+X@/8BL*38
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MYR#A1&-.52B633DZ36U$9)4U:E/\UIE,'@XV;[)1.6KK0#BC O<3[G> H,E
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MIZ%R;R=+QM[6C,B3]FK??6 QJMTH?>[F5YWD/*>LC'P-92=HL+=/"=35?U?
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MB1>>8EQ#%;2-@;=L;'6O&]((,].884F <[A'P&BS\,$2]>@ :9\R)Z6*SQ7
M]OSTC.WJ,\6G+G3GCK[W#_<U3VG1-BS*;Y$ 7 =W C0Q+1WLEW549)LH%I,G
M7LF*"96&"7Q:YW0S#MUBY659M[J(T=\X:VMA3:IHNK/8;(/2E(,@C4?M1Z?7
M20"'1E-;\33#%%A^.[-'-0,K7>8-$H =-3%9BM5=WF 9)?N;4E5U8,OPD4%<
M)FPE):\1"*:'7\');]L01T>=7=#U33)B0EI&%RT-G_]T#MFG9 WV[;YQ)M-J
M[>^%5O5I1VHB(IO$BD4:IAUD'9]::E-C,Z@;A>)-V:E"0_(X6ZT^.XVK"8-/
M$0M%X;8(D#@(=GT2/3<A(;=DG&UZ+>-*W'/9ZV>C4H:W*S3(GH--A29P40/$
MGE(,MNYLF&)2\:L)?_M*8E,KOC4 $:LM_8(AR-B5(I>G$6(9!/FB"]H\!9;,
M@?_!R3*2^@=CZ[\:5>YV#W!H3L*9<*GRT^JPJ7MVPHO.3/UKK?I<1O<YU!JC
M.$6%Z3);"5EX98_<M<S#@>VXM,]>Q4#Q(5#A/9=SQ=.7!&_P,O]B3<P3KA<^
MO;2K)NP F0ZB0C@'(9Q>B\(\%3F^<+):Y\BJM_D)6%NTM.:<;\4<>L7QP0(E
M=PVSG[?458XMQ M4R1;W7*B[JA(KN3#LM1*UMKS2\B2MQ)>7!.@"QB.A[1!6
MY'JF2WQDR8.-.'=7*5<C)^&72[I*G2#!>)E?W\KZ%=GGC0,9*CW0 H U[H+E
MI+&*W?@L#_DLYL<,^_?[WR4R4B\F*GE"F0A?I22\U*.5K,*%C=DK9^0S9S:-
M:M-[CS3W?9S!:#&NF6]:[FX\$B'1Q^7/'M>.!"B^LG;D<RG?V<J+U1%Z.*W9
M;](G+4S0R16@ OD3[TG%B?Q>*_V_T>']0@_YBXW5]A==Z[_DQR4(12U+X>!2
M8GT["9"W"#6$_FODORZD0ZA<7-SE"S#$VB2"V_;;N-G>5R?H7;:O,:9<O'4^
MM2/E0;_;4CS#>;%1N #.S@H#SWH+@N)J=CN/973ARJ6-NOYOWKN=__D]-U3F
M8B_72D/F=3,QJHG93QS_:.OI,(^*4&<)>&KWM@*(UQYODH"\A?AQ&$2VG_KL
MO#+/,!*7_6D1QIUGDZSO897^SV*:_R/D3*!X0.N9UWHM4GU+ 'NM[]E$(0*T
M,)KT9MPNXG:V]]D#B/3#GT]Q%*/-FPOI^!3(1?)\71LC 1X4@+OQK+K$QU5H
M*"'L&0GPZ"K4[B\6U?/9V=YIC8+_30WXM.MO@I0#W6E;$SE\'K=*T8-Y6I%O
M(B6SBC9&3?/$K&9,NE<>Z5;98'Q/FOV-OXS<93)#MMN"^)J;=*B9BI_'RU_Z
M1G,7L";6C9>=!\-%B(.*0>S92U/MI2*'I?K%O%^<2GR1#P?\)=S4R2N]]'$]
MYW!NG_R+A7F!K0Z5+8S! ;)40J*1U3#/5B/SVZW4/NNF CSD"V/^["#^-\.H
M OEOS:TG5R$" 8H_<&'%8$/_(ZVP>Q,,!4<.KYA%6L_DAK=>^C&B7(=4BLOC
MU%M/V5,]TQ7,)',<W#.FY=B+XV5NN=T=<!K1FJ;?;#DD6/Q3R-C0$7BI^K,3
M^AFX\6DTZ@EHZ\-H\N#&E,US6EG=%4J/WME8:YCV/ZD_.\4;.:"]VJ7VO 3M
M4SD20"YV6ZR]P2AB5"&K$&G"=8L7^;-RI_OQ/!VB#\5  BR+"'"H;^F.MAS8
M!MH"K^')#\2'#P$6)$"EU"/RPGV@.$QU%_B';A4"<04;0]01(,_!%DT@^>YW
M[_+_+_T,K3+4VP*%GN!22G"-3T-1ALG[NK QH\F-*6&3=S)#UPY%56IS0J7Q
M5YN&_JV>G%?>7M!2L1*4ND"0O<],KZ@/^\YL#9EZ97)L7>AVW@\A3097O4Y8
M14(,TICX84-^&L'TSQ$YBA4DL!T2193!TKP_=, '0A8XQ\P:P@RJ(N^/S02F
M\C ]Y#<QG79;%<X\,CB_U@"-/+@@#OL<M-B!6.L'&M;71M,D,C\\=_7%TY!N
M*ICKT_O'K_.6TF<1*\S'^<NSM<<')_R@^1/)UR1 >.&1H]6V5WWL30YO"Q.S
M;<[=P=L55#\%+@2) L':#R:DX.*.F=<J?:VIC]/>XOP?:U"7<]HE$+2"C(0]
MUJTR,$-$C9S+Y)FT!A&N5E?L)(_4SJ'"20!EX@6034M%#J(?FX/\==$%8J,>
M<VO(#>'1/;^M(USG=6GT>W4BNR" 0O031;R3_Y$C>?(]<.1E>%V8^H<T8J2]
M3?Z6:WG82&*G!-DD=6S*(?_DJ?R71?[?$DY*Z(Y!/'CY[UA45(!(B>/Y.Z^&
M)5<:V5/N_LA?T?6]TCKTV#>K@3^UM@BLJS&R$SX0D?#*UHV"TMS?1@MPR$4E
M7ZX)>*NF_D<J9P%*B&6!K)<^R<]94$LJ#M 9QUL6MX)*='P+D.NE3E[.R>+W
MN>Q2_%*RS8=:.8E,NG]G8-O%FV[KH,WZG (PY/'PNS"]L7)GZH^H(Q,CU=_K
MGRBR8?WK?W6A\Y[H^'L(8(S):84RXKP.IURWG&'^<<9&#1-63J5RDA%VL\M+
M2XG-LI85.85(!X52%VLG^L\-R4:<0A?"5#Y1=)KFQB7K%J3/YM*4NNQ,0Q1+
M55 _E< 3Y43AWU4?.P>;?2ZZR=9Z-0G=QI,7)93( +9NXV<</K@V<C!]-";^
M\H>BX>\N?I"DO-YJ6&^7WW$QD0W2?9R@OF5;1S:;6\;^]T>/-D%M1_C?()#4
M)&J)G-1U/QP5""->C9=_'N>2^N+Y2P"?&Z"4J(AS>K78<AFG:SA.Y][^Q7+
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MYTU$#28>G5N@HBH1#;XCO\X]@#2Q/T88Z@A+MU,GRR5=MWO"FOR<*53K]D#
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M]@/^PP,2(+S,56Z6\M?<YK,<DXQGU_96KJ.3[^IK&<F_X*1F *P#)<#BN21
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M?%/';&>:J^O(F.Q.V(/&^"]BQ.>L&E3N%98TL#O(S?&,4QO^,K=_#A%R6CI
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M8U^A7/K?N8))P&CXI@/1A$M_L: %9MP2'?L,A_UC_3M:#G=:3B6<NHBR3IG
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MV]+.3WQI [6T39QHH+H+7%2>>#Q*VN\^3H0-?KH9. 0#&_;I >_=+"@]65J
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MF&U F:IHM'1_V6)CDN/#G>%5C!/.!]]6/DXMO7O*U$_C:N&P,YZV'#(C ?(
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M5P4BNY.YLZU*<*G?>_P0\6.:J('"%R@Z[#EQ<]85_6Y0V3%PIM5=E1U1:AZ
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MCRM5^YVR;2;81=!7?<R3<5KUT9UFE#S;S;!DVK+ Z=)8U_0C &QB3 6]U[<
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M!IU@P$,";8FJE@@X/@.IX=3G;O9 )A[LOJHG;\]T8:_UM@X]DU@0T@]"O9>
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MPU,NE=^2:]C5M\]6<=-K%Q7&6!4O%1]P?^//VO&J;/HZ*C>3>/JQRL6E]X\
MU#X2#F+!1X"A;4]*@HU[Z\EZ:31O5!U':PC&HL=_$UHI'?W%\!=!2+LR"2UI
M)77]5<2+XE'&5L'ORJ%9-@)LWZZ=MDPQ.=FZ<;IL<#^C=;EGW58+I!J&XP2>
M'C89L^XSGC"4RA&IB9?@&_R>S\D<D3ZF@;NTD3S<F;7=2P+'TO98'29Z<V?Y
M(JG,A)]8<QA"1NYN6)7I/'A9\H%5&-_**T*WWO$0"1^A8&]7,OM; 1GC*Q,K
M,TE5S:\X/MY\V/A+K79Q\7ZDAGU$=14CY';WAK>IOV\B/=/?-=Q.SPCQXH$-
M<4L0[FIU$N?Z\MD%IZ MQ?M/,L<;L\<3KBA,4.817MR\M1$]?W6.N7 =HU>(
MEPK++C!8X$@.V0_X!<7^Q&YT?E/E,IV>>1.2(\K&Q0/3,_KA5#KP:0@]]V8"
MK.E:&NS^V7]7X#XDZ963</[[LS)PV5F-9KA!W4ZIG0I_4ZS._>!0A525MCOU
M%A=.S6Q/4?P^8\E]";-]:$A>VJY,+$X.;>^[)Z).G-X)1?^['K=8?>*HT)#5
MA+U_Q3EW_(Y)04K.8@^3AM/[4>')*O:-B'@)HXOY[T??LH^6<8E^\3#(!&%_
M%R/.&VB;F7IE@L<ERU!F/S^+&]WK:^N3JTRI=)7%%4F>B*%66>-.AE6S%]O!
M/'#<&A"L-IV/:"3Q]N*&;!F[BF=YN#[6;(*-7Q1*6[YGNC)W9V7)-WZW_*I^
M:BC3Q9Q/ (^I"_-.(%KH!'=%<,?_8NR]@YJ*HVWA($B1IO0J2A&5)KV#@C01
M >DU()T80B?4*$IO A($!*1*"Y'>"4@3D-XD]"X]H886'M[[WC=7[YO[O;_(
MG/F%R>3LLG;6V6M]/P&OF=@WU]:$LCJF_E;OVU<O9)*B@-JU\J@N3J_EYU9&
M J^B.F;W F81)X-SKZ&^!)#? MM&LB8NLL;3)69!QQK#'YD\(8H^9.8P70P@
M6-J6[&R^#V+M(^TM["WIEINHI^QNK KVMQCD,V<OLIK^%GPSF$KM)^@;1B'Q
M=I,=ED\KI4?%%VG1LL6E\8AE]N:+"4.]B9P'M[],.&2M'WF+]#&D>V?:5#^M
MQ _4&,-9'<P3WT22OF)W)VLA<"5^H8(%GN*15C#*6(=_^%$4>Z.*4*C<;1<>
MEN=H^:G\M$#B0L_Q-WEM);+CKDSW!I<_Z*R-OD($_+5?,PA"WTZ6*+0KW= F
M@DW&/^-*6+S_K*,QWW9VPX1T*B[IC6SLDR6R@ZLBM/72^U<;S@3AA'\0IC]>
M4AFHJ9[@RQ6L"[L]FM;[F$'=F.:V"#6%S*@[K-OW"GB7.6M?/'RV[;EIPK\E
M, _?,%OGBM$M=2"]_9)DUBJR.'$+<%3Z\"\E ?UCT<CRLN^XJ44Q4\5VL++:
MA&>X^#IBBQF<^.13=?;1L4OK1Y//R;\$)CR*CTD<^_R]DT'T\&0'R+7Z)Q0/
MV$"\LS?H -3-?-0:F/[T+W/D_GQC58T9&^!GB_>MJV,UJ]PG::Y'TQ19!%F'
M]I2N2DNO%PHP'EYXV6F:P(#CU5+:UTL0BT*1UTC4UV2VK&^K\!?-34HP<5\3
M$9WBVK3T70!R..$%L7;]B86_7^WJ)QJKEPK)R;JZ9 6;/0B/U0QI 7G9,-UA
M;WEW7(S"Y 4[UW=UF#U@RC;?U"!_9/"*T$D"\/G10[\#*[4"\2&<CWK9T"]3
MIQKGZNI'>3E.X]CO\4^75F<-;M*[,[E]J.VDT^6(W/UZB MJ?B(4VGM5_$]\
MTY)6% A&A2KC)GO;)$_]31 =^6$05T.<Y,>-,F([[EN5'QZQ?O9J7;=$6%IC
M4&W>&0]QC/.:LLL: HG:9;6.RZ$/#(X>?GM9SD?!Y@5XM/5D-5^CRG9+_W7Z
M9#P&V&$J&2-.SHP0TXPRBY+5C'H_RO_US/+3G',2#URLCL!'RDHD[PF3^/CY
M/_KE&V*ZM&:]\LU9%SD@M[L)#'K,L3PMK#>SHPON''9WRQUT"?V]2J4A=J3J
M5F]:'M8%N:6Y$$>2%J&:*!'GO9X_]Z3(0OS+ ]=-JL//Q&25TMQTTH=,Q7/D
MX@C%CD<;J6/PN$(G&FUNUV="2^A$7\=KW>37E#N?+(293D]4R@N"7_9:C&:0
M7@(J.#^J\;3K)$7Y/N]N&BV_5</!!_!A>]<I_C^%86%L_Y\^AIS5KZHYO/ \
MBTM1D+\/F<HY,B&R984P7*.^@"H;I^ZV7&@:XE"YF@B<Y<]?SJ8?A\D.Y!^
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M.X0<%!PTF*Q*TEK/:MS[\(:\,593NH607QMPH^=_OHF&RD'[#;(;?&__IV.
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M$+)+P/M===8W'),U*"&/LRE+V #BZM9<6QU)TQK_,J)8 ;D3NFUT9J8.UQ"
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MHSU'Y0\EFK,#6'&(T@!E[-->Q8@ 'E@VN3U4@/_57M4#,RX:IH[1;"F,G^1
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M7<)0!E<IX<J\.K)5];2B/D&9GX=XL>>QL$ G@159IT?L/8L;$5488$?J0'2
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M^-2S+M_(V\_?['5\?\F/'.ZC6'CI-@9=!DU<\KN[6CI>I7)4%V"T>Y/I-RK
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M8V"Q+'V!BX#^_@2C_9<H<.<:0-*ZFHY1Q;:)9)VS/\+)@R4V@:\!CP4PCM>
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MT$H>/Z..TUJ?:T#6Z]_<*>F:56,^^C"C+1JW$ZTGFV[*;*<4=\;YU^=)*ID
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M'$\#D?1Q;9 V4J+SS>21L+?)?=] E31)5)EA?Y4>J:XBB^>3@WCJ-QJ-]!+
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MNK0ODY&5*MYUP?O6P8>61+#(134!P/=8__78$[HOE(A"I+9)8NF)OMO/H1O
M/7#9#>#VA[-?9"R8(J,KVY&55$W'4\/WXS3]9" Y)Q%;U(7;WV(5>1!R[3<
M>*8'GOY/F1F*C*F8 X/"E9/LR"!<#<2AT5XBM6%$1,2)H6CG4H@?!WRI2^7
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MH0QL4%P4E][DMQK*XQD#J4+;D4HC_V7!MP>&9V)BU&)E@BN14Y]\N,IDEV\
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MI[ &NC',PNX*WNO'5.QE*[T/;B9+*^(]5!0O;N'ZX0A9J(XR)]NF)XSR.*B
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MIM$%AB7(L )1>&^>V^%E?'C\XRU"'..JB7&_%4""KB WB,+_%?=J+#:<>??
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M/B6$,&5YV, JG)?[]D^N(:G,AP3M0P*%OTFQ'[;;?G3?T.;J58D['>>.Z99
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MLZPF=/P@MR4(F/=Z3 U*#CC<GZT7$+M)(,VCC;;>O (<YV%]O0O6Y]011=>
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M706TDL?'6&UQX>A:^;^$]'QR%\U'+K4QW?=Z1W^N%FSG]=2L5/;4?)Q?2I+
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M8>ZE];5PN7'LN'<%(/R5?B3G98A<PM[C<$- F-Q]KA^&(+V@<.14Q_EXRIU
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M%[B<_-51&*7Y"46J'?P2 @8RG>(:7U*?<'41\GG+=M)6ZML\N3]Q2Z,X<._
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M&2W9BN-2-M>YT\VME"*X1?TX;#7Y8>0<,S'KPQA$H3T YS"EXS+-OIEV$\N
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MZDE4ASQKQ[+7ZL(81"6#CR9_-EMJL'V<%O-]YE #*#2_?T>! K'T9U/FF %
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MS0$?2P2#$Y9/ %;D"C8?/M:$IOWIHWD4'>U#@9S,+[)U2V>>X*_Z3MMJ6MT
M0Q:YE<]]$2<ZX[?A9PD1)ZKM-G4RBO[KI4Q1VM7UD YN0\LYM13]/5%AW0-[
M/M8X:M\PFY;_T=Z71K/==7W'7',5-8L:2HTU5DVAK>E2I2U5<Q4U2U65$HFA
MAIK2:M')4$-1(F@(-<2L*%ICC2%FBIB#B#>NZ[[7<U7O];[W6N^[GN?]<'_(
MAYR5=?[[[+/_9^_?SCZ_'4/_/'+YN9:52L2K)+YNY^JD]OBM\CET@%H7,ZAQ
M>^";H1).87&'ZW0#79IQ*R3"_*3S6YEG&?S3?IV0[F.].?OQ;7.7^1(N2WB_
M6M14MV@'DK'TC!B0"_33J >SZ6R#[NM2F;FE55IT>8J+F CB.P3\8-D_!!B.
M?]Z;UI(_JMS$'(2L8C93%__00![OI5D;CDP'_<J;/J\&D(H^WA9S>>FW(<#R
M/-F6)[7(Q]D77QSP(,[K$)!]*VELD![?3;J<?I)LB([@ V%4T4J(1OA_-[VW
M5NY1/X[?TH)DFR4<NS5<Y0Z0>MH#FT8%%)":#X!'2U-;+C@^ EC..WIQ:SEA
MK3MPT$_G"C+J.V\19,/5@"20UN8.XM!'+-.KKE2AA+4C9OHFS-8*69D>M45T
MQPBB]T(8)GXEGR"_;7_G>\Y@V3NZBBM>!UQ7.;K'4!(&/%!VVQJQ8)]@W>73
M$H/]J&<EO4'M+><!BKC(K^WS=&JR,H1'#@&Z"/_C.; ,EL4*<#1V71YRD3P3
M&7&.!=EVWL?^2H$0HGZ$VK3^1?WA_V5-HC%A+I,0U%S^W-5_G!M\R@-,93.,
M4CEITW8O>A[2.Z<07]40%HI6_4+5:S&1_L03HCSY&%DHUCL39?/:[\S!BP^'
M )?A/-<L77J*>U+K&>+2AG<#'Q9B8]-H^JL=D&Y&CG/#(V55(UHYSGF&+LH?
M%MA27[7,]U#&U-],PH8U<HX&B%Q+U\=#8W-'F\',G8AWID:<R+UL9^T3]NYG
M\&BR^9&-0NS ]2D8O 0FP)8L@-%T1#,[KMT+=U? ;_<Q\SV#\42]6OQ@5*W0
MXB!O5]9D-,(I(#N-V8AL>"YIM,Y/-#H\97Y$.<?([^PRMHQUVK7B^/],>:UT
M#\^VJ,%:434>'43[?.N.-;6IQO*4O6QVK(V.<F=2SVVKA8W4_-1X)6:E.7=9
M"&*"+:Q=GQ[B7D<Z':22]&AGSZNL8Y?F@_9N64IG=/@720)?*/<<9PK9:XG,
M%C^:(HF5@RX@5[W)MJQ55N+LO9U<TK!SRE:-B><# T]-US>Z:1I'2T<2^[++
MJC?I:TEW[MX(9F/W)E7&L933JE3X+_R_(?\J!94/E9WWW]N)\A+I_9F0@1\7
M[::VT!NX2ZE*>S'\7%RD5/(M.F^\VD3SWQNH<:S&O=%,KIPT\"H[)VZL8=NR
M<9"BSYN=H^U)$]TH0:>Z&\//M-GE[HP>VTT2K(6O _$O&KC&Z? ' V_S;&1^
M+C_LC6V4ZI!IF>_U-5@QDF>MU+E[K5G;6/TXZU [D>H;BEED_ZXQNWEU/^)#
MY;-+:"OI1Y1?))M*=9^@8ZDKF,P2 H3N&_O9_9KL1S@CTA.)<5/] L=8?^>(
M\#<Z(^F$Y''B>'I-V11Q[];!'3NR+L> 1[JL:27KTF1C]QO=<XC;FNYL/$[3
MLGK9X:M*^=I"Z8+_ DU9?,=3:[^O7L*O=7[P$TM#HEM=%X/'L2"76)];7EG2
MZ0_?^0GVXX#<&N:Y 2[-;Y*6 OY@AEK;2K]M"^T32#ZK3V,IA$H6:KX0\G6R
MO(2?RJY^,O5Z62K+P.;(0?+%0<AUSH<.@M<ZV^?C$&B>&]6"%Y>N0('I9#3X
MS,A0;@F]=0A@@73^7ERX:S0E3LR6VO8G1P_BT;#-2X/]*(!%(ZCD C&<?!B5
M-N/ !V<JD94%QVH0O]&1/3G*HIXO/0'*PBN#CMT",Q0[.V[3F9R%&/&1MBSI
M/3UW[^O1MW7_,0NAQU,UCK,0?@Q/@]@@%@4!M>HTR>L->]NLLBO]L=E>:OJ4
MNR$*Y3W7S!+DTX(PL78T^ OQ%E<%E:J"KGL[[<MVN@>K/WJT<@@PEP3/U_C"
M6ZI7)[L;L6%:0,+H\P"KQS-K_1]>RB;"" 9@V9UAC82(\QNE%4STDCI4DJZY
MV2G=Z[#>]0J3"9A<)\RHJ_5;WS_*1A^+M[ ^3:=[:'M-AA$GFY_1"BU!?+WU
MN=!])6:(8>G9HS26$W,Q<Q@73(P=]=I.7+5Y#D&N.3!I4TTQ&O/)>^MT=1A.
MQ6#4IJ&7]IG$/5<\$G4R8,$*R(9Q/0?A*R*,#V ;S^4/!UA<+:NH2#,JX7@Q
M-J9J'7!=Y9U^7W5V2$WXG2G]24P3['3GU"Z19PI!I==3]EJI>SE6/9T5J]E?
M_8S^BC=\5I=/I$!A^TSH%+=P3- >EG@(H$[OL*O7Y,K!F&S8I_@.+&UD;7\C
M"*>I$'8^+O9"NVHE"._$/I7'^W6"FEI:*$^?URB+ON*#FA-]D6@,C1WL@O'6
MLD("UU+@LGX@ ,0[O([$'^!H@'JLQ"W;KFJC_CA!P5_09_A38G7F(0"!0<0+
M_\RNQICY /'7^)89R!AJ2?L;B<.&**VF4EAL/V*_V GS\WEP<W:#4;C4R_05
M]9W(+TB;@RR86WH4C%+IRR:2A]!&!'[T2/:G,JXR5L'ALV@89T,Y/+5N^:F*
MWLN#=H ^)2#P@D!N=ZCXVLOQBVNP6&5J3-^6H4Q$Z>DK/V)*PK3KQ-/4F9@L
M,HFW\+QD?%/W>?LMF/-=8']+JJ]7+G:TKI3/,DTA;^*90:.71J YCL_G\Z!N
MD#W4]L;N3UWJ+"E-Y4<CM?%$-$B*:+QFW6"G^<U[DY6#-+K7@ISLU(&\7>+$
M,X_:0:[$MU53Q4U].V"&(B$7X :QDZN1[(T;;;[O95,\R]G_./%8ILEHIH2:
M*K%"(R2X8,,.?()XO89 QU5'ELGYQS+1[!DBBG@6ZBG<Z<2D"#T[E'Y^RA_;
M94*DQ5R%L&>-$6#UGUE28 _0*0,J)ZUM;"3JDJ_$F[]B?4!/] CF$'/)Z4\/
M!G:;:)'*6^U<L4&@9*P,S 3C'B-1:&PB11@2;^P^.5P_B>5U]0U )!JLLAN7
M]N3VB3TI<'9R8)"/$\AV+N9V\OV27RN #"6")A'0G4EL1$;Q9_.-%520K=)"
MBN\?>9"RQ'/F/)8A#2D P5;.]+7]1MZ62I])OH.SQE;]#PO:BIRKOR<L9(#/
M#(B[^E.I@44>WE'1"\@E,E3WE<5?;K8JRO=Q8QZ;+N91*K"4Q3Q8C$,HZOKR
M@^E3X&,1=4,[KQ+=])?EEG*W=AX/=?S<)F&0"_;U2H_+D$#(76L9V74!/E,O
MW16Y]P-*^[$\-%6G99]?5EY]>V[XQ_BS)UU_%#<'2ZWY-MB/V/'TWN@UJ<5\
M[O5.MG;]Z9T9J?O5A-WY0_LSQ^=]X=V=S\,4;6L&7KL$*U>C58I'#;U)GG+2
M#G'@..\;@8(FPOF$MPUJP/B'C1\(X?K%@TH'.)/2194V#>LHO>&)N+@T-]5<
MXYNDSS![_$1J;O<,R24-VEE^WPW*W*^T1IM#F^62WP;.$[#"T><^3I8(N?N-
M0E #(P'(N$_[N#/ L-^S6F8M9L.T3\-_TDN0E6#PZ<$:(>SQZFCLX#HNX!(U
M=78D[8T1\T=S+SFWL%$:<ED$D!'\ZK>'!3)<U^*2C8RUQH2>&EX4E0RA.%M[
M&\;NQF4O*%1:B1]X>6K#ZLV8=,K-S[Q1;P6^Z%6L^\Y,S;(G,8;RT8Y9G;MH
MD4N.H-NQ@\[O6225SJ8-'@(4EW+NM'/SARF<6+67@$A^1O=IR<VG)).H$[O;
MDSW.9>_KKAFKW=QNNU\"6M%/1A:7TS(/]-5-'-QT<3F=[D)3R'"+^[JCKO3M
M""JJ%VU3 [5Z!/]L#SN>@TREZWF7\RWYANZ%!=M-CX=^-.*NN1OAI'-:0)!K
M?PX\A ])N!1?DXDF.Q9(3 I^[(B":F4EF'VMH.E%@-$D.+KLMFQRPVV9.FOT
M2SVAT?8TA[N('7_O%A:?T#:DS$&RAC$P5AG#;F^89^.Q%S9L-=)=4#9?$?UJ
MMM)$C+*9-Z\=%9Y_3L%I$^FQ-JW2&W#!TKKC]JJ7[B?4,R/?;6<_*HV.YY]R
MQ[NY.P/T?W;C8HU]FZV66R.)RK /;KZO)JJ,.CW']+GAG>LK#A8=&@\V6>)+
MRIT>\+[4NB@GE%Y7 ^O8.P2$!48UV5KCC!.JW.C"/:O/^#I*\X!&]I*:JV>U
M#>_$\LLR1 S[OMO"E9#8AHDV42UI(M5KH[5<;QOW0F*L^8*Y3"O>&(F;F3E1
M&I@I:#&Z"(4%S258X)0_("9A</\T<33^,L3PPKA@[+723Z4UJ(35J\*&U:MC
MHP8ANN<?,LT;'@R<$.$,W5>%=EW G(!83HSL>ZF;]$Q%-0Y'%&%HWS[@5:Y.
MGJ7WFG*FFY-O$27'R8*;-['VH(,J8G+-6(WA0N;Z :CS .O_/>W7W,^U-2C<
M!P=D6K3R*NEM&C1]%;6->%Y=)H2_\BS*>%%/[P(+"ONW6L9\HB'.5JI^3Z8+
MB<".+ 3:YM$&=>32\]\I-K6$ YQ""3UNRO=4QY2^3\.8H#R$C4G_F,X:)%&H
M8*(J-V[4D@!K[,[Y UEJNT&U_93BXLDBE@>L?(\VEK=TRSHUO0ME.G\*^NU]
M&A9_I:B6Q]0,J@G1F2JS^^BU)6;]\ 'H=,:;J2,N;70?IF1618&C=O_F\.X5
MIKFN2[P@XXXO7;H!<S_W<5[ )NRIE;>Z?<I2$@C4Z]->P%MK3]Y\'63I:7W:
MH^BKD.V&RH,EP=^&T4J-:?A[%8X'7+ *;T1+N109N@D/V:C>$'F9/XQ52)K8
M"]/TF#L$#"DV\7K-E@5[G<V6K3;QR\W96AQW:]R_9":MTB;3,WHUY['Z73&?
M-$[M9DE8$S0]BX0IR 6%!I+R]AZ5_LH^@0C\LJ9/#'<X,G[0P;F8$.6EXP37
M4J@BN2D7,@(3),=:E(< ,NJ>SF"&'4L/-1S+'_U)M<0J<Y"+F8X@0\Q*<I2=
M-86\@?QMY+]XF1A_:2!8M%TA]W?^Z:IAP&[W?RLW]!+OT=]\$U":0T";?"]H
MJ6:.E&1LN_5[W=W>[S5T%EXV)L<I!B2H"ON4JC2MQHV"E@SDA)[S7D@(:"R0
M8E)XIG])+29Y8("/+P"QC#,0>GI)G\.=\[H^ *#&D!P#F(3^O4#-UBXK8^%-
MH][@7C!B(4$WB;E)<M_6MRQ2G]II8KNMZ";.@AA5*P#[0481Y5Q)8Z84]F=_
MO]&?!'G[:P+&E.[?H (&_%9I%DQGKP6K!V&FOY(X8#\$8)N.@]\> BS8<L@J
M\UB[<! [;$%ZN:@\,GAL1(EBY+LN!T4#1)$,L>>:0/O<9&1O@)"J*F*?3"=&
M:9TAFUH+=D_7S78,\)CNO_?&>;#)44MB]N-L;<L%OR=:^@ 6[+]>J_8;.3[R
MD&+DJ-ZV'B)Y"("O"L)^=)#-+O/.D7E'V*\=3'7O\WB#-J]RCG^C^[7F*=B&
M]=?KQ;9; ,ZZ_WT!D\ 6QW5M?I,0T+3G44VD(S5HS[UWJ;SHMSR+*86-7!UF
M5T2+GJP/730IUFJE((+ =?3BUX.V3Y23G^>A+=!_/(E2]6:R]M<V4 !_)3+^
M@%2NS9%,"K;)QS<2?!JV0*V\)?"OQ@"<OV=0D/E2,Y@?0)(.2 #V$T& D^U*
M5ULP=JVC<9@6F;> UA*IJ(YL&1^WQ=S%][A[\CU([!89N29B2F>2HOFX50!8
M;RO;H8]G>>OEG-==^+&1WNL:KMG+^(O\V1:&D@RAL\W\IU0FWL7@,*ZO9)!^
M,LR.O1\P_3*/VOC:_'FM&DIM=$_<BW&=B<<&%7%G.%,4+Z4%6]>KU:VQAJ.,
MKPHTK'>=VYB))JU3[>@(!5.(?/MN,@'NWG*0>PJSC:[6-B&*VG'MDI65T]F*
MW%,JF]/2P,O%*6-XF_.L37Q]7>4NC=1OEUFKGC%'.S]V\!;=39XB6)9VA-7H
M9P6$  D&U7(1U,%%GB_Z8%E&/9\9U$;5;DM1_M4^J4ID7Z7UG^V3T$M'5SC3
M/.A<J?95.F978$'^K;M;&<Q[$Z2_\1X6K5> _EY\(T%5?90?/$:!B%P;&.\V
MQ=^X;6LYYG[*=O2C]<C(6'"JE:[^BYTXG9O<9G?-^_N+*6[>TE(E3WVAFKQ[
M':P',F%5KQ&X2M-/5Q+S+E+TG61%@JR>BHLYF=FF#LVE4_A%]D/H^*\]91PR
MVO;E\&GZ&-*2*!E^ZN.%#J%I8=]G9FQ66L?J$)%&/9XH=>Y"U)*JM#2..V%\
M6)[? QM!17F\2.=6C_NU^:YSS9;_7NNB6=BD>@_+=_C11<F*@V4D<*XG1*,7
MMXW$Q0)/-WI]6%3+C4*]GM"1+?2:2&NV%CUI:FUT5KOE*OS4G3CYV9IP$W20
MM6FBK6% \VOB$&5XF"' "W"'*A0+<$HKFTGGU&+&$I9LC&\,+/X8TUM#H%)N
M&'QHTWC]/4T&TR1H,,T]\H*;.HYAZ]7+UE-2\H],*1S[]K\#(\<=9/KA2?^/
M20WW6*<&\B<O*LO07>[7XA-OEF.WU?7QR77%M0_<B^'X<?9EVX,.?L/D>-\J
MT6< Y3D,)<0!WVNQ9@<7)IY$$]R*QFQM;R^\B?ML&S+F!_#1K$@>_:0K07]F
M>-*?1O7LYV[X9XC:3A.2TBU0E"3:"_%7LCC+;-'H:ZWGN;F,1W2,!K^WN@#W
MB:(O>57,Y]-Y-P#<J,6(-VF"1UF9@D]ZW-(*)@[K1^=@(F<;=BR?71LTT6K!
M;J?&JE+GQ5&VG]>3R/E>BR:ES""'OTEZ.??N#<XA"7Y:+__1CHAJ^A P;%G-
M@UL]21C7]*^#%\(9YI,7_/*M/&ZZH2T>V+:5,UYM,$/QE_@_&JY4O=GI3>H<
M)\<>$=932X< .@\MMMZ',+9QUX5\G0*WO9F!8A=4PG6>T)G/E&8_NK(E=EEP
M>B>$*^R'L^I]B)YKV#B4 1DH3_+!&>?/=ZKD?U3N\P]\>5,:/L,5-LMD+=M#
M#S[O[;B>L&=?XFE*,+$L^RXK@SJX;#:H(>6&HQDXX_&A-FPL)@+UF8N]JYWB
MQ;FRAF*F1TS7+S^J@08:D^+WI+Q7VD?D4CHFCAH,=)@4+<V2G1U\7'$0XZ%Y
M>7(G<O- @94JX,(UN.F:-P)BO<QT+V)<(H,J%/[R74+GEU:0H44S#$7W<Q67
MS@=YL.8WV ",#00^(>KC4EGX6#D)@1M.@[1#%G=MA)D^"\#1J@(!WAX7?7UE
M[4&U78/KM>18Q>JZC__Z?A$2K&[7JHAOW9XBH)$!L?6"Y]?$GVPRVH=#+Z[Q
M!?@;)/=/\R95I3R,M%1HMK1\-@=XJ*G:/5*K48$NPX.B[U7WBWZ7$>E=X;6]
M)A*%TN&[9Z[U4<MA$_EN,_W'0\LE>SH968BS+R@4RF=U6089=6/('.QWQ<7Q
ML<A<:#*=-^NU+'&0-L2@#$^JFA2P;X2*]'G]E%:NT5KLL5?S>_J&G?UQ814<
M_U[:Y(Z"^U)V7OOY_B*GZOY$BRU_:#Q#K'>ALPS[)^BUY:I *3FS[B]*! 12
M+EJ("\0.<C6RIS=Q]^,F7CZC;AS]3 ^L@=A=O\"V$:D9'(#L)0?+N1.D7/PG
M'4Q%+>$]#OAT>_A;V&+/JMV[CFE]U/.91!,F;F"=Q5=%: OF)%2, *[;)O$0
MJB:7+S><)]A--?#"HZ7O<IT:7XC\62IZ1@=^_^DI%:_=]K2R'7@D!.0Q"6)>
ML!*+=B[M];K[*42^C:TEE$M\$'"K_7NX+1BL;KLZHLNU$2SM*%59A(WX6;Z[
M 4E4FL^,^?)M'1E/XG[1%(@._:HEKL5=B>YS5OFDJRY=.EI6%9WDR'_U?:63
M-T-D/I2UL0#6H#NE'N^^;Z@6.VJ=T_(Z"]OIRW&JT.;KE8\?1"1+@=*4&1*[
MKQ+=,2T(UB:U_I:W9U.R/6[&GG63V6)EQ%KJP]C5% SB.>=/OG0&!?G<":2(
MZSL$4&G0^$YT,%^R1H!,>SL;ZFFJ UL^I*"?@D^5MK*_:FEFK)AB/7-1M"03
MZ'8(L 5US*U;B/7NK1X\A@PM'OE\SG50?+7A#-$"W;=<S?.QT<L%IWK+^%']
MUMOD5_1-#^2&:MN+3[9*^DA) ,^/:G-N-9^ERV';<>'9/@0HU2]Q"4X@*G46
ML&]V'2=)E;GN0!2U]W!Y#BY:UEOLK4GMF@#BJP?M5L6P])#]EY8SKRUVY#])
MRH\3718#"8WUH%-0X#R0@PA"N/.BPS<'*ZNK>B/A!S4*H_/W%!_4SR885K];
M><P>W0M.?R(J2,:5;) &^T:7OG1."(]XDUS4<'=4YAM5T=IH(;>^5R,LA=?K
MA);O5%UCN=]2"0L'T?N!HMXDE^2[!WX-3&HIX+![:/I4 _7*4+%*=EO55.QV
MOQF3J-&[M%36YB6I3L?)J&BA7ME[88M&-[ZWN8NYW#]Q-[R-UB15QR9#FLJ)
MTJ,5Y(+ANIP#T>Y_&)3.O"C( K^)+C]M=?76F[AD8=V-CHXY&^NF4_J,\>^U
MM6ZKQ_)3@MB-8(3[*?70='P#Y 9!W)_LOH?I; 8]<] ]6_MRC+>!+!YGG380
MR,S/GQ_14('77UMRMJB4EO _;\8^^4P7O=6=, A5K,$SP5@9YM=O>S3+(69)
M0[5NPJ[3C%3EMY0-Y47?VSS5;N4$-@-#U-!-K EJ<S$_,VWE;I3B^^.@_&NG
M9\:\\IK]?$7. %;6A^R4?>(4CB:'1]AQK>DAUKI@?.X@5M"D#>WW[-*!'W8C
M[<I5 XDB_!^+J[QO#UP$)&H770EQC#GGUG$( $,UL.F' .$M3F,;S#*V7G^=
MN%NN^:D^??W< G!K"4@*.Z?A/"DEQQ\ ]>*[KL!X,2?28OU+FWQ[8MXT6Y@I
M5>LE-\BOE23E>3QS6@($]DDL(Z&TV[JXHO\T'U"Y4.FQ7.I/Z3>ZP\M,^BO.
MAA0ZP^\3ODE]S\N$"RT]2$-F#R\-VPZD!G.EN_CQQ+CN<(YF'W'F("8Q#//C
MK#VXWH<RDAUZO;C]Y/+STO+([V845BA3"C/E AYE/E5<7)YS)?K5BH;#67U0
M @=)&1H#D.)J&><_!#QIK?^\';H-+X6Y+^R<!KD.8=HW')VP:!'5L7=.+@*Z
M7M>U!1VR _1Q'^*SA]SP!&S]*F<A/:4BX=*2C[EIQCOWU/N2V&U@,WQ/ ,)'
MGBX8>PB0D?I.1L[JI$8"><&7D>$P/+SJ$#"3 _P!.PV:]\.#26P[,"(*>24S
M1 /6@F6"BD)T\)US45M@_@ K335\B[@'B'ZT5:7_N3U#9_YYZN66/])JI'[\
MC5%!**%]G"^_* O]5/:>N>4],XIIQM3W\!NTUQ1[S^8>57FL#@=-RAP"6L$A
MM0KXTZ^#P!^P2X]BP<S]/QPYG S@R</TK1TC ]4W]0D>^W== W43WGJL\4U&
MEW\*E<$Q9]F\*.&0G-Y1I:RMS@S1,B$O2VJ;; N9<#SF$$"-5H+('*22R,"O
M\0]7+*>69$!50^!0#TH]E9<1QCK4Z3WB?'_BV10=G?_%%:DEAK_:$^9)__3:
M7/)#H] Q S2BA:89NM2)A@"?-M$#8Q/R2<0\DUK[WD43T<<V.MP5SU%\-;3G
MBD/DK9OUU*=.:/K>O*Y-0X9%)T<M1\;:J+JI?36KTSQEA&GE:WNJ4C19!AR>
M#T6OWOSS1 ,W(8=&ILR J-QHD@11>@WV!&4^L!EK+!D$/FG9?7_284Y(J*ZM
M-7"O/0:P"R*=1([(D6) #61<>&JTGQDV&;4<@3-FO-XC!Q6!R*L$1J"27U!_
M+S*O1M] A/^8>+-'B@%L@(8*)FUWZH&A6DQXV9P@<)Z]ZR/A 8\"TX9S?+[\
M11,L%U?M7I,C7#,I%^^41-M"-D1?=(G&).VVKK2YD9\0UP,ZK]:^OKX_F;^I
M3V_?VH:KUU.;UC2E>7;RTBAH4:YX^JF:\VB&;.;/9X:HPA,$*3\3\O$NK5K,
M)96171M-O&*S*<S-=6=5TURME.^UJM*$JB+?$H'XJ.T:/.@)RH3%+9VMEB?^
M@GY)N$G9J?D=:9+9]4*WBAUU,Z?!'YNF=&0$BH^ #L$VKY/(>'$B>?8]WO[G
MUEJOY4$F%$C4(^1.R=%YJ-BQH?L<T&7?I%W02;6#=,E#H^?OF[/:A0P._$-R
MQ:&1,4.PZ#=]Z>05YXAI[19QR2^6AO./JF3U[XE4YN>1337"<WFJ.GGA3KQW
MCFZ,80-@)>;VQ^1%;=EIEI&W_Z6! 95M+WDT.H9**=+RJBO7UP< Z1^+]^G$
MTVC(0)Z"9B:^-L=#K&RLVN)6#Y.&HM!#AWF=B;Y-LDWH;//!RF.[/S5OEP!?
MRJJP*M[S1?O;.%$EO,Z?_S,C=>+.)W19(L[@3L(Y67XCQ9;0JT6<IHIL?<NZ
M-FGM= Y_F@QS:FKM6S=F1#;;\,BE,-7W$93"$MP,'U4!@0QOR,<$R.Q;X58L
M0A:WJ/+XX0BRW/IDD]>+]D3I=WZ[8C[A2\M6?S&XTW6!4#MU\&BRIZH5A\BN
M81M!;*Z\M%433?V.W=$R,VGG:*9-FQLRYAC@?0D&1?Z_6M[@ ,>_V):J[B&N
M"5@,E#9 JCD9JC"@U EN$A1>,]YYZNW],'I<_?Z.L$([9YW(K)[JIG!-3PP@
MYZ/KFT>5GMM[\?%E1!85E(6\=$SCF6(= 86, ^T"GY82O;P8-@X'<SV 8%BJ
M+D!7#*5HR)%X!2XJBO)NI[^D0TTV\>>M=]VM)#(HLZP#DB=73HNR?_D(E[A>
MF60HF;TE=-J3902.,"1KC68FB;PK,H@_=Z5HZ,QKJBSX)59JL\V_]I0K664O
MHC)L<5SJ%?TM^:^A?4EG7D[L4%-JUAW9-$-DD'I0OLSTFQ,SB6-?BZNCN9MF
M+!G/:;(,.G_YV>2OK/P70OSGQ\P+S&XC.BNJF%DJG:,W<TNH-+R/TOR!^K)@
MDMB?OZ#8,%F6PM/A[.%0>8@&(1;?T90F^,TOG6'(?MBQZ71/-W_8M' B)YTS
M<]\.9^PAX(3%<LHA0!<X"2/1>WN0CZ@CN$*XA/'$[$D< AC)^V#D>P/:#:,D
M&N+IKN$3X+A.:^.!LD[[UL"B*LVNEPG/O"MZO0U-^2G/MV-?(0ND(M=VB E8
M9MA/99]#P(>1=D XSJ5^!!P]G)!48$V(LL(G8SZT2I]T'V8J$1V_4G7U67'R
M1;9G+R^W3W-2L]E@0T#.Z0Q$]4%4O%Z'V1K+>]J$GN[<A3=I'WJ'K6W:"S_9
M2+*12G:^&(J&.'E2O-G^0P)>A=XZ@ :&[Z!@@UN[KO_D'GH 52083:1'HY,O
M0,_ADV-Q4@7L;]W*C$X4"0KZKJ?<T.Y618P(T%WM6?5>E=Y<LK:N*@[#!3B8
M/2Z7[1NO<RY'4FG2V&?&)ST#5UB<<\%_:O@,:_(X! A:S^.;<4O[NL65_11@
M!0..?#,1U;KAFBH+"UT!;P%ISJ\0;8++)#PF4')!2_+[Q("T.;$IP3-2;]@L
MR?G,RZ1[=-1.I]0'373/OO@>KU*FKSD!!,P#&8GB#I/IC LE;KP"T<[EGYXD
MED3>;>417;^=5K/T/C/FPXB_4W9RM$1FS&4--(E7O!&V,?,1ALTC[]0,$/]=
MB^QMTV5ND@[TR6Z.[!)9":[IS(> [J.Z+6C6(6#J):SQ"@%,@I29[&\!#P'\
M9+<(FLR$7#@$:%GE'NS!#P$)UP\!S.R3F-WU?M!J'XSX@.RG#@&13_%8XJY[
M^LXBB'3Q*OE[&+[RHMJCG/2]2:Z_IH$1E4PB#P%S'6:'  QYCK5V$X(KG'EK
MGR4_?6_J'S^R_S?DB1PD1X81A5Z9Z'"3?I%(L1/1PG  2_B!L_'_43#]WV0@
M \[_*2W]1YC_"/,?8?XCS'^$^8\P_[\)8VF%:0'3>UA]B()I%J%>N'&9^%.V
M\I^Q'*9W.+,^)^+Y-:!5*)A>%^!.AK._/"WKF,3D./_8P^"_"7Q=F^ZWM?\F
MLB[@M\4?DYD<\\+^YX0AJ_EPZ'\!4$L#!!0    ( +N*=%9%]2IORQ(! ':4
M"P 5    97AD>"TR,#(R,3(S,5]L86(N>&ULW+WIDMPXEB;ZOY^"MWIL)M,L
M4$F0( G4=/=8:*O1C#)#)BFKIF_:-3>L(4YZN$>1[B%%/_T%N/CN=( .,IBM
M'Z%8G, Y'\B/!P=G^9?_\?UA'CS)HLR7BW_]$_QS^*= +OA2Y(O[?_W3KU_>
M ?RG__%O__1/__+_ /!_7GWZ$+Q9\O6#7*R"UX6D*RF";_GJ:_!W(<O? U4L
M'X*_+XO?\R<*P+]5%[U>/CX7^?W751"%47SXU^(O+,*(\!0#EG ($&44$(4A
MX#02<019 IF\N?]+&DF4DHR!+(T50#$5@#(F@,A"I!04C$-1#3K/%[__Q7QA
MM)2!5FY15C_^ZY^^KE:/?_GIIV_?OOWY.ROF?UX6]S]%81C_U'[Z3\W'OQ]]
M_EM<?1H20GZJ_KKY:)F?^J >%O[T?W[^\)E_E0\4Y(MR11?<3%#F?RFK7WY8
M<KJJ,+\H5W#V$^8GT'X,F%\!&($8_OE[*?[T;_\4!#4<Q7(N/TD5F/]__?3^
M[)3D)_.)GQ;RWJSL1UGD2_%Y18O5!\KD7$M?C;9Z?I3_^J<R?WB<R_9W7PNI
M3@\[+XJ]48V4Q$@)4R/E/Y^;[*<KQ/<D[^I85@_"5>K^XDO&+DQ_\2;N%\T/
M<GB!=Z:Y6N3ZAGJ[$&/=NYNIKA9]>(E]W1;+%9V/<%MLI]D1>6Y^\4%_UTQC
M!NH@TVJ>AKIW1)7?5W(A9,V6>T,'N?C7/^GO9O*[^#[[N&;SG-\II==Z<?^S
M?&"RF'&<XB23#$B12H!21 %-L@CPA":4$Y1(%<U6FYMZ)A?@U\_M_-4D%V;X
MDX-NJS//:"'+Y;K@V[?;P_S4*TN_K<S[#?^TH ^R?*3-!5I,8PC4DO];+6/0
M"ODO/VTUZ8/??'A4YJ,"$OQ62_C_78N,:*RLRD08%J&]J5[^UEGR/1'FQDQ:
M%H?*+_EEY6O>,1_3O!)%,*KMHG\^?^%/1TMU6[3BT()?0+/YQ$]\J4V]QQ78
MN_6,:6PI]VIIN;HU0GK:/P7+0LA"F^\G5-C<;>L2W%/Z.'N_X-IT+^4;6?__
M?O%YM>2_?UW.]1CEVW^L\]7SI^5\_FY9?*.%F*4\"[F((A"1# ,D$@X8Q@*0
M)&,9%$(E(;)AN9[S3XT#6_&#'UH%?@SR1;"KPW\+:BV"WXP>0:.()2GT7:9N
M,AT!_(&I=@#<K;GF2O2V%E"I%:^@4[1DE>[-T#\9BOI)SE=E^YN*M"K"ZCO[
M*'1V)30MV5T[3#\J_"#+4LJ[1UGHM]_B_H.9\4-.63[7TWRDS^:]6+Y9RQEB
M.&,AYH# 2 $4IA' ',8@BC(B*&.(1=K2V]BI%Q]#VXF=R.^,->[S(:Q,\> A
M7^0/ZX=@7CV/CXVX;O1F#;T=KPT!Z,"$5HM\$VR$#BJI;X*-W#?!:ADP&7RD
MN?!'8JY0>6(OZVE'I2U7, [YROGZ?D1E'(EB/9=WZC4MO]XNA/G/L.$3G9L9
MOE VEU_T9O:55N[W&>0T##$, >=9"A"-$: H$D#)E%(ALR0EL8O)YC;]U"RV
M5OI@J0(C>$ 7HOYF1P4W]G)<#SL.&P[E@9G,"N#@MTK^P"@05!IX-,SZ0>>)
MV1PG'Y7?^@%SR'(]1W'C.B'SV=O%2O/FK1#Z]BP_+DMM;?R_^>/KI9"S.(Q%
M1A@"A',.D$Q30.*0@I"%$,DH2J.8V7!:]S13XZY:TJ 1]2:HA0VTM($1UXZU
M+B#;S4[^\!J8A?I"94TV=DB<()52\C_?+Y]^T@/4?**_V=+(A6%'H0L[U5I:
ML/QT/U/G7;XP9Z65)?7)'!S?J5]+>:O-K-5,$(K2& F D=)VC: 8X)1@$%*6
M<"(X2V/J8M=TS#4U(FA$K?=<-T%UI Z6"JSU#HP:@6\"JK0@ >5\_;">5V?S
M]&%9K/+_J%R[;@9.URK863.>L!V8-%I8FZW7IQ96+6IPNPOK[0ZLMS:P.MLP
M%H!Y,EBZ9AK5.K%0^= 4L;G$C7@J/_O[Q6+Y1%?K\D.NY&>>2SU'^4$N3!S,
MN_5"-.<R2$044HD!C! !"#$!".$0P# D61C++ N5]8F?W9Q3(Z*-U($1.VCE
M#AK! R.YP_&7)? 61X7^X1S<HWT9R3XGBI:0.IPQ^H=VI%/'JVY6MZ-(-XPZ
M#R<MAQKON-)-M[T#3,=+>U#W)W,;S3\6RT=9K)Y?/7_18]Q^S\M93+*,Z8TB
MH$IDFJSC"+",*, S0F-.4\Q@8DW6YV:9&CW7<@:MH#<!>PZ,K,%O1EH7&CF+
MJP47^T!K8/8= 2@'AO4!V$B<>@XX3SQZ"8E.YCQ[\7A<>4G^/7:\^.%^>^AV
MP(]ZX5:W"V%<=8_FUKAEY:J@W'8/=W&<"3W/V_NQDK;R06_DU0]U([%'I[,U
M.IZV;9?G&W7S9JW^X1;._L)^=_\;J6112/%^P9</\@O]_O;[HUR4\I5<2)6O
M7B\7JWRQUO9'<VRW7)2;YP)'C,6,$2 0C0%*8@HP2B!0!*L(1VDBJ).'Z0I9
MIF99M*K\Q<V3=,UJV+'42!@/S%^M%D&M1J#U"!I%@A\:57Z\";;:!%MU!J$W
M#[!Z(KYK)!F5$CU =DB6/H;L:T0T4U<16)^_4GVWWZU7)I7);-YF69; &,D0
MT(@F (6$ 4;TCRSBD/,4*<:$"U5>F&]J=%@+&"RW$@8_Y(N@K'[]HQM'7H+:
MUEKS!N#@MEI+=I6H-T$#YHZT/LTT*UB\&6G=LXULHEFI?FR@V5W6,^ARN;C_
M(HN'-Y*M?J:K=9&O<EE^DFT<X9WZ6.0+GC_2^?O%OTM:?/FVG*54AE0)!2A)
MB8EH2@!!# (:HUA$*HM(9.5XOT:(J3&0OO>08]!E'^CMR&=H0 =F)",^,/('
M1H&;H%%![R:-K($6UF, YA50^0K&["/"N(&95X!T%*1YS5@]/-)FGO<+;815
M[KA?UL;#?:=^UJ;:U_FS^0.=SZN)9YG(8I2F(9!)(K0-I3>>!.$4X!2G&4JC
MB FKH":W::=&9+6H)GKPH18VR'>D=?#$V@-OX<,>!,[!-Y%L%6R%O@D::.]4
MT @>O!\:6@>O]R 0C^0&]P6UFW?<&;%.=[G]:./YSYTUW'.HNU_=U\>X.T]U
MVH-XE+(XB0!*% =(D P0F#! H9!1A&2JJ%/0_?$44^/M@T? Z>2L TA;K]\U
M\(S+PY>0Z>&;.Z>\-Y?;T00C>]+.*7CL(#O[R>L#4#>I/#,(,R)YE $DN;;4
M8"@ IBP$88(S$A.9(*5<,@!/SN+T@(^6[E>G^<T;(;7EW#^4=(NGW4-^-4H#
M/^<'X:,;$8>)"CU"8(!XT.T<+Q8)>J1F5PSH\8<]'YG_M5B6Y2S,.,L@30&E
MI@@"93%@498!FG*.)$:<4:<B"-W33>U%7_/ 8R-S=;0N6X%=/=V=,-LZNGV!
M-[B?NR,FX2:HQ!TA'F$/EJ&#$>K)IA&)L*>X=1C"_E6]BZS4QW5O\I+/E^6Z
MD(ZGVATC3.@.WSFLWLHYR'&T!1[^ZFR<G6GLFAJ75#Y1/^/B)3YVO.]H7OR-
MSM=RQH12- DI8(0@O>T5$K T12#B+())%*>,615!NS#/U%Z)1^X?(VE0B;KS
M)%RS%]Y"W&=#W NXL;V3;IA=N4L^0F20K?)VEA?<+Q^IVKUI/O[X=8%WFGX^
M;'>+9]^SLU!KFA@K6G#!])[:%/4-0U-HC,$0IS*+,CS;+5EI'0IF*8'5LW&Q
M.*??]ZF0*E_D*[/A?C(IG":SS7''[;H.MOSB']N10^N,F;(C^TW0::#[#Z5S
MA,YS^)SM["\2,N<(S;DP.==A^A'=K1"Y.5VB<U.:Z?WB-7W,]0YY)@6-4YY@
M0(C0MA"#$M!(<J!00CCF0@D!76RA,_-,S1;:BAD\:CE!O@AX+:D;;YV#U8Z?
M/( U, _MX&1$-.4+7U_ R9EJ+J#@B5+.S3(J=5Q0]9 B+GV\5Z#'*=9YEW^7
MHLI(+S7GO%^L]#V0LWF=I%[.E(BP$$0 '(7"I!BDVNI),: JIHHP@M(HL;-Z
M>LLP/;OG%2WS,A"Y*71;I^CJAT,9):IW<KY1P,D@ZK](W90S+/ O;115*M35
M+\I *Q%LM6A^.S3Z3B$DPZ[":-$D ZR&:VA)?R0O1)GT&'C,@)/^>A_$GEPQ
M4#]#]!>Y,J78M)W[E LI7CW_6II4D?>+)UF:>I2W?)4_56)TYEEQ*!2)*0>9
M8#% <6QJJV&E7TD)DU*D/(R=HJO]B#4U,[>J:*CFRV]EW>DH;]4)Z$8?Q^0X
M3^MG9R"/ORH#O\*T0G69R58EDXK^@]%*K\V/P4:Q8*O9F ET?O'V9+E[$FI4
M0]\OD(?[ L^C]]A&F''-&'_/5U]?K\O5\D$6)EX]7U1SZ#^76K)ZPD^2R_S)
MU-N<08E1*$(,,AQ#@)0( 4,D TD,LT0P&A-L'SS>3X:I4?2.Q":<G-X74MH'
M*5RS&!8;AN$A'IAO6P4"HT'0JG 3["A1\>M6C6"KQ_!+X+!K&'XI1MHW#+,D
M;AN'Z\#LW#KT''J\S<-UNN]M'ZX<JM\&XDM!%Z7>MIB]R6=9/.7<O-U4'6&7
MFWRH]I"P-+5IRM-_>K-\H+E^Y%@H(RDH(#1) 4HX 3B,!-#O(AAS$5*LG-S?
M/H6;VIMJ(^G.@;@V0VMA'6/HO2ZBW5[BI99FX#=<SU5QWAH, 9^G#8)7T4;=
M)@P!ZN%F89 Y/.8I[+0<,8FL[_23,5.QY"0E#*15Y?Q(F3 +E@ B!)9,<B;#
MK&_5[*Z)IT:Y^E9//:0NG(+8CC2' &X40CQ.<-AM3=3DR!O)!\Y[Z,!JR%2(
M4].^?'9$!QA6"1-=U[LQ4EFL9I_T72/;*MD)9!R2%*0,(X!") !C+-)HQQQ)
M&@F%L0WA'(P[-3[Y;#9WY2KGVESX64.[+F2=[.=DQ!V"UTTE5T R,%/T1L.:
M&L[HWO7DZTMVGGK]T_:)/QQME ?ZC KM\WKNSSU\BJ_F:_GY:R[G;;GO&,L(
MRS@"J> 4( XS@#,::5,@0E)Q3 6R+UU_./K4'DTC7U +Z.!W.L+,PJEW#1(#
M/Y$[(/0I(W^$AH-_[1I41O*<V=PB;GZP<TIW>KB.+AK/=W5.WCVOU-D/7=O(
M\-UZI5\1/]>M1)LZR(U%\FY9['=4/.RGIY(40YD*0.*8 ,0XTP:&";;,.(JX
M1$I)IVQ,+U)-C0-WN_+5:@6-7D%;PKO1+%#+XK -:>^&B->LJ]TV:O35&MIR
MNFZA1FJLZ %K[_T6KY'IA=HP>H#Q?'=&'X/WY'53*?)]6:ZE>+,N]!P?99$O
M15T[LOKCW6-U7O[VNRQX7DHQDUB8E!\("(FU08K"U)P6<)!&^B^"9G%*G-Q2
M[B),C;%;P0P1E$;@8%E+W+^R;(]UB2(I98@2$$,9Z9>K7A*2< &@#".5I3"D
M,'/+RAIH948-4-Z(-NI:6+X0![WSAW[[&2G!*VJ@?;U\,,6MZW/JVZ(P6^'*
MB<">@]W/-:06W'ZCA3 =U"OM;H)6ORIZO ;!XZNP-\J^WGON HS[DNL-T-$;
MK?](_5Y?^Z_&OTO36%"*VR?]VWMI4I.7Z\7JDZ89+0BO4E=E1O5[*@,R@QB@
M6%& ,Q@!39XIH5)P%5OUENHKP-1>75NC=-YC]^ ,OQTO#@GJP*QX8.3?!*WT
M02-^T,H?& 5N@D8%?W37%SQ/9.<\_:A4UQ><0Z+K/8Z/&A[O%YH99%F-;[SW
M4C2SZ+EG"L<HRS(!<()C@#(6 8HI B'F@A&L0@Z=4@+LIYX:M;6R!GJE9/ #
M+0,:/-;2.AJ #O#;$=PPH Y,;4=50#8 UTQ6BQYL91^J((@-7H/4".F<^ 7+
MAM@ TEU)Q&J$GMRU*1!SIW;W"9]DU93[];)<E96!R,P6H75[N+:2NFJ2"3UD
M)W=+.QNJ01I&>0'/UQ-WG3#C/H5>@#MZ,OV,VN/L^62XR9?E*VFBA=ZLY:W2
M++&)G9)0((H(!!0Q"E"*4\ R"$%$"&0D92+-[--8G*:>FJ7QY:LF3VHD=#BF
M=0/;XD1[, @'ICR[4#6M0%!!;!&T=BW8#@?F@X$^TFFZ?_#=SMY[X==Y,.\V
MXGBG]KTTW3O2[S="C_? I^4SG:^>[]@\OZ_NOZTQ>*<^T[DL9YP*#CD.08*J
MLNK<=&N'"L"(QDF4T)@DW+Y'^\7YIL;XC<3!<B/R3;NW-(= "[D*2B.W2S?R
MRZ!;O 3\0CDP\[<HWNV@N)77 /G9/X@NS=V]@CE6F_<K077L^FX-47?_]\O#
MC-@)WEJG_9[P]I?U/.Q8:3OS%ZT +;_6]8*;GK*S*)$,<\I 0C((4&("MU$<
M@EAF-$NXC(0,VZ/?+PZ'&^<F['',^V6,PPPCK^,)QEE,+8\JKH)HI#,)(V/0
M"-FVJ?ZAD?.\*]3]Y.$2%KZ.&,[.,^Y9PB5UCPX-+E[@N06&_G[79OQD3BGN
MU*]E7<.H,A=ON7XIK2O'PAOY6$B>5]2EK[Q]6!:K_#_JUV241JDI< >2)#0%
M,C'7>WW,0(8026C*XI@[90@/+_+4+,:/)YMPW!A3T5,G#G^K;4=]TUK#@3GT
MH.#PS7[%X>JGO:UT4&D-E@IHO>MZ;S?-%GI']V!7^6J07?5'Z##B?:F&[E+B
M3^!I=#KQO@#6W5+\S]SO[?5Z711:G.K428_\0=_,\R_T>_-J?"474N6KF8"(
MBQ1&(&61R1S %#"6A(#&,LZB,(9<.1UK6\TZM7=():W;V\(.73O"]X[9P)S=
MR%L?3%?L6HE<E>ILA Y^:,3V: 8[P>2)+^WF')7RG& X9"VWB_L1S]N'Q_GR
M6<HZ+O';0C_ 7_-'PY-O/]]]_+B<Y_QY1@F$*::&<A*IO^B=-0F3#*3ZBTIE
MF%#JQ#LVDTZ/=K2L)R)]W9C("FX[(O(-XL \U(H;5/(&&X$K4U)OQ+7,/VJ[
MLA([^*WY?Y"L(!?@/#&3U92C$I,+"(>\Y'3M<.5AONC%D;,L@J9I!00L"C5!
MA?H['$,),D[#*,6)@BCU71^FFGEJ!*5ONL1_@9@:9#M&&@2Z29R[5P>^E>CC
MUHC90VO$(C'UO).K$K,'1Y\R,?L#]*Y:7OLM/U2M=16*24(S$(<R 2A+.6!Q
M1(%,"%815F&29BZ=M?=&=Z*8$3IJFY+5\ZZNKQ: B802E$(($F$,RA0*P%+!
M $YBHB*HF,).3M3^@(W R5X BR&24,4@9!AKP$*I-_TD!1%%5''&4$KE[$D6
M;#DX9+NS3!LTNQ=6;R &?BD9!-H3*B/:C\'M:E7D;+VJ<N7UF^DC+;SFRYQ$
MPE_1]IVQQZZ]?JS6B1+J)SYT71-)D[[^6O^?KV9)$BG%$0.01JDV4)D"%')-
M?9F D7YYP#1V(KSC*:;&>IMV,)7CB5<R]NL!N0.CW1-]'3@#/]8;7(QTP>MN
M7'JW:3Q6W7,GQIT)7J39XK&"Y_HIGOADSY:)BU4N\OEZE3_)SY*OBZJCPMOO
M?+X64KS3HAJ7T+J.:KI3;VFQR!?WY4=95#'JMP\F$VZ69I2$(I4@8HD *$I"
M0$(4 @F3#$>4XE0Z;56]2#4U\C!*@5:KH-RH%<A&K[I]#=]JUK^F@9]EM6.F
MT1=K8#+;U2?8*A2\W5NF'9U,T%VKE8G%JVLBW 2U9AY[2/H$VE?'22\RC=N?
MTB>,1]TLO0[N7N_U=7VBJV=_JY3DJ[I"PYVZ%77-FMOO>3G#, M-Y7^09HG>
M>/&8 HI9")! +$XE29+8*KK;=L*I,?%6YJ 6^J:I2F*>Y%;PX#<CND.U6"OH
MNREU"$ '/X7U@*53K5D7@*XH0FLUS6C5:5V4WBU;ZW3=M;4C?Z:KAO#NU(?E
MXMZT23&)R(=E(A6-$X7UEE$*33\XXX!DA!B3D2LJ1(QQU*],I)T 4Z.CCD*#
MM_?W115@?5!K<+TJ5W0A3"&25\NB6'XS+Y&^I2$ME\W.&AQR,0:FLMUUV IO
M?C+B R-_4%5)&*>RHQM^WHLX6D[_0O4:W< Y7YK1<9R>#+EFI?S'6C^^;Y_T
M%].!I#(&4L%A@B4"4(32'+'$)J\CT\882B2'2$:9<"+"T_-,CN\V8@:5G($1
MU,G<N@2L)55=#]?0C-0'*7?*Z<;!%[.<F65< NE6]8@G+GS<1U6[G9[4.V>Z
MFP(I(:<I9Y@ O3?3'(%,858L8B 4DTDLLRBFI']%N^[)IT8<U]7"=H+=CD&&
M G-@6OD@RU+*F\.2U6>"1 8I2M,'N4%*V%V8^@7+U]F!TEVZSG*,GA&V_UCK
M6\7XLY8+/7+3J#!E..1AJ#=V"=&$):D +.09B#(%3;9JQKC36<#)6:;&3+60
MP4;*GATC3R-JQT57XS0PZ;A#Y![_V@6!KX#7DW.,&^':I>912&OGA[WM9]I6
MLVF*(H0DB"&' *4J!!ASS04A883%/$30*23@[$Q3(X SEGHO%C@/;^]]S>38
MH"=>/O8V@]#"^7E>>G_330^7+^@95V"R#,MW-"_^1N=KN2UZ-Z,X4SQ%(6 D
M(0!!R0$3E(,PY2E5,4>4(Y>XTK,S.5'$"#&F7\P<CL?X9U&T/)KW@<W0Q^V5
MC#>!D3*HQ RV<GH\/+\$A:\#\;/SC'O(?4G=HX/KBQ?TJ#3VO^A"#[OXJ,5;
M5J=-]X6L"ITVK>M41&B<LA1 9?8*(<3:7$@SD":,,ZHD8LJ^QN2%R:9F,33B
M!AMY@XW #A6Q+B'<S1.^<1N8*CH@Z]-)\1)V#J7$/&(X4AVQ/K>?6^TP2TPZ
M"X==&F.\JF&6VNR5#+.]YOI,PL/R#KOE7B3")*.A #"+3"%?H?=D:88!2U.6
MI4RI-.G=9[YCWJGQ[:YLYDRW:H@2T.JUUS^[L MX.QMM #@'IN&#S,)3I7"&
MJ7/C"-4 :85=L[Y84J$%%%TIA3:7]V2HUIK<:3Q>)U'77[>Q)5&44!R9/B8T
MC@"B @&&D (93!#'5-'$D:-L9YX:2^WL@G9$=R4H:]PM*6H(-(<FJ9- CE.'
MP1DO7TQE/>^X7.4*QQ%;.0_0L]*BOH-^T?=4%4.2)'$201*!E.HO*(YC@+,(
M LY3#D-,B=ZC.M5$W!E\:JQ352HQPO6*PMF#S8Y1^H(Q,&E8X^!>HN^$PKZ*
MZ>T./6[9NQ-*'16H._69OL=.CX_SZN&G\]>T_/INOOSVMO[%MJ$0IY*$4&8
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M'(:CR5XP8>&<XMW9"6>O&JCOPX4:VUMOQJ;&]BP):019Q$!(XA"@F&! $*:
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MK<5S75#OL(ADF.A=&4(IX)Q @-(D CA!&&@.X<1$&)&06]?>N3S?U(R"5N+
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MG<_70@J3\VGZ%:QKC\R=>DL+4V*B_"B+FNV>3P]0/1&1H)'"* 0")A*@B,:
MQ$R!#'%*J%*42N)T*CN<K%.CK5U)@ZVHO4AKR"6V]$-,8^&&=F[T6S-WI\?P
M:/KRI PHZ;CNF>$A/_+YC##E53$X.R=>;4R(D"SC(46 8:SWV@@QP,(L!A(Q
M'/(8X5 X500Z.]/DZ+J)(CG./^U]9MZ!LL@B(ED,E##E]#+]A80I S2EH8QX
M'&6I='*1>T%Y!*_YJ"A;OME\8#?T>ZF!;2_@8*@HI_-(^ UT.C'/2\0ZG5?W
M3+A3QP77UU!I[]T(RC1). (**P+T]EX +$,$*.4"Q32"!*=]"Z1,E(%?+8MB
M^<V\ 4%+"H_+PKP;^]=$:>&$D9 TQ1)$%,< 8:8)-X49@$3Q,&-,"2IZ-./H
MB^KXG3>&!->.9Z^\ P=FV,-2,6VR_;:BR#"%8H9AV%,SO%B)EPNLVO71:P^>
MC'TM%V7M:=D)Y7KUO/U,4UOY]ALMQ-UCU8EU4QSK_:*.?#^HT]G^_6.1<SEC
M20BC)$9 0%/+2D58&W,( XXSR9.4,4Z=2N:-*_[4W@*M<"+X(5\$8CF?TZ(,
M'K6E6!J=+<LJO]"MX'HN-K4%'OH<S2@%*JV"7=7W(F9-Y^W=#S;Z!Q4 ICQ^
M!<'-MJ!@52^E@N$F:($(VN+&[:>""HLASNW&7$/OYWRC"/]"YX)C+LSY<\11
MI>CWOCS3MGP;!+UI6S[#.$P%RSB (F, \5@"EK 84$B$2C&*<9RY."[LIYZ:
M)T-+'G M>O##VK!4OO@Q>&RT, RFMJD8&Q7<7ET.JV+WVAD&ZX%?&09F(W7P
M<0?<'WYM(=])NK@,LS/)NR/FB: =)AZ57-T!.23&'B/T=G$OUPO32J7J_FG\
MYF[QDN<'F-#CL14R:*4<)&[R,AC^?(/G)AK;.7A!X1/>P4M7]+N3_T:+W%10
MJ9I"O%Z6JQD-(88$Z1=PBA! C$0 $RD!ITKC*14)8>*RXSR:86J;PE; ILT.
MUR*ZO4R/,;0C@:N0&?C9WX#2] E[W86*\Q-_5G-/#_KQ^*,^WV?5.WRLSW^P
M;_>%@Z*0.]4@6X<JPB)3!*= AN9XD"AS'*L($%S E+ H2V/E8F5;S#DU\[HM
M@'I=.6 7T.T(P3.4 U/$J3*RN^5C!SA$= #(6V^&RS..W*+!&H+C3@WVE_9T
MCIL>)E^7<WU%^?8?ZWSUO+&+*11,(A8!F<@,H) D "N]N2=8$P\/<40H=G)D
MGYUJ:O;%KJ3_+9"5K']Q]#2?Q]72*^P%K:$]N'M U6(&MZM5D;/UJC)&5LO@
M(ZV(>HA]R&60?+E(ST\TKCOSHL)'KL?+5[@Q1UFL9J_7#^LY-7%H;Y62O"D(
M=:=NQ;+R5S9Y00EA##(2 D*C%* D$X"&- 0\ICS-5(8HLCH*LY]R:DRRE3JH
MQ;YI:Y(M5="*[IBTY;  W50S#*P#4XXG1*VIQAVD+LK1H^W0C?YI2S4.$XU"
M.>Z*M]33X\KK:D/5R11?Z'=I4K3T_Z_U+_-5.8MPFD24"Y!!"K4)DV2 <I7H
M+Q$C610EB#A5D;LTX=3H9U.>**_3?U9&XGZ5GLYB;&?.^$1N8(;9@-;D3%7"
M5GLE4^2ID==_(:=+R'BNWG1VNA<IV71)^7-UFBY>U_.TX,$$P_U'$XF_.8TP
M_AXSC\F--\[=<B9CI5#"(Z 0@B:0D /"(04J"5&4H02'H7**C[><>&I$LRNW
M>1$+4[Q!--)6ST[UF[PLUUJCVF7K&MAMNR:6YSD#(#WTZ<X!R%6%C/<MI)7D
M%=0;V3T>^#BBY>OXQW;:<0^#',$X.AIRO=Y]@_8S_;_+XO6Z7&EV+.K$/@55
M%'&2@33,3.YF*@%+502BB(09RPB/L94M='KXJ1%2*YQ3?N49Y"[OHJ[#8_ =
MDQT43ENB\QI?L?TY,>AH6YWS"NUN:SH^U<_2J)_^^CBIS21Y_D6+VQQ#& \L
MRD(!8ICBNGH:8W$&,@Y3&H84$R1<#(P+\TWM,:[D#)9LGM_3)M!S(5=5#^YK
MTA8NH6YG0GC$<F *:"1MCX8WPMX$6W']&0N6N'BR$2[--JII8*GZH45@>UE/
M-\FFE->=ZA^)^D5^7[W2NOX^BV,&H>$D#%$,]/:' PHS!KB$+.(A55PZQ9MX
MEF]J'/:9?Y5B/9>&M;12#]IXKYSRP2=9RN))BN#=L@C>K5>FREUKSCLZ:3RO
ML*5/Y^76;6@7T+;LH%ZTZ_,4@M^^5*=A1M>@4M9G$<-AEL&7O\FS=..ZIX:!
M]LB;-= T/4,"&K[:E65WGHJ\FKR$O]'YNA90\]9#_;OJ5M]R":-)"+'B(%;F
M$)"I%%":42 %25*4PBA43F\+O^)-^67QCN9%8%20P8[\-\W;HU'1,2S![]I:
MAC*\V(H-'?ZPLU@=.6I[ZW43;%3<7=5!WQ##+("OT J_PHT;CC$(L$<A',/,
MTN_M8-(U3.]R_9\))WFB<_-.JF+<G[?$$&)*TY!3$*95H3A% 99Q#!@F889Y
MF@KFE 1M->O4N-Q(>U.G*^T(7;GHM>F_*G)N4E/-W]U(W&X)[+C9.[!#.S,-
MF@;!0UAOZHR7Y^"WYO]!F-0)+D\$:3?GJ+SG!,,AG;E=W+MV;F&<*6]D_?_[
MQ=VC+*A)Q]EWLLPP590S2 &), 0H00(0EB5 $DPBEO!(1$XGN-8S3XVM-F(V
M636]*W#98V]'48,@.C!-M3('/[12_VCJ$FPQKAW;&]&]EM]U0\M?,5[+><<N
MS>L&QXE"O8X#7+OK-OO^Y<)PXIW:Q+<T*0"OY$*J?'6P#>,J@IK"!)!1J+?8
M7&6 4:E BF@4QCA*HJ3G%MM9EJFQVH'SM5'&_+2-[MKDP_S0J.1:5>:*I7/=
M00^Z("-NE^W78J2=<6]@O6^#W25YH3UO;\C.;W#[#SEV;;#:Y:IGU:;L1WV;
M_Z)O_#;M :HT30@'F$L"D,IB@ G)M$F9A5F&HPS#:)P*8.>%G!I/U\<D1M2K
M6]AX7$E+=G[A]1F8MEV69L3"69>Q>_'R6!TB_D&*8%T&V5^I*XNY^I%\G8&2
M/\G-&^437<E/TJ"G3?=*P-=?C7SO%SL-@.LTVZU#=3Y??C-'\S/-XTG&*0,9
M%Z88+U> 8()!*"&C--%?6-:C>JQG,:T89/S*L[4&9C/\M#D'H:W,;I3O>UWM
MV/XEEFD<HM]HMFN/&^6"?>UN@NTB[C5 KW7</>!JM:R2]+C7*+.!UL'32\.W
M=*.^+P:"]O!5,=0T/=\2^VW=3K_'?EDNGF1IZBZ:EU59=?W=_;N)X?]EN?IW
MN3)JW"_R_]#ON"KU\=VR:'YE/@=GF8HP2U@&*!00H#22@&D^!B'BE&>)Q)@Y
M570?5_RI;1_J(_9E>\1NTHN"Q7(5/,M54&Q4N='?&WO".&"_M:5A:5,:U@!C
M_O!8Z>OX)AKWWK%\44WVCAC:SW0J%&-K@%9!S[72;82&T5+_MKY?/NW<+TUJ
MN5H6P8ZR'E]B+[)&OMYQXPH_[BOP11;FZ WY,E+T+66VY%**TG2RJOC8;.+*
M6<B(8%!PD$0F!Y^'"# %&>!)J!2282(RIQ92IZ>9V@NIE3(PMY9^'U5AWV7U
MEC))L)IZU@L-;="N<!,D]E'/_]6<#!JE7(N:G83?[EUQ/:@#<_H^G@U81D:?
MI<JZ,/!6G>SD)",7).M2]+@&6>>GW;A"?A??S8@/<O55KDO]$"X+LRRYJ6S.
M?Y8/3!8SBD/!5<R PA@#)%0,6 8)X#34MK&(>2B0#6/83#9!WFC$#7;EM:,"
M*W2["<$W9L/3PBFX;HP'X\_!;[6\EB<)5NB))5\;([)ZLXZ&XMZL+X3F]43K
M@DI-M^:*BD-A%,.*1ZW&&(5-7;1I.=7IFJ&[-[Q>FO+4:_V[)J)%;YTW10JY
M2!#** $X3H3)VN" 4I2 B%&.TPB23#JY)_R(-36VKH)0U7SYK;%+3K5Y<"P<
MZ6G][,R^\5=EX/=!C_X09O??ZA9LE1ND7J5?O$?O+M$IU$0[3]@ V;\KA=7H
M;D0N9#Y[JT==/7^2][D9:K$R1Z$S',(T(D0 GID>H*;M#J8FNX(*F<8*4LR)
M#26?FV!JY%K+&&R%#(R4=FQZ%L1N7O0!S="'=&ZH6%/4)=5/D$TI^9_OET\_
MZ4MKGM'?;.GE[("C$,4E==I'_N+GKBBK_;YR]+Q9%Z8)2.5PJQQXY2_R6_4G
M4Y\R2B61"$118AYI;6#A-)0 2H0PH8H1QIU+;%^<=FH/^J:$V5*U+K)%\+AF
M\YSK7REI%-G4?=DO(6=^\U_0#8J3JC]DU1.R= W?M5LK.XO*_PH,?5A2 5Y+
M'-0B;]HGUE+?!%KN^A,>O6UN0/DLXWUYTO%+>EL#<;*\M_W5/=EL_?@XSV7Q
MVFBT6-5VSJ>\_+UQBD21RJ)($B#34 %$<-7RE@$,>43"-*51"IUHK'N^J?%7
M*VZP)V]@!'9DH@LX6U*0/_2&YI[SP%WVW;DSCATNOJCFPFSC<HR=ZD?D8GG9
M0+'WYP)%35V,JBS&3HZ[R1$PZ=1O<K-E6P@32303:0BKIJ2Q2%. )(* *IH
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MR95@'>6D7#M>#U_@A^7B_HLL'DS7O5\7;6]#$Q>H.4.6J]L'\_,L$SR*">9
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MQC A$#LDM%\GC=7#-7Z.^UX9+[%3QFM%OP>\5L&QHWB_Q;)SU0R(_4AF9:M
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M@MLA73$)B%TZ$:QH)JF0L/#:!_%J?6K#;BW_OURSU2Q1G;6& EOU]$U?#&B
MKG ;%J,!''GHLG8?C3JS9*]*;VTWX](>\(^WPZP'2+ /0"V8,KM/VR,+M@^
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M26IO0A98"09MJ//<^PT:]TPV&(!GYZKAGGSGV6B39F&S->?(S,CS@D.@2D0
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M43?U=B-WAU8'S, CD_?/JJK^+?G669JPSM0[,UTO(%[(@IM). 5(*V05"G/
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MN&,8._Q36>4/LU+YIC;LBWJ_LU.,#_KU8KDSOSTO,5JDA11"4I *828*1&/
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MO%$^^!O.=%_TK<L&QOB(KTKN]OD_7]=+<V_5Z$C9W/8V=K=J@W>/MYHSK8F
M N08%@!1C@'G10$@46F)<Y7)C'FE @ZU9&HTT#EBXWT^'*I,=>'HOB*O@SO(
M;=XR"NR16>88\6,O_J73^+..S/8=L$\(L$<XM;I&E&3NNY$-%18TV(YQ@X3N
MA>LL9.CN!PZLH< 639F&7Q2SM1GLDO+M1OW_W;UIC^0XDB;\?7^%@%WL= /.
M68FB#NX "T3ET6]L5V7D9D9U8U ?'#PC->WA'NURS\J87_^2.OQV.4E1"M4
MW5F1&9+,[*'TT$C:\<^M6++79NLFQ1G$41J!B,6ZQA/% &=Z2QZ3A.4PRY"P
M(D\#F5.CR0--@YVJCOMI)I";T:%G( <F/D<,[7L%F*/BJPN @<1QZ_N;0W!6
MN=_B5H<XH<??5U^W+R^+0GVT3;J/1$Q )"#(XRP#B$8QP)!G(,84XC#),I$:
M)65<>?[4J$1I&.Q4M(C$N(!<-TMXP&-@1CB"PJ7[\P5,+()*^F$S4BR(V>MB
M%[=QW?#.<(L+MXT7)7%=YZ/@AH[+>N25G+EC^V96^R4,44Y1CF ((&/*.8)8
M DQ9"G!.\HSPC,#$OG.(B>2I,=RE58U#:H@1Z(;KQB&@''J=>&UM>-1F;YC%
MH"U</G-"C.2.GQ%B \?%?!"K!SA'96S6!=N(*M![CIG,,(LQ2' <*\<*9R 7
M3("4$Q(BS%)&C7:T+S]^:JRSUZ[*\+".<3A$SHQ5W/$8F#H.H'C7!85+Q, %
MB_T=_1\^?.PS_ N&73B,OW25HV-1/"T+63 =8-E1*C,1F$4T$X"@F *4<?63
M9,JU@$1]OE!&!'$KK\)([-0^[J_;YV>R?JWV3/<&7"IV:>EHF V"H9?A'=JA
M78QN*(?R+JQ@\N5:F D=UZ^P N+,J;"[VXVD/CR_+%:O0GP5Z^\%$Y=[O7Q:
M+;\K9A2\;EQ5A3(?_O[=JMPHA^??Q>8P2H@0EHLT 2)7'@HBD>ZSF$: \3SC
MD#-&L95S,IBFDZ/"PQZ,LV"[W$<6Z:3\?7,IW5_$C@V'&VTS IW$& [-N9=Z
M?!T&@^[L:UM_:8/TPB]X%9N#J*99</>LOWI_Q#PX_)ZX?#@]1Z7_P>$^G3&&
M%^C80* MQ5-7XOFXW:@U\2_%4A>#:CZ1\OU6W"\_JJ_PWP59EW.44QPIWQ=@
MH1QBA*ERB,.,@I#'$:<2$T:LO&)[%:8V+:BO)+$L\6\/NQF-#POFP/Q\7A>J
MUC]H#&A)6_U"V:#+XF@K@LH,C[7UG2'T53#?7H%QJ^ [ W16VM[]22-WYFW:
M(AZ$:7U9+18?5VO]RWF81G&:R1"DL:0 12$!E' *6"(P#A/*4&Q5Y&48-:=&
MFY^V^HSH?_[W* W_38? .;4V'V9 #3<=WGR81G28'9OG[MKC'D8X_J;-#1I[
M?6YO##H@;]T0MUO)/T;O6R.@O;6Y-9/6+R"Z?)#O-&@Z?4)+>Y!?BO(?/[WJ
M/S\2IE[8@V-JF,5YF&/ 69@#Q+@$.9,1(#1)E3=-:8R92RBTA0Y3FP0.0W*/
M;-#_H/6?:8+1/P2U)54ZY^'NJ1IPL7:+E;89.\,I8=@1&9KO6^W-1V.,P&@'
M,#V'1-MH\";!T X070N#=GF4&X5^)@6_7_ZU6*H_%=>(<C.'(4E%FN4@1R$$
MB%()2,PC$&59FM&08$:,ZHU=%S$U ORT6H*J+&+1*.A6+_H"EF:,U0^A@0E)
M*P>*)=#J!:U^_@CFNNV>^.."@%'IX;J!IU]_QY5OOM16&JV+95FPIH0T(HPC
MQ0R44 :0R+@^OA+JKS&*TU!1!;/K+3>4IE.CF@-%9\'=T].ZJFX=[)2^43UT
MY&$>?0WN/GA_S&7XS'CDWW(A?GE4IK<6/]'SC[H<OPSW@"OR*P(=\EM^$5RM
M"-?BCG]7ZT+R))JTA)!2AE*HEMD<"S5?Q#' ) D!RV&$*.8PA<@XR>6*D*E1
M?:MFL-/3(K7C&I#=C.P+GH')]!P9E^R7:Q!9I,!X@&JD/!B+E\DN&>8&!)T9
M,=?N'2\MYH;V1[DQMZX=LO%*W7MQ+F.89RRA0/G'F2[E#0'.<P[2"%(6,;74
M5D\>JO-*K8/1N_V':[WBWI?5:OP,_6'?PS'!1BRU]F-W8CG&;-16+(WH"?9B
M.0;%K1G+R3,<]Q*O54T^J(-)$A$*A"1(.0\!2M(84(X)()3',H%9Q&*KFJ<&
M,J?F%W;6+.]5JM1D  QW)/W".C!S_;Q:/H&?B^^*IA[5OQ?Z-*0J]SM >04+
M9'QM8!I(''='TQR"LRU.BUO=2.A^R=8ZDNF]J/][OVS2 \HO@HGBNSXJF\<A
M%*EDB4X(Y+K8'0&492'(*$LY31%-$M[Z868\9"+6P?4:F(I:'75YSD;)6; 4
MEG'S1I";\8XW&,<AGE;=X$^MPG_6[NH.UKW2_@C(!B)/#&0D<E0*L@'AE(.L
M[K4OKOE5,.58;5[5DNZQV&BRB4@<0X& I D"*$M"D*<Y!#$C.5(2,T2,ZD==
M>OC4?)M**;V"B^"?Z)^#5EWSPIIGZ'7S1E],!N8'6SBLBFI>L]NIHN;9PT8K
MIWG-C,-:FE>O<=BB?E=M']0+GKOOI%CH[_WC:OT7O8_PZU(]Y?&;@&&$M8_2
MUFC"+$\HX0"BD  4\EPW:> @$4E&(Y@P*(R..UT5F-IG_J[9@JEL"$AK1+4]
M\U3MQVRU'<'FFPBT)=5*QV)KUV6,#';&!T9^8#)I0*_5#W;ZZQC>H+(@J$P(
M'@]!=]E8=T'?8M-]X%$8:4/>:30\[=GW0+!S/]_EN>/M]?>P^N@<H,]S'.:;
M]X)N[I?E9KVM^U5\%TLEIRGGWC2M(,KZ>B-N'I(4IQ&"@*(JCP520$D4 YGF
M,<Q)C!-AM$'F('MJL\RC6#\'BQ59S@+6J#Y3*]6ZO\'+7GO]LU+?@N$LQ\1@
M:AD.Z8%G%:UXL-=<YUNW4+>M) [4;_;_AX/:8AX9#O*1IA"_T-M-(6[@=<X>
MEH\<;^)PL_5HSG!\A,-T\7/!=.3QW=-:5,>A]1/OI")</7&)M>YE_)4L1/F3
M>"J6:M[ZLGHEBZH/Y>HGH6-(YUAFF#)$0,1X#!"D*5"K% DHA2''84@H3HWG
M$ \*36UBJ4VH5BOK5E?=?(QJ RRXS<=8&<PM(X_ T(<UM37!SIQ9PVQ!95&P
M-RFH; HJHRJ_>F=6\+A2_QQHRT8>+HOY:>1A&VG2&FOX[*8SCUAWSG$^Y(PW
M\7E$Y6@V]/E<UYY\Y4:W;FZ[.,]C@E-($ <LCB. .(2 ,,:!B)%:R@G):$)L
MNB6?"K":PD9KF+S:5>MH$I8L4_?/8#0[I>L#SN";9$JU.J3B%B(.[>\NF^VM
MP=W)XT=N87?9N/,F=5>NZ[TU4C5F?VU^>BZVSXI6= HD>1)SGC$68Q0"'J44
M((12D%-, (4\(7',)<S-X\>-Q4[-;SW8$'G9::U_U&KK79!&;^?E>=<06&^"
M> )V[/V/O=I!HW?P>5ADG?<\/"'\5ML=;DCWV><P ,QBBZ/K:6^UNV%@8<?&
MALG=;@[;L9R?BZ6XWXCG<HX1BW(!&8AEKHA=9LIO0R$#:19)')$LI)'15L4-
M.5-C\I-O(?A-:QI4JEK&?%X#ULR3\P#7N/QLAI2U:W<#!T\>WC4IHSIZ-TP]
M]?=N7>ZZ?JO.X'1L>EV"[$'6!W*?2=U^2WF851OW?9>(\HZ657OD.<.8"(HA
M""7D )$P!I@Q!$**$L$S*5-B5<*GCS)3(Y9W!\DQMFO!'D-BNFX<!^C!UYCU
MT;^V8Q;4EE2E^2M;E%]#UG4R=[4.K0PZ:EK3FN21OWP@ZVT9VT.5D9>\_4$[
M7QY[>*8CIRY(638-5/=^0 +CD*!< )2S!"C72@ :$P3B* JIB#A'&%J1Y24I
MDV-!K>2NPW /[^HRIH9LUQ>IH6G, 21[8NH"P1?C7)0Q+I5TF7G&$9T7]VQD
M7.4]Z0VZGPM"BT6A-]V;7J;\8?E%!]+JM#]UP:>5[IU0__4G4A:EOK_: W@4
M[-NR^.=6E/MW/@[3- NC!"0ID0 QD@*2Z;KC&,8DC<.8T,2I"_) "D^-DK2]
MC5=PV GX?OFR;3:L=]8$>W-Z4-?@;X09"TYIG <FU"&'V+T-],"X^^XA/92Z
M;]. >F#PKW:O'EJNCTX7K6JO\S")61SA$$@<8H!P&($\)1!0FE,9TB2-J5&&
MU TY4YL2]KT6%E42X6(_5GU:6>QQ13B1$:81((F"%-$H!#F$F>[0BW2%3T(A
MM#D4]X'K:&?C V%J-NMY0&K@R>JDT<<LV"DY5!N/,Q0&Z=6QE_*&#3G.3.WN
MNG%^N6,#W"K*YO4O6Z)3&80H]6Y$L:EZ>-3=LN89C003B@-(&#* <IP DD?*
MC><1CSF-,;&KOW%;Y-18M^EG\]STLZD#0%^KJD*UWI:M<V]C;D89?I$<F#T:
M98.]MK/@0%__S=G,T?'5CO>VP'%;]!H#<-:VU_Q.QQ)H8J%^^_07L52DME ^
MY1W77U=9%2__+MI(H293D,9)*&7&=:O+1#DEG ,BLA0@F.5ADB4L":W*BUM)
MGQH9-<K/@J=:_6J52(X,L"QG9C469LPT&,(#D]0.W+\<@'NL^RY*\':>K'U)
M,Q?8?-4TLY(];E$S%UC.JIHY/<1Q:[58ZM2>8T_MH#7:'.=AB"$1@*6A!"@A
M"5"LQ@&43* D36F>6RVS;@F<YGJK=:CJ=5<31F2YZ+H)M>&>HT< A]XSK%4]
M6X3-ZGPD3SD2ML#XVM2[)6[<33E#X\\VU4SO\T@OOY!-5?"DZNRS;X#$$,U3
M3$(0<H( 2L,8Y'D: YFGD)$DR[BPZAIN(7MRGM/V^9FL7_7YY?5OJ#7% PM=
M&9$>A-0?YS?CIH]%R13EZW:@.XP';4/E ."0''9%\MO363<D1LQVXQ&NX;]2
MK->"/Y(?!R<2<XEDF"4X!6F:<(!DRH%Z*26(DH3&,2,L8W!7#]O<@;HLS>C+
M.JE\/8+W]$EL MXH'&S(#_<MZRL@FU%4#\S&"@1N,%(:!@<JSH)/'04K'2*!
MNW#P%@A\4<C(<<!=AIZ' 7=>W;<_U5]6*U[6IY'B^66Q>A7BJUA_+Y@H']=D
M61*F3R1_>OVZ?7E9%&)]]Z,HY[G$RO"$@9QDL6*/, (TEB&(9<8YCA*8978[
M2;W4F9Z#5.L6_*:ULPP>Z3DRAOM*H^$]]$:3(=0]>CCU0<A[HR8G9=ZH&U,?
MX*ZW7.KU5#>R_%F4I1"'+IM.!ZT:A5;1P]$\1*$,$YT5F[)(K0Y1IKPII)RK
M,*<LPU1(F=GPX4V)4Z.\=L&RJ!<L&YTN6W43J?6UH\#;>)NQG%<4!R:R6M?9
MZ8KZL0'RW2T@K0G.&!Q/''9;WJ@T96S^*1.9W^A(-GL?3[%<%:G\;;50]Y>Z
M8O_F=9?X@_.4$ZPS"[BNC"OC%%#!(8A)*J.02"I@;L4YAH*G1CT'>M?=T0\T
M_Y>@UMV2?TR'P)"&!@!V:#8ZP;16=)#\*5MT?-&1J=AQ6<D2C#-RLKU_H.[&
MY8T.F%7!U_)^69<O^KLHGKYM!+_[+M;D27SXH<L8E>+S6CEU<X*2,!8(@BC7
M&^\AC0"&>0@$$PG-,(Q%:)5R.J+N4V/*2G/!JXYM?+58D'6I2Y?4Q<1MF[>-
M^ K8KFDG-;!#+X -NB.7INV1:P1T'Y6VV5R+0M# $+0X!!40(_9,]C]Z8W51
M]JCYM/HJ^Q\2ZT[+ ZC@4$VKZFO*1"-_'D4T@9GRQSG+&$#Z#QI2 J),Q(R1
M."(A-2Z9=?SLJ4TIC78'Q5R;\!.+<DTGZ'6S?4],!F;C%H[/?4&P*$SE#L9(
MU:=,0;$K+W79[,X:4B>WC%<HZK*N1]6@KESBZ)^3A6BRG-\I$BQXE?*P6M9=
MMG0>VL%6Z3Q.A$Q"1 &FL>Y[H)QKDF((",T8$A G.;<*;;&2/C5"^[Q>,2%X
M&>@A#%ZV=%&P8"6E6%?QK-8=^NR&PM#3'0K@H7U54K?D:LJW'.D>M,H'.D5W
MK[Y'#],%-5\^HI7L<;T\%UC._#2GASAX6C<=PFO^8%L2YFZYW)*%+JM%%HO*
M@YRS1)_09!CD4D+%?U$&\CS$($UY%B9ADH>YT0[#4 I.C2+W99=(I6OP7915
M.F-QH+2%ZS/$F!HXD6\\4A/8%PA^ZMP6:,;Y00:UI<']=,;7PC]^XW$>R<E^
ML_&V\]H''(Q.UW\(N>.M'P9$[6@1,J0<MY5,VQ]8"=-!L>^VZ[5>'I-(S<TR
M10#%.MY"9!#D*<- 8L0P#M.4(*.NH-UBIC;Q[II;O]1JVJU$KD!IMN3H#]#0
M.R\M-HV&:GE1Z^AO =&-@:>5PA4AHRX)N@T]]?UO7#W0">.-?=^_*9=4\*99
M JOBR?4_/6PWBIJ67!?@>7I:5Z'F]\N-6MN7!:O*]\S3,$PX3E+ \B0$*$PR
M@'F2@!R%(::,02'\GC<.9<G4V*LV9-<@1)NB,^WT/\^"G0W!SHBZGI?G4\G!
M7AM/9Y13>!FFL#(Q/+#L?*<.4'%YP?P?80X]N&,=: YFQ[2.-X<>+NO#SL$5
M<HQ87"V?= RDKE??I+ 5HOS2]K,H'^1G)8P5+WIEH!,7/RHNF=.0)R++(4!I
MIN992G0"6@)U,DDFHS@5F;!RX9VTF-H<J;[%U#)6T0E\L]EJ<$@'GFFT_J"*
MH-86['.29W7ZK-;68QQC'[!\!34ZZ3!NA&,?F,["'7L]S([MN"CF=UM>J+?@
M9_TRZ'W'/$=1AB@"#$N]#1%B@$.( )59'"(L890956:^\.RI,5.C7M#J9\92
MET#KYIZ>4 R]RV"*@C%]=-A[@11*P?[U:?7]?ZF[:CY0/^QIX-*S1OFX.XQH
M/]FN2QS. 3^MEN](^:W*OVA*#LTI0:$DB52 T 0@#!- <Q@#&I(H1;H>$#'Z
M&J\)F-HGJ50$3.G8U/UI^I!:',Q< M'@X*PG- -_HAH5K5Z=0=56&>N)BL5Q
M4T]T1CHNLD3)[I"G X+.0YI+]XUWR-*A]=$A2==U;@NHOQ.]QMLTE0'S,$TH
M1 *$J="]8](,$(1U@GT<05V_$:56&Y!'3Y\:AS7*E7K7YD4]])M^&YES)ZUC
M),U6.<[X#$QDC5X#E$>\:+&G)<CQLT==6EPTZW3)</DB^Z7 A^5&K20_%@NQ
M?D<VXFFU?IU'*4\CKAT0RA% 3*B50)1CD)%(_2<,!<)&'36O/']JWVZM8E#I
M&+1*FJ\++B%X>VW0$Y>!OUD[2*P6"1V&.RT4+CUOM,5"AS&'"X:NRQP6#?^7
M+,M2++_>__+YX=-],TG$,>1I&L> 5=%_&.D2HC #<4+#"&*9282-5PV7)$SM
ML_U)=\GY^JT0B^OE+0VQ,U@L]$5DX ^V42_X4Z/@GV]/MX;86"P9^F(TTIKA
M#"M/RX4N\SO7"Q=O'&_!T*7WT8JA\T*W)4.;IO!1J71?EEN=.Z)K4.Q:8,X1
MI402M6Y@F&9J&1%'(,]2 A!4GD@4XB0+K<Y7;DJ<&L\=9W)LOHF@:-2N*]/L
MUQ@ZX?4LT^-IO2HMJP#>'A2S%8E7J <FT&.4[P\0/NS5ZV_M8HR-I_7,;7FC
MKG&,S3]=]YC?Z.!856UU'YI/IYG_0A@R)ED&>*;Y!T,*<MUL(I))FN1Q!D,4
M&?M5%P1,C6[J9M.MCA;>PR7P#!RKGI ,3 O':+@X59=@L?"I>L(SDDME^-+8
M^5,=IG>Z4Y?N&\^;ZM#ZR)GJNLYQ^_6X*L!Q\_"#Z!G=HY'-$912GS2!%,=J
MO<B9!#A.,J"X+8J9%#AB5MUXK:1/C?1:Y0%IRH,L=[EA55&9,MB6=4B>\K=>
MMANA$VB#A?*L]H5G9@'5IE55:>J;+$O1V(V?X:;P4*,R]*;Q:;V6?;)>K?MQ
M5&2EOL>-91?4?&T\6\D>=V/:!9:SC6NGAS@X<W6!PRMM$A]7/PG=&.7]5MQ)
MQ3#[<#XB<PF5NX?"- :(IAA0R3$@'/((ISR,L5$1 7<5IL:-CVJ>$D1K:.'U
MN(%OX"X.#NG Q-;61[W>//6P;\\L4*8$%?@&L7Z^AL'"/1U\.$9R8(<<%CNO
MMQ>BG7ZQVY/'\YQ[67[D6_=[DIOWW>2+?12Z9L3BD?QH8BI^$DLAB\T<$P1S
MA!A(*,]TC"4$)$PI(&F,:4YX(G*C\QE#>5.;11H][3SB6YB:^< >D1IX<F@T
M#1I5JSXEC;+!GQIU/9Q66 +CR;&])6U45];0]%/GU?2V226+-N4!=5)K9WG2
M+(6$)#$'6003@%#( .8D47] D4-")4JM3EK>UIRI$6!C5"#VZH]3P';8E\:,
M@O\XK\+ ##]:TN@!-%.J?CO*.$\[?]34F/\*2:26 S=2)JFM5BZ5=/]V__7#
MN\?WCTI<<^C#< 1)%*GY-$$<(#6K BK2! B4LCA+HE! HZC**\^?VGQ7:1@H
M%0.MHTT%V7/H#/:%^@$R,.L?8^%RBG@!%)O2NKW &:N\KMD+8UE=]ZKEW15V
MSV\;L<KN59V/*^U>O\RQ1M6B E/PR[3;YA QQ'*:2PQ"C"* 8O43I3IC%.6,
MIXS'66;5K\=,[-3HK8HU ;1RT-BA(V>5OF8)O9FS[1_0$9WBG;.[G^1G_M*Z
MW"#R51++3.BX);*L@#@KF65WM^/&ZNKYN=A4>?#*D]/MR0KU8BR9;DP<)6'*
M4D2 (#$"*")";UGH[L](,$[RC&16.68=LJ9&0 >J5DM =JAL\*=/JXT($LN]
MA"ZH#?=:_0 X]#[K"79'>GK<7[T-AJ^]U0Y)X^ZKWC;Y;$_5X!;[O+:O@E4U
M4C[\8-_T1/))O0YSP1G+<)0#B+AR76"8 <*1  GAA$K(.3/K$'!-P-0XHM4Q
M:)4,M);FJ6T70>PF A_0#.UNV*%BE=W69;I3>MO%!XZ6W]9ESF&"6^=U;W,8
M<A!*U+F!#27B.*,QR'', !(D!33&$8@XE +'"8NR=/Y2M5WZNB'KS3AG'X;:
MVWQ5IS8,>-1Q%)HGGHKE4D=44+*H<BJF<.IA^G8D208991# +,P!DB0$)$HB
MP+ED,.1<+7F3YNWXL.1_\'>CM6"D-^-#]=\_Y&LQSJG7  /]!SK>.GI7_C G
M6)9C-I&C*E.M_U!G4I9#X?OPR5:\X^[(@I3E@VS*@3RLOVA)[U?/I%C.0RQA
M*C(*,J;6/"C*"2"2)+I(*8N2,,[4#U:[(]=E36WE4ZFJLP7:ZC.K=5"I&_Q6
M*VQX^&("L^'.B!_PAMX9<<?-?GOD-B*^MD<Z)(V[/7+;Y+/M$8-;7+(C"%VM
M]0"]ZH[J+YJ\FG/%E- X(R(#C&>I8HV, THA C#&2"I"B0DR8HUN,5,CC+VB
M@6@UM0FTOPJGP=FU%Y &)H8#?'9*NAQD7P?*)NO !V!C919< ,Y7JL M&+K3
M :[>/6+(_RT+CL/Z;U[M6H1$2+%>"UX=ZM9], A+."89!B*5"*!$MT]!,0.$
MI1&E*,RRR.J4^X*,J5'@3L6ZFL@L^!_AOX9A%+R0=?!=*_QO013.PK#Z?YL7
M2[:;;ZMU\9]"+=V6J_9?=842W0)U':SV7G! -L%[P:H1"^)H%NAWLCI_.?W7
MR+9>R?GXF3EE/4=E8,[=#TC3:;92<%95)Q'7BUXYU"*YBH*WZB/G$D:N-W+5
MQ/,*(]<O=7"T/OQX*>HFLO^7+".L.R,T$QY)\I3S+ $Y1)FBF(B"/((8<)80
MR!B%&4+&CM95,5-CF79A(78*!TKC+5'S8X2KK]^P<\0-= W\+B^8#<P!'XY@
MVD'DXGI=Q\K"]?*"V4BNUQ7L/'E?-Y'H]+ZNWSV>]W73@B/OZ_;5#NQX<77;
MU@1HBRJW^V5\SI,H3TD4 HEUD<LPS4%.$PIBR'"&4:ATBHTITT[VU'AT7Q#C
M][;VM&AUM:]!XC(8!@P[',1OM0]VV%YX5_1[9\%P8%M0]'"@C\3;OL&WXW4W
M^#K)WO*1X\T ;K8>30N.CW N%_HBUIO7S^I]V>B\GG8?X.=B*>XWXKF<YQD.
M10@%P*&4 .%< !*Q"+ LIC 6"29V=:UNBYS:S-!J/ LJG>L$P?V>G=8[J!2W
M/ ,Q -]TU>T3TL$7X;W1="D.:@B0O^J@MP2.71[4$( +]4%-[W2CH"_BNUAN
MA:X_JF-5UX1M_EYLOKW;EIO5LUA_^,$6VZI'95GJ*B3\D?R88X%SDL 8)()&
MNA<S!I3D*<ACQ"3/=-PZM.$D!QVF1E*-"78,Y(*]&24-C.C '-5H7]<N;O4/
M?E<&!*T%.HFFL2%HC=#U1?R15@\(/;&8BP:CTEH/B$YYKL^C7+O$_%TL%G]=
MKGY??A6D7"T%KS:BU_,H9A'-HPA$F10 (4H4LY$0A*GB-J06Z)!8]HNY(FEJ
M)-:T2=':@G]H=8-6WWJ/WK!4VVV$NTG,*VY#[V<Z0^;09>8&'#WZS5Q[\LB=
M9VX8>-Z#YM8-[BEZ3?GU=^2EV)!%7<[SBRC%^KO@'U?KC]O-=BW:BNWS2!(:
MPP2",-&U-C/$  TE!3Q)LE3$&4DBNVIHMAI,C4K>'?9Q6#=:!W*U#F2E][[I
M@W-]8?M1,O.=!L5^Z'V^@^8.LZ!1ORTQ_.5P&&H3=ITA_&8).L'G,7?03O[H
M&85.\%S*,W1[D'-4R0LI>),$K9:B5<5W[8]MRGD<9DF81AG($YD#I*NN$:96
MA$F:9#*2>2PBJ\3E+F%3H[I&U[920IV"NZHZ"+"F "*I%+>. KF.M^G&E!\4
M!]^2J@%L2T-J_.H.#'?=N+E$AMP$Q%^(R'518\>*W#3Z0M#([7OLUUWO5M_5
M4VA9K>\,5@%'UT_HC:WT"GYK-?.P57K56B>G_OA)HSGQ%PTX=-HO7^ V'[T7
M='._5(^JCO >=?6S>:R3WN,0@H3F(4!"9H!@K!/B"<V@B"*<&"7$=\B8VNSS
ME7T3?+NH6GO]O%H^ 27T.="*!WO-R^"W2GG+$Y)+$)O-/#V!&_CS/</LT0DS
MZ^FG Q5/L\XE":-.-ATFGLXQ79>Z44)=)[TJCUY^7BT*]OHH?FQ^6N@6?YBD
M(8MQ"D*&]*9>G *<D1Q0DB%)H?H-L0J [I U-8JHE;3[]+N@-*, 3P -3 5M
MHX1:S^"W6M- JQI4NGK\_ T0\40#79)&I0,#DT]IP>06-WKX2(IU%?]\OWS9
M;LJ?Q7>QB)N0T2QCRKR0@!!#W3Y,0$ @# 'F.0_CG(M$9C;TT"%K>O2@=/N?
M_SU*PW^+[4BB"U SDO $T\ DH;7<)2M4BFK"4*H&\>W 96N:,,#$$TUT21J5
M)@Q,/J4)DUM<#P;_MEILEQNRKEO<E_.4II))K%84E'. <HH!96IM(46,.!=1
M'.9&OL-5"5.CA.94:Z=E4*MI>_QWBJ/IL5\/=,8Y[C,&QN&0[XKQ/0[W3I\X
M\J'>%8/.#_.N7>@VV_]EM>*_%XO%_?.+HHHJ9&I5EO.,8T1R2$&<1PB@$%%
M*4^!D%F4JZ^:PLRH_W&WF*E]T*V6P5Y-NZG^"II)' GE-DG 4D$ $HSH.%4(
M<L%AC*3NP!+-E^))%U4='$]<XWDH;@1$"[^(FOE-_=^Z@8FR57!V\,8%6D=_
M?E(W!IY<I"M"1O6.N@T]=8QN7.VXV5J4;+$JM^NZ.?VN?- 7L=#?VKM5N2G/
MJ@>5^RV#/((P2:#N#B&$6EXE$<!)GJGE59; 5"*<A591[#WUF1H]5Z>X3:FP
M*B[;<I^VY^@8[NF.A_G0^[_=!=J#WP;9_O&$GZ^=XI[:C+NK[ >ZLQUH3X]U
MX]0/4@JV*;ZK%2Q;/8M'\N.+DOI%:$R*15%I\FFUY()OU65T(9K3V.HH=IZP
M3'(>ZPTK@I7G!0F@)*8 <J+8%,M(AK#UO![-B;674@Y>VN,([*KT!7N%=W$:
M=AS;;[3,&'9X\$=:);=V!+4A5>-/;4IP;,LL.+*F#0"9U=$?L^"S4 KY*"_D
M%6!/!-Q/EU'IUPMLI^3KYZ&.)P'%4D?$58<,)\4L]9RPVBXW6IGF_9LS&.6*
M5'7Z)5;>:Q@*0&B8@5C&<9RD$,9FK<[<Q$_-66VT#Q8.QXJ6P!L>(@P&Y]#G
M"@V236_VLZ+ K?85=PY AV[ ^3I\L!,^[GF$$S!G1Q1N3W$IRM1FA>HV.:5R
M5'4P17,0)\,$8I$@D,8I!"B%'& F4I#$DH4Y":$41AN>MP1-C:;V2<V5KD&C
MK$V!H0Y4NYG))U9#^VJ787(JR-2!ETU))C^XC564R?(ULRS*=!N+[K),'?>/
M6)CIMA7'I9D,KG=@R>. LRK$^;7YZ;G8/C<\K-CY;KG<DL67VO-4KRL5&#*N
M5M@923A 3+E^>19E@.$X1WDL.(Z,@D-Z:3$U?JUB)A<KHE9QI-(T6+>J!L4R
M>-D9%BBWG2PVK[H+1F.:!:DX#YH!0X\Q% /3]TG0JG(2][@W9@1[.V9!;4FP
M,V6,D;#@_C%&9*2)8;"1L9M!^B+:.;TX/WR\N:>O_4<34^^'.15<K7N0W3VM
M174\T1:CJM/]VE_K?+^V/-4<93'A629 G.4$H"1- <UQ#A*>)YA(1"-J%+#D
MJL#4YJI]<<&FH+-HE:YR87<5!]WJ#+J,D,GZ85C<AUY7M,T(=^H?5KMK,I)W
M-@3*B%T)O(&AMZH..^@0C%8WUO]0V-:6=<;Q1M59^^>.68_6V>J32K7NSW&8
M<.X86V\%_[D@M%@4FT*4[]2E!2.+KYLM?WU7YS3/:9C@6,0(Q%)W8Y(Y E3"
M!'"*0I&I=S(T2_FVD#FU::71.F"-KD&IE0V(/M8H-J\6/&:(N<&LX1_)@2>*
M%L0#C6=!JW-0*:W^7JOM'U&+R< _LB/QOQ>$[0C?#JM.CC=\U'BT;F?;$9-;
MWFJ?O_"^>:-*?:BZ?M'M903_Z?6+;@$AE&G[F*\DR\(\PE M#*(,((34$@&G
M!/ HA1PRQ@0V*CUN)75J!+Y3/#C47'?TW.ENGO-@CGTWC0^&Z-!;4;?!]!Q9
MYX244R*%N931DBNL#3],N+"_V;%H4!,SUT34/:X>R0]=U_';:J&K.2J/]7);
MTGF6"R9D& (J)%/>)2:*GB0"6<0EEIQ)F88.X6VN^DPTLJTU1^]L;,@/M8S3
M15*_B04/5LO@NRCU!Z@$;M8%V[2-L(+MLK N1N0ZCF81'(,.RTA%C&H39E6L
MVX'NL\O-H??1QAZK&_5$T5?E(U<UQJV*U!.LLXI)?9_G6/)B[TK>+>L67UJB
MXAY]B+IYG<=9 D-*)8ABHOP\3!G(:<H!A;G>(\88$C[?K#9D8<:@MP1:N7@[
ML0,>4VH9P6*O=55>K#S0^U^J#JFFRW5CX,V8SR>< S/<SR<8?NA&S;X\AB$4
MOFIDW!(W;J$,0^//JF68WN=&+VVEI ?YONDBJ&BM+@.GQ!T(K\KW'.1[)1&E
MN@INPJH2VJ%B'2DDP&D2LR@4$4R->@'VU&-JZ\W#PE.M(97#4)M2?58'QM@Q
MDNM8F1'5"",P,']9@M^4_QJF%%!/-#U1H*L6HS)C3ZA.";/OX]QX]%'=]B /
MO/Z['T4YYQG,9<08$%AQ(\H0!)ADI'+5TBR.<&S6_J]3RM0X\-UJL:@;7^L$
MH<.T2_T!'OZ]K@&[^4:6P?%-OVF[+&L97AX!,^[KC>O S#8\I-8$UPF9)_JZ
M+&-4<NHT\Y1ZNB_N'="JBZLNB0Z:7>H%IEKR*!/NE^J;%F65:'"_9&N=B_!>
MU/^=8X)9FN69(ARFXUHA!C1%'$0R$RAE-..)45Z3#V6F1E.[\-: -:;,@J+1
M.=BLU,^U+8'>.G6.HK0?,X,CX!%'8N@CA=,8RM88G3@*]N;HLFS-<-2I4JU-
MP9]:JVP"NOJ.D7/ ZZ!C]59QKT.,69\86&>0+4)A[66\542L,QH=@;'NSW3<
M!%TMGW39:ZV%GF0KURX3>4@E$X#36+>D@ R0"$4@39(,A6F,$)16!7\O")G:
MI'5< 'P6:#V=O.6+B!KN:/;$:>A=S*-ZWV80V6]E=F#@:_ORDHAQMRP[C#S;
MINRZME]]OR]J'?-QM?Z=K/D<DD1YK2$$G#&UH*:8JF]><J ^=BPR78 JLRKR
M?4'&U#[Y71VZW[220:.EY>=^"4NSK[TG0@-_[+;@.->@NV"^YP)TAQ+>I/K<
M!1.OE9Z[=*G3\G:W07>P+U<U9'^0OY:B[3V%U7HURW1%3\$ RE@(2*PWU9B:
M^4.:R!1F%J$B%J(G&A52J:EWN;>ZF9)%ZRD;U(W6H=Y '&NY>7 J<!0M6T/Z
M( .E]JVN5,Z06BT;?4,[VNK0!\2VRS\;L&ZL\HP>->9BSL:VDS6;U:VN79I.
M#EG:.>)NR=6*4+T:NK13\P%@&-(<4JI(/(L!RJ$ 6+(<Q"R6.(UBC!FQ:]]D
M+GQJ?MW]D@M9+(N-"!:%;MKITD/0"GTSAV\H3,>D]EJ[6;!S#_4QR5YY[VT'
M73#SUA#*0O3(G:+L03EO(>7P##<B>U@_D67QG]7T^&ZU+%>+@E=_4:(^ZP;'
MS=3Y(.NR3X7.Z5 >7Q44:-CRT*NL"7U\A_;H_> #BZI/[] F[;?NK KV9GGM
MMC@(T)Z^6#\ZC?HI>X7Q]!OW^W!?7LQ:U^HGD'*D=YIB*I33PK!:>481!XRD
M**$P24B";6)K+XNQ\DQ&BZA]TJH%O)U6-VI:]>.AK,V[(/3'ZTV\CK77-@C=
M( SF1JQ';X/0;>AMUV#=OPW"84^%Y=//VB^O'O[_B87.OE>+IAWU/,BZKNW#
M6A^!K<4WL2QWQ6X__-CHO^JBMDNUZE[7*WXN6<(B(4"*8MV#3F*0AR$!B#*&
M2!K*'%FUIAE4V\FMEW;&SNJ>KI6]]4<W"[3)0*[6X%==:'5GMG8VFA+5JW5P
M9'K[[[_MK0\.S+?<8!_VQ3%CR\F\#@.3[F3>!&LJ'V6$/,T(P^HZZL0R"NRG
M\],X0AU.73ZM/OQX*>KG-,5;29K$4@H,I&189W.$ $=I"#*L/D:!0XFY45OU
M*\^?VE3R::5[1#0J6FSS7T#.X)2D'QX#<^D1%"XU@2]@8G',T0^;D8XTS%X7
MNR.+ZX9W'D]<N&V\HXCK.A\=.W1<YJ^M,VS>M51 %!+=S)GP3#G2<0@H5#^Q
M)",HHC$GPJA(E8&LJ;'805MGV+^M,^S=UMD!IH')[7I;9SA26V<X6EMG.)6V
MSM"^K?/I+>Y%5(OETV&*;/-.0Y:A.(\@2* NA:335FE.<Q"F$D9)*A#.C9H3
MWI0T-8K8ZQH<*FM??_,RK@;.CR^T!F:**T Y-4GH0LR^-&EOY,:M06K\JCG5
M%^T$PZ20Z.4'C%XQM-..2Z5!NV]PX,MWBT*]$\U;F44R% F6($FYWI<,,T"Y
M2$&$,@PYC'!.H3$_'CYY:GQ8ZV;Q,1_!9$!WKL8/3&^U6BYL=@2 !7NY C$2
M6]UX$>S(Z9*MG61T=,-XY'-)SR.RN7B!?8W*ILKEQZ)D9/'O@JP_+/E[LA%S
M(A-"".8@#E$($..ZF3S,@$0TB7&(0\:P:4G*:T(F1SFUGD&M:* U#92JP7OC
MK-).2+LYR1=00].3"T96121O@>!4,_+J0T<K$7G+K,.*D#>O=4S-$V4IQ,-+
MM3&]?*IZX;71IJ^_+GG3!T]PY<FH2^^>]=_F$-(TCE@"I$0$((FJGG4YB"G*
M9493)&GN4/W121FC#V'\(']MR_\.BF>U2A9\EXUNF>7G-#AF6T##83U2GF"E
M_RS86=!VZ=P9,0L.S0AJ.X+:$(^IA'UP])5KZ*3#N,F(?6 ZRU;L]3#';O!D
MO52RRL^B+A3YOECH+WN>Y3B/DC@%+,(Q0"F/  E%!/(T32'*8IJ8M5FX(6=J
M?M$GL0D6.L),#4+=DF<6\%K5JDL/U]5KU@>_-JSO< MN,W+S .+0.U:-AKK%
M6%V!=A8T6GILI]X-@Z]&Z5>DC-L"O=O4L^;F-RYWK,9(=-VR:J?GDQK[!_FX
M)LN25"W&WJ^>2;&<HY!P%$JJ^($*@"CG(&=2T47(8JZ\IY3E5G1Q6^34F$-K
MK*-Y*IV#WVHE+<.U#( V(PJ_\ W,&9;(V1<]- ;#5WW#VP+'+65H#,!9U4+S
M.QVIY6)QZH-:93^][B]I:EW?Z03OZH^_J:6'HCO%=L6*1W,<PRR%>0PRCG5=
M0T8 B2D&8<HHX4E"X]"H7^X0RDV.KJJ/;?6B+2IG5<U^O=AXJ;2U9"V?8VC(
M;V\T,D,SX4')_D/#CFHITM?+I?VU9;/Z/T%C8?"Y>SCMJ70 W'V1KD_5QJ7G
M 4 ](_(A9/3KS=+,*_=EN=5UNMZMRDTYAUDHHYPB(&FL*#R,$^5")@*$+,IS
MAC(89U&/_BN79$YTHZW]KI5C5#3J!DSK&ZSK5@^Z&N3+EBX*IJZ1:FB63V[-
M52X.A!D/]\9UU"8IY=[+;#4-*E7]]T+I L1SOY.+HMZDITF7T=?ZEG3>TZ]X
M3YU_I7YH_^W##\U\XH@!E_PGL12RV)3OR$NQ(8LFY?-!?A&E4+*_J4OTC>MB
M=P!<?R%<X@@S(@&!D #$F "$)4S7C\@EXXEDPKS9]6AJ3\T//59??Z#KQH J
M15L<FU SH%L)G(%?AV["G.X@#TR]%U-1]<^[7S26SXX]7CWXK?7J5\=OR8,,
M6@2"NV7]B,.WI)O4WY0TG&HM3>=M>8MR3=-X:YQK/XTS>*;EHP;6YDTJ4(V#
M\+4B5B-)=UMLW?'_V):;RM-Z7-UQ7N@'D\5G4O#[9:-*M?"CIVO#+[H[65EL
MQ%>Q_EXP42_^O@BV>EI63ZG"Y>="0LA2D@/$6010C#. $2(@3'F,<(SS!!OE
MZ(VE\-3\G\K[!94QRKG96V.WE!M\F,V6@U,:O(']FKO/]^]N]M@\*"XOJ_1N
M771^;Y._9>=8P'M:N@ZN[JC+W[' /UU"CR;7;>IYI]%;;NJ,RR]%^8^?7G<E
MW6,A0Y[Q&'"24H"DH(!"%@-&(<G4K^+(KN)BAZRI$?Z1JH'6U;U<?A?$9HSM
M";B!R=81,VL:-4##$P-V21J5O Q,/N4=DUL<HW;W]6";N.!Y&N8TC& &4ISK
M),D\4OXEA(!D(4_S+$UR[-I'N!%A11"CU3EC3?#YPK4MYP4LS2BA'T(#,\%1
MZ>9&O4%: 9^8[K_Y;RO@K=K]GAC8T>#W],J1(SUVJ=EJH;U]K@,6-.M\7(NC
MYCZ_%,OB>?L\AR@4)$LA8$FHEJ6()8 FRK=(*$91CJC(I95O,9;B4W-4M*I
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MW8+)^N._ 8*G[_^:E%$IX(:IIRQPZW(W(CCS*3Z)C6*!/"<1BW7;H0R@,"2
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M79@1FD:,@3PA'* DX0!'. )ZXDNC!#%*[7=U1E!\:C/?]8Z'M;Y3ZWC8#/_
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M5+<]R#N^JI;33:1KSE!(\@@#0:N,[C %A"O?18&+DY!#1F)BPQ^7A$R--13
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MX)TNJ;P]MT^HON#OMSK$NFX\5W%^TYFC_/!#K%E1"OY);.9)&G.*$081#5.
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MR$&#<4^'W"$Z.S;J\:AKO'?X+JBES3_^SW]K_T7]H3-,_L]_^_\!4$L#!!0
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M?\22#(AD+ ;&K=(M7(Z[WKT?/#I.?#82Z]C9S\K#$L.&;IF9#M%R0"7([NG
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MWZ*E+,<&PV9N_ WZN1=%",>KQ65$?ZY#)FG?1FFM(X?=1;=?I>T=#Q^YN<B
M4#A6DCUL.K?;8U@;M1<V0O*QVDU7(!A>P#EO&6IAK&R?C>NZ(\U1[LEQ NX
M(K_BNKKW[Y:++U,*%Y]_^VV%^?7\8HC;,UI+7Z;K*:[JU/;I_(R^M_OA8GXE
M(/!%TJ9+*X'7!'4V$:*K#;QIB12F'=KFUT_;4-Z)IWP@?FZ?4#VU,ON \)5S
M.84LTG]KP\+:19X,,SB)!0P*V@ <0XRMF[0=<" Z%*#&0,"#QZ2/44?#A&"C
M<KM:##5/TQE>8^KC8D\97\BS*!%CD QT0%_G7UJ(R3 0Z)RK,UJD:3T$9P@^
MQMVW.\#VZ.#H8HG45/_;4@=(U[MAN^K!U8?%++]$HBI-MY"8YV<GB^5Z^L_-
M/R>TJ85@8X Z@IP<<880C9)0)P8;ITSDI7V#L0,('=> CX^P.T8_#ZOL#ER(
MJ[1?')7-/YV/O7XY7:7%&:ED$JU*!+,"3'#BRS(.+I 9B27:8%20RK8^%-B7
MMG&-<W>X'42E'4!U6]C]7]-Y/A]Y.TF.8U2A@-:Q4,A@-(3B YB@;8[)6JY:
M!U^WJ1BWU5EW\#M231T [>7NM1<33+&N&_K[!7US2@O'VY!1H 'I&3E2RE7Q
M>(2B:HM!1JY4:'U>\3V:QNUXUAT(FZIP[,SVKXMYE=V;6C]W/C2^$$+0&0.:
MEP@*:Q&NC@Z*S\$[)WQAWZW2N._AX[8LZP9+363?@3E[?7(:ILMM0<.;Q?S3
MF^D7S,]6*URO_A-G^=5B2?*;,)<5!J[!N#J6N<YF#LIEX,;8S$).R%JGQ_<B
M;-Q&9=V <3AE=H#0&F/]/IW-+IG;9-#0*JDX6>:,R$'ERD4H"J26+D;G<@JM
M9R3=3<FXK<BZPV #=74 NO/)T=>OADXLQL!*3=9Z7T]-90+/"OFJG%N5L7"\
MV9SI^&/".RD9MZ=8=Z!KH*X.0+<Y6B>?(I'DMI(\=RJR%YKY4B\I!$M.A:@U
MA9ON)SR88GRVL?7^>R\QX_8"ZPYZ;9363P.PVW=R+B2WNS9_(;844K9%>>"N
MUI"4>ARKZQ#0))P1TI>D0VNO<&_J1F[XU1U.!])K!V;S-F?/TC:)27+'Z9=-
M.0NY'9I[1;*R=<J29!F\EP%<9BHI)TPTK<^_]Z&KMWDN;3#Q7>@=J:!CK66#
MEI^W6'JW1')X\\[X/YOG%V?+JH/-_K"-P28U<<0+*EJ_I=2Q-08B%PPLCSQ:
MR02MX;WR,@>]OK<Y+TVQ]D1:&15Y#XCRW G9<K=C3'G-'%,&R =.=4EI\/4K
M$F:V*05F2NM3N3U)ZVT S!.9O>/5U"O^SN6W286^F88XG6UN6!?K';,,I-2T
MM 2/$#4F0)U-8@H]<\/ONO<0U]L8F*?"8 -5=>WTO0O?-@Z%$B[7#C9@M:O+
MJA[BF)C!F51$*(GI-'QT<H.HWN:]/+&[=XAJ>L7:\HSHV*V>Z>8 <7LSXF)Y
M7?YL4M!:J4F:SCH%*C $+Y0"&3%XJSSRU#I7?2S-O8V >3JD#J78#H"\?ZGH
M1$EA,(@$+),_K&+)$".7((2GI2J<)+=DM)L+X[J/'13<#J3(PR&ZH"4Y)$1?
MS[_@ZA'"#476P=D!LN>.%B:)V<M,ZS3ZD#EG(4CV-/!]).6=W %[,^3%FR&5
MV8&5W4T%J7UGT_\]FRZ1^">FUM]JF^4U[2>UE]%I_<BD7K0LW 0(3M/B+)F6
M?^ "$#/)'+WCNO4%B/VIZ_+*SJ#8N56L.(@BNXCA;_&V<7*(P7Q6!8N[W(1G
M):$7'@KGGC8I'B!:VDQD\3I6[R?XU@?>^U'6Y9V;4<%YO +[.83<7[X3Z8*U
M/M*N5(RD6#(+"%'7PP,F)$]&JC+>3M^EH_J4*!U(D?TZJA<W*O84;F3.AR0U
M*(4(2M?Q($EK,#YY(21*9_W3P/>1E(\+[:=Q5(=49@^.ZG*1R$%9U3EW=T]=
M"CEF;J*!Q&L/1)%E;;7KP>B,W%N!7+;N@/Q=HKIT2P=%RLV=OZG:>L#ASI5Y
MC[.-&['X&+[^?;K^7%N_DOA>+9;WU?>5DNOL>MJ4:OJM!$6;$CDWL1C/K?:^
M--_[#Z6U2W_U25'[%$KNQX.]M4BW(\&RM-Q9G6K+:F+&(.U/PA:H#6*+5U&C
M:)U6O9N2+CW34:WHXQ74@^F\PL5NBL?Y-K":Z*R9J;G>$,@9HMB/OF(E@[#!
MY1BY-:9U:X&'Z!GWP+TSR!VEK Z MY4;;HH(WBVG),+3.EUK:^,G*O'$& 6*
MMC"24E2YCBK2$+0K2OK(E6W=(/U!@L8]=^\ >NW4U47V\CV>[FA_6WY=K/&B
MLB#(Z&22 8(M@3B)$9P6 HP36>N<LW.M@7<?+>.>H'> N29*ZM.CNQP4?V52
MS<2:;'@R''*Q')0- 7SB%FSD(>J@4W"M<SG?)6K<VXD=H+"MVCK8>=]=+*J[
M!DW42E),&7CQF<3%R'V5H4!(/OCD;.9VJ /%N^@9]YIB#^AKI:Q^[.#^4IV@
M"I(E*4%K%4%YGL%A(D%Z(TN*3(30&HW[4S?N/<8.L#F0(CLXFZELU?_7\_DO
M8;9-.Y'$IHE60OW!LWF^_HTKG]S.Q;Q=&IAF9S51]<O7]#G,/^%[6E6_E(*;
M2J[ C(H6.(5PH'A2$*./@#X'BVBU5:W3D$_+X;B1>^.SGH[!\:,OG0D6*S,:
M V4S,XN;!%%I#BA+,<J%$$WSB9G'$#QN7J G8#]*=4<.0R2^E^L.T.JXCZ*>
MBV&]]Z*X(,=?2 LI9$7;'6J-7=GM<3,*7:'U,:KK90;LV>GI;"/ ,#L?'?9Z
M7A;+DW!M[B M0A%LB" J5ZHP!XX%#L[H+(*1ACROQJC<D[1Q<PF-\3>$.CK(
M#IRWU:R--NL4]^AB5")YB#Q3C!DED<^MJ\V7'$9'3GWS$.P&"6./RAI S;>N
M$1TN\PX@<Y>(?ME^XS+0I'56<NV&F;*SH"SQY!/))Q3!8I!&N]Q\Y.T>=(V;
M8'H"DW24(CH U_OII\_KM^6WU;8@^6U<!Y(515#GH=*KQ?+JX=3EA63KLB]%
MU&8,EE91L10X>57 *,9<8JRT3V4>3&Q_-NXXW-P\R7D2)8[=2??B-L>[LR6Q
MM<+\VSS7?@V71U=OXVSZ:9N"FS"E%0\&@7E9+YZZ"(%; 59SQ^L<>95N]&2[
MIYG+X]X[\@6QH: VM 8Z,(6[F\N;7C1YNCXCU;W>M@+)S\_6Q.3_QHT+,:&%
MH3'7!@RBCA'F08)'3. H%$]%!>=5ZW/$?6D;N>I[:$,WB(K&MFOG[<[/AS9N
M#I_>8YJ%U6I:IK46LRX\LM889<G2%O";N_3)U%ML9*VM8 %1HN$WRW;N,6E[
MOW+DS/*@UFP8N3=#T[_]?$OFY,;^8_.CS4_J;[W'\E/]^[?WKZ\]'[^&3SC_
M<UJ<;!_^=ODIS,\G!5VC=#4](1E_#S77?O_G2QIN4K=[S"T4[$\/?EW3VL;\
MIR-[M5YYP0O:C!:S:3X?^?/N"M$7,U;"["):N((MD47!8 %-HJ@3Z8\@70+-
MC0V:!8^LM8_;A/"C.]W>1\3SL)JNWI:KA#P_6Y&SN5J]Q%5:3D_/QRIM6\K0
MLGI'OYRFN/I(FGT^JP4=VDGA--EEE[(&E1,#S[*M149%"+3!A];[YZ ,C1M=
M/#W2;[78[08M?1K?#V<G)V'Y;5$^3#_-:6=)]7;Z+8X/,<M[/KF!P3Z$AT:F
M_/9K+GNT6&%,3+6>PL9M-L?37@T\Z1(YIJA,ZZS7_=0<G>=[2+*7Z\$R*SGY
M-A!3J(U8O8?@92+/QV7.7%$\MFY6M1]E(T\@;(.26SF_]DKITTAMVA-<[!!7
M4O 'N8OW/JR%[[@?I4=:GTV(<.^K+MN;&0R>HP81%"-L)02']6S>*F<2SR5K
MME=(]MU7'15C7N^S>]$T[<751J?W=D_9;M W^JY=8M]K;7T.%&M[1R(HA0(P
M8IR6%XJ(C)NJA'U$,""1X]BF 3!T+8+M1:M]6K3GB^5R\3N9ZX-<JRN_W<!F
MW4=+(Q?I)<9U'0TZ6ZS.EG@!+*6$05(6.!7JC-#:O0X] VV2%5%F%U1K]^AN
M2HX?ZGCUJ9<@52(P854&1T$"**7IJU1J&[WD;4&A4_/V1_>0,J[STT#_MX<P
M'B_R/NU"O5LRW8S^"/.\K=ZFGQ\:@CWPM 9V8U]:&]F1R]?5S>3:^^Z 5])"
M.A$\V%(;NBINP'G:(D1V,61>M,GM1Z,_@L#C!\;O\;++E9&T*9BE!Q]H!U>B
M<-HQ8X:8!:? (QLN6@^!>AR%X]JHX;!U>_;[8'KKTZ*]"M/EW\+L#/^*H?*V
MO5-]@#&[^T$-[-@>%#8R81=ONE3UE4R T9XQ3ZZLC;)F.05X3UNC0Q6+\%(%
MW3IW\A ]1U_RO^/9E[@V,6A$(4$+84%)4<O<F ?41@2B,V'S\ND'"1K7_#3#
MQ:VK^\V4T*=QV5R,K%V Z"6[0^%#,M6WG](B*_T=VAK9E.VC+]#"ZB5XF1%T
MX+4S> S@F*'PW1G&%8KD4NNHXSH%1V>:;XFMEO#<M3<ZX;S4)M1MF.!+'()W
M6D%.B:O,4]:AM8NW-W'CVI,C,'$KQSR(.CJV)MN&>#4C=; IN?*(5G;D/JI:
MY6@N]+EI;W#10&W7<&U3?;)IL19K8=WYQ?3+ UI9<M'D 1>F'*F>-JOH* P/
MG-L2%9.%M3XT/X[BHW,^^[[]^=6W7TE49(F1=G'PTM>&3=[2SEL\*,>3,[IH
M[UK7;AQ)\L@YI*?#YZU<TQ.JND^SN)TZ^S%\/2P)=?77&YC#>ZEI9 HOGG]7
MSE(K&8IG$+*N,W2]JE5W$KQV2GO/C',#C 6[CYP&HZEN/OH2ML)DZY1-P'@]
M8L%4^XM@!).CTUX2<FWKV]@/T3/ZK-LFF+ACAE0;#?1I.)XIQO]QJ"=U^<L-
MC,8]E+3+3%]L"YN;Q^OI-HMT!URTYHJS.K0NEEKOD0,$%FLMF]8N60KG#39>
M5X\@[^C^4O2>[5NV$R5H<UQ>O.XYSK%,UW?F.34FKYF4D$)-J4JWN9.M@/9F
MKIC(AOGF[48/I'7T3/4@6+O5?.HI--FGV=JOG'#XTLBG+Y$<JU22V:101 NE
M[G>TU9%_CDR"T8DG[[/EHK5?-5RIY(O%/)&*MMVVWD]7_WA!J)ZNZU>3Q)3T
M(=8J8:YJ)H9!M#)"]IB+38PIVYK1!\CIMBCR,7BX?<#61OQ=7/K;=#*YV4:J
M2NO;E0"3IQ)D<(#6F]I?C7Q/3DSIG(P6.FMAFQ_M[D/8N)=-AT)7<Y5T@+-[
MR_!N\D5D,_18>UQ$<BBBH:B':0LA2FD%MYAP@*;P>]$V[N72@= VB&(Z -Q?
M%HO\^W0V(Y9>U^JA3],XVPV=N\F99=P73I(SGCQ)9;R 4#0'$VTPVO$DFO='
MW)^Z<6^@#@2Z@933 >S>('&Q[3)QBY7(@S*Z]G NM2F8\Q0K%<8J4]I;0Q:]
M^6'B ^2,VUMP(&"U$O_8=^)?T'<I@)I]6)_E;UM&;K*3E)9", T.R0M01FD2
MDU"T3B@ 5LIBX#?0=,^U@^^_:]S&?HVA,H1\.S \[_$+SL^PMI&O%7]5/'5\
MU8NSU7IQ4I,KU[GSSFO.%(*U,8,*]4I_*IYBE9)34L6@;5T)]C@*QVWF-Y!Y
M&E!)74!PA41 #5Y>$J.SQ<:/W-W.V?(V0:.BJ&.$3)VHH0Q&<*90>,P2_==G
MIP<8@/)=LL9MTS88V-JJHP.$/<M?*%:9KLZ[E=Q<,)GGQ*W5P)DF<0ED$$L*
MH$5F3@8;,F_=F_0[)(W;Q7\@9+540P>H^N7D=+;XAKBM@OI]3@_^/#VM ?$O
M']Z^VZV4XK/2OF0HG%'XJVV J&PMFG=),F,3ZM:':OO0M5]^E?U@ &NND0Y0
M5D_5EOBYGGE]P>VI_-V.)U?HO*HW3U.A8(61SQE<-,"5E#%$B1A;;Y'[TK8?
MVGZ\=/X FND <1>E'S?Y,%9:'X0$7FH^S[A:IL82I%Q(7()SXP8KO#D(43]:
M"K^)Y#M T"]A.:^7MM_A=OKQK9RPT5%H9< Z84!M&H!4&;&(=4R#1QE:CPO^
M#DG[X>E'2]*WU$,'L/J GVHH\AY/%\L+6=VRMA)3,*%>*=#UZI"C5>.8#L1C
M\58ES$FVME)[$;8?Q'ZTE'Q[G70 M%_Q]ROB6B[F]&7:7KZ\FS\*=P/+4D&Q
MU:<DP8$W+(,3W.I-ZW36^BCHL33N![\?+7$_J*8Z0.)=%X#O66(:50Q.@HS$
MCM+&0XR(%$N3AUEC&LE:GQ+M3=Q^V/M13@*&U<V/7'CXL;8R'[#L</?\)RLZ
MO(N?X4L.%:D4N<Z0!7I061$F<XH@0^;!6Y,R=XU7\H#=&=-GS&<DQ7I%Z4KY
MV]M2R]Z>?ZM_OJ+W+)97SNXIV.$,'>24:X><&" DYP%CJ;>D3 [-VQ,=0&:W
M)8J/P<\M=VY@=76PI;Z<KL*G3TO\=,[8]G!ML]8OF6(EN+*YCEP41=P\<XCD
MJX+P3E:/U7&O&F-P+\*Z+5T\!G7M5=(!SLZ74F7GQ@# &S6:5TYN,W)O5*&U
M4Z_#JZ A9/))N&,HK1%6B.9#\AY/9K<%C2TLWU#JZ@J1]S!V?;VER(5F40)S
MF7SC'#B%2G7$K^31!8P"36L3^#@*NZUQ;(/#YDKJ"H+/2'1Y.CM;3[_@!TQG
MRTTCU5^^UI'3F+>E+B>G9^=-^&^F,J^<&B=I"Q,%F*X5[8XBK%B'U'$MBY=1
MRJB:-_9NSD6W595MH#R*LON,I._M:WQX\/R]1P[9/'R $'G/]L]H S-DYB 5
M1<@4W()GUH#5=02?P'AE).4X+<0OW-L=^#9%+[M97--_8M[UH3Z_R+HM9+_K
MXBI'BQKK& \G'/D9==Q@9)KXQ:@"\_3*UKF]8VGNNG/X8Z!SN\'O$RJS@QW[
MWHL^5TZG,5OR?1GD4-MK$3?@1-3T3R^*LSGSY@UMOT_5.('R$P"PL4(Z@-BE
MGW!^P>=*ZCQ%=(&V^9 WU\<X)U8*!YNR,8Q+-*7UR=H#Y(P3^3X!J%JIH"LT
MW3&GX7KP),BS%4D&<"K)FE%"<-IQR(6%9(*EG[>^G[P_=>-$MT^*M:8*ZM/=
MOYQ@<;A_?^L932=K#'C(=<]\!5\29A,32)\(/$$B!)<%*!\2"YDP9%K;]&'F
M:UPB^:]AO0MJWY8WB_FGC[@\J>^\@>=<>Z,S8R 967NF^PA19P^2.\DD1=BN
MM#[:>RR-74[D> QB[C<W RBI3Z-S__B+PXW0=Y\YZ-B. 8W4XP8L:".DU\E
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M\=QCY-\!E'9F_;Z:K1@DNA039)]J#L-E<)'Y6A21DN0:B]WK2.,1:'J8HLX
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MF(98J_-0<E&R#5;?G-MUS]9^^]D_%J*.4>NBG8P[L'S/\G^?K=:;'>758OG
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ML23>)M(I-#P(T([7%DV&3+12"!H5HG<R.M:ZAFHOPG[,6Y)MP-A><QW L1Y
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M:#+&44:*3G+E2I/\A&-%B9*3CND ^_7,(\?M]36P^6HEZNZLUSO$-U_GE[7
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M8&MK(O1.P;/U&3G#(GP,8$2F9>6$A6!2 &V,+5S94ESS+C1/4C-R=7(3;>\
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MB-\N%^E+[:W]>8%K\WR?I:LD=XJ&O% &1#P9:"85^* UA*PDHK5!JITF;;R
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M%+^%A>2WN. \:R7KL"I>!5., (>,=G&,+#,F$GJ])RCN/:*+E.]0H#A&G/V
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M<C%I_=Q6G(J?BQH[7]),\<@W:_X'@R=PREV.O9?[&"UXPJ9>UYMUN-J]B?F
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MFO^;(1($Y2XG/LI#M!8\8;.HZ\TZ0NW>QGS #6G4RO6[<7X_PC636]\HP(_
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MEGXC,B+=6SID">DE01GH.-X('<<(9HD _\JT1=BSXJ7^VO'R_. @'Z@&)@"
MT93<)'(B6#AD10\2Y=$12J9)(N%FT!WE":')E&2)41E#D/ WSNH -I2,<&6#
M(A$-<$L1.8(T&^GKK51(6,"TIFIJJXSH#<.X2WUJW L1#(84SB=A#%LAX J^
M"-42-$<D(5-D$O,@)CJS'XOV$Z98WHF=P(AK 0-EO=B$FQ@3U"D+7("VWQ2A
MR1#3'*-92 ;3Y678A@C/BOK&&^J?#O6,1#P!KBQ$%S@J O*HCF*U5,Z3")LF
MM1D#O@<B"]$GL+H$FB)PSI68DA10LRRQ[!%B08,<@?K>T&!:Z%*1HJV1"50
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MZN[+R!@K_G5Q]^+ZV7\ 4$L#!!0    ( +N*=%8-$T2G!P4  $@>   1
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M2P$"% ,4    " "[BG16 #XV<0P#  "*"P  &               @ $
M97@R,S$M,C R,F)D;V-O;G-E;G0N:'1M4$L! A0#%     @ NXIT5L4/#^W
M+P, Z2L: !$              ( !0@,  &5X9'@M,C R,C$R,S$N:'1M4$L!
M A0#%     @ NXIT5MSJ8"[$$@  *,T  !$              ( !,3,# &5X
M9'@M,C R,C$R,S$N>'-D4$L! A0#%     @ NXIT5C&N70K9)0  RGL! !4
M             ( !)$8# &5X9'@M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( +N*=%;+ \N5[5@  (7< P 5              "  3!L P!E>&1X+3(P
M,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " "[BG16X^=W'G%Q  "3=   %
M            @ %0Q0, 97AD>"TR,#(R,3(S,5]G,2YJ<&=02P$"% ,4
M" "[BG16&<M,]=X( P!D4P, %               @ 'S-@0 97AD>"TR,#(R
M,3(S,5]G,BYJ<&=02P$"% ,4    " "[BG16@+D X-E"! #QNP0 %
M        @ $#0 < 97AD>"TR,#(R,3(S,5]G,RYJ<&=02P$"% ,4    " "[
MBG161?4J;\L2 0!VE L %0              @ $.@PL 97AD>"TR,#(R,3(S
M,5]L86(N>&UL4$L! A0#%     @ NXIT5LI-(W.NGP  PTX' !4
M     ( !#)8, &5X9'@M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( +N*
M=%;WN3^KB@@  "@O   1              "  >TU#0!X9VXS,3$M,3(S,3(R
M+FAT;5!+ 0(4 Q0    ( +N*=%8,<_.<? @  !,O   1              "
M :8^#0!X9VXS,3(M,3(S,3(R+FAT;5!+ 0(4 Q0    ( +N*=%8-$T2G!P4
M $@>   1              "  5%'#0!X9VXS,C$M,3(S,3(R+FAT;5!+!08
1    #0 - %,#  "'3 T    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
